Clustering O 0 1.840344884840306e-05
of O 0 1.515671215202019e-07
missense O 0 9.272674651583657e-05
mutations O 0 2.8972213840461336e-05
in O 0 3.625977029741989e-08
the O 0 9.154862823379517e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
gene O 0 0.00013044873776379973
in O 0 1.857047138287271e-08
a O 0 9.736988459962959e-08
sporadic B-Disease 0 0.057652853429317474
T I-Disease 1 0.9995551705360413
- I-Disease 0 0.43751221895217896
cell I-Disease 0 0.15578974783420563
leukaemia I-Disease 0 0.15828832983970642
. O 0 2.798282991989254e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.8616870641708374
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.818734383211677e-09
is O 0 4.909236905881187e-10
a O 0 3.4627487544014457e-09
recessive B-Disease 0 0.00018825441657099873
multi I-Disease 0 0.0056016105227172375
- I-Disease 1 0.9689004421234131
system I-Disease 0 0.022592579945921898
disorder I-Disease 1 0.9897108674049377
caused O 0 1.0537837624724489e-07
by O 0 1.545347183551371e-09
mutations O 0 2.3570986229515256e-07
in O 0 2.138377031002392e-09
the O 0 4.547991760972536e-09
ATM O 0 4.912149506708374e-06
gene O 0 1.4375251566889347e-06
at O 0 2.2027469981367176e-07
11q22 O 0 4.365967924968572e-06
- O 0 1.0621622095641214e-05
q23 O 0 2.5002327674883418e-06
( O 0 3.26522382465555e-08
ref O 0 4.750311290990794e-06
. O 0 3.7080567505398676e-09
3 O 0 3.24160609466162e-08
) O 0 1.7451267098067547e-08
. O 0 6.606660463148728e-08

The O 0 1.4865923958495841e-06
risk O 0 1.0236485650239047e-05
of O 0 1.7392650875081017e-08
cancer B-Disease 0 4.904534944216721e-05
, O 0 6.1026237396788474e-09
especially O 0 4.310835421961201e-08
lymphoid B-Disease 0 1.60984000103781e-05
neoplasias I-Disease 0 3.9892813219921663e-05
, O 0 1.51879753218509e-08
is O 0 7.498543119766055e-09
substantially O 0 2.998424974975933e-07
elevated O 0 2.039849277934991e-06
in O 0 2.7800908242170408e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.0024401277769356966
and O 0 2.8166088128500633e-08
has O 0 2.6007475284473003e-08
long O 0 2.7160587023900007e-07
been O 0 2.0802545463993738e-08
associated O 0 6.918136818967469e-08
with O 0 2.2899048701674474e-07
chromosomal O 1 1.0
instability O 1 1.0
. O 0 9.297841643274296e-07

By O 0 1.6907306417124346e-06
analysing O 0 9.731452882988378e-05
tumour B-Disease 1 0.9999992847442627
DNA O 0 2.1838768589077517e-06
from O 0 5.903575583943166e-08
patients O 0 6.311037168416078e-07
with O 0 9.83970505075149e-09
sporadic B-Disease 0 0.0016252571949735284
T I-Disease 1 0.994073212146759
- I-Disease 0 0.01774420030415058
cell I-Disease 0 0.030126769095659256
prolymphocytic I-Disease 0 0.03470791131258011
leukaemia I-Disease 1 0.6564425230026245
( O 0 4.220797791276709e-07
T B-Disease 0 0.00022171699674800038
- I-Disease 0 1.036544836097164e-05
PLL I-Disease 0 2.4705983378225937e-05
) O 0 8.406319196296863e-09
, O 0 6.40865527312684e-10
a O 0 1.7147767650271817e-09
rare O 0 1.0283560669677172e-08
clonal B-Disease 0 1.0636787010298576e-05
malignancy I-Disease 0 0.00014003341493662447
with O 0 3.0911082582463223e-09
similarities O 0 3.415313543086995e-08
to O 0 4.164931066696909e-09
a O 0 5.6555052196927136e-08
mature B-Disease 0 3.3773062568798196e-06
T I-Disease 0 0.00041177228558808565
- I-Disease 0 3.973797720391303e-05
cell I-Disease 0 0.0002534954692237079
leukaemia I-Disease 0 0.0003360346599947661
seen O 0 7.079196961967682e-07
in O 0 2.1441696418378342e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
, O 0 1.6604985830781516e-08
we O 0 9.154311975123619e-09
demonstrate O 0 7.603332186079115e-09
a O 0 1.7099757165794927e-09
high O 0 1.1777282260538868e-08
frequency O 0 7.145179381495836e-08
of O 0 4.391557784089173e-09
ATM O 0 7.55775035941042e-05
mutations O 0 1.4857171663607005e-05
in O 0 1.105599451989292e-07
T B-Disease 0 0.0006834580563008785
- I-Disease 0 8.702543709659949e-05
PLL I-Disease 0 0.000257485662586987
. O 0 1.1253339380346006e-06

In O 0 4.444254670943337e-07
marked O 0 9.91949036688311e-07
contrast O 0 8.577585219882167e-08
to O 0 9.429348857281639e-09
the O 0 5.824764226503021e-09
ATM O 0 6.161251803860068e-05
mutation O 0 5.557275017054053e-06
pattern O 0 2.5064207420655293e-06
in O 0 4.25999537867483e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 3.2387557080681972e-09
the O 0 5.560019666894789e-10
most O 0 7.31263438691343e-10
frequent O 0 3.346196919551403e-08
nucleotide O 0 3.2345721479032363e-07
changes O 0 1.296840945741451e-08
in O 0 2.0985455595479152e-09
this O 0 6.937346697100111e-09
leukaemia B-Disease 0 0.00011444288247730583
were O 0 2.2478640460121824e-07
missense O 0 2.4940602088463493e-05
mutations O 0 8.289742254419252e-06
. O 0 2.41689917857002e-07

These O 0 1.2206147630422493e-06
clustered O 0 6.16070883552311e-06
in O 0 1.4246625212877007e-08
the O 0 6.348533698741221e-09
region O 0 1.086313705656039e-08
corresponding O 0 1.0944789075040262e-08
to O 0 2.4589108527095505e-09
the O 0 1.4124564851059063e-09
kinase O 0 4.287875015052123e-07
domain O 0 6.685200304445971e-08
, O 0 1.981882213897279e-09
which O 0 8.725110078877663e-10
is O 0 5.019898385860699e-10
highly O 0 3.830728179110565e-09
conserved O 0 5.895178567527637e-09
in O 0 7.52099882372903e-10
ATM O 0 5.584662631008541e-06
- O 0 1.2954400290254853e-06
related O 0 1.212277478401802e-08
proteins O 0 1.0402199990267036e-08
in O 0 2.258188525061655e-09
mouse O 0 6.38585618162324e-07
, O 0 4.5012948923783824e-09
yeast O 0 2.963911356346216e-07
and O 0 2.226897244383963e-08
Drosophila O 0 8.732008041079098e-07
. O 0 1.9847850296628167e-07

The O 0 1.489601004323049e-06
resulting O 0 3.660238007796579e-06
amino O 0 1.84724797236413e-06
- O 0 3.7142988276173128e-06
acid O 0 1.638000100001591e-07
substitutions O 0 8.456061095785117e-08
are O 0 3.898050771056205e-09
predicted O 0 3.913040558245484e-08
to O 0 2.001854237931866e-09
interfere O 0 4.402958495575149e-07
with O 0 3.796933967237237e-08
ATP O 0 1.79394191945903e-06
binding O 0 1.7044073956640204e-06
or O 0 2.9520688826778496e-07
substrate O 0 7.039160209387774e-06
recognition O 0 1.0035901141236536e-06
. O 0 2.92971606086212e-07

Two O 0 5.996903382765595e-07
of O 0 2.622855532763424e-08
seventeen O 0 1.621452270228474e-06
mutated O 0 1.4518450370815117e-05
T B-Disease 0 0.00017760772607289255
- I-Disease 0 4.846363481192384e-06
PLL I-Disease 0 2.108795160893351e-05
samples O 0 1.635561829971266e-06
had O 0 7.037851901259273e-07
a O 0 5.0145441576887606e-08
previously O 0 4.9644618229649495e-06
reported O 0 1.182122650789097e-05
A B-Disease 1 0.999994158744812
- I-Disease 1 0.9999901056289673
T I-Disease 1 1.0
allele O 0 2.9340344553929754e-05
. O 0 1.9241582549511804e-07

In O 0 5.788313046650728e-07
contrast O 0 3.1905346986604854e-07
, O 0 1.3692798894737734e-08
no O 0 2.4755614447258267e-08
mutations O 0 1.4705022977068438e-06
were O 0 1.0730952482163048e-07
detected O 0 1.0565933905581915e-07
in O 0 8.710743237827501e-10
the O 0 2.28130647705882e-09
p53 O 0 5.244443102014884e-08
gene O 0 7.207169261391755e-08
, O 0 1.6688037618450835e-09
suggesting O 0 1.7724598677659742e-08
that O 0 1.2516894187797334e-09
this O 0 6.131746221882395e-09
tumour B-Disease 1 0.9999998807907104
suppressor O 0 6.536319574479421e-07
is O 0 2.9499052089931865e-09
not O 0 7.0805992180567046e-09
frequently O 0 1.2428466789060622e-07
altered O 0 3.137959367904841e-07
in O 0 3.3873830407316063e-09
this O 0 1.0463768518320649e-08
leukaemia B-Disease 0 0.00047553915646858513
. O 0 1.0655143256599331e-07

Occasional O 0 0.00035823677899315953
missense O 0 0.0008293939754366875
mutations O 0 9.167346433969215e-05
in O 0 6.733689161819711e-08
ATM O 0 1.5911624359432608e-05
were O 0 2.784591515592183e-06
also O 0 5.346860731947345e-08
found O 0 5.733030050691923e-08
in O 0 1.719861408844281e-08
tumour B-Disease 1 0.9999998807907104
DNA O 0 6.947809652046999e-07
from O 0 2.194083492668142e-08
patients O 0 1.3286691569192044e-07
with O 0 1.8489995312620522e-08
B B-Disease 0 0.05211171135306358
- I-Disease 0 0.00011397926573408768
cell I-Disease 0 0.0005421980749815702
non I-Disease 0 0.003036194946616888
- I-Disease 1 0.6965867280960083
Hodgkins I-Disease 1 0.9999992847442627
lymphomas I-Disease 1 0.9178194999694824
( O 0 2.1520406789932167e-07
B B-Disease 0 9.831647912506014e-05
- I-Disease 0 3.1771492103871424e-06
NHL I-Disease 0 4.83984649690683e-07
) O 0 5.461401553219503e-09
and O 0 1.1233952434963612e-08
a O 0 1.2110149327781983e-07
B B-Disease 0 0.0007545972475782037
- I-Disease 0 8.816456102067605e-06
NHL I-Disease 0 4.122911377635319e-06
cell O 0 3.3483279366919305e-06
line O 0 1.1829661161755212e-05
. O 0 2.021204181801295e-07

The O 0 3.438216538143024e-07
evidence O 0 5.307224526518439e-08
of O 0 2.656617814622564e-09
a O 0 5.163802274665841e-09
significant O 0 1.3021402622825917e-08
proportion O 0 1.0340485090409857e-07
of O 0 4.3378043379505016e-09
loss O 0 2.2621227344643557e-06
- O 0 6.549631507368758e-06
of O 0 2.3188068354329516e-08
- O 0 0.0002213777625001967
function O 0 2.0921495433867676e-06
mutations O 0 9.998329005611595e-06
and O 0 2.0326973881878985e-08
a O 0 7.836776561020997e-09
complete O 0 1.027162568334461e-07
absence O 0 5.793963353539766e-08
of O 0 3.7370806449388283e-10
the O 0 5.3977640135371985e-09
normal O 0 5.3226237639592e-08
copy O 0 3.538996651286652e-08
of O 0 4.220684357569837e-10
ATM O 0 1.1114503877251991e-06
in O 0 3.198795450742864e-09
the O 0 6.841527344647602e-09
majority O 0 2.2771340368876736e-08
of O 0 9.855558147364718e-09
mutated O 0 0.001773415133357048
tumours B-Disease 1 1.0
establishes O 0 1.3424752296486986e-06
somatic O 0 1.3014520163778798e-06
inactivation O 0 9.155849056696752e-07
of O 0 1.99511873688607e-09
this O 0 1.168818819508033e-09
gene O 0 4.5087467981375084e-08
in O 0 1.0480620815656039e-09
the O 0 4.3213872480407645e-09
pathogenesis O 0 7.351014374989973e-08
of O 0 5.3637116970151055e-09
sporadic B-Disease 0 0.0018871283391490579
T I-Disease 1 0.9404316544532776
- I-Disease 0 4.715245813713409e-05
PLL I-Disease 0 1.8334358173888177e-05
and O 0 4.7053763552185046e-08
suggests O 0 2.2696326595905703e-08
that O 0 9.329021999349152e-10
ATM O 0 5.929304052187945e-07
acts O 0 1.2068068144799327e-07
as O 0 2.1530048854856432e-08
a O 0 3.502119341192156e-07
tumour B-Disease 1 0.9999998807907104
suppressor O 0 3.4221040550619364e-05
. O 0 3.6438927963899914e-07

As O 0 6.085714403525344e-07
constitutional O 0 1.532616380472973e-07
DNA O 0 3.5212320881328196e-07
was O 0 6.951177056180313e-08
not O 0 1.9736359213595733e-09
available O 0 1.4617216326229254e-09
, O 0 5.904267630363336e-10
a O 0 6.026512622270275e-09
putative O 0 2.4501077859895304e-05
hereditary O 1 0.8620904088020325
predisposition O 0 0.0002170438674511388
to O 0 6.019163265591487e-07
T B-Disease 1 0.8134652376174927
- I-Disease 0 4.728119165520184e-05
PLL I-Disease 0 1.3043101716903038e-05
will O 0 4.732149783137629e-09
require O 0 1.0158403895843549e-08
further O 0 7.565459370084682e-09
investigation O 0 6.87284185119097e-08
. O 0 1.2293756235237652e-08
. O 0 3.681279991951669e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.0004037564794998616
kinase O 0 3.6627734516514465e-05
is O 0 4.8805514296645924e-08
involved O 0 1.386752934706692e-08
in O 0 3.041727147934381e-10
the O 0 3.173210305629226e-10
modulation O 0 1.3755885319710615e-08
of O 0 7.615025277019072e-10
the O 0 5.427413185543628e-09
Ca2 O 0 1.347667648587958e-06
+ O 0 2.19622870645253e-06
homeostasis O 0 1.3555843906942755e-05
in O 0 2.7496939836169076e-08
skeletal O 0 7.712123624514788e-05
muscle O 0 4.0856142732081935e-05
cells O 0 2.249928002129309e-06
. O 0 1.6259305368748755e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997556805610657
DM B-Disease 1 1.0
) O 0 2.867099624381808e-07
, O 0 7.085161901621007e-10
the O 0 5.656136115028687e-10
most O 0 1.6035939243153052e-09
prevalent O 0 4.888367584499065e-06
muscular B-Disease 1 0.6671940684318542
disorder I-Disease 1 0.5249047875404358
in O 0 8.070489165845629e-09
adults O 0 3.997515250375727e-06
, O 0 2.228893514200081e-09
is O 0 2.084821426606709e-09
caused O 0 9.530444344818534e-08
by O 0 9.308052995038452e-09
( O 0 1.7307140609545968e-08
CTG O 0 1.2105904261261458e-06
) O 0 5.785810497371813e-09
n O 0 8.352667464350816e-07
- O 0 2.937996669061249e-06
repeat O 0 1.260496560462343e-06
expansion O 0 1.844969510500505e-08
in O 0 1.1049322568013054e-09
a O 0 2.547331456881352e-09
gene O 0 3.1825599933199555e-08
encoding O 0 3.782607294056106e-08
a O 0 1.291859064167511e-08
protein O 0 2.47361725769224e-07
kinase O 0 1.9152446839143522e-05
( O 0 3.150165639453917e-07
DM B-Disease 1 0.9999996423721313
protein O 0 1.1618643611654988e-06
kinase O 0 6.091217528592097e-06
; O 0 5.1400842693283266e-08
DMPK O 0 4.146115770709002e-06
) O 0 3.5160114819632327e-09
and O 0 1.3123298003847594e-09
involves O 0 4.889269877850211e-09
changes O 0 6.9863981266848896e-09
in O 0 4.2148622370064e-09
cytoarchitecture O 0 1.8286038994119735e-06
and O 0 3.343389920473783e-08
ion O 0 7.225499757623766e-06
homeostasis O 0 0.0002307783142896369
. O 0 3.142445450521336e-07

To O 0 3.3352822015331185e-07
obtain O 0 3.106323731572047e-07
clues O 0 2.3357240763743903e-07
to O 0 1.2332248999769035e-08
the O 0 1.2066533550125769e-08
normal O 0 3.486888999759685e-07
biological O 0 8.773636182013433e-07
role O 0 2.3073273069940115e-08
of O 0 1.4164034389807512e-09
DMPK O 0 1.7387332036378211e-06
in O 0 2.916210384285023e-09
cellular O 0 3.3520103670525714e-07
ion O 0 6.798064191571029e-07
homeostasis O 0 4.014622390968725e-05
, O 0 1.4165122408371644e-08
we O 0 1.106312019771849e-08
have O 0 2.084264760782162e-09
compared O 0 8.047539523658997e-09
the O 0 3.7123168983299593e-09
resting O 0 2.267141070433354e-07
[ O 0 1.475222699554024e-08
Ca2 O 0 5.2988600174330713e-08
+ O 0 1.6656285595217923e-07
] O 0 1.7191274537253776e-07
i O 0 4.26937447173259e-07
, O 0 8.20441214965939e-10
the O 0 5.59075230555095e-10
amplitude O 0 1.8834441561921267e-08
and O 0 1.4148623606047295e-08
shape O 0 3.4561529105303634e-07
of O 0 7.249257194530401e-09
depolarization O 0 6.212239327396674e-07
- O 0 3.541250043781474e-05
induced O 0 1.514625455456553e-05
Ca2 O 0 1.4598134612242575e-06
+ O 0 6.895569981679728e-07
transients O 0 1.675395765232679e-06
, O 0 4.545355647422866e-09
and O 0 3.4164651108170574e-09
the O 0 1.5339851611173572e-09
content O 0 7.688087499957419e-09
of O 0 1.0312468656792362e-09
ATP O 0 3.3654313824627025e-07
- O 0 1.597338950887206e-06
driven O 0 6.814986477365892e-07
ion O 0 2.48064537800019e-07
pumps O 0 5.839829100295901e-07
in O 0 4.484472793109262e-09
cultured O 0 4.5964205241944e-07
skeletal O 0 2.475755991326878e-06
muscle O 0 8.822208314995805e-07
cells O 0 4.685056609332605e-08
of O 0 1.4314113228053316e-09
wild O 0 5.31426458394435e-08
- O 0 9.465875336900353e-07
type O 0 5.025042264605872e-05
and O 0 1.8419584080220375e-07
DMPK O 0 0.00010240585106657818
[ O 0 1.1613635706453351e-06
- O 0 1.305351634073304e-05
/ O 0 6.300853419816121e-05
- O 0 7.618285599164665e-05
] O 0 3.0361884455487598e-06
knockout O 0 0.0007264615851454437
mice O 0 0.00013499842316377908
. O 0 3.6096994904255553e-07

In O 0 6.0579936871363316e-06
vitro O 0 0.00023443694226443768
- O 0 6.539207242894918e-05
differentiated O 0 3.236897100578062e-05
DMPK O 0 5.8576017181621864e-05
[ O 0 2.701310677366564e-06
- O 0 1.5733887266833335e-05
/ O 0 7.603928679600358e-05
- O 0 4.72464926133398e-05
] O 0 1.3374888112593908e-06
myotubes O 0 1.645725660637254e-06
exhibit O 0 4.813103871015301e-08
a O 0 1.8160090320407107e-08
higher O 0 1.7425449527763703e-07
resting O 0 8.331894605362322e-07
[ O 0 3.003805559842476e-08
Ca2 O 0 1.2739188548493985e-07
+ O 0 3.6103327261116647e-07
] O 0 2.3263538651008275e-07
i O 0 1.0994044430390204e-07
than O 0 4.034619305315346e-09
do O 0 4.9722761019665995e-08
wild O 0 2.602623183634023e-08
- O 0 1.984101118068793e-06
type O 0 0.00010970862786052749
myotubes O 0 3.076803113799542e-05
because O 0 2.2548711342551542e-08
of O 0 1.0278065065705277e-09
an O 0 6.141812392002066e-09
altered O 0 5.607422508546733e-07
open O 0 4.9790141787298126e-08
probability O 0 1.2902140689163843e-08
of O 0 3.4722595909641996e-09
voltage O 0 5.158201383892447e-05
- O 0 4.1442988731432706e-05
dependent O 0 7.921438736957498e-06
l O 0 2.4824184947647154e-06
- O 0 3.150190082124027e-07
type O 0 7.03265868651215e-07
Ca2 O 0 8.393078587687341e-07
+ O 0 3.4903226264759724e-07
and O 0 5.993684482064054e-08
Na O 0 9.917778697854374e-06
+ O 0 2.301294216522365e-06
channels O 0 4.302159595681587e-06
. O 0 4.0890304831009416e-07

The O 0 1.133755404225667e-06
mutant O 0 1.0389002454758156e-05
myotubes O 0 4.9559707804291975e-06
exhibit O 0 8.552296293373729e-08
smaller O 0 5.12287776643916e-08
and O 0 1.0817030826615337e-08
slower O 0 1.5100026757863816e-06
Ca2 O 0 1.3055567933406564e-06
+ O 0 4.31936229006169e-07
responses O 0 1.4869779363380076e-07
upon O 0 1.0304647801717692e-08
triggering O 0 1.1472452143834744e-07
by O 0 4.605342773800203e-09
acetylcholine O 0 5.321902563082404e-07
or O 0 2.243328083295637e-07
high O 0 2.1250059489830164e-07
external O 0 5.552465154323727e-05
K O 0 2.2792801246396266e-05
+ O 0 2.3233017145685153e-06
. O 0 1.3815329680255672e-07

In O 0 4.5886508814874105e-07
addition O 0 8.52537525020125e-08
, O 0 7.721151717987595e-09
we O 0 6.147566899983303e-09
observed O 0 5.835595118242054e-09
that O 0 3.2483554734952236e-10
these O 0 1.2956460349045074e-09
Ca2 O 0 3.632075618043018e-07
+ O 0 2.451712816764484e-06
transients O 0 3.654270403785631e-05
partially O 0 2.764968121482525e-05
result O 0 4.913579232379561e-08
from O 0 1.847591968306972e-09
an O 0 9.88807036250705e-10
influx O 0 8.73390515465644e-09
of O 0 1.0724579002641121e-09
extracellular O 0 2.1962569007882848e-07
Ca2 O 0 4.713307930614974e-07
+ O 0 3.538460759955342e-07
through O 0 2.7030599980548686e-08
the O 0 2.4279158239437493e-08
l O 0 1.044468490363215e-06
- O 0 4.076835296018544e-07
type O 0 1.4458252053373144e-06
Ca2 O 0 1.94829544852837e-06
+ O 0 1.4217573607311351e-06
channel O 0 4.843179794988828e-06
. O 0 4.490073024498997e-07

Neither O 0 1.941233131219633e-05
the O 0 5.375963851861343e-08
content O 0 1.545425050153426e-07
nor O 0 8.577061549885912e-08
the O 0 1.7485578540643587e-09
activity O 0 1.322365950073845e-08
of O 0 1.2317903363978644e-09
Na O 0 1.3216493925938266e-06
+ O 0 5.831414569001936e-07
/ O 0 6.267115395530709e-07
K O 0 6.612232255065464e-07
+ O 0 3.293807253612613e-07
ATPase O 0 2.1711596218665363e-06
and O 0 7.899494391949702e-08
sarcoplasmic O 0 6.5518738665559795e-06
reticulum O 0 4.731899934995454e-06
Ca2 O 0 3.866504812322091e-06
+ O 0 2.2253595943766413e-06
- O 0 1.2827224509237567e-06
ATPase O 0 6.5666495174809825e-06
are O 0 4.1223582769589484e-08
affected O 0 1.0263185146186515e-07
by O 0 1.2730415832606923e-08
DMPK O 0 7.822076440788805e-06
absence O 0 3.694994461511669e-07
. O 0 8.898359737941064e-08

In O 0 9.59517478804628e-07
conclusion O 0 3.356917943619919e-07
, O 0 1.303656116391494e-08
our O 0 2.3632876988699536e-08
data O 0 2.1248634851644965e-08
suggest O 0 6.613669967237001e-08
that O 0 3.080843136160638e-09
DMPK O 0 2.258148242617608e-06
is O 0 1.317868147943102e-09
involved O 0 4.106825546301707e-09
in O 0 5.725757090679906e-10
modulating O 0 1.384747463362146e-07
the O 0 1.613171485281839e-09
initial O 0 4.935574171582857e-09
events O 0 3.4552078975735867e-09
of O 0 1.6826303683714627e-09
excitation O 0 5.776308626082027e-06
- O 0 0.002698876429349184
contraction O 0 6.67841886752285e-05
coupling O 0 9.656508154876065e-06
in O 0 4.7992251950290665e-08
skeletal O 0 0.0001811537949834019
muscle O 0 1.6584039258304983e-05
. O 0 3.4440901686139114e-08
. O 0 8.548936847319055e-08

Constitutional O 0 5.5607641115784645e-05
RB1 O 0 0.002147446619346738
- O 0 3.218969504814595e-05
gene O 0 1.7567343093105592e-05
mutations O 0 5.012912879465148e-06
in O 0 1.7276205355187813e-08
patients O 0 1.3110328609400312e-06
with O 0 1.749479316970337e-08
isolated O 0 2.4738470528973266e-05
unilateral B-Disease 0 0.00011234705743845552
retinoblastoma I-Disease 0 0.0006342762499116361
. O 0 5.132677642905037e-07

In O 0 4.3645798086799914e-07
most O 0 1.259461726021982e-07
patients O 0 1.304814986724523e-06
with O 0 6.688833043000386e-09
isolated O 0 2.7153641894983593e-06
unilateral B-Disease 0 2.5395973352715373e-05
retinoblastoma I-Disease 0 0.0002895630896091461
, O 0 7.497759213492827e-08
tumor B-Disease 0 1.2236275779287098e-06
development O 0 3.707979034928144e-09
is O 0 5.011011050548575e-10
initiated O 0 2.82610534974026e-09
by O 0 5.374503064814462e-10
somatic O 0 1.7439779753658513e-07
inactivation O 0 1.386906944844668e-07
of O 0 8.60410520608923e-10
both O 0 8.274964713450572e-09
alleles O 0 1.2225692103129404e-07
of O 0 1.4794514502369793e-09
the O 0 5.638982614186716e-08
RB1 O 0 2.4700893845874816e-05
gene O 0 1.4218671822163742e-06
. O 0 1.6484449361087172e-07

However O 0 1.9877109025401296e-06
, O 0 8.201834766907723e-09
some O 0 4.264446018531487e-10
of O 0 3.101837953156661e-10
these O 0 3.6107850043265444e-09
patients O 0 6.661652207640145e-08
can O 0 2.0889302732030046e-08
transmit O 0 0.004168607294559479
retinoblastoma B-Disease 0 0.0018094830447807908
predisposition O 0 0.0004568394797388464
to O 0 7.345870756125805e-08
their O 0 3.791452172663412e-06
offspring O 0 3.0481845897156745e-05
. O 0 1.8515623878556653e-07

To O 0 4.7265416469599586e-07
determine O 0 2.2849050651529978e-07
the O 0 6.032860877525081e-09
frequency O 0 4.523304255599214e-07
and O 0 2.736331694563887e-08
nature O 0 2.5448221308010943e-08
of O 0 1.353987699737047e-09
constitutional O 0 2.684861044599529e-07
RB1 O 0 0.00019514778978191316
- O 0 3.834542894765036e-06
gene O 0 1.61329114689579e-06
mutations O 0 1.7042383433363284e-06
in O 0 4.914223250551686e-09
patients O 0 1.3257074726880091e-07
with O 0 3.965876071987395e-09
isolated O 0 1.646381861064583e-06
unilateral B-Disease 0 3.0421358587773284e-06
retinoblastoma I-Disease 0 1.4991913303674664e-05
, O 0 1.70778626795709e-08
we O 0 1.3643475682556527e-08
analyzed O 0 4.5807105664152914e-08
DNA O 0 8.67313474373077e-08
from O 0 7.096688570129572e-09
peripheral O 0 1.3217125342634972e-05
blood O 0 1.3034522453381214e-05
and O 0 6.355029569249382e-08
from O 0 1.1785870412950317e-07
tumor B-Disease 0 6.116876465966925e-05
tissue O 0 1.0494795787963085e-05
. O 0 2.392628744019021e-07

The O 0 6.262258693823242e-07
analysis O 0 4.277096934401925e-07
of O 0 1.2176217012438428e-07
tumors B-Disease 1 1.0
from O 0 9.94104780716043e-08
54 O 0 7.643902790732682e-07
( O 0 2.3952765104695573e-08
71 O 0 2.0934399458383268e-07
% O 0 1.085336176487317e-08
) O 0 4.714696966168219e-10
of O 0 5.922257129142849e-10
76 O 0 8.167680931592258e-08
informative O 0 9.283742656407412e-06
patients O 0 7.213957724161446e-05
showed O 0 9.712552127894014e-06
loss O 0 1.2567980434141646e-07
of O 0 4.180004786746849e-09
constitutional O 0 6.736971158716187e-07
heterozygosity O 0 0.0005446808063425124
( O 0 2.8506203761935467e-06
LOH O 1 0.9999966621398926
) O 0 2.084338035501787e-07
at O 0 8.783824796410045e-07
intragenic O 0 2.8996979381190613e-05
loci O 0 7.602756340929773e-06
. O 0 2.8035691457262146e-07

Three O 0 2.6745262857730268e-06
of O 0 5.2127298033610714e-08
13 O 0 4.60865351215034e-07
uninformative O 0 0.02171522006392479
patients O 0 0.0010385554051026702
had O 0 2.0432436542705545e-07
constitutional O 0 1.1803665245224693e-07
deletions O 0 8.586940566601697e-06
. O 0 4.0681663904251764e-07

For O 0 6.685060043309932e-07
39 O 0 1.4343028169605532e-06
randomly O 0 1.0637684226821875e-06
selected O 0 2.8699821541522397e-06
tumors B-Disease 1 1.0
, O 0 6.029975452293002e-08
SSCP O 0 1.1522978638822678e-05
, O 0 3.2945827399544214e-08
hetero O 0 1.5885212633293122e-05
- O 0 9.233522177964915e-07
duplex O 0 2.888395556510659e-06
analysis O 0 5.230856814364415e-08
, O 0 1.2992591447158475e-09
sequencing O 0 1.1577609093649244e-08
, O 0 1.4844233620081582e-09
and O 0 3.712409046841003e-09
Southern O 0 1.594816012584488e-08
blot O 0 2.1130610548425466e-05
analysis O 0 1.5880220871622441e-07
were O 0 2.3557186068501323e-07
used O 0 6.25285352384708e-08
to O 0 2.8277082009253718e-08
identify O 0 1.6874439097591676e-05
mutations O 0 1.6828013031044975e-05
. O 0 1.7297429621976335e-07

Mutations O 0 0.0036458068061619997
were O 0 3.2906689284573076e-06
detected O 0 1.0145565738639561e-06
in O 0 9.821386370845175e-09
21 O 0 5.4173117547406946e-08
( O 0 5.5314730573741144e-09
91 O 0 4.2099632224790184e-08
% O 0 6.329430757290311e-09
) O 0 1.9586579025343553e-09
of O 0 5.491578747296444e-09
23 O 0 0.004204585216939449
tumors B-Disease 1 1.0
with O 0 2.6184870876022615e-05
LOH O 1 0.9999996423721313
. O 0 1.711143454485864e-06

In O 0 1.7436699408790446e-06
6 O 0 7.045359780022409e-07
( O 0 2.6200556391131613e-08
38 O 0 8.494210845810812e-08
% O 0 1.0759723778619446e-08
) O 0 7.222603071177502e-10
of O 0 2.189584069611783e-09
16 O 0 0.000721838150639087
tumors B-Disease 1 1.0
without O 0 0.00023631012300029397
LOH O 1 0.9999942779541016
, O 0 1.4452854024682438e-08
one O 0 1.4045027363351892e-08
mutation O 0 9.19254318887397e-07
was O 0 2.0899631181237055e-07
detected O 0 4.1567204789316747e-07
, O 0 2.6671631569996634e-09
and O 0 6.41665787171064e-09
in O 0 2.9736026974092056e-09
9 O 0 8.742843249365251e-08
( O 0 5.170543548871365e-09
56 O 0 2.6010994247371855e-08
% O 0 4.043740897685666e-09
) O 0 6.025406285026236e-10
of O 0 1.5411819598298848e-09
the O 0 1.1965234989474993e-05
tumors B-Disease 1 1.0
without O 0 0.00405731750652194
LOH O 1 0.9999964237213135
, O 0 2.53426755136843e-08
both O 0 3.664327152819169e-08
mutations O 0 4.797880137630273e-06
were O 0 1.293064997298643e-07
found O 0 7.632409904090309e-08
. O 0 5.3122175103226255e-08

Thus O 0 1.1161207112309057e-05
, O 0 5.1601425354874664e-08
a O 0 7.784620059680947e-09
total O 0 4.207231896202757e-09
of O 0 7.741970953212274e-10
45 O 0 3.556481686928237e-08
mutations O 0 7.641410206815635e-07
were O 0 1.0877199230208134e-07
identified O 0 2.3363701018297434e-07
in O 0 2.6117831453120743e-08
tumors B-Disease 1 1.0
of O 0 1.1836622348937453e-08
36 O 0 2.440187472529942e-06
patients O 0 8.822124186735891e-07
. O 0 1.4880077969792183e-07

Thirty O 0 0.00014500624092761427
- O 0 4.0587146941106766e-05
nine O 0 1.310566233314603e-07
of O 0 1.5169322464814172e-09
the O 0 6.229020410586372e-09
mutations O 0 1.7418433344573714e-06
- O 0 2.651858608260227e-07
including O 0 5.245440970469417e-09
34 O 0 7.513234123734946e-08
small O 0 1.780836633713534e-08
mutations O 0 2.203873918915633e-05
, O 0 3.575892915108625e-09
2 O 0 3.224873923457494e-09
large O 0 2.65294186618803e-09
structural O 0 3.894184374075849e-06
alterations O 0 7.950599865580443e-06
, O 0 1.6346893616514535e-08
and O 0 6.868972501905546e-09
hypermethylation O 0 2.7218197828915436e-06
in O 0 1.2009567562643042e-08
3 O 0 1.1570683454920072e-05
tumors O 1 1.0
- O 0 0.021288888528943062
were O 0 2.1923365238762926e-06
not O 0 9.923842192449683e-09
detected O 0 8.597682921163141e-08
in O 0 5.284582216269484e-10
the O 0 1.9178967303190575e-09
corresponding O 0 1.5149197452046792e-07
peripheral O 0 9.187877003569156e-05
blood O 0 1.9638362573459744e-05
DNA O 0 3.5296509395266185e-06
. O 0 1.979903885285239e-07

In O 0 1.2198235026517068e-06
6 O 0 1.4187761507855612e-06
( O 0 1.9603406897772402e-08
17 O 0 2.8923148320814107e-08
% O 0 5.747994080707031e-09
) O 0 2.1335196109806276e-10
of O 0 1.579261721396108e-10
the O 0 6.367913307769868e-09
36 O 0 2.8488761927292217e-07
patients O 0 6.915142591878976e-08
, O 0 6.413570785568368e-10
a O 0 4.03582012253878e-09
mutation O 0 1.675987050475669e-06
was O 0 1.8531274292854505e-07
detected O 0 1.3464969583765196e-07
in O 0 1.2859949771737433e-09
constitutional O 0 8.742805590600256e-09
DNA O 0 6.712466529279482e-07
, O 0 8.80697470506675e-09
and O 0 1.1940339383897935e-08
1 O 0 1.8941717083720278e-09
of O 0 1.7235966820461357e-10
these O 0 2.7009250391785145e-09
mutations O 0 7.643684512004256e-07
is O 0 9.16477171930552e-10
known O 0 3.036140894252526e-09
to O 0 4.294665956194876e-09
be O 0 4.273178788594123e-08
associated O 0 4.078833271137228e-08
with O 0 1.502933599795142e-08
reduced O 0 3.0366027203854173e-06
expressivity O 0 0.0003374793741386384
. O 0 4.985400892110192e-07

The O 0 3.450165877438849e-07
presence O 0 1.1579910363934687e-07
of O 0 2.2014476908083225e-09
a O 0 9.646683452047e-09
constitutional O 0 3.625022770847863e-08
mutation O 0 2.6778800474858144e-06
was O 0 2.5315773655165685e-07
not O 0 4.528351915666917e-09
associated O 0 2.925397035724586e-09
with O 0 5.371295075384808e-10
an O 0 1.8077209729128185e-09
early O 0 2.0933300959313783e-07
age O 0 1.0758050166259636e-06
at O 0 2.0526536559373199e-07
treatment O 0 4.0607628193356504e-07
. O 0 6.536506447218926e-08

In O 0 1.1020578085663146e-06
1 O 0 5.251409902484738e-07
patient O 0 1.6435956240457017e-06
, O 0 4.470058101446739e-09
somatic O 0 1.3159268519302714e-06
mosaicism O 0 2.098323602695018e-05
was O 0 7.306471729862096e-07
demonstrated O 0 3.0054099653398225e-08
by O 0 5.438373640309635e-10
molecular O 0 1.1249305487126549e-08
analysis O 0 1.2098151813688673e-08
of O 0 1.990656084416287e-09
DNA O 0 2.0207221496093553e-07
and O 0 2.0573368786358515e-08
RNA O 0 1.7804197227633267e-07
from O 0 2.5996561348051728e-08
peripheral O 0 0.00027411655173636973
blood O 0 0.0001505732798250392
. O 0 5.001668341719778e-07

In O 0 7.558970764875994e-07
2 O 0 1.3647895684698597e-06
patients O 0 1.1183774404344149e-05
without O 0 3.632040801448966e-08
a O 0 4.1163161768054124e-08
detectable O 0 0.006332160905003548
mutation O 0 5.155763574293815e-06
in O 0 6.260703511173915e-09
peripheral O 0 0.0007863217615522444
blood O 0 0.00036960880970582366
, O 0 9.322516092424848e-09
mosaicism O 0 3.499759714031825e-06
was O 0 2.469883497724368e-07
suggested O 0 3.135993154046446e-08
because O 0 1.5610540637922554e-09
1 O 0 3.2738450839175925e-10
of O 0 1.1415247913593163e-10
the O 0 1.0955482743213452e-08
patients O 0 8.144212415572838e-07
showed O 0 1.622984382265713e-05
multifocal O 1 0.9998972415924072
tumors B-Disease 1 1.0
and O 0 3.472049741048977e-07
the O 0 6.10821349056323e-09
other O 0 4.064200531672668e-09
later O 0 7.009224844978235e-08
developed O 0 2.5180236207233975e-07
bilateral B-Disease 0 2.3970944766915636e-06
retinoblastoma I-Disease 0 8.629218791611493e-05
. O 0 3.2559145779487153e-07

In O 0 5.772260465164436e-07
conclusion O 0 1.6221190435317112e-07
, O 0 7.113791777868528e-09
our O 0 1.641979707756036e-08
results O 0 1.4017514260444841e-08
emphasize O 0 8.204967372194005e-08
that O 0 1.2944481042609368e-09
the O 0 1.2773339053140376e-09
manifestation O 0 2.838082480138837e-08
and O 0 6.848995592889651e-09
transmissibility O 0 1.0542743922314912e-07
of O 0 1.151626682904805e-09
retinoblastoma B-Disease 0 2.657182278653636e-07
depend O 0 3.0526219774174024e-08
on O 0 8.248271399224905e-09
the O 0 2.4712856205866274e-09
nature O 0 3.6889538090889573e-09
of O 0 2.209607358194532e-10
the O 0 2.337687599052174e-09
first O 0 5.337374275882212e-08
mutation O 0 2.706212569592026e-07
, O 0 1.110806668869202e-09
its O 0 6.427090526450741e-10
time O 0 4.8600936608522716e-09
in O 0 4.281348886525649e-10
development O 0 1.149568107372545e-09
, O 0 8.318574162835546e-10
and O 0 1.616423772610176e-09
the O 0 2.6211124937169927e-10
number O 0 7.491733899911424e-10
and O 0 8.858657141175286e-10
types O 0 1.1988695369780089e-08
of O 0 7.85420561921768e-10
cells O 0 2.2339508021218535e-08
that O 0 3.406559756502503e-10
are O 0 2.797685860755905e-09
affected O 0 2.8101480253894806e-08
. O 0 2.194450621217925e-09
. O 0 2.8614715930075363e-08

Hereditary B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999946355819702
of I-Disease 0 5.419999382638707e-08
the I-Disease 0 7.489898479207113e-08
fifth I-Disease 0 8.689624451108102e-07
component I-Disease 0 1.00450392892526e-07
of I-Disease 0 2.0659436383851926e-09
complement I-Disease 0 1.5512475215473387e-07
in O 0 1.6241816780393492e-08
man O 0 1.8677236539588193e-06
. O 0 5.256380219975654e-08

I O 0 0.004206122364848852
. O 0 7.368965270870831e-06

Clinical O 0 0.027201084420084953
, O 0 3.5696396594175894e-07
immunochemical O 0 8.945597073761746e-06
, O 0 2.667993825866688e-08
and O 0 2.415799471577884e-08
family O 0 1.7153870146557892e-07
studies O 0 4.2802224697879865e-07
. O 0 2.6731672164714837e-07

The O 0 4.1891337332344847e-07
first O 0 8.152117203508169e-08
recognized O 0 5.514831613595561e-08
human O 0 2.0900420949487852e-08
kindred O 0 1.3220251275924966e-06
with O 0 1.3680039501196006e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9862480759620667
of I-Disease 0 1.4951530014073455e-09
the I-Disease 0 1.7193299228779324e-08
fifth I-Disease 0 3.7780039292556467e-06
component I-Disease 0 2.4226335426646983e-07
of I-Disease 0 3.2236440183908144e-09
complement I-Disease 0 6.892295232319157e-07
( O 0 4.3958589657222547e-08
C5 O 0 2.6823142889043083e-06
) O 0 8.146300523037553e-09
is O 0 4.821168353430494e-09
described O 0 2.886876018237672e-07
. O 0 1.2610253463662957e-07

The O 0 8.295842803818232e-07
proband O 0 1.3864027096133213e-05
, O 0 1.1596969606841867e-08
a O 0 1.2170592533777835e-08
20 O 0 2.1144488826507768e-08
- O 0 5.2656127991213e-07
year O 0 1.3253202091334515e-08
- O 0 2.429316054985975e-06
old O 0 2.5052306682482595e-06
black O 0 2.676220560715592e-07
female O 0 7.053353101582616e-07
with O 0 2.030870064118062e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999946355819702
erythematosus I-Disease 1 1.0
since O 0 3.8207048191907234e-07
age O 0 5.892859462619526e-07
11 O 0 2.3167554985548122e-08
, O 0 2.067390258986279e-09
lacked O 0 1.5498457059948123e-06
serum O 0 1.0441087397339288e-05
hemolytic O 0 3.583606667234562e-05
complement O 0 2.4258935127363657e-07
activity O 0 3.2872708288778085e-07
, O 0 5.821220838697627e-09
even O 0 2.9740920837184603e-08
during O 0 2.846966822289687e-07
remission O 0 8.57400391396368e-06
. O 0 1.6631919663723238e-07

C5 O 0 0.0032801132183521986
was O 0 4.265096504241228e-05
undetectable O 0 7.994211046025157e-05
in O 0 6.178791522870597e-08
her O 0 3.875109939599497e-07
serum O 0 1.5209360526569071e-06
by O 0 4.53249082710272e-09
both O 0 2.7189241080805004e-08
immunodiffusion O 0 2.7852929633809254e-05
and O 0 4.0793281641526846e-07
hemolytic O 0 0.0004227213794365525
assays O 0 5.723500726162456e-05
. O 0 4.94643416004692e-07

Other O 0 4.0032165316006285e-07
complement O 0 1.3082762961857952e-06
components O 0 1.1688269978549215e-06
were O 0 1.1679417610821474e-07
normal O 0 8.433607945335098e-08
during O 0 7.693871140190822e-08
remission O 0 4.420865877818869e-07
of O 0 5.30087884698105e-09
lupus O 0 6.111354741733521e-05
, O 0 1.0449847209770269e-08
but O 0 2.0782794152296447e-08
C1 O 0 0.0002609051007311791
, O 0 9.790898758410549e-09
C4 O 0 1.6988427660180605e-06
, O 0 1.5318018853349713e-08
C2 O 0 1.74664419319015e-05
, O 0 9.809386192216607e-09
and O 0 3.52863018804328e-08
C3 O 0 6.824210868217051e-05
levels O 0 2.9516530048567802e-05
fell O 0 0.00016313443484250456
during O 0 1.1902932328666793e-06
exacerbations O 0 0.0003891044470947236
. O 0 3.227066542876855e-07

A O 0 1.087338023353368e-05
younger O 0 1.0320410183339845e-05
half O 0 8.311863552989962e-07
- O 0 8.56726910569705e-06
sister O 0 1.3026518900005613e-05
, O 0 6.896633042430267e-09
who O 0 4.8966636967406885e-08
had O 0 2.254736415352454e-07
no O 0 3.7230583416203444e-07
underlying O 0 0.0006497768335975707
disease O 0 0.00356676010414958
, O 0 2.6410720277425526e-09
was O 0 1.1000442157182988e-07
also O 0 1.0940510719592567e-08
found O 0 6.476822633771917e-09
to O 0 6.708023025936427e-09
lack O 0 3.7386785152193625e-06
immunochemically O 0 0.000857560255099088
detectable O 0 0.011730638332664967
C5 O 0 0.00010470560664543882
. O 0 5.028863938605355e-07

By O 0 3.02141961583402e-06
hemolytic O 0 0.0021545288618654013
assay O 0 3.139867840218358e-05
, O 0 3.327536717279145e-07
she O 0 4.83998519484885e-07
exhibited O 0 5.676692467204703e-07
1 O 0 1.7318367184770977e-08
- O 0 6.058514827600447e-07
2 O 0 3.263013681475968e-08
% O 0 3.5715101986966147e-09
of O 0 3.1602062633417916e-10
the O 0 1.518948167245071e-08
normal O 0 5.828645157635037e-07
serum O 0 1.0633191322995117e-06
C5 O 0 1.379751665808726e-06
level O 0 3.501511685044534e-07
and O 0 2.8964885601112655e-08
normal O 0 8.891674951883033e-08
concentrations O 0 7.74383863699768e-08
of O 0 6.662168039461847e-10
other O 0 3.3380738173605096e-09
complement O 0 2.3616976818630064e-07
components O 0 5.229652742855251e-06
. O 0 2.440210096210649e-07

C5 O 0 0.0004921765066683292
levels O 0 3.531415359248058e-06
of O 0 3.6676466308449562e-09
other O 0 1.8659973566315102e-09
family O 0 6.0517155731076855e-09
members O 0 3.785593172267454e-09
were O 0 1.076763140872572e-07
either O 0 5.900806598901909e-08
normal O 0 1.6576639438881102e-07
or O 0 1.4228110956082674e-07
approximately O 0 1.9530929762368032e-08
half O 0 2.239548706484129e-07
- O 0 2.107970794895664e-05
normal O 0 1.6865162706380943e-06
, O 0 5.0393555994787675e-09
consistent O 0 3.644021262516617e-07
with O 0 2.3144234972960476e-08
autosomal O 0 0.0015335599891841412
codominant O 0 5.193543984205462e-06
inheritance O 0 2.3281337746539066e-07
of O 0 2.682207567161754e-09
the O 0 3.4009538296686515e-08
gene O 0 3.60936792276334e-05
determining O 0 0.011612380854785442
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.2076350230927346e-06

Normal O 0 0.0025224867276847363
hemolytic O 0 0.24969415366649628
titers O 0 0.0016203699633479118
were O 0 1.4466071661445312e-05
restored O 0 8.557140063203406e-07
to O 0 2.734839554818791e-08
both O 0 1.5205821455310797e-06
homozygous O 1 0.9999113082885742
C5 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
( O 0 1.4740583537786733e-05
C5D B-Disease 1 1.0
) O 0 9.603305528571582e-08
sera O 0 3.6309120332589373e-07
by O 0 9.663638778079076e-10
addition O 0 1.1676021260953462e-09
of O 0 9.846796711343586e-10
highly O 0 1.7867080259748036e-07
purified O 0 9.151021345132904e-07
human O 0 1.639849216417133e-07
C5 O 0 1.3672563000000082e-05
. O 0 4.988453952137206e-07

In O 0 3.583788270589139e-07
specific O 0 5.997583798489359e-07
C5 O 0 1.9025035726372153e-05
titrations O 0 2.179883813369088e-05
, O 0 2.572625490415703e-08
however O 0 8.883991320374207e-09
, O 0 2.4124457986829384e-09
it O 0 2.208243587986658e-09
was O 0 4.2419305401608653e-08
noted O 0 3.175773199970422e-09
that O 0 2.6033650235568473e-10
when O 0 1.068280908178565e-09
limited O 0 9.782680221448459e-10
amounts O 0 5.964325144880434e-10
of O 0 3.984844954008082e-10
C5 O 0 1.2071641322108917e-06
were O 0 1.17754225925637e-07
assayed O 0 5.161678586773633e-07
in O 0 1.2720239306318604e-09
the O 0 1.2846906871644137e-09
presence O 0 3.906357015637241e-09
of O 0 7.420457026618976e-10
low O 0 1.1128471442134469e-06
dilutions O 0 1.80523284143419e-06
of O 0 1.2808305527300945e-08
either O 0 3.414310049265623e-05
C5D B-Disease 1 1.0
serum O 0 5.7511962950229645e-05
, O 0 7.384597822124306e-09
curving O 0 3.040576075363788e-07
rather O 0 1.886651368465664e-08
than O 0 1.9813151119763006e-09
linear O 0 4.0498019160395415e-08
dose O 0 1.2525733836810105e-06
- O 0 2.5519732389511773e-06
response O 0 5.8001884184477603e-08
plots O 0 5.176961508368549e-07
were O 0 1.9421993329160614e-06
consistently O 0 5.158350631973008e-06
obtained O 0 2.0550464441271288e-08
, O 0 1.4138230586269174e-09
suggesting O 0 1.3075133864504096e-08
some O 0 1.2683559758031038e-09
inhibitory O 0 2.3240609436925297e-07
effect O 0 2.4490341843375063e-07
. O 0 1.0404188799384428e-07

Further O 0 4.212636667944025e-06
studies O 0 7.582971193187404e-07
suggested O 0 1.92182355363002e-07
that O 0 1.2517592296035218e-08
low O 0 5.6966018746607006e-06
dilutions O 0 2.5345358153572306e-05
of O 0 2.3552941286197893e-07
C5D B-Disease 1 1.0
serum O 0 0.00029029976576566696
contain O 0 5.355735765988356e-07
a O 0 4.291483080010039e-08
factor O 0 1.1031265501060261e-07
( O 0 3.4379712410270713e-09
or O 0 3.53904390237858e-08
factors O 0 4.3578086916795655e-08
) O 0 1.5132506359094577e-09
interfering O 0 3.1303937220172884e-08
at O 0 2.0290638502729053e-08
some O 0 5.770048328024302e-10
step O 0 9.51120959769014e-09
in O 0 1.2118607228828182e-09
the O 0 7.74755903876212e-09
hemolytic O 0 4.994422397430753e-06
assay O 0 2.500632945157122e-07
of O 0 3.6321774476988367e-09
C5 O 0 6.069263690733351e-06
, O 0 4.904494144142291e-09
rather O 0 9.303722237063994e-09
than O 0 1.8682659863600293e-09
a O 0 1.0473352851647633e-08
true O 0 1.3617845695534925e-07
C5 O 0 5.343727934814524e-06
inhibitor O 0 1.3705925994145218e-06
or O 0 7.661360541533213e-07
inactivator O 0 2.8532222131616436e-05
. O 0 6.563753913724213e-07

Of O 0 4.905034529656405e-07
clinical O 0 3.7180394429014996e-05
interest O 0 2.3453061714917567e-07
are O 0 6.035958932670837e-08
( O 0 5.440627948161136e-09
a O 0 1.0398509608933182e-08
) O 0 1.2876983923604257e-09
the O 0 7.201254037525473e-10
documentation O 0 1.5053642243856302e-07
of O 0 1.3897450301669778e-08
membranous O 1 0.994939923286438
glomerulonephritis B-Disease 1 1.0
, O 0 6.555574145750143e-06
vasculitis B-Disease 1 1.0
, O 0 4.870016141467204e-07
and O 0 0.0001585900754434988
arthritis B-Disease 1 1.0
in O 0 1.6059331642281904e-08
an O 0 1.0014847617867417e-08
individual O 0 1.608777466799438e-07
lacking O 0 3.08536641568935e-06
C5 O 0 1.990311375266174e-06
( O 0 5.2226192259752224e-09
and O 0 2.180976954591074e-09
its O 0 2.618255834363481e-09
biologic O 0 1.3054393832589994e-07
functions O 0 8.018845676360797e-08
) O 0 6.807826302690501e-09
, O 0 1.899247425996009e-09
and O 0 2.728269699048269e-08
( O 0 2.3194171916429696e-08
b O 0 1.6749244196034851e-06
) O 0 5.860332219498332e-10
a O 0 2.5627704403063944e-09
remarkable O 0 3.1395664734645834e-08
propensity O 0 1.2566187024276587e-06
to O 0 1.2888339142591576e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.7072325775302488e-08
the O 0 1.1198440397208742e-08
proband O 0 3.829616161965532e-06
, O 0 1.5484510340613156e-09
even O 0 2.5239430545553887e-09
during O 0 1.3503672846582049e-08
periods O 0 7.00305022860448e-08
of O 0 3.6434175676447467e-09
low O 0 0.0008753343136049807
- O 0 4.4363194319885224e-05
dose O 0 1.8047061303150258e-06
or O 0 6.747021075170778e-08
alternate O 0 1.1232500440883086e-07
- O 0 4.243073817633558e-06
day O 0 3.3053527204174316e-07
corticosteroid O 0 0.00014394040044862777
therapy O 0 5.230636088526808e-05
. O 0 3.682808085159195e-07

Other O 0 3.587549883832253e-07
observations O 0 1.8463040305505274e-06
indicate O 0 2.3323279947362607e-06
that O 0 1.7975034793948907e-08
the O 0 1.206957591648461e-07
C5D B-Disease 1 1.0
state O 0 5.3029824975681095e-09
is O 0 1.103194979812372e-09
compatible O 0 5.086987187041814e-08
with O 0 8.552145658313748e-09
normal O 0 2.1890345180963777e-07
coagulation O 0 1.4054705843591364e-07
function O 0 9.090111774412435e-08
and O 0 1.0075392076203116e-08
the O 0 1.5589415314209987e-09
capacity O 0 6.854013800960956e-09
to O 0 2.2198058946543142e-09
mount O 0 1.0952808224828914e-06
a O 0 7.011557272562641e-07
neutrophilic O 1 0.5385254621505737
leukocytosis O 0 0.0008991400827653706
during O 0 7.72863222664455e-06
pyogenic B-Disease 1 0.8348753452301025
infection I-Disease 0 0.4521603286266327
. O 0 1.0463752886380462e-07
. O 0 2.1724302712300414e-07

Susceptibility O 0 0.012945418246090412
to O 0 0.00010043558722827584
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.00017688270600046962
twins O 0 0.023947862908244133
: O 0 3.843594775787551e-09
the O 0 9.927018096433926e-10
role O 0 5.856066742637722e-09
of O 0 5.425444538076363e-10
genes O 0 6.545738528984657e-08
, O 0 2.761528783423728e-09
HLA O 0 1.504170228372459e-07
, O 0 2.7603015428923072e-09
and O 0 6.902634019922971e-09
the O 0 2.7618199283097056e-08
environment O 0 6.788119435441331e-07
. O 0 6.117065254329646e-08

OBJECTIVE O 0 1.3240401131042745e-05
To O 0 5.2155346708104844e-08
determine O 0 9.236078568619632e-08
the O 0 3.2785834047643903e-09
relative O 0 1.1148447498499081e-07
effects O 0 9.796317499422003e-07
of O 0 8.188919542462259e-10
genetic O 0 9.524073334432615e-07
and O 0 1.0027845220861309e-08
environmental O 0 1.88352320407148e-08
factors O 0 1.5813492737493107e-08
in O 0 6.996759616129111e-09
susceptibility O 0 6.9623944000341e-05
to O 0 6.334277713904157e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.005654535721987486
AS B-Disease 1 0.999998927116394
) O 0 8.86255264731517e-08
. O 0 7.999779683132147e-08

METHODS O 0 0.0007010962581261992
Twins O 0 0.10366353392601013
with O 0 3.4120881764465594e-07
AS B-Disease 1 0.9999995231628418
were O 0 3.2076486604637466e-06
identified O 0 8.915620242078148e-08
from O 0 1.285499706682458e-09
the O 0 2.082460648367146e-09
Royal O 0 2.2530426235789491e-07
National O 0 3.39446415864586e-07
Hospital O 0 1.9029145050808438e-06
for O 0 3.350897870291192e-08
Rheumatic B-Disease 1 0.9964504241943359
Diseases I-Disease 0 0.00028974260203540325
database O 0 4.6135303932715033e-07
. O 0 2.067459092813806e-07

Clinical O 0 0.0040250541642308235
and O 0 7.970648994160001e-07
radiographic O 0 0.0002774288586806506
examinations O 0 0.013795371167361736
were O 0 7.061503310978878e-06
performed O 0 9.353132668366015e-07
to O 0 1.2721677933313913e-08
establish O 0 2.1892840322834672e-06
diagnoses O 1 0.7382217049598694
, O 0 9.505772879947472e-08
and O 0 6.417942131520249e-06
disease O 1 0.8559902906417847
severity O 0 0.00024393026251345873
was O 0 1.0454949688210036e-06
assessed O 0 5.840052352823477e-08
using O 0 1.3241781005035591e-08
a O 0 1.1185076864705934e-08
combination O 0 1.6617158848930558e-07
of O 0 4.171864631530298e-09
validated O 0 1.2829511888412526e-06
scoring O 0 9.290917660109699e-06
systems O 0 4.571847512124805e-06
. O 0 2.7678746050696645e-07

HLA O 0 0.0005440633394755423
typing O 0 0.00010542223753873259
for O 0 4.310277006425167e-07
HLA O 0 3.085791104240343e-05
- O 0 5.18531987836468e-06
B27 O 0 3.925947567040566e-06
, O 0 4.2136264255532296e-08
HLA O 0 1.4432738453251659e-06
- O 0 1.1288142331977724e-06
B60 O 0 1.6007976455512107e-06
, O 0 1.2730683174311253e-08
and O 0 2.250982333862339e-08
HLA O 0 3.6132853438175516e-06
- O 0 1.2306833014008589e-05
DR1 O 0 0.0032173357903957367
was O 0 5.483281029228237e-07
performed O 0 9.28419083834342e-08
by O 0 1.942670690979753e-09
polymerase O 0 1.1738174521269684e-07
chain O 0 6.291525096457917e-07
reaction O 0 1.923715409191118e-08
with O 0 3.0011810814301043e-09
sequence O 0 6.843749389418008e-08
- O 0 7.416021219341928e-08
specific O 0 1.1501762209320532e-08
primers O 0 5.7041202126129065e-06
, O 0 1.7931204965293546e-08
and O 0 2.6447986911648513e-08
zygosity O 0 7.902312063379213e-06
was O 0 1.4761268118945736e-07
assessed O 0 8.559820230402693e-08
using O 0 1.3260920184166025e-07
microsatellite O 0 5.2057996072107926e-05
markers O 0 8.583883754909039e-05
. O 0 3.5443881074570527e-07

Genetic O 0 0.00018227518012281507
and O 0 1.5036452793992794e-07
environmental O 0 1.0262911587233248e-07
variance O 0 5.592869811721357e-08
components O 0 3.558376192813739e-06
were O 0 1.394720925418369e-06
assessed O 0 1.2522278325377556e-07
with O 0 1.6247324596818657e-09
the O 0 3.701880357809273e-09
program O 0 3.063143694248538e-08
Mx O 0 3.840812496491708e-06
, O 0 1.5669965325315616e-09
using O 0 5.77465320006354e-09
data O 0 8.845631072063043e-08
from O 0 1.5486164572919847e-09
this O 0 3.144369487007026e-10
and O 0 3.93289711908551e-09
previous O 0 1.4077886589802802e-07
studies O 0 1.24072281337817e-08
of O 0 2.555633926704104e-09
twins O 0 9.798207611311227e-05
with O 0 4.880513770899597e-08
AS B-Disease 1 0.9999966621398926
. O 0 2.494756756732386e-07

RESULTS O 0 0.00012357719242572784
Six O 0 4.0721721461522975e-07
of O 0 7.657734890642587e-09
8 O 0 2.381219701419468e-07
monozygotic O 0 1.62979013111908e-05
( O 0 1.7652810413437692e-07
MZ O 1 0.9931414723396301
) O 0 4.185958246694099e-08
twin O 0 5.288016836857423e-05
pairs O 0 1.1519694453454576e-05
were O 0 2.4488164854119532e-05
disease O 0 7.178020314313471e-05
concordant O 0 6.085261929911212e-07
, O 0 9.983607718311305e-09
compared O 0 2.492884476623658e-08
with O 0 3.4102538570834895e-09
4 O 0 1.7602975077579686e-08
of O 0 2.1136172811964116e-09
15 O 0 1.1732668525610279e-07
B27 O 0 5.2431760195759125e-06
- O 0 1.88890153367538e-05
positive O 0 5.284699113872193e-07
dizygotic O 0 1.5502415408263914e-05
( O 0 1.0951475104548081e-07
DZ O 0 0.00039132393430918455
) O 0 1.94796623276261e-08
twin O 0 7.732407539151609e-06
pairs O 0 4.5912992163721356e-07
( O 0 1.2796438575435332e-08
27 O 0 5.075841968960049e-08
% O 0 8.888415337082733e-09
) O 0 1.0112274351214978e-09
and O 0 2.653650188477741e-09
4 O 0 5.405614622588928e-09
of O 0 1.5964283228697695e-09
32 O 0 1.604820909051341e-06
DZ O 1 0.7944357395172119
twin O 0 0.0007532773888669908
pairs O 0 3.514650416036602e-06
overall O 0 2.64535424321366e-06
( O 0 7.724922923557642e-09
12 O 0 7.992668749068343e-09
. O 0 7.305204219321126e-10
5 O 0 4.674441722585243e-09
% O 0 7.815490477014464e-09
) O 0 5.158949267780599e-09
. O 0 3.2759285062411436e-08

Nonsignificant O 0 0.0005676305154338479
increases O 0 4.468391580303432e-06
in O 0 8.92293172682912e-09
similarity O 0 2.3986549635424126e-08
with O 0 1.4366190459469408e-09
regard O 0 1.5445374756950514e-08
to O 0 1.105521008071264e-08
age O 0 4.9273326112597715e-06
at O 0 5.138273991178721e-06
disease O 0 0.0005506898160092533
onset O 0 6.736670002283063e-06
and O 0 9.888716512307383e-09
all O 0 1.0877686529298103e-09
of O 0 5.909405187409789e-10
the O 0 2.965452097214438e-07
disease O 0 0.008830862119793892
severity O 0 5.279629021970322e-06
scores O 0 2.374426230744575e-06
assessed O 0 3.419779375235521e-07
were O 0 9.600962158629045e-08
noted O 0 3.79078315404513e-08
in O 0 5.489005161507521e-08
disease O 0 0.040525030344724655
- O 0 0.002298944164067507
concordant O 0 0.017267147079110146
MZ O 1 0.9999943971633911
twins O 0 0.0006427047774195671
compared O 0 6.625285209338472e-07
with O 0 1.9993564137621433e-07
concordant O 0 0.00034866071655415
DZ O 1 0.998979389667511
twins O 0 0.0006985857617110014
. O 0 4.573844307742547e-07

HLA O 0 0.004927885252982378
- O 0 0.0002929170150309801
B27 O 0 1.1870728485519066e-05
and O 0 7.719020800323051e-08
B60 O 0 9.686101520856027e-07
were O 0 5.551653714519489e-08
associated O 0 8.949060159579858e-09
with O 0 1.2585528175179661e-09
the O 0 1.0103222081170316e-07
disease O 0 4.1047544073080644e-05
in O 0 1.559027795750012e-09
probands O 0 3.6497604014584795e-06
, O 0 6.871763158500244e-09
and O 0 5.02282215819605e-09
the O 0 5.764748678416254e-09
rate O 0 6.990345582380542e-07
of O 0 4.036682099695099e-09
disease O 0 7.421131613227772e-06
concordance O 0 4.233984896018228e-07
was O 0 1.7998559087573085e-07
significantly O 0 1.7357464798806177e-07
increased O 0 1.4901479516993277e-07
among O 0 3.697627093401934e-08
DZ O 0 0.04410865157842636
twin O 0 7.007582462392747e-05
pairs O 0 2.356995167929199e-07
in O 0 3.227101252889497e-09
which O 0 7.32425187166541e-09
the O 0 1.99759480068451e-08
co O 0 0.00010840003233170137
- O 0 2.9555909350165166e-05
twin O 0 0.005995020270347595
was O 0 1.8852256289392244e-07
positive O 0 4.875896575384786e-09
for O 0 5.131839952987605e-10
both O 0 1.4136430692701651e-08
B27 O 0 1.2334422763160546e-06
and O 0 8.603686296737578e-08
DR1 O 0 0.0015713156899437308
. O 0 4.132341189233557e-07

Additive O 0 4.5797827624483034e-05
genetic O 0 2.804376526910346e-05
effects O 0 1.2840154340665322e-05
were O 0 4.654097836009896e-07
estimated O 0 2.2291326118306642e-08
to O 0 3.237322632188011e-09
contribute O 0 3.550334781721176e-08
97 O 0 4.333291414582163e-08
% O 0 7.205448682157112e-09
of O 0 3.7913866490768555e-10
the O 0 4.14780787494351e-09
population O 0 5.755322440847976e-09
variance O 0 5.7199013525632836e-08
. O 0 5.478671383229994e-08

CONCLUSION O 0 1.2380003681755625e-05
Susceptibility O 0 2.8452743208617903e-05
to O 0 5.463200523081468e-07
AS B-Disease 1 0.9999954700469971
is O 0 1.956698447713734e-08
largely O 0 3.832688832972053e-08
genetically O 0 3.543724957921768e-08
determined O 0 4.032344236293284e-08
, O 0 6.57325804898079e-10
and O 0 1.9348718183209712e-09
the O 0 1.5927177354768673e-09
environmental O 0 2.073737626062666e-08
trigger O 0 1.0783081734189182e-06
for O 0 2.9874853701983284e-09
the O 0 2.2710123914748692e-07
disease O 0 9.277769277105108e-05
is O 0 2.4297166500986123e-09
probably O 0 5.760014687439252e-08
ubiquitous O 0 1.8392235006103874e-06
. O 0 9.345502860469423e-08

HLA O 0 0.00603343453258276
- O 0 0.00041865778621286154
B27 O 0 1.4288677448348608e-05
accounts O 0 2.6305343681087834e-07
for O 0 3.2242710723551227e-09
a O 0 4.698854194629121e-09
minority O 0 1.897680590445816e-08
of O 0 3.833723061230643e-10
the O 0 6.995331869319443e-09
overall O 0 9.948527122105588e-07
genetic O 0 7.049822215776658e-06
susceptibility O 0 2.6385566798126092e-06
to O 0 1.6475442521368677e-07
AS B-Disease 1 0.9999984502792358
. O 0 4.575082925839524e-07

Cell O 0 0.0019727544859051704
cycle O 0 0.00014493519847746938
- O 0 1.4125365851214156e-05
dependent O 0 2.2494409677165095e-06
colocalization O 0 1.0015918405770208e-06
of O 0 5.91240700842377e-09
BARD1 O 0 8.715372132428456e-06
and O 0 2.5169544670688992e-08
BRCA1 O 0 9.553151357977185e-06
proteins O 0 2.7864556884082958e-08
in O 0 3.2767641933162395e-09
discrete O 0 3.1616147566637665e-07
nuclear O 0 1.4859283510304522e-05
domains O 0 5.629650331684388e-06
. O 0 6.285545737227949e-07

Germ O 0 0.053809307515621185
- O 0 0.012013886123895645
line O 0 4.8898196837399155e-05
mutations O 0 9.640788221076946e-07
of O 0 8.813691998454942e-10
the O 0 6.188968448839205e-09
BRCA1 O 0 2.3061249521560967e-05
gene O 0 5.453658786791493e-07
predispose O 0 6.103604732743406e-07
women O 0 5.3521461040872964e-08
to O 0 6.646458494685703e-09
early O 0 5.686570148100145e-07
- O 1 0.8605908751487732
onset O 1 0.9999948740005493
breast B-Disease 1 1.0
and I-Disease 1 0.9999949932098389
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 8.993566780191031e-09
compromising O 0 2.3375250748358667e-06
the O 0 9.321627025826729e-09
genes O 0 6.882947900521685e-07
presumptive O 0 1.787099063221831e-05
function O 0 1.3421625055798359e-07
as O 0 2.8711646393730916e-08
a O 0 2.335815310061662e-07
tumor B-Disease 0 1.832166890380904e-05
suppressor O 0 1.6905381926335394e-05
. O 0 2.8467877655202756e-07

Although O 0 1.9800256723101484e-06
the O 0 3.107111368194637e-08
biochemical O 0 4.806338438356761e-07
properties O 0 6.586415679521451e-08
of O 0 2.9721398675519595e-09
BRCA1 O 0 3.6305740650277585e-05
polypeptides O 0 2.5833259087448823e-07
are O 0 7.187330286484439e-09
not O 0 9.611145657117959e-09
understood O 0 2.8516915051568503e-08
, O 0 8.157227116001309e-10
their O 0 6.997440404887811e-09
expression O 0 4.615483817360655e-08
pattern O 0 5.611466349364491e-07
and O 0 2.0239578901737332e-08
subcellular O 0 6.910664978931891e-06
localization O 0 1.2633414598894888e-06
suggest O 0 1.0100042402427789e-07
a O 0 1.2546586880546329e-08
role O 0 8.00927608679558e-08
in O 0 9.234525144563577e-09
cell O 0 5.86567784921499e-06
- O 0 4.9767986638471484e-05
cycle O 0 6.036672402842669e-06
regulation O 0 1.6080011846497655e-06
. O 0 1.1604574723378391e-07

When O 0 8.644752597319894e-06
resting O 0 2.37331296375487e-05
cells O 0 4.976546392754244e-07
are O 0 7.679558322593039e-09
induced O 0 2.5854873797470646e-07
to O 0 8.598466827436368e-09
proliferate O 0 2.6831305603991495e-06
, O 0 3.989044650154483e-09
the O 0 3.022954775389053e-09
steady O 0 1.5248980389515054e-06
- O 0 2.1958506124519772e-07
state O 0 2.011986577343805e-09
levels O 0 1.4634632172771944e-08
of O 0 3.9707179211312393e-10
BRCA1 O 0 2.1159523555525084e-07
increase O 0 4.273021936285204e-09
in O 0 2.9828679526389124e-09
late O 0 2.488086714436122e-08
G1 O 0 1.6074232007667888e-06
and O 0 1.7338926738830196e-08
reach O 0 2.9750452767984825e-08
a O 0 8.95503671216602e-09
maximum O 0 9.55091721266399e-08
during O 0 4.1962547925322724e-07
S O 0 5.463557317852974e-05
phase O 0 9.916747103488888e-07
. O 0 2.503620635252446e-07

Moreover O 0 6.2774856814939994e-06
, O 0 3.696054662327697e-08
in O 0 1.1432865321125973e-08
S O 0 6.553236289619235e-06
phase O 0 4.019643427000119e-07
cells O 0 1.696154185992782e-07
, O 0 3.6856482310554384e-09
BRCA1 O 0 1.5306839031836716e-06
polypeptides O 0 2.7081904363512876e-07
are O 0 8.091034509050132e-09
hyperphosphorylated O 0 6.795322065045184e-07
and O 0 3.572472451196518e-08
accumulate O 0 9.621317076380365e-07
into O 0 1.7956256925799607e-08
discrete O 0 7.614944479428232e-07
subnuclear O 0 5.767793481936678e-05
foci O 0 6.016939369146712e-05
termed O 0 1.0273707630403806e-05
" O 0 5.468407948683307e-07
BRCA1 O 0 3.257095886510797e-05
nuclear O 0 1.0985480003000703e-05
dots O 0 4.700839053839445e-05
. O 0 4.81548227071471e-07

" O 0 4.4055344915250316e-05
BRCA1 O 0 0.0004984603729099035
associates O 0 7.674196240259334e-06
in O 0 3.2427504237375615e-08
vivo O 0 4.2287292671971954e-06
with O 0 4.967069866523843e-09
a O 0 6.562590471048679e-08
structurally O 0 3.628197009675205e-05
related O 0 7.462191575768884e-08
protein O 0 4.5103212187314057e-07
termed O 0 7.406319582514698e-06
BARD1 O 0 4.845263174502179e-05
. O 0 2.8937259344274935e-07

Here O 0 1.9776516637648456e-06
we O 0 1.2563103268803388e-07
show O 0 4.932340047503203e-08
that O 0 1.5369988615177022e-09
the O 0 6.773981375829408e-09
steady O 0 1.9143271856592037e-06
- O 0 4.656886005705019e-07
state O 0 3.31981309109608e-09
levels O 0 2.7920044942675304e-08
of O 0 6.490459281138783e-10
BARD1 O 0 9.866655545920366e-07
, O 0 4.999507474678921e-10
unlike O 0 2.4382866836702988e-09
those O 0 1.0822597262816203e-09
of O 0 3.5582628510333336e-10
BRCA1 O 0 4.733922196464846e-06
, O 0 1.1165381508249084e-08
remain O 0 4.624066463065901e-08
relatively O 0 2.1375218040020627e-08
constant O 0 1.2383898706502805e-07
during O 0 6.664479883511376e-07
cell O 0 0.00010872031270992011
cycle O 0 4.3070736865047365e-05
progression O 0 1.766083914844785e-05
. O 0 2.885882395275985e-07

However O 0 6.230143299035262e-06
, O 0 1.2701850948815263e-07
immunostaining O 0 9.501342901785392e-06
revealed O 0 8.241966611421958e-07
that O 0 6.156672949231279e-09
BARD1 O 0 5.307059382175794e-06
resides O 0 1.5244502549194294e-07
within O 0 2.5188899854811098e-08
BRCA1 O 0 4.2574552026053425e-06
nuclear O 0 5.357983923204301e-07
dots O 0 1.0054505992229679e-06
during O 0 1.1266283905797536e-07
S O 0 2.2412953057937557e-06
phase O 0 2.1643977277108206e-08
of O 0 1.055017739837183e-09
the O 0 1.231227209075314e-08
cell O 0 2.0309553292463534e-06
cycle O 0 1.2159824791524443e-06
, O 0 4.022248756285762e-09
but O 0 2.2628796614299063e-09
not O 0 1.9913357629519624e-09
during O 0 7.1410624080670004e-09
the O 0 1.1063837845881608e-08
G1 O 0 7.696123248024378e-06
phase O 0 5.332103683031164e-07
. O 0 1.5142379083954438e-07

Nevertheless O 0 0.00012640994100365788
, O 0 5.282079200696899e-07
BARD1 O 0 6.441764980991138e-06
polypeptides O 0 4.5233213086248725e-07
are O 0 1.485823464264513e-08
found O 0 5.803671321302772e-09
exclusively O 0 6.630934912266184e-09
in O 0 5.525175317266928e-10
the O 0 1.234193747201573e-09
nuclear O 0 3.407752302564404e-08
fractions O 0 1.5007938003464005e-08
of O 0 4.872157122193244e-10
both O 0 1.0463688582262876e-08
G1 O 0 4.6477375690301415e-06
- O 0 4.640156021196162e-06
and O 0 2.5540180104144383e-07
S O 0 3.234203904867172e-05
- O 0 1.2023500630675699e-06
phase O 0 8.34142724670528e-07
cells O 0 7.351911222031049e-07
. O 0 6.813168340613629e-08

Therefore O 0 8.538296242477372e-06
, O 0 1.6613547870747425e-07
progression O 0 6.209781417965132e-07
to O 0 2.869768600533007e-08
S O 0 7.403062045341358e-05
phase O 0 4.6077789761511667e-07
is O 0 4.253473573356814e-09
accompanied O 0 1.3014127553390153e-08
by O 0 1.122649306850576e-09
the O 0 1.5065232394917416e-09
aggregation O 0 1.9430606457149224e-08
of O 0 3.256980685151234e-09
nuclear O 0 1.1075196653109742e-06
BARD1 O 0 5.202130068937549e-06
polypeptides O 0 5.978670287731802e-07
into O 0 5.3534730426463284e-08
BRCA1 O 0 4.305985203245655e-05
nuclear O 0 4.145226739638019e-06
dots O 0 2.722699719015509e-05
. O 0 5.092535957373912e-07

This O 0 5.105933382765215e-07
cell O 0 1.4681717402709182e-05
cycle O 0 8.52988159749657e-06
- O 0 6.67391441311338e-06
dependent O 0 1.276138391403947e-06
colocalization O 0 1.7427738612241228e-06
of O 0 6.128040297426196e-09
BARD1 O 0 2.6010729925474152e-05
and O 0 1.495720596267347e-07
BRCA1 O 0 0.00015909990179352462
indicates O 0 3.229794174330891e-07
a O 0 1.4997178610087758e-08
role O 0 5.8409099779055396e-08
for O 0 1.0353861767953276e-08
BARD1 O 0 6.462199053203221e-06
in O 0 4.754979698873285e-08
BRCA1 O 0 0.0013297505211085081
- O 0 0.0003692232130561024
mediated O 0 0.003164122346788645
tumor B-Disease 0 0.0003706723218783736
suppression O 0 5.739052994613303e-06
. O 0 7.592225870212133e-07

Ethnic O 0 1.2059113032591995e-05
differences O 0 8.14360555523308e-06
in O 0 5.581913953278672e-08
the O 0 1.3416517674613715e-07
HFE O 0 0.0008129667839966714
codon O 0 1.143678673543036e-05
282 O 0 3.2092157198349014e-06
( O 0 5.562400247072219e-07
Cys O 0 0.0014154176460579038
/ O 0 8.889110176824033e-05
Tyr O 0 7.146057760110125e-05
) O 0 1.9128820838432148e-07
polymorphism O 0 1.726104528643191e-05
. O 0 9.313620807915868e-07

Recent O 0 9.6288249551435e-07
studies O 0 2.449260989578761e-07
have O 0 8.04286344191496e-08
shown O 0 3.397848900021927e-07
that O 0 1.2144398624513997e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.03888868913054466
HH B-Disease 1 0.9998296499252319
) O 0 1.6221878951228064e-08
is O 0 4.401855768776386e-09
likely O 0 3.234423573417189e-08
to O 0 9.307627557575415e-09
be O 0 1.8544800184372434e-07
caused O 0 2.649611303695565e-07
by O 0 2.9135807100288957e-09
homozygosity O 0 6.747329166501004e-07
for O 0 1.7512279404385822e-09
a O 0 2.83424181901637e-08
Cys282Tyr O 0 7.336233466048725e-06
mutation O 0 5.079498350823997e-07
in O 0 2.442252178269655e-09
the O 0 1.0181332221748107e-08
HFE O 0 3.222544910386205e-05
gene O 0 9.021941878017969e-07
located O 0 2.4026186906667135e-07
4 O 0 3.229030482998496e-07
. O 0 2.1302125219335721e-07

5 O 0 2.6767340386868455e-05
Mb O 0 8.330953278345987e-05
telomeric O 0 0.00015991114196367562
to O 0 1.4396598544408334e-06
HLA O 0 0.0003182812943123281
- O 0 0.00017219973960891366
A O 0 1.8422376797389006e-06
. O 0 3.2460769716635696e-07

Population O 0 1.908173544507008e-06
studies O 0 7.579328098472615e-08
of O 0 2.367992690821552e-09
this O 0 1.5602563685490622e-09
polymorphism O 0 7.381221394098247e-07
are O 0 7.404569402069683e-09
facilitated O 0 3.008220161859754e-08
by O 0 1.8290891024008715e-09
the O 0 1.9464130307511596e-09
fact O 0 4.255250374285424e-09
that O 0 8.625630765202175e-10
the O 0 7.1732926265610786e-09
Cys282Tyr O 0 8.583248927607201e-06
mutation O 0 1.2148905170761282e-06
creates O 0 6.423835685609447e-08
a O 0 5.144792325495473e-08
Rsal O 0 2.6159166282013757e-06
restriction O 0 1.7130263074705e-07
site O 0 4.988035584574391e-07
. O 0 1.28468826687822e-07

We O 0 9.682577911007684e-06
have O 0 8.425006825518722e-08
studied O 0 1.88356324315464e-07
the O 0 1.381599545879908e-08
codon O 0 1.2087377854186343e-06
282 O 0 4.1105857917500543e-07
( O 0 5.281383863575684e-08
Cys O 0 0.0005786095862276852
/ O 0 2.80373224086361e-05
Tyr O 0 4.948589321429608e-06
) O 0 8.28175394929076e-09
polymorphism O 0 2.476085967373365e-07
in O 0 3.117914149086687e-09
different O 0 7.046781824726622e-09
ethnic O 0 5.4840867846905894e-08
groups O 0 1.2309176611324801e-07
. O 0 1.1712746328385037e-07

In O 0 9.248521450899716e-07
agreement O 0 9.92702595681294e-08
with O 0 3.5845519885668864e-09
previous O 0 5.408742609347428e-08
observations O 0 3.156595198561263e-07
the O 0 1.4432442796419309e-08
Tyr O 0 1.8537102732807398e-06
allele O 0 7.457417154910218e-07
appeared O 0 1.6533600444290641e-07
to O 0 2.9780982124805178e-09
be O 0 1.2965590379110381e-08
rare O 0 6.365144411546453e-09
or O 0 7.932247854114394e-07
absent O 0 5.685572546099138e-07
in O 0 1.4965709782543968e-09
Asiatic O 0 2.8718547540051986e-08
( O 0 1.3862551107024501e-09
Indian O 0 1.0621855617287679e-09
, O 0 8.397196271658913e-10
Chinese O 0 1.0395688754272214e-09
) O 0 3.4894880318603327e-09
populations O 0 4.966295463759707e-08
. O 0 3.334740839022743e-08

The O 0 6.183478262755671e-07
highest O 0 3.7531785324063094e-07
allele O 0 8.651752523292089e-07
frequency O 0 6.132158318905567e-07
( O 0 6.422240961256875e-09
7 O 0 8.57086046579525e-09
. O 0 6.126155138730383e-10
5 O 0 5.8101399247334484e-09
% O 0 9.966218073031996e-09
) O 0 2.534604526260864e-09
was O 0 1.0940117789459691e-07
found O 0 1.621652856442779e-08
in O 0 7.497427567670911e-09
Swedes O 0 6.829978701716755e-06
. O 0 1.6296812077598588e-07

Saamis O 0 0.001343464944511652
( O 0 2.120925501003512e-06
2 O 0 3.590839412481728e-07
% O 0 4.246650320283152e-08
) O 0 4.364594019534707e-09
and O 0 1.4526174041407103e-08
Mordvinians O 0 1.4296227845989051e-06
( O 0 2.8489608450144033e-09
1 O 0 2.260330145276157e-09
. O 0 5.664168023500338e-10
8 O 0 9.507383325058072e-09
% O 0 6.2146607859858705e-09
) O 0 1.3019060274288563e-09
had O 0 5.240003986273223e-08
significantly O 0 5.246263867775269e-08
lower O 0 4.367036154917514e-08
frequencies O 0 1.0546686013412909e-07
of O 0 1.476083144602569e-09
the O 0 3.484780819462685e-08
Tyr O 0 9.737323125591502e-06
allele O 0 4.0882141547626816e-06
. O 0 2.3082654365680355e-07

Comparisons O 0 2.671138645382598e-06
with O 0 1.8152510961044754e-07
allele O 0 1.0148594355996465e-06
frequencies O 0 4.12256753179463e-07
based O 0 1.3905246731837906e-08
on O 0 2.897129469658921e-08
prevalence O 0 3.0916401101421798e-06
estimates O 0 3.4662793524375957e-08
of O 0 4.1230716618656515e-09
HH B-Disease 1 0.9974609613418579
showed O 0 9.728903023642488e-06
some O 0 3.1816664858297372e-09
disagreements O 0 1.0537079333516886e-06
with O 0 5.4696891460537245e-09
the O 0 8.969446518847235e-09
RFLP O 0 5.748929652327206e-06
data O 0 2.7829378268506844e-07
, O 0 2.4251420871479468e-09
particularly O 0 1.1383732179126582e-08
in O 0 4.608558867857937e-09
Finns O 0 7.041798653517617e-06
. O 0 1.537522109629208e-07

The O 0 1.3882927305530757e-06
newly O 0 3.3401026939827716e-06
described O 0 8.447016170975985e-07
HFE O 0 0.0002484832366462797
marker O 0 2.24038694796036e-06
provides O 0 3.062267239783978e-08
a O 0 6.333173985240137e-09
new O 0 1.1693984669491897e-09
approach O 0 1.8232627851944017e-08
to O 0 1.1914375042110237e-09
the O 0 9.737630701778244e-10
screening O 0 2.5036820616719524e-08
of O 0 2.7035020888632744e-09
HH B-Disease 0 0.18620333075523376
as O 0 2.5194040631504322e-08
well O 0 1.3950407051765978e-08
as O 0 2.4347268645641407e-09
studies O 0 1.5975371026044627e-09
of O 0 1.9129052508670696e-10
the O 0 4.158882571658751e-09
relationship O 0 8.30333206636169e-08
between O 0 1.243945391138368e-08
the O 0 4.9619686137702956e-08
HFE O 0 0.00023882639652583748
Tyr O 0 4.015982995042577e-06
allele O 0 6.300825816651923e-07
and O 0 3.042647023221434e-08
different O 0 1.7720617506711278e-07
disorders O 1 0.5912919044494629
including O 0 9.222494554705918e-07
cancer B-Disease 0 0.008885138668119907

Autosomal B-Disease 1 0.9999831914901733
dominant I-Disease 1 0.9989460110664368
neurohypophyseal I-Disease 1 0.9999421834945679
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999295473098755
associated O 0 2.8824113542214036e-05
with O 0 3.6132604464000906e-08
a O 0 8.836979503712428e-08
missense O 0 3.574081347323954e-05
mutation O 0 2.152437900804216e-06
encoding O 0 1.1683443972287932e-06
Gly23 O 0 0.00022447286755777895
- O 0 0.0009598300675861537
- O 0 0.00020843443053308874
> O 0 5.259486897557508e-06
Val O 0 0.00029113958589732647
in O 0 2.8369765914249e-07
neurophysin O 0 7.374343113042414e-05
II O 0 2.9307821023394354e-05
. O 0 3.271863704412681e-07

Autosomal B-Disease 1 0.9999911785125732
dominant I-Disease 1 0.9997420907020569
neurohypophyseal I-Disease 1 0.9999815225601196
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999730587005615
( O 0 6.258846497075865e-06
ADNDI B-Disease 0 0.00027701968792825937
) O 0 1.956881412468192e-08
is O 0 3.395857595123175e-09
an O 0 4.590235107571061e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 1.5230697272272664e-06
by O 0 7.801832957454735e-09
progressive O 0 2.8154865503893234e-05
degeneration O 0 0.00017017587379086763
of O 0 2.8895343895385395e-09
the O 0 1.7734304691430225e-08
magnocellular O 0 2.455608864693204e-06
neurons O 0 1.6055939511261386e-07
of O 0 1.220643475186023e-09
the O 0 4.314436363728191e-09
hypothalamus O 0 1.939199734124486e-07
leading O 0 7.385545330862442e-08
to O 0 4.258482011465503e-09
decreased O 0 8.70539281550009e-07
ability O 0 9.834380421125388e-08
to O 0 6.247641515244595e-09
produce O 0 4.4320941583464446e-08
the O 0 6.058068890979484e-08
hormone O 0 3.8735652196919546e-06
arginine O 0 8.883586701813329e-07
vasopressin O 0 4.858048328060249e-07
( O 0 3.775774004566301e-08
AVP O 0 1.6856173488122295e-06
) O 0 3.556807470772583e-08
. O 0 4.5403670156929365e-08

Affected O 0 4.920800347463228e-05
individuals O 0 3.8892565612513863e-07
are O 0 1.0058072597018963e-08
not O 0 1.3067730009197476e-08
symptomatic O 0 9.80287722995854e-07
at O 0 2.267618839368879e-07
birth O 0 8.62184060679283e-06
, O 0 4.067977510402443e-09
but O 0 4.210089610268142e-09
usually O 0 3.2562934393354226e-07
develop O 0 6.571000267285854e-05
diabetes B-Disease 1 0.9978246688842773
insipidus I-Disease 0 0.05207667499780655
at O 0 1.4387663895831793e-06
1 O 0 4.258618844232842e-07
- O 0 0.00021875539096072316
6 O 0 1.0419057616672944e-06
yr O 0 0.00017165351891890168
of O 0 3.700887063473601e-08
age O 0 2.0347531517472817e-06
. O 0 2.4330157089025306e-07

The O 0 4.39659743278753e-07
genetic O 0 2.2167978386278264e-06
locus O 0 1.1911698720723507e-06
of O 0 1.4079115651099983e-08
the O 0 1.4692000149807427e-07
disease O 0 0.0029629836790263653
is O 0 3.069727805282696e-09
the O 0 1.4252712787765631e-08
AVP O 0 0.00039035797817632556
- O 0 0.0025443569757044315
neurophysin O 0 0.00035680970177054405
II O 0 3.393120277905837e-05
( O 0 3.722677988093892e-08
NPII O 0 1.686710788817436e-06
) O 0 3.762084865854831e-09
gene O 0 3.4787110081424544e-08
, O 0 6.530294638373846e-10
and O 0 4.06689126819515e-09
mutations O 0 5.763893682342314e-07
that O 0 2.0218655638615246e-09
cause O 0 4.6854232493842574e-08
ADNDI B-Disease 0 1.3367618521442637e-05
have O 0 3.497186469303415e-07
been O 0 9.554998570138196e-08
found O 0 5.1232853515159604e-09
in O 0 4.2911513231658205e-10
both O 0 1.5934167318931713e-09
the O 0 7.421673831053965e-10
signal O 0 6.84941667827843e-08
peptide O 0 1.5782756435100964e-08
of O 0 4.756970373165359e-10
the O 0 7.1555961156377634e-09
prepro O 0 6.9859861469012685e-06
- O 0 1.2326448995736428e-05
AVP O 0 4.049624840263277e-05
- O 0 1.3261189451441169e-05
NPII O 0 5.538450295716757e-06
precursor O 0 2.1035964437032817e-07
and O 0 4.202437864364583e-08
within O 0 5.703396865897048e-08
NPII O 0 9.681081792223267e-06
itself O 0 2.082992693885899e-07
. O 0 8.747146296173014e-08

An O 0 2.1624723558488768e-06
affected O 0 6.664520242338767e-06
girl O 0 8.029246964724734e-05
who O 0 1.1955441436839465e-07
presented O 0 1.315929765155488e-08
at O 0 8.10878972856699e-08
9 O 0 7.134230628480509e-08
months O 0 1.0456466803532294e-08
of O 0 4.747996440457314e-10
age O 0 4.693052062521019e-07
and O 0 2.243815266922411e-08
her O 0 8.690279287293379e-07
similarly O 0 8.934888455769396e-07
affected O 0 2.2071188254813023e-07
younger O 0 1.7183243983254215e-07
brother O 0 5.002412422072666e-07
and O 0 3.600491638167114e-08
father O 0 7.82621725647914e-07
were O 0 1.7009959663027985e-07
all O 0 1.0076693923721791e-09
found O 0 2.27058394308699e-09
to O 0 2.3792339209904867e-09
have O 0 2.1630482294199282e-08
a O 0 1.0738278710675786e-08
novel O 0 7.48871258338113e-08
missense O 0 7.0015871642681304e-06
mutation O 0 1.050461150953197e-06
( O 0 2.9425281766748412e-08
G1758 O 0 1.3476111462296103e-06
- O 0 1.0263385775033385e-05
- O 0 3.712201214511879e-05
> O 0 4.048368737130659e-06
T O 0 9.31644444790436e-06
) O 0 2.3487984890380176e-09
encoding O 0 2.186213343691179e-08
the O 0 6.844711908371437e-09
amino O 0 1.1419107437404818e-07
acid O 0 5.479716236322929e-08
substitution O 0 7.390773504312165e-08
Gly23 O 0 7.54062148189405e-06
- O 0 1.4408821698452812e-05
- O 0 1.628377867746167e-05
> O 0 3.108248847638606e-06
Val O 0 0.00014436582569032907
within O 0 8.817329444354982e-07
NPII O 0 5.704200157197192e-05
. O 0 5.373615294956835e-07

The O 0 1.4450215530814603e-06
mutation O 0 2.243396193080116e-05
was O 0 1.685386195049432e-07
confirmed O 0 3.7596908697423714e-08
by O 0 2.10815787049512e-09
restriction O 0 4.7748283549253756e-08
endonuclease O 0 1.1163293493154924e-05
analysis O 0 9.564842002873775e-07
. O 0 4.3001682570320554e-07

A O 0 1.772696487023495e-05
T1 O 0 0.0003327492158859968
- O 0 5.740454525948735e-06
weighted O 0 5.67608083201776e-07
magnetic O 0 1.837377539004592e-07
resonance O 0 5.057311796008435e-07
imaging O 0 2.2042964701540768e-05
of O 0 1.9801031925226198e-08
the O 0 6.681261766061652e-07
fathers O 0 0.043672241270542145
pituitary O 0 0.00034834578400477767
gland O 0 6.7564092205429915e-06
demonstrates O 0 2.3296463780297927e-07
an O 0 3.9870382551043804e-08
attenuated O 0 0.00029215950053185225
posterior O 0 0.4575223922729492
pituitary O 0 0.13770785927772522
bright O 0 6.366914021782577e-05
spot O 0 0.00012224218517076224
. O 0 9.749854825713555e-07

This O 0 2.4642602625135623e-07
mutation O 0 8.702763807377778e-06
may O 0 1.858390845654867e-07
be O 0 1.7544976582684058e-09
valuable O 0 4.6636832173874154e-09
for O 0 9.081231322483063e-10
developing O 0 2.7092022847341468e-08
models O 0 1.5758818960875942e-07
of O 0 9.16381459603599e-09
dominantly B-Disease 0 0.06794334948062897
inherited I-Disease 1 0.987270712852478
neurodegeneration I-Disease 1 1.0
, O 0 2.426790857157357e-08
as O 0 2.405457388832133e-09
the O 0 1.0033464059588937e-09
early O 0 1.0508329317815424e-08
age O 0 2.2106213748429582e-08
of O 0 7.338147867130829e-10
onset O 0 1.5361196346930228e-05
of O 0 2.6997573954190557e-08
symptoms O 0 0.09063329547643661
suggests O 0 2.270468257847824e-08
that O 0 8.72011907127046e-10
this O 0 1.3998510128843122e-09
mutation O 0 4.314135821914533e-06
may O 0 1.1310810066333943e-07
be O 0 3.774936807587892e-09
particularly O 0 5.172141825937615e-09
deleterious O 0 8.037094403334777e-07
to O 0 9.08431907475915e-09
the O 0 1.8408181645668265e-08
magnocellular O 0 6.375532848323928e-06
neuron O 0 2.176313046220457e-06
. O 0 2.2717850711728715e-08
. O 0 6.610328284750722e-08

Frequent O 0 0.00020449656585697085
inactivation O 0 0.0001111948222387582
of O 0 3.929544334368984e-07
PTEN O 0 0.00024512302479706705
/ O 0 0.00014166629989631474
MMAC1 O 0 0.00032269174698740244
in O 0 5.257373345557426e-07
primary O 1 0.9999958276748657
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1629683740466135e-06

Sporadic B-Disease 1 0.9999995231628418
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 2.751667409484071e-07
the O 0 1.6884751374846019e-09
most O 0 1.4061450892555172e-09
common O 0 2.1062260202597827e-07
male B-Disease 0 0.0006519599701277912
cancer I-Disease 0 2.22359676627093e-06
in O 0 5.51827694650342e-10
the O 0 2.4850215218918947e-09
Western O 0 1.1597987459310843e-08
world O 0 1.0134551757801091e-06
, O 0 2.7692508286492057e-09
yet O 0 3.125428360561955e-09
many O 0 9.52496137518466e-11
of O 0 7.033145593693391e-11
the O 0 9.782474830188903e-10
major O 0 6.952606490528979e-09
genetic O 0 1.0145937778816005e-07
events O 0 2.2985071623793374e-08
involved O 0 5.2556583085561215e-08
in O 0 1.4373700008007972e-09
the O 0 2.754322103726281e-09
progression O 0 1.7744936542385403e-07
of O 0 2.2157101153830183e-10
this O 0 1.7960770648528523e-09
often O 0 3.087805089307949e-05
fatal O 1 0.9953305721282959
cancer B-Disease 0 0.07999604940414429
remain O 0 2.4213494498326327e-07
to O 0 7.523427214550793e-09
be O 0 1.1210796913019294e-07
elucidated O 0 6.321461114566773e-06
. O 0 7.288274161965091e-08

Numerous O 0 1.1351272405590862e-05
cytogenetic O 0 0.00039455003570765257
and O 0 9.122815640694171e-07
allelotype O 0 3.4256827348144725e-05
studies O 0 4.620967501978157e-07
have O 0 1.542108236662898e-07
reported O 0 2.949114161765465e-07
frequent O 0 3.391860445844941e-06
loss O 0 3.249482688261196e-06
of O 0 1.53864796459402e-08
heterozygosity O 0 2.3383381630992517e-05
on O 0 7.008622446846857e-07
chromosomal O 1 0.7578076720237732
arm O 0 0.49038752913475037
10q O 0 2.088551082124468e-05
in O 0 2.769221225662477e-07
sporadic B-Disease 1 0.9999936819076538
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1237638091188273e-06

Deletion O 0 0.0003182891814503819
mapping O 0 2.9960441679577343e-05
studies O 0 5.263225375529146e-06
have O 0 4.771783324031276e-07
unambiguously O 0 4.571213139570318e-05
identified O 0 3.270104684816033e-07
a O 0 5.4819717654197575e-09
region O 0 1.752047396053058e-08
of O 0 2.0957335866711446e-09
chromosome O 0 2.4552891773055308e-05
10q23 O 0 7.451673127434333e-07
to O 0 1.8290586822899968e-08
be O 0 1.4455804553392682e-08
the O 0 3.5630254302532194e-09
minimal O 0 6.621224315495056e-07
area O 0 1.6512832701209845e-07
of O 0 1.6300100824651054e-08
loss O 0 1.7422553355572745e-06
. O 0 1.381584269211089e-07

A O 0 1.3925065331932274e-06
new O 0 1.5909644446310267e-07
tumor B-Disease 0 9.761059118318371e-06
suppressor O 0 2.5289882614742965e-06
gene O 0 7.776666848258174e-07
, O 0 2.2391807519284157e-08
PTEN O 0 1.5445217286469415e-05
/ O 0 1.638972207729239e-05
MMAC1 O 0 8.117459219647571e-05
, O 0 3.5255492747410244e-08
was O 0 3.015320828581025e-07
isolated O 0 4.266020710019802e-07
recently O 0 1.2657181969188969e-07
at O 0 1.8421562941739467e-08
this O 0 3.7982483824805513e-10
region O 0 3.273696869143805e-09
of O 0 1.0192401367348225e-09
chromosome O 0 1.3134095752320718e-05
10q23 O 0 3.943949877793784e-07
and O 0 1.1785934006525167e-08
found O 0 5.639312572469635e-09
to O 0 2.2318031867030186e-09
be O 0 5.775909084348996e-09
inactivated O 0 1.0500919955802601e-07
by O 0 6.702750576792482e-10
mutation O 0 6.33445722542092e-08
in O 0 6.975719113455625e-09
three O 0 0.0010827678488567472
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 6.194607703946531e-05
lines O 0 8.521426207153127e-05
. O 0 2.7163176241629117e-07

We O 0 1.6019253962440416e-05
screened O 0 7.995797204785049e-05
80 O 0 6.115453288657591e-05
prostate B-Disease 1 0.9999978542327881
tumors I-Disease 1 1.0
by O 0 3.512728596888337e-08
microsatellite O 0 2.7897692689293763e-06
analysis O 0 2.027229015766352e-07
and O 0 7.15655446015262e-08
found O 0 1.0783004711356625e-07
chromosome O 0 2.065314220089931e-05
10q23 O 0 6.36168806522619e-07
to O 0 1.1260811838553764e-08
be O 0 1.2994581410907813e-08
deleted O 0 1.466694470764196e-06
in O 0 5.605404584940743e-09
23 O 0 9.79443299797822e-08
cases O 0 1.6429948956897533e-08
. O 0 9.315409243981776e-08

We O 0 1.40189431476756e-05
then O 0 1.1476129202492302e-07
proceeded O 0 6.030654020605652e-08
with O 0 1.3986474201033161e-09
sequence O 0 9.114658361397687e-09
analysis O 0 4.265993780450117e-09
of O 0 1.2540312122055752e-09
the O 0 2.2558348078405288e-08
entire O 0 1.8723353605309967e-06
PTEN O 0 3.320146061014384e-05
/ O 0 5.626376150758006e-06
MMAC1 O 0 8.740616976865567e-06
coding O 0 4.71495377496467e-06
region O 0 6.888903953949921e-07
and O 0 3.322469126487704e-07
tested O 0 5.632066859106999e-06
for O 0 2.7636364308136763e-09
homozygous O 0 2.096275693475036e-06
deletion O 0 1.9504298620631744e-07
with O 0 2.667626120000932e-09
new O 0 1.1910041841645125e-08
intragenic O 0 7.565046416857513e-06
markers O 0 4.922715561406221e-06
in O 0 2.3507884527873557e-09
these O 0 3.1428237790009916e-09
23 O 0 3.45511743660154e-08
cases O 0 3.944617077422663e-09
with O 0 7.405854596242989e-09
10q23 O 0 1.3535950529330876e-05
loss O 0 3.593552548863954e-07
of O 0 1.4217525823312371e-08
heterozygosity O 0 2.48257983912481e-05
. O 0 3.8730632923034136e-07

The O 0 2.888820347379806e-07
identification O 0 1.7919586525749764e-07
of O 0 6.080293157850747e-09
the O 0 7.541399504873425e-09
second O 0 1.9395011463529954e-07
mutational O 0 2.02402825379977e-05
event O 0 3.5542211662686896e-07
in O 0 9.719172133770826e-09
10 O 0 2.1912271108703862e-08
( O 0 7.233153187513608e-09
43 O 0 7.316575789673152e-08
% O 0 1.065120187604407e-07
) O 0 3.2038471431405924e-07
tumors B-Disease 1 1.0
establishes O 0 1.9473687643767335e-05
PTEN O 0 9.362324635731056e-05
/ O 0 5.340865391190164e-05
MMAC1 O 0 4.5165546907810494e-05
as O 0 3.4173531560099946e-08
a O 0 2.0884323603809207e-08
main O 0 1.173423527234263e-07
inactivation O 0 8.185122624126961e-07
target O 0 1.3899470729938912e-07
of O 0 2.882477589949417e-09
10q O 0 2.24224663725181e-06
loss O 0 2.9979673854541034e-07
in O 0 2.741325744182177e-08
sporadic B-Disease 1 0.9999909400939941
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.540194957300628e-08
. O 0 1.0194782618100362e-07

Risk O 0 0.0016027899691835046
reversals O 0 1.1202477253391407e-05
in O 0 1.1084414808237852e-07
predictive O 0 1.2537789189082105e-05
testing O 0 2.4332079192390665e-05
for O 0 2.20331321543199e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.6427402367044124e-07

The O 0 4.898803354080883e-07
first O 0 1.2229143919739727e-07
predictive O 0 3.5660777939483523e-06
testing O 0 2.7205664991925005e-06
for O 0 4.137684470606473e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.0256802457652157e-08
HD B-Disease 0 0.0001548755681142211
) O 0 2.253998232504273e-08
was O 0 8.303078402605024e-08
based O 0 1.2970504670306582e-09
on O 0 3.977701279467283e-09
analysis O 0 1.880798450315524e-08
of O 0 2.429030754313999e-09
linked O 0 2.570740207374911e-06
polymorphic O 0 1.9097738004347775e-06
DNA O 0 9.782704637473216e-07
markers O 0 1.4115059912001016e-06
to O 0 9.533223099822408e-09
estimate O 0 3.989107355550914e-08
the O 0 2.3739303856018523e-09
likelihood O 0 2.1140618144954715e-08
of O 0 1.448311914842293e-09
inheriting O 0 9.628834050090518e-07
the O 0 1.2125133785900744e-08
mutation O 0 6.63059495309426e-07
for O 0 2.0973621062125858e-08
HD B-Disease 0 9.874869283521548e-05
. O 0 6.336994715638866e-07

Limits O 0 2.927042260125745e-06
to O 0 7.148695857495113e-08
accuracy O 0 7.604958227602765e-07
included O 0 2.0136230460821025e-08
recombination O 0 1.6404106872869306e-07
between O 0 1.9448256338705505e-08
the O 0 1.3324577885498456e-08
DNA O 0 7.92789990100573e-07
markers O 0 1.3348789252631832e-05
and O 0 3.369509471440324e-08
the O 0 9.92456072879122e-09
mutation O 0 2.7880723791895434e-06
, O 0 5.3678670397516726e-09
pedigree O 0 1.3993493439556914e-06
structure O 0 5.356384349397558e-07
, O 0 2.576537871945561e-09
and O 0 2.651661779040637e-09
whether O 0 4.191900604411103e-09
DNA O 0 1.0392844274065283e-07
samples O 0 4.091198491096293e-08
were O 0 6.642291339176154e-08
available O 0 2.4707014212310696e-09
from O 0 4.2941414868380434e-09
family O 0 2.7613195285880465e-08
members O 0 2.129050180599279e-08
. O 0 3.650319868597762e-08

With O 0 4.813168175132887e-07
direct O 0 8.050918722801725e-07
tests O 0 2.2608328436035663e-06
for O 0 6.0522693523523685e-09
the O 0 7.136051305423052e-09
HD B-Disease 0 7.688625919399783e-05
mutation O 0 2.044278062385274e-06
, O 0 4.1898227109982145e-09
we O 0 6.019941434232123e-09
have O 0 1.6669460256579782e-09
assessed O 0 1.7364378379625123e-08
the O 0 9.466862849194513e-10
accuracy O 0 1.2204227459733374e-06
of O 0 1.907499269648838e-09
results O 0 1.174542489934538e-06
obtained O 0 3.726329111941595e-08
by O 0 2.953288724683034e-09
linkage O 0 3.9739879298394953e-07
approaches O 0 1.867668686372781e-07
when O 0 1.0835490726890384e-08
requested O 0 2.4948998422757995e-09
to O 0 4.29960023140552e-09
do O 0 1.3208581322032842e-06
so O 0 5.852817341889249e-09
by O 0 4.994589186679832e-10
the O 0 2.2317860892684394e-09
test O 0 2.436401018712786e-07
individuals O 0 4.7207127096271506e-08
. O 0 2.6643425243833008e-08

For O 0 1.5054935431635386e-07
six O 0 4.8971497079719484e-08
such O 0 2.4288222544299742e-09
individuals O 0 9.589355087769036e-09
, O 0 1.2307662666799501e-09
there O 0 2.14863060676862e-09
was O 0 2.748970118204852e-08
significant O 0 2.4917754526398994e-09
disparity O 0 2.1242152925537994e-08
between O 0 5.8994418239421975e-09
the O 0 3.365661882526183e-08
tests O 0 5.808186870126519e-06
. O 0 7.822010417157799e-08

Three O 0 6.835230578872142e-06
went O 0 2.5620788619562518e-06
from O 0 9.023946034858454e-09
a O 0 2.6045995582535397e-08
decreased O 0 2.4139804736478254e-05
risk O 0 5.223887455940712e-07
to O 0 3.5705631784566094e-09
an O 0 3.742488985380987e-09
increased O 0 8.568392786401091e-07
risk O 0 2.26412812480703e-05
, O 0 3.6603504671717246e-09
while O 0 6.427093968142117e-09
in O 0 4.893083160872891e-10
another O 0 8.706594556429081e-09
three O 0 8.454670741286918e-09
the O 0 2.877206028983892e-08
risk O 0 3.823857696261257e-06
was O 0 2.960436518151255e-07
decreased O 0 2.1734485926572233e-06
. O 0 1.1968913327109476e-07

Knowledge O 0 6.573633299922221e-07
of O 0 1.1795716403639744e-08
the O 0 5.771657818343101e-09
potential O 0 1.1091770169002757e-08
reasons O 0 3.6367246991630964e-09
for O 0 3.4500563517170235e-10
these O 0 8.787640060070601e-10
changes O 0 5.300333061342144e-09
in O 0 3.315585805907517e-09
results O 0 9.125147357735841e-07
and O 0 3.192987563238603e-08
impact O 0 2.061292292410144e-08
of O 0 4.3785333692092365e-10
these O 0 5.219492393848668e-09
risk O 0 5.61047741598486e-08
reversals O 0 1.535522820006463e-08
on O 0 1.8257058087556288e-08
both O 0 3.6387879731591966e-07
patients O 0 3.416649860810139e-07
and O 0 3.1569606928627536e-09
the O 0 2.8261160078812964e-09
counseling O 0 2.575517896730162e-07
team O 0 3.226659828214906e-08
can O 0 4.44090941797981e-09
assist O 0 7.942579927089355e-09
in O 0 6.330924118280734e-10
the O 0 4.52874654444102e-10
development O 0 3.851386431996673e-10
of O 0 9.705712622487539e-11
strategies O 0 2.4886940508395128e-08
for O 0 7.722061323711671e-10
the O 0 3.021888073106993e-09
prevention O 0 1.3265270126794348e-07
and O 0 3.376212731609485e-08
, O 0 1.6308520089935996e-09
where O 0 1.8455069694667259e-09
necessary O 0 1.05217274892766e-08
, O 0 1.0298905062100516e-09
management O 0 1.461704979277556e-09
of O 0 2.39914671462671e-10
a O 0 2.02557224326938e-08
risk O 0 6.532829388561368e-07
reversal O 0 2.1880863343426427e-08
in O 0 1.3677966537173347e-09
any O 0 3.814396798418329e-09
predictive O 0 1.166465153801255e-06
testing O 0 9.979553396988194e-07
program O 0 4.7897145805109176e-08
. O 0 5.882688558500604e-09
. O 0 2.7884176745374134e-08

A O 0 8.69616815180052e-06
novel O 0 3.1024383133626543e-06
common O 0 6.026273808856786e-07
missense O 0 4.229308251524344e-05
mutation O 0 1.1646171515167225e-05
G301C O 0 1.523586888652062e-06
in O 0 1.189560272507606e-08
the O 0 2.390789610728916e-08
N O 0 6.838164699729532e-05
- O 0 5.992185833747499e-05
acetylgalactosamine O 0 0.011497988365590572
- O 0 0.0001883150835055858
6 O 0 1.7637661358094192e-06
- O 0 3.217087942175567e-05
sulfate O 0 1.2293437066546176e-05
sulfatase O 0 1.8138569430448115e-05
gene O 0 1.4019634591022623e-06
in O 0 5.164938343682479e-08
mucopolysaccharidosis B-Disease 0 4.464644007384777e-05
IVA I-Disease 0 0.00013835944992024451
. O 0 6.353635626510368e-07

Mucopolysaccharidosis B-Disease 1 0.989250659942627
IVA I-Disease 1 0.9996757507324219
( O 0 0.037570804357528687
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 1.4046773344489338e-07
is O 0 9.145585622150065e-09
an O 0 2.5250518120856213e-08
autosomal B-Disease 1 0.9999802112579346
recessive I-Disease 1 0.9999994039535522
lysosomal I-Disease 1 0.9999970197677612
storage I-Disease 1 0.999984860420227
disorder I-Disease 1 1.0
caused O 0 3.738100758710061e-06
by O 0 3.184871921746435e-09
a O 0 4.972376359546615e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.1222542894984144e-07
N O 0 0.01946946792304516
- O 0 0.0012384792789816856
acetylgalactosamine O 0 0.1722717583179474
- O 0 0.009576470591127872
6 O 0 1.2375883670756593e-05
- O 0 0.0013416130095720291
sulfate O 0 3.753927012439817e-05
sulfatase O 0 5.438626612885855e-05
( O 0 7.642825750053817e-08
GALNS O 0 4.3482918954396155e-06
) O 0 4.5213546684408357e-08
. O 0 7.052189943124176e-08

In O 0 5.707770469598472e-07
previous O 0 3.542076854046172e-07
studies O 0 1.145877277508589e-07
, O 0 1.4361321021283402e-08
we O 0 2.1253013571254087e-08
have O 0 4.596549363355962e-09
found O 0 5.51389200964536e-09
two O 0 2.3005499727446477e-09
common O 0 4.551031196342592e-08
mutations O 0 6.504760676762089e-07
in O 0 2.846505919862352e-09
Caucasians O 0 1.241728426748523e-07
and O 0 2.125098674810033e-08
Japanese O 0 7.51531217701995e-07
, O 0 1.780116853922209e-08
respectively O 0 3.3153159506582597e-07
. O 0 5.022661753173452e-08

To O 0 6.936805903023924e-07
characterize O 0 4.458026978682028e-06
the O 0 3.8869163887511604e-08
mutational O 0 6.0763586589018814e-06
spectrum O 0 1.613677653722334e-07
in O 0 1.8251267164259843e-09
various O 0 4.8017132492361725e-09
ethnic O 0 2.256936504352325e-08
groups O 0 2.036644097813678e-08
, O 0 4.747265247573296e-09
mutations O 0 2.2621173911829828e-07
in O 0 5.202235864310012e-10
the O 0 2.2142450095685717e-09
GALNS O 0 1.6683389958416228e-06
gene O 0 1.4454072072567214e-07
in O 0 7.808353075233754e-09
Colombian O 0 5.104358933749609e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.0008029007003642619
were O 0 2.0059073335687572e-07
investigated O 0 1.77477460283626e-07
, O 0 2.271550059163019e-09
and O 0 3.5353651117731033e-09
genetic O 0 6.286768439167645e-07
backgrounds O 0 6.239498020477185e-07
were O 0 8.560767383869461e-08
extensively O 0 7.903443588475056e-08
analyzed O 0 1.3556685019011638e-07
to O 0 7.504852739259604e-09
identify O 0 9.364762263430748e-07
racial O 0 1.1743084087356692e-06
origin O 0 4.1790499949456716e-08
, O 0 1.8043693206237776e-09
based O 0 1.972025431840052e-09
on O 0 1.4386873914418175e-08
mitochondrial O 0 4.3042180664087937e-07
DNA O 0 5.454979827845818e-07
( O 0 1.1961811097194186e-08
mtDNA O 0 4.7084785137485596e-07
) O 0 4.1995374289172105e-08
lineages O 0 8.542659202248615e-07
. O 0 2.0212348772474797e-07

Three O 0 5.801604402222438e-06
novel O 0 3.2989896681101527e-06
missense O 0 7.013491995166987e-05
mutations O 0 0.0001740724837873131
never O 0 1.490731392550515e-05
identified O 0 1.0618355190672446e-06
previously O 0 1.2769270085755124e-07
in O 0 1.276079797385421e-09
other O 0 1.5098775563160416e-09
populations O 0 2.5141188686461646e-08
and O 0 2.2286098300128288e-08
found O 0 4.2554148649287526e-08
in O 0 1.3596836989648864e-09
16 O 0 1.2919353586937632e-08
out O 0 6.756458059697934e-09
of O 0 1.9130301787129156e-09
19 O 0 3.5792660924016673e-07
Colombian O 0 8.021658686629962e-06
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 0.9999740123748779
unrelated O 0 4.63796510530301e-07
alleles O 0 6.048135219316464e-07
account O 0 7.001688118180027e-08
for O 0 7.630703180439014e-09
84 O 0 6.005585078128206e-07
. O 0 1.4964295758090884e-07

2 O 0 4.872654699283885e-06
% O 0 3.222094164812006e-07
of O 0 3.6082996590636185e-09
the O 0 9.990274385529574e-09
alleles O 0 1.231504711540765e-07
in O 0 1.6841040784143502e-09
this O 0 1.1688789935959676e-09
study O 0 2.743046501052504e-08
. O 0 3.728291630977765e-08

The O 0 1.2692227073785034e-06
G301C O 0 8.51991444505984e-06
and O 0 1.7844568844793685e-07
S162F O 0 4.157824605499627e-06
mutations O 0 2.559563199611148e-06
account O 0 1.2240649027717154e-07
for O 0 1.2761364409641374e-08
68 O 0 1.2943570482093492e-06
. O 0 1.3408038057605154e-07

4 O 0 2.1234320229268633e-05
% O 0 1.2196129546282464e-06
and O 0 1.2738728116801212e-07
10 O 0 1.7324107659533183e-07
. O 0 1.467011827571696e-07

5 O 0 6.602719622605946e-06
% O 0 4.507225241923152e-07
of O 0 8.430725451091803e-09
mutations O 0 3.6922119761584327e-06
, O 0 1.2536874649526908e-08
respectively O 0 2.0175988879600482e-07
, O 0 5.712800454915623e-09
whereas O 0 2.4934454501135406e-08
the O 0 8.005362595042698e-09
remaining O 0 2.919677513091301e-07
F69V O 0 9.299267730966676e-06
is O 0 4.917730223041872e-09
limited O 0 7.66980878807999e-09
to O 0 7.560425174801821e-09
a O 0 1.3382820895913028e-07
single O 0 1.176667501567863e-05
allele O 0 7.589919277961599e-06
. O 0 1.7184325429298042e-07

The O 0 1.733117642288562e-06
skewed O 0 1.4177227058098651e-05
prevalence O 0 2.4216080419137143e-05
of O 0 1.7593441370422624e-08
G301C O 0 5.563880449699354e-07
in O 0 6.253352502483267e-09
only O 0 1.156269124891196e-08
Colombian O 0 2.214390377730524e-07
patients O 0 4.1738803702173755e-07
and O 0 5.476975761808944e-09
haplotype O 0 2.9147170721444127e-07
analysis O 0 2.638440221858218e-08
by O 0 4.648843088261856e-09
restriction O 0 3.9676027796531343e-08
fragment O 0 3.028970638752071e-07
length O 0 5.623852530334261e-07
polymorphisms O 0 7.044297490210738e-06
in O 0 2.9084004093959948e-09
the O 0 7.547731328827467e-09
GALNS O 0 4.307245944801252e-06
gene O 0 2.4684942445674096e-07
suggest O 0 2.999740189579825e-08
that O 0 1.090581625007303e-09
G301C O 0 1.509674376620751e-07
originated O 0 1.8523069300613315e-08
from O 0 1.7246895023248499e-09
a O 0 4.438826195496404e-09
common O 0 4.143334209061322e-08
ancestor O 0 5.809532694911468e-07
. O 0 8.631761261312931e-08

Investigation O 0 1.1544574363142601e-06
of O 0 1.6686518833353148e-08
the O 0 1.6578434625103e-08
genetic O 0 1.4551305866916664e-06
background O 0 4.866404310632788e-07
by O 0 4.00288557855788e-09
means O 0 1.6225840226979926e-08
of O 0 4.4380280006528494e-10
mtDNA O 0 5.712682877856423e-07
lineages O 0 2.082387027257937e-07
indicate O 0 2.829505660884024e-07
that O 0 2.793377529286545e-09
all O 0 4.334702374819699e-09
our O 0 2.3431110207638994e-07
patients O 0 7.550989522542295e-08
are O 0 1.8730434980795962e-09
probably O 0 6.685172859732802e-09
of O 0 6.499601967746571e-10
native O 0 3.0632897107807366e-08
American O 0 1.5169148355198558e-06
descent O 0 0.0004862776549998671

Low O 0 8.993985102279112e-05
frequency O 0 2.909933527917019e-06
of O 0 6.658870432829644e-08
BRCA1 O 0 0.00028057509916834533
germline O 0 1.7658294382272288e-05
mutations O 0 2.5448207452427596e-06
in O 0 1.2508356128648757e-08
45 O 0 3.1027232694214035e-07
German O 1 0.9999991655349731
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.2885136533877812e-06
. O 0 2.272721815188561e-07

In O 0 3.37746939749195e-07
this O 0 1.2620968270482535e-08
study O 0 1.301008190068842e-08
we O 0 1.552681005989598e-08
investigated O 0 1.4009486903887591e-07
45 O 0 1.810614094210905e-07
German O 1 0.9999940395355225
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5298302002975106e-07
for O 0 4.461412572709378e-09
germline O 0 9.286169188271742e-06
mutations O 0 4.722450285044033e-06
in O 0 5.214616738413724e-09
the O 0 2.71113567151815e-08
BRCA1 O 0 6.440805736929178e-05
gene O 0 5.706732281396398e-06
. O 0 2.328993247147082e-07

We O 0 9.337089068139903e-06
identified O 0 1.3544204193749465e-06
four O 0 5.629643595739253e-08
germline O 0 5.790052455267869e-06
mutations O 0 4.036895461467793e-06
in O 0 1.2802321869287425e-08
three O 0 2.48137689595751e-06
breast B-Disease 1 0.9999994039535522
cancer I-Disease 0 0.019467366859316826
families O 0 5.347635578800691e-08
and O 0 4.773314632444681e-09
in O 0 6.743004821174736e-09
one O 0 0.0035454132594168186
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 8.991271727154526e-08
. O 0 7.318983752391262e-10
among O 0 1.106670310946356e-09
these O 0 1.5187937574268062e-09
were O 0 4.180644452844717e-08
one O 0 1.1988946724272864e-08
frameshift O 0 2.8860833481303416e-05
mutation O 0 4.4515609260997735e-06
, O 0 4.50473880420077e-09
one O 0 1.32985027434529e-08
nonsense O 0 6.530171958729625e-06
mutation O 0 1.6290359781123698e-06
, O 0 5.405140335312808e-09
one O 0 1.1519852627372984e-08
novel O 0 5.9197219570705784e-08
splice O 0 3.3882319257827476e-05
site O 0 1.2955611055076588e-06
mutation O 0 2.9537122827605344e-06
, O 0 1.0834871666531853e-08
and O 0 1.5228353689167307e-08
one O 0 8.919855076783278e-08
missense O 0 5.434390914160758e-05
mutation O 0 4.107839777134359e-05
. O 0 7.035368980723433e-07

The O 0 3.149978510919027e-06
missense O 0 0.00022709641780238599
mutation O 0 0.00017723387281876057
was O 0 1.910486162159941e-06
also O 0 5.552204029868335e-08
found O 0 3.505299517314597e-08
in O 0 5.338359088113975e-09
2 O 0 2.001449104227504e-07
. O 0 8.121759975665555e-08

8 O 0 1.0623314665281214e-05
% O 0 3.0054965804993117e-07
of O 0 1.269769622780359e-09
the O 0 2.349300309845148e-09
general O 0 4.014921284323236e-09
population O 0 4.422921140445624e-09
, O 0 1.2694161277693183e-09
suggesting O 0 3.5256967123586946e-08
that O 0 5.845261497050558e-10
it O 0 1.4276757553943753e-09
is O 0 2.391568498794072e-09
not O 0 1.7814319619446906e-07
disease O 0 1.2383239663904533e-05
associated O 0 1.132388049995825e-07
. O 0 8.597945111432637e-08

The O 0 6.654490221080778e-07
average O 0 5.233284809946781e-06
age O 0 4.163242692811764e-07
of O 0 3.265080650294294e-08
disease O 0 0.008676256984472275
onset O 0 7.877151801949367e-05
in O 0 7.597591000774173e-09
those O 0 3.8830187065741484e-08
families O 0 1.4274864668095688e-07
harbouring O 0 0.00013543321983888745
causative O 0 0.00017682064208202064
mutations O 0 3.0216100640245713e-05
was O 0 1.2296881379825209e-07
between O 0 2.2992701076418598e-08
32 O 0 5.286483428790234e-07
. O 0 6.952662801040788e-08

3 O 0 2.7009424229618162e-05
and O 0 9.163414347312937e-07
37 O 0 5.527543635253096e-06
. O 0 6.059127599655767e-07

4 O 0 1.2724362932203803e-05
years O 0 1.8515092392590304e-07
, O 0 7.862452910956108e-09
whereas O 0 3.628897005114595e-08
the O 0 2.4015838206992157e-09
family O 0 4.5112674484926174e-08
harbouring O 0 3.673428409456392e-06
the O 0 6.347685932439617e-09
missense O 0 2.7219186904403614e-06
mutation O 0 1.6281662738037994e-06
had O 0 9.592066163577329e-08
an O 0 2.315976743716419e-09
average O 0 2.9006573640799616e-06
age O 0 2.3392104253616708e-07
of O 0 3.6692069382837644e-09
onset O 0 1.8139226085622795e-05
of O 0 2.854020308973304e-08
51 O 0 6.794532509957207e-06
. O 0 3.6576625461748336e-07

2 O 0 2.77999097306747e-05
years O 0 1.1893536111529102e-06
. O 0 4.1988528209913056e-07

These O 0 6.929400910848926e-07
findings O 0 1.9125612027437455e-07
show O 0 1.6026933735702187e-07
that O 0 2.773775875652973e-09
BRCA1 O 0 5.3765237680636346e-05
is O 0 6.80519107731925e-09
implicated O 0 2.1022849239216157e-07
in O 0 5.801388258674933e-10
a O 0 1.1136174205006455e-09
small O 0 1.5422435550860314e-09
fraction O 0 3.3023841439216994e-08
of O 0 3.9310134525294416e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.317215717084764e-07
suggesting O 0 7.867527074267855e-08
the O 0 1.2348105871140547e-09
involvement O 0 1.5948709020108254e-08
of O 0 1.019321849149435e-09
another O 0 5.462185370674888e-08
susceptibility O 0 1.4413933058676776e-05
gene O 0 1.2390894880809356e-05
( O 0 4.934193498229433e-07
s O 0 6.646042311331257e-05
) O 0 8.736772656448011e-07

Paternal O 0 0.3496876060962677
transmission O 1 0.7416220307350159
of O 0 2.3619873900315724e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 3.349621329107322e-05

We O 0 1.1835776604129933e-05
report O 0 7.310842420338304e-08
a O 0 8.990685529397524e-09
rare O 0 1.3974641888125916e-08
case O 0 1.0952119211538047e-08
of O 0 3.105890655774601e-08
paternally O 1 0.9994358420372009
transmitted O 1 0.9999991655349731
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.02088535763323307
DM B-Disease 1 1.0
) O 0 1.2353152669675183e-06
. O 0 3.1829947033656936e-07

The O 0 2.612972139104386e-06
proband O 0 5.633599357679486e-05
is O 0 7.798919909873803e-08
a O 0 1.7107399941096446e-08
23 O 0 3.4210707156034914e-08
year O 0 3.7327083646232495e-09
old O 0 2.235412011941662e-06
, O 0 2.501476892291521e-08
mentally B-Disease 1 1.0
retarded I-Disease 1 0.9999920129776001
male O 0 1.7053867850336246e-05
who O 0 1.5368565300377668e-06
suffers O 0 0.20272541046142578
severe O 1 0.5494534969329834
muscular B-Disease 1 0.9975554347038269
weakness I-Disease 1 0.6815712451934814
. O 0 6.904479619151971e-07

He O 0 4.2477945498831104e-06
presented O 0 2.841316870672017e-07
with O 0 1.59305201918869e-07
respiratory O 0 0.47342169284820557
and O 0 3.2679784567335446e-07
feeding O 0 7.659851689822972e-05
difficulties O 0 3.491430834401399e-05
at O 0 1.1420722785260295e-06
birth O 0 3.5264391044620425e-05
. O 0 2.47514861939635e-07

His O 0 1.4652064237452578e-05
two O 0 3.438456360527198e-06
sibs O 1 0.9864082336425781
suffer O 0 0.08626734465360641
from O 0 3.06152315943109e-07
childhood O 0 0.184605672955513
onset O 1 0.9999747276306152
DM B-Disease 1 1.0
. O 0 7.508644557674415e-06

Their O 0 4.088159585080575e-06
late O 0 5.56491556835681e-07
father O 0 6.962468432902824e-07
had O 0 2.654360287124291e-08
the O 0 9.959220115263179e-10
adult O 0 4.9401165824747295e-08
type O 0 2.0998934360250132e-06
of O 0 6.880500791339728e-08
DM B-Disease 1 1.0
, O 0 4.85229705304846e-08
with O 0 2.7643652700248822e-08
onset O 0 0.0016767872730270028
around O 0 6.553584626090014e-07
30 O 0 5.328494623313418e-08
years O 0 2.582802949291363e-08
. O 0 4.614489412801959e-08

Only O 0 9.440831263418659e-07
six O 0 2.9267546608480188e-08
other O 0 9.98642168958952e-10
cases O 0 1.1099637875489066e-09
of O 0 6.177089395542623e-10
paternal O 0 0.1522192507982254
transmission O 1 0.8281885385513306
of O 0 7.887838933129387e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0003722627297975123
been O 0 4.740816166304285e-06
reported O 0 3.822395683528157e-06
recently O 0 1.4951929188100621e-06
. O 0 2.235059639588144e-07

We O 0 1.460373141526361e-06
review O 0 3.9425128051107095e-08
the O 0 4.227849181859256e-09
sex O 0 1.6113170886455919e-07
related O 0 5.355321519573408e-08
effects O 0 1.2152012459409889e-05
on O 0 2.7969889515588875e-07
transmission O 0 0.036768555641174316
of O 0 1.511107598162198e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 3.3485259791632416e-06

Decreased O 0 0.0012992939446121454
fertility O 0 1.2748229892167728e-05
of O 0 1.4568404260728585e-08
males O 0 2.2751528661046905e-07
with O 0 6.1274674223454895e-09
adult O 0 7.429760444210842e-05
onset O 1 0.9999059438705444
DM B-Disease 1 1.0
and O 0 2.925677563325735e-06
contraction O 0 1.6688398318365216e-05
of O 0 1.6764156729465185e-09
the O 0 9.811930823389048e-09
repeat O 0 8.835654625727329e-07
upon O 0 2.0220440433149633e-08
male O 0 7.52859705244191e-07
transmission O 0 2.6994487143383594e-06
contribute O 0 1.3960469225082761e-08
to O 0 4.108039686201437e-09
the O 0 8.488279412688371e-09
almost O 0 3.738367482242211e-08
absent O 0 1.069921324869938e-07
occurrence O 0 5.1580272497631086e-08
of O 0 3.639847756531367e-09
paternal O 0 0.002785125281661749
transmission O 0 0.23038843274116516
of O 0 4.484151759243105e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 3.824226041615475e-06

Also O 0 1.872835468930134e-06
the O 0 3.8140345992587754e-08
fathers O 0 4.782193059327255e-07
of O 0 1.2757536138607861e-09
the O 0 1.1106546793371308e-08
reported O 0 4.90572233502462e-07
congenitally O 0 2.8737436878145672e-05
affected O 0 5.321389835444279e-07
children O 0 3.745822994005721e-07
showed O 0 7.025961963336158e-07
, O 0 1.9893275915450204e-09
on O 0 1.2877579891323876e-08
average O 0 3.1274271350412164e-06
, O 0 8.607885959577288e-09
shorter O 0 3.348171230754815e-05
CTG O 0 6.481946184067056e-05
repeat O 0 6.504148586827796e-06
lengths O 0 2.2613530745729804e-05
and O 0 4.192398606051029e-08
hence O 0 1.8282186431406444e-07
less O 0 1.0517898374473589e-07
severe O 0 0.2241874486207962
clinical O 1 0.7718306183815002
symptoms O 1 0.6238387227058411
than O 0 6.291540177727484e-09
the O 0 1.018105955097326e-08
mothers O 0 2.758788014034508e-06
of O 0 2.3098887247385846e-09
children O 0 5.397354243541486e-07
with O 0 6.4365449361503124e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 2.637117631820729e-06

We O 0 3.884540547005599e-06
conclude O 0 3.4169596574429306e-07
that O 0 6.357209425544852e-09
paternal O 0 8.037598308874294e-05
transmission O 0 0.07115329802036285
of O 0 6.523528668367362e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 2.3734453691304225e-07
rare O 0 3.224186784223093e-08
and O 0 1.4673370962725585e-08
preferentially O 0 2.2743283523141145e-07
occurs O 0 7.139209667883506e-09
with O 0 2.501408635779967e-09
onset O 0 1.7261638276977465e-05
of O 0 1.322893581345852e-07
DM B-Disease 1 1.0
past O 0 0.00010578668297966942
30 O 0 4.4908864538228954e-07
years O 0 1.4572989925909496e-08
in O 0 1.0403702344063959e-09
the O 0 5.521490820115105e-09
father O 0 1.9593731792610924e-07
. O 0 2.48491716092758e-09
. O 0 2.3885109001753335e-08

The O 0 3.560755885700928e-06
RB1 O 0 0.0003941466275136918
gene O 0 9.973321539291646e-06
mutation O 0 3.4761624192469753e-06
in O 0 1.1405987265789008e-08
a O 0 3.9006412322351025e-08
child O 0 1.7525942894280888e-05
with O 0 6.759791517652047e-07
ectopic B-Disease 1 0.9999998807907104
intracranial I-Disease 1 0.9999980926513672
retinoblastoma I-Disease 1 0.9711627960205078
. O 0 2.0380798559926916e-06

The O 0 2.5672979973023757e-06
RB1 O 0 0.0004790261446032673
gene O 0 1.1248081136727706e-05
mutation O 0 6.096796369092772e-06
was O 0 6.83146339497398e-08
investigated O 0 8.401209328212644e-08
in O 0 2.637110529946085e-09
a O 0 1.8334665341512846e-08
child O 0 1.7635860785958357e-05
with O 0 3.3283046718679543e-07
ectopic B-Disease 1 0.9999997615814209
intracranial I-Disease 1 0.9995858073234558
retinoblastoma I-Disease 0 0.0005448947777040303
using O 0 1.5094310583663173e-06
DNA O 0 9.053988492269127e-07
obtained O 0 2.761072082080318e-08
from O 0 2.65294186618803e-09
both O 0 5.1203250528431e-09
the O 0 1.4426277061829751e-08
pineal B-Disease 0 2.4712244339752942e-06
and I-Disease 0 2.7815897851724003e-07
retinal I-Disease 0 0.00010412978008389473
tumours I-Disease 1 1.0
of O 0 2.633618301217666e-08
the O 0 2.417897349005216e-07
patient O 0 3.538627424859442e-05
. O 0 2.734952317950956e-07

A O 0 1.4744886357220821e-05
nonsense O 0 5.0627379096113145e-05
mutation O 0 4.762386197398882e-06
in O 0 3.548161586763854e-08
exon O 0 1.7602675370653742e-06
17 O 0 2.248833084195212e-07
( O 0 1.548611194834848e-08
codon O 0 4.2861987026299175e-07
556 O 0 3.912234802783132e-08
) O 0 9.233199205205267e-10
of O 0 3.492336142496555e-10
the O 0 1.5886651993923806e-08
RB1 O 0 4.4323032852844335e-06
gene O 0 3.296248962669779e-07
was O 0 8.315249999668595e-08
found O 0 5.6438533846403516e-09
to O 0 1.901629076428435e-09
be O 0 5.779126954763569e-09
present O 0 4.3901340340823936e-09
homozygously O 0 5.89682315421669e-07
in O 0 1.295334839390705e-09
both O 0 7.736010942949179e-09
the O 0 8.753384683757304e-09
retinal B-Disease 0 2.141178470083105e-07
and I-Disease 0 1.80122952997408e-07
the I-Disease 0 2.9644877486134646e-07
pineal I-Disease 0 0.0063034361228346825
tumours I-Disease 1 1.0
. O 0 4.774882995661756e-07

The O 0 6.502373253169935e-07
same O 0 1.4254921154588374e-07
mutation O 0 6.999525226092373e-07
was O 0 5.35475983554079e-08
present O 0 6.359271331746186e-09
heterozygously O 0 5.513605287887913e-07
in O 0 1.4047806251582529e-09
the O 0 1.7570629395891046e-09
DNA O 0 7.756492692578831e-08
from O 0 1.12929410267526e-09
the O 0 1.1093711504983617e-09
constitutional O 0 1.0781437076445854e-08
cells O 0 6.907059368899127e-09
of O 0 2.4096807882401095e-10
the O 0 7.744780816665298e-09
patient O 0 1.1615230732786586e-06
, O 0 1.9740913348442746e-09
proving O 0 1.2332100141065894e-07
it O 0 1.3566140433241003e-09
to O 0 2.5885715793094732e-09
be O 0 8.088133718331392e-09
of O 0 3.0143183504804938e-09
germline O 0 1.0051428034785204e-05
origin O 0 4.569850489133387e-07
. O 0 2.1272850858622405e-07

The O 0 2.924582247487706e-07
initial O 0 6.896293029967637e-07
mutation O 0 1.4019473155713058e-06
was O 0 7.601826723657723e-08
shown O 0 9.709204107366531e-09
to O 0 4.612929593861281e-09
have O 0 1.0420593099524922e-07
occurred O 0 1.3808202936615999e-07
in O 0 4.742043202554669e-09
the O 0 2.3738499166370275e-08
paternally O 0 1.9308070477563888e-05
derived O 0 9.405135870110826e-07
RB1 O 0 2.7247411708231084e-05
allele O 0 8.512995009368751e-06
. O 0 2.3538368054687453e-07

The O 0 6.38151504972484e-07
mutation O 0 1.8032128537015524e-06
is O 0 6.8911103490165715e-09
in O 0 5.425899729516459e-10
an O 0 5.184930262913667e-10
area O 0 8.503836745887838e-09
of O 0 1.929615356388581e-10
the O 0 2.900512052761428e-09
gene O 0 3.4518766511837384e-08
that O 0 5.115237122765848e-10
encodes O 0 1.8896873399398828e-08
the O 0 6.0330913598249936e-09
protein O 0 7.616805675070282e-08
- O 0 3.737426652605791e-07
binding O 0 8.021598318919132e-08
region O 0 1.600102628174227e-08
known O 0 1.2471621957388379e-08
as O 0 2.7508255673325266e-09
the O 0 3.275883120323897e-09
pocket O 0 9.32536022446584e-06
region O 0 1.0820563289826168e-07
and O 0 1.2168462149020343e-07
has O 0 3.677910953570063e-08
been O 0 1.4259348368739211e-08
detected O 0 2.789342978815057e-08
in O 0 9.894650376818248e-11
other O 0 2.563140533151653e-10
cases O 0 9.96765781025033e-10
of O 0 7.044198557792924e-10
retinoblastoma B-Disease 0 2.3843856524763396e-06
. O 0 1.2347925348876743e-08
. O 0 6.993479928496527e-08

Low O 0 0.023726385086774826
levels O 0 1.2271110790607054e-05
of O 0 5.7913971396317265e-09
beta O 0 8.477022817032775e-08
hexosaminidase O 0 1.2076017128492822e-06
A O 0 1.585450526420118e-08
in O 0 4.001480924387124e-09
healthy O 0 2.0495355101957102e-07
individuals O 0 6.400986851673451e-09
with O 0 7.169011606578124e-09
apparent O 0 4.7152952902251855e-05
deficiency O 0 0.0001309358631260693
of O 0 5.270711089799818e-10
this O 0 2.212155569836227e-09
enzyme O 0 1.0295412948835292e-06
. O 0 6.545713659988905e-08

Appreciable O 0 0.00030998894362710416
beta O 0 3.0881434213370085e-05
hexosaminidase O 0 0.00013998604845255613
A O 0 7.750545591989066e-07
( O 0 2.4048208757676548e-08
hex O 0 3.727477633219678e-07
A O 0 2.1565968566505944e-08
) O 0 9.38026545327375e-10
activity O 0 1.1692251611350457e-08
has O 0 3.6311242901376772e-09
been O 0 6.267454111252846e-09
detected O 0 6.614086345280157e-08
in O 0 1.2646141911432096e-09
cultured O 0 6.180489435791969e-07
skin O 0 0.00028689729515463114
fibroblasts O 0 3.019245866653364e-07
and O 0 1.1819970495707821e-06
melanoma B-Disease 1 0.7505363821983337
tissue O 0 2.2687427190248854e-05
from O 0 2.591013092967387e-08
healthy O 0 9.605034847481875e-07
individuals O 0 9.992008997983248e-09
previously O 0 5.988484872432309e-07
reported O 0 5.071516397947562e-07
as O 0 6.856370049490579e-08
having O 0 0.004331966862082481
deficiency B-Disease 0 2.6169045668211766e-05
of I-Disease 0 2.4391877406770845e-10
hex I-Disease 0 1.8483795827251015e-07
A I-Disease 0 2.0801195432795794e-08
activity O 0 5.6779978052645674e-08
indistinguishable O 0 1.0343483580754764e-07
from O 0 5.376081246843967e-10
that O 0 2.425622203094946e-10
of O 0 1.1734426763609918e-09
patients O 0 3.4803576909325784e-07
with O 0 1.8826052837539464e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9927082657814026
( O 0 9.404637069110322e-08
TSD B-Disease 0 3.307297811261378e-05
) O 0 8.862687650434964e-08
. O 0 1.4143637372399098e-07

Identification O 0 2.4794493583613075e-05
and O 0 8.262436494987924e-07
quantitation O 0 3.0050032364670187e-05
of O 0 4.839726841510128e-08
hex O 0 4.791387254954316e-06
A O 0 1.7270495789034612e-07
, O 0 7.684480607395017e-09
amounting O 0 1.6160239368900875e-08
to O 0 1.189231291220949e-08
3 O 0 1.885372995502621e-07
. O 0 9.781028609268105e-08

5 O 0 4.929959322907962e-05
% O 0 1.4398946404980961e-05
- O 0 5.106177559355274e-05
6 O 0 1.7888064576254692e-06
. O 0 1.647149900918521e-07

9 O 0 2.0425011825864203e-05
% O 0 2.2968555413171998e-07
of O 0 4.06834255173294e-09
total O 0 1.6088273824266253e-08
beta O 0 4.664672914600487e-08
hexosaminidase O 0 1.423689468538214e-06
activity O 0 4.1983602727668767e-07
, O 0 6.028191279483508e-09
has O 0 8.357972092198906e-09
been O 0 8.414868801764896e-09
obtained O 0 1.298105622993262e-08
by O 0 1.3951151345281687e-08
cellulose O 0 2.262021735077724e-05
acetate O 0 5.090143167763017e-05
gel O 0 0.00016250289627350867
electrophoresis O 0 8.18704029370565e-06
, O 0 8.046622212987131e-08
DEAE O 0 4.8948236326396e-06
- O 0 1.25911253689992e-06
cellulose O 0 2.8503211524366634e-06
ion O 0 1.3010773045607493e-06
- O 0 4.124248334846925e-06
exchange O 0 1.798464381863596e-07
chromatography O 0 1.5941857327561593e-06
, O 0 2.19469882267731e-08
radial O 0 1.3986982594360597e-06
immunodiffusion O 0 3.998361535195727e-06
, O 0 7.845345706414264e-09
and O 0 3.071673759791338e-08
radioimmunoassay O 0 1.895966852316633e-05
. O 0 1.672154041898466e-07

Previous O 0 1.325820448982995e-05
family O 0 3.912634554126271e-07
studies O 0 7.77666855356074e-08
suggested O 0 4.074883364069137e-08
that O 0 9.820518842573733e-10
these O 0 2.7765811871915957e-09
individuals O 0 6.718727796339863e-09
may O 0 5.2565404473625676e-08
be O 0 8.168798970586977e-09
compound O 0 1.862666287877346e-08
heterozygotes O 0 4.3822470985332984e-08
for O 0 3.575290896673522e-10
the O 0 1.2565980478385086e-09
common O 0 1.851268649488702e-08
mutant O 0 1.6115642438307987e-06
TSD B-Disease 0 4.2981409933418036e-06
gene O 0 3.354543309797009e-07
and O 0 1.4082447208352278e-08
a O 0 1.204751498562473e-08
rare O 0 2.916150876330903e-08
( O 0 1.6241724409837843e-08
allelic O 0 1.2906346000818303e-06
) O 0 2.030930090768379e-08
mutant O 0 2.9714185529883252e-06
gene O 0 4.065229404659476e-06
. O 0 2.495625324172579e-07

Thus O 0 6.173806923470693e-06
, O 0 3.462777087293034e-08
the O 0 4.985987178685036e-09
postulated O 0 1.7066831503598223e-07
rate O 0 1.7269030649913475e-07
mutant O 0 5.599358701147139e-07
gene O 0 1.6408910141763045e-07
appears O 0 2.046714442371922e-08
to O 0 1.3058428782741771e-09
code O 0 5.189018548179547e-09
for O 0 6.253194073657653e-10
the O 0 1.3540417675983463e-09
expression O 0 1.1437598423924555e-08
of O 0 1.1765038943067907e-09
low O 0 8.055502803472336e-06
amounts O 0 2.792020481479085e-08
of O 0 3.926361458184147e-09
hex O 0 4.125900886720046e-06
A O 0 4.065389589413826e-07
. O 0 1.550473882616643e-07

Heterozygotes O 0 0.0002781534567475319
for O 0 5.3882004635852354e-08
the O 0 9.145288970557885e-09
rare O 0 1.883588041096118e-08
mutant O 0 1.4988105476732017e-06
may O 0 2.508579939330957e-07
be O 0 1.2934886939319767e-08
indistinguishable O 0 2.9996490980011004e-07
from O 0 5.825875337706066e-09
heterozygotes O 0 3.1208378459268715e-07
for O 0 1.2917917846522187e-09
the O 0 8.224329661743468e-09
common O 0 2.093809428060922e-07
TSD B-Disease 0 4.745927071780898e-05
mutant O 0 1.1381080184946768e-05
. O 0 4.0261733147417544e-07

However O 0 1.9022703554583131e-06
, O 0 1.7674500085718137e-08
direct O 0 4.401950448595926e-08
visualization O 0 2.1066650788270636e-06
and O 0 5.748890430368192e-07
quantitation O 0 6.583293725270778e-05
of O 0 1.4562654193639446e-08
hex O 0 2.5910806016327115e-06
A O 0 2.3806242310797643e-08
by O 0 5.631066168909626e-10
the O 0 5.565833904874751e-10
methods O 0 8.47828403038875e-08
described O 0 2.435044450521673e-07
may O 0 1.101360567190568e-07
prevent O 0 2.3882608957137563e-07
false O 0 5.348803711058281e-07
- O 0 6.7974556259287056e-06
positive O 0 5.749882916461502e-07
prenatal O 1 0.99846351146698
diagnosis O 1 0.6947583556175232
of O 0 1.1053312931608161e-08
TSD B-Disease 0 4.44369507022202e-05
in O 0 7.512202415682623e-08
fetuses O 0 0.0035383314825594425
having O 0 9.741155508891097e-07
the O 0 8.559114306194715e-09
incomplete O 0 1.0953203855024185e-06
hex B-Disease 0 4.994688879378373e-06
A I-Disease 0 2.8988213216507575e-06
deficiency I-Disease 0 0.00010041040513897315
of O 0 4.36284397498099e-10
the O 0 3.2998448418197768e-09
type O 0 3.214766547898762e-05
described O 0 3.1693065238869167e-07
in O 0 2.320544423284332e-09
the O 0 1.1013138845328285e-08
four O 0 5.469028678817267e-07
healthy O 0 1.317569513048511e-06
individuals O 0 2.5703110395625117e-07

The O 0 5.894658443139633e-06
tumor B-Disease 0 0.00024287504493258893
suppressor O 0 5.490450348588638e-05
gene O 0 1.8971859390148893e-05
Smad4 O 0 3.916312925866805e-05
/ O 0 2.04669722734252e-05
Dpc4 O 0 9.495055564912036e-06
is O 0 8.461188194530678e-09
required O 0 1.4355324040593587e-08
for O 0 1.2246592628883946e-09
gastrulation O 0 2.5120775148934626e-07
and O 0 5.1041514126382026e-08
later O 0 2.2826393220043428e-08
for O 0 3.1887499307714506e-09
anterior O 0 1.7239148291992024e-05
development O 0 6.658182449825745e-09
of O 0 1.3659352537942482e-09
the O 0 1.328058196747861e-08
mouse O 0 4.167201041127555e-06
embryo O 0 2.615921857795911e-06
. O 0 1.8706795401612908e-07

Mutations O 0 0.0006615230813622475
in O 0 1.846247812409274e-07
the O 0 1.0443116593705781e-07
SMAD4 O 0 0.00036507766344584525
/ O 0 0.0004715223622042686
DPC4 O 0 0.0013584669213742018
tumor B-Disease 0 8.20724235381931e-05
suppressor O 0 3.995308361481875e-06
gene O 0 5.934542741670157e-07
, O 0 7.580394978390359e-09
a O 0 6.345410419328346e-09
key O 0 2.5058994879145757e-07
signal O 0 4.740870451769297e-07
transducer O 0 1.0762688589238678e-06
in O 0 3.94033072836919e-09
most O 0 6.079017289550848e-09
TGFbeta O 0 3.872062279697275e-06
- O 0 1.122906724049244e-06
related O 0 2.7323210360918893e-08
pathways O 0 8.419304009521511e-08
, O 0 1.94830707123117e-09
are O 0 6.107744310313024e-10
involved O 0 3.5307827772612654e-09
in O 0 8.659786776554768e-10
50 O 0 8.689722719168458e-09
% O 0 1.1239953856545526e-08
of O 0 2.577006164017348e-08
pancreatic B-Disease 1 0.9934402108192444
cancers I-Disease 1 0.9935641884803772
. O 0 4.703133527073078e-07

Homozygous O 0 0.018020696938037872
Smad4 O 0 0.0009356621303595603
mutant O 0 0.0004784967750310898
mice O 1 0.6442681550979614
die O 0 0.01384138222783804
before O 0 1.6694818327778194e-07
day O 0 1.217391911723098e-07
7 O 0 3.196705620212015e-07
. O 0 1.493387316031658e-07

5 O 0 1.5952175090205856e-05
of O 0 3.248663063004642e-07
embryogenesis O 0 3.094168641837314e-05
. O 0 1.6644581819491577e-06

Mutant O 0 0.00011553124204510823
embryos O 0 3.211794683011249e-05
have O 0 1.9936786088692315e-07
reduced O 0 7.874582763633953e-08
size O 0 9.08933159848857e-08
, O 0 2.76021374645552e-08
fail O 0 9.857441000349354e-06
to O 0 2.344967953149535e-08
gastrulate O 0 0.00028599987854249775
or O 0 5.343649718270171e-07
express O 0 5.3719460879619874e-08
a O 0 1.567774532418298e-08
mesodermal O 0 1.5250116121023893e-06
marker O 0 6.275779924180824e-06
, O 0 6.305788780025523e-09
and O 0 8.364606784994066e-09
show O 0 9.244042189493484e-07
abnormal O 0 1.9279217667644843e-05
visceral O 0 6.1805048972018994e-06
endoderm O 0 9.345937723992392e-05
development O 0 6.131164127509692e-07
. O 0 3.615849379912106e-07

Growth B-Disease 1 0.9999997615814209
retardation I-Disease 1 1.0
of O 0 7.327776785359674e-08
the O 0 6.525220896946848e-08
Smad4 O 0 0.00046838633716106415
- O 0 0.0035991729237139225
deficient O 0 0.0004895406309515238
embryos O 0 7.903938694653334e-07
results O 0 3.642085744104406e-08
from O 0 7.232960008707323e-09
reduced O 0 1.14134024897794e-07
cell O 0 4.979850700692623e-07
proliferation O 0 2.7709330652214703e-07
rather O 0 1.007973526867545e-08
than O 0 3.035006024276754e-09
increased O 0 2.3524476944203343e-07
apoptosis O 0 2.032261136264424e-06
. O 0 1.1600182148185922e-07

Aggregation O 0 2.2891392291057855e-05
of O 0 3.773852199628891e-07
mutant O 0 3.938658119295724e-05
Smad4 O 0 6.0903523262823e-05
ES O 0 3.185904279234819e-05
cells O 0 6.142899451333506e-07
with O 0 1.4392334435342491e-08
wild O 0 1.8278038282915077e-07
- O 0 6.165093509480357e-06
type O 0 8.007577707758173e-05
tetraploid O 0 5.6187858717748895e-05
morulae O 0 3.66204694728367e-05
rescues O 0 1.359245379717322e-05
the O 0 1.2986137676307408e-07
gastrulation B-Disease 0 2.0414710888871923e-05
defect I-Disease 0 5.826424967381172e-05
. O 0 4.936349000672635e-07

These O 0 3.5056789329246385e-06
results O 0 1.1940768445128924e-06
indicate O 0 6.183460641295824e-07
that O 0 6.847010070032411e-09
Smad4 O 0 1.704605665509007e-06
is O 0 5.834415617300692e-09
initially O 0 5.3577736025545164e-08
required O 0 6.73674360740506e-09
for O 0 2.033889862085303e-10
the O 0 3.7382924533702067e-10
differentiation O 0 6.816570863321658e-09
of O 0 2.712395030801673e-10
the O 0 2.069970639340113e-09
visceral O 0 2.1270943761919625e-07
endoderm O 0 8.045354661589954e-06
and O 0 3.634590939327609e-08
that O 0 1.3914311924878575e-09
the O 0 6.117938156080527e-09
gastrulation B-Disease 0 1.5879039665378514e-06
defect I-Disease 0 2.454808054608293e-06
in O 0 3.263783909801532e-09
the O 0 9.331411199298145e-09
epiblast O 0 1.6111200693558203e-06
is O 0 5.95630167410377e-09
secondary O 0 2.9181381933085504e-07
and O 0 1.0541899087002093e-07
non O 0 1.6820071323309094e-05
- O 0 0.00022342870943248272
cell O 0 1.4912660844856873e-05
autonomous O 0 1.7357559727315675e-06
. O 0 2.0992516169826558e-07

Rescued O 0 0.0016407383373007178
embryos O 0 0.00046993818250484765
show O 0 5.898891686229035e-05
severe O 0 0.08880186825990677
anterior O 1 0.9149942994117737
truncations O 0 0.002251060912385583
, O 0 2.442901632093708e-07
indicating O 0 2.341893832635833e-06
a O 0 2.3767858792211882e-08
second O 0 1.2586116326929186e-07
important O 0 5.261974855841345e-09
role O 0 4.9197215190588395e-08
for O 0 5.309925388274905e-09
Smad4 O 0 5.137151674716733e-06
in O 0 1.9130311557091773e-08
anterior O 0 0.0003650922735687345
patterning O 0 1.664957744651474e-05
during O 0 7.289364134521747e-07
embryogenesis O 0 8.658456863486208e-06
. O 0 6.615549636990181e-07

Prevalence O 0 0.002668255940079689
of O 0 3.3270447374889045e-07
p16 O 0 1.3387367289396934e-05
and O 0 2.9337027740439225e-07
CDK4 O 0 6.128735549282283e-05
germline O 0 3.4679695090744644e-05
mutations O 0 4.2134524846915156e-06
in O 0 1.5006049736143723e-08
48 O 0 1.9376886939426186e-06
melanoma B-Disease 1 0.9875621795654297
- O 0 0.10238189250230789
prone O 1 0.9925761222839355
families O 0 3.030038897122722e-06
in O 0 6.769901972347725e-08
France O 0 0.0001045890458044596
. O 0 1.8708203697315184e-07

The O 0 1.6050902331699035e-06
French O 0 0.00011085424921475351
Familial B-Disease 1 0.9673654437065125
Melanoma I-Disease 1 0.9984845519065857
Study O 0 2.522655677239527e-06
Group O 0 1.6950526742220973e-06
. O 0 2.7253082635070314e-07

Germline O 0 0.0029028060380369425
mutations O 0 0.00024847942404448986
in O 0 6.967517407474588e-08
the O 0 1.3000332366175371e-08
p16 O 0 5.033657544117887e-07
and O 0 1.240805591606886e-08
CDK4 O 0 2.9779689612041693e-06
genes O 0 8.417230219492922e-07
have O 0 8.852416044646816e-08
been O 0 6.779127659228834e-08
reported O 0 4.934598152317449e-08
in O 0 2.871265725179484e-10
a O 0 8.486915614724921e-10
subset O 0 1.2318143838285778e-08
of O 0 2.2001505062263504e-09
melanoma B-Disease 0 0.00026787022943608463
pedigrees O 0 5.285533006826881e-06
, O 0 1.0658757432224775e-08
but O 0 6.2145422141668405e-09
their O 0 7.543403057752585e-08
prevalence O 0 2.1499436115846038e-05
is O 0 5.360806909493476e-09
not O 0 1.2343780220192002e-08
well O 0 2.871471416199256e-08
known O 0 1.8173089699757838e-07
. O 0 8.615937474587554e-08

We O 0 2.6054376576212235e-06
searched O 0 6.553971729772456e-07
for O 0 5.259957802650206e-09
such O 0 6.481802650171176e-09
germline O 0 1.2310823876759969e-05
mutations O 0 4.386380169307813e-06
in O 0 1.0684138906924545e-08
48 O 0 9.102219564738334e-07
French O 0 0.0024184458889067173
melanoma B-Disease 1 0.9987521171569824
- O 0 0.03283797204494476
prone O 0 0.4140810966491699
families O 0 1.199309025423645e-07
selected O 0 1.0258406568652845e-08
according O 0 2.1696500152046383e-09
to O 0 2.6288140553276662e-09
two O 0 1.0264904481971371e-08
major O 0 7.163600912463153e-08
criteria O 0 1.6447152120235842e-06
families O 0 1.791691417452057e-08
with O 0 4.8256123541534635e-09
at O 0 2.744099276696943e-07
least O 0 1.2099305557455864e-08
three O 0 6.82906353688395e-09
affected O 0 2.3489432621204287e-08
members O 0 3.1816298484699246e-09
( O 0 4.594025160287174e-09
n O 0 1.2803227036783937e-05
= O 0 2.562949521234259e-05
20 O 0 3.871009468525699e-08
) O 0 3.284466920661089e-09
or O 0 7.548425884351673e-08
families O 0 2.2953965839178636e-08
with O 0 3.1469327144151293e-09
two O 0 5.934192159884333e-08
affected O 0 7.07890066564687e-08
members O 0 2.604767068703495e-09
, O 0 5.081610132684489e-10
one O 0 3.188006802989918e-10
of O 0 1.0377220610591209e-10
them O 0 3.7836875854679874e-09
affected O 0 1.621160983233949e-08
before O 0 4.337506354090692e-09
the O 0 1.4026440009473617e-09
age O 0 1.3517357011494369e-08
of O 0 3.6084768506583487e-10
50 O 0 9.600811701204748e-09
( O 0 4.9239714527971046e-09
n O 0 1.2820845768146683e-05
= O 0 3.8885362300788984e-05
28 O 0 2.413867719042173e-07
) O 0 2.5641393452957573e-09
, O 0 1.897607182499428e-09
and O 0 6.2847878012917135e-09
one O 0 5.485778942215802e-09
additional O 0 1.8798193224256465e-08
minor O 0 2.3138356937124627e-06
criterion O 0 2.288508540004841e-06
. O 0 2.5076687393266184e-07

Sixteen O 0 3.9544385799672455e-05
different O 0 9.765404911377118e-07
p16 O 0 2.1917656340519898e-05
germline O 0 2.0355513697722927e-05
mutations O 0 3.993895370513201e-05
were O 0 2.4971728862510645e-07
found O 0 4.1322536503685114e-08
in O 0 3.719106356214752e-09
21 O 0 7.037167648604736e-08
families O 0 1.2114545810959498e-08
, O 0 1.049298314903524e-09
while O 0 4.510964046744448e-09
one O 0 8.833184850232101e-09
germline O 0 1.2687652315435116e-06
mutation O 0 4.220334801630088e-07
, O 0 1.9361416914165375e-09
Arg24His O 0 3.9668015006100177e-07
, O 0 5.070575070931227e-09
was O 0 3.564753825457956e-08
detected O 0 1.4461822672728886e-07
in O 0 1.4566896577861144e-09
the O 0 1.079637712564363e-08
CDK4 O 0 9.549889909976628e-06
gene O 0 1.9461710962787038e-06
. O 0 2.408769432804547e-07

The O 0 4.126300439111219e-07
frequency O 0 7.664334589208011e-07
of O 0 1.6675572922508763e-08
p16 O 0 2.136585862899665e-06
gene O 0 5.588469775830163e-07
mutation O 0 3.1900569297249604e-07
in O 0 3.6399172564927085e-09
our O 0 1.6733018526338128e-08
sample O 0 4.229311301173766e-08
( O 0 7.255938516692595e-09
44 O 0 1.4522130165062208e-08
% O 0 4.595926750283752e-09
) O 0 6.139700969853834e-10
is O 0 3.3991215397932706e-10
among O 0 7.046980221581123e-10
the O 0 2.4165445200452496e-09
highest O 0 3.933582490844856e-07
rates O 0 1.3975481124361977e-05
yet O 0 2.5664726877039357e-07
reported O 0 1.2408723648604791e-07
and O 0 3.0347167001565367e-09
the O 0 4.816003595919938e-09
CDK4 O 0 2.972293077618815e-05
mutation O 0 4.965168614035065e-07
is O 0 1.413003491990139e-09
the O 0 1.798644677641903e-09
second O 0 2.717524978379515e-07
mutation O 0 1.5936111594783142e-06
detected O 0 2.8906586635457643e-07
in O 0 7.312467298348224e-10
this O 0 1.0793262950059557e-09
gene O 0 1.7988210743169475e-07
worldwide O 0 1.9228721725994546e-07
. O 0 1.6661988411215134e-07

In O 0 1.034654701470572e-06
summary O 0 3.6489561807684368e-06
, O 0 2.97855997644092e-08
our O 0 4.366061645555419e-08
results O 0 6.00077569856694e-08
show O 0 9.987763149865714e-08
frequent O 0 1.1373134611858404e-07
involvement O 0 5.999334007356083e-08
of O 0 8.791294914267667e-10
the O 0 3.606180687398819e-09
p16 O 0 2.542658990023483e-07
gene O 0 1.6365791566386179e-07
in O 0 4.5579962026920384e-09
familial B-Disease 0 0.014855809509754181
melanoma I-Disease 1 0.8741777539253235
and O 0 5.985241813277753e-08
confirm O 0 5.767968218606256e-07
the O 0 3.0756350799521215e-09
role O 0 1.3668479681427925e-08
of O 0 5.376060707718011e-10
the O 0 8.44770742247647e-09
CDK4 O 0 1.671085669840977e-06
gene O 0 8.473757162619222e-08
as O 0 5.930817170707314e-09
a O 0 1.2889380229808012e-07
melanoma B-Disease 0 0.030484581366181374
- O 0 8.080293810053263e-06
predisposing O 0 1.4590697901439853e-05
gene O 0 1.5093130514287623e-06
. O 0 3.8154027492964815e-08
. O 0 1.5180393120317603e-07

Progression O 0 0.0002768913400359452
of O 0 3.633953724602179e-07
somatic O 0 8.454037742922083e-05
CTG O 0 0.0004618803213816136
repeat O 0 1.0537900379858911e-05
length O 0 5.433920478026266e-07
heterogeneity O 0 3.0041840659578156e-07
in O 0 4.809146858519853e-09
the O 0 1.315337527785232e-08
blood O 0 3.138655756629305e-06
cells O 0 2.526758180465549e-07
of O 0 3.298128703477232e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.6867054104804993
. O 0 3.838626412289159e-07

The O 0 4.749899176204053e-07
genetic O 0 2.139024218195118e-06
basis O 0 1.8823996583705593e-07
of O 0 4.147533445575391e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.08204939216375351
DM B-Disease 1 1.0
) O 0 7.08691132444983e-08
is O 0 1.488829726170593e-09
the O 0 5.991003804162176e-10
expansion O 0 3.5034131151689962e-09
of O 0 1.4521928104471726e-09
an O 0 2.974670998412421e-08
unstable O 0 0.001538855372928083
CTG O 0 1.1144360541948117e-05
repeat O 0 6.375012731041352e-07
in O 0 2.791300302007471e-09
the O 0 3.0576317033848e-09
34 O 0 2.267719878545904e-08
UTR O 0 1.9658642713693553e-07
of O 0 1.9963672936995636e-09
the O 0 5.5750618344063696e-08
DM B-Disease 1 0.9999998807907104
protein O 0 1.2749633242492564e-06
kinase O 0 3.0982755561126396e-06
gene O 0 8.517457104062487e-07
on O 0 8.935947448662773e-08
chromosome O 0 2.9705983251915313e-05
19 O 0 5.477437525769346e-07
. O 0 1.0828264151996336e-07

One O 0 1.0350752290833043e-06
of O 0 5.144004333601515e-09
the O 0 2.662319253943224e-09
principal O 0 2.4045915480996882e-08
features O 0 1.342506195101123e-08
of O 0 1.813937888783812e-09
the O 0 8.241518685281335e-07
DM B-Disease 1 1.0
mutation O 0 9.136834705714136e-05
is O 0 2.2197761406772543e-09
an O 0 6.090550841442166e-10
extraordinarily O 0 1.2497558543600462e-07
high O 0 1.8666359835606272e-07
level O 0 1.6194913143863232e-07
of O 0 1.5269180364541057e-09
somatic O 0 2.831102847267175e-06
mosaicism O 0 1.4166483197186608e-05
, O 0 9.835389391810168e-09
due O 0 1.5518342166842558e-08
to O 0 4.354516303095579e-09
an O 0 7.1642682897277155e-09
extremely O 0 4.2109593323402805e-07
high O 0 4.820839905050889e-08
degree O 0 1.1333513683098317e-08
of O 0 1.779389413592014e-09
somatic O 0 6.026370101608336e-06
instability O 0 2.511193997634109e-06
both O 0 5.856561102746127e-08
within O 0 2.0436560888015265e-08
and O 0 1.7399354845792914e-08
between O 0 1.4211614995929267e-08
different O 0 1.6176836936665495e-07
tissues O 0 1.049099228112027e-05
. O 0 1.2787184289209108e-07

This O 0 5.223155312705785e-07
instability O 0 4.016730144940084e-06
appears O 0 2.155635314693427e-07
to O 0 8.003973483994287e-09
be O 0 6.9619217057947935e-09
biased O 0 1.58875678835102e-07
towards O 0 1.695588913719348e-08
further O 0 3.2778832981250616e-09
expansion O 0 1.3849793312203929e-08
and O 0 2.186684611160672e-08
continuous O 0 4.6387216912080476e-07
throughout O 0 9.411205326159688e-08
the O 0 6.146078312951886e-09
life O 0 3.3161677848170257e-09
of O 0 9.316195731523536e-11
an O 0 8.375346527422778e-10
individual O 0 8.30269453189203e-09
, O 0 6.835967347740279e-10
features O 0 3.002906012739004e-08
that O 0 7.027400439341136e-09
could O 0 7.253623266478826e-07
be O 0 1.7352757453181766e-08
associated O 0 5.30126298414757e-09
with O 0 1.0516023607465286e-09
the O 0 3.744310195230582e-09
progressive O 0 3.5165842859896657e-07
nature O 0 1.0961878516013712e-08
of O 0 1.0782871262549065e-09
the O 0 2.1686628315364942e-07
disease O 0 0.00010975142504321411
. O 0 6.471083224823815e-08

Although O 0 2.5699239358800696e-06
increasing O 0 1.8176555727222876e-07
measured O 0 1.3400193665802362e-06
allele O 0 7.694544592595776e-07
size O 0 5.7090996818942585e-08
between O 0 3.5640738360598334e-08
patients O 0 2.7942533051827922e-06
clearly O 0 5.824766802220438e-08
correlates O 0 4.391803187786536e-08
with O 0 2.219543215886688e-09
an O 0 1.3724116287860966e-09
increased O 0 1.6904552069263445e-07
severity O 0 3.348819518578239e-05
of O 0 2.0209565576578825e-08
symptoms O 0 0.024766063317656517
and O 0 9.523372312969514e-09
an O 0 3.2227465140977074e-09
earlier O 0 2.3036912466523063e-07
age O 0 3.178666077019443e-07
of O 0 1.1742373740020184e-09
onset O 0 2.873157245630864e-05
, O 0 3.624025524118224e-09
this O 0 3.2796826365810716e-10
correlation O 0 3.206078247330879e-07
is O 0 8.817866437027533e-09
not O 0 6.772469696159078e-09
precise O 0 6.210045739862835e-06
and O 0 1.6064639396518032e-07
measured O 0 1.3278348887979519e-05
allele O 0 1.374232397211017e-06
length O 0 2.3337900074693607e-06
cannot O 0 1.9369499568711035e-06
be O 0 8.577892174344015e-09
used O 0 3.852110097568584e-08
as O 0 8.613830537740341e-09
an O 0 2.23285057110445e-09
accurate O 0 0.001013933215290308
predictor O 0 0.00046121416380628943
of O 0 4.689425736614794e-09
age O 0 4.4675633148472116e-07
of O 0 1.7443747779566365e-08
onset O 0 0.00046804134035483
. O 0 5.776902867182798e-07

In O 0 5.362057891034056e-07
order O 0 9.284934776587761e-08
to O 0 6.237199645653391e-09
further O 0 1.6399328117699952e-08
characterize O 0 8.430132538705948e-07
the O 0 1.3419047206753021e-08
dynamics O 0 7.553321665909607e-07
of O 0 8.402170692534128e-08
DM B-Disease 1 1.0
CTG O 0 0.0005188966752029955
repeat O 0 6.8737253968720324e-06
somatic O 0 5.27386191606638e-06
instability O 0 2.8026706786477007e-06
, O 0 2.1169347164118335e-08
we O 0 1.4861976538327326e-08
have O 0 2.5758106758644317e-09
studied O 0 5.555953919156309e-08
repeat O 0 1.233455236615555e-06
length O 0 1.3724731218189845e-07
changes O 0 2.1208389711091513e-08
over O 0 7.932708712132808e-09
time O 0 2.6292216404044666e-08
in O 0 9.108853227246527e-09
111 O 0 1.1124461707368027e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.01311253011226654
with O 0 1.4828818173384661e-08
varying O 0 8.367744044335268e-07
clinical O 0 0.00033637185697443783
severity O 0 0.001693241996690631
and O 0 2.292427325301105e-06
CTG O 0 3.5793545976048335e-05
repeat O 0 3.057772573811235e-06
size O 0 7.752203146083048e-08
over O 0 4.933986375021959e-08
time O 0 1.3554823397043947e-07
intervals O 0 3.128620164716267e-06
of O 0 2.4807311760355333e-09
1 O 0 1.4302254669473768e-07
- O 0 2.4252387447631918e-05
7 O 0 2.9337334694901074e-07
years O 0 7.380194233519433e-08
. O 0 1.0935466576711406e-07

We O 0 1.3904224942962173e-05
have O 0 8.526220085514069e-08
found O 0 1.004066785270652e-08
a O 0 1.3669358978063428e-09
direct O 0 4.8486523240853785e-08
progression O 0 3.645627430159948e-06
of O 0 1.0769635183649484e-09
the O 0 3.5410339105368394e-09
size O 0 2.3551610439653814e-08
heterogeneity O 0 1.284979873616976e-07
over O 0 2.8900759119210306e-08
time O 0 2.6513445661180413e-08
related O 0 1.0600852640152425e-08
to O 0 5.532834190802305e-09
initial O 0 1.9239453763475467e-07
CTG O 0 5.5704867918393575e-06
repeat O 0 4.1914472603821196e-07
size O 0 2.533938747717457e-08
and O 0 1.8316979932819777e-08
the O 0 3.383095803499714e-09
time O 0 4.5644885204865204e-08
interval O 0 9.350216032544267e-07
and O 0 2.364838991297802e-08
always O 0 3.516697333338925e-08
biased O 0 1.3934868547949009e-07
towards O 0 2.801457021917031e-08
further O 0 2.6812267961418e-08
expansion O 0 1.5663688657241437e-07
. O 0 2.2367419205693295e-07

Attempts O 0 1.4259193449106533e-05
to O 0 2.589798384633468e-07
mathematically O 0 1.1571381719477358e-06
model O 0 1.743665478670664e-07
the O 0 1.548806238815814e-08
dynamics O 0 1.7502239870736958e-06
have O 0 4.102756747670355e-07
proved O 0 2.722686986089684e-06
only O 0 5.9263200569148466e-08
partially O 0 3.9642177398491185e-06
successful O 0 4.714971524322209e-08
suggesting O 0 3.5228332251335814e-08
that O 0 5.693728266642495e-10
individual O 0 8.744735491283961e-10
specific O 0 5.455695895051349e-09
genetic O 0 6.410617174879008e-07
and O 0 3.915310031743502e-08
/ O 0 5.3670883062295616e-05
or O 0 8.239569524448598e-07
environmental O 0 9.411240853296476e-08
factors O 0 1.5183114498995565e-07
also O 0 2.2194427629074198e-08
play O 0 7.336811336244864e-08
a O 0 5.4159556839294964e-09
role O 0 4.013881849118661e-08
in O 0 1.5770952321858545e-09
somatic O 0 1.1267792388025555e-06
mosaicism O 0 4.352888481662376e-06
. O 0 2.627241535435587e-08
. O 0 1.1006675038061076e-07

Aspartylglucosaminuria B-Disease 1 0.9999929666519165
among O 0 3.356742809046409e-06
Palestinian O 0 4.25255493610166e-05
Arabs O 0 6.594721071451204e-06
. O 0 3.077068981838238e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.37768372893333435
AGU B-Disease 1 0.9999998807907104
) O 0 2.0360543828701338e-07
is O 0 2.929668729834134e-09
a O 0 4.830133182309737e-09
rare O 0 1.3847051150150946e-07
disorder B-Disease 0 0.18173855543136597
of I-Disease 0 3.1456905968951787e-09
glycoprotein I-Disease 0 4.6423989260802045e-05
metabolism I-Disease 0 0.024657445028424263
caused O 0 2.5551830731274094e-06
by O 0 5.09772712931067e-09
the O 0 8.6227437634534e-08
deficiency B-Disease 0 3.306197322672233e-05
of I-Disease 0 5.183278806164537e-10
the I-Disease 0 1.2078738009790868e-08
lysosomal I-Disease 0 8.618315041530877e-05
enzyme I-Disease 0 1.6606893041171134e-05
aspartylglucosaminidase I-Disease 0 2.270868390041869e-05
( O 0 5.105806621941156e-08
AGA O 0 9.646784064898384e-07
) O 0 5.171394690250963e-08
. O 0 1.0481829804120935e-07

AGU B-Disease 1 0.9999996423721313
is O 0 1.1194157195859589e-05
inherited O 0 9.758801752468571e-05
as O 0 2.5507800316404428e-08
an O 0 1.3266657106214552e-08
autosomal O 1 0.9526485800743103
recessive O 1 0.9981138706207275
trait O 0 0.00014348448894452304
and O 0 6.680395614466761e-08
occurs O 0 1.2506614410767725e-08
with O 0 1.4576122531195779e-09
a O 0 1.5724493707125475e-08
high O 0 6.793210332034505e-07
frequency O 0 3.702485264511779e-05
in O 0 3.1610895234734926e-08
Finland O 0 3.5696939448826015e-05
because O 0 8.9589491381048e-09
of O 0 4.840940426298346e-10
a O 0 1.6599887686652437e-08
founder O 0 2.2955985912176402e-07
effect O 0 1.0365979363768929e-07
. O 0 3.581410012998276e-08

While O 0 5.731406872655498e-06
very O 0 1.8863819661874004e-07
few O 0 1.3516148555936525e-07
patients O 0 1.1957680499108392e-06
with O 0 4.720154223036843e-08
AGU B-Disease 1 1.0
have O 0 3.0131843686831417e-06
been O 0 3.879069936374435e-07
reported O 0 2.2701873092501046e-07
from O 0 7.650990063723384e-09
non O 0 6.667997695330996e-06
- O 0 9.2697828222299e-06
Finnish O 0 1.1547830581548624e-05
origin O 0 1.3093631423544139e-07
, O 0 1.1947628664188414e-08
we O 0 1.2349677263046033e-06
diagnosed O 0 0.00011381004878785461
the O 0 7.2669634754163326e-09
disorder O 0 9.578913886798546e-05
in O 0 9.563158043235376e-10
8 O 0 6.66613928501647e-08
patients O 0 2.9518030686404018e-08
originating O 0 8.314041011203699e-09
from O 0 1.8110409838456576e-09
3 O 0 1.4192923281086678e-08
unrelated O 0 3.2565846908028107e-08
families O 0 3.201463982804853e-08
, O 0 2.523586895009089e-09
all O 0 2.6565063482308915e-09
Palestinian O 0 1.2415014225553023e-06
Arabs O 0 7.710588789677786e-08
from O 0 2.617766448054226e-09
the O 0 4.6049737356668174e-09
region O 0 1.6603276975502013e-08
of O 0 4.632167982521196e-09
Jerusalem O 0 3.918059064744739e-06
. O 0 1.481163849348377e-07

The O 0 2.0746417703776387e-06
clinical O 0 0.004690743517130613
diagnosis O 1 0.9987045526504517
of O 0 4.2195622995677695e-07
AGU B-Disease 1 1.0
is O 0 2.4510413254574814e-07
often O 0 1.0820021998370066e-06
difficult O 0 7.340418505918933e-06
, O 0 5.7459774716051015e-09
in O 0 7.855733286099564e-10
particular O 0 6.876877289840877e-09
early O 0 5.955770987497999e-08
in O 0 1.105265323708693e-09
the O 0 3.726803754489083e-09
course O 0 7.924122513713883e-08
of O 0 3.493135503074285e-10
the O 0 2.2018018341896095e-07
disease O 0 3.122441557934508e-05
, O 0 5.191391760916986e-10
and O 0 7.871092111422229e-10
most O 0 1.5633715155782824e-10
of O 0 1.3188683478659868e-10
the O 0 1.4565681105693784e-08
patients O 0 3.16538887545903e-07
are O 0 2.6985327394868364e-07
diagnosed O 0 0.0009130059625022113
after O 0 4.4968757606511645e-09
the O 0 3.2252676085420262e-09
age O 0 5.019290583163638e-08
of O 0 5.047645634803644e-10
5 O 0 2.3722114050883647e-08
years O 0 3.170944751218485e-08
. O 0 6.735628943488337e-08

However O 0 3.779221970034996e-06
, O 0 4.402403774861341e-08
since O 0 1.2736001586688417e-08
these O 0 9.56283408015679e-09
patients O 0 1.393559898588137e-07
excrete O 0 9.520978494492738e-08
early O 0 6.501018834370598e-09
large O 0 2.4525546038489665e-09
amounts O 0 3.861141184557937e-09
of O 0 1.1572701685835796e-09
aspartylglucosamine O 0 5.002859779779101e-06
in O 0 5.241480582895974e-09
urine O 0 1.070487314791535e-06
, O 0 1.7582026945461848e-09
biochemical O 0 1.0425980434547455e-07
screening O 0 2.983151432545128e-07
is O 0 8.539155160747214e-09
easy O 0 5.961043711977254e-07
by O 0 2.600667947660895e-08
urine O 0 1.9769199752772693e-06
chromatography O 0 3.7998104289727053e-06
. O 0 4.21596588751072e-08
. O 0 6.539586649978446e-08

Detection O 0 2.383849277975969e-05
of O 0 9.716469406839678e-08
heterozygous O 0 8.095141311059706e-06
carriers O 0 6.094426225899952e-07
of O 0 6.744509839506918e-09
the O 0 1.0465982995810919e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 2.9322930572561745e-07
ATM O 0 6.2377885114983656e-06
) O 0 1.0428184538113783e-08
gene O 0 4.8422936771430614e-08
by O 0 4.758959892825487e-09
G2 O 0 1.7108840211221832e-06
phase O 0 5.088365355732094e-07
chromosomal O 0 4.43908320448827e-05
radiosensitivity O 0 4.236644599586725e-06
of O 0 2.2216790185325408e-08
peripheral O 0 0.0005739395855925977
blood O 0 0.0017737426096573472
lymphocytes O 0 1.9944172890973277e-05
. O 0 2.532350151795981e-07

In O 0 0.000160697745741345
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.15614444017410278
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4658691327440465e-07
patients O 0 8.357208685083606e-07
, O 0 1.6905503663622312e-09
mutations O 0 2.969391346141492e-07
in O 0 8.809120100039536e-10
a O 0 6.939834928942901e-09
single O 0 1.7879366396300611e-06
gene O 0 3.346944197346602e-07
, O 0 2.345485805577141e-09
ATM O 0 2.0203303847665666e-06
, O 0 3.2823002094062304e-09
result O 0 1.233928426103148e-08
in O 0 5.73659297842255e-09
an O 0 3.4955217415699735e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.3757092354182987e-08
embraces O 0 4.9389203837790774e-08
a O 0 4.28014290676515e-09
variety O 0 3.805066484119379e-09
of O 0 1.174853436758383e-09
clinical O 0 1.220304056914756e-06
features O 0 2.392761871305993e-06
and O 0 6.813595518906368e-07
manifests O 0 5.461320142785553e-07
extreme O 0 2.6498789793549804e-06
radiosensitivity O 0 2.895702164096292e-05
and O 0 4.325958258277751e-08
a O 0 3.6308421158537385e-08
strong O 0 5.795112656414858e-07
pre O 0 0.05145201086997986
- O 0 0.004124585539102554
disposition O 0 7.619516054546693e-06
to O 0 2.2384256226359867e-07
malignancy B-Disease 0 0.0003637155459728092
. O 0 3.8583718264817435e-07

Heterozygotes O 0 0.0005215485580265522
for O 0 1.3264384790545591e-07
the O 0 1.533298465972166e-08
ATM O 0 2.143400479326374e-06
gene O 0 1.0295374295310467e-06
have O 0 4.6323378910528845e-08
no O 0 3.4578864216427974e-08
clinical O 0 6.383785944308329e-07
expression O 0 9.012665458385527e-08
of O 0 3.6422662219592894e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 4.5443394469657505e-07
may O 0 7.3499626296325e-07
be O 0 4.244488138738234e-07
cancer B-Disease 0 5.869354026799556e-06
prone O 0 5.755990059697069e-06
with O 0 3.6917411350145812e-09
a O 0 1.767342183711662e-08
moderate O 0 3.469220928309369e-06
increase O 0 4.8063519386687403e-08
in O 0 9.045658444506444e-09
in O 0 2.774835472507675e-08
vitro O 0 0.00010700759594328701
radiosensitivity O 0 3.1211373425321653e-05
. O 0 1.0736029310010053e-07

We O 0 1.948174940480385e-05
performed O 0 1.979410399144399e-06
a O 0 9.408602608118599e-08
blind O 0 2.832153313647723e-06
chromosomal O 0 7.624117188242963e-06
analysis O 0 1.9844728171847237e-07
on O 0 1.3574705803875986e-07
G2 O 0 6.028008101566229e-06
- O 0 5.284414328343701e-06
phase O 0 1.4423203538171947e-06
lymphocytes O 0 1.4903412193234544e-06
from O 0 1.598976773209415e-08
7 O 0 1.5556726395971054e-07
unrelated O 0 8.221414304898644e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.0003552140260580927
, O 0 1.714234088012745e-09
13 O 0 7.062174844918445e-09
obligate O 0 4.1250490312449983e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 7.999663648661226e-05
( O 0 1.4449685004080948e-08
parents O 0 2.403674415063506e-08
of O 0 5.379836021113249e-10
the O 0 2.072840032951717e-08
patients O 0 2.081715848589738e-07
) O 0 8.910732707256841e-10
, O 0 6.457490098199514e-10
and O 0 6.769615534807372e-09
14 O 0 1.4329526898393397e-08
normal O 0 2.043586100342054e-08
controls O 0 4.564706159726484e-07
following O 0 5.3414176193200547e-08
X O 0 0.0002969559282064438
- O 0 3.4090214739990188e-06
irradiation O 0 2.8624549486266915e-07
with O 0 1.1646534403553233e-08
1 O 0 2.6700504918153456e-08
Gy O 0 4.46202921011718e-06
in O 0 2.7832727234056165e-09
order O 0 4.943714770888619e-09
to O 0 4.073917647673397e-09
evaluate O 0 6.347349312818551e-08
this O 0 1.0888937529429654e-09
cytogenetic O 0 6.622404953304795e-07
method O 0 9.804937661783697e-08
as O 0 3.910039403365317e-09
a O 0 2.3912718472018923e-09
tool O 0 2.4936460363278456e-07
for O 0 1.2370902080505175e-09
detection O 0 1.9430075326454244e-07
of O 0 1.0906070713190275e-08
ATM O 0 0.00011324150545988232
carriers O 0 1.0735097021097317e-05
. O 0 2.9337923024286283e-07

Both O 0 0.00010848575038835406
A B-Disease 1 0.9999969005584717
- I-Disease 1 0.9999923706054688
T I-Disease 1 1.0
homozygotes O 0 0.00024817214580252767
and O 0 6.950567410513031e-08
heterozygotes O 0 2.4158191536116647e-06
showed O 0 3.214467199086357e-07
significantly O 0 1.6497612875809864e-07
increased O 0 3.609175536212206e-08
levels O 0 8.663793238383732e-08
of O 0 8.827256259280603e-09
radiation O 0 0.25434574484825134
- O 0 0.040322866290807724
induced O 0 0.0010557823115959764
chromatid O 0 0.0057877735234797
damage O 0 1.273016277991701e-05
relative O 0 2.438072499444388e-07
to O 0 7.223860620797495e-09
that O 0 1.2201593069249839e-09
of O 0 2.668307796938052e-09
normal O 0 1.2075763606844703e-06
controls O 0 5.328589759301394e-05
. O 0 3.221734345970617e-07

These O 0 1.0227224720438244e-06
results O 0 4.199577574581781e-07
show O 0 1.3050372160705592e-07
that O 0 2.4161574962988652e-09
the O 0 5.3098241359350595e-09
G2 O 0 2.0462421161937527e-06
- O 0 2.612747948660399e-06
phase O 0 6.560149472534249e-07
chromosomal O 0 0.00022523780353367329
radiosensitivity O 0 7.977311724971514e-06
assay O 0 2.9439706850098446e-06
can O 0 3.208246823760419e-07
be O 0 6.185380652112826e-09
used O 0 1.7842502586518094e-08
for O 0 1.0230303271185903e-09
the O 0 4.912264373047037e-09
detection O 0 2.0648631107178517e-06
of O 0 2.1744739342466346e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.000372812821296975
. O 0 4.3096397916997375e-07

In O 0 7.033014526314219e-07
combination O 0 3.4306376051063125e-07
with O 0 1.3428493872424951e-08
molecular O 0 2.225450771220494e-06
genetic O 0 1.7587119145900942e-05
analyses O 0 8.535397682862822e-06
, O 0 1.1133207244995447e-08
this O 0 1.148115380544823e-09
test O 0 6.149743057903834e-06
may O 0 5.472790576277475e-07
be O 0 1.5888946824915706e-09
of O 0 5.815533471453804e-11
value O 0 7.800072809871494e-10
in O 0 1.5227466509948329e-10
studies O 0 1.2343679411941366e-09
of O 0 2.4064703008086497e-10
familial B-Disease 0 1.017068643704988e-05
and I-Disease 0 6.483041943283752e-07
sporadic I-Disease 0 0.2969283163547516
cancers I-Disease 1 0.9998776912689209
aimed O 0 9.405887794855516e-06
at O 0 2.9181185823290434e-07
determination O 0 1.6402456282094136e-08
of O 0 1.9257694050534013e-10
the O 0 1.4157606198494932e-09
potential O 0 5.638280065056733e-09
involvement O 0 1.5256727436963047e-08
of O 0 1.2347894928765868e-09
ATM O 0 6.674128235317767e-05
mutations O 0 2.0195260731270537e-05
in O 0 1.566800023056203e-08
tumor B-Disease 0 2.976646828756202e-05
risk O 0 7.448653605024447e-07
or O 0 1.5604207703745487e-08
development O 0 8.152300168262627e-09
. O 0 5.072654740700955e-09
. O 0 1.8294006309815813e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
: O 0 1.211148173752008e-06
identification O 0 6.037860202923184e-07
and O 0 2.2096349638900392e-08
detection O 0 3.974219282554259e-07
of O 0 4.7615298370828896e-09
founder O 0 3.9702339904579276e-07
- O 0 6.353336175379809e-06
effect O 0 1.112172967054903e-07
mutations O 0 4.5745025545329554e-07
in O 0 7.048310823876136e-10
the O 0 1.1946437172838387e-09
ATM O 0 8.855875535118685e-07
gene O 0 1.9169034715105226e-07
in O 0 3.7135208241778628e-09
ethnic O 0 4.383417717690463e-08
populations O 0 4.6880109039193485e-07
. O 0 6.979701083764667e-08

To O 0 4.0025105363383773e-07
facilitate O 0 2.3279805816400767e-07
the O 0 1.3451360914018551e-08
evaluation O 0 4.533547937057847e-08
of O 0 1.90958138190922e-09
ATM O 0 1.4834901776339393e-05
heterozygotes O 0 1.4911188372934703e-06
for O 0 1.036357777373098e-09
susceptibility O 0 1.7545160346799094e-07
to O 0 2.288248479587196e-09
other O 0 1.9189990041468263e-08
diseases O 0 4.368660302134231e-05
, O 0 2.7630131516076517e-10
such O 0 6.780505601433617e-10
as O 0 2.8020826903230045e-06
breast B-Disease 1 0.9999991655349731
cancer I-Disease 0 0.006264705676585436
, O 0 5.533002944702048e-09
we O 0 2.2035910873796638e-08
have O 0 3.5883276350290316e-09
attempted O 0 8.025455144888838e-08
to O 0 4.982279921961208e-09
define O 0 1.0477907608219539e-06
the O 0 2.5916244705825875e-09
most O 0 1.999286292075908e-09
common O 0 9.569951053833847e-09
mutations O 0 2.47778672246568e-07
and O 0 2.46615328158839e-09
their O 0 7.68817542962097e-09
frequencies O 0 6.9057637119840365e-06
in O 0 1.3870434258933528e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.000899063772521913
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.711621244737671e-08
homozygotes O 0 1.3605530284621636e-06
from O 0 3.826259309391844e-09
10 O 0 6.651949657765499e-09
ethnic O 0 3.498820078107201e-08
populations O 0 5.41722840807779e-07
. O 0 8.078993829485626e-08

Both O 0 1.1943411664105952e-06
genomic O 0 8.767364306550007e-06
mutations O 0 1.4973667020967696e-05
and O 0 2.8483373881726948e-08
their O 0 3.152804239903162e-08
effects O 0 5.002779630558507e-07
on O 0 1.2791313785953662e-08
cDNA O 0 1.0690686025327523e-07
were O 0 1.8969338100305322e-07
characterized O 0 7.937779855637928e-07
. O 0 1.242911906729205e-07

Protein O 0 6.930949166417122e-05
- O 0 1.0614919119689148e-05
truncation O 0 2.6461793822818436e-06
testing O 0 7.356652531598229e-07
of O 0 4.05631706001941e-09
the O 0 5.546474834972059e-09
entire O 0 4.470171077741725e-08
ATM O 0 8.393118946514733e-07
cDNA O 0 4.427743078849744e-07
detected O 0 1.1660414429570665e-06
92 O 0 2.4070129711617483e-07
( O 0 2.0532873179490707e-08
66 O 0 9.37354869279261e-08
% O 0 1.840182761725373e-08
) O 0 7.490823072942021e-09
truncating O 0 6.709087756462395e-07
mutations O 0 7.468954663636396e-07
in O 0 4.1287377960941285e-09
140 O 0 4.363647576610674e-08
mutant O 0 1.9070930648013018e-06
alleles O 0 2.139154958058498e-06
screened O 0 1.1812458069471177e-05
. O 0 3.5644723084260477e-07

The O 0 1.8652156086318428e-06
haplotyping O 0 6.18885678704828e-06
of O 0 2.796726938925076e-08
patients O 0 1.0251050298393238e-05
with O 0 2.3537149118624257e-08
identical O 0 0.018008917570114136
mutations O 0 0.0033729139249771833
indicates O 0 6.661315978817584e-07
that O 0 1.2357106449201183e-09
almost O 0 1.988152753540362e-08
all O 0 3.150120164718828e-10
of O 0 6.157947068929914e-11
these O 0 1.0968983499282103e-09
represent O 0 2.1784751780273837e-08
common O 0 6.712812705700344e-08
ancestry O 0 4.069372153026052e-06
and O 0 3.0987013843741806e-08
that O 0 2.2237893748666693e-09
very O 0 2.136176746603269e-08
few O 0 7.168303284288413e-08
spontaneously O 0 5.875850774827995e-07
recurring O 0 3.121372174064163e-06
ATM O 0 7.358824950642884e-05
mutations O 0 2.5549841666361317e-05
exist O 0 5.706078241018986e-07
. O 0 1.2806258098407852e-07

Assays O 0 8.009700832189992e-05
requiring O 0 3.5606744859251194e-06
minimal O 0 1.260948693015962e-06
amounts O 0 1.8475471819101585e-08
of O 0 3.51650775165524e-09
genomic O 0 4.4356548301038856e-07
DNA O 0 1.7663481912677526e-06
were O 0 1.0037991415856595e-07
designed O 0 5.029534833056459e-08
to O 0 4.1021670504903796e-09
allow O 0 1.2647113578623248e-08
rapid O 0 8.669297812957666e-08
screening O 0 2.028132115583503e-07
for O 0 4.881786974664237e-09
common O 0 1.1176892655839765e-07
ethnic O 0 1.7934219442850008e-07
mutations O 0 4.1917894122889265e-05
. O 0 2.8027511689288076e-07

These O 0 1.137354047386907e-06
rapid O 0 2.211666696894099e-06
assays O 0 1.7708700397633947e-05
detected O 0 1.2015043466817588e-05
mutations O 0 4.208055088383844e-06
in O 0 7.593419226736842e-09
76 O 0 1.2897631052055658e-07
% O 0 1.803485893958623e-08
of O 0 2.080186023434294e-09
Costa O 0 6.761551958334167e-07
Rican O 0 7.524170996475732e-06
patients O 0 1.2332164942563395e-06
( O 0 2.4593704850417453e-09
3 O 0 5.947752956814156e-09
) O 0 9.461610384065011e-10
, O 0 9.29453014553161e-10
50 O 0 2.0274844025891525e-09
% O 0 2.830431888867224e-09
of O 0 8.116456395867999e-10
Norwegian O 1 0.9907670021057129
patients O 0 1.0460621524543967e-05
( O 0 1.4836364359283039e-09
1 O 0 2.911130891902758e-09
) O 0 9.253439126055696e-10
, O 0 9.746586870917895e-10
25 O 0 1.5909811246217487e-09
% O 0 1.4874615983373474e-09
of O 0 1.0128565763878328e-09
Polish O 0 0.2333836406469345
patients O 0 5.31069463249878e-06
( O 0 2.645069718809623e-09
4 O 0 6.090507209677298e-09
) O 0 1.1441542158152629e-09
, O 0 1.0608655065524886e-09
and O 0 7.869669360616172e-09
14 O 0 1.568306906563066e-08
% O 0 2.20810436601937e-09
of O 0 5.792299972995352e-10
Italian O 0 0.17729897797107697
patients O 0 1.0170977475354448e-05
( O 0 3.4107809909755815e-09
1 O 0 4.701175448929007e-09
) O 0 1.5459603597278715e-09
, O 0 7.321804273985322e-10
as O 0 2.1356625357071835e-09
well O 0 8.129505957299443e-09
as O 0 2.263561560411631e-09
in O 0 1.1632452778798097e-09
patients O 0 1.02276160873771e-08
of O 0 4.817415910629563e-10
Amish O 0 2.995280738105066e-06
/ O 0 5.2457112360571045e-06
Mennonite O 0 2.1450300664582755e-06
and O 0 4.4821322831012367e-07
Irish O 0 8.401099876209628e-06
English O 0 2.087683060381096e-05
backgrounds O 0 9.208879419020377e-06
. O 0 2.832410928022e-07

Additional O 0 4.53299617220182e-06
mutations O 0 6.849853525636718e-05
were O 0 2.4204211968026357e-07
observed O 0 6.526664719785913e-08
in O 0 9.043445992062971e-10
Japanese O 0 7.923760136918645e-08
, O 0 1.249599757002784e-09
Utah O 0 3.002337489732554e-09
Mormon O 0 6.951015318890086e-09
, O 0 1.2758364364984232e-09
and O 0 3.147016647275791e-09
African O 0 2.0250313426117827e-08
American O 0 3.059191158172325e-07
patients O 0 3.9880504232314706e-07
. O 0 3.601254050522584e-08

These O 0 5.855823701494955e-07
assays O 0 3.765525661947322e-06
should O 0 5.809123138078576e-08
facilitate O 0 3.358480071824488e-08
screening O 0 4.401102842166438e-07
for O 0 2.3279162064682168e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 9.147887794824783e-06
in O 0 1.4688400495899145e-09
the O 0 3.446677387941577e-09
populations O 0 2.052797931639816e-08
studied O 0 4.361242744721494e-08
. O 0 7.76914887978819e-09
. O 0 4.0558237657251084e-08

The O 0 1.1385291145415977e-05
von B-Disease 1 0.9927781224250793
Hippel I-Disease 1 0.9996980428695679
- I-Disease 1 0.9978711605072021
Lindau I-Disease 1 0.9998797178268433
tumor I-Disease 0 0.006744395941495895
suppressor O 0 1.8635815649759024e-05
gene O 0 1.4521141338263988e-06
is O 0 8.551363173125992e-09
required O 0 1.6729730489828398e-08
for O 0 4.859426194769867e-09
cell O 0 7.661910785827786e-06
cycle O 0 4.499770511756651e-06
exit O 0 2.4961971121229e-06
upon O 0 3.2621431955703883e-07
serum O 0 1.5556295693386346e-05
withdrawal O 0 7.95799587649526e-06
. O 0 4.308024870169902e-07

The O 0 8.417873118560237e-07
inactivation O 0 5.920754119870253e-06
of O 0 4.5411464810740654e-08
the O 0 2.8015861630592553e-07
von B-Disease 1 0.9990696310997009
Hippel I-Disease 1 0.9999905824661255
- I-Disease 1 0.9999454021453857
Lindau I-Disease 1 0.9999822378158569
( I-Disease 0 8.16920419310918e-06
VHL I-Disease 0 0.002593828598037362
) I-Disease 0 1.7593684731309622e-07
tumor I-Disease 0 7.034248028503498e-06
suppressor O 0 5.039213647251017e-06
gene O 0 1.5224713934003375e-06
predisposes O 0 2.605619101814227e-06
affected O 0 2.750145711161167e-07
individuals O 0 1.4373817691648583e-08
to O 0 3.1828861768445904e-09
the O 0 4.019244315145443e-08
human O 0 3.714247213792987e-05
VHL B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999995231628418
and O 0 2.8960245757048142e-08
is O 0 4.342622261788165e-09
associated O 0 5.961531712728174e-08
with O 0 1.237143294474663e-07
sporadic B-Disease 1 0.9999732971191406
renal I-Disease 1 1.0
cell I-Disease 1 0.9999998807907104
carcinomas I-Disease 1 1.0
( O 0 3.8613277865806594e-05
RCC B-Disease 0 0.010609989985823631
) O 0 7.583579275660668e-08
and O 0 2.4727447112127265e-07
brain B-Disease 0 0.017618563026189804
hemangioblastomas I-Disease 0 0.00022181954409461468
. O 0 2.8455227152335283e-07

VHL O 0 0.12937377393245697
- O 0 0.0006360026309266686
negative O 0 2.6757441446534358e-05
786 O 0 1.255576171388384e-05
- O 0 3.567791645764373e-05
0 O 0 1.1368193781891023e-06
RCC B-Disease 0 4.5404143747873604e-05
cells O 0 1.2867619716416812e-06
are O 0 1.985265285497917e-08
tumorigenic O 0 2.6269667614542414e-06
in O 0 2.5413054771661336e-08
nude O 1 0.5081560611724854
mice O 0 3.746763468370773e-05
which O 0 9.961219404885924e-09
is O 0 2.2380353126294494e-09
suppressed O 0 1.7535082719177808e-08
by O 0 3.9015746189363654e-10
the O 0 2.5797293190521486e-09
reintroduction O 0 1.2188253606382204e-07
of O 0 1.6891524623474652e-08
VHL B-Disease 0 9.776378283277154e-05
. O 0 2.7167942562300595e-07

Remarkably O 0 0.010452008806169033
, O 0 3.774621859520266e-08
this O 0 3.3263223286894572e-09
occurs O 0 1.250828507437518e-08
without O 0 1.2323549292148073e-08
affecting O 0 5.0520235106432665e-08
the O 0 6.616835079853445e-09
growth O 0 6.804467034271511e-08
rate O 0 6.055713583918987e-07
and O 0 4.018707855379944e-08
cell O 0 4.767875907418784e-07
cycle O 0 9.360881136899479e-08
profile O 0 4.293603694804915e-08
of O 0 1.343086974969765e-09
these O 0 8.432092357679721e-09
cells O 0 3.8181688921667956e-08
in O 0 2.7392754731181412e-09
culture O 0 9.546072732291577e-08
. O 0 5.3405617705948316e-08

The O 0 2.5936938072845805e-06
786 O 0 1.3708924598176964e-05
- O 0 5.630505984299816e-05
0 O 0 1.92092738870997e-06
cell O 0 1.902364715533622e-06
line O 0 6.692537681374233e-06
, O 0 2.7072071251410534e-09
like O 0 3.740134424390362e-09
many O 0 6.4198650839841775e-09
cancer B-Disease 0 2.6268564852216514e-06
cells O 0 2.2313530578799146e-08
, O 0 9.073924944758005e-10
fails O 0 3.0538330975105055e-08
to O 0 3.125821823601882e-09
exit O 0 2.049787099167588e-06
the O 0 5.5016883493408386e-08
cell O 0 7.569455647171708e-06
cycle O 0 1.4533651437886874e-06
upon O 0 6.424853182807055e-08
serum O 0 2.5906481369020185e-06
withdrawal O 0 1.4609777281293646e-06
. O 0 1.4866404285385215e-07

Here O 0 4.134061782679055e-06
, O 0 4.298118483347935e-08
it O 0 3.0051907629058405e-09
is O 0 4.722508495369482e-10
shown O 0 1.8767303266997715e-09
that O 0 1.2730330678500934e-10
reintroduction O 0 3.1503979425195894e-09
of O 0 2.1851397080663304e-10
the O 0 2.588986358631473e-09
wild O 0 5.2037695041917686e-08
- O 0 6.074655175325461e-06
type O 0 0.00010691549687180668
VHL B-Disease 0 0.00025028601521626115
gene O 0 2.094355522785918e-06
restores O 0 4.3289628592901863e-07
the O 0 5.366372235471317e-09
ability O 0 9.761236441363508e-08
of O 0 1.3752448957404795e-08
VHL O 0 0.0002580167492851615
- O 0 3.626529360190034e-05
negative O 0 0.0001988406147575006
RCC B-Disease 0 0.01819014362990856
cancer I-Disease 0 4.5240511099109426e-05
cells O 0 7.520905143110213e-08
to O 0 3.5709990520160773e-09
exit O 0 4.1549645857230644e-07
the O 0 2.463456105772366e-08
cell O 0 1.7314871456619585e-06
cycle O 0 6.448548219850636e-07
and O 0 2.09909085668869e-08
enter O 0 4.779033702106972e-07
G0 O 0 3.09159149765037e-05
/ O 0 5.0876897148555145e-06
quiescence O 0 8.611256816948298e-06
in O 0 1.1535017563346628e-07
low O 0 0.0014147694455459714
serum O 0 0.00013505277456715703
. O 0 4.1854954702102987e-07

Both O 0 1.6266536476905458e-05
VHL O 0 0.0017065239371731877
- O 0 6.338658567983657e-05
positive O 0 6.119848876551259e-07
and O 0 1.1414621781113965e-07
VHL O 0 0.0001433064608136192
- O 0 1.1054967217205558e-05
negative O 0 1.0559106158325449e-05
RCC B-Disease 0 5.708368553314358e-05
cells O 0 9.217052365784184e-07
exit O 0 7.031612767605111e-07
the O 0 2.0436951686519933e-08
cell O 0 1.8182690837420523e-06
cycle O 0 5.63829360089585e-07
by O 0 8.288233210862472e-09
contact O 0 2.9291227292560507e-06
inhibition O 0 4.470440671866527e-06
. O 0 5.647501097882923e-07

The O 0 3.3800126857386203e-06
cyclin O 0 0.0002130444918293506
- O 0 1.0182885489484761e-05
dependent O 0 2.9610623641929124e-06
kinase O 0 9.186792340187822e-06
inhibitor O 0 1.526562755316263e-06
, O 0 1.0941470840464262e-08
p27 O 0 6.122324407442647e-07
, O 0 5.139934700082449e-09
accumulates O 0 4.650166829378577e-08
upon O 0 4.7875201580893645e-09
serum O 0 1.8566460369129345e-07
withdrawal O 0 1.758318575184603e-07
, O 0 1.3744810845039979e-09
only O 0 1.6448753470399424e-09
in O 0 4.304890610651313e-10
the O 0 1.479821043481877e-09
presence O 0 1.042635400239078e-08
of O 0 1.615887534889282e-09
VHL B-Disease 0 1.6371255696867593e-05
, O 0 5.031998817628391e-09
as O 0 2.124133091641056e-09
a O 0 2.54548604416982e-09
result O 0 5.3102091612799995e-09
of O 0 6.202918734210527e-11
the O 0 8.073041124490032e-10
stabilization O 0 1.153586026703124e-08
of O 0 3.409484916616634e-10
the O 0 3.3998432957815794e-09
protein O 0 1.5892750582224835e-07
. O 0 9.813244616907468e-08

We O 0 2.737237991823349e-06
propose O 0 3.459311983533553e-07
that O 0 3.839725870591337e-09
the O 0 3.9049270483815235e-09
loss O 0 2.488361872110545e-08
of O 0 1.0882086343144692e-09
wild O 0 7.782603717032543e-08
- O 0 3.3112013625213876e-05
type O 0 0.017595849931240082
VHL B-Disease 0 0.010970131494104862
gene O 0 6.8332556111272424e-06
results O 0 3.4442285823388374e-07
in O 0 2.726057379831559e-09
a O 0 5.947129455563527e-09
specific O 0 7.101823484845227e-08
cellular O 0 2.4196273443521932e-05
defect O 0 2.073464565910399e-05
in O 0 6.858172252321992e-09
serum O 0 3.2828513667482184e-06
- O 0 7.118162557162577e-06
dependent O 0 3.320398946016212e-06
growth O 0 2.7564894367060333e-07
control O 0 2.2624584516961477e-07
, O 0 1.424284135076448e-09
which O 0 1.4050700603007726e-09
may O 0 2.7598979102094745e-08
initiate O 0 4.5100716761226067e-07
tumor B-Disease 0 7.729170647507999e-06
formation O 0 1.6950626502421073e-07
. O 0 7.045601790878209e-08

This O 0 1.8190915795912588e-07
is O 0 2.375290364398097e-08
corrected O 0 1.7365361770771415e-07
by O 0 4.6259585051444674e-10
the O 0 5.849566941940054e-10
reintroduction O 0 2.7840757255148674e-08
of O 0 9.628386976601178e-10
wild O 0 1.0757860025023547e-07
- O 0 5.8581095800036564e-05
type O 0 0.11722968518733978
VHL B-Disease 0 0.10690866410732269
, O 0 4.460189728661135e-08
implicating O 0 2.032372503890656e-05
VHL B-Disease 0 6.256922642933205e-05
as O 0 2.2046084069415883e-08
the O 0 4.083283489109135e-09
first O 0 3.0929911076782446e-08
tumor B-Disease 0 3.676866526802769e-07
suppressor O 0 1.2256055015313905e-07
involved O 0 1.1051161763475648e-08
in O 0 1.4560951333564276e-09
the O 0 1.284695572145722e-09
regulation O 0 3.4484283872870947e-08
of O 0 2.1799122507104585e-09
cell O 0 2.2056151465221774e-06
cycle O 0 1.2799240494132391e-06
exit O 0 5.7577913139539305e-06
, O 0 2.7664647461733693e-08
which O 0 6.646914574304219e-09
is O 0 4.98834618056776e-09
consistent O 0 3.826108638804726e-07
with O 0 2.0654666865738136e-09
its O 0 6.931236473661784e-09
gatekeeper O 0 7.178126111284655e-07
function O 0 6.619033854349254e-08
in O 0 2.5419344407140443e-09
the O 0 3.6405715775345016e-08
kidney O 0 1.866747766143817e-06
. O 0 7.014143488248692e-09
. O 0 5.2134758732336195e-08

Piebaldism B-Disease 1 1.0
with O 0 0.008457343094050884
deafness B-Disease 1 1.0
: O 0 2.0668400679824117e-07
molecular O 0 5.262770628178259e-07
evidence O 0 5.329226482331251e-08
for O 0 3.4786959979271614e-09
an O 0 4.5891756172977693e-08
expanded O 0 0.0461873821914196
syndrome O 1 0.9999985694885254
. O 0 1.6383251022489276e-07

In O 0 5.847307420481229e-07
a O 0 1.129982365455362e-07
South O 0 1.1748030459557413e-07
African O 0 6.734433810606788e-08
girl O 0 6.96169820457726e-07
of O 0 3.3763591922308933e-09
Xhosa O 0 4.2141382436966524e-05
stock O 0 3.685112517359812e-07
with O 0 1.6789252654803022e-08
severe O 0 0.0014782157959416509
piebaldism B-Disease 0 0.00016428521485067904
and O 0 2.846285269697546e-07
profound O 0 8.649205119581893e-05
congenital O 1 1.0
sensorineural B-Disease 1 0.9999994039535522
deafness I-Disease 1 1.0
we O 0 0.0023557497188448906
identified O 0 1.689771579549415e-06
a O 0 1.1429550639263653e-08
novel O 0 6.078811054521793e-08
missense O 0 7.917956281744409e-07
substitution O 0 3.6667600511464116e-08
at O 0 4.5447684726696025e-08
a O 0 1.06316715431376e-08
highly O 0 5.630588972849182e-08
conserved O 0 7.225600029414636e-08
residue O 0 3.2578526543147746e-07
in O 0 1.3234048301669077e-09
the O 0 1.2006927674335088e-09
intracellular O 0 1.5875784242780355e-07
kinase O 0 2.557127913860313e-07
domain O 0 3.4863699482912125e-08
of O 0 1.9455814737057153e-09
the O 0 1.2877137578470865e-08
KIT O 0 1.450474974262761e-05
proto O 0 0.0006317556253634393
- O 0 4.3048723455285653e-05
oncogene O 0 1.380326193611836e-05
, O 0 4.5518472546746125e-08
R796G O 0 2.6899406293523498e-06
. O 0 1.2076795030679932e-07

Though O 0 9.5026289272937e-06
auditory B-Disease 0 7.3063543823082e-05
anomalies I-Disease 0 0.00031190612935461104
have O 0 1.3395491578194196e-06
been O 0 8.638694737328478e-08
observed O 0 7.321769146528823e-08
in O 0 2.720992542393219e-09
mice O 0 3.915425622835755e-06
with O 0 2.5502009393107983e-08
dominant O 0 0.0027666958048939705
white O 0 5.764004527009092e-06
spotting O 0 0.00043815289973281324
( O 0 1.5848947043650696e-07
W O 0 0.1841474175453186
) O 0 5.356953991508817e-09
due O 0 1.709767794011441e-08
to O 0 1.3002267706951898e-08
KIT O 0 0.12219223380088806
mutations O 0 0.3126317262649536
, O 0 3.2650282832946687e-07
deafness B-Disease 1 1.0
is O 0 8.361659098454766e-08
not O 0 2.0828588631616185e-08
typical O 0 1.1377105124665832e-07
in O 0 1.4301402728733592e-08
human O 0 2.5661546487754094e-07
piebaldism B-Disease 0 4.79188202007208e-05
. O 0 2.4221299099735916e-07

Thus O 0 6.215236226125853e-06
, O 0 1.3789589914381395e-08
the O 0 3.1534159727897304e-09
occurrence O 0 8.469653067777472e-08
of O 0 1.0033087249894379e-08
sensorineural B-Disease 1 0.9997177720069885
deafness I-Disease 1 1.0
in O 0 2.702944641441718e-07
this O 0 2.2595768811584094e-08
patient O 0 1.2117131973354844e-06
extends O 0 2.1948496353729752e-08
considerably O 0 8.285454811129966e-08
the O 0 1.5718698564981537e-09
phenotypic O 0 3.5901885553357715e-07
range O 0 4.142189311551192e-07
of O 0 4.250189089560763e-09
piebaldism B-Disease 0 3.907797236024635e-06
due O 0 3.102634238416613e-08
to O 0 6.656531770232732e-09
KIT O 0 1.3049994777247775e-05
gene O 0 1.2118356380597106e-06
mutation O 0 3.7934816532469995e-07
in O 0 2.72073830132058e-09
humans O 0 3.8519484490961986e-08
and O 0 1.7562731713383073e-08
tightens O 0 2.6736295694718137e-05
the O 0 2.6139558073623448e-08
clinical O 0 5.457384304463631e-07
similarity O 0 1.0583643472727999e-07
between O 0 4.153082144853215e-08
piebaldism B-Disease 0 3.123293208773248e-05
and O 0 6.9570109673122715e-09
the O 0 5.316510010011655e-10
various O 0 2.8760522852167014e-09
forms O 0 1.6637424948839907e-07
of O 0 4.464028222628258e-07
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999995231628418
. O 0 3.279635762964972e-08
. O 0 1.7318807010724413e-07

Cycloheximide O 0 0.00012683894601650536
facilitates O 0 4.719249773188494e-06
the O 0 6.883914238642319e-08
identification O 0 1.921446113328784e-07
of O 0 6.316333234224203e-09
aberrant O 0 3.6546502997225616e-06
transcripts O 0 6.078352271288168e-06
resulting O 0 2.4365085664612707e-06
from O 0 1.74643215444803e-08
a O 0 2.8331500701028745e-08
novel O 0 8.524562389311541e-08
splice O 0 0.000677830190397799
- O 0 6.560407200595364e-05
site O 0 1.0123512765858322e-06
mutation O 0 9.88524789136136e-07
in O 0 4.1066838818437645e-09
COL17A1 O 0 3.329197852508514e-06
in O 0 2.138646149063561e-09
a O 0 2.9215453167807937e-08
patient O 0 5.475983016367536e-06
with O 0 7.439226834549117e-08
generalized O 0 0.0010842366609722376
atrophic B-Disease 1 0.9999817609786987
benign I-Disease 1 0.9999306201934814
epidermolysis I-Disease 1 0.9997690320014954
bullosa I-Disease 1 0.9970769882202148
. O 0 9.774668797035702e-06

Patients O 1 0.9971824884414673
with O 0 3.3657763651717687e-06
generalized O 0 0.0016405460191890597
atrophic B-Disease 1 0.9999791383743286
benign I-Disease 1 0.9999434947967529
epidermolysis I-Disease 1 0.999809205532074
bullosa I-Disease 1 0.9945927262306213
often O 0 5.121440699440427e-05
show O 0 4.817282842850545e-06
decreased O 0 8.19357046566438e-06
expression O 0 1.113752290393677e-07
of O 0 8.297471154605773e-09
type O 0 0.0003478506696410477
XVII O 0 0.00017341444618068635
collagen O 0 1.3020209735259414e-05
, O 0 2.009786115308998e-08
a O 0 2.8944340257908152e-08
transmembrane O 0 2.682352487681783e-06
hemidesmosomal O 0 1.8462105799699202e-06
protein O 0 6.605588964703202e-08
encoded O 0 6.48155804583439e-08
by O 0 4.022281530069449e-08
COL17A1 O 0 2.3183718440122902e-05
. O 0 2.0785061849437625e-07

This O 0 3.4505114854255226e-07
report O 0 1.4322974095648533e-07
documents O 0 3.3444294444962e-08
a O 0 2.5300753492274453e-08
novel O 0 2.3575594809699396e-07
splice O 0 0.016435282304883003
- O 0 0.0004548619326669723
site O 0 1.3495802022589487e-06
mutation O 0 2.799857611535117e-06
in O 0 5.54851720124816e-09
COL17A1 O 0 6.72137139190454e-06
in O 0 2.795776055108945e-09
a O 0 6.81362237742178e-08
patient O 0 2.986626441270346e-06
with O 0 5.1525898214777044e-08
generalized O 0 0.0006854651728644967
atrophic B-Disease 1 0.9999426603317261
benign I-Disease 1 0.9996621608734131
epidermolysis I-Disease 1 0.9957461953163147
bullosa I-Disease 1 0.9450908899307251
, O 0 1.8855942585105367e-07
and O 0 7.893738107611625e-09
applies O 0 7.033810422996112e-09
a O 0 1.5022507682260766e-09
new O 0 1.6439594130446267e-09
methodology O 0 3.928700564870269e-08
to O 0 5.366699973308187e-09
define O 0 1.2193058864795603e-06
and O 0 1.0160190555552617e-07
characterize O 0 1.5141253015826805e-06
the O 0 4.8494197102399994e-08
resulting O 0 4.4895506334796664e-07
mRNA O 0 7.935130952319014e-07
splice O 0 5.1831320888595656e-05
variants O 0 1.593599699845072e-05
. O 0 1.4284398730524117e-06

Mutational O 0 0.0006784254219383001
analysis O 0 4.65091716250754e-06
of O 0 1.989587445905272e-07
COL17A1 O 0 9.337787196272984e-05
identified O 0 3.7998936477379175e-06
a O 0 1.9264146544628602e-07
maternally O 0 3.2472427847096696e-05
inherited O 0 1.4326050404633861e-05
G O 0 1.5334935596911237e-06
- O 0 1.2688691413131892e-06
to O 0 1.1525857956939944e-07
- O 0 0.004445905331522226
T O 0 0.00015931850066408515
transversion O 0 8.300519311887911e-07
at O 0 3.6002788306177536e-08
the O 0 5.1353188368352676e-09
- O 0 2.4525425601495954e-07
1 O 0 8.124235506556943e-09
position O 0 7.573143534500559e-08
of O 0 3.122341940553497e-09
exon O 0 1.177477543023997e-06
32 O 0 5.456691951621906e-07
. O 0 7.629891740634775e-08

This O 0 3.2764475577096164e-07
acceptor O 0 1.4627817108703312e-06
splice O 0 7.971921149874106e-05
- O 0 2.1279078282532282e-05
site O 0 8.61556543441111e-07
mutation O 0 9.143441275227815e-07
led O 0 1.9168480136499966e-08
to O 0 1.5556029797636484e-09
the O 0 2.734431125972492e-09
formation O 0 1.2011010852575055e-08
of O 0 8.02872435201607e-10
aberrant O 0 2.6979409994964954e-07
transcripts O 0 3.158106949285866e-07
present O 0 3.387662417253523e-08
at O 0 2.6951713039125025e-07
extremely O 0 1.7699518366498523e-06
low O 0 0.004160501062870026
levels O 0 2.239347668364644e-05
. O 0 2.3626121503639297e-07

Based O 0 3.4321820407967607e-07
on O 0 6.157861065503312e-08
our O 0 3.889615740604313e-08
recent O 0 1.297036433811627e-08
finding O 0 2.3940295079682983e-08
that O 0 6.533662499919046e-09
cycloheximide O 0 6.639139428443741e-06
stabilized O 0 5.0093396566808224e-05
mutant O 0 1.8024495602730894e-06
COL17A1 O 0 1.5884628510320908e-06
transcripts O 0 3.140219746455841e-07
in O 0 1.3322342340416071e-08
keratinocytes O 0 1.4682534583698725e-06
homozygous O 0 1.5477363604077254e-06
for O 0 2.0735506645053192e-09
a O 0 1.5060011904211024e-08
frameshift O 0 3.968185410485603e-05
mutation O 0 3.250620011385763e-06
, O 0 4.251437868418861e-09
the O 0 1.4156904537543369e-09
effects O 0 5.39839390967245e-07
of O 0 1.2569071339285642e-09
the O 0 1.4534099257446087e-08
splice O 0 0.005323535297065973
- O 0 4.4227133912499994e-05
site O 0 3.305942186671018e-07
mutation O 0 3.5526591091183946e-07
on O 0 8.915786331442632e-09
splicing O 0 1.5414391896229063e-07
of O 0 6.085769665986618e-09
COL17A1 O 0 1.6463175143144326e-06
transcripts O 0 2.438425781292608e-07
were O 0 8.055098987824749e-08
determined O 0 6.692894061188781e-08
using O 0 5.36618074420403e-08
reverse O 0 1.898480604722863e-06
transcriptase O 0 4.242402155796299e-06
polymerase O 0 1.9178976344846888e-06
chain O 0 1.7262128721995396e-06
reaction O 0 4.166760803059333e-08
of O 0 1.9810317830604163e-09
total O 0 1.1474154071322573e-08
RNA O 0 8.88741880089583e-08
from O 0 1.8156903536237223e-08
keratinocytes O 0 6.198131927703798e-07
incubated O 0 1.732123422470977e-07
for O 0 6.815374486990322e-09
2 O 0 1.0218104762316216e-07
. O 0 1.1011043454800529e-07

5 O 0 9.501813110546209e-06
h O 0 1.526217965874821e-05
in O 0 1.5914311646270107e-08
the O 0 7.452715777844787e-09
presence O 0 5.926703749992157e-08
or O 0 1.7751096947904443e-07
absence O 0 4.546745202560487e-08
of O 0 1.7525946249818958e-09
10 O 0 5.488649179596905e-08
microg O 0 6.746982762706466e-06
cycloheximide O 0 7.612637546117185e-06
per O 0 2.8793093065360154e-07
ml O 0 1.922969750012271e-05
. O 0 2.2302687341380079e-07

Using O 0 1.7334086805931292e-06
this O 0 2.0618230678337568e-08
approach O 0 1.3891546757349715e-07
, O 0 4.546603982191755e-09
an O 0 5.885449017029032e-09
abnormally O 0 0.00010117440251633525
spliced O 0 0.0005907830782234669
transcript O 0 2.5046165319508873e-05
was O 0 5.903614237467991e-06
identified O 0 1.3943962073881266e-07
that O 0 2.755361216966179e-10
contains O 0 5.431574079395318e-10
an O 0 4.777228612695694e-10
extra O 0 1.708372643349776e-08
264 O 0 7.626603348853678e-08
bases O 0 1.262170741256341e-07
upstream O 0 3.420222327576994e-08
from O 0 2.641923346757835e-09
exon O 0 1.2678601990501193e-07
32 O 0 8.608250112729365e-08
, O 0 6.1414144880700405e-09
resulting O 0 2.8253900552499545e-08
in O 0 1.7568820842583932e-09
a O 0 9.705134118576098e-08
premature O 0 7.705318239459302e-06
termination O 0 1.209743345498282e-06
codon O 0 3.1133840820984915e-06
27 O 0 4.2639138086997264e-07
bp O 0 8.678692324792792e-07
downstream O 0 1.3377434981975966e-07
from O 0 5.328999908016385e-09
the O 0 1.2100343838028493e-08
cryptic O 0 8.914376508073474e-07
splice O 0 4.963026367477141e-05
site O 0 2.942174432973843e-06
. O 0 4.5194408926363394e-07

Three O 0 8.298667353301425e-07
other O 0 2.064562032444428e-08
splice O 0 3.0513372621499002e-05
variants O 0 2.8462495720305014e-06
, O 0 1.0479706880062167e-08
including O 0 3.07975622781953e-09
one O 0 6.2750018514634576e-09
derived O 0 1.0936984651266357e-08
from O 0 1.2620118283734882e-09
the O 0 1.0199402433741511e-09
skipping O 0 2.093884532428092e-08
of O 0 4.641557693751963e-10
exon O 0 7.695030035392847e-08
32 O 0 1.019141961933201e-07
, O 0 4.6773309669845275e-09
were O 0 7.772842991471407e-08
also O 0 6.106631644797744e-08
identified O 0 7.230865435303713e-07
. O 0 8.204654733390271e-08

These O 0 1.4763254512217827e-06
results O 0 4.6586805524384545e-07
indicate O 0 2.0168813819054776e-07
the O 0 2.6804176656014533e-09
usefulness O 0 6.311410771786541e-08
of O 0 1.9515875582243325e-09
cycloheximide O 0 2.5804818051256007e-06
treatment O 0 5.931680036042053e-08
in O 0 9.999152617012896e-10
evaluating O 0 4.7238469136345884e-08
the O 0 3.7269742847456655e-09
abnormal O 0 1.6647328493490932e-07
processing O 0 1.972635743641149e-08
of O 0 1.032309460136105e-09
mRNA O 0 4.385675467233341e-08
due O 0 3.258399061678574e-08
to O 0 7.265591239757896e-09
splice O 0 0.09883889555931091
- O 0 0.0005820492515340447
site O 0 1.674724785516446e-06
mutations O 0 9.042037163453642e-06
, O 0 4.666619979332154e-09
because O 0 5.4730389109636235e-09
( O 0 2.7053796980425204e-09
i O 0 7.884833053140028e-08
) O 0 1.5210057657810694e-09
aberrant O 0 1.7847018796146585e-07
splicing O 0 8.185270417016e-07
often O 0 2.4532187126169447e-07
generates O 0 6.302111899003648e-08
a O 0 6.17293736127067e-08
premature O 0 3.499292461128789e-06
termination O 0 6.980392868172203e-07
codon O 0 1.2571243814818445e-06
, O 0 1.7449703904048874e-08
( O 0 1.0458321320072628e-08
ii O 0 3.340598198064981e-07
) O 0 6.142538921949381e-09
transcripts O 0 4.134485607210081e-07
with O 0 1.5082943605193577e-07
premature O 0 1.2524763405963313e-05
termination O 0 7.750819008833787e-07
codons O 0 4.819185619453492e-07
can O 0 4.520682139741439e-08
occur O 0 5.165706440379836e-08
at O 0 1.8755795849756396e-07
low O 0 0.025113722309470177
or O 0 3.9565475162817165e-05
undetectable O 0 0.003626644378527999
levels O 0 1.1132993904539035e-06
due O 0 3.877926246786956e-08
to O 0 1.924376036299691e-08
nonsense O 0 1.1465924217191059e-05
- O 0 1.7938409655471332e-06
mediated O 0 1.0301384918420808e-06
mRNA O 0 2.8521873218778637e-07
decay O 0 3.118005622582132e-07
, O 0 2.461059800396015e-09
and O 0 3.3584717229473426e-09
( O 0 2.214908256803483e-09
iii O 0 2.712666713478029e-08
) O 0 5.848495576721291e-10
the O 0 5.527662771953601e-10
levels O 0 1.6677354608418682e-08
of O 0 1.028198082231313e-10
these O 0 6.734222623983044e-10
transcripts O 0 1.0324325216970465e-07
can O 0 1.7016174069794943e-07
be O 0 1.4705592299435466e-08
increased O 0 2.8783038175106412e-08
by O 0 1.621658896056033e-08
cycloheximide O 0 8.198971954698209e-06
. O 0 9.671263256905149e-08

A O 0 1.259500095329713e-05
deletion O 0 0.00012826366582885385
mutation O 0 3.270180241088383e-05
in O 0 4.663134234306199e-08
COL17A1 O 0 1.848576903284993e-05
in O 0 8.767520931485251e-09
five O 0 1.8022788594862504e-08
Austrian O 0 4.7521269152639434e-05
families O 0 1.7722038592182798e-07
with O 0 8.072586155094541e-08
generalized O 0 0.0007311220979318023
atrophic B-Disease 1 0.9999643564224243
benign I-Disease 1 0.9993771910667419
epidermolysis I-Disease 1 0.9980012774467468
bullosa I-Disease 1 0.5019568204879761
represents O 0 9.361762067783275e-07
propagation O 0 4.6279134835458535e-07
of O 0 9.146387647263055e-09
an O 0 9.828582392401586e-09
ancestral O 0 4.987206466466887e-06
allele O 0 2.8838521757279523e-05
. O 0 3.222183124762523e-07

Patients O 1 0.9994850158691406
with O 0 2.2674921638099477e-06
generalized O 0 0.002996530383825302
atrophic B-Disease 1 0.9999927282333374
benign I-Disease 1 0.9999934434890747
epidermolysis I-Disease 1 0.9999783039093018
bullosa I-Disease 1 0.9996817111968994
, O 0 3.598106559365988e-07
a O 0 2.405637644642411e-08
usually O 0 6.15363475731101e-08
nonlethal O 0 5.096466679788136e-07
form O 0 1.8103689569670678e-07
of O 0 1.1870132254898635e-07
junctional B-Disease 1 0.997404158115387
epidermolysis I-Disease 1 0.9991717338562012
bullosa I-Disease 1 0.9633520841598511
, O 0 5.6197951181502503e-08
have O 0 1.0944246398025825e-08
generalized O 0 5.105426907903166e-07
blistering B-Disease 0 0.017873717471957207
, O 0 4.647803848456533e-07
nail B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999667406082153
, O 0 1.9775525572640618e-07
patchy B-Disease 1 0.9946931004524231
alopecia I-Disease 1 0.9999996423721313
, O 0 1.5490431337639166e-07
and O 0 5.820224373564997e-07
dental B-Disease 1 0.9998311996459961
abnormalities I-Disease 1 0.9999990463256836
. O 0 9.062367780643399e-07

Skin B-Disease 1 0.9999992847442627
fragility I-Disease 0 0.0006495678680948913
in O 0 2.775004936950154e-08
most O 0 6.104230454440085e-09
cases O 0 3.845501250765437e-09
is O 0 8.149715347016695e-10
due O 0 7.686548286756079e-09
to O 0 8.398385986652102e-09
mutations O 0 4.482847089093411e-06
in O 0 7.598413009901606e-10
the O 0 2.1049595400057797e-09
gene O 0 1.2489408618421294e-07
encoding O 0 5.01752936088451e-07
type O 0 0.00023818443878553808
XVII O 0 6.207665137480944e-05
collagen O 0 9.869396308204159e-06
( O 0 2.562914005466155e-07
COL17A1 O 0 2.8552063668030314e-05
) O 0 1.0373554459874867e-07
. O 0 1.095839152753797e-07

Recently O 0 4.878208346781321e-05
, O 0 2.1243859293917922e-07
we O 0 8.005946483535809e-08
reported O 0 5.084794807430626e-08
five O 0 5.645726997016709e-09
Austrian O 0 1.0383237167843617e-05
families O 0 8.396339268301745e-08
with O 0 5.682667492123983e-08
generalized O 0 0.00018808145250659436
atrophic B-Disease 1 0.9997701048851013
benign I-Disease 1 0.9964213371276855
epidermolysis I-Disease 1 0.9912885427474976
bullosa I-Disease 1 0.9807564616203308
who O 0 2.9760905817965977e-05
share O 0 2.1828805074619595e-07
the O 0 1.3795035336272576e-08
same O 0 9.316653404312092e-08
COL17A1 O 0 8.525945304427296e-05
mutation O 0 7.93584968050709e-06
. O 0 1.5769508365792717e-07

Affected O 0 9.437581320526078e-05
individuals O 0 7.396116643576534e-07
in O 0 6.919770534352665e-09
three O 0 1.3128661713324163e-08
families O 0 1.5389092666850956e-08
are O 0 7.2034147535759985e-09
homozygous O 0 6.073491931601893e-07
for O 0 2.145346567061779e-09
4003delTC O 0 5.135615310791763e-07
, O 0 1.7430901166903823e-09
whereas O 0 1.2120184855746174e-08
those O 0 2.993069347922983e-09
in O 0 4.945504006315105e-10
two O 0 1.792047044091305e-08
others O 0 8.626329872640781e-08
are O 0 1.3438050672220925e-08
compound O 0 2.6766136329570145e-07
heterozygotes O 0 3.0281842100521317e-06
. O 0 1.128661963889499e-07

To O 0 1.2882931059721159e-06
determine O 0 1.5154660104599316e-06
if O 0 2.5764359534719006e-08
the O 0 2.31348673551679e-09
occurrence O 0 9.4427427654864e-08
of O 0 1.1420305812137599e-09
4003delTC O 0 7.798828960403625e-07
in O 0 1.7875023683444624e-09
these O 0 3.5480651749963954e-09
unrelated O 0 3.659096137198503e-08
families O 0 1.0616433065990805e-08
signifies O 0 3.4187008779440475e-09
propagation O 0 1.0773256065021997e-08
of O 0 3.609185728059572e-10
an O 0 1.7090856507806507e-09
ancestral O 0 1.5399301673824084e-06
allele O 0 4.3635122892737854e-06
or O 0 9.258160815761585e-08
a O 0 1.9043739030166762e-08
mutational O 0 2.768194826785475e-05
hot O 0 0.00031120333005674183
spot O 0 0.007218670565634966
, O 0 2.1034995967283976e-08
haplotypes O 0 4.040837211505277e-07
were O 0 4.289126138701249e-07
determined O 0 8.505625004318063e-08
for O 0 1.2504651758504792e-09
polymorphisms O 0 2.3523616619058885e-05
both O 0 9.154943825251394e-08
within O 0 3.698085748737867e-08
and O 0 5.220769949687565e-08
flanking O 0 0.00014882441610097885
COL17A1 O 0 0.0012227268889546394
. O 0 1.8986530392339773e-07

Five O 0 2.1082623788970523e-05
intragenic O 0 0.00014198396820575
polymorphisms O 0 0.00036513892700895667
were O 0 9.27229564240406e-07
chosen O 0 9.458965877229275e-08
based O 0 1.104928681883166e-08
on O 0 4.517251639413189e-08
their O 0 1.8508173127429473e-07
informativeness O 0 1.7069862224161625e-05
. O 0 1.144856014434481e-07

One O 0 6.590839234377199e-07
of O 0 4.670644759841025e-09
these O 0 5.848855177958967e-09
, O 0 5.1007424950455515e-09
not O 0 3.570149686993318e-08
previously O 0 2.0420684450073168e-06
reported O 0 9.804915634958888e-07
, O 0 4.349261839564633e-09
was O 0 1.4291536842847563e-07
2988 O 0 3.069577587666572e-07
A O 0 9.57130552592389e-08
or O 0 7.808392297192768e-07
C O 0 1.639043716750166e-06
that O 0 7.619500586031336e-10
introduces O 0 8.798478390303899e-09
a O 0 4.106363249434253e-09
new O 0 2.9267028800461503e-09
restriction O 0 5.514586565169566e-09
site O 0 1.2292514561806911e-08
for O 0 4.980778456342705e-09
Eco0109 O 0 2.9325212835829007e-06
I O 0 8.601899935456458e-06
. O 0 6.608941305330518e-08

All O 0 3.0863415645399073e-07
the O 0 3.441765628053872e-08
4003delTC O 0 1.3586884506366914e-06
alleles O 0 9.168588803731836e-07
showed O 0 4.6207867399061797e-07
the O 0 1.0839703579179627e-09
same O 0 2.2893789086708694e-09
haplotype O 0 2.6819019893764562e-08
for O 0 7.07888081485919e-10
these O 0 2.791268327584362e-09
five O 0 1.7120456163866038e-08
polymorphic O 0 5.847508418810321e-06
markers O 0 6.674700853182003e-05
. O 0 2.5774835421543685e-07

Fourteen O 0 0.00014001659292262048
microsatellite O 0 0.00021838361863046885
polymorphisms O 0 0.0009672411251813173
were O 0 2.7884500468644546e-06
selected O 0 5.746024100972136e-08
based O 0 1.046794029235798e-08
on O 0 1.1829354384929047e-08
their O 0 4.606346593050148e-08
high O 0 2.2036337554709462e-07
heterozygosity O 0 6.266284913181153e-07
and O 0 1.8522857914149427e-08
their O 0 2.1628913771110092e-08
location O 0 1.4487125099549303e-07
within O 0 6.171688937683939e-08
10q23 O 0 2.3935012904985342e-06
- O 0 8.558302397432271e-06
q25 O 0 5.641764346364653e-06
near O 0 4.748830178868957e-06
COL17A1 O 0 3.7251484172884375e-05
. O 0 5.496689254869125e-07

Three O 0 6.02586442255415e-06
families O 0 1.7389089634889388e-06
shared O 0 7.624311137988116e-07
microsatellite O 0 3.674486288218759e-05
polymorphisms O 0 0.0002245306532131508
covering O 0 2.98232971545076e-05
at O 0 4.525021211065905e-07
most O 0 7.672968926897283e-09
19 O 0 5.226568333682735e-08
cM O 0 3.078075678786263e-07
, O 0 5.913557643566492e-09
whereas O 0 3.1542718659238744e-08
the O 0 1.067523758280231e-08
others O 0 4.583822033055185e-08
shared O 0 1.621018874686797e-08
smaller O 0 2.9493270048419618e-08
regions O 0 1.925955501747012e-07
consistent O 0 9.090957973967306e-06
with O 0 3.899153355746421e-08
cross O 0 0.0008536421228200197
- O 0 0.00026258910656906664
over O 0 9.498668163132606e-08
events O 0 6.802714835885126e-08
during O 0 7.427727410913576e-08
passage O 0 1.670928995167742e-08
of O 0 5.723442275673563e-10
this O 0 9.650966692476004e-10
mutation O 0 7.38293977065041e-08
through O 0 7.07602243465999e-09
several O 0 2.0114582000019254e-08
generations O 0 4.07546679070947e-07
. O 0 7.761553177942915e-08

These O 0 2.590707481431309e-06
results O 0 1.5699223467890988e-06
indicate O 0 7.036959459583159e-07
that O 0 6.980217737151406e-09
4003delTC O 0 1.1640381671895739e-06
occurs O 0 9.16577214127301e-09
on O 0 4.888430549243594e-09
a O 0 9.921684807068232e-09
single O 0 9.068739359463507e-07
ancestral O 0 9.38930099891877e-07
allele O 0 2.3357849840976996e-06
. O 0 1.865681475976544e-08
. O 0 1.363172259516432e-07

The O 0 2.4738371848798124e-06
haptoglobin O 0 0.0001127776995417662
- O 0 1.0516206202737521e-05
gene O 0 2.275824272146565e-06
deletion O 0 5.595639322564239e-06
responsible O 0 7.203038876468781e-07
for O 0 2.9495463849116277e-08
anhaptoglobinemia B-Disease 0 2.689050779736135e-05
. O 0 2.239209209164983e-07

We O 0 1.9150929801980965e-05
have O 0 4.553444910015969e-08
found O 0 9.1626608522688e-09
an O 0 1.8078003538590792e-09
allelic O 0 7.523766498707118e-07
deletion O 0 3.029611434612889e-06
of O 0 9.449315108156497e-09
the O 0 5.1947456114476154e-08
haptoglobin O 0 8.131964932545088e-06
( O 0 1.531273063903882e-08
Hp O 0 4.834587485902375e-08
) O 0 1.4742992382466014e-09
gene O 0 2.4142883248146063e-08
from O 0 1.5753304216659103e-09
an O 0 2.5393951386121216e-09
individual O 0 2.339580262855634e-08
with O 0 4.9320576067657385e-08
anhaptoglobinemia B-Disease 0 0.00015059813449624926
. O 0 2.4254839559034735e-07

The O 0 1.044516352521896e-06
Hp O 0 1.4447859939537011e-06
gene O 0 1.1026254469470587e-06
cluster O 0 2.58185053780835e-07
consists O 0 9.519559363013741e-09
of O 0 8.300236609137812e-10
coding O 0 7.606394660797378e-07
regions O 0 1.2357848788724368e-07
of O 0 2.6928388408009596e-09
the O 0 1.3031911549887809e-08
alpha O 0 3.646965396342239e-08
chain O 0 6.120076250226703e-07
and O 0 9.825302349497633e-09
beta O 0 1.601778976123569e-08
chain O 0 4.609827186641269e-08
of O 0 2.989353486970714e-10
the O 0 2.9192599448890633e-09
haptoglobin O 0 2.475831024639774e-07
gene O 0 8.854138400238298e-08
( O 0 2.651206587600541e-09
Hp O 0 1.1655133747012769e-08
) O 0 7.714818783810529e-10
and O 0 9.292934199933711e-10
of O 0 2.852379443751829e-10
the O 0 2.0758696983591562e-09
alpha O 0 2.351480432594144e-08
chain O 0 3.0591735367124784e-07
and O 0 7.191252038296625e-09
beta O 0 1.5253323937258756e-08
chain O 0 5.476707087836985e-08
of O 0 5.810757430779745e-10
the O 0 8.417934793669701e-09
haptoglobin O 0 2.6335439997637877e-06
- O 0 5.25566861142579e-07
related O 0 5.926478152673553e-08
gene O 0 3.8664205703753396e-07
( O 0 9.503883902084453e-09
Hpr O 0 8.486056231049588e-07
) O 0 6.449837108846168e-09
, O 0 1.6998072949192533e-09
in O 0 9.516395449438164e-10
tandem O 0 2.4984212814160855e-06
from O 0 8.853628052918339e-09
the O 0 1.0038485598329316e-08
5 O 0 6.35293346817889e-08
side O 0 3.1357326406578068e-06
. O 0 1.2949703886988573e-07

Southern O 0 2.0503895939327776e-05
blot O 0 0.00018612368148751557
and O 0 2.0768655417668924e-07
PCR O 0 5.5400460041710176e-06
analyses O 0 5.463567958940985e-06
have O 0 2.090694550815897e-07
indicated O 0 1.6775560141013557e-07
that O 0 5.592437068990819e-10
the O 0 1.2023015916184931e-09
individual O 0 2.745353500088754e-09
with O 0 4.311491164088466e-09
anhaptoglobinemia B-Disease 0 6.74727198202163e-05
was O 0 3.965462269661657e-07
homozygous O 0 1.7911077065946301e-07
for O 0 2.543310562153067e-10
the O 0 1.6517857082121168e-09
gene O 0 6.56476899507652e-08
deletion O 0 2.2391216702999373e-07
and O 0 3.247330226940903e-08
that O 0 8.354349989581067e-10
the O 0 2.83121481814419e-09
gene O 0 1.1537900235225607e-07
deletion O 0 5.768623054791533e-07
was O 0 3.4952324767800746e-07
included O 0 9.01092622740407e-09
at O 0 1.678548215977571e-07
least O 0 5.922971890726103e-09
from O 0 7.354148956473239e-10
the O 0 1.6922021561782685e-09
promoter O 0 1.3836188372806646e-07
region O 0 1.1908746877509202e-08
of O 0 1.0071582456916417e-09
Hp O 0 5.7278924714410095e-08
to O 0 1.327095944247958e-08
Hpr O 0 1.6420335668954067e-06
alpha O 0 4.022388822022549e-08
but O 0 9.97766758104035e-09
not O 0 6.442582911603267e-09
to O 0 2.0370871212094244e-08
Hpr O 0 1.6245421647909097e-05
beta O 0 7.255096647895698e-07
( O 0 1.3029965373334562e-07
Hpdel O 0 6.823598141636467e-06
) O 0 6.553759135385917e-08
. O 0 6.306176203452196e-08

In O 0 3.347924177887762e-07
addition O 0 7.316980799032535e-08
, O 0 1.586721154467341e-08
we O 0 2.2300937985164637e-08
found O 0 6.621556636332571e-09
seven O 0 9.727963323769018e-09
individuals O 0 3.012766258692068e-09
with O 0 3.138726167861705e-09
hypohaptoglobinemia B-Disease 0 3.0112626063782955e-06
in O 0 3.684242466661658e-09
three O 0 3.1465383187878615e-08
families O 0 3.4556908445892986e-08
, O 0 1.0007987771842863e-09
and O 0 2.84750489853991e-09
the O 0 5.679435588490378e-09
genotypes O 0 1.7006424002374843e-07
of O 0 7.257637268942574e-10
six O 0 1.4370582057665615e-08
of O 0 3.5228969741396554e-10
the O 0 3.883253718584001e-09
seven O 0 2.5842318507329765e-08
individuals O 0 5.731354058013949e-09
were O 0 5.166445760096394e-08
found O 0 3.154318140019541e-09
to O 0 4.967856348514488e-09
be O 0 8.057710942921403e-08
Hp2 O 0 4.8705383960623294e-05
/ O 0 1.2483526006690226e-05
Hpdel O 0 3.262569953221828e-05
. O 0 3.7600821656269545e-07

The O 0 2.236459067717078e-06
phenotypes O 0 1.0448806278873235e-05
and O 0 1.1637212793402796e-07
genotypes O 0 3.25382711707789e-06
in O 0 5.228958599445832e-09
one O 0 4.445062096181118e-09
of O 0 7.539555091362615e-10
these O 0 5.06594455274012e-09
three O 0 6.873142410768196e-08
families O 0 6.105432248659781e-08
showed O 0 1.2055442084601964e-06
the O 0 8.031055820367783e-09
father O 0 3.3185108350153314e-07
to O 0 4.597496161551362e-09
be O 0 2.1434008345977418e-08
hypohaptoglobinemic B-Disease 0 1.0111721167049836e-06
( O 0 5.676197289972151e-09
Hp2 O 0 5.14883197411109e-07
) O 0 4.554016275193362e-09
and O 0 9.36957711417108e-09
Hp2 O 0 3.718126436069724e-06
/ O 0 3.0831192816549446e-06
Hpdel O 0 3.0920796234568115e-06
, O 0 6.0158775738727854e-09
the O 0 6.180451261883491e-09
mother O 0 2.2748164951735816e-07
to O 0 3.5430740563668905e-09
be O 0 1.3419865219077565e-08
Hp2 O 0 7.638240617779957e-07
- O 0 1.198566337734519e-06
1 O 0 2.192155079683289e-08
and O 0 2.2499007101828283e-08
Hp1 O 0 3.2841103347891476e-06
/ O 0 1.4627412383561023e-06
Hp2 O 0 1.532698320261261e-06
, O 0 3.0711742038391776e-09
one O 0 1.048534037373372e-09
of O 0 1.9318542598956157e-10
the O 0 2.902398987814081e-09
two O 0 2.3922128278286436e-08
children O 0 9.41547853017255e-08
to O 0 4.9133892510155874e-09
be O 0 6.661970530785766e-08
hypohaptoglobinemic B-Disease 0 2.5709289275255287e-06
( O 0 1.082276757102818e-08
Hp2 O 0 3.656333831258962e-07
) O 0 1.697034290870647e-09
and O 0 4.200672698573271e-09
Hp2 O 0 3.1500505883741425e-06
/ O 0 1.6933852293732343e-06
Hpdel O 0 3.8438943192886654e-06
, O 0 3.6345473297672015e-09
and O 0 1.181155950824575e-09
the O 0 4.923705887449614e-10
other O 0 6.444915157111097e-10
child O 0 2.598595472136367e-08
to O 0 2.6164885813528826e-09
be O 0 1.957642936645243e-08
Hp1 O 0 8.995402822620235e-07
and O 0 3.427824424306891e-08
Hp1 O 0 9.22142862691544e-06
/ O 0 5.474207682709675e-06
Hpdel O 0 5.962185241514817e-06
, O 0 9.255685107234513e-09
showing O 0 2.4680610977156903e-07
an O 0 1.2622574097065353e-09
anomalous O 0 1.1869520477603146e-07
inheritance O 0 1.9495315939366265e-07
of O 0 3.4113534219670782e-09
Hp O 0 4.4759175921171845e-07
phenotypes O 0 2.9839673061360372e-06
in O 0 3.664765602096054e-09
the O 0 1.1780854514142902e-08
child O 0 1.0520221849219524e-06
with O 0 2.1278161455029476e-08
Hp1 O 0 3.0130637242109515e-05
. O 0 1.8342980467878078e-07

The O 0 3.896770067512989e-06
Hp2 O 0 8.519021503161639e-05
/ O 0 4.956948396284133e-05
Hpdel O 0 2.3410220819641836e-05
individuals O 0 2.779407566322334e-07
had O 0 9.12586344270494e-08
an O 0 3.3018030531906106e-09
extremely O 0 5.507887408384704e-07
low O 0 0.0003263831604272127
level O 0 2.017877022808534e-06
of O 0 2.132926724129902e-09
Hp O 0 1.096621105034501e-07
( O 0 6.328295665269934e-09
mean O 0 3.8775862520878945e-08
+ O 0 1.016542370280149e-07
/ O 0 7.791438747517532e-07
- O 0 4.8752153816167265e-06
SD O 0 0.03643377870321274
= O 0 1.8505823391024023e-05
0 O 0 1.0629647562154787e-07
. O 0 4.876361536787499e-09
049 O 0 1.0733557473940891e-06
+ O 0 2.484753451881261e-07
/ O 0 8.608313919467037e-07
- O 0 1.1750331623261445e-06
0 O 0 1.698347347200979e-07
. O 0 1.0136881556377375e-08
043 O 0 1.966169520528638e-06
mg O 0 1.414844291502959e-06
/ O 0 1.7451056919526309e-06
ml O 0 2.68207668341347e-06
; O 0 3.502686141132472e-08
n O 0 3.533268227329245e-06
= O 0 2.610001047287369e-06
6 O 0 7.907650001470756e-08
) O 0 5.342138287289799e-09
, O 0 2.0299066871842797e-09
compared O 0 1.0127024552275543e-08
with O 0 1.7924083328679785e-09
the O 0 5.705983685544425e-09
level O 0 5.215952683101932e-07
( O 0 1.7120839190809534e-09
1 O 0 8.798575201751646e-10
. O 0 3.327659536811467e-10
64 O 0 8.177825527866389e-09
+ O 0 2.723382586111711e-08
/ O 0 1.438152850141705e-07
- O 0 4.58226594446387e-07
1 O 0 7.422357395370227e-09
. O 0 1.7369602423045194e-09
07 O 0 4.6738017545067123e-07
mg O 0 5.680099093297031e-07
/ O 0 4.336665142545826e-07
ml O 0 7.398635943900445e-07
) O 0 2.6989372958752256e-09
obtained O 0 6.837079347121744e-09
from O 0 9.648836396536353e-09
52 O 0 2.9243284416224924e-07
healthy O 0 1.6741485353577445e-07
volunteers O 0 5.5287124212100025e-08
having O 0 1.0291609697787862e-07
phenotype O 0 8.623933922535798e-07
Hp2 O 0 7.136829367482278e-07
, O 0 3.717702146133206e-09
whereas O 0 8.946073215554406e-09
the O 0 3.0434463837991643e-09
serum O 0 2.0924758814544475e-07
Hp O 0 2.7446480643789073e-08
level O 0 2.8721505174189588e-08
of O 0 5.584527840163389e-10
an O 0 2.867452497667955e-09
individual O 0 1.4999324449149753e-08
with O 0 4.565167444070539e-08
Hp1 O 0 0.00016137213970068842
/ O 0 1.9990842702100053e-05
Hpdel O 0 3.383430157555267e-05
was O 0 1.640474692976568e-06
0 O 0 4.5242833834890916e-07
. O 0 1.2380120040234033e-07

50 O 0 1.0806866157508921e-05
mg O 0 1.4709620700159576e-05
/ O 0 1.4216735507943667e-05
ml O 0 1.3584238331532106e-05
, O 0 1.5958567800566925e-08
which O 0 6.1385798666435676e-09
was O 0 2.3484412636776142e-08
approximately O 0 3.590189923130538e-09
half O 0 2.761749939850233e-09
the O 0 1.4317280694342571e-09
level O 0 1.8971013204804876e-08
of O 0 5.930474444859613e-10
Hp O 0 3.453779839901472e-08
in O 0 5.046357998139683e-09
control O 0 2.0649105863412842e-05
sera O 0 6.16123725194484e-06
from O 0 4.5322487984833515e-09
the O 0 8.431335629666137e-09
Hp1 O 0 9.183552833746944e-07
phenotype O 0 2.1606015820907487e-07
( O 0 2.8439659516266147e-09
1 O 0 2.260519993413368e-09
. O 0 5.543521197637347e-10
26 O 0 9.887566321253871e-09
+ O 0 3.6241100787037794e-08
/ O 0 2.622983856781502e-07
- O 0 6.927768936293432e-07
0 O 0 5.3882622808032465e-08
. O 0 2.226947293237913e-09
33 O 0 8.618008706662295e-08
mg O 0 2.636619740314927e-07
/ O 0 3.2621431955703883e-07
ml O 0 1.3326467751539894e-06
; O 0 1.3273010246450667e-08
n O 0 4.096074007975403e-06
= O 0 7.680669114051852e-06
9 O 0 7.565564175138206e-08
) O 0 3.853056096403407e-09
, O 0 3.6243710255234873e-09
showing O 0 2.0779275189397595e-07
a O 0 3.472426612916024e-08
gene O 0 1.1177867236256134e-06
- O 0 9.652347216615453e-06
dosage O 0 2.5026707589859143e-05
effect O 0 9.79060132522136e-07
. O 0 1.3748389449119713e-07

The O 0 2.414523692095827e-07
other O 0 2.8976048227491447e-08
allele O 0 1.4245450756789069e-06
( O 0 2.2306979374775437e-08
Hp2 O 0 4.823489234695444e-07
) O 0 1.0251984816633808e-09
of O 0 3.1378508125179394e-10
individuals O 0 4.377316287218491e-09
with O 0 7.108338806460779e-09
Hp2 O 0 9.586681699147448e-05
/ O 0 2.1034305973444134e-05
Hpdel O 0 2.932104325736873e-05
was O 0 1.3174035302654374e-06
found O 0 1.1219541740103978e-08
to O 0 2.5398601000148346e-09
have O 0 1.0864633281926217e-07
, O 0 6.718570699781878e-10
in O 0 1.7470368207650466e-10
all O 0 7.876348462332317e-10
exons O 0 1.5646297413240973e-07
, O 0 7.621190789564025e-09
no O 0 2.2832271184825004e-08
mutation O 0 4.6369169837134905e-08
, O 0 4.950619358901065e-10
by O 0 8.926604455616882e-10
DNA O 0 9.735911277175546e-08
sequencing O 0 5.625799985864433e-07
. O 0 1.3099651141601498e-07

On O 0 3.7906139027654717e-07
the O 0 9.797417988011148e-09
basis O 0 6.876890168427963e-09
of O 0 2.4564905665158676e-10
the O 0 1.2186359699128957e-09
present O 0 2.8195958901022777e-09
study O 0 1.0473467648708379e-09
, O 0 4.487431537469888e-10
the O 0 3.376209312122569e-10
mechanism O 0 1.6040138106632185e-08
of O 0 9.205714524007647e-10
anhaptoglobinemia B-Disease 0 3.0674052595713874e-06
and O 0 1.5544292963909356e-08
the O 0 1.046755571110225e-09
mechanism O 0 1.5175523060406704e-08
of O 0 4.662845110026126e-10
anomalous O 0 8.568281373300124e-08
inheritance O 0 1.1336727823163528e-07
of O 0 1.5017207477541206e-09
Hp O 0 4.1850165644063964e-07
phenotypes O 0 1.533760041638743e-05
were O 0 3.670689636692259e-07
well O 0 1.4112029589341546e-07
explained O 0 1.0395018534836709e-06
. O 0 1.079078160159952e-07

However O 0 1.9563983642001403e-06
, O 0 1.989867648433119e-08
the O 0 4.508366124866825e-09
mechanism O 0 5.847341455478272e-08
of O 0 1.370424307367557e-08
hypohaptoglobinemia B-Disease 0 0.00010572031169431284
remains O 0 2.4037171897361986e-06
unknown O 0 3.814125875578611e-06

ATM O 0 0.0011192860547453165
mutations O 0 0.0008512934437021613
and O 0 8.067866019700887e-07
phenotypes O 0 0.00011498115782160312
in O 0 1.0229858844468254e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 0.005607379600405693
in O 0 1.747705091759144e-08
the O 0 1.3106894236614153e-08
British O 0 1.550178239995148e-06
Isles O 0 8.26803272957477e-07
: O 0 2.908189689065921e-09
expression O 0 6.0281335478862275e-09
of O 0 5.174487505144043e-10
mutant O 0 1.1669887101106724e-07
ATM O 0 4.5167692519498814e-07
and O 0 8.431191744762145e-09
the O 0 5.8073257314106286e-09
risk O 0 2.1080207091017655e-07
of O 0 7.1291674785811665e-09
leukemia B-Disease 1 0.6479735374450684
, O 0 2.5846391054074047e-06
lymphoma B-Disease 1 1.0
, O 0 1.4436453454891307e-07
and O 0 2.0229281290085055e-05
breast B-Disease 1 0.9999998807907104
cancer I-Disease 0 0.4323112368583679
. O 0 3.321069073081162e-07

We O 0 4.092962171853287e-06
report O 0 4.3744808664314405e-08
the O 0 2.0594008720564716e-09
spectrum O 0 2.9835636183861425e-08
of O 0 2.6849305001519497e-09
59 O 0 2.5419413418603654e-07
ATM O 0 5.3069965360919014e-05
mutations O 0 1.7012171156238765e-05
observed O 0 7.237026125039847e-07
in O 0 4.5786578084516805e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.007267764303833246
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3865671633084276e-07
patients O 0 3.6020858829033386e-07
in O 0 1.1444859504550209e-09
the O 0 1.1511726683011148e-08
British O 0 3.0863611755194142e-06
Isles O 0 7.431110589095624e-06
. O 0 2.4263795239676256e-07

Of O 0 5.401545308814093e-07
51 O 0 4.273979811841855e-06
ATM O 0 4.1773040720727295e-05
mutations O 0 8.572349179303274e-05
identified O 0 5.258767146187893e-07
in O 0 3.762838485243947e-09
families O 0 1.1784629272426628e-08
native O 0 2.3526633974313427e-09
to O 0 3.044270835417251e-09
the O 0 1.9879443868831004e-08
British O 0 6.136603133199969e-06
Isles O 0 2.457370555930538e-06
, O 0 5.494711352582726e-09
11 O 0 1.3521095354462886e-08
were O 0 4.122901131609069e-08
founder O 0 4.249324092597817e-08
mutations O 0 3.0689864161104197e-07
, O 0 1.3270547993826654e-09
and O 0 1.917516145866216e-09
2 O 0 1.1818185319256713e-09
of O 0 1.8625544162542695e-10
these O 0 3.842612450455363e-09
11 O 0 3.606168519354469e-08
conferred O 0 1.8047936478637894e-08
a O 0 8.418015617905894e-09
milder O 0 1.5175706721493043e-05
clinical O 0 0.00011273070413153619
phenotype O 0 4.37470816905261e-06
with O 0 4.03306499308087e-09
respect O 0 4.317037394230283e-09
to O 0 7.562314330300524e-09
both O 0 1.1452724493210553e-06
cerebellar B-Disease 0 0.0028213649056851864
degeneration I-Disease 0 0.0066866278648376465
and O 0 7.303595594976287e-08
cellular O 0 2.6519571747485315e-06
features O 0 5.340630195860285e-06
. O 0 5.694498668162851e-07

We O 0 5.290680201142095e-05
report O 0 3.9613161106899497e-07
, O 0 1.0768243186021209e-08
in O 0 3.0266702477632634e-09
two O 0 5.792350066258223e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 3.8536023794222274e-07
, O 0 8.741234402975806e-10
an O 0 1.3092347206367094e-09
ATM O 0 1.9880479158018716e-05
mutation O 0 2.6538798465480795e-06
( O 0 1.938115445909716e-08
7271T O 0 8.916672413761262e-07
- O 0 1.2316778338572476e-05
- O 0 1.9567005438148044e-05
> O 0 9.295864629166317e-07
G O 0 2.3350210085482104e-06
) O 0 1.216339362564156e-09
that O 0 6.468485747035402e-10
may O 0 5.316170614833027e-08
be O 0 5.018598869810376e-09
associated O 0 3.179694729738003e-09
with O 0 8.665685391484601e-10
an O 0 1.8608828922239695e-09
increased O 0 2.997687431616214e-07
risk O 0 3.9435462895198725e-06
of O 0 3.588644403862418e-08
breast B-Disease 1 0.9999786615371704
cancer I-Disease 0 6.018913700245321e-05
in O 0 1.9990040733830483e-09
both O 0 3.0746338808285145e-08
homozygotes O 0 2.1019790438003838e-05
and O 0 6.458802204178937e-08
heterozygotes O 0 3.1533420496998588e-06
( O 0 2.3974292773232264e-08
relative O 0 1.0516921520320466e-06
risk O 0 9.457778105570469e-06
12 O 0 2.822115163780836e-08
. O 0 1.587907028088864e-09
7 O 0 2.8588148737185293e-08
; O 0 2.8515611205648383e-08
P O 0 0.029132647439837456
= O 0 1.3144921467755921e-05
. O 0 7.089842934959734e-09
0025 O 0 2.7308992684993427e-06
) O 0 4.144454557319932e-09
, O 0 7.501385623776002e-10
although O 0 2.268012888606563e-09
there O 0 1.880937627873891e-09
is O 0 8.283235763961727e-10
a O 0 1.3076530969158284e-08
less O 0 1.0145632813873817e-06
severe O 1 0.976348340511322
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 1.4824535355728585e-05
in O 0 2.1778800984861846e-09
terms O 0 5.177491324559469e-09
of O 0 1.5870463276890234e-10
the O 0 1.5532281016916727e-09
degree O 0 2.979827051774464e-08
of O 0 4.1443616538572314e-08
cerebellar B-Disease 0 0.014985622838139534
degeneration I-Disease 0 0.07943590730428696
. O 0 6.67922904540319e-07

This O 0 7.893964948380017e-07
mutation O 0 8.054534191614948e-06
( O 0 1.6930107449297793e-07
7271T O 0 2.6280542897438863e-06
- O 0 1.8304866898688488e-05
- O 0 1.5513034668401815e-05
> O 0 1.585644554324972e-06
G O 0 2.093311195494607e-06
) O 0 2.716994185192334e-09
also O 0 2.5825550586944246e-09
allows O 0 2.79821943394154e-09
expression O 0 1.5253556640004717e-08
of O 0 1.3987702107698397e-09
full O 0 1.4161022932057676e-07
- O 0 3.7612546748277964e-06
length O 0 5.789643182652071e-07
ATM O 0 7.295321665878873e-06
protein O 0 6.383554307376471e-08
at O 0 1.4899270261992115e-08
a O 0 3.4169147511420306e-09
level O 0 7.036899773993355e-08
comparable O 0 7.92363863411083e-08
with O 0 5.248303125426901e-09
that O 0 4.7093249300189655e-09
in O 0 5.9886078318527325e-09
unaffected O 0 4.126015028305119e-06
individuals O 0 4.995442282051954e-08
. O 0 6.965989030049968e-08

In O 0 3.654621991699969e-07
addition O 0 7.457653339315584e-08
, O 0 8.09447708860489e-09
we O 0 1.4730856534583836e-08
have O 0 7.959990000472317e-09
studied O 0 4.882795678895491e-07
18 O 0 5.712754500564188e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.996422209544107e-05
, O 0 7.372829013974069e-10
in O 0 3.1545693834900135e-10
15 O 0 2.4853865632223915e-09
families O 0 2.136167687183388e-09
, O 0 5.552706627831583e-10
who O 0 1.4708172457744695e-08
developed O 0 6.035628393874504e-05
leukemia B-Disease 1 0.9987070560455322
, O 0 2.878468649214483e-06
lymphoma B-Disease 1 1.0
, O 0 9.787840582475837e-08
preleukemic O 0 0.0001364133058814332
T O 0 0.0043337526731193066
- O 0 1.941009031725116e-05
cell O 0 1.9923641957575455e-05
proliferation O 0 5.42880025022896e-06
, O 0 4.110651730115933e-08
or O 0 0.06723560392856598
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.28207337471531e-08
mostly O 0 2.1251027604307637e-08
in O 0 2.7324512430482173e-08
childhood O 0 0.00012362259440124035
. O 0 3.5166243605999625e-07

A O 0 1.7474720834798063e-06
wide O 0 2.0984489879083412e-07
variety O 0 3.5377279772319525e-08
of O 0 3.9095771064978635e-09
ATM O 0 9.123358904616907e-05
mutation O 0 8.826189514365979e-06
types O 0 6.221903845471388e-07
, O 0 3.6579077544729444e-09
including O 0 3.6382372670118457e-09
missense O 0 1.8213901057606563e-05
mutations O 0 3.235336043871939e-05
and O 0 6.150935405457858e-08
in O 0 1.2008193550627766e-08
- O 0 2.1431616914924234e-05
frame O 0 0.016792243346571922
deletions O 0 1.390226316289045e-05
, O 0 1.4695783079332614e-07
were O 0 1.5154559207530838e-07
seen O 0 1.5976269196471549e-07
in O 0 1.7065089341627981e-09
these O 0 3.376289825496315e-08
patients O 0 2.830401797382365e-07
. O 0 5.626637999966988e-08

We O 0 1.917849112942349e-05
also O 0 5.6167088757774764e-08
show O 0 9.1090647913461e-08
that O 0 2.1348722789582553e-09
25 O 0 7.1963563996746416e-09
% O 0 2.8308635435791984e-09
of O 0 7.5764022833269e-10
all O 0 2.6090154392477416e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.00022996058396529406
carried O 0 4.174537195922312e-07
in O 0 4.676215858978594e-09
- O 0 5.959610462014098e-06
frame O 0 0.0003941601898986846
deletions O 0 1.0712997209338937e-05
or O 0 1.2409047940309392e-06
missense O 0 1.2790877008228563e-05
mutations O 0 6.44865531285177e-06
, O 0 1.6613849185276308e-09
many O 0 2.207943411436375e-10
of O 0 3.2894054147192264e-10
which O 0 4.8802164087646815e-08
were O 0 1.6380031411245e-06
also O 0 3.6345976894835985e-08
associated O 0 1.8334036511191698e-08
with O 0 1.4183120233823843e-09
expression O 0 1.6976372307908605e-08
of O 0 1.4746396326259514e-09
mutant O 0 7.999365720934293e-07
ATM O 0 6.236100034584524e-06
protein O 0 1.8399637156107929e-06
. O 0 5.747897944274882e-07

The O 0 2.9146190172468778e-06
DMPK O 0 5.3837065934203565e-05
gene O 0 4.055838871863671e-06
of O 0 8.017407537863619e-08
severely O 0 0.028732240200042725
affected O 0 0.0003226717235520482
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9951608777046204
is O 0 4.0793313615949955e-08
hypermethylated O 0 2.449450448693824e-06
proximal O 0 4.706091203843243e-06
to O 0 6.299876531556947e-08
the O 0 5.1218130181496235e-08
largely O 0 3.1021139079712157e-07
expanded O 0 2.3093562049325556e-06
CTG O 0 7.802325853845105e-05
repeat O 0 1.9894248907803558e-05
. O 0 4.3669822957781435e-07

Using O 0 7.66351877246052e-06
methylation O 0 1.377169246552512e-05
- O 0 5.946478722762549e-06
sensitive O 0 1.8029256807494676e-06
restriction O 0 1.48327288229666e-07
enzymes O 0 2.629814161991817e-07
, O 0 5.483142828666132e-09
we O 0 5.188622420604361e-09
characterized O 0 1.1583021652938896e-08
the O 0 1.1372658370589761e-09
methylation O 0 5.562316118812305e-08
pattern O 0 1.2820522670153878e-06
on O 0 3.786375302183842e-08
the O 0 1.1492025997483779e-08
5 O 0 1.4552241189846882e-08
side O 0 1.4065875575397513e-07
of O 0 7.551126390836771e-10
the O 0 2.8749896685553722e-08
CTG O 0 5.910960226174211e-06
repeat O 0 8.397690294259519e-07
in O 0 1.1881379213818377e-09
the O 0 1.6380438117025165e-09
DMPK O 0 4.062692084971786e-07
gene O 0 1.6985119088985812e-08
of O 0 4.985680202018727e-10
normal O 0 2.5870873443523124e-08
individuals O 0 1.0774340308827846e-09
and O 0 1.5904623174023413e-09
of O 0 1.4521734925665442e-09
patients O 0 4.368519626041234e-07
affected O 0 1.5323635693675897e-07
with O 0 4.952470931129938e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 5.590437979208218e-08
showing O 0 2.877719964544667e-07
expansions O 0 6.04735603815243e-08
of O 0 1.9933994455101356e-09
the O 0 1.7875576574510887e-08
repetitive O 0 9.796796803129837e-05
sequence O 0 1.7204262121595093e-06
. O 0 2.7719110562429705e-07

The O 0 6.860712460365903e-07
gene O 0 2.5874185212160228e-06
segment O 0 1.3504583193935105e-06
analyzed O 0 5.342981808098557e-07
corresponds O 0 1.4108235291132587e-07
to O 0 1.3925204989106987e-08
the O 0 2.98264737352838e-08
genomic O 0 3.418342203076463e-06
SacI O 0 0.00013402875629253685
- O 0 3.864643440465443e-05
HindIII O 0 8.223506483773235e-06
fragment O 0 7.332474183385784e-07
carrying O 0 1.4875340070830134e-07
exons O 0 1.6560252333874814e-06
11 O 0 3.7716642964369385e-07
- O 0 2.384358595008962e-06
15 O 0 2.324009926724102e-07
. O 0 1.1495856711007946e-07

There O 0 1.4216217323337332e-06
is O 0 2.4010626376025357e-08
constitutive O 0 1.9106869331153575e-07
methylation O 0 2.808734222981002e-07
in O 0 1.011841366249655e-08
intron O 0 1.216311920870794e-05
12 O 0 2.271694654609746e-07
at O 0 2.4239874107934156e-08
restriction O 0 1.10781970263929e-08
sites O 0 1.2006956318089124e-08
of O 0 3.389140967868798e-09
SacII O 0 1.841261109802872e-06
and O 0 4.007876697187385e-08
HhaI O 0 1.2476651818360551e-06
, O 0 2.5130966196940108e-09
localized O 0 5.86401647240109e-08
1 O 0 9.144050849840824e-09
, O 0 1.4748027243882689e-09
159 O 0 2.8331283985494338e-08
- O 0 4.318036417316762e-07
1 O 0 1.0519439541667452e-08
, O 0 1.978535779656454e-09
232 O 0 2.8758233128201027e-08
bp O 0 3.858581862914434e-07
upstream O 0 2.5394934155542614e-08
of O 0 1.3295985423766865e-09
the O 0 1.4922846958143055e-08
CTG O 0 2.7546182082005544e-06
repeat O 0 3.202863467777206e-07
, O 0 1.665935167594057e-09
whereas O 0 7.52506323919988e-09
most O 0 1.1076944916865727e-09
, O 0 1.2876296695552014e-09
if O 0 1.4225113309507265e-09
not O 0 1.877646926828902e-09
all O 0 3.775136314665417e-10
, O 0 1.4556612859539797e-10
of O 0 5.7709479556189436e-11
the O 0 3.1215424689534643e-10
other O 0 3.887490607201727e-10
sites O 0 1.3842952562015398e-08
of O 0 1.106655433957826e-09
SacII O 0 1.1034712770197075e-06
, O 0 6.8549286247332475e-09
HhaI O 0 4.2378104581075604e-07
, O 0 2.5447479679030494e-09
and O 0 3.934337744482264e-09
HpaII O 0 4.639287851659901e-07
in O 0 1.2535409377179008e-09
this O 0 6.376076888692239e-10
region O 0 9.181450266737556e-09
are O 0 4.05193256725056e-09
unmethylated O 0 4.987060151506739e-07
, O 0 1.3447428726109933e-09
in O 0 6.349499259705738e-10
normal O 0 4.7582457085582064e-08
individuals O 0 2.6836097788418556e-09
and O 0 7.592053652416553e-10
most O 0 3.807895943008788e-10
of O 0 2.841253621266304e-10
the O 0 3.181777330496516e-08
patients O 0 5.903394821871188e-07
. O 0 3.874658460745195e-08

In O 0 2.8936042895111314e-07
a O 0 1.4604684572816495e-08
number O 0 3.396965153612541e-09
of O 0 4.3405001814988964e-10
young O 0 3.697112305189876e-08
and O 0 3.703831197299223e-08
severely O 0 0.0070962742902338505
affected O 0 9.585425004843273e-07
patients O 0 3.473176093393704e-07
, O 0 7.119652090104012e-10
however O 0 1.6149169779211547e-09
, O 0 3.7794736784668714e-10
complete O 0 1.1058240989569867e-09
methylation O 0 7.693706116640442e-09
of O 0 3.466017750586303e-10
these O 0 1.2222369782932674e-09
restriction O 0 9.621453855856998e-09
sites O 0 8.930154393738121e-08
was O 0 5.534726028599835e-07
found O 0 1.1222816453937412e-08
in O 0 1.2449131725489337e-09
the O 0 1.5725124313803462e-08
mutated O 0 2.045011115114903e-06
allele O 0 3.234956238884479e-06
. O 0 1.1979201985923282e-07

In O 0 1.2876479615897551e-07
most O 0 7.710188043574817e-09
of O 0 5.479522946494342e-10
these O 0 6.450427747495269e-09
patients O 0 1.0924895121888767e-07
, O 0 2.807536148008438e-10
the O 0 1.1379731601479648e-09
onset O 0 6.986585958657088e-06
of O 0 2.324380465879017e-09
the O 0 6.577053227374563e-06
disease O 1 0.9807878732681274
was O 0 1.6933829101617448e-05
congenital O 1 0.999645471572876
. O 0 2.61413106272812e-07

Preliminary O 0 3.014072535734158e-05
in O 0 1.0974963515764102e-06
vivo O 0 0.00013738921552430838
footprinting O 0 0.00014797414769418538
data O 0 8.964385074250458e-07
gave O 0 1.2456709441721614e-07
evidence O 0 2.3152711747798094e-08
for O 0 2.53547494111217e-09
protein O 0 1.595297476342239e-07
- O 0 3.5845002912537893e-06
DNA O 0 1.0258962674924987e-06
contact O 0 3.514640184221207e-06
in O 0 9.213799501139874e-09
normal O 0 5.275041417007742e-07
genes O 0 2.6869946623264696e-07
at O 0 3.2599345445305516e-08
an O 0 3.0931726069383103e-09
Sp1 O 0 2.9476436225195357e-07
consensus O 0 2.326399695107284e-08
binding O 0 3.8363310750355595e-08
site O 0 5.537587810522382e-08
upstream O 0 2.4817829569201422e-08
of O 0 6.633334992400819e-10
the O 0 1.1289025714233958e-08
CTG O 0 3.4433855944371317e-06
repeat O 0 8.715469448361546e-07
and O 0 7.736394636026489e-09
for O 0 6.302202093522169e-10
a O 0 2.4777802032360796e-09
significant O 0 3.38171513014629e-09
reduction O 0 4.079422577518699e-09
of O 0 1.0112694015518287e-10
this O 0 2.2327559245916007e-10
interaction O 0 9.282699942048112e-09
in O 0 5.8545701620005275e-09
cells O 0 2.6102194183863503e-08
with O 0 3.33328942225819e-09
a O 0 6.364345495057933e-08
hypermethylated O 0 1.964995863090735e-05
DMPK O 0 7.063247721816879e-06
gene O 0 3.6661418789663003e-07
. O 0 1.2222655776383817e-08
. O 0 4.859002444845828e-08

The O 0 5.959337613603566e-06
hemochromatosis B-Disease 1 0.9999982118606567
gene O 0 9.124762982537504e-06
product O 0 3.446489245106932e-07
complexes O 0 1.9333073453253746e-07
with O 0 5.359477750488395e-09
the O 0 5.58334889433354e-09
transferrin O 0 2.273890373771792e-07
receptor O 0 3.8969756133155897e-07
and O 0 1.1723336967861542e-08
lowers O 0 2.1505941560917563e-07
its O 0 1.0437133379781471e-09
affinity O 0 1.0032436215112739e-08
for O 0 1.4206132936678273e-09
ligand O 0 5.801770797120298e-08
binding O 0 4.3623577994367224e-07
. O 0 1.5516941687110375e-07

We O 0 3.256775744375773e-05
recently O 0 1.0263836429658113e-06
reported O 0 1.0074684553273983e-07
the O 0 2.043195390655228e-09
positional O 0 2.4925333264036453e-07
cloning O 0 5.0888896652168114e-08
of O 0 5.738471919869426e-10
a O 0 6.2628053854041354e-09
candidate O 0 4.0709065274313616e-07
gene O 0 7.1555555223312695e-06
for O 0 3.0954311114328448e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.004376336466521025
HFE O 1 0.7261691689491272
. O 0 2.0785071228601737e-06

The O 0 5.150781703378016e-07
gene O 0 1.2571136949190986e-06
product O 0 9.53126289005013e-08
, O 0 2.414931810079679e-09
a O 0 1.53585000273182e-09
member O 0 2.9664535272644343e-09
of O 0 1.854645464982596e-10
the O 0 8.497395564965871e-10
major O 0 6.348872538808337e-09
histocompatibility O 0 1.3439465362807823e-07
complex O 0 1.4423003236174736e-08
class O 0 8.292600739423506e-08
I O 0 7.175578502938151e-06
- O 0 5.979571255920746e-07
like O 0 2.7849944572722052e-08
family O 0 3.839010176420743e-08
, O 0 1.8640124999080854e-09
was O 0 4.9222837361639904e-08
found O 0 3.520024272063438e-09
to O 0 2.2680388678253394e-09
have O 0 1.880593991643309e-08
a O 0 1.0774859227069555e-08
mutation O 0 5.393927153818368e-07
, O 0 4.572624945353709e-09
Cys O 0 1.2926996532769408e-05
- O 0 3.309930889372481e-06
282 O 0 1.5588121868859162e-06
- O 0 3.371824641362764e-05
- O 0 2.9123852073098533e-05
> O 0 1.698821733953082e-06
Tyr O 0 4.949339654558571e-06
( O 0 3.615438615156563e-08
C282Y O 0 2.422809188828978e-07
) O 0 2.281193012265703e-09
, O 0 4.447663348727815e-10
in O 0 3.4799818582342823e-10
85 O 0 8.428892250833542e-09
% O 0 4.722600976947433e-09
of O 0 3.306617868403805e-09
patient O 0 2.3240907012223033e-06
chromosomes O 0 4.294379778002622e-06
. O 0 3.619454673753353e-07

This O 0 6.744184020135435e-07
mutation O 0 4.791706942341989e-06
eliminates O 0 1.1649009366010432e-06
the O 0 1.654520431770834e-08
ability O 0 7.557387249335079e-08
of O 0 2.334029858275244e-09
HFE O 0 5.33218371856492e-05
to O 0 2.8422483921985986e-08
associate O 0 4.1747162526917236e-07
with O 0 2.9693650205331323e-08
beta2 O 0 0.0017944829305633903
- O 0 0.0012847712496295571
microglobulin O 0 4.139038355788216e-05
( O 0 2.2632173468650763e-08
beta2m O 0 5.665243634211947e-07
) O 0 3.723649166786913e-09
and O 0 6.619864656443042e-09
prevents O 0 7.038160987349329e-08
cell O 0 9.522065624878451e-07
- O 0 7.66274388297461e-06
surface O 0 1.837928175518755e-05
expression O 0 2.71697535936255e-06
. O 0 2.3418174066591746e-07

A O 0 1.6462121493532322e-05
second O 0 2.8864844807685586e-06
mutation O 0 2.5021265628311085e-06
that O 0 7.527029666221097e-09
has O 0 2.5574687256835205e-08
no O 0 2.565393053544085e-08
effect O 0 2.2245794539799135e-08
on O 0 2.99768139200296e-08
beta2m O 0 2.0266161300241947e-05
association O 0 2.7206775499166724e-08
, O 0 3.01672842262235e-09
H63D O 0 3.193833435943816e-06
, O 0 8.730641098964043e-09
was O 0 8.346712832008052e-08
found O 0 5.7020121957407355e-09
in O 0 1.1515562947650437e-09
eight O 0 1.8535297741095746e-08
out O 0 7.745239116729863e-09
of O 0 1.36489342050794e-09
nine O 0 5.304619321577775e-07
patients O 0 1.5788288010298857e-07
heterozygous O 0 2.216258110365743e-07
for O 0 1.444570907338516e-09
the O 0 9.779383525199137e-09
C282Y O 0 2.2691579033562448e-06
mutant O 0 4.456492661120137e-06
. O 0 2.6387880325273727e-07

In O 0 3.258014089624339e-07
this O 0 1.0970872210691596e-08
report O 0 1.9827185226972688e-08
, O 0 9.590960248218039e-10
we O 0 2.7721362982902065e-09
demonstrate O 0 8.102941428944632e-09
in O 0 1.6634396082793046e-09
cultured O 0 1.6798037449916592e-07
293 O 0 2.501882931937871e-07
cells O 0 1.6507543421084847e-07
overexpressing O 0 4.083265594090335e-06
wild O 0 1.717644408927299e-07
- O 0 7.019392000984226e-07
type O 0 8.797172995400615e-06
or O 0 2.1179289433348458e-07
mutant O 0 2.257971800645464e-06
HFE O 0 9.485707778367214e-06
proteins O 0 2.78827414490479e-08
that O 0 8.477661350703158e-10
both O 0 1.4441439155632452e-09
the O 0 2.4969470935332083e-09
wild O 0 2.850256031194931e-08
- O 0 2.144003246939974e-06
type O 0 7.173188350861892e-05
and O 0 3.863217443722533e-07
H63D O 0 9.178245818475261e-05
HFE O 0 4.661030106944963e-05
proteins O 0 1.538895304520338e-07
form O 0 1.647438949703428e-07
stable O 0 1.6481476450280752e-06
complexes O 0 3.135383508379164e-08
with O 0 5.608580710969591e-09
the O 0 1.8747170926758372e-08
transferrin O 0 4.537701897788793e-06
receptor O 0 2.236689397250302e-06
( O 0 9.807686751628353e-08
TfR O 0 1.0218703209829982e-05
) O 0 1.029781415695652e-07
. O 0 7.544884539356644e-08

The O 0 2.43675958699896e-06
C282Y O 0 3.534694405971095e-05
mutation O 0 1.2567045814648736e-05
nearly O 0 6.662745590801933e-07
completely O 0 1.0682854281185428e-06
prevents O 0 3.1832826152822236e-08
the O 0 1.4879184551119806e-09
association O 0 4.090268124201657e-09
of O 0 3.311640406344907e-10
the O 0 6.907506566733446e-09
mutant O 0 6.53584811516339e-06
HFE O 0 5.737172978115268e-05
protein O 0 1.2772521529313963e-07
with O 0 1.1537334643207942e-08
the O 0 9.703265391181048e-08
TfR O 0 0.000165621328051202
. O 0 5.27625900303974e-07

Studies O 0 5.34896889803349e-06
on O 0 3.449843575253908e-07
cell O 0 4.584190264722565e-06
- O 0 5.293296453601215e-06
associated O 0 1.1437646207923535e-07
transferrin O 0 4.5548915750259766e-07
at O 0 8.408487417455035e-08
37 O 0 1.1181370496160525e-07
degrees O 0 4.6979602075225557e-07
C O 0 3.113188722636551e-05
suggest O 0 1.5961558119670372e-07
that O 0 1.592329046395946e-09
the O 0 1.3264329190576518e-08
overexpressed O 0 1.54271140218043e-06
wild O 0 4.366911454667388e-08
- O 0 3.5588541891229397e-07
type O 0 4.331554009695537e-06
HFE O 0 3.0726947443326935e-05
protein O 0 1.7233855942322407e-07
decreases O 0 1.5092311400621838e-07
the O 0 2.413826694080967e-09
affinity O 0 2.0288432267534517e-08
of O 0 4.0409964263687925e-09
the O 0 3.616514732129872e-08
TfR O 0 1.0221930097031873e-05
for O 0 2.201238658017246e-08
transferrin O 0 6.154084985610098e-06
. O 0 2.822617091169377e-07

The O 0 2.106225110765081e-06
overexpressed O 0 7.196277874754742e-05
H63D O 0 1.69186714629177e-05
protein O 0 5.158686917638988e-07
does O 0 7.452491956883023e-08
not O 0 7.833802051493421e-09
have O 0 2.9399236378679916e-09
this O 0 4.810152831602466e-10
effect O 0 1.3443434809801147e-08
, O 0 5.616596077118174e-10
providing O 0 2.5399959913130488e-09
the O 0 4.562760169690705e-10
first O 0 1.7306207578116073e-09
direct O 0 9.333778194786646e-09
evidence O 0 3.582134056046016e-08
for O 0 3.0407423246003873e-09
a O 0 1.9168332698882296e-08
functional O 0 3.2106911476148525e-06
consequence O 0 2.3640185986550932e-07
of O 0 2.795882636519309e-09
the O 0 6.688108555863437e-08
H63D O 0 0.00013861748448107392
mutation O 0 7.639788236701861e-06
. O 0 1.4154514360598114e-07

Addition O 0 1.8796956737787696e-06
of O 0 1.3405085041995335e-07
soluble O 0 3.2865166303963633e-06
wild O 0 6.037928983460006e-07
- O 0 9.338140444015153e-06
type O 0 0.000925772066693753
HFE O 0 0.32407018542289734
/ O 0 6.0584061429835856e-05
beta2m O 0 1.0482222023711074e-05
heterodimers O 0 5.949212663836079e-06
to O 0 4.341647397154702e-08
cultured O 0 1.879193973763904e-06
cells O 0 6.003592716297135e-07
also O 0 2.9366185927415245e-08
decreased O 0 3.22058554047544e-07
the O 0 3.1119256060918588e-09
apparent O 0 2.263890763742893e-08
affinity O 0 1.534041516038087e-08
of O 0 1.977004338016286e-09
the O 0 5.332762231802235e-09
TfR O 0 1.609891342013725e-06
for O 0 1.6507464284387652e-09
its O 0 2.950602873141861e-09
ligand O 0 1.7648964956151758e-08
under O 0 3.3137666832772084e-08
steady O 0 3.523452733134036e-06
- O 0 6.350679768729606e-07
state O 0 6.387656625861382e-09
conditions O 0 1.6551933867958724e-07
, O 0 6.161192667164528e-10
both O 0 1.5181566004329738e-09
in O 0 1.2713812225229049e-09
293 O 0 2.8155293207987597e-08
cells O 0 1.824988338228195e-08
and O 0 3.3140306054946223e-09
in O 0 6.017599307739374e-09
HeLa O 0 4.9419163588027e-06
cells O 0 2.952902207198349e-07
. O 0 6.314697742482167e-08

Furthermore O 0 2.5878483938868158e-05
, O 0 1.2748243705118512e-07
at O 0 4.6159946975876665e-08
4 O 0 2.209997340685277e-08
degrees O 0 2.2787430680182297e-06
C O 0 0.02847013622522354
, O 0 1.8282598546193185e-08
the O 0 1.2933654147673224e-08
added O 0 9.57913698584889e-07
soluble O 0 7.123040290935023e-08
complex O 0 1.8740054841259735e-08
of O 0 6.001346086748072e-09
HFE O 0 0.0007453353609889746
/ O 0 1.243444512510905e-05
beta2m O 0 5.650875209539663e-06
inhibited O 0 5.80098458158318e-07
binding O 0 3.2269554139929824e-08
of O 0 1.6506898070645093e-09
transferrin O 0 2.382582664495203e-07
to O 0 4.059802094502629e-08
HeLa O 0 9.745052011567168e-06
cell O 0 2.9593063572974643e-06
TfR O 0 2.7197338567930274e-06
in O 0 6.544837560795713e-09
a O 0 1.9088979286152608e-08
concentration O 0 1.9627519577625208e-05
- O 0 1.984937443921808e-05
dependent O 0 2.7250300718151266e-06
manner O 0 3.2133377771970117e-06
. O 0 9.254559074634017e-08

Scatchard O 0 0.0004176540533080697
plots O 0 5.521079401660245e-06
of O 0 2.5355827659723218e-08
these O 0 1.1147464284988473e-08
data O 0 2.0320408111729193e-07
indicate O 0 1.1787661833295715e-06
that O 0 3.4223999190174936e-09
the O 0 1.4826074590246208e-08
added O 0 5.195607286623272e-07
heterodimer O 0 8.421156962867826e-07
substantially O 0 9.173346597890486e-07
reduced O 0 1.8245360777768838e-08
the O 0 7.719940242623125e-10
affinity O 0 1.2838095919676107e-08
of O 0 4.9208170871395396e-09
TfR O 0 4.895514848612947e-06
for O 0 2.4518589825106574e-08
transferrin O 0 5.528439487534342e-06
. O 0 1.6172178618489852e-07

These O 0 2.117768417519983e-06
results O 0 1.5541912716798834e-06
establish O 0 5.389761668084248e-07
a O 0 3.7574398703554834e-08
molecular O 0 6.358752102642029e-07
link O 0 9.112207408179529e-06
between O 0 3.451785062225099e-07
HFE O 0 0.07748360931873322
and O 0 6.358982318488415e-08
a O 0 1.1382559783612578e-08
key O 0 4.413401200054068e-07
protein O 0 5.017778192950573e-08
involved O 0 1.8859029893292245e-08
in O 0 3.419072580612692e-09
iron O 0 4.266950327291852e-06
transport O 0 2.9507629051295226e-07
, O 0 3.3305442848075018e-09
the O 0 1.6256561652383539e-09
TfR O 0 7.718386427768564e-07
, O 0 1.190174736542815e-09
and O 0 1.2472900490223537e-09
raise O 0 5.6581028751168105e-09
the O 0 1.0993090882038814e-09
possibility O 0 2.236208995753941e-09
that O 0 1.3506080975833612e-10
alterations O 0 3.8881694308656733e-08
in O 0 5.310226147692276e-10
this O 0 2.56111742924503e-10
regulatory O 0 4.3910912239653044e-08
mechanism O 0 1.0169908364332514e-06
may O 0 3.786538229633152e-07
play O 0 3.548709770484493e-08
a O 0 3.2742402122920566e-09
role O 0 1.3214128458116647e-08
in O 0 5.891691023940382e-10
the O 0 2.4612660798339903e-09
pathogenesis O 0 1.3104012452913594e-07
of O 0 3.61408005744579e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.2064700740666012e-06
. O 0 2.826927243404498e-07

Genomic O 0 6.0388632846297696e-05
organization O 0 9.972056886908831e-07
of O 0 1.439873287267801e-08
the O 0 2.6208153869333728e-08
UBE3A O 0 6.26998589723371e-05
/ O 0 7.863685823394917e-06
E6 O 0 3.4130846415791893e-06
- O 0 1.5721212548669428e-05
AP O 0 1.8115060811396688e-05
gene O 0 9.650262882132665e-07
and O 0 2.4472148751897294e-08
related O 0 1.628839072509436e-07
pseudogenes O 0 3.925977125618374e-06
. O 0 4.824174197892717e-07

The O 0 3.2888995065150084e-06
UBE3A O 0 0.0002226597280241549
gene O 0 3.00110514217522e-06
encodes O 0 7.469517413483118e-07
the O 0 8.575590015880152e-08
E6 O 0 2.0185334506095387e-06
- O 0 9.135421350947581e-06
AP O 0 1.2410833733156323e-05
ubiquitin O 0 1.1878482837346382e-06
- O 0 3.46795644645681e-07
protein O 0 5.3919531950441524e-08
ligase O 0 3.315751939680922e-08
and O 0 1.1280976153216216e-08
has O 0 1.0988170373593675e-08
recently O 0 5.734528230050273e-08
been O 0 7.833667936552047e-09
shown O 0 4.630453798171175e-09
to O 0 2.4403243870096958e-09
be O 0 1.4183235919063009e-08
mutated O 0 3.7420597891468788e-06
in O 0 1.6839336467455723e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.008857961744070053
who O 0 1.4666271397345554e-07
lack O 0 3.665166445898649e-07
15q11 O 0 9.793770004762337e-06
- O 0 2.7218067771173082e-05
q13 O 0 5.294341463013552e-06
deletions O 0 9.825324013945647e-06
or O 0 6.672921244899044e-06
chromosome O 0 0.0005928438040427864
15 O 0 2.2599101612286177e-06
paternal O 0 0.0016709276242181659
uniparental B-Disease 0 0.28699153661727905
disomy I-Disease 0 0.0011705411598086357
. O 0 1.7939298686542315e-06

Previous O 0 3.702308458741754e-05
UBE3A O 0 0.0002771982690319419
cDNA O 0 3.855590875900816e-06
analysis O 0 5.83895996442152e-07
has O 0 5.4971568630435286e-08
shown O 0 2.8010402886025076e-08
a O 0 4.452512136765563e-09
coding O 0 1.3922822290624026e-06
region O 0 3.498366396570418e-08
of O 0 1.6925055801308986e-09
approximately O 0 3.18680584143749e-08
2 O 0 1.4212109533673356e-07
. O 0 8.78878836374497e-08

6 O 0 2.097861397487577e-05
kb O 0 2.2007694497006014e-05
and O 0 1.160865892302354e-07
a O 0 8.141022789232011e-08
3 O 0 4.933953619001841e-07
- O 0 5.4257794545264915e-05
untranslated O 0 0.005036142189055681
region O 0 2.5382062176504405e-06
( O 0 3.0407210971361565e-08
UTR O 0 5.931170790063334e-07
) O 0 3.255310243588383e-09
of O 0 1.5549207477150162e-09
< O 0 2.8724909384436614e-07
50 O 0 6.014916920094038e-08
bp O 0 1.295449919780367e-06
, O 0 2.288305100961452e-09
whereas O 0 6.816363029571448e-09
Northern O 0 5.882418996350225e-09
analysis O 0 3.110763913127812e-08
has O 0 9.943148526758705e-09
indicated O 0 2.389631781340995e-08
mRNA O 0 1.9028925990483003e-08
sizes O 0 4.297667288710727e-08
of O 0 3.8428620285912984e-09
5 O 0 9.617603780043282e-08
- O 0 5.153177880856674e-06
8 O 0 3.264514418788167e-07
kb O 0 1.594641071278602e-05
. O 0 5.105154627926822e-07

We O 0 6.985213531152112e-06
have O 0 4.171134548869304e-08
analyzed O 0 4.44732002335968e-08
additional O 0 5.93740434595702e-09
cDNA O 0 1.3679282062639686e-07
clones O 0 5.884542133571813e-07
and O 0 8.115516259010747e-09
provide O 0 3.439593143639286e-08
evidence O 0 3.1417346946227553e-08
for O 0 1.986935060926953e-09
an O 0 7.044901106922907e-09
additional O 0 3.727260633468177e-08
0 O 0 1.6029363223424298e-06
. O 0 1.2966559381766274e-07

5 O 0 5.039300049247686e-06
kb O 0 6.276839030761039e-06
of O 0 6.375206851316761e-08
5 O 0 3.2253345239041664e-07
- O 0 3.9900887713884e-06
UTR O 0 7.953928616188932e-06
and O 0 6.457828760630946e-08
> O 0 2.1162853158784856e-07
2 O 0 3.6761015564934496e-08
kb O 0 2.612023081383086e-06
of O 0 2.781644781180148e-08
3 O 0 9.52898801642732e-07
- O 0 6.138561730040237e-05
UTR O 0 7.106900011422113e-05
. O 0 7.047980261631892e-07

We O 0 9.1750334831886e-06
have O 0 4.671145958923262e-08
established O 0 1.2305885199737077e-08
the O 0 2.5600246367218915e-09
genomic O 0 8.052686695236844e-08
organization O 0 1.0345767798014549e-08
of O 0 7.418305969508765e-10
UBE3A O 0 1.2710371493085404e-06
and O 0 5.868321384383535e-09
the O 0 4.51978321436286e-09
sequence O 0 5.1266113132442115e-08
of O 0 1.32608883873786e-08
intron O 0 5.458500891108997e-05
- O 0 4.741489465232007e-05
exon O 0 1.7615118849789724e-05
borders O 0 5.98188034928171e-06
. O 0 4.140206613101327e-07

We O 0 1.9246466763434e-05
have O 0 7.175183469598778e-08
also O 0 1.3961320100008834e-08
mapped O 0 4.171497209881636e-07
two O 0 1.5065699798810783e-08
highly O 0 4.094000871646131e-08
homologous O 0 5.882657205802388e-07
processed O 0 4.96289601414901e-07
pseudogenes O 0 9.354336611977487e-07
, O 0 3.445088836429022e-08
UBE3AP1 O 0 6.734184808010468e-06
and O 0 9.261428601803345e-08
UBE3AP2 O 0 1.0227683560515288e-05
, O 0 8.532528461557831e-09
to O 0 3.899657041728233e-09
chromosomes O 0 4.835878826270346e-07
2 O 0 4.3642717884040394e-08
and O 0 1.1725095561132548e-07
21 O 0 2.1313870490757836e-07
, O 0 4.8462087676170995e-09
respectively O 0 2.0280661772176245e-07
, O 0 2.884622540832993e-09
and O 0 1.0520803783720112e-08
determined O 0 1.2572643015573703e-07
their O 0 3.414447036220736e-08
genomic O 0 1.0247307500321767e-06
organization O 0 2.735826285515941e-07
. O 0 1.2696521878297062e-07

These O 0 1.1948332030442543e-06
results O 0 5.123493451719696e-07
will O 0 7.443864635803266e-09
form O 0 5.519953383270604e-09
the O 0 1.775572022744143e-09
basis O 0 2.701667112248174e-09
for O 0 4.3243536529402604e-10
studies O 0 5.674822833867665e-09
of O 0 1.1167633484632233e-09
mutation O 0 4.297757811855263e-07
and O 0 1.1005054645352175e-08
imprinting O 0 1.9923322724935133e-06
of O 0 1.6115306777919614e-07
UBE3A O 0 0.0002681428741198033
. O 0 1.2728712590615032e-06

Mutation O 0 0.00012879337009508163
spectrum O 0 8.17933050711872e-06
and O 0 4.078647179994732e-07
genotype O 0 0.000373105111066252
- O 0 4.29582541983109e-05
phenotype O 0 2.1160250980756246e-05
analyses O 0 2.0904981283820234e-06
in O 0 5.614523956865014e-08
Cowden B-Disease 0 0.04546380043029785
disease I-Disease 1 0.6136361956596375
and O 0 3.9817498986849387e-07
Bannayan B-Disease 1 0.9972386360168457
- I-Disease 1 0.9999986886978149
Zonana I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
, O 0 2.7997371532251236e-08
two O 0 1.204514177288729e-07
hamartoma B-Disease 1 0.9430170059204102
syndromes I-Disease 0 0.19811242818832397
with O 0 2.252666746471732e-07
germline O 0 0.0009047690546140075
PTEN O 0 0.0007480023195967078
mutation O 0 0.00014883704716339707
. O 0 1.940277570611215e-06

The O 0 1.9381066522328183e-05
tumour B-Disease 1 0.9999970197677612
suppressor O 0 9.963382035493851e-05
gene O 0 8.834678737912327e-06
PTEN O 0 1.2584867363329977e-05
, O 0 2.2389501808106615e-08
which O 0 2.820133682135406e-09
maps O 0 2.112454069447267e-07
to O 0 1.4509441825794056e-07
10q23 O 0 3.1583491363562644e-05
. O 0 3.4749385235954833e-07

3 O 0 5.469365078170085e-06
and O 0 6.280140496528475e-08
encodes O 0 4.449696007213788e-07
a O 0 6.760869553090743e-08
403 O 0 2.856727974176465e-07
amino O 0 6.282051572270575e-07
acid O 0 2.0027856351134687e-07
dual O 0 1.0814987945195753e-06
specificity O 0 2.255004619655665e-05
phosphatase O 1 0.8561060428619385
( O 0 1.1737816407730861e-07
protein O 0 5.163076934877608e-07
tyrosine O 0 1.581754804647062e-05
phosphatase O 0 0.010637395083904266
; O 0 3.7224008764269456e-08
PTPase O 0 1.2967713018952054e-06
) O 0 4.4165564538900526e-09
, O 0 9.774417941699198e-10
was O 0 3.2581876752146854e-08
shown O 0 7.546061553398431e-09
recently O 0 1.5356780735942266e-08
to O 0 1.6327535989901776e-09
play O 0 1.0039676112683082e-07
a O 0 4.504360884283187e-09
broad O 0 1.1719684778199735e-07
role O 0 9.878465334622888e-08
in O 0 9.188808824944772e-09
human O 0 1.3935891729488503e-07
malignancy B-Disease 0 8.116995559248608e-06
. O 0 8.706366116939535e-08

Somatic O 0 0.0009197320905514061
PTEN O 0 0.0005074730725027621
deletions O 0 5.5281194363487884e-05
and O 0 1.0828146059793653e-06
mutations O 0 5.61854503757786e-05
were O 0 2.7435547167442564e-07
observed O 0 1.9942852702570235e-07
in O 0 1.2277845407027144e-08
sporadic B-Disease 0 0.00469482084736228
breast I-Disease 1 0.9999939203262329
, I-Disease 0 7.032230087133939e-07
brain I-Disease 0 0.16155025362968445
, I-Disease 0 2.228759115041612e-07
prostate I-Disease 1 0.9145064949989319
and I-Disease 0 1.296772916248301e-05
kidney I-Disease 1 0.9712672829627991
cancer I-Disease 0 0.443708211183548
cell O 0 0.00012428910122253
lines O 0 0.0008107866160571575
and O 0 3.6963790250865713e-08
in O 0 1.6223852261632032e-09
several O 0 1.1257290211119653e-08
primary O 1 0.54961758852005
tumours B-Disease 1 1.0
such O 0 4.694153687978542e-08
as O 0 1.4650527191406582e-05
endometrial B-Disease 1 0.9999985694885254
carcinomas I-Disease 1 1.0
, O 0 0.11078055202960968
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 0 0.09294670075178146
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 2.880819238271215e-06

In O 0 5.226000325819768e-07
addition O 0 1.5127902486256062e-07
, O 0 2.5168967354716187e-08
PTEN O 0 6.446570750995306e-06
was O 0 1.1512883446584965e-07
identified O 0 3.481645194369776e-08
as O 0 1.065712518233397e-09
the O 0 1.6110651701595202e-09
susceptibility O 0 2.979049611440132e-07
gene O 0 2.2210950589851564e-07
for O 0 5.523471013901826e-09
two O 0 1.1152940260217292e-06
hamartoma B-Disease 1 0.9999775886535645
syndromes I-Disease 1 0.9999804496765137
Cowden B-Disease 1 0.988822340965271
disease I-Disease 1 0.9999704360961914
( O 0 1.658891193301315e-07
CD B-Disease 0 2.0150398995610885e-05
; O 0 3.148525991036877e-07
MIM O 0 9.501088788965717e-05
158350 O 0 2.6476204766368028e-06
) O 0 1.629223689292303e-08
and O 0 4.606891224057108e-08
Bannayan B-Disease 0 0.0002104694431181997
- I-Disease 0 0.00043674156768247485
Zonana I-Disease 0 0.00026404467644169927
( I-Disease 0 9.220149621569362e-08
BZS I-Disease 0 1.560744203743525e-05
) I-Disease 0 5.886417397960031e-08
or I-Disease 0 2.2488374895601737e-07
Ruvalcaba I-Disease 0 3.197668775101192e-05
- I-Disease 0 0.000123589692520909
Riley I-Disease 0 6.726681749569252e-05
- I-Disease 1 0.5703119039535522
Smith I-Disease 0 0.29967862367630005
syndrome I-Disease 1 0.9998332262039185
( O 0 8.222702518878577e-08
MIM O 0 2.4472545192111284e-05
153480 O 0 4.7485309551120736e-06
) O 0 7.414153913032351e-08
. O 0 1.054688709700713e-07

Constitutive O 0 7.014455331955105e-05
DNA O 0 8.589013305027038e-06
from O 0 2.981834370530123e-07
37 O 0 9.199366104439832e-07
CD B-Disease 0 2.3132929527491797e-06
families O 0 1.7332916968371137e-07
and O 0 3.940452586448373e-08
seven O 0 7.052230444060115e-08
BZS B-Disease 0 1.9381159290787764e-05
families O 0 1.2270780302969797e-07
was O 0 6.188155765585179e-08
screened O 0 6.22193965682527e-07
for O 0 4.3855251874447276e-08
germline O 0 8.014591730898246e-05
PTEN O 0 0.00015582761261612177
mutations O 0 3.864101745421067e-05
. O 0 4.868158498538833e-07

PTEN O 0 0.004494915716350079
mutations O 0 0.0013321038568392396
were O 0 4.251320206094533e-06
identified O 0 2.5946093273887527e-07
in O 0 3.0738407374997223e-09
30 O 0 3.037843976372301e-09
of O 0 3.657982527993653e-10
37 O 0 1.1115367470893034e-07
( O 0 1.1032565971902386e-08
81 O 0 1.990473492696765e-07
% O 0 2.431511880729431e-08
) O 0 1.9708634724224794e-09
CD B-Disease 0 7.362295377788541e-07
families O 0 2.908912399846031e-08
, O 0 8.68817684462897e-10
including O 0 1.8401046242288999e-09
missense O 0 2.003430608965573e-06
and O 0 8.405055496041314e-08
nonsense O 0 7.486707545467652e-06
point O 0 3.5892199434783834e-07
mutations O 0 3.845855644613039e-06
, O 0 2.2755177742084243e-09
deletions O 0 1.7882538827507233e-07
, O 0 5.675396153037582e-09
insertions O 0 8.547254992663511e-07
, O 0 7.298063486871342e-09
a O 0 1.3536629595023442e-08
deletion O 0 3.1748371839057654e-05
/ O 0 6.215313533175504e-06
insertion O 0 3.1456074793823063e-06
and O 0 2.3501625889821298e-07
splice O 0 0.0013562608510255814
site O 0 1.3503215996024664e-05
mutations O 0 6.286372081376612e-05
. O 0 4.6353341076610377e-07

These O 0 2.2522722247231286e-06
mutations O 0 2.3780752599122934e-05
were O 0 3.0143201001919806e-07
scattered O 0 1.407751142323832e-07
over O 0 1.6241662237348464e-08
the O 0 8.289339881173419e-09
entire O 0 5.020573823344421e-08
length O 0 1.0726839150265732e-07
of O 0 3.4042360042008113e-09
PTEN O 0 4.856440227740677e-06
, O 0 9.070485695872321e-09
with O 0 1.3704445356310657e-09
the O 0 3.320902219883237e-09
exception O 0 8.000661466667225e-09
of O 0 5.142236081390195e-10
the O 0 4.733160974268458e-09
first O 0 2.1270214745072735e-07
, O 0 3.167366458001197e-08
fourth O 0 2.9134712349332403e-06
and O 0 6.704546251512511e-08
last O 0 6.76551366041167e-08
exons O 0 3.288883817731403e-06
. O 0 2.1163216956665565e-07

A O 0 1.3138781469024252e-05
hot O 0 0.0001002708959276788
spot O 0 3.802520586759783e-05
for O 0 9.096806508068767e-08
PTEN O 0 4.463605728233233e-05
mutation O 0 3.7577017337753205e-06
in O 0 1.1450935311074772e-08
CD B-Disease 0 3.3891799375851406e-06
was O 0 7.57591635647259e-07
identified O 0 3.614762889014855e-08
in O 0 5.099202726732699e-10
exon O 0 7.183837880120336e-08
5 O 0 6.943197572439885e-09
that O 0 5.363688382331588e-10
contains O 0 3.9885423852581425e-09
the O 0 6.500274984944099e-09
PTPase O 0 1.6848621271492448e-06
core O 0 3.5502068840287393e-07
motif O 0 9.493234642832249e-08
, O 0 1.5368258887704656e-09
with O 0 7.361166121100382e-10
13 O 0 3.909845780469823e-09
of O 0 3.3118047193525513e-10
30 O 0 7.809202173802987e-09
( O 0 2.825453204735595e-09
43 O 0 2.4111454166586554e-08
% O 0 9.04395136558378e-09
) O 0 2.500721629772329e-09
CD B-Disease 0 1.4441591247305041e-06
mutations O 0 7.249560894706519e-06
identified O 0 9.459344596507435e-08
in O 0 1.546349603920305e-09
this O 0 1.5306679257420797e-09
exon O 0 1.4442913425227744e-06
. O 0 1.8729626560798351e-07

Seven O 0 6.778870101697976e-06
of O 0 3.8025870452429444e-08
30 O 0 1.1756334572510241e-07
( O 0 9.25646226335175e-09
23 O 0 5.408123726624581e-08
% O 0 1.661486948023594e-08
) O 0 3.367965684120122e-09
were O 0 8.170610499291797e-08
within O 0 2.3876167709602214e-09
the O 0 3.2328308918749826e-09
core O 0 5.951353045929864e-07
motif O 0 6.667881535804554e-08
, O 0 1.4573565687570067e-09
the O 0 1.3868528547789083e-09
majority O 0 1.2523969417088665e-08
( O 0 3.0772606685047776e-09
five O 0 3.793993119671768e-09
of O 0 5.070147079955234e-10
seven O 0 2.1476402878306544e-08
) O 0 4.1665979000349296e-10
of O 0 1.5740561631893968e-10
which O 0 4.430097622076801e-09
were O 0 9.47052001265547e-08
missense O 0 2.1250111785775516e-06
mutations O 0 2.1679857127310243e-06
, O 0 4.740922321389007e-09
possibly O 0 4.957323795906632e-08
pointing O 0 2.0004016221264465e-07
to O 0 3.604557763381422e-09
the O 0 4.518645457807224e-09
functional O 0 1.9931539441131463e-07
significance O 0 1.2680833272327163e-08
of O 0 1.2009562233572524e-09
this O 0 4.928237373746924e-09
region O 0 1.1381825970602222e-07
. O 0 8.752921587529272e-08

Germline O 0 0.002778095193207264
PTEN O 0 0.0012525860220193863
mutations O 0 0.0008652419783174992
were O 0 2.1201449271757156e-06
identified O 0 3.986818626344757e-07
in O 0 3.7336769231899325e-09
four O 0 8.760816960773354e-09
of O 0 1.1559245782777339e-09
seven O 0 2.389208475506166e-07
( O 0 2.447961833240697e-08
57 O 0 2.2534617016845004e-07
% O 0 2.8615097846795834e-08
) O 0 1.068907096168914e-08
BZS B-Disease 0 8.682751285959966e-06
families O 0 1.6213596154557308e-07
studied O 0 6.159741587907774e-07
. O 0 1.1646683617527742e-07

Interestingly O 0 3.663604729808867e-05
, O 0 1.8430426962368074e-07
none O 0 8.962233266629482e-08
of O 0 5.784295820099317e-10
these O 0 1.1098732599634786e-08
mutations O 0 3.5580537769419607e-06
was O 0 1.336210857516562e-07
observed O 0 3.43478774311734e-08
in O 0 1.0795115912287656e-09
the O 0 1.1827819612619805e-08
PTPase O 0 1.0841240509762429e-05
core O 0 4.203282514936291e-06
motif O 0 1.3990597835800145e-06
. O 0 1.458673466459004e-07

It O 0 7.423853958243853e-07
is O 0 2.2185201231650353e-08
also O 0 1.3412751798114186e-08
worthy O 0 2.1472020605983744e-08
of O 0 1.2934806559172785e-09
note O 0 3.0203773349057883e-07
that O 0 2.7882991471273044e-09
a O 0 1.8483438779526296e-08
single O 0 1.3886642591387499e-05
nonsense O 0 9.84913367574336e-06
point O 0 1.2015988204439054e-07
mutation O 0 7.044808967293648e-07
, O 0 5.822475390715454e-09
R233X O 0 2.793419469071523e-07
, O 0 8.348428615079229e-09
was O 0 3.5757310001827136e-08
observed O 0 2.0603842187938426e-08
in O 0 8.423214903352516e-10
the O 0 2.1756005885720242e-09
germline O 0 7.138850719456968e-07
DNA O 0 1.2130689697187336e-07
from O 0 5.6394524605707375e-09
two O 0 1.8050000605285277e-08
unrelated O 0 1.5584510038024746e-07
CD B-Disease 0 3.419551831029821e-06
families O 0 1.4560535532837093e-07
and O 0 1.4138103132665947e-08
one O 0 4.464359903977311e-08
BZS B-Disease 0 5.6834913266357034e-05
family O 0 4.0174592186303926e-07
. O 0 1.7017877951275295e-07

Genotype O 0 0.0020902466494590044
- O 0 0.0001393168931826949
phenotype O 0 2.2626494683208875e-05
studies O 0 2.907992495693179e-07
were O 0 6.047945362297469e-07
not O 0 1.5593229818477994e-08
performed O 0 2.7528906798579555e-07
on O 0 6.9333516705683e-09
this O 0 6.206933855779084e-10
small O 0 6.322407930525742e-09
group O 0 1.0144346695994955e-08
of O 0 1.6923699108772894e-09
BZS B-Disease 0 1.2600839909282513e-05
families O 0 3.127642855815793e-07
. O 0 8.315504373967997e-08

However O 0 3.2776840726000955e-06
, O 0 1.3616079286293825e-07
genotype O 0 2.728831532294862e-05
- O 0 3.5115310765831964e-06
phenotype O 0 4.696204996434972e-06
analysis O 0 1.171026724477997e-07
inthe O 0 4.921466825180687e-06
group O 0 1.63494888738569e-07
of O 0 2.770212281788531e-09
CD B-Disease 0 5.664039690600475e-06
families O 0 2.4694972466932086e-07
revealed O 0 1.9016559349438467e-07
two O 0 2.6897999383379556e-09
possible O 0 8.444871468782367e-09
associations O 0 3.7984406731084164e-08
worthy O 0 3.808248649761481e-08
of O 0 2.3425528183906863e-09
follow O 0 4.762349590237136e-07
- O 0 0.0004448503896128386
up O 0 1.6953775912043056e-06
in O 0 5.204660258328886e-09
independent O 0 4.6123599162228857e-08
analyses O 0 2.610732963148621e-06
. O 0 2.1408884265383676e-07

The O 0 2.66145832483744e-07
first O 0 1.232176742860247e-07
was O 0 1.1537679966977521e-07
an O 0 2.397949394605803e-09
association O 0 3.495565081834684e-08
noted O 0 2.4356571870498556e-08
in O 0 1.0231845370967108e-09
the O 0 2.5681528015297772e-09
group O 0 3.771237544469841e-09
of O 0 2.3642499069609357e-10
CD B-Disease 0 5.716966597901774e-07
families O 0 3.116340252518057e-08
with O 0 1.4598607549487497e-06
breast B-Disease 1 0.9999995231628418
disease I-Disease 0 0.12252005189657211
. O 0 2.4051979607975227e-07

A O 0 5.046922979090596e-06
correlation O 0 6.558988388860598e-06
was O 0 5.833467184857e-07
observed O 0 4.2857653426153774e-08
between O 0 2.875887528119847e-09
the O 0 5.689399618091784e-09
presence O 0 1.1655439635660514e-07
/ O 0 1.1224946319998708e-05
absence O 0 6.590110501747404e-08
of O 0 1.0668596006624398e-09
a O 0 2.4042890345299384e-08
PTEN O 0 1.4337079846882261e-05
mutation O 0 6.045552254363429e-07
and O 0 2.5179136553532544e-09
the O 0 1.5373066153401282e-09
type O 0 1.3435895880320459e-06
of O 0 1.2518094116842349e-08
breast O 1 0.6709129810333252
involvement O 0 4.6266172830655705e-06
( O 0 2.5991411689574306e-07
unaffected O 0 2.5496316084172577e-05
versus O 0 6.638378545176238e-05
benign O 0 0.36625415086746216
versus O 0 0.0008289155666716397
malignant O 0 0.32166174054145813
) O 0 1.2938617999225244e-07
. O 0 8.055790345906644e-08

Specifically O 0 5.690004854841391e-06
and O 0 8.813464091872447e-08
more O 0 4.310208634450419e-09
directly O 0 5.350094411937789e-08
, O 0 1.9480099755497804e-09
an O 0 1.5990552215683351e-09
association O 0 9.245491128240246e-08
was O 0 1.2289206097193528e-06
also O 0 1.1053312931608161e-08
observed O 0 1.553551953747956e-08
between O 0 1.1124923204874904e-09
the O 0 1.110476155474771e-09
presence O 0 2.300756252182623e-09
of O 0 4.175014500784613e-10
a O 0 3.011096083582743e-08
PTEN O 0 5.666077049681917e-05
mutation O 0 1.0062438377644867e-05
and O 0 3.925584678654559e-06
malignant B-Disease 1 0.9999973773956299
breast I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9978189468383789
. O 0 3.2889485623854853e-07

Secondly O 0 0.00036050615017302334
, O 0 3.9090727455004526e-07
there O 0 5.469524921863922e-08
appeared O 0 2.44204926502789e-07
to O 0 5.244960465944359e-09
be O 0 9.588294602735914e-09
an O 0 9.940128720131725e-10
interdependent O 0 1.588866871315986e-05
association O 0 4.0371997300781004e-08
between O 0 1.2092015388986965e-08
mutations O 0 7.471796834579436e-07
upstream O 0 5.3325205584542346e-08
and O 0 7.694190173879178e-09
within O 0 5.501370470284428e-09
the O 0 6.8354752968957655e-09
PTPase O 0 1.255404072253441e-06
core O 0 1.3281793371788808e-06
motif O 0 1.8443664373535285e-07
, O 0 2.1751027645677823e-09
the O 0 9.092462338600171e-10
core O 0 1.4463353181781713e-07
motif O 0 3.1150864998608085e-08
containing O 0 4.435643852218618e-09
the O 0 6.389370699189101e-10
majority O 0 2.3354593814417512e-09
of O 0 6.375979744177585e-10
missense O 0 5.894697551411809e-06
mutations O 0 4.636219273379538e-06
, O 0 2.077889860174764e-09
and O 0 2.6993489665727566e-09
the O 0 1.3335325066421433e-09
involvement O 0 2.5851882412553095e-08
of O 0 9.59289980784206e-10
all O 0 4.481018667235048e-09
major O 0 3.862690078904052e-08
organ O 0 3.6762321542482823e-06
systems O 0 2.132799181708833e-06
( O 0 7.140217306300656e-09
central O 0 3.0582164356474095e-08
nervous O 0 4.950363745592767e-06
system O 0 1.415192230069806e-07
, O 0 2.1943387551459637e-08
thyroid O 0 0.031141573563218117
, O 0 4.9038046512350775e-08
breast O 0 0.3305080533027649
, O 0 2.6989084744855063e-07
skin O 1 0.9978906512260437
and O 0 8.087981404969469e-05
gastrointestinal O 1 0.995637834072113
tract O 0 0.03173619508743286
) O 0 8.147080876597101e-08
. O 0 7.929625667202345e-08

However O 0 2.5057420316443313e-06
, O 0 1.2856180120479621e-08
these O 0 6.8661526464453e-10
observations O 0 2.065972104503544e-08
would O 0 1.884263411966458e-08
need O 0 3.048455710086273e-08
to O 0 2.394157583296419e-08
be O 0 4.661906984892994e-07
confirmed O 0 3.342515952908798e-08
by O 0 3.324931441284207e-10
studying O 0 1.3108137908446338e-09
a O 0 6.167188426609016e-10
larger O 0 2.721807446093294e-09
number O 0 2.8205855429064286e-09
of O 0 1.219575329614031e-09
CD B-Disease 0 1.0898358596023172e-05
families O 0 2.8232361160007713e-07
. O 0 5.3365194929710924e-08

Molecular O 0 0.0025656071957200766
defects O 1 0.9999215602874756
leading O 0 1.040227857629361e-06
to O 0 1.2870091659067384e-08
human O 0 4.9530804346886725e-08
complement B-Disease 0 3.121310146525502e-05
component I-Disease 1 0.9994706511497498
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 5.480288667314426e-09
an O 0 4.123229313535148e-09
African O 0 1.2718625441721088e-07
- O 0 6.705839950882364e-06
American O 0 3.4190620112894976e-07
family O 0 3.292937265086948e-07
. O 0 8.668652640153596e-08

Complement B-Disease 0 0.003476553363725543
component I-Disease 1 0.9991088509559631
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 8.966266022980562e-07
C6D B-Disease 0 5.455586142488755e-05
) O 0 5.6362619460514907e-08
was O 0 2.8275194381421898e-06
diagnosed O 0 0.0004879189364146441
in O 0 1.477779010272684e-09
a O 0 1.8576033156136873e-08
16 O 0 1.278398968906913e-07
- O 0 2.5898157218762208e-06
year O 0 3.807348036843905e-08
- O 0 3.990373897977406e-06
old O 0 2.779643182293512e-06
African O 0 2.2796893262011508e-08
- O 0 1.237565783185346e-07
American O 0 6.411717379251058e-08
male O 0 6.236749641175265e-07
with O 0 3.590335779790621e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999998807907104
. O 0 1.1175491181347752e-06

The O 0 4.98161125506158e-06
patients O 0 0.0001558316289447248
father O 0 1.0979988473991398e-06
and O 0 5.20140801540947e-08
two O 0 1.5574852341160295e-07
brothers O 0 0.0035237246192991734
also O 0 3.5643907381199824e-07
had O 0 2.150773752873647e-06
C6D B-Disease 0 6.469617346738232e-06
, O 0 2.82982171029289e-09
but O 0 1.3833443279764879e-09
gave O 0 7.721976835739497e-09
no O 0 9.181730042939762e-09
history O 0 5.529078528354603e-09
of O 0 1.3593136394263183e-08
meningitis B-Disease 1 1.0
or O 0 1.3672727163793752e-06
other O 0 9.196772765562855e-08
neisserial B-Disease 1 0.7918838858604431
infection I-Disease 0 0.13638506829738617
. O 0 1.6240151978763606e-07

By O 0 4.2572582970024087e-07
using O 0 2.545048403135297e-07
exon O 0 1.893315015877306e-06
- O 0 7.408979740830546e-07
specific O 0 9.438439008135902e-08
polymerase O 0 1.642113488742325e-06
chain O 0 3.81478457711637e-06
reaction O 0 1.9895834668659518e-07
( O 0 1.636820456951682e-08
PCR O 0 9.189738534587377e-07
) O 0 1.1435614233334945e-08
/ O 0 3.604518781230581e-07
single O 0 4.7874227675492875e-06
- O 0 2.556809022280504e-06
strand O 0 5.065947448201769e-07
conformation O 0 3.565822339623992e-07
polymorphism O 0 5.067450388196448e-07
as O 0 9.024634373133722e-09
a O 0 4.221266447501648e-09
screening O 0 6.49702940336283e-08
step O 0 6.459245582846052e-08
and O 0 6.084887704815856e-09
nucleotide O 0 5.389043167269847e-08
sequencing O 0 8.876692270121112e-09
of O 0 8.637962012336686e-10
target O 0 2.0829629931995441e-07
exons O 0 5.469659640766622e-07
, O 0 2.3297834772506576e-08
we O 0 2.810437571554303e-08
determined O 0 1.6976599681584048e-08
that O 0 1.161489460166365e-09
the O 0 5.486029852619367e-09
proband O 0 1.1153397281304933e-05
was O 0 1.5310182277517015e-07
a O 0 8.28785395867726e-09
compound O 0 8.0383856015942e-08
heterozygote O 0 1.951455033122329e-07
for O 0 1.3034365808906045e-09
two O 0 2.760835116077942e-08
C6 O 0 1.754142613208387e-05
gene O 0 5.1061260819551535e-06
mutations O 0 9.827076610235963e-06
. O 0 3.0926022986932367e-07

The O 0 8.525250336788304e-07
first O 0 3.375099595359643e-07
, O 0 1.2349762101848683e-08
1195delC O 0 1.379508063337198e-07
located O 0 1.5727072977256285e-08
in O 0 1.6260158774983324e-09
exon O 0 1.9703256270986458e-07
7 O 0 1.4470596454430051e-07
, O 0 3.066122911121738e-09
is O 0 1.2963481399452803e-09
a O 0 3.094400069514336e-09
novel O 0 3.324757003042578e-08
mutation O 0 2.957530114144902e-07
, O 0 2.0859829419350717e-09
while O 0 3.6542469050715454e-09
the O 0 4.47775505563186e-09
second O 0 5.451464630823466e-07
, O 0 4.775754902652807e-09
1936delG O 0 4.8556856313553e-08
in O 0 9.155773361690933e-10
exon O 0 4.7123460689135754e-08
12 O 0 6.812219055518653e-08
, O 0 2.103193619262811e-09
has O 0 3.5762475203426902e-09
been O 0 1.2902559021199522e-08
described O 0 2.1412105866147613e-08
before O 0 6.890413573046317e-09
to O 0 9.332318917643079e-09
cause O 0 5.431003842204518e-07
C6D B-Disease 0 9.94142556010047e-06
in O 0 2.2317392378568e-09
an O 0 3.306321216811625e-09
unrelated O 0 3.374204382566859e-08
African O 0 7.549319036570523e-08
- O 0 1.5352304671978345e-06
American O 0 2.3239766733240685e-07
individual O 0 9.741093265347445e-08
. O 0 1.155881435010997e-07

Both O 0 1.1536536476342008e-05
mutations O 0 0.00036637569428421557
result O 0 6.571546009581652e-07
in O 0 4.7521325541310944e-08
premature O 0 2.2660335162072442e-05
termination O 0 6.636682883254252e-06
codons O 0 3.6854435165878385e-06
and O 0 2.1589063692317723e-07
C6 O 0 7.774356345180422e-05
null O 0 2.8736285457853228e-05
alleles O 0 1.3041471902397461e-05
. O 0 7.448425662914815e-07

Allele O 0 0.0001737272395985201
- O 0 1.0995960110449232e-05
specific O 0 3.5850086987920804e-07
PCR O 0 7.076577730913414e-06
indicated O 0 4.993760853722051e-07
that O 0 2.250749364662852e-09
the O 0 4.076964543742179e-09
probands O 0 2.49950335273752e-06
two O 0 1.2080285216597986e-07
brothers O 0 2.9003449526499026e-05
also O 0 2.9227607001303113e-08
inherited O 0 2.002149130930775e-06
the O 0 6.690900278272238e-09
1195delC O 0 8.108926294880803e-07
mutation O 0 2.7845439376505965e-07
from O 0 5.0685446950637925e-09
their O 0 5.213296816464208e-08
heterozygous O 0 1.7739361283020116e-05
mother O 0 9.132496074926166e-07
and O 0 4.125329411408529e-09
the O 0 3.454634800448275e-09
1936delG O 0 5.941723202340654e-07
mutation O 0 3.0476280699076597e-07
from O 0 5.582220019562101e-09
their O 0 9.724942628963618e-08
homozygous O 0 6.213529559317976e-05
father O 0 2.962823089092126e-07
. O 0 6.487789860898374e-09
. O 0 5.2814439044368555e-08

PAX6 O 0 0.051750145852565765
mutations O 0 0.0023967195302248
reviewed O 0 4.2009534809039906e-05
. O 0 2.4244834548881045e-06

Mutations O 0 0.0009117384906858206
in O 0 1.6703211258572992e-07
PAX6 O 0 3.0503801099257544e-05
are O 0 3.664173320316877e-08
responsible O 0 1.0910818559750624e-07
for O 0 2.8965423393145784e-09
human O 0 9.775471454531726e-08
aniridia B-Disease 1 1.0
and O 0 7.563189114989655e-07
have O 0 2.3297661755350418e-07
also O 0 9.237981402065998e-08
been O 0 4.968673650296296e-08
found O 0 1.1141513489576482e-08
in O 0 5.082824383606521e-09
patients O 0 4.36106006418413e-07
with O 0 4.3687940376457846e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 8.600091518928821e-07
with O 0 6.621018837904558e-05
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.999994158744812
, O 0 1.315076669783366e-08
with O 0 3.1577872761090475e-08
autosomal B-Disease 1 0.9987063407897949
dominant I-Disease 1 0.7688233256340027
keratitis I-Disease 0 0.00945439375936985
, O 0 3.575594575977448e-08
and O 0 1.370868663030933e-08
with O 0 1.9114962412913883e-07
isolated B-Disease 1 0.9741266369819641
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 1.9899073322449112e-06

No O 0 1.1531806194398087e-05
locus O 0 6.672139079455519e-06
other O 0 2.9596620265692763e-08
than O 0 2.2893365425602497e-08
chromosome O 0 3.760207982850261e-05
11p13 O 0 1.7473271327617113e-06
has O 0 4.609563220014934e-08
been O 0 1.0021462770737344e-07
implicated O 0 2.0171692085568793e-06
in O 0 7.188827311210844e-08
aniridia B-Disease 1 1.0
, O 0 4.485313453983508e-08
and O 0 1.6500012023357158e-08
PAX6 O 0 5.685470114258351e-06
is O 0 7.463270890184504e-09
clearly O 0 2.6846144862702204e-08
the O 0 9.007364298874165e-10
major O 0 1.1198440397208742e-08
, O 0 3.1523694765667187e-09
if O 0 2.7108033595624192e-09
not O 0 2.8243647420822526e-09
only O 0 1.3916143792869207e-09
, O 0 2.1123114368748475e-09
gene O 0 1.1553668599617595e-07
responsible O 0 2.4222916295002506e-07
. O 0 8.11977827197552e-08

Twenty O 0 9.978605521610007e-05
- O 0 5.8139703469350934e-05
eight O 0 6.389693680830533e-07
percent O 0 1.870731267672454e-07
of O 0 1.73270831016481e-09
identified O 0 4.3270063088129973e-07
PAX6 O 0 1.1484943570394535e-05
mutations O 0 3.4808199416147545e-06
are O 0 5.205427200394297e-08
C O 0 7.482795626856387e-05
- O 0 0.0025400209706276655
T O 0 0.00015695631736889482
changes O 0 7.562433523844447e-08
at O 0 7.729362749842039e-08
CpG O 0 1.3170217698643683e-06
dinucleotides O 0 1.840827394516964e-06
, O 0 2.6932396313128493e-09
20 O 0 3.205311793763599e-09
% O 0 2.3094308687632292e-09
are O 0 1.6660877122376405e-09
splicing O 0 1.1017981478289585e-06
errors O 0 3.281867248006165e-05
, O 0 9.629310682157666e-09
and O 0 6.523750428755193e-09
more O 0 5.759536736427151e-10
than O 0 3.109736024242693e-09
30 O 0 3.773597434530984e-09
% O 0 4.309320900119928e-09
are O 0 1.6972900862555207e-09
deletion O 0 6.88944339799491e-07
or O 0 1.216560860939353e-07
insertion O 0 8.901939168026729e-07
events O 0 1.0536698482610518e-06
. O 0 8.996373139780189e-07

There O 0 1.8778681578623946e-06
is O 0 2.738618753994615e-08
a O 0 1.77311250126877e-08
noticeably O 0 1.3076476079731947e-06
elevated O 0 1.6059017298175604e-06
level O 0 2.416924189674319e-07
of O 0 3.433286099863153e-09
mutation O 0 3.677252493616834e-07
in O 0 3.2073115274755537e-09
the O 0 7.090640519180624e-09
paired O 0 3.5647749996314815e-07
domain O 0 4.732017089281726e-08
compared O 0 5.9001759922239216e-08
with O 0 1.9883148461019573e-09
the O 0 4.5455119668247335e-09
rest O 0 1.0402557037991755e-08
of O 0 3.922654145949167e-10
the O 0 1.01697450460847e-08
gene O 0 7.958792593854014e-07
. O 0 8.662421890903715e-08

Increased O 0 1.1653460205707233e-05
mutation O 0 6.188898169057211e-06
in O 0 1.1744687888892713e-08
the O 0 5.875870012772566e-09
homeodomain O 0 3.8110681543912506e-07
is O 0 7.730244000470066e-09
accounted O 0 6.990066481193935e-08
for O 0 6.695493048880508e-10
by O 0 3.0500477699035855e-09
the O 0 8.979597510005988e-09
hypermutable O 0 1.0424571883049794e-05
CpG O 0 1.5329191001001163e-06
dinucleotide O 0 1.4174062243910157e-06
in O 0 1.1458211268688956e-08
codon O 0 1.1601591722865123e-06
240 O 0 3.0738544865016593e-07
. O 0 1.4221137689673924e-07

Very O 0 8.287039236165583e-06
nearly O 0 2.5020929683705617e-07
all O 0 1.5123280405759942e-08
mutations O 0 6.35985031749442e-07
appear O 0 9.17991300752874e-08
to O 0 2.1054905374739974e-08
cause O 0 6.25307256996166e-06
loss O 0 2.642903496052895e-07
of O 0 8.440391163766492e-10
function O 0 3.7458619317476405e-08
of O 0 8.777321647279734e-10
the O 0 4.1190317823236455e-09
mutant O 0 2.8311981736806047e-07
allele O 0 1.294561684517248e-07
, O 0 1.3387697617162075e-09
and O 0 4.880062465240087e-10
more O 0 2.390814490826898e-10
than O 0 1.4669782055776182e-09
80 O 0 6.528031892827357e-09
% O 0 3.225846034737856e-09
of O 0 2.2819417466735104e-09
exonic O 0 7.50215258449316e-06
substitutions O 0 9.747075182531262e-07
result O 0 7.334921292567742e-07
in O 0 3.0280112639502477e-08
nonsense O 0 2.112142465193756e-05
codons O 0 6.693080194963841e-06
. O 0 2.9449941507664334e-07

In O 0 3.527318881424435e-07
a O 0 5.0393971662288095e-08
gene O 0 2.2295797919014149e-07
with O 0 3.296850126233153e-09
such O 0 3.6213168019827435e-09
extraordinarily O 0 1.1970755622314755e-06
high O 0 1.1658985243911957e-07
sequence O 0 3.924566271962249e-08
conservation O 0 2.0036150516489215e-09
throughout O 0 1.0336749234340914e-09
evolution O 0 2.2253590081788843e-09
, O 0 5.488392518238072e-10
there O 0 1.5840502243236187e-09
are O 0 1.1239483121983085e-08
presumed O 0 4.044205070385942e-06
undiscovered O 0 1.7457515468777274e-06
missense O 0 5.540653091884451e-06
mutations O 0 3.873495188599918e-06
, O 0 1.7740958702106013e-09
these O 0 8.735767664802552e-10
are O 0 7.697429915687337e-10
hypothesized O 0 1.1342336847519618e-08
to O 0 3.004697823882907e-09
exist O 0 3.545090621059899e-08
in O 0 1.3848703295238352e-09
as O 0 1.8775372723212058e-07
- O 0 0.0007742074667476118
yet O 0 1.1997934734608862e-06
unidentified O 0 5.618558134301566e-06
phenotypes O 0 1.1729172229024698e-06
. O 0 9.659700594966125e-09
. O 0 7.531657075787734e-08

Genetic O 0 0.000589709379710257
heterogeneity O 0 2.969204797409475e-05
and O 0 5.70568033708696e-07
penetrance O 0 1.659419467614498e-05
analysis O 0 6.62497043890653e-08
of O 0 6.238198846375553e-09
the O 0 2.781490948677856e-08
BRCA1 O 0 0.0002698866883292794
and O 0 2.1635192126723268e-07
BRCA2 O 0 0.0004564066184684634
genes O 0 2.3248198885994498e-06
in O 0 1.303030074950584e-07
breast B-Disease 1 0.9999964237213135
cancer I-Disease 0 0.027103956788778305
families O 0 6.824274123573559e-07
. O 0 1.1196138416380563e-07

The O 0 0.00432644784450531
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0005269818939268589
Consortium O 0 1.894618799269665e-05
. O 0 1.0574195812296239e-06

The O 0 2.9571745585599274e-07
contribution O 0 1.5657610674679745e-07
of O 0 1.653113557154029e-08
BRCA1 O 0 9.127552038989961e-05
and O 0 8.940982070271275e-07
BRCA2 O 0 0.19383259117603302
to O 0 4.080688813701272e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 6.6364423219056334e-06
assessed O 0 2.428717778002465e-07
by O 0 1.6349911424740071e-09
linkage O 0 2.3448931187886046e-06
and O 0 1.2244127844951436e-07
mutation O 0 1.098589677894779e-06
analysis O 0 6.19913080868173e-08
in O 0 5.008347958579407e-09
237 O 0 4.374130568862711e-08
families O 0 4.439116452203962e-08
, O 0 1.534924631840795e-09
each O 0 8.11348488394259e-10
with O 0 3.762601785695097e-09
at O 0 1.6948233394487033e-07
least O 0 2.732564619023492e-09
four O 0 1.6223603571674516e-09
cases O 0 1.5747807502464184e-09
of O 0 3.706488627130966e-08
breast B-Disease 1 0.9999998807907104
cancer I-Disease 0 0.0237628985196352
, O 0 3.4856035835417742e-09
collected O 0 6.949053776850178e-09
by O 0 7.781710387178009e-09
the O 0 0.00038916917401365936
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 3.72445210814476e-05
Consortium O 0 4.651861672755331e-06
. O 0 3.929881700059923e-07

Families O 0 0.00010674039367586374
were O 0 8.995935445454961e-07
included O 0 1.5971600930697605e-08
without O 0 1.1843668268340934e-08
regard O 0 2.7496296350904004e-09
to O 0 5.78644743232104e-10
the O 0 1.7054027079410616e-09
occurrence O 0 2.1253768522910832e-07
of O 0 3.702206896605276e-08
ovarian B-Disease 1 0.9988718628883362
or I-Disease 0 1.3934205753685092e-06
other I-Disease 0 2.744203868587647e-07
cancers I-Disease 1 0.9268861413002014
. O 0 1.5473068515348132e-07

Overall O 0 0.000978349125944078
, O 0 3.1610043151886202e-06
disease O 0 0.03423795849084854
was O 0 1.0912525283401919e-07
linked O 0 3.4775871426973026e-07
to O 0 8.455380395844259e-09
BRCA1 O 0 3.568584725144319e-05
in O 0 3.744745846745445e-09
an O 0 1.6396880520019863e-09
estimated O 0 1.0771550762456172e-08
52 O 0 3.107834345428273e-08
% O 0 4.096842420864277e-09
of O 0 9.5144359057997e-10
families O 0 3.001629167442843e-08
, O 0 1.4648503521286216e-09
to O 0 5.551724413521697e-09
BRCA2 O 0 2.5007168005686253e-05
in O 0 3.069470011496378e-09
32 O 0 5.6022010141987266e-08
% O 0 1.9511221527324096e-09
of O 0 2.3806942528459274e-10
families O 0 7.920522904214522e-09
, O 0 7.617320663122484e-10
and O 0 1.2678166294577409e-09
to O 0 4.299239186877912e-09
neither O 0 8.337833179439258e-08
gene O 0 3.139644277894149e-08
in O 0 1.3102289253552613e-09
16 O 0 2.3139291371876425e-08
% O 0 4.006460496697173e-09
( O 0 2.7976643224292275e-09
95 O 0 2.8616243596957247e-08
% O 0 7.740412399925845e-08
confidence O 0 2.909134673245717e-05
interval O 0 4.23073215642944e-05
[ O 0 1.382938307870063e-06
CI O 0 9.54923416429665e-06
] O 0 1.393124193782569e-07
6 O 0 3.42780452911029e-08
% O 0 2.223603701168031e-08
- O 0 9.349850529360992e-07
28 O 0 5.858505147671167e-08
% O 0 5.869217112319802e-09
) O 0 5.684266390915127e-10
, O 0 3.230080092286869e-10
suggesting O 0 1.442660746420188e-08
other O 0 2.974708923630942e-09
predisposition O 0 4.66489655082114e-06
genes O 0 9.682370318842004e-07
. O 0 1.0693317165078042e-07

The O 0 8.318334039358888e-07
majority O 0 3.615487571551057e-07
( O 0 3.234768897186768e-08
81 O 0 6.811829678099457e-08
% O 0 2.909288143726485e-09
) O 0 2.718340552654297e-10
of O 0 4.181916202217195e-10
the O 0 6.330559244815959e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.7069870611740043e-07
were O 0 4.1123769278783584e-08
due O 0 1.0180400522585842e-08
to O 0 7.070153795751821e-09
BRCA1 O 0 0.0006646258989349008
, O 0 4.405122933093253e-09
with O 0 1.2553474926235708e-09
most O 0 6.029180266153844e-09
others O 0 1.0336896139051532e-07
( O 0 3.551938076995498e-09
14 O 0 2.0378449150371125e-08
% O 0 9.921949484237302e-09
) O 0 2.263928600143572e-09
due O 0 2.164781598423815e-08
to O 0 1.2648710878693237e-07
BRCA2 O 0 0.0013795621925964952
. O 0 3.2511053404959966e-07

Conversely O 0 6.859652057755738e-05
, O 0 1.205995801001336e-07
the O 0 5.079877851699166e-09
majority O 0 9.394056199596434e-09
of O 0 9.842365811252307e-10
families O 0 1.352137957155719e-08
with O 0 4.366742523131961e-09
male B-Disease 0 2.717524694162421e-06
and I-Disease 0 2.841864557012741e-07
female I-Disease 0 0.22996267676353455
breast I-Disease 1 0.9999992847442627
cancer I-Disease 0 0.0339391827583313
were O 0 1.0946045847504138e-07
due O 0 3.738367482242211e-08
to O 0 1.0548657058961908e-07
BRCA2 O 0 0.016393020749092102
( O 0 2.8709347787980732e-08
76 O 0 1.346027147519635e-07
% O 0 3.996022357455331e-08
) O 0 9.319350624537037e-09
. O 0 4.576588352733779e-08

The O 0 1.0948442650260404e-06
largest O 0 2.897296269566141e-07
proportion O 0 3.274027164934523e-07
( O 0 2.170420998481859e-08
67 O 0 1.5302722999877005e-07
% O 0 6.409991204492371e-09
) O 0 7.020002357194244e-10
of O 0 4.2372363950882175e-10
families O 0 1.7815024122569412e-08
due O 0 8.916398286373806e-09
to O 0 4.266522690699048e-09
other O 0 3.6400351621779237e-09
genes O 0 5.343552516023919e-07
was O 0 2.789402628877724e-07
found O 0 7.848578675861972e-09
in O 0 1.1721161818911696e-09
families O 0 9.788564625523577e-09
with O 0 1.925358983356773e-09
four O 0 2.3896225442854302e-08
or O 0 8.366605186438392e-08
five O 0 2.468449666892525e-09
cases O 0 1.0405925010559258e-09
of O 0 3.1320941396018043e-09
female O 1 0.8934023976325989
breast B-Disease 1 0.9999997615814209
cancer I-Disease 0 0.009044657461345196
only O 0 9.260227074037175e-08
. O 0 1.6217678933116986e-07

These O 0 1.5891507700871443e-06
estimates O 0 1.4651188848802121e-06
were O 0 5.522430228666053e-07
not O 0 1.90167348534942e-08
substantially O 0 1.6812508363273082e-07
affected O 0 4.522777885540563e-08
either O 0 7.0110406369394696e-09
by O 0 1.0306725473085976e-09
changing O 0 3.3800013454765576e-08
the O 0 1.8672754453774587e-09
assumed O 0 1.1035600522291134e-07
penetrance O 0 1.6582774264861655e-07
model O 0 1.9463470835034968e-08
for O 0 1.9314942978354566e-09
BRCA1 O 0 1.6459753169328906e-05
or O 0 7.297705195696835e-08
by O 0 9.632833419814801e-10
including O 0 3.4086544697942145e-09
or O 0 1.3317823288616637e-07
excluding O 0 1.7384031707479153e-06
BRCA1 O 0 0.0005151767982169986
mutation O 0 3.345882760186214e-06
data O 0 1.8764629885481554e-06
. O 0 3.675895356991532e-07

Among O 0 7.469731144738034e-07
those O 0 8.710784982213227e-08
families O 0 7.821756753401132e-08
with O 0 6.059768509203423e-08
disease O 0 0.00040472991531714797
due O 0 1.808032301653384e-08
to O 0 1.6559441817776133e-08
BRCA1 O 0 0.021190635859966278
that O 0 5.944773207033904e-08
were O 0 2.4412161110376474e-06
tested O 0 1.0873750397877302e-06
by O 0 3.2220931478477155e-10
one O 0 3.7211336789688687e-10
of O 0 8.708778143073914e-11
the O 0 5.813030057311153e-10
standard O 0 7.901634546669811e-08
screening O 0 3.527768654976171e-08
methods O 0 4.4064870508009335e-07
, O 0 1.3087909422893063e-08
mutations O 0 4.991399009668385e-07
were O 0 7.420081971076797e-08
detected O 0 1.091404513431371e-07
in O 0 1.301838969958169e-09
the O 0 3.264829961935334e-09
coding O 0 7.120098644008976e-07
sequence O 0 2.7938273206018494e-07
or O 0 8.865257683510208e-08
splice O 0 1.04244727481273e-05
sites O 0 3.36464211159182e-07
in O 0 6.209210479113381e-09
an O 0 6.76556277667828e-09
estimated O 0 3.082472943560788e-08
63 O 0 1.1162596535996272e-07
% O 0 1.5101834449637863e-08
( O 0 5.079131781826618e-09
95 O 0 4.169956824284782e-08
% O 0 1.3408012478066667e-07
CI O 0 1.0856191693164874e-05
51 O 0 1.139071287070692e-06
% O 0 1.9493792535740795e-07
- O 0 1.0243067663395777e-05
77 O 0 6.205773388501257e-07
% O 0 9.568658754233184e-08
) O 0 2.775333030058391e-08
. O 0 6.046283829164167e-08

The O 0 6.606571787415305e-07
estimated O 0 3.278704525655485e-07
sensitivity O 0 6.750277634637314e-07
was O 0 6.248132535802142e-07
identical O 0 1.4607753939799295e-07
for O 0 7.923873224235933e-10
direct O 0 7.571956395224788e-09
sequencing O 0 8.27673645176219e-08
and O 0 2.1211667089460207e-08
other O 0 4.983097046107332e-09
techniques O 0 6.357991424010834e-06
. O 0 3.994300641352311e-07

The O 0 1.8226614884042647e-06
penetrance O 0 2.347697773075197e-05
of O 0 9.932897881981262e-08
BRCA2 O 0 0.00044375701691024005
was O 0 3.3662018950053607e-07
estimated O 0 2.1124092697277774e-08
by O 0 3.091527034371211e-09
maximizing O 0 2.056029302366369e-07
the O 0 3.545536841897956e-08
LOD O 0 7.527469279011711e-05
score O 0 8.618913852842525e-06
in O 0 4.62024907221803e-08
BRCA2 O 0 0.0008349628769792616
- O 0 2.5183693651342764e-05
mutation O 0 5.655684162775287e-06
families O 0 9.31658163949578e-08
, O 0 2.0951060886176265e-09
over O 0 2.083334837976736e-09
all O 0 1.7654679940193319e-09
possible O 0 3.121926539506603e-08
penetrance O 0 4.4550051825353876e-06
functions O 0 5.00512271628395e-07
. O 0 2.6429083277434984e-07

The O 0 6.345842393784551e-07
estimated O 0 1.7660271112163173e-07
cumulative O 0 2.601998403406469e-07
risk O 0 1.152265326709312e-06
of O 0 2.2123760601289177e-08
breast B-Disease 1 0.9999988079071045
cancer I-Disease 0 0.11867522448301315
reached O 0 8.302886840283463e-07
28 O 0 5.196687524744448e-08
% O 0 7.535360779797884e-09
( O 0 2.2524155873782092e-09
95 O 0 4.8630820259631946e-08
% O 0 8.673051610230686e-08
CI O 0 6.5491381064930465e-06
9 O 0 1.6616905895716627e-07
% O 0 5.3342503747444425e-08
- O 0 7.107501005521044e-07
44 O 0 6.462695978370903e-08
% O 0 1.293005258418134e-08
) O 0 8.144401264509327e-10
by O 0 1.0174319164946155e-09
age O 0 2.487251471450236e-08
50 O 0 2.336600024577251e-09
years O 0 1.264826465785518e-09
and O 0 4.036451617395187e-09
84 O 0 1.591270049061677e-08
% O 0 2.8074358393581633e-09
( O 0 1.4048208152317443e-09
95 O 0 2.156823342147618e-08
% O 0 5.737898334245983e-08
CI O 0 2.0964196210115915e-06
43 O 0 1.3076110860765766e-07
% O 0 3.4013627470130814e-08
- O 0 7.216013386823761e-07
95 O 0 8.123804917659072e-08
% O 0 1.1862590021394226e-08
) O 0 1.421822326541644e-09
by O 0 1.7963854848090932e-09
age O 0 1.1322692472504059e-07
70 O 0 2.4308302926101533e-08
years O 0 1.817734762710188e-08
. O 0 5.721341622688669e-08

The O 0 1.2913158570881933e-05
corresponding O 1 0.999686598777771
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.019923459738492966
were O 0 4.360893512966868e-07
0 O 0 6.497674007732712e-07
. O 0 1.3467371218212065e-07

4 O 0 9.603663784218952e-06
% O 0 7.550908662778966e-07
( O 0 2.795228226659674e-08
95 O 0 9.570283054927131e-08
% O 0 1.3711046165099106e-07
CI O 0 1.1618262760748621e-05
0 O 0 3.613663750456908e-07
% O 0 1.1899487617483828e-07
- O 0 1.53222333665326e-06
1 O 0 5.2097082203772516e-08
% O 0 1.0658106397443134e-08
) O 0 7.683070291086835e-10
by O 0 9.5705665614787e-10
age O 0 1.6424966275963016e-08
50 O 0 4.938531361631249e-09
years O 0 2.3074757660168643e-09
and O 0 6.2022507130166105e-09
27 O 0 3.233584777717624e-08
% O 0 3.3994218551214317e-09
( O 0 2.1408215200580116e-09
95 O 0 1.1910451291896607e-08
% O 0 2.1066314914719442e-08
CI O 0 1.9013181145055569e-06
0 O 0 7.904829857352524e-08
% O 0 4.371828410398848e-08
- O 0 1.0120828619619715e-06
47 O 0 6.025767902428925e-07
% O 0 1.8001109935994464e-08
) O 0 2.285164724113997e-09
by O 0 2.289601841454214e-09
age O 0 1.5260270913586282e-07
70 O 0 1.8304755045051024e-08
years O 0 1.9726885014392792e-08
. O 0 3.832805717252086e-08

The O 0 1.3631818092108006e-06
lifetime O 0 9.646375474403612e-06
risk O 0 7.610837656102376e-06
of O 0 8.692660458109458e-08
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.5564926266670227
appears O 0 9.749625462518452e-08
similar O 0 3.574992746280259e-09
to O 0 5.887604626053644e-09
the O 0 5.517619783290684e-08
risk O 0 1.7287529772147536e-06
in O 0 2.5794537616974367e-09
BRCA1 O 0 1.5047705346660223e-05
carriers O 0 8.023799864531611e-07
, O 0 2.3924944247966096e-09
but O 0 1.3590017999831616e-09
there O 0 1.2576146790621578e-09
was O 0 4.951405507824802e-09
some O 0 3.2648656000944243e-10
suggestion O 0 4.92466645241052e-09
of O 0 8.962978137461164e-10
a O 0 5.5710756896587554e-08
lower O 0 0.00010406734509160742
risk O 0 1.1734301551769022e-05
in O 0 9.113892751599906e-09
BRCA2 O 0 1.3420280993159395e-05
carriers O 0 2.6155524324167345e-07
< O 0 2.7972075145044073e-07
50 O 0 2.5000172598765857e-08
years O 0 5.86507642452716e-09
of O 0 2.7837609994918466e-09
age O 0 6.422440037567867e-07
. O 0 8.80375381484555e-08

Eye B-Disease 1 0.9999116659164429
movement I-Disease 0 0.0032757199369370937
abnormalities I-Disease 1 0.9678090810775757
correlate O 0 1.8288084902451374e-05
with O 0 6.323568868538132e-08
genotype O 0 0.000847154762595892
in O 0 1.4531072167756065e-07
autosomal O 1 0.9996476173400879
dominant O 1 0.8439608812332153
cerebellar B-Disease 0 0.26727622747421265
ataxia I-Disease 1 0.999994158744812
type I-Disease 1 0.999993085861206
I I-Disease 0 0.1692882776260376
. O 0 4.656308760786487e-07

We O 0 3.402783477213234e-05
compared O 0 8.787595788817271e-07
horizontal O 0 0.04700016975402832
eye O 1 0.99681156873703
movements O 0 0.0004601268738042563
( O 0 1.9325146638493607e-07
visually O 0 1.0988086387442308e-06
guided O 0 1.5531953977188095e-05
saccades O 0 0.012500131502747536
, O 0 4.833066569176481e-08
antisaccades O 0 5.450666321848985e-06
, O 0 8.273323359730966e-09
and O 0 1.040986141731537e-08
smooth O 0 1.6739742250138079e-06
pursuit O 0 5.788572707388084e-06
) O 0 5.9439995148125035e-09
in O 0 1.531590743120148e-09
control O 0 3.388406355497864e-07
subjects O 0 4.091010850970633e-06
( O 0 4.897280447835328e-08
n O 0 2.4985165509860963e-05
= O 0 7.726641342742369e-05
14 O 0 7.348435104859163e-08
) O 0 2.178947910991269e-09
and O 0 5.551801862679895e-08
patients O 0 1.7759766990366188e-07
with O 0 1.1342676797809759e-09
three O 0 8.491291225709574e-09
forms O 0 2.2494372586834288e-08
of O 0 2.0294857350222628e-08
autosomal O 1 0.9550082087516785
dominant O 0 0.04142996668815613
cerebellar B-Disease 0 0.0008210595115087926
ataxias I-Disease 0 0.003370358608663082
type I-Disease 1 0.5292294025421143
I I-Disease 0 0.0010939992498606443
spinocerebellar B-Disease 0 0.020309193059802055
ataxias I-Disease 0 0.00012981156760361046
1 I-Disease 0 1.9848420151902246e-07
and I-Disease 0 1.1835891911005092e-07
2 I-Disease 0 2.106591807660152e-07
( O 0 5.698036176227106e-08
SCA1 B-Disease 0 2.742005199252162e-05
, O 0 3.358230316052868e-08
n O 0 6.30693693892681e-06
= O 0 1.3397826478467323e-05
11 O 0 1.1353346707210221e-07
; O 0 1.8220251973843915e-08
SCA2 B-Disease 0 6.257362201722572e-06
, O 0 2.0165940028959994e-08
n O 0 6.0361248870322015e-06
= O 0 9.16989847610239e-06
10 O 0 2.2242739206035367e-08
) O 0 1.002218574797098e-08
and O 0 4.5501894874178106e-07
SCA3 B-Disease 1 1.0
/ O 0 0.00044028967386111617
Machado B-Disease 0 6.947703514015302e-05
- I-Disease 0 0.001677191350609064
Joseph I-Disease 0 0.0004317749117035419
disease I-Disease 0 0.02167588099837303
( O 0 5.4531707149862996e-08
MJD B-Disease 1 0.9999998807907104
) O 0 1.761016044099506e-08
( O 0 1.3589610325936974e-08
n O 0 1.8867554899770766e-05
= O 0 5.7513938372721896e-05
16 O 0 1.9840621234834543e-07
) O 0 2.029934975666947e-08
. O 0 5.682136361429002e-08

In O 0 1.7969812233786797e-06
SCA1 B-Disease 0 3.8281537854345515e-05
, O 0 6.928582507725878e-08
saccade O 0 7.001259746175492e-06
amplitude O 0 7.678666520405386e-07
was O 0 6.770340519324236e-07
significantly O 0 3.1474993988922506e-07
increased O 0 1.965052547348023e-07
, O 0 1.4849479867962145e-08
resulting O 0 7.88796157280558e-08
in O 0 1.7632881821327828e-08
hypermetria B-Disease 0 3.159222615067847e-05
. O 0 1.606813242460703e-07

The O 0 2.3259176487044897e-06
smooth O 0 1.0935702448477969e-05
pursuit O 0 1.018353668769123e-05
gain O 0 2.64528498519212e-05
was O 0 1.1849635484395549e-05
decreased O 0 1.0885664778470527e-05
. O 0 8.559526065710088e-08

In O 0 2.7692842650139937e-06
SCA2 B-Disease 0 2.6544657885096967e-05
, O 0 5.141054870705375e-08
saccade O 0 9.494901860307436e-06
velocity O 0 5.7973957154899836e-06
was O 0 5.352355287868704e-07
markedly O 0 5.568160759139573e-06
decreased O 0 1.0682359061320312e-05
. O 0 2.1586099308024131e-07

The O 0 7.231417384900851e-07
percentage O 0 2.2531123704538913e-06
of O 0 1.0371334013825617e-08
errors O 0 2.304474264747114e-06
in O 0 6.448631850730635e-09
antisaccades O 0 3.0132992833387107e-05
was O 0 8.251766416833561e-07
greatly O 0 3.384562319297402e-08
increased O 0 2.4310807589245087e-08
and O 0 1.7072130376050154e-08
was O 0 3.60882452810074e-08
significantly O 0 2.187961278821149e-08
correlated O 0 9.487423824339203e-08
with O 0 9.813915013978658e-09
age O 0 9.715976148072514e-07
at O 0 4.92638810101198e-06
disease O 0 0.0013024997897446156
onset O 0 0.00012976191646885127
. O 0 3.5477495430313866e-07

In O 0 4.396295594233379e-07
addition O 0 9.946055001819332e-08
, O 0 4.892460214733774e-09
a O 0 3.0454903043874992e-09
correlation O 0 1.1731382443258553e-07
between O 0 3.07507370678195e-08
smooth O 0 1.5585279470542446e-05
pursuit O 0 9.384822078573052e-06
gain O 0 3.9582300814799964e-05
and O 0 9.548840296247363e-08
the O 0 2.114068919922829e-09
number O 0 4.031803779724896e-09
of O 0 4.126675001714375e-09
trinucleotide O 0 2.8077962269890122e-05
repeats O 0 6.602644134545699e-06
was O 0 8.371399644602207e-07
found O 0 1.0153797802558984e-07
. O 0 5.7454325741446155e-08

In O 0 5.81639005758916e-06
SCA3 B-Disease 1 0.9999992847442627
, O 0 3.597691602408304e-07
gaze B-Disease 0 0.001523175509646535
- I-Disease 0 8.852371684042737e-05
evoked I-Disease 0 2.4310020307893865e-05
nystagmus I-Disease 0 0.0482037179172039
was O 0 7.834087227820419e-07
often O 0 3.66072221424929e-08
present O 0 4.075860537966491e-09
as O 0 7.974183091619125e-09
was O 0 6.99397375569788e-08
saccade O 0 6.227636276889825e-06
hypometria O 0 5.617465376417385e-06
and O 0 7.265788326549227e-08
smooth O 0 2.223482397312182e-06
pursuit O 0 7.4339527600386646e-06
gain O 0 2.8321150239207782e-05
was O 0 5.116879947308917e-06
markedly O 0 1.8771466784528457e-05
decreased O 0 8.540258932043798e-06
. O 0 1.0129154759397352e-07

Three O 0 5.751452590629924e-06
major O 0 7.720506687292072e-07
criteria O 0 8.319024118463858e-07
, O 0 1.2163538620768577e-08
saccade O 0 1.2560687991935993e-06
amplitude O 0 2.3771536916683544e-07
, O 0 6.774213634486159e-09
saccade O 0 1.1431293387431651e-06
velocity O 0 5.850091042702843e-07
, O 0 4.132409081591959e-09
and O 0 3.777003598770534e-09
presence O 0 4.8943267216827735e-09
of O 0 1.8076313779147313e-09
gaze B-Disease 0 0.0256546288728714
- I-Disease 0 5.5810312915127724e-05
evoked I-Disease 0 5.2338587011036e-06
nystagmus I-Disease 0 4.295993858249858e-05
, O 0 6.98627866668744e-09
permitted O 0 8.567721643260029e-09
the O 0 3.3937983534571003e-09
correct O 0 6.040094717718603e-07
assignment O 0 9.28227876784149e-08
of O 0 1.0225152946574667e-09
90 O 0 7.348614161628575e-09
% O 0 2.893715045360068e-09
of O 0 4.1427455910181266e-10
the O 0 9.553263957684521e-09
SCA1 B-Disease 0 1.847057865234092e-05
, O 0 2.1012809270359867e-09
90 O 0 3.3487044248659004e-09
% O 0 2.690000000526993e-09
of O 0 4.1399966788091547e-10
the O 0 8.88800855136651e-09
SCA2 B-Disease 0 1.1150536920467857e-05
, O 0 2.427845036123699e-09
and O 0 4.581406809478494e-09
93 O 0 1.738177424215337e-08
% O 0 1.2518158731822382e-09
of O 0 1.5811846276747588e-10
the O 0 1.7756745407382368e-08
patients O 0 3.799781609359343e-07
with O 0 2.6075323233953895e-08
SCA3 B-Disease 1 1.0
to O 0 6.248824035992584e-08
their O 0 4.855056090491416e-07
genetically O 0 4.2558494328659435e-07
confirmed O 0 1.760372185799497e-07
patient O 0 3.4786188507496263e-07
group O 0 1.025590279368771e-08
and O 0 1.2054893083757179e-08
, O 0 2.2861412762864575e-09
therefore O 0 1.3168185653000819e-08
, O 0 1.2004363059148204e-09
may O 0 2.18359215153896e-08
help O 0 1.4719399032969704e-08
orient O 0 4.996265488443896e-06
diagnoses O 0 7.405230280710384e-05
of O 0 5.257299928729253e-09
SCA1 B-Disease 0 2.1762964024674147e-05
, O 0 7.959412684499512e-09
SCA2 B-Disease 0 2.6930154035653686e-06
, O 0 3.836204687246436e-09
and O 0 6.84226080238659e-08
SCA3 B-Disease 1 1.0
at O 0 6.645984740316635e-07
early O 0 1.0268903594123913e-07
clinical O 0 7.34818229375378e-07
stages O 0 2.436241004488693e-07
of O 0 3.0327145239539277e-09
the O 0 1.7468560997713212e-07
diseases O 0 0.00026767898816615343
. O 0 1.2239733671037811e-08
. O 0 8.262698258931778e-08

Genetic O 0 4.925814573653042e-05
basis O 0 1.0133961723113316e-06
and O 0 1.0114057857890657e-07
molecular O 0 8.151732799888123e-06
mechanism O 0 0.00019059913756791502
for O 0 2.4240711354650557e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 1.3852171832695603e-05

Ventricular B-Disease 1 0.9998939037322998
fibrillation I-Disease 1 0.9998856782913208
causes O 0 5.692408012691885e-05
more O 0 3.4305777774079615e-08
than O 0 1.2010002770068695e-08
300 O 0 1.1429682089669768e-08
, O 0 1.737490373798778e-09
000 O 0 1.9647091065166933e-08
sudden O 0 2.311031863655444e-07
deaths O 0 2.600110917683196e-07
each O 0 5.597946994839731e-09
year O 0 6.94809942913821e-09
in O 0 2.7016926473777403e-09
the O 0 3.4048156294375076e-08
USA O 0 8.879658707883209e-06
alone O 0 2.2000681099143549e-07
. O 0 2.302429891187785e-08

In O 0 6.795659714953217e-07
approximately O 0 2.943045558367885e-07
5 O 0 1.6461888208141318e-07
- O 0 9.43367581385246e-07
12 O 0 3.6173631201563694e-08
% O 0 3.0644276005631355e-09
of O 0 1.491927553720629e-10
these O 0 1.7480642489076104e-09
cases O 0 3.039095863854868e-09
, O 0 1.612417754870421e-09
there O 0 3.200498088773429e-09
are O 0 8.89014550864431e-09
no O 0 1.2705581298178004e-07
demonstrable O 0 0.3262600004673004
cardiac O 0 0.0029246159829199314
or O 0 1.3110730833432171e-05
non O 0 0.1676267385482788
- O 1 0.9915539622306824
cardiac O 0 0.16134114563465118
causes O 0 4.546458853837976e-07
to O 0 1.0329086919114161e-08
account O 0 3.122427472135314e-07
for O 0 1.1365025587295463e-09
the O 0 3.2014382256306817e-09
episode O 0 8.422353516834846e-07
, O 0 4.095600303344327e-09
which O 0 4.4206944771474355e-09
is O 0 2.2476434047291605e-09
therefore O 0 1.8903760334865183e-08
classified O 0 2.6836985398404067e-06
as O 0 2.5343761080875993e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999997615814209
fibrillation I-Disease 1 1.0
( O 0 0.00015944524784572423
IVF B-Disease 1 1.0
) O 0 8.932221930990636e-07
. O 0 3.931849619220884e-07

A O 0 1.6010129684218555e-06
distinct O 0 4.740956569548871e-07
group O 0 7.224276998840651e-08
of O 0 8.039025445327752e-09
IVF B-Disease 1 1.0
patients O 0 0.1933283507823944
has O 0 3.361523681633116e-08
been O 0 1.7925460227274925e-08
found O 0 4.554494115183161e-09
to O 0 2.0686683477322276e-09
present O 0 9.824590030405034e-09
with O 0 4.530641195543694e-09
a O 0 4.7764135757688564e-08
characteristic O 0 1.7473255866207182e-05
electrocardiographic O 0 0.00019871932454407215
pattern O 0 3.853246380458586e-05
. O 0 2.827172522756882e-07

Because O 0 9.119118544731464e-07
of O 0 7.494696419030333e-09
the O 0 1.762520573933557e-09
small O 0 2.2445931779913053e-09
size O 0 5.470419228714718e-09
of O 0 6.449575318256962e-10
most O 0 1.949779226961823e-09
pedigrees O 0 9.466047004025313e-07
and O 0 1.1863382276544598e-08
the O 0 3.2943925365458426e-09
high O 0 2.4325379399670055e-07
incidence O 0 0.0004543983959592879
of O 0 6.080339343128571e-09
sudden B-Disease 0 4.18662011725246e-06
death I-Disease 0 3.26845821518873e-07
, O 0 3.1683675683069623e-09
however O 0 3.151888749997056e-09
, O 0 7.55905227300957e-10
molecular O 0 1.0601463884540863e-07
genetic O 0 5.392538469095598e-07
studies O 0 1.8790737854601502e-08
of O 0 6.799093288378799e-09
IVF B-Disease 1 1.0
have O 0 5.768178198195528e-06
not O 0 1.6992254359138315e-07
yet O 0 6.85576821979339e-08
been O 0 6.451254819239693e-08
done O 0 1.8815993030329992e-07
. O 0 7.644676713880472e-08

Because O 0 0.00017995179223362356
IVF B-Disease 1 1.0
causes O 0 0.14312121272087097
cardiac O 1 0.926708996295929
rhythm O 0 0.03396081179380417
disturbance O 0 5.511315521289362e-06
, O 0 2.278228805607796e-08
we O 0 3.127385639345448e-08
investigated O 0 8.871685253097894e-08
whether O 0 1.3271263199499117e-08
malfunction O 0 1.3829568388246116e-06
of O 0 5.739117514558245e-10
ion O 0 6.206489899795997e-08
channels O 0 1.145538772107102e-05
could O 0 7.5859829848923255e-06
cause O 0 5.271807594908751e-07
the O 0 1.8163623494160674e-08
disorder O 0 8.287894888781011e-05
by O 0 5.752542886483525e-10
studying O 0 9.272312695429719e-09
mutations O 0 1.4416848159726214e-07
in O 0 1.06553366130413e-09
the O 0 1.0740552447430218e-08
cardiac O 0 5.2491241149255075e-06
sodium O 0 4.18604628293906e-07
channel O 0 3.672132606880041e-06
gene O 0 8.507881830155384e-06
SCN5A O 0 5.203020918997936e-05
. O 0 4.7353577770081756e-07

We O 0 2.2961245122132823e-05
have O 0 1.0259799410050618e-07
now O 0 4.281655208160373e-08
identified O 0 8.993398381562656e-08
a O 0 8.472233581358068e-09
missense O 0 2.0730256437673233e-05
mutation O 0 3.685141109599499e-06
, O 0 5.057959828747016e-09
a O 0 1.270092386818078e-08
splice O 0 0.42006543278694153
- O 0 0.007934427820146084
donor O 0 6.151599336590152e-07
mutation O 0 1.835220245993696e-05
, O 0 7.632304566129733e-09
and O 0 7.254043143944955e-09
a O 0 2.611185401235616e-08
frameshift O 0 0.00010914442827925086
mutation O 0 1.6264126543319435e-06
in O 0 1.8180043026561066e-09
the O 0 1.938831983849809e-09
coding O 0 9.621583103580633e-07
region O 0 5.63538051778778e-08
of O 0 6.838526633856645e-09
SCN5A O 0 2.2025984435458668e-05
in O 0 1.0717633003309857e-08
three O 0 3.800147965193901e-07
IVF B-Disease 1 1.0
families O 0 8.677517371324939e-07
. O 0 9.995081029501307e-08

We O 0 4.445604645297863e-06
show O 0 2.163890542306035e-07
that O 0 1.8384873623489284e-09
sodium O 0 1.4497167022398116e-08
channels O 0 2.8267590934660802e-08
with O 0 3.7087286575143708e-09
the O 0 5.9376197292237975e-09
missense O 0 2.1683310478692874e-05
mutation O 0 7.251179340528324e-06
recover O 0 1.5842101674934383e-06
from O 0 2.5135087344807516e-09
inactivation O 0 2.1255490878502314e-07
more O 0 1.8764583220587383e-09
rapidly O 0 7.249924038887912e-08
than O 0 1.9505306259048893e-09
normal O 0 5.545684444996368e-08
and O 0 4.500633643544916e-09
that O 0 8.810144835891265e-10
the O 0 7.05022396019217e-09
frameshift O 0 0.0001234842638950795
mutation O 0 4.7669118430349045e-06
causes O 0 5.723928353518204e-08
the O 0 3.4278091476380723e-09
sodium O 0 3.336204201787041e-08
channel O 0 5.359823376238637e-07
to O 0 1.310222152994811e-08
be O 0 6.074940017697372e-08
non O 0 1.4929943290553638e-06
- O 0 1.1464316230558325e-05
functional O 0 1.395151048200205e-05
. O 0 2.8347400871098216e-07

Our O 0 1.9458704628050327e-05
results O 0 7.472488618986972e-07
indicate O 0 2.2947054389987898e-07
that O 0 1.6573716843382158e-09
mutations O 0 8.205254857784894e-07
in O 0 2.4650623764443935e-09
cardiac O 0 4.0953918301056547e-07
ion O 0 2.0735743078148516e-07
- O 0 1.5623751323801116e-06
channel O 0 1.4662189187220065e-06
genes O 0 1.0211402212689791e-07
contribute O 0 6.656608153576826e-09
to O 0 1.6417911474775337e-09
the O 0 7.157588743922361e-09
risk O 0 4.2506616892978855e-08
of O 0 6.750142667044656e-10
developing O 0 5.257693942439801e-07
IVF B-Disease 1 0.9999997615814209
. O 0 2.3253793557387326e-08
. O 0 6.697312215919737e-08

Molecular O 0 5.998240158078261e-05
heterogeneity O 0 5.48609605175443e-05
in O 0 8.279419034806779e-07
mucopolysaccharidosis B-Disease 0 0.00013200799003243446
IVA I-Disease 0 0.00016099757340271026
in O 0 7.147210112634639e-08
Australia O 0 4.882660391558602e-07
and O 0 8.036714405079692e-08
Northern O 0 3.31596112346233e-07
Ireland O 0 1.0661221494956408e-05
: O 0 4.942187548095944e-09
nine O 0 1.1756252860095628e-08
novel O 0 1.1600554294943777e-08
mutations O 0 2.1463509369823441e-07
including O 0 2.0408661427495645e-09
T312S O 0 3.770592797991412e-07
, O 0 1.007715466627701e-09
a O 0 1.5063911229518112e-09
common O 0 1.5201770509065682e-08
allele O 0 2.0390662314184738e-07
that O 0 1.5117130880426544e-09
confers O 0 1.4913976542629825e-07
a O 0 1.0911817582837102e-07
mild O 0 0.0009971994441002607
phenotype O 0 0.00026210735086351633
. O 0 3.1331060768025054e-07

Mucopolysaccharidosis B-Disease 1 0.9802439212799072
IVA I-Disease 1 0.9996680021286011
( O 0 0.01603543572127819
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.9167998150114727e-07
is O 0 1.120202863802433e-08
an O 0 3.227681588668929e-08
autosomal B-Disease 1 0.9999929666519165
recessive I-Disease 1 0.9999990463256836
lysosomal I-Disease 1 0.9999953508377075
storage I-Disease 1 0.9999890327453613
disorder I-Disease 1 1.0
caused O 0 5.889600743103074e-06
by O 0 4.3478598499291365e-09
a O 0 2.7140336555930844e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 8.300972353936231e-08
N O 0 0.0052744667045772076
- O 0 0.003150393720716238
acetylgalactosamine O 0 0.18759198486804962
- O 0 0.005397542845457792
6 O 0 1.8470613213139586e-05
- O 0 0.004804305266588926
sulfate O 0 0.00010466227104188874
sulfatase O 0 0.00015201141650322825
( O 0 4.2059542693095864e-07
GALNS O 0 1.0466249477758538e-05
) O 0 1.1110322617469137e-07
. O 0 7.166539717218257e-08

Previous O 0 4.87748957311851e-06
studies O 0 4.544967850961257e-07
of O 0 2.9627118536268426e-08
patients O 0 3.8345574466802645e-06
from O 0 8.675248963641025e-09
a O 0 7.984962024920605e-08
British O 0 0.0005196958081796765
- O 0 0.0012195116141811013
Irish O 0 1.0715531061578076e-05
population O 0 2.3671583804230067e-08
showed O 0 4.214743967168033e-07
that O 0 7.294844728278349e-10
the O 0 1.7032961707741379e-09
I113F O 0 3.6935392699888325e-07
mutation O 0 1.7510458860670042e-07
is O 0 5.489387278068136e-10
the O 0 2.910474361517146e-10
most O 0 7.276071967154962e-10
common O 0 1.350568190616741e-08
single O 0 2.2849492324894527e-06
mutation O 0 3.547665301084635e-06
among O 0 1.6800919411252835e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.05792885646224022
and O 0 6.812778252651697e-08
produces O 0 2.6486361548450077e-07
a O 0 4.756848284159787e-07
severe O 1 0.5901339650154114
clinical O 0 0.003812819719314575
phenotype O 0 0.0006209754501469433
. O 0 3.3075315286623663e-07

We O 0 4.087871275260113e-06
studied O 0 7.380685929092579e-07
mutations O 0 2.4110595404636115e-06
in O 0 2.892275086097129e-09
the O 0 1.0225431168464638e-08
GALNS O 0 6.792706244596047e-06
gene O 0 3.8342213315445406e-07
from O 0 9.880741558276895e-09
23 O 0 8.931738904038866e-08
additional O 0 2.1221381985014887e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.012415539473295212
( O 0 3.6147213222648134e-08
15 O 0 3.2675227856771016e-08
from O 0 5.27670884764575e-09
Australia O 0 5.25559826769495e-08
, O 0 4.340767301158621e-09
8 O 0 7.273660784790081e-09
from O 0 3.5281708665735323e-09
Northern O 0 9.005757561908467e-08
Ireland O 0 2.967083219118649e-06
) O 0 4.080153992447322e-09
, O 0 4.623629812350316e-10
with O 0 4.703630818170268e-10
various O 0 4.777880135975465e-08
clinical O 0 0.0064557502046227455
phenotypes O 0 0.001224971143528819
( O 0 1.2180885278212372e-07
severe O 0 0.0011257746955379844
, O 0 7.693632397831607e-09
16 O 0 1.8948737690038797e-08
cases O 0 2.3639896706839636e-09
; O 0 2.5281250426445467e-09
intermediate O 0 6.451586642697293e-08
, O 0 3.5180374169385686e-09
4 O 0 1.5366859784649023e-08
cases O 0 1.8660230693967605e-08
; O 0 8.238903603796643e-08
mild O 0 0.0014715454308316112
, O 0 4.0034372261743556e-08
3 O 0 7.039356120230877e-08
cases O 0 2.042623492570783e-08
) O 0 1.407017702348412e-08
. O 0 5.412550763139734e-08

We O 0 7.324329089897219e-06
found O 0 8.770435044880287e-08
two O 0 7.062834761484282e-09
common O 0 2.7501975807808776e-08
mutations O 0 9.952105983757065e-07
that O 0 1.9498462844325104e-09
together O 0 5.211964548834658e-08
accounted O 0 6.120893658589921e-07
for O 0 2.048799130349721e-09
32 O 0 3.949226012878171e-08
% O 0 2.2398032317738625e-09
of O 0 2.067065824062908e-10
the O 0 2.9741360485502355e-09
44 O 0 2.498834916764281e-08
unrelated O 0 2.6989644297259474e-08
alleles O 0 5.658969115529544e-08
in O 0 1.802797133798606e-09
these O 0 2.4082728700136613e-08
patients O 0 4.929885335513973e-07
. O 0 5.532404401265012e-08

One O 0 1.3293096117195091e-06
is O 0 4.5373283796834585e-08
the O 0 1.652076520031187e-08
T312S O 0 2.5842127797659487e-06
mutation O 0 1.91942945093615e-06
, O 0 2.7871505103860272e-09
a O 0 5.323006480040249e-09
novel O 0 6.27419041165922e-08
mutation O 0 4.856700002164871e-07
found O 0 1.4560403549523926e-08
exclusively O 0 2.608984850382967e-08
in O 0 9.154451419135512e-09
milder O 0 7.69199978094548e-05
patients O 0 3.0811545002507046e-05
. O 0 1.2595049270203162e-07

The O 0 2.444514279886789e-07
other O 0 1.54324482082302e-08
is O 0 4.733513137011869e-09
the O 0 3.853504182416145e-09
previously O 0 3.1634664310331573e-07
described O 0 6.551184839054258e-08
I113F O 0 2.58679193620992e-07
that O 0 1.7863298618081558e-09
produces O 0 3.473745024962227e-08
a O 0 9.594499772447307e-08
severe O 0 0.0007461800705641508
phenotype O 0 3.434085374465212e-05
. O 0 1.8091141384957155e-07

The O 0 1.1499226957312203e-06
I113F O 0 6.23197365712258e-06
and O 0 6.937667507145306e-08
T312S O 0 2.7898756798094837e-06
mutations O 0 4.197802354610758e-06
accounted O 0 3.8433515214819636e-07
for O 0 3.906193146718806e-09
8 O 0 3.74132049785203e-08
( O 0 8.028880671417937e-09
18 O 0 3.8926739165390245e-08
% O 0 6.878031477697277e-09
) O 0 8.19899925730283e-10
and O 0 6.856838208335603e-09
6 O 0 2.909800222994363e-08
( O 0 3.224492450826233e-09
14 O 0 1.0022682239707592e-08
% O 0 2.063108350824905e-09
) O 0 2.681060373710409e-10
of O 0 2.605794191534727e-10
44 O 0 1.785717529401154e-08
unrelated O 0 4.896887872973821e-08
alleles O 0 2.3520460956660827e-07
, O 0 1.3276174826160059e-08
respectively O 0 6.153911158435221e-07
. O 0 1.0592449228852274e-07

The O 0 3.4596584441715095e-07
relatively O 0 3.334455129788694e-07
high O 0 3.339015393066802e-07
residual O 0 8.039287422434427e-06
GALNS O 0 2.528015829739161e-05
activity O 0 7.943156674627971e-07
seen O 0 4.3333164967407356e-07
when O 0 7.811689961556567e-09
the O 0 2.312728009101761e-09
T312S O 0 1.1485150253065513e-07
mutant O 0 1.1124465970624442e-07
cDNA O 0 5.3785893072699764e-08
is O 0 3.6948828441296655e-09
overexpressed O 0 4.949553158439812e-07
in O 0 6.676494912483122e-09
mutant O 0 5.056988925389305e-07
cells O 0 8.893642444718353e-08
provides O 0 2.890504724462062e-09
an O 0 1.0642784431524888e-09
explanation O 0 9.837116010658065e-09
for O 0 1.909392199905824e-09
the O 0 2.4586492841649488e-08
mild O 0 0.00020733494602609426
phenotype O 0 9.346820297650993e-05
in O 0 1.625188872367289e-08
patients O 0 8.233458856921061e-07
with O 0 3.483981547702797e-09
this O 0 1.0610117229248317e-08
mutation O 0 6.65031711832853e-06
. O 0 1.5046393286866078e-07

The O 0 4.4065964743822406e-07
distribution O 0 6.247846329188178e-08
and O 0 6.3178036135980165e-09
relative O 0 1.4374420764795559e-08
frequencies O 0 6.796087603788692e-08
of O 0 8.019984676366221e-10
the O 0 6.9924905865548226e-09
I113F O 0 2.905048575030378e-07
and O 0 2.237515772662846e-08
T312S O 0 3.986316698956216e-07
mutations O 0 4.392678647491266e-07
in O 0 3.1736417938077466e-09
Australia O 0 1.5838486078223468e-08
corresponded O 0 1.8548490743341972e-08
to O 0 5.141924663831787e-09
those O 0 1.7195988633034176e-08
observed O 0 3.363210510087811e-08
in O 0 1.2610733568507726e-09
Northern O 0 4.775994355554758e-08
Ireland O 0 2.260207793369773e-06
and O 0 2.4408704391021274e-08
are O 0 1.0986278553559714e-09
unique O 0 8.064883760816599e-10
to O 0 8.528619477310428e-10
these O 0 1.6168432148688794e-09
two O 0 7.8773441103408e-09
populations O 0 1.8658168343677062e-08
, O 0 7.830810444531267e-10
suggesting O 0 1.2822115813548862e-08
that O 0 6.120876583359802e-10
both O 0 7.779914490413375e-09
mutations O 0 5.878798106095928e-07
were O 0 9.262346623017947e-08
probably O 0 1.3860919523267512e-08
introduced O 0 3.4588607533692084e-09
to O 0 6.074173164449803e-09
Australia O 0 3.5859351044109644e-08
by O 0 2.8770834603619733e-09
Irish O 0 1.1530101318157904e-07
migrants O 0 1.1829557777787159e-08
during O 0 8.558101782796257e-09
the O 0 5.500216282428028e-09
19th O 0 3.4181493901996873e-07
century O 0 4.2001943256764207e-07
. O 0 1.3755943939486315e-07

Haplotype O 0 0.00014721584739163518
analysis O 0 1.4143572570901597e-06
using O 0 7.390589189526509e-07
6 O 0 8.470871080135112e-07
RFLPs O 0 1.8806802017934388e-06
provides O 0 2.154056488734568e-08
additional O 0 4.9885366948387855e-09
data O 0 3.266476653607242e-07
that O 0 1.9110899529550807e-09
the O 0 3.852703045481576e-09
I113F O 0 5.4329308341039e-07
mutation O 0 1.4717718954671e-07
originated O 0 1.3862980985379636e-08
from O 0 1.3828749256816764e-09
a O 0 6.432575805348506e-09
common O 0 3.88032361797741e-08
ancestor O 0 4.838877885049442e-07
. O 0 1.0949761986012163e-07

The O 0 2.4382094920838426e-07
other O 0 2.5344705889551733e-08
9 O 0 1.1047899306504405e-07
novel O 0 1.0496915336943857e-07
mutations O 0 1.3659237083629705e-06
identified O 0 1.406111493906792e-07
in O 0 1.1801470911620981e-09
these O 0 6.108784589287097e-09
23 O 0 7.907972303655697e-07
patients O 0 3.0267239026215975e-07
were O 0 4.731493419285471e-08
each O 0 1.527325710348748e-09
limited O 0 8.540605556106584e-09
to O 0 7.454791450811626e-09
a O 0 2.067478703793313e-07
single O 0 0.00013356715498957783
family O 0 7.939407851154101e-07
. O 0 9.439501269525863e-08

These O 0 4.584714190514205e-07
data O 0 2.9828527203790145e-07
provide O 0 5.2966466768111786e-08
further O 0 2.7190692364342794e-08
evidence O 0 2.0903650366221882e-08
for O 0 2.4245501162312166e-09
extensive O 0 5.383504912970238e-07
allelic O 0 1.5354064089478925e-05
heterogeneity O 0 5.23038079336402e-06
in O 0 1.2937523479195079e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
in O 0 2.1571530339770106e-07
British O 0 0.000908484507817775
- O 0 0.005552560091018677
Irish O 0 2.3473196051781997e-05
patients O 0 2.657952791196294e-07
and O 0 1.0012779494417146e-09
provide O 0 3.6298917205357384e-09
evidence O 0 1.1099664298797052e-08
for O 0 2.5718389640161377e-09
their O 0 1.2948913763466408e-07
transmission O 0 1.1810679097834509e-05
to O 0 1.2909428193097483e-08
Australia O 0 4.9415117331363945e-08
by O 0 4.109818707576096e-09
British O 0 6.535112788697006e-06
- O 0 1.480798891861923e-05
Irish O 0 1.403516648679215e-06
migrants O 0 1.234040638564693e-07
. O 0 6.336339453127948e-09
. O 0 4.3247453618278087e-08

Identification O 0 3.1746535569254775e-06
of O 0 6.194922974600559e-08
constitutional O 0 7.934237942208711e-07
WT1 O 0 0.0001922656228998676
mutations O 0 4.514604006544687e-05
, O 0 6.907796556987478e-09
in O 0 2.7435422822463806e-09
patients O 0 2.7462405682854296e-07
with O 0 9.205614048823918e-09
isolated O 0 0.0002464964345563203
diffuse B-Disease 1 0.9907742142677307
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.00248296728023e-08
and O 0 3.387538027865844e-09
analysis O 0 1.1490315365847437e-08
of O 0 7.621103748078895e-09
genotype O 0 0.0018728006398305297
/ O 0 9.028822387335822e-05
phenotype O 0 5.609520940197399e-06
correlations O 0 3.7595765434161876e-07
by O 0 2.248106589775034e-09
use O 0 1.0602105859902622e-08
of O 0 2.0978572212726476e-09
a O 0 3.6440731321363273e-08
computerized O 0 0.0016318379202857614
mutation O 0 2.6851277652895078e-05
database O 0 1.4440572613239055e-06
. O 0 4.4338534621601866e-07

Constitutional O 0 9.987732482841238e-06
mutations O 0 9.115284228755627e-06
of O 0 1.701264373821232e-08
the O 0 2.1651533899103015e-08
WT1 O 0 1.0683836990210693e-05
gene O 0 4.98780707403057e-07
, O 0 4.708004208708871e-09
encoding O 0 8.572597209877131e-08
a O 0 3.451673080689943e-07
zinc O 0 0.23891553282737732
- O 0 5.8189023548038676e-05
finger O 0 0.0008309143013320863
transcription O 0 4.075096512679011e-06
factor O 0 1.7101437777000683e-07
involved O 0 5.3421409518250584e-08
in O 0 1.422588002952807e-08
renal O 0 0.00015705375699326396
and O 0 1.3622808126001473e-07
gonadal O 0 0.0010951519943773746
development O 0 4.183548085734401e-08
, O 0 3.7519809481523225e-09
are O 0 9.018676361272071e-10
found O 0 1.7172251398633875e-09
in O 0 3.0125696381944067e-10
most O 0 2.6930135899050356e-09
patients O 0 7.941128643551565e-08
with O 0 5.667405389431224e-08
Denys B-Disease 1 0.9999994039535522
- I-Disease 1 1.0
Drash I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 3.2079134371088003e-07
DDS B-Disease 1 1.0
) O 0 6.912807748449268e-08
, O 0 1.4854691698928946e-08
or O 0 2.517709390303935e-06
diffuse B-Disease 1 0.9999274015426636
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 6.855467290733941e-06
DMS B-Disease 0 0.22752270102500916
) O 0 4.880923754058131e-08
associated O 0 1.1049543502394954e-07
with O 0 1.0376245285215191e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.5141084077185951e-05
/ O 0 0.052672985941171646
or O 0 6.0416168707888573e-05
Wilms B-Disease 1 0.9996127486228943
tumor I-Disease 0 0.05033382028341293
( O 0 1.1391213092792896e-06
WT B-Disease 1 0.9999992847442627
) O 0 4.38356806853335e-07
. O 0 1.8762396791771607e-07

Most O 0 3.0594237614423037e-06
mutations O 0 0.00018007382459472865
in O 0 6.39102211152931e-07
DDS B-Disease 1 1.0
patients O 1 0.9993131160736084
lie O 0 0.00011934111535083503
in O 0 6.6718994773395934e-09
exon O 0 4.5295030304259853e-07
8 O 0 9.974132098022892e-08
or O 0 3.698657025097418e-08
exon O 0 3.0564441999558767e-07
9 O 0 1.0054296950556818e-07
, O 0 2.726244563433511e-09
encoding O 0 1.0662599834176945e-06
zinc O 1 0.7643680572509766
finger O 1 0.9819514751434326
2 O 0 7.375482709903736e-06
or O 0 0.0001422898640157655
zinc O 1 0.6010580658912659
finger O 1 0.7644761204719543
3 O 0 8.081181022134842e-07
, O 0 1.5740818426479564e-08
respectively O 0 4.509607265390514e-07
, O 0 2.823729250422957e-09
with O 0 2.0835930758522636e-09
a O 0 8.530417261454204e-08
hot O 0 0.0001265137834707275
spot O 0 0.12112197279930115
( O 0 4.0084344732349564e-08
R394W O 0 1.3877458115985064e-07
) O 0 1.2782185310200589e-09
in O 0 1.4249199598026507e-09
exon O 0 9.53510550516512e-07
9 O 0 6.502310725409188e-07
. O 0 1.5085848303897365e-07

We O 0 8.899291970010381e-06
analyzed O 0 7.624354907420638e-07
a O 0 1.8510073473976263e-08
series O 0 1.7142120611879363e-08
of O 0 2.816349375933669e-09
24 O 0 1.7713956594889169e-06
patients O 0 9.054066367752966e-07
, O 0 2.14178941249088e-09
10 O 0 6.232894644853104e-09
with O 0 2.0360616304060386e-08
isolated B-Disease 0 0.0021177458111196756
DMS I-Disease 1 0.9815199971199036
( O 0 2.102565588302241e-07
IDMS B-Disease 0 0.0004379704187158495
) O 0 1.3752895711149904e-08
, O 0 1.3676766386083727e-09
10 O 0 5.443399508919811e-09
with O 0 2.4379577467925628e-08
DDS B-Disease 1 1.0
, O 0 2.2894637652370875e-07
and O 0 2.6372426020770945e-08
4 O 0 3.0548932272722595e-08
with O 0 2.1429430674402283e-08
urogenital B-Disease 0 0.1170908659696579
abnormalities I-Disease 1 0.9999709129333496
and O 0 1.1402353266021237e-06
/ O 0 0.02115153893828392
or O 0 0.0024113652762025595
WT B-Disease 1 1.0
. O 0 3.5021603252971545e-06

We O 0 1.847642670327332e-05
report O 0 1.5669965023334953e-06
WT1 O 0 9.155605221167207e-05
heterozygous O 0 3.533003109623678e-05
mutations O 0 3.4145073186664376e-06
in O 0 1.1974777613943388e-08
16 O 0 1.573722272496525e-07
patients O 0 3.8999274920570315e-07
, O 0 4.738587300323616e-10
4 O 0 2.0572887837744247e-09
of O 0 8.464347556191854e-10
whom O 0 3.6772803468920756e-07
presented O 0 9.088412866731232e-08
with O 0 2.059119879049831e-07
IDMS B-Disease 1 0.9275352358818054
. O 0 6.836552870481682e-07

One O 0 1.9454082575975917e-06
male O 0 6.259300789679401e-06
and O 0 2.4639730256126313e-08
two O 0 3.856756691789087e-08
female O 0 0.0008495171787217259
IDMS B-Disease 1 0.9999432563781738
patients O 0 0.0001982208777917549
with O 0 1.705025454157294e-07
WT1 O 0 0.03586406260728836
mutations O 0 0.01814347505569458
underwent O 0 9.940265590557829e-05
normal O 0 3.128542812191881e-05
puberty O 0 0.0010525105753913522
. O 0 1.4336027334138635e-06

Two O 0 1.2766186955559533e-05
mutations O 0 0.0012726226123049855
associated O 0 8.29758334930375e-07
with O 0 2.5579419471455367e-08
IDMS B-Disease 0 0.06604748219251633
are O 0 1.3359593431516714e-08
different O 0 4.147934440368317e-09
from O 0 3.699043071847541e-09
those O 0 1.6404522185098358e-08
described O 0 1.5934151065266633e-07
in O 0 6.578419231573207e-08
DDS B-Disease 1 1.0
patients O 0 0.0030784241389483213
. O 0 2.644256937855971e-07

No O 0 3.38354948326014e-05
WT1 O 0 0.0006036380073055625
mutations O 0 0.00030255888123065233
were O 0 8.191002507373923e-07
detected O 0 6.561651275660552e-07
in O 0 2.055531522771048e-09
the O 0 2.176472113646355e-09
six O 0 1.740446364806303e-08
other O 0 1.3888918459770139e-08
IDMS B-Disease 1 0.9974231719970703
patients O 0 9.190139280690346e-06
, O 0 2.049373559742662e-09
suggesting O 0 8.037833509888515e-08
genetic O 0 4.5332322429203487e-07
heterogeneity O 0 3.995382158450411e-08
of O 0 4.03893096745378e-09
this O 0 4.578422263534776e-08
disease O 0 0.0012988075613975525
. O 0 8.801269046898597e-08

We O 0 5.368936854210915e-06
analyzed O 0 7.49056380300317e-06
genotype O 0 7.250226917676628e-05
/ O 0 2.158380812034011e-05
phenotype O 0 4.521200935414527e-06
correlations O 0 3.134856569886324e-06
, O 0 1.9472160772693314e-08
on O 0 6.7298091543932514e-09
the O 0 1.7998630363891266e-09
basis O 0 6.606317715096566e-09
of O 0 7.60601137628214e-10
the O 0 5.103252931348834e-09
constitution O 0 5.841152006524908e-09
of O 0 3.3032754309658685e-10
a O 0 1.4353927824117818e-08
WT1 O 0 6.64738763589412e-06
mutation O 0 2.80717301848199e-07
database O 0 3.6293673844056684e-08
of O 0 4.428897693031786e-09
84 O 0 4.6676950660184957e-07
germ O 0 9.082638280233368e-05
- O 0 5.6242537539219484e-05
line O 0 0.000283382018096745
mutations O 0 3.3958415315282764e-06
, O 0 2.033774482157469e-09
to O 0 9.019364144435826e-10
compare O 0 4.5169066709149774e-08
the O 0 1.352400302856438e-09
distribution O 0 4.8952419895442745e-09
and O 0 4.503055262006228e-09
type O 0 4.158663386988337e-07
of O 0 1.7134822449804687e-09
mutations O 0 6.210223546077032e-06
, O 0 7.978561145094432e-10
according O 0 4.932880770525117e-10
to O 0 9.298998793205726e-10
the O 0 9.314410576166665e-09
different O 0 2.8096292226109654e-07
symptoms O 0 0.00011012515460606664
. O 0 6.28024849902431e-08

This O 0 4.3786130277112534e-07
demonstrated O 0 1.0861811006179778e-06
( O 0 3.4512840585421145e-08
1 O 0 1.398168070210204e-08
) O 0 1.976065533426663e-09
the O 0 1.6128883784105597e-09
association O 0 6.626029058764971e-09
between O 0 8.165808473847846e-09
mutations O 0 1.4898638482918614e-06
in O 0 1.2365027890481883e-09
exons O 0 2.3753204914100934e-07
8 O 0 5.7753830162710074e-08
and O 0 3.751195620793624e-08
9 O 0 1.0351871537750412e-07
and O 0 1.0268276184888236e-07
DMS B-Disease 0 0.12937738001346588
; O 0 8.327738498792314e-09
( O 0 1.2178807962115457e-09
2 O 0 1.6158813176403442e-09
) O 0 1.6036427741283887e-09
among O 0 8.527371697653052e-09
patients O 0 6.423811527156431e-08
with O 0 5.276225678585433e-09
DMS B-Disease 0 0.06606904417276382
, O 0 5.046569828692782e-09
a O 0 2.4852537805486463e-09
higher O 0 9.483964724665839e-09
frequency O 0 1.1368569374781146e-07
of O 0 1.343086974969765e-09
exon O 0 3.687081289172056e-07
8 O 0 5.885138065764295e-08
mutations O 0 2.857891558960546e-07
among O 0 5.045376116896705e-09
46 O 0 1.3734734238823876e-07
, O 0 1.0427846142135877e-08
XY O 0 0.01242082566022873
patients O 0 9.554102007314214e-07
with O 0 5.1540318679599295e-09
female O 0 1.732212240312947e-06
phenotype O 0 8.617093385510088e-07
than O 0 4.674432396711836e-09
among O 0 4.705553724448919e-09
46 O 0 1.0135957495549519e-07
, O 0 1.2321904385714788e-08
XY O 0 0.005325232166796923
patients O 0 3.8786185996286804e-07
with O 0 3.5562903732966333e-09
sexual O 0 2.9386785627139034e-07
ambiguity O 0 2.2881758354742487e-07
or O 0 3.0782421163166873e-06
male O 0 5.0467588152969256e-05
phenotype O 0 9.137807865045033e-06
; O 0 1.932390425452013e-08
and O 0 4.8122959839247414e-08
( O 0 1.2251739178736898e-08
3 O 0 1.5548740961435215e-08
) O 0 2.7018525194932863e-09
statistically O 0 1.8143165902984038e-07
significant O 0 8.506367166205564e-09
evidence O 0 4.8934147400814254e-08
that O 0 1.0717754683753355e-08
mutations O 0 2.1498838123079622e-06
in O 0 1.4709007345459213e-09
exons O 0 4.2849970327552e-07
8 O 0 1.182560254164855e-07
and O 0 2.195933923587745e-08
9 O 0 7.822980307992111e-08
preferentially O 0 3.4825490047296626e-07
affect O 0 2.5184581886605883e-07
amino O 0 1.1794607246429223e-07
acids O 0 1.1586556603049303e-08
with O 0 3.393330616496826e-10
different O 0 2.4836286360852e-09
functions O 0 2.0004430112408045e-08
. O 0 1.0475350364913538e-08
. O 0 7.42233225992095e-08

The O 0 3.61154548045306e-06
185delAG O 0 6.303143163677305e-05
BRCA1 O 0 0.000355401512933895
mutation O 0 2.7138987661601277e-06
originated O 0 2.0722676197237888e-07
before O 0 2.75537974658846e-08
the O 0 1.3117867903034153e-09
dispersion O 0 2.148593409856403e-07
of O 0 2.6346569370616635e-09
Jews O 0 5.408010039786859e-08
in O 0 1.1700700408567855e-09
the O 0 1.7913420746751285e-09
diaspora O 0 1.5245442241962337e-08
and O 0 1.2879495692175169e-08
is O 0 1.5031708100465835e-09
not O 0 2.243347507757676e-09
limited O 0 4.816123055917387e-09
to O 0 2.1648311587796343e-08
Ashkenazim O 0 0.00026338142924942076
. O 0 1.1747638239967273e-07

The O 0 1.433809188711166e-06
185delAG O 0 2.3743903511785902e-05
mutation O 0 5.903535111428937e-06
in O 0 2.469571924734737e-08
BRCA1 O 0 4.25137513957452e-05
is O 0 1.407962724186973e-08
detected O 0 2.4049202806963876e-07
in O 0 1.912822122918101e-09
Ashkenazi O 0 5.930152155997348e-07
Jews O 0 1.772101576591467e-08
both O 0 2.821161304566999e-09
in O 0 1.0479467071888848e-08
familial B-Disease 1 0.9998419284820557
breast I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.8529506462527934e-07
in O 0 1.6100544231179015e-09
the O 0 3.1776998810073565e-09
general O 0 1.6954402326518903e-08
population O 0 1.937831051179728e-08
. O 0 5.038935668721933e-08

All O 0 3.4481568036426324e-06
tested O 0 1.6593878171988763e-05
Ashkenazi O 0 3.490598464850336e-05
mutation O 0 3.1373508591059363e-06
carriers O 0 4.1787870941334404e-07
share O 0 2.4382879715290073e-08
the O 0 3.894550903993377e-09
same O 0 2.2311402503305544e-08
allelic O 0 1.4819750049355207e-06
pattern O 0 9.212331860908307e-06
at O 0 2.0817000745410041e-07
the O 0 9.286954139042791e-08
BRCA1 O 0 9.021033474709839e-05
locus O 0 3.7731315387645736e-05
. O 0 6.924591957613302e-07

Our O 0 6.7597738961922005e-06
previous O 0 4.578701293667109e-07
study O 0 8.36732283460151e-08
showed O 0 2.3594375875291007e-07
that O 0 4.577596635080283e-10
this O 0 7.951488356638947e-10
Ashkenazi O 0 4.026275746582542e-06
mutation O 0 5.773818543275411e-07
also O 0 7.592809936340927e-09
occurs O 0 6.706615707230412e-09
in O 0 1.8465280415824736e-09
Iraqi O 0 1.1794004421972204e-06
Jews O 0 2.2138957334050247e-08
with O 0 1.6357648568998684e-09
a O 0 9.013074731001325e-09
similar O 0 6.190906987058042e-08
allelic O 0 1.2136364603065886e-05
pattern O 0 3.4921831684187055e-05
. O 0 2.2534982235811185e-07

We O 0 5.140562734595733e-06
extended O 0 2.519995803140773e-07
our O 0 1.9939479400932214e-08
analysis O 0 6.0284208736050005e-09
to O 0 1.580262920519715e-09
other O 0 4.366384587228822e-09
non O 0 1.2346320090728113e-06
- O 0 1.036850562741165e-06
Ashkenazi O 0 1.0433276429466787e-06
subsets O 0 5.7014283072476246e-08
354 O 0 2.556649292273505e-08
of O 0 2.2104096331077017e-09
Moroccan O 0 4.21095137426164e-07
origin O 0 3.076645782584819e-08
, O 0 2.2762123297326298e-09
200 O 0 4.975129197504202e-09
Yemenites O 0 5.017156468056783e-07
and O 0 5.061665753203215e-09
150 O 0 1.0915644388376222e-08
Iranian O 0 1.7628080684062297e-07
Jews O 0 1.8003484569817374e-07
. O 0 6.42104325265791e-08

Heteroduplex O 0 0.000371121393982321
analysis O 0 2.652336434039171e-06
complemented O 0 1.1456787660790724e-06
by O 0 1.3091154826838647e-08
direct O 0 5.5266564658040807e-08
DNA O 0 1.4659613611911482e-07
sequencing O 0 1.0982559217609378e-07
of O 0 7.764748843896996e-09
abnormally O 0 6.677715191472089e-06
migrating O 0 8.707744569846909e-08
bands O 0 5.220695129537489e-07
were O 0 3.213017407688312e-07
employed O 0 3.072517074542702e-06
. O 0 1.310277610855337e-07

Four O 0 4.289463959139539e-06
of O 0 6.545713659988905e-08
Moroccan O 0 2.662379756657174e-06
origin O 0 1.3004007826111774e-07
( O 0 3.861155839501862e-09
1 O 0 3.5628555661304517e-09
. O 0 5.082404497258608e-10
1 O 0 4.315539037236249e-09
% O 0 6.56614362881669e-09
) O 0 1.1869215610360584e-09
and O 0 9.117387733681426e-09
none O 0 4.7280114046088784e-08
of O 0 2.0557344715399495e-10
the O 0 6.484919268245903e-09
Yemenites O 0 5.372604391595814e-06
or O 0 2.5891861810123373e-07
Iranians O 0 4.813517051616145e-08
was O 0 3.9209151481145454e-08
a O 0 1.710347641292742e-09
carrier O 0 2.2354255335699236e-08
of O 0 5.979382544651912e-10
the O 0 1.8378500499238726e-08
185delAG O 0 7.3126802817569114e-06
mutation O 0 2.192945203205454e-06
. O 0 1.2094510282167903e-07

BRCA1 O 0 0.00811502244323492
allelic O 0 0.00010910905984928831
patterns O 0 0.00044990837341174483
were O 0 9.035969014803413e-06
determined O 0 2.670756487077597e-07
for O 0 1.6557729631827556e-09
four O 0 5.084036303060202e-09
of O 0 1.9404551576673867e-10
these O 0 2.141691490820108e-09
individuals O 0 3.273522120039729e-09
and O 0 2.4691091393691522e-09
for O 0 1.4697144612441093e-09
12 O 0 2.2349395223386637e-08
additional O 0 1.4876155418619419e-08
non O 0 4.2315086830058135e-06
- O 0 5.2627783588832244e-06
Ashkenazi O 0 9.215741556545254e-06
185delAG O 0 8.461375955448602e-07
mutation O 0 3.305542009002238e-07
carriers O 0 1.85281109565949e-07
who O 0 1.5801316521901754e-07
had O 0 4.1296432755189016e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.8047200001092278e-06

Six O 0 3.6688314139610156e-05
non O 0 0.0001141443572123535
- O 0 5.346062971511856e-05
Ashkenazi O 0 8.571629587095231e-05
individuals O 0 8.831958808741547e-08
shared O 0 2.0683142309962932e-08
the O 0 1.9731729583583046e-09
common O 0 3.6076684750696586e-08
Ashkenazi O 0 8.20436889625853e-06
haplotype O 0 1.1062128351113643e-06
, O 0 2.0209990125863442e-08
four O 0 2.0401820677307114e-08
had O 0 8.022730924039934e-08
a O 0 3.6485219290227633e-09
closely O 0 6.634707006014651e-08
related O 0 1.1876151617684627e-08
pattern O 0 2.734529743975145e-06
, O 0 4.306444978396939e-09
and O 0 1.4781349477743788e-08
the O 0 1.2934320281487999e-08
rest O 0 1.244183209792027e-07
( O 0 9.854091764793793e-09
n O 0 2.5944013032130897e-05
= O 0 0.00013320543803274632
6 O 0 2.1884082457290788e-07
) O 0 2.356453920882018e-09
displayed O 0 1.1241416331131404e-07
a O 0 2.968504198008759e-08
distinct O 0 6.297522077147732e-07
BRCA1 O 0 0.00011727866512956098
allelic O 0 2.2585751139558852e-05
pattern O 0 5.3008105169283226e-05
. O 0 6.921006843185751e-07

We O 0 2.1274970549711725e-06
conclude O 0 1.9483867674807698e-07
that O 0 2.1528561156003434e-09
the O 0 8.162039932813059e-09
185delAG O 0 1.2484823855629656e-05
BRCA1 O 0 0.0015404109144583344
mutation O 0 4.819488822249696e-06
occurs O 0 2.232681239888734e-08
in O 0 1.127096971309527e-09
some O 0 4.3857655285250985e-09
non O 0 1.8564930996944895e-06
- O 0 4.665114829549566e-06
Ashkenazi O 0 1.2927032912557479e-05
populations O 0 5.036475414499364e-08
at O 0 1.4045776985938119e-08
rates O 0 7.203637153452291e-08
comparable O 0 5.247144585496244e-08
with O 0 2.001338872403835e-09
that O 0 1.3434918733068457e-09
of O 0 2.612319693895415e-09
Ashkenazim O 0 9.16369172045961e-05
. O 0 1.1672548083652146e-07

The O 0 2.50206909413464e-07
majority O 0 1.0098886349396707e-07
of O 0 3.949149007809183e-09
Jewish O 0 3.0002729545230977e-07
185delAG O 0 1.4188234445100534e-06
mutation O 0 1.029342115543841e-06
carriers O 0 1.9480133062188543e-07
have O 0 2.8943001328940454e-09
a O 0 3.7424321419621265e-09
common O 0 3.394758252284191e-08
allelic O 0 1.3515392538465676e-06
pattern O 0 1.4809909771429375e-05
, O 0 6.170981059483438e-09
supporting O 0 3.567338424659283e-08
the O 0 4.086057270313859e-09
founder O 0 4.8913708639020115e-08
effect O 0 1.4243174639716472e-08
notion O 0 1.8432459114592348e-08
, O 0 1.7918341255196424e-09
but O 0 1.9505455028934193e-09
dating O 0 8.324263944814447e-08
the O 0 8.08423106235523e-09
mutations O 0 1.691690556526737e-07
origin O 0 7.79136311024331e-09
to O 0 2.6210438264229197e-09
an O 0 2.3007340477221305e-09
earlier O 0 3.797078917955332e-08
date O 0 1.0272468387029221e-07
than O 0 1.7300935795105943e-08
currently O 0 3.883329924292411e-08
estimated O 0 6.880395631014835e-08
. O 0 7.092902620797759e-08

However O 0 2.550980525484192e-06
, O 0 1.776568758771191e-08
the O 0 3.0019766672495507e-09
different O 0 4.338101877721101e-09
allelic O 0 6.049185117262823e-07
pattern O 0 9.297946235165e-06
at O 0 2.2346972627929063e-07
the O 0 1.9227508474273236e-08
BRCA1 O 0 3.181268402840942e-05
locus O 0 8.843924774737388e-07
even O 0 2.1737934119414604e-08
in O 0 9.871092832014483e-10
some O 0 3.11155146093256e-09
Jewish O 0 8.582937027767912e-08
mutation O 0 3.198120168690366e-07
carriers O 0 8.355760172662485e-08
, O 0 1.903240010037166e-09
might O 0 6.8327117297428686e-09
suggest O 0 1.398248006267977e-08
that O 0 8.99335661497247e-10
the O 0 6.1335008183505124e-09
mutation O 0 9.511628036307229e-07
arose O 0 5.74617757820306e-08
independently O 0 2.3941717586239974e-07
. O 0 1.202728761029448e-08
. O 0 6.492124526857879e-08

Crystal O 0 8.029170567169785e-05
structure O 0 2.455042022120324e-06
of O 0 1.7968076804208977e-08
the O 0 1.9012894370007416e-07
hemochromatosis B-Disease 1 1.0
protein O 0 1.548650106997229e-05
HFE O 0 0.0006655294564552605
and O 0 4.267477393682384e-08
characterization O 0 1.7082511760690977e-07
of O 0 2.5914268508842042e-09
its O 0 1.147647399335483e-08
interaction O 0 9.03231764937118e-08
with O 0 3.7266776331534857e-08
transferrin O 0 1.3960348951513879e-05
receptor O 0 5.585467079072259e-06
. O 0 3.998462432264205e-07

HFE O 0 0.008323084563016891
is O 0 5.570443022406835e-07
an O 0 3.478578136650867e-08
MHC O 0 1.201794293592684e-05
- O 0 2.7642552140605403e-06
related O 0 6.695510990084586e-08
protein O 0 4.071698000984725e-08
that O 0 7.840031401862291e-10
is O 0 5.403509306667331e-10
mutated O 0 1.9038727927522814e-08
in O 0 8.326797029667432e-10
the O 0 4.0049268790198767e-08
iron B-Disease 1 0.999681830406189
- I-Disease 1 0.9999997615814209
overload I-Disease 1 0.9999994039535522
disease I-Disease 1 0.9999998807907104
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 3.34386968461331e-05

HFE O 0 0.0032219591084867716
binds O 0 1.2780427823599894e-05
to O 0 3.47087450336403e-07
transferrin O 0 7.36144966140273e-06
receptor O 0 5.974137820885517e-06
( O 0 6.660420126536337e-08
TfR O 0 3.143025878671324e-06
) O 0 6.099901028733257e-09
and O 0 4.843796475029194e-09
reduces O 0 2.3654886049939705e-08
its O 0 1.9891910341129915e-09
affinity O 0 3.088340250201327e-08
for O 0 2.3100133361708686e-08
iron O 0 0.002828045515343547
- O 0 4.232221544953063e-05
loaded O 0 3.593217343222932e-06
transferrin O 0 8.337283929904515e-07
, O 0 8.890416403062318e-09
implicating O 0 2.1699095213989494e-06
HFE O 0 0.00010029567056335509
in O 0 7.300517523844974e-08
iron O 0 0.00020581007993314415
metabolism O 0 3.626826583058573e-05
. O 0 3.630167668688955e-07

The O 0 3.841292254946893e-06
2 O 0 4.739198175229831e-06
. O 0 1.0772432688099798e-06

6 O 0 6.669190770480782e-05
A O 0 1.1380657269910444e-06
crystal O 0 2.601993628559285e-06
structure O 0 8.191283313863096e-07
of O 0 1.0697536190207302e-08
HFE O 0 0.0005879300297237933
reveals O 0 4.2033360614368576e-07
the O 0 4.259879116119691e-09
locations O 0 4.8268294250419785e-08
of O 0 4.169893585981299e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 0.3681291937828064
and O 0 1.8718235139658645e-07
a O 0 7.704267090957728e-08
patch O 0 0.020515309646725655
of O 0 9.890999130846012e-09
histidines O 0 6.931047209945973e-06
that O 0 5.2672866068803614e-09
could O 0 8.954646801839772e-08
be O 0 5.903932898121411e-09
involved O 0 9.450307203451302e-09
in O 0 4.598163183544557e-09
pH O 0 0.0001908915874082595
- O 0 2.4597606170573272e-05
dependent O 0 1.080786319107574e-06
interactions O 0 6.67617825911293e-07
. O 0 2.1020584028974554e-07

We O 0 2.973241180370678e-06
also O 0 1.7432737919875763e-08
demonstrate O 0 4.137695697181698e-08
that O 0 4.173623224801304e-09
soluble O 0 1.1688938457155018e-06
TfR O 0 8.715854164620396e-06
and O 0 3.371142298647101e-08
HFE O 0 4.6099245082587004e-05
bind O 0 1.5977580005710479e-06
tightly O 0 6.772892902517924e-06
at O 0 7.535162893645975e-08
the O 0 2.878532745498319e-09
basic O 0 3.7598628210844254e-08
pH O 0 2.9551898705904023e-07
of O 0 3.0046731769317603e-10
the O 0 5.378238299158511e-09
cell O 0 2.5931151981239964e-07
surface O 0 5.19286049893708e-06
, O 0 7.067079810241239e-09
but O 0 5.3433510949219e-09
not O 0 2.0469643757792255e-08
at O 0 4.033382339230229e-08
the O 0 2.6442741329901764e-08
acidic O 0 6.180658601806499e-06
pH O 0 2.2672088562103454e-06
of O 0 8.248648875053277e-09
intracellular O 0 6.700501671730308e-06
vesicles O 0 1.616138979443349e-05
. O 0 5.709241008844401e-07

TfR O 1 0.9069820642471313
HFE O 0 0.01979321613907814
stoichiometry O 0 0.00012040438741678372
( O 0 3.10480618281872e-06
2 O 0 2.765637248103303e-07
1 O 0 4.021007882215599e-08
) O 0 5.479441789191242e-09
differs O 0 3.541420667829698e-08
from O 0 1.9836074116597047e-08
TfR O 0 2.1888912669965066e-05
transferrin O 0 1.2740105148623115e-06
stoichiometry O 0 6.575934321517707e-07
( O 0 2.9858348682409996e-08
2 O 0 1.516279368729556e-08
2 O 0 1.9900269876416132e-08
) O 0 2.65236477225983e-09
, O 0 1.6459925644696227e-09
implying O 0 3.791137359598906e-08
a O 0 1.4374248458182137e-09
different O 0 1.7202869129206988e-09
mode O 0 6.186586176681885e-08
of O 0 8.896280934145295e-10
binding O 0 8.221447700407225e-08
for O 0 1.0313987885979259e-08
HFE O 0 0.0001278528943657875
and O 0 5.375912692784368e-08
transferrin O 0 4.258330079665029e-07
to O 0 3.794950131918995e-08
TfR O 0 1.4952406672819052e-05
, O 0 1.0379031856189158e-08
consistent O 0 1.0228868774220246e-07
with O 0 3.2724609688727924e-09
our O 0 3.942467685646989e-08
demonstration O 0 2.01355394580105e-08
that O 0 4.0204382045772036e-09
HFE O 0 7.355751222348772e-06
, O 0 1.242044067595316e-08
transferrin O 0 3.530145704644383e-07
, O 0 1.5934508823534088e-08
and O 0 4.054454549873299e-08
TfR O 0 1.5151961633819155e-05
form O 0 8.937038131762165e-08
a O 0 1.0671698902342541e-07
ternary O 0 3.147039024042897e-06
complex O 0 1.501908400314278e-06
. O 0 4.798708346243075e-07

Identification O 0 3.7632460134773282e-06
of O 0 2.3709359808776753e-08
three O 0 3.877371668181695e-08
novel O 0 9.242793197472565e-08
mutations O 0 1.2364324675218086e-06
and O 0 5.098709898732068e-09
a O 0 7.47041983828467e-09
high O 0 1.2189148890229262e-07
frequency O 0 1.3460377203955431e-06
of O 0 2.3103428059556563e-09
the O 0 1.9692674158022783e-08
Arg778Leu O 0 1.3985601071908604e-05
mutation O 0 6.489506176876603e-07
in O 0 9.69410418605321e-09
Korean O 0 1.1344454833306372e-05
patients O 0 8.853164672473213e-07
with O 0 6.220213322194468e-08
Wilson B-Disease 0 0.0011614226968958974
disease I-Disease 0 0.0002626534551382065
. O 0 1.1935789245853812e-07

Four O 0 3.227012712159194e-05
mutations O 0 0.0003124337818007916
- O 0 6.857317202957347e-05
- O 0 1.831403460528236e-05
R778L O 0 5.4895153880352154e-06
, O 0 1.0248412785074379e-08
A874V O 0 1.612500710734821e-07
, O 0 2.4011850285887704e-09
L1083F O 0 5.352891463417109e-08
, O 0 1.2375763747130009e-09
and O 0 3.026075834355879e-09
2304delC O 0 7.131774282242986e-07
- O 0 2.0829263576160884e-06
- O 0 1.1823510703834472e-06
in O 0 2.439654256392032e-09
the O 0 9.7668753085145e-09
copper O 0 1.0960101235468755e-06
- O 0 1.266372606778532e-07
transporting O 0 7.230011078718235e-08
enzyme O 0 1.8088606168475962e-07
, O 0 4.426186972494861e-09
P O 0 1.77136007550871e-06
- O 0 3.2057329235612997e-07
type O 0 2.935927113867365e-06
ATPase O 0 6.212753305590013e-06
( O 0 4.909035666855743e-08
ATP7B O 0 1.7522230564281926e-06
) O 0 5.014522574953162e-09
, O 0 1.1325187454502839e-09
were O 0 1.4696507122380353e-08
identified O 0 2.888830685776611e-08
in O 0 2.114282526832767e-09
Korean O 0 6.124576884758426e-06
Patients O 0 4.5228296130517265e-07
with O 0 3.987486962842013e-08
Wilson B-Disease 0 0.0019288264447823167
disease I-Disease 0 0.00031467038206756115
. O 0 7.33415248532765e-08

Arg778Leu O 0 0.001123341848142445
, O 0 1.159216367341287e-07
the O 0 8.9882679077391e-09
most O 0 6.444868638766366e-09
frequently O 0 1.2990079767405405e-06
reported O 0 2.849425300155417e-07
mutation O 0 8.347031155153672e-08
of O 0 2.6815513698430493e-10
this O 0 4.484556614947621e-10
enzyme O 0 1.616699734086069e-07
, O 0 3.121174874110011e-09
was O 0 1.089345573745959e-07
found O 0 6.20690165931137e-09
in O 0 3.9902600668106913e-10
six O 0 2.865746751012921e-09
of O 0 4.839998957173464e-10
eight O 0 1.0568836472657495e-07
unrelated O 0 2.6029886157630244e-07
patients O 0 1.2657315551223292e-07
studied O 0 2.349498728904109e-08
, O 0 5.140666781144887e-10
an O 0 2.714982683116318e-10
allele O 0 3.980845519890863e-08
frequency O 0 9.865303951528404e-08
of O 0 6.3069189870645914e-09
37 O 0 5.997721359563002e-07
. O 0 8.405665852251332e-08

5 O 0 9.256124940293375e-06
% O 0 5.570432222157251e-07
, O 0 6.766104565514297e-09
which O 0 1.8270285284671672e-09
is O 0 7.681312252927341e-10
considerably O 0 1.287389661541738e-08
higher O 0 1.7360965998136635e-08
than O 0 2.6797479790729994e-09
those O 0 1.4404163417580662e-09
in O 0 3.58509000264462e-10
other O 0 1.23124055395607e-09
Asian O 0 8.292063569115271e-08
populations O 0 2.9498175990738673e-07
. O 0 5.634445798818888e-08

The O 0 1.1125882792839548e-06
novel O 0 1.041224322761991e-06
single O 0 6.444908535740979e-07
nucleotide O 0 1.7969640566661838e-06
deletion O 0 4.653867563320091e-06
, O 0 3.072476317811379e-08
2304delC O 0 8.88072349880531e-07
, O 0 1.197829568866382e-08
was O 0 6.9895193632874e-08
found O 0 4.346898396789811e-09
in O 0 1.2022992601501414e-09
one O 0 4.3205158561931967e-08
patient O 0 1.5371599602076458e-06
. O 0 6.320035339513197e-08

Since O 0 5.856739790033316e-06
a O 0 2.716037670325022e-07
mutation O 0 3.7731356314907316e-06
at O 0 1.3120981634529016e-07
cDNA O 0 2.9902289497840684e-06
nucleotide O 0 2.4055880203377455e-05
2302 O 0 0.00010144093539565802
( O 0 6.785543860132748e-08
2302insC O 0 7.611582759636804e-07
) O 0 2.2258271670239083e-08
had O 0 7.946353548504703e-07
been O 0 9.318785743062108e-08
previously O 0 2.4985686764011916e-07
described O 0 2.9902690101835105e-08
, O 0 7.373222588036299e-10
this O 0 2.2632540286338099e-10
region O 0 1.958321727002499e-09
of O 0 3.677984583561056e-10
the O 0 6.498551918809881e-09
ATP7B O 0 3.214662501704879e-05
gene O 0 4.7472539677073655e-07
may O 0 3.699891948372169e-08
be O 0 3.451789298836161e-09
susceptible O 0 2.0420164048573497e-07
to O 0 6.05638073025716e-09
gene O 0 5.404532203101553e-06
rearrangements O 0 1.982315552595537e-05
causing O 0 0.00023954932112246752
Wilson B-Disease 0 0.0010785942431539297
disease I-Disease 0 0.0019855722784996033
. O 0 2.05542349362986e-07

Disruption O 0 5.024447455070913e-05
of O 0 1.1189904114417004e-07
splicing O 0 4.811796770809451e-06
regulated O 0 1.3180496125642094e-06
by O 0 8.003897100650192e-09
a O 0 1.847205410854258e-08
CUG O 0 2.4496455807820894e-05
- O 0 6.768481171093299e-07
binding O 0 3.3922088960025576e-07
protein O 0 4.066056362717063e-07
in O 0 1.4822518323853728e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.2431856905313907e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9996886253356934
DM B-Disease 1 1.0
) O 0 1.6153879869307275e-06
is O 0 2.211768546089843e-08
caused O 0 7.616892361284044e-08
by O 0 2.6961795018820567e-09
a O 0 1.0294216146178314e-08
CTG O 0 9.04019202607742e-07
expansion O 0 1.717992681449232e-08
in O 0 2.5199746733761685e-09
the O 0 4.902277250806719e-09
3 O 0 2.065436355280781e-08
untranslated O 0 1.2856519333581673e-06
region O 0 5.1647212728767045e-08
of O 0 9.60850599085461e-09
the O 0 1.1913243724848144e-06
DM B-Disease 1 1.0
gene O 0 1.9585411791922525e-05
. O 0 3.810748694377253e-07

One O 0 7.010721674305387e-07
model O 0 1.527602535134065e-06
of O 0 1.234835309560367e-07
DM B-Disease 1 1.0
pathogenesis O 0 8.45369231683435e-06
suggests O 0 1.9071534040904226e-07
that O 0 1.9866885914154864e-09
RNAs O 0 1.1993411419553013e-07
from O 0 5.6047633201217195e-09
the O 0 2.292756873245594e-09
expanded O 0 4.655509400208757e-08
allele O 0 1.084314504851136e-07
create O 0 1.1186399362372867e-08
a O 0 1.0195712718541472e-08
gain O 0 1.6786470951046795e-06
- O 0 5.324645826476626e-06
of O 0 8.597301537349722e-09
- O 0 6.725821549480315e-06
function O 0 1.3445517765831028e-07
mutation O 0 6.35498125234335e-08
by O 0 4.3675066341286595e-10
the O 0 5.389140800282632e-10
inappropriate O 0 2.0323057015048107e-08
binding O 0 7.4262658245061175e-09
of O 0 5.166686523061514e-10
proteins O 0 5.1029998004992194e-09
to O 0 2.784950714485035e-09
the O 0 2.2434472057852872e-08
CUG O 0 7.628259481862187e-05
repeats O 0 7.875401024648454e-06
. O 0 1.3127302622706338e-07

Data O 0 5.4281736083794385e-06
presented O 0 5.261125011202239e-07
here O 0 2.6601382430158083e-08
indicate O 0 9.461149375056266e-08
that O 0 1.220182621608501e-09
the O 0 6.233964455759633e-09
conserved O 0 2.1586428999853524e-07
heterogeneous O 0 4.826976578442554e-07
nuclear O 0 8.78842513429845e-07
ribonucleoprotein O 0 1.6999642866721842e-06
, O 0 2.3037738827724752e-08
CUG O 0 3.899089733749861e-06
- O 0 3.6888295085191203e-07
binding O 0 1.9379092464077985e-07
protein O 0 1.2813441685466387e-07
( O 0 2.2955978451477677e-08
CUG O 0 9.628663974581286e-06
- O 0 7.816662218829151e-06
BP O 0 5.453520770970499e-06
) O 0 2.805979670839065e-09
, O 0 4.831199329480285e-10
may O 0 3.567445450158857e-09
mediate O 0 8.353944025429882e-08
the O 0 1.2016762696021033e-08
trans O 0 4.3007179328924394e-07
- O 0 7.815075150574557e-06
dominant O 0 1.6016130075513502e-06
effect O 0 9.499425246417559e-09
of O 0 6.028555987747097e-10
the O 0 3.915218815819799e-09
RNA O 0 3.0961197694523435e-07
. O 0 1.0710810727232456e-07

CUG O 0 0.1166715994477272
- O 0 0.14890694618225098
BP O 0 0.0001223449216922745
was O 0 1.2853769248977187e-07
found O 0 9.179698778893908e-09
to O 0 1.2642452640321267e-09
bind O 0 4.6333806125176125e-08
to O 0 5.8122897605983326e-09
the O 0 9.97612659148217e-09
human O 0 9.698435832206087e-08
cardiac O 0 4.1575826799089555e-06
troponin O 0 1.8571323380456306e-05
T O 0 3.1580326322000474e-05
( O 0 2.9442517757161113e-08
cTNT O 0 2.3804206250588322e-07
) O 0 7.385640543589034e-09
pre O 0 8.652719770907424e-06
- O 0 5.127979420649353e-06
messenger O 0 4.0298920112036285e-07
RNA O 0 8.825274022683516e-08
and O 0 2.6967246213871476e-09
regulate O 0 4.138847842227733e-08
its O 0 9.709537174273919e-09
alternative O 0 1.5338257242092368e-07
splicing O 0 4.226447344990447e-06
. O 0 2.6327856517127657e-07

Splicing O 0 6.598540494451299e-05
of O 0 4.605380468092335e-07
cTNT O 0 1.5413144865306094e-05
was O 0 1.3575072443927638e-06
disrupted O 0 1.594093737367075e-05
in O 0 1.1738040939235361e-07
DM B-Disease 1 1.0
striated O 0 0.021747039631009102
muscle O 0 0.00018895593530032784
and O 0 7.352921471692753e-08
in O 0 1.2311755170912875e-08
normal O 0 6.528545100081828e-07
cells O 0 2.0471603079386114e-07
expressing O 0 1.6740168362616714e-08
transcripts O 0 1.413596493193836e-07
that O 0 1.5912549500285422e-08
contain O 0 1.0877485010496457e-06
CUG O 0 0.0001418926112819463
repeats O 0 1.6489542758790776e-05
. O 0 3.765637188735127e-07

Altered O 0 7.112892490113154e-05
expression O 0 1.230988573297509e-06
of O 0 1.5794924479450856e-08
genes O 0 8.62619572217227e-07
regulated O 0 1.5777631006130832e-06
posttranscriptionally O 0 6.109222795203095e-06
by O 0 4.739007763987502e-08
CUG O 0 0.00014598264533560723
- O 0 5.5654425523243845e-05
BP O 0 1.4193258721206803e-05
therefore O 0 3.789973135326363e-08
may O 0 1.2010002770068695e-08
contribute O 0 1.743416788713148e-08
to O 0 6.525034024207343e-08
DM B-Disease 1 1.0
pathogenesis O 0 1.131433054979425e-05
. O 0 4.5368871326445515e-08
. O 0 1.0670803618495484e-07

Identification O 0 4.257495675119571e-06
of O 0 3.754502486685851e-08
a O 0 1.106671163597639e-07
novel O 0 3.727751618498587e-07
nonsense O 0 9.993629646487534e-06
mutation O 0 1.7326747183687985e-06
and O 0 1.7517031380975823e-08
a O 0 1.2787507941425247e-08
missense O 0 1.5510240700677969e-06
substitution O 0 4.295839772794352e-08
in O 0 3.997506770048176e-09
the O 0 7.4460091425976316e-09
vasopressin O 0 3.37124561156088e-07
- O 0 1.8130658645532094e-06
neurophysin O 0 2.209590093116276e-06
II O 0 1.0170695077249547e-06
gene O 0 1.0707644548801909e-07
in O 0 3.639021528556441e-09
two O 0 1.50484691374686e-08
Spanish O 0 2.012085360547644e-06
kindreds O 0 8.788384548097383e-06
with O 0 1.8210910468496877e-07
familial B-Disease 1 0.999862551689148
neurohypophyseal I-Disease 1 0.9995166063308716
diabetes I-Disease 1 0.9999982118606567
insipidus I-Disease 1 0.9970079064369202
. O 0 3.0799187697994057e-06

Familial B-Disease 1 0.9999978542327881
neurohypophyseal I-Disease 1 0.9999966621398926
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999996423721313
( O 0 0.014035072177648544
FNDI B-Disease 1 1.0
) O 0 7.137415281022186e-08
is O 0 4.5197143805353335e-09
an O 0 1.1857499870870924e-08
autosomal B-Disease 1 0.9999955892562866
dominant I-Disease 1 0.9999978542327881
disease I-Disease 1 0.9999003410339355
caused O 0 2.5779802399483742e-06
by O 0 3.6110691326030064e-08
deficiency O 0 0.000679390097502619
in O 0 2.3598722975748387e-09
the O 0 6.55808563010396e-08
antidiuretic O 0 0.000373037182725966
hormone O 0 1.1289421308902092e-05
arginine O 0 1.013790551951388e-06
vasopressin O 0 2.8496424420154653e-07
( O 0 1.728470877537802e-08
AVP O 0 3.9682544183961e-07
) O 0 1.5126908614604417e-09
encoded O 0 6.791756934632076e-09
by O 0 1.7458650081181304e-09
the O 0 1.0425618590659269e-08
AVP O 0 5.909573701501358e-06
- O 0 5.432217676570872e-06
neurophysin O 0 1.2575654182001017e-05
II O 0 6.1282753449631855e-06
( O 0 4.881352211327794e-08
AVP O 0 5.9562748901953455e-06
- O 0 6.580918125109747e-06
NPII O 0 7.572025424451567e-06
) O 0 1.0865872646093067e-08
gene O 0 1.383267829169199e-07
on O 0 5.2048218179834294e-08
chromosome O 0 4.199804607196711e-05
20p13 O 0 1.0935473255813122e-05
. O 0 5.29806698068569e-07

In O 0 4.002521620805055e-07
this O 0 1.329216292589308e-08
study O 0 1.589641307475631e-08
, O 0 6.049222900372797e-09
we O 0 9.381880161640765e-09
analyzed O 0 3.3467522086993995e-08
two O 0 2.2663360965680113e-08
families O 0 4.0640014020709714e-08
with O 0 2.0919046050948964e-08
FNDI B-Disease 1 1.0
using O 0 1.1155466950185655e-07
direct O 0 1.1496875629291026e-07
automated O 0 7.429526158375666e-05
fluorescent O 0 9.090386811294593e-06
, O 0 1.2749126199196326e-08
solid O 0 4.7439186801057076e-07
phase O 0 9.553723145927506e-08
, O 0 7.33044336342914e-09
single O 0 1.4600863096347894e-06
- O 0 2.1422008558147354e-06
stranded O 0 1.4020996275121433e-07
DNA O 0 3.022656258622192e-08
sequencing O 0 3.1500750452551074e-08
of O 0 3.4720142316757574e-09
PCR O 0 8.720651749172248e-06
- O 0 8.321322638948914e-06
amplified O 0 1.651902130106464e-05
AVP O 0 4.567130235955119e-05
- O 0 2.0204914108035155e-05
NPII O 0 2.9506452847272158e-05
DNA O 0 3.8128312098706374e-06
. O 0 3.072465233344701e-07

In O 0 1.9786844518421276e-07
one O 0 1.5903204086953338e-08
of O 0 7.162146431483052e-10
the O 0 3.938121828639396e-09
families O 0 2.328224191217032e-08
, O 0 3.0311184673337266e-09
affected O 0 5.348308818042824e-08
individuals O 0 5.9265428120625074e-09
presented O 0 4.47227543887152e-09
a O 0 9.555942703798337e-09
novel O 0 1.0439153186325711e-07
nonsense O 0 7.707647000643192e-07
mutation O 0 1.0998994071087509e-07
in O 0 1.7536279095509144e-09
exon O 0 8.440141385790412e-08
3 O 0 1.4617866028743265e-08
of O 0 8.864488032500617e-10
the O 0 5.9391038753631165e-09
gene O 0 1.4753189248040144e-07
, O 0 1.4705837658723908e-09
consisting O 0 2.823756117820153e-09
in O 0 1.1816404521525214e-09
a O 0 1.84612751752411e-08
G O 0 1.3069195574644255e-06
to O 0 3.982736274110721e-08
T O 0 5.201383464736864e-05
transition O 0 1.1165727187290031e-07
at O 0 1.2933054449604242e-07
nucleotide O 0 1.4719686305397772e-06
2101 O 0 9.456726388634706e-07
, O 0 4.243595252972909e-09
which O 0 1.2772680690886773e-09
produces O 0 7.372776167358097e-09
a O 0 8.872882872879018e-09
stop O 0 1.314980551114786e-07
signal O 0 9.702040415504598e-07
in O 0 1.1871350125147728e-08
codon O 0 2.258148242617608e-06
82 O 0 6.576906343980227e-07
( O 0 2.9101222764893464e-08
Glu O 0 1.0317005035176408e-05
) O 0 9.3709351389748e-09
of O 0 7.738018226177701e-09
NPII O 0 2.8340116841718554e-05
. O 0 3.652548912214115e-07

The O 0 2.432471092106425e-06
premature O 0 1.3382184988586232e-05
termination O 0 9.871832844510209e-07
eliminates O 0 2.630283404414513e-07
part O 0 1.0992907917284356e-08
of O 0 2.0231194497455363e-09
the O 0 4.9692992831751326e-08
C O 0 0.00017174733511637896
- O 0 5.314180270943325e-06
terminal O 0 3.5055879266110423e-07
domain O 0 3.2166806107625234e-08
of O 0 1.7821542019902381e-09
NPII O 0 3.492621090117609e-06
, O 0 1.8157068071289473e-09
including O 0 7.641448029893638e-10
a O 0 3.6992124918810987e-09
cysteine O 0 1.422487549973539e-08
residue O 0 6.925820628111978e-08
in O 0 2.103948126830346e-09
position O 0 5.96160077748209e-07
85 O 0 1.5076910386824238e-08
, O 0 1.2140377592118057e-09
which O 0 2.258472742155959e-09
could O 0 7.693386550045034e-08
be O 0 6.832294729974819e-09
involved O 0 3.519843083665819e-09
in O 0 8.698954889752031e-10
the O 0 1.5067826097947545e-08
correct O 0 1.6126610717037693e-05
folding O 0 2.6407417408336187e-06
of O 0 4.769101114021623e-09
the O 0 4.4634745677285537e-08
prohormone O 0 6.252258026506752e-05
. O 0 2.114489916493767e-07

In O 0 6.915424819453619e-07
the O 0 6.824431153518162e-08
second O 0 2.0697986258255696e-07
family O 0 3.407128446042407e-08
, O 0 9.71846270125809e-10
a O 0 1.273507299615062e-09
G279A O 0 8.004678875295212e-08
substitution O 0 7.78135422763171e-09
at O 0 5.07903763491413e-08
position O 0 2.6085504032380413e-06
- O 0 7.14834072823578e-07
1 O 0 2.7324187357180563e-09
of O 0 2.5958085680954923e-10
the O 0 2.115053021611857e-09
signal O 0 3.9118435779528227e-07
peptide O 0 1.0780824766243313e-07
was O 0 3.617314803250338e-08
observed O 0 1.5282823895290676e-08
in O 0 7.142801905501983e-10
all O 0 3.412284010906319e-09
affected O 0 1.5095449157342955e-07
individuals O 0 3.8358187737230764e-08
. O 0 4.681903220671302e-08

This O 0 1.0081352002089261e-06
missense O 0 5.7425037084612995e-05
mutation O 0 1.902293115563225e-05
, O 0 2.5284931481905915e-08
which O 0 2.3993871778316134e-08
replaces O 0 8.160491233866196e-06
Ala O 0 1.011803760775365e-05
with O 0 2.9713932647723595e-08
Thr O 0 6.195860623847693e-05
, O 0 3.979287122035657e-09
is O 0 5.262072444445209e-10
frequent O 0 9.801591005498267e-08
among O 0 2.570080539499031e-07
FNDI B-Disease 1 1.0
patients O 0 0.000637928897049278
and O 0 1.3381219687857993e-08
is O 0 1.6853413109529924e-09
thought O 0 6.035439259477471e-09
to O 0 7.8323042496109e-10
reduce O 0 8.676592955225715e-08
the O 0 4.352639138005543e-09
efficiency O 0 2.9501709519763608e-08
of O 0 5.342563613730533e-10
cleavage O 0 1.2348958762231632e-06
by O 0 5.8030078520232564e-09
signal O 0 1.2246011920069577e-06
peptidases O 0 3.857797764794668e-06
. O 0 1.8951556768342925e-08
. O 0 4.449203316880812e-08

Genetic O 0 6.331922486424446e-05
heterogeneity O 0 1.1086726772191469e-05
of O 0 2.6794228347171156e-07
Saethre B-Disease 1 0.9090840220451355
- I-Disease 1 0.9999840259552002
Chotzen I-Disease 1 0.9999957084655762
syndrome I-Disease 1 1.0
, O 0 1.159254647831176e-08
due O 0 2.574083168838115e-08
to O 0 1.1094139829026517e-08
TWIST O 0 8.145624633471016e-06
and O 0 8.909149755709223e-07
FGFR O 0 0.0017580603016540408
mutations O 0 4.529416764853522e-05
. O 0 2.426777427899651e-07

Thirty O 0 0.00035458049387671053
- O 0 0.00013872749696020037
two O 0 9.867938643992602e-08
unrelated O 0 2.2451117729360703e-06
patients O 0 1.2960084632140934e-06
with O 0 8.704133525050395e-10
features O 0 7.118191547306196e-08
of O 0 2.5220485255772473e-08
Saethre B-Disease 1 0.9998236298561096
- I-Disease 1 0.9999986886978149
Chotzen I-Disease 1 0.999998927116394
syndrome I-Disease 1 0.9999996423721313
, O 0 1.8529844325598788e-09
a O 0 3.456460451189969e-09
common O 0 1.09215477550606e-06
autosomal B-Disease 1 0.9921547770500183
dominant I-Disease 1 0.5788710713386536
condition I-Disease 0 1.5940982848405838e-05
of O 0 1.2513081237841561e-08
craniosynostosis B-Disease 1 0.537696361541748
and O 0 2.6049206098832656e-06
limb B-Disease 0 0.19699183106422424
anomalies I-Disease 0 0.000751739542465657
, O 0 3.920212421348879e-08
were O 0 7.373904509222484e-08
screened O 0 4.502404920003755e-07
for O 0 7.558075054703295e-09
mutations O 0 2.4460352960886667e-06
in O 0 4.871936631900553e-09
TWIST O 0 4.238067049300298e-06
, O 0 5.080985232552848e-08
FGFR2 O 0 3.381552596692927e-05
, O 0 9.170774362132761e-09
and O 0 7.01422635529525e-08
FGFR3 O 0 6.297796062426642e-05
. O 0 1.3972487522551091e-07

Nine O 0 3.5631503124022856e-05
novel O 0 1.736617036840471e-06
and O 0 5.637036082362101e-08
three O 0 9.446417692515752e-08
recurrent O 0 0.000211952647077851
TWIST O 0 6.0453632613644004e-05
mutations O 0 0.002007250441238284
were O 0 1.3827959719492355e-06
found O 0 2.505229801386122e-08
in O 0 3.920898272724571e-09
12 O 0 1.296175042853065e-07
families O 0 1.4106566936789022e-07
. O 0 7.718887928831464e-08

Seven O 0 4.082183659193106e-05
families O 0 1.0382041182310786e-06
were O 0 2.7246016998105915e-07
found O 0 7.426280035360833e-09
to O 0 3.254397640262141e-09
have O 0 1.9062783351841972e-08
the O 0 1.0700106578553914e-08
FGFR3 O 0 4.191517655272037e-05
P250R O 0 1.0869302968785632e-06
mutation O 0 3.7209923675618484e-07
, O 0 2.387452679997182e-09
and O 0 3.0295463915308574e-09
one O 0 3.4080303024097702e-09
individual O 0 4.670306363863119e-09
was O 0 1.43248868766932e-07
found O 0 3.623527922158587e-09
to O 0 2.8317546085787626e-09
have O 0 1.7088355619421236e-08
an O 0 1.0457343435632538e-08
FGFR2 O 0 0.00010640176333254203
VV269 O 0 3.806909035120043e-06
- O 0 1.4978660374254105e-06
270 O 0 3.5404420373197354e-07
deletion O 0 1.3746775039180648e-05
. O 0 5.463299999064475e-07

To O 0 1.4817164810665417e-06
date O 0 7.707617442065384e-07
, O 0 1.1315433923186902e-08
our O 0 1.4618953159128978e-08
detection O 0 1.4110507606801548e-07
rate O 0 2.016156344097908e-07
for O 0 1.1896935658839425e-09
TWIST O 0 3.457508455539937e-06
or O 0 3.258861170252203e-06
FGFR O 0 0.00035361875779926777
mutations O 0 1.3812070392305031e-05
is O 0 9.111181142884561e-09
68 O 0 6.932310014917675e-08
% O 0 1.0880825129788718e-08
in O 0 2.797733600345964e-09
our O 0 1.9880294530594256e-06
Saethre B-Disease 0 0.12793375551700592
- I-Disease 1 0.9987844824790955
Chotzen I-Disease 1 0.9998865127563477
syndrome I-Disease 1 0.9999998807907104
patients O 0 4.299153260944877e-06
, O 0 8.828968667273784e-10
including O 0 1.2707339624995484e-09
our O 0 8.835732501211169e-08
five O 0 2.9833358894393314e-08
patients O 0 2.0329596850388043e-07
elsewhere O 0 7.787711808759923e-08
reported O 0 7.267119173093306e-08
with O 0 1.2661064197061478e-08
TWIST O 0 5.4258056479739025e-05
mutations O 0 0.0002107256732415408
. O 0 2.2464494975338312e-07

More O 0 4.0087635966301605e-07
than O 0 2.3118468917004975e-08
35 O 0 3.2333382193883153e-08
different O 0 4.269779196874879e-09
TWIST O 0 5.961202873550064e-07
mutations O 0 2.6491352400626056e-05
are O 0 3.789351765703941e-08
now O 0 1.0725812238376875e-08
known O 0 8.827390374221977e-09
in O 0 1.2770196011757662e-09
the O 0 8.915990612479163e-09
literature O 0 3.3451502901016283e-08
. O 0 6.225435811302305e-08

The O 0 4.5700070927523484e-07
most O 0 1.5392643604172918e-08
common O 0 8.940512330468664e-09
phenotypic O 0 4.711366443643783e-07
features O 0 2.6327679734095e-06
, O 0 2.2383524367342034e-08
present O 0 4.133071218603845e-09
in O 0 7.71676111899211e-10
more O 0 8.590134159547347e-10
than O 0 1.972488172796716e-09
a O 0 1.0423371499257428e-08
third O 0 5.208775064602378e-07
of O 0 1.6635950395027521e-09
our O 0 7.2134815809477e-07
patients O 0 4.73315431293031e-08
with O 0 1.6570651517611168e-09
TWIST O 0 8.10078654467361e-06
mutations O 0 8.421371603617445e-05
, O 0 6.299681221122455e-09
are O 0 4.024305333416578e-09
coronal B-Disease 0 1.2583665920828935e-05
synostosis I-Disease 0 6.429581117117777e-05
, O 0 2.532160969792585e-08
brachycephaly B-Disease 0 7.102890776877757e-06
, O 0 3.178174523554844e-08
low B-Disease 0 0.24822033941745758
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 3.301942115285783e-06
facial B-Disease 1 0.9932384490966797
asymmetry I-Disease 0 0.0002791976439766586
, O 0 1.6476936082199245e-07
ptosis B-Disease 0 0.39111703634262085
, O 0 6.242986216875579e-08
hypertelorism B-Disease 0 7.24943820387125e-05
, O 0 1.2263100757081702e-08
broad B-Disease 0 6.87956855927041e-07
great I-Disease 0 5.469576649375085e-07
toes I-Disease 1 0.9749400019645691
, O 0 1.8165042803275355e-08
and O 0 5.3221665297087384e-08
clinodactyly B-Disease 0 2.964932173199486e-05
. O 0 2.2405251343116106e-07

Significant O 0 7.640617695869878e-06
intra O 0 0.0004921269719488919
- O 0 0.012328979559242725
and O 0 2.2245716024826834e-07
interfamilial O 0 3.556934188964078e-06
phenotypic O 0 3.2806419767439365e-06
variability O 0 1.2833513665100327e-06
is O 0 1.0777386982852022e-08
present O 0 6.3933240923574886e-09
for O 0 5.500079947040604e-09
either O 0 5.27625900303974e-07
TWIST O 0 4.31816115451511e-05
mutations O 0 0.0010551578598096967
or O 0 3.055452452827012e-06
FGFR O 0 0.0007526574190706015
mutations O 0 6.578423199243844e-05
. O 0 2.3175958574483957e-07

The O 0 5.967789888927655e-07
overlap O 0 8.197582133107062e-07
in O 0 2.4295138345564737e-08
clinical O 0 5.250909680398763e-07
features O 0 5.536995786314947e-07
and O 0 1.992745239931537e-07
the O 0 1.3256336472977637e-08
presence O 0 2.8024830456274685e-08
, O 0 1.891911516338496e-09
in O 0 3.622261657287851e-10
the O 0 5.037565919963072e-10
same O 0 4.335422243428866e-09
genes O 0 1.615308953262229e-08
, O 0 2.951665301065276e-10
of O 0 1.219279260888939e-10
mutations O 0 7.43976613648556e-08
for O 0 4.3946812855466533e-10
more O 0 8.328989165029554e-10
than O 0 2.2488870765613456e-09
one O 0 3.0757835389749744e-08
craniosynostotic B-Disease 0 6.779481191188097e-05
condition I-Disease 0 2.0720042357424973e-06
- O 0 1.9975020393303566e-07
such O 0 3.7041121281333744e-09
as O 0 8.600471090858264e-08
Saethre B-Disease 0 1.6109102944028564e-05
- I-Disease 0 5.041827989771264e-06
Chotzen I-Disease 0 3.0662265544378897e-06
, I-Disease 0 5.6402162940116796e-09
Crouzon I-Disease 0 4.2905378450086573e-07
, I-Disease 0 4.252767915602362e-09
and I-Disease 0 3.17166453100981e-08
Pfeiffer I-Disease 0 7.6133175753057e-05
syndromes I-Disease 0 0.00014941593690309674
- O 0 4.098619115211477e-07
support O 0 1.465653198806649e-08
the O 0 4.5418717675715925e-09
hypothesis O 0 3.0004041917663926e-08
that O 0 1.0786245230320901e-09
TWIST O 0 1.336627803993906e-07
and O 0 2.9856639827130493e-08
FGFRs O 0 1.115767418014002e-06
are O 0 3.034375195554162e-09
components O 0 3.826392358519115e-08
of O 0 6.215107872797887e-10
the O 0 3.0872311373997263e-09
same O 0 3.726448483121203e-09
molecular O 0 1.2557700301840669e-07
pathway O 0 4.6643261697454363e-08
involved O 0 1.136013327851515e-08
in O 0 3.579302965128761e-10
the O 0 5.079003329022669e-10
modulation O 0 5.184184104223277e-08
of O 0 2.7168387539688865e-09
craniofacial O 0 9.90414191619493e-05
and O 0 3.006901181379362e-07
limb O 0 5.083385622128844e-05
development O 0 1.0375686976260567e-08
in O 0 3.964393702204916e-09
humans O 0 6.91204320446559e-08
. O 0 3.5864735625779076e-09
. O 0 3.935796044629569e-08

Mutation O 0 0.00019893771968781948
analysis O 0 2.9571169761766214e-06
of O 0 2.875177074201929e-07
UBE3A O 0 0.09632221609354019
in O 0 8.202586468541995e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.8332579731941223
. O 0 9.816480996960308e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.4319973587989807
AS B-Disease 1 0.9999998807907104
) O 0 5.509059519681614e-08
is O 0 9.870908534992395e-09
caused O 0 5.839450523126288e-08
by O 0 5.580005790761788e-09
chromosome O 0 6.49223366053775e-05
15q11 O 0 2.309807769051986e-06
- O 0 2.20627566704934e-06
q13 O 0 1.1642802064670832e-06
deletions O 0 6.797363880650664e-07
of O 0 1.7096571269803462e-08
maternal O 0 7.181143155321479e-05
origin O 0 2.514603920644731e-07
, O 0 1.3075084126512593e-08
by O 0 2.8298231313783617e-08
paternal O 0 0.005404633469879627
uniparental B-Disease 1 0.8589872121810913
disomy I-Disease 0 0.0795469731092453
( O 0 9.002405931823887e-06
UPD B-Disease 1 1.0
) O 0 7.396555190553045e-08
15 O 0 1.5675773568091245e-08
, O 0 8.531320094817829e-10
by O 0 1.2944704197437318e-09
imprinting O 0 0.0007667376194149256
defects O 1 0.987633466720581
, O 0 3.377177426600042e-09
and O 0 1.1298865176812e-09
by O 0 1.8896033626703e-09
mutations O 0 2.38151500298045e-07
in O 0 1.5484952209376956e-09
the O 0 5.115807866218347e-08
UBE3A O 0 6.788965401938185e-05
gene O 0 4.1109328776656184e-06
. O 0 2.526068954011862e-07

UBE3A O 0 0.0033794925548136234
encodes O 0 3.249757719459012e-05
a O 0 6.132848398010537e-07
ubiquitin O 0 3.4266913644387387e-06
- O 0 1.733488034005859e-06
protein O 0 1.4058969100005925e-07
ligase O 0 1.592505185499249e-07
and O 0 1.4881264220889534e-08
shows O 0 1.4631193607783644e-06
brain O 0 0.004286513663828373
- O 0 4.115015599381877e-06
specific O 0 2.270211041377479e-07
imprinting O 0 2.281556953676045e-05
. O 0 4.1388011595699936e-07

Here O 0 3.788094545598142e-06
we O 0 6.612124821003817e-07
describe O 0 1.6121991848194739e-06
UBE3A O 0 5.182756285648793e-05
coding O 0 5.161340959602967e-05
- O 0 0.00014051013567950577
region O 0 1.5734747194073861e-06
mutations O 0 2.337468322366476e-05
detected O 0 9.891151648844243e-07
by O 0 3.1670990274790256e-09
SSCP O 0 6.978343094488082e-07
analysis O 0 1.9417344176986262e-08
in O 0 1.0361210556197875e-08
13 O 0 3.107271595581551e-07
AS B-Disease 1 0.9999698400497437
individuals O 0 3.372518619926268e-08
or O 0 2.7121811285724107e-07
families O 0 3.166110502661468e-07
. O 0 1.3590691594345117e-07

Two O 0 1.9487528334138915e-05
identical O 0 0.0006445152685046196
de O 0 0.00032983621349558234
novo O 0 1.2216059076308738e-05
5 O 0 5.140368557476904e-07
- O 0 1.7628060504648602e-06
bp O 0 1.6159519873326644e-06
duplications O 0 1.6132080418174155e-06
in O 0 1.1063542082467848e-08
exon O 0 8.078006317191466e-07
16 O 0 2.626373145631078e-07
were O 0 2.060899646494363e-07
found O 0 1.231998112416477e-07
. O 0 1.3173341528727178e-07

Among O 0 1.948665442341735e-07
the O 0 8.201647361261166e-09
other O 0 1.1032875724126257e-09
11 O 0 4.67252503355553e-09
unique O 0 4.849833423747896e-09
mutations O 0 2.52166455538827e-06
, O 0 1.618941536385421e-09
8 O 0 9.48304190728777e-09
were O 0 1.0209762812962708e-08
small O 0 6.2649081478127755e-09
deletions O 0 7.857626656004868e-07
or O 0 5.809976073578582e-07
insertions O 0 8.264041753136553e-06
predicted O 0 1.4093919162405655e-05
to O 0 2.4195742298616096e-07
cause O 0 2.369902176724281e-05
frameshifts O 0 0.00012673521996475756
, O 0 3.9976917776129994e-08
1 O 0 3.710386309307978e-08
was O 0 1.3245751517843019e-07
a O 0 6.8797634256156925e-09
mutation O 0 1.8570177928722842e-07
to O 0 4.820120302895248e-09
a O 0 1.671588911733579e-08
stop O 0 2.237478042843577e-07
codon O 0 2.3133981130740722e-07
, O 0 4.226785144112455e-09
1 O 0 5.326205698708009e-09
was O 0 1.5412796372515913e-08
a O 0 6.153702880595802e-09
missense O 0 2.662016640897491e-06
mutation O 0 5.948300554337038e-07
, O 0 4.428669875267133e-09
and O 0 4.14007761406765e-09
1 O 0 1.0214086465509808e-08
was O 0 4.344936428424262e-07
predicted O 0 2.0351653517991508e-07
to O 0 1.5669675335061584e-08
cause O 0 1.0566539287992782e-07
insertion O 0 1.2268299087736523e-07
of O 0 5.492521548688956e-09
an O 0 3.870115961035481e-08
isoleucine O 0 0.010672157630324364
in O 0 3.806372994574758e-09
the O 0 3.2476756839372456e-09
hect O 0 2.0476288398185716e-07
domain O 0 8.29256574519377e-09
of O 0 8.031970644140074e-10
the O 0 4.4015786571094395e-09
UBE3A O 0 2.604744395284797e-06
protein O 0 3.375955159867772e-08
, O 0 1.5611136827686778e-09
which O 0 5.21606646763928e-10
functions O 0 6.190007173501044e-09
in O 0 1.5522714225113532e-09
E2 O 0 2.4798129061309737e-07
binding O 0 1.77676952262118e-07
and O 0 1.9715674426379337e-08
ubiquitin O 0 2.41472861262082e-07
transfer O 0 2.2603599347803538e-07
. O 0 1.4024394090483838e-07

Eight O 0 4.3535069380595814e-06
of O 0 1.552189488052136e-08
the O 0 1.3750481642205159e-08
cases O 0 1.923436698803016e-08
were O 0 5.479078026837669e-07
familial O 0 0.0001127687719417736
, O 0 7.620554498544152e-08
and O 0 1.2089527956504753e-07
five O 0 2.7428930593487166e-07
were O 0 8.74269062478561e-07
sporadic O 0 1.2641088687814772e-05
. O 0 3.27900465890707e-07

In O 0 6.886473897793621e-07
two O 0 7.166662641111543e-08
familial O 0 0.0002908108872361481
cases O 0 5.023111953050829e-07
and O 0 1.9493160152705968e-07
one O 0 7.513721556051678e-08
sporadic O 0 2.666619184310548e-05
case O 0 1.2168554519575991e-07
, O 0 9.917711096818493e-09
mosaicism O 0 2.2906397134647705e-06
for O 0 2.2737097538083617e-08
UBE3A O 0 0.0003766793815884739
mutations O 0 0.00010743753227870911
was O 0 5.352503649191931e-07
detected O 0 3.714486638273229e-07
in O 0 2.978615354365388e-09
the O 0 1.6977701022824476e-08
mother O 0 1.9414715097809676e-06
of O 0 1.1791706500119403e-09
three O 0 5.975854264761438e-07
AS B-Disease 1 1.0
sons O 0 0.007679405156522989
, O 0 1.5465737579489769e-09
in O 0 1.6581011563765458e-10
the O 0 2.8473963187281015e-09
maternal O 0 1.5240114407788496e-05
grandfather O 0 1.6924470855883555e-06
of O 0 8.750475899432786e-10
two O 0 7.741918750525656e-08
AS B-Disease 1 0.9999985694885254
first O 0 3.533709218572767e-07
cousins O 0 0.00020128264441154897
, O 0 1.3066159709751446e-08
and O 0 7.592897866004478e-09
in O 0 1.2640885005410496e-09
the O 0 1.3538023146963951e-08
mother O 0 5.756268706136325e-07
of O 0 3.6627023636270906e-10
an O 0 1.649290126692904e-08
AS B-Disease 1 0.9999990463256836
daughter O 0 0.00026832162984646857
. O 0 1.1440112501759359e-07

The O 0 2.740377738064126e-07
frequencies O 0 6.637491196670453e-07
with O 0 1.5676370423989283e-08
which O 0 1.666708371317327e-08
we O 0 2.4709573054337852e-08
detected O 0 1.7241482908048056e-07
mutations O 0 1.2539873068817542e-06
were O 0 4.761259475571933e-08
5 O 0 4.075720649865389e-09
( O 0 2.52048915072578e-09
14 O 0 1.588344034075817e-08
% O 0 4.712073842227937e-09
) O 0 3.879609411505669e-10
of O 0 6.624711335057043e-10
35 O 0 3.446153229447191e-08
in O 0 2.5497621791714664e-09
sporadic O 0 1.0519786883378401e-05
cases O 0 1.6480235842664115e-07
and O 0 1.5756324955873424e-07
8 O 0 7.619158992611119e-08
( O 0 3.480136179234705e-09
80 O 0 8.061981304763322e-09
% O 0 3.77316577981901e-09
) O 0 2.7327509699581753e-10
of O 0 1.671721094886891e-10
10 O 0 7.70946773087644e-09
in O 0 3.5610552284737196e-09
familial O 0 0.0006126113003119826
cases O 0 2.3963372086655e-07
. O 0 1.959159590114723e-08
. O 0 7.910290378276841e-08

The O 0 1.1631409506662749e-05
hemochromatosis B-Disease 1 0.9999972581863403
845 O 0 6.326068250928074e-05
G O 0 0.00015099052689038217
- O 0 2.9653505407623015e-05
- O 0 7.459568678314099e-06
> O 0 4.5499942302740237e-07
A O 0 5.1967770531291535e-08
and O 0 1.3478558713586608e-08
187 O 0 8.638052406695351e-08
C O 0 7.0316991696017794e-06
- O 0 7.211966931208735e-06
- O 0 1.266011440748116e-05
> O 0 1.3828196188114816e-06
G O 0 7.770567208353896e-06
mutations O 0 5.750163381890161e-06
: O 0 1.441467034624111e-08
prevalence O 0 1.498517576692393e-06
in O 0 1.6283070891631723e-08
non O 0 1.869534025900066e-05
- O 0 0.00012520850577857345
Caucasian O 0 6.664213287876919e-05
populations O 0 1.2744587820634479e-06
. O 0 9.224775965321896e-08

Hemochromatosis B-Disease 1 0.8679080605506897
, O 0 1.9147817056364147e-06
the O 0 2.24188738684461e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 3.638197298982959e-08
iron I-Disease 0 0.1311611831188202
metabolism I-Disease 0 0.0006432672962546349
, O 0 2.0544781875742046e-08
leads O 0 8.702149045802798e-08
, O 0 5.065103891865874e-09
if O 0 2.2467959936989246e-08
untreated O 0 3.8037590002204524e-06
, O 0 9.176543414035621e-10
to O 0 5.765408594982091e-09
progressive O 0 0.0008135014213621616
iron B-Disease 1 0.9991183876991272
overload I-Disease 0 0.198832705616951
and O 0 6.0712554841302335e-06
premature B-Disease 0 0.00012904439063277096
death I-Disease 0 1.0692577916415757e-06
. O 0 8.090867709142913e-08

The O 0 1.267063544219127e-05
hemochromatosis B-Disease 1 0.9999997615814209
gene O 0 0.00010231878695776686
, O 0 1.314071766955749e-07
HFE O 0 7.542694947915152e-05
, O 0 4.742552661696209e-08
recently O 0 1.6349083864497516e-07
has O 0 1.5079383075544683e-08
been O 0 1.6830195903594358e-08
identified O 0 4.548185117414505e-08
, O 0 7.12543912761987e-10
and O 0 1.0484459966875193e-09
characterization O 0 4.2032397118418885e-08
of O 0 2.0898127672808187e-10
this O 0 2.5827756600094176e-10
gene O 0 9.035815651259327e-08
has O 0 9.166367220814209e-09
shown O 0 1.5704562983387405e-08
that O 0 8.184234956409853e-10
it O 0 3.415414340235401e-10
contains O 0 6.174910027745284e-10
two O 0 7.2007222406966775e-09
mutations O 0 1.9824669834633823e-06
that O 0 3.0708284803893093e-09
result O 0 3.382568181109491e-08
in O 0 7.470135621190366e-09
amino O 0 4.435025005022908e-07
acid O 0 7.033048632365535e-08
substitutions O 0 1.5655251672797021e-07
- O 0 2.1651725035098934e-07
cDNA O 0 5.298915652929281e-07
nucleotides O 0 1.7511611360987445e-07
845 O 0 2.9808109047735343e-07
G O 0 8.0807490121515e-07
- O 0 2.3186094040283933e-06
- O 0 3.4517399853939423e-06
> O 0 3.2879512446015724e-07
A O 0 5.437975403310702e-08
( O 0 5.291938443008348e-09
C282Y O 0 7.088128484156186e-08
) O 0 9.484267815551561e-10
and O 0 1.7278931618847082e-09
187 O 0 3.572738194179692e-08
C O 0 3.3594203614484286e-06
- O 0 9.65603885560995e-06
- O 0 2.7341484383214265e-05
> O 0 2.4773194127192255e-06
G O 0 1.0113049938809127e-05
( O 0 1.0131048355788153e-07
H63D O 0 1.1487780284369364e-05
) O 0 4.180165902312183e-08
. O 0 5.180259776693674e-08

Although O 0 0.0003688375873025507
hemochromatosis B-Disease 1 1.0
is O 0 1.230177133493271e-07
common O 0 2.634738649476276e-08
in O 0 3.973690265723917e-09
Caucasians O 0 1.090085106625338e-06
, O 0 6.081116943335019e-09
affecting O 0 1.0039829589914007e-07
> O 0 2.2107715835772979e-07
= O 0 3.1349579785455717e-06
1 O 0 2.8484025804687008e-08
/ O 0 2.8673400720435893e-07
300 O 0 1.0887863055586422e-08
individuals O 0 3.0197622180594408e-09
of O 0 5.271093006520289e-10
northern O 0 5.762926846841765e-08
European O 0 1.7670171246209065e-06
origin O 0 1.8793718936649384e-07
, O 0 2.666089793379456e-09
it O 0 1.1926312160071006e-09
has O 0 2.171815394191867e-09
not O 0 3.3805671595388276e-09
been O 0 4.553364796322512e-09
recognized O 0 1.0231591129894468e-09
in O 0 4.103472006633524e-10
other O 0 2.8121358575106115e-09
populations O 0 1.3450083713451022e-07
. O 0 5.105417244521959e-08

The O 0 3.351620421199186e-07
present O 0 5.2027772312612797e-08
study O 0 1.0617607237861648e-08
used O 0 3.4114268743223874e-08
PCR O 0 2.7988833153358428e-06
and O 0 3.199858866764771e-08
restriction O 0 8.178437127526195e-08
- O 0 2.958579443657072e-07
enzyme O 0 3.4558760830805113e-07
digestion O 0 1.2352099076906597e-07
to O 0 3.1513476272948537e-09
analyze O 0 6.395326579422544e-08
the O 0 3.870092246671675e-09
frequency O 0 7.007526647839768e-08
of O 0 1.5360257510366182e-09
the O 0 4.023522404139612e-09
845 O 0 1.6573098093886074e-07
G O 0 1.2076823168172268e-06
- O 0 7.637337375854258e-07
- O 0 9.454075211579038e-07
> O 0 9.856370297711692e-08
A O 0 2.8693087017472862e-08
and O 0 7.284129299733877e-09
187 O 0 4.5197680265118834e-08
C O 0 1.0009576953962096e-06
- O 0 1.053013875207398e-06
- O 0 1.4052295682631666e-06
> O 0 5.705435910385859e-07
G O 0 1.726646019051259e-06
mutations O 0 9.217000069838832e-07
in O 0 7.608917940160609e-09
HLA O 0 1.1662672250167816e-06
- O 0 5.946360488451319e-07
typed O 0 9.113372243518825e-07
samples O 0 4.636103412281045e-08
from O 0 3.69338892802773e-09
non O 0 9.421376034879358e-07
- O 0 3.005367034347728e-06
Caucasian O 0 3.637795771282981e-06
populations O 0 1.0223777735518524e-07
, O 0 1.196317378493461e-09
comprising O 0 2.6670867736555692e-09
Australian O 0 1.7189627499192284e-08
Aboriginal O 0 1.579395991768706e-08
, O 0 1.1021202839245348e-09
Chinese O 0 1.1534534438695232e-09
, O 0 1.8531859380388482e-09
and O 0 4.808733855554692e-09
Pacific O 0 1.1149893452966353e-07
Islanders O 0 3.6663095670519397e-07
. O 0 4.9378748201434064e-08

Results O 0 0.00012116153084207326
showed O 0 2.598149876575917e-06
that O 0 5.933510127675845e-09
the O 0 5.023521154612354e-09
845 O 0 3.1213528473017504e-07
G O 0 4.597183760779444e-06
- O 0 2.7586471333052032e-05
- O 0 1.2102661457902286e-05
> O 0 3.527668468450429e-07
A O 0 7.232769405618455e-08
mutation O 0 1.6749644373703632e-06
was O 0 3.655566160887247e-08
present O 0 2.617446925867739e-09
in O 0 6.327399160177549e-10
these O 0 1.935037907685455e-09
populations O 0 1.6014306325473626e-08
( O 0 1.362027601814475e-09
allele O 0 4.6036671363935966e-08
frequency O 0 3.42625270377539e-07
0 O 0 7.58621325758213e-08
. O 0 2.6932807095647604e-09
32 O 0 6.139050867659535e-08
% O 0 1.2880135180637353e-08
) O 0 1.9551866792255623e-09
, O 0 1.7254263573462936e-09
and O 0 1.776758473681639e-08
, O 0 3.3402391963477385e-09
furthermore O 0 2.179514169142749e-08
, O 0 3.835626927184421e-09
it O 0 3.985241914250537e-09
was O 0 4.4337224380797124e-07
always O 0 1.0563959307319237e-07
seen O 0 4.733136194090548e-08
in O 0 4.1871039968555124e-10
conjunction O 0 7.721563832774336e-09
with O 0 1.353980572105229e-08
HLA O 0 4.122439349885099e-06
haplotypes O 0 5.572350119109615e-07
common O 0 4.9621291964285774e-08
in O 0 6.386036144334639e-09
Caucasians O 0 3.1320246307586785e-07
, O 0 7.0931429618781294e-09
suggesting O 0 6.22605327293968e-08
that O 0 2.8566276011332548e-09
845 O 0 1.332918344587597e-07
G O 0 5.869460437679663e-06
- O 0 3.437604755163193e-05
- O 0 3.2013635063776746e-05
> O 0 2.3703623241999594e-07
A O 0 1.5518541829351307e-07
may O 0 4.6056351266088313e-07
have O 0 1.0498993674445956e-08
been O 0 3.0281772644968896e-09
introduced O 0 1.5900830652171294e-09
into O 0 2.4027839717888355e-09
these O 0 2.845821800434578e-09
populations O 0 1.262412219205089e-08
by O 0 2.954370081909019e-09
Caucasian O 0 8.483393116875959e-07
admixture O 0 3.132166966679506e-06
. O 0 5.09402696025063e-07

187 O 0 0.0001088584031094797
C O 0 0.00019041965424548835
- O 0 2.4238262994913384e-05
- O 0 1.2867453733633738e-05
> O 0 1.7978588857658906e-06
G O 0 8.175868060789071e-06
was O 0 1.849190596203698e-07
present O 0 8.684685859350338e-09
at O 0 8.232977855016088e-09
an O 0 7.600283180586587e-10
allele O 0 1.108754403844614e-07
frequency O 0 1.5839383138427365e-07
of O 0 6.859375734080686e-09
2 O 0 1.7015833009281778e-07
. O 0 1.1442141101269954e-07

68 O 0 0.00041320931632071733
% O 0 1.9905564840883017e-06
in O 0 6.809007579988702e-09
the O 0 3.116796598590099e-09
two O 0 3.0161702024855686e-09
populations O 0 3.230638156992427e-08
analyzed O 0 5.513390277656072e-08
( O 0 4.2913659292764805e-09
Australian O 0 2.797420250999494e-08
Aboriginal O 0 8.60060254126438e-08
and O 0 1.299029506185434e-08
Chinese O 0 9.264269351660914e-09
) O 0 1.3993953551505456e-08
. O 0 3.565923378801017e-08

In O 0 6.642100629505876e-07
the O 0 2.6505761141493167e-08
Australian O 0 8.162744080664197e-08
Aboriginal O 0 7.972528948130275e-08
samples O 0 2.66734243581368e-08
, O 0 1.7127992357757194e-09
187 O 0 1.876992605787109e-08
C O 0 1.991923681998742e-06
- O 0 6.240085895115044e-06
- O 0 6.6111124397139065e-06
> O 0 6.974869961595687e-07
G O 0 6.187198778206948e-06
was O 0 1.9141157281410415e-07
found O 0 1.2974521013120466e-08
to O 0 2.3613444533054917e-09
be O 0 1.3626518580167613e-08
associated O 0 1.7516196493261305e-08
with O 0 1.1960487711348833e-08
HLA O 0 6.007423507981002e-06
haplotypes O 0 6.972302912799933e-07
common O 0 3.560717232176103e-08
in O 0 3.991609709430577e-09
Caucasians O 0 4.293906670227443e-07
, O 0 3.08151903993803e-09
suggesting O 0 3.8594571094563435e-08
that O 0 1.652141756736114e-09
it O 0 1.7804623331230118e-09
was O 0 8.153202557537043e-09
introduced O 0 7.347044750360965e-09
by O 0 2.511031382823603e-09
recent O 0 3.536095505296544e-08
admixture O 0 2.589971245470224e-06
. O 0 4.306858158997784e-07

In O 0 2.292833158890062e-07
the O 0 2.0316779369977667e-08
Chinese O 0 6.431778665216825e-09
samples O 0 1.4626427180530754e-08
analyzed O 0 6.271067576335554e-08
, O 0 3.901978296028119e-09
187 O 0 6.371413974193274e-08
C O 0 3.474332970654359e-06
- O 0 2.597850198071683e-06
- O 0 6.864908300485695e-06
> O 0 7.477456733795407e-07
G O 0 7.430295681842836e-06
was O 0 1.6745046593769075e-07
present O 0 9.371275311309546e-09
in O 0 1.683959527376544e-09
association O 0 1.3767855300272913e-08
with O 0 1.9107948556751353e-09
a O 0 6.260226115273326e-09
wide O 0 5.608722730698901e-08
variety O 0 1.377544656122609e-08
of O 0 4.629836070080273e-09
HLA O 0 1.7162573158202576e-06
haplotypes O 0 7.016520839897566e-07
, O 0 9.064380357415303e-09
showing O 0 4.028669877698121e-07
this O 0 1.1577824254871416e-09
mutation O 0 6.515943340446029e-08
to O 0 1.8099427512296984e-09
be O 0 2.5944140169542607e-09
widespread O 0 7.747631869392535e-09
and O 0 3.5065102821363325e-08
likely O 0 9.289894364883367e-08
to O 0 4.572450418294238e-09
predate O 0 5.454106144497928e-07
the O 0 1.3009007204800582e-09
more O 0 8.992498967685947e-10
genetically O 0 1.2071183164152899e-08
restricted O 0 1.2358174039661662e-08
845 O 0 9.665252065360619e-08
G O 0 2.3228453756019007e-06
- O 0 1.379928562528221e-05
- O 0 2.1098110664752312e-05
> O 0 1.2654843430937035e-06
A O 0 4.5271278281688865e-07
mutation O 0 1.4645553164882585e-05
. O 0 2.624727812872152e-07

Genotype O 0 0.015968941152095795
- O 0 0.001458945102058351
phenotype O 0 0.0003954202402383089
correlations O 0 5.972498911432922e-05
in O 0 3.6783083032787545e-06
attenuated B-Disease 1 0.999968409538269
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999998807907104
. O 0 1.0337037565477658e-05

Germ O 0 0.03386949747800827
- O 0 0.0015768161974847317
line O 0 3.646552795544267e-05
mutations O 0 3.4413303637848003e-06
of O 0 6.5619119027360284e-09
the O 0 3.306827878191143e-08
tumor B-Disease 0 3.5317050333105726e-06
suppressor O 0 2.4752177978371037e-06
APC O 0 7.68180143495556e-07
are O 0 1.1177974990062012e-08
implicated O 0 2.3122299808164826e-06
in O 0 3.192936617324449e-07
attenuated B-Disease 1 0.9999910593032837
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.00010698595724534243
AAPC B-Disease 1 1.0
) O 0 2.444141387059062e-07
, O 0 5.183578011269674e-09
a O 0 1.4401699388599809e-08
variant O 0 0.00020517586381174624
of O 0 4.786025783687364e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 3.322531483718194e-05
FAP B-Disease 0 0.00010809129889821634
) O 0 6.618484462705965e-07
. O 0 4.0623314134791144e-07

AAPC B-Disease 1 0.9999991655349731
is O 0 2.735941052378621e-06
recognized O 0 1.2708696317531576e-07
by O 0 1.8119186151466238e-09
the O 0 1.676131122785307e-09
occurrence O 0 5.74611220827137e-08
of O 0 1.5667036556976655e-09
< O 0 2.2610313408222282e-06
100 O 0 9.07303245867297e-08
colonic B-Disease 0 1.878222610685043e-05
adenomas I-Disease 0 4.8494504881091416e-05
and O 0 1.4670041181830129e-08
a O 0 1.856505527086938e-08
later O 0 1.7883851910482917e-07
onset O 0 0.004251033067703247
of O 0 0.000577998929657042
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 6.357903430398437e-07
age O 0 7.569091735604161e-07
> O 0 1.8433202342293953e-07
40 O 0 1.3910690199736564e-07
years O 0 2.6882933212846183e-08
) O 0 2.682725686042886e-08
. O 0 1.0531950778158716e-07

The O 0 3.0811216333859193e-07
aim O 0 4.262080324224371e-07
of O 0 1.2924227243971131e-09
this O 0 7.770893373226784e-10
study O 0 4.114273366440102e-09
was O 0 2.3111679681164787e-08
to O 0 3.794673464341258e-09
assess O 0 1.9416104350966634e-06
genotype O 0 0.00034426257479935884
- O 0 6.797698006266728e-05
phenotype O 0 2.635821874719113e-05
correlations O 0 9.916133421938866e-06
in O 0 5.221038463787409e-07
AAPC B-Disease 1 0.9999996423721313
families O 0 3.7970464745740173e-06
. O 0 3.6265137737245823e-07

By O 0 6.674829364783363e-07
protein O 0 2.1316095626389142e-06
- O 0 3.011630269611487e-06
truncation O 0 8.023303053050768e-06
test O 0 2.446682810841594e-05
( O 0 5.1652929045076235e-08
PTT O 0 8.31357567676605e-07
) O 0 1.794998261139824e-09
assay O 0 4.4158426248941396e-08
, O 0 1.3786716213104455e-09
the O 0 9.331904138321079e-10
entire O 0 1.322537368508847e-08
coding O 0 1.4111047619280725e-07
region O 0 9.020159730255273e-09
of O 0 7.113069022679497e-10
the O 0 3.761152278514146e-09
APC B-Disease 0 1.8305826188225183e-07
gene O 0 1.8535693868670933e-07
was O 0 4.107516815565759e-08
screened O 0 8.343433677282519e-08
in O 0 2.7480775433019744e-09
affected O 0 2.511612251510087e-08
individuals O 0 3.345850485558799e-09
from O 0 4.8190722523600016e-09
11 O 0 8.375736229027098e-07
AAPC B-Disease 1 0.9999992847442627
kindreds O 0 5.831028101965785e-05
, O 0 1.7330131996118325e-08
and O 0 9.425842328880663e-09
their O 0 2.152274092281914e-08
phenotypic O 0 1.0390112038294319e-05
differences O 0 6.410907371900976e-05
were O 0 5.107772722112713e-06
examined O 0 6.2298699958773796e-06
. O 0 2.557454763518763e-07

Five O 0 8.083761713351123e-06
novel O 0 6.431164365494624e-06
germ O 0 0.0001720334985293448
- O 0 0.00014831994485575706
line O 0 3.8325259083649144e-05
APC B-Disease 0 3.177940016030334e-06
mutations O 0 2.837173497027834e-06
were O 0 7.881720875957399e-08
identified O 0 1.153434681100407e-07
in O 0 3.85787268797344e-09
seven O 0 1.0697662133907215e-07
kindreds O 0 2.8470847610151395e-05
. O 0 3.1488744411944936e-07

Mutations O 0 0.003500474849715829
were O 0 2.2670078578812536e-06
located O 0 5.437187411416744e-08
in O 0 3.4532445791768396e-09
three O 0 3.776549739598067e-09
different O 0 1.9293255881791538e-09
regions O 0 7.148857061878289e-09
of O 0 4.827524491268775e-10
the O 0 6.8278782627828605e-09
APC B-Disease 0 1.1255319520842022e-07
gene O 0 3.4403871751464976e-08
( O 0 1.0941965111754826e-09
1 O 0 1.3659768871576716e-09
) O 0 1.0505238901004077e-09
at O 0 2.4624883465662606e-08
the O 0 7.583402350519464e-09
5 O 0 1.3532421405670902e-08
end O 0 5.2130580741049926e-08
spanning O 0 1.4834552075626561e-07
exons O 0 6.588005021512799e-07
4 O 0 7.925149958509792e-08
and O 0 3.9771190785131694e-08
5 O 0 1.9452929933549967e-08
, O 0 2.380477592822672e-09
( O 0 7.286070635714736e-10
2 O 0 2.089678430294839e-09
) O 0 6.787363449056727e-10
within O 0 1.1286006573740792e-09
exon O 0 4.2781859832530245e-08
9 O 0 8.899581871446571e-08
, O 0 3.3454166104007754e-09
and O 0 1.0106667502896016e-08
( O 0 2.0085701990524285e-09
3 O 0 5.623652210573482e-09
) O 0 1.2404335336668737e-09
at O 0 9.06175312564983e-09
the O 0 1.6372442290801814e-09
3 O 0 9.908559306381903e-09
distal O 0 4.969944029653561e-07
end O 0 9.458064198497595e-08
of O 0 2.4971946732676997e-09
the O 0 2.1336846955932742e-08
gene O 0 7.254391221067635e-07
. O 0 1.2607486610249907e-07

Variability O 0 1.4443243344430812e-05
in O 0 5.62402000525708e-08
the O 0 1.0121366855742053e-08
number O 0 3.483205901488873e-08
of O 0 3.996318355348194e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.0009182924404740334
most O 0 1.0132706229626365e-08
apparent O 0 6.709075250910246e-08
in O 0 2.071684823690134e-09
individuals O 0 6.420000087103972e-09
with O 0 4.605342773800203e-09
mutations O 0 1.0136078344658017e-05
in O 0 3.3567362223152486e-09
region O 0 5.351839504896816e-08
1 O 0 2.733160364698506e-08
, O 0 2.56860377412238e-09
and O 0 3.9462744183538234e-08
upper O 0 0.23630934953689575
- O 1 0.9921668767929077
gastrointestinal O 0 0.03173955902457237
manifestations O 0 1.3199213753978256e-05
were O 0 4.5646842750102223e-07
more O 0 3.467394815714897e-09
severe O 0 3.0495102691929787e-05
in O 0 6.501018834370598e-09
them O 0 5.24566381443492e-08
. O 0 9.0860218904254e-08

In O 0 2.665512397470593e-07
individuals O 0 5.912094280802194e-08
with O 0 1.2690221318223394e-08
mutations O 0 1.7437316273571923e-05
in O 0 1.007268224384461e-08
either O 0 4.268356690317887e-07
region O 0 2.0407412648637546e-07
2 O 0 2.3757236533583637e-07
or O 0 7.30092040157615e-07
region O 0 1.9236242110309831e-07
3 O 0 1.75153360260083e-07
, O 0 1.4357752764482257e-09
the O 0 2.0301507142050923e-09
average O 0 1.4036970696906792e-07
number O 0 3.3477591809827345e-09
of O 0 1.2355503287153624e-09
adenomas B-Disease 0 2.27016857934359e-06
tended O 0 1.0626338280417258e-06
to O 0 1.1207329286833101e-08
be O 0 5.526066004790664e-08
lower O 0 1.255169053138161e-07
than O 0 7.566614002030292e-09
those O 0 3.1273483802607416e-09
in O 0 3.661067837779086e-10
individuals O 0 1.5017722621024632e-09
with O 0 1.5096239813772172e-09
mutations O 0 8.949675134317658e-07
in O 0 1.0438447883842628e-09
region O 0 1.4826413874402533e-08
1 O 0 1.0126966820678263e-08
, O 0 1.5116468077280842e-09
although O 0 1.6885790543597068e-08
age O 0 3.3710045954649104e-07
at O 0 3.084749380377616e-07
diagnosis O 0 0.08667512983083725
was O 0 2.7159651949659747e-07
similar O 0 7.763981813013743e-08
. O 0 1.2737817201013968e-07

In O 0 2.574493919382803e-06
all O 0 7.407298312500643e-07
AAPC B-Disease 1 0.9999991655349731
kindreds O 0 0.00014557816029991955
, O 0 1.801642923737745e-08
a O 0 4.414383525386256e-09
predominance O 0 1.0974022188747767e-06
of O 0 2.7782141032162144e-08
right O 1 0.9464231133460999
- O 1 0.999998927116394
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.0024893165100365877
rectal B-Disease 1 0.9999986886978149
polyp I-Disease 0 0.32021811604499817
sparing O 0 8.60277759784367e-06
was O 0 8.394687824875291e-07
observed O 0 5.979970296721149e-07
. O 0 1.307563763930375e-07

No O 0 0.0005035243812017143
desmoid B-Disease 1 0.99024498462677
tumors I-Disease 1 1.0
were O 0 1.692935620667413e-05
found O 0 6.452620482377824e-08
in O 0 4.413272414183211e-09
these O 0 3.2377446501641316e-08
kindreds O 0 4.938763959216885e-05
. O 0 5.414469796960475e-07

Our O 0 3.08273979499063e-06
data O 0 3.275904134625307e-07
suggest O 0 1.6758242793457612e-07
that O 0 3.898839029403689e-09
, O 0 4.450236623654291e-09
in O 0 1.4219125432646251e-08
AAPC B-Disease 1 1.0
families O 0 5.56230986603623e-07
, O 0 1.0171660180802178e-09
the O 0 4.658871621820992e-10
location O 0 8.998748413091562e-09
of O 0 9.700832359627043e-10
the O 0 1.899505619462616e-08
APC B-Disease 0 4.319504114391748e-06
mutation O 0 1.036680259858258e-05
may O 0 3.988427295098518e-07
partially O 0 1.6769781723269261e-06
predict O 0 1.4616688304158743e-07
specific O 0 3.130584858013208e-08
phenotypic O 0 9.241536645276938e-06
expression O 0 1.881205662357388e-06
. O 0 2.630639528433676e-07

This O 0 2.2593363269152178e-07
should O 0 5.558010229833599e-08
help O 0 1.4247169666248283e-08
in O 0 8.279539276401238e-10
the O 0 5.844247308317563e-10
design O 0 4.089661587158844e-08
of O 0 2.751224359442972e-09
tailored O 0 0.00019440583128016442
clinical O 0 0.00021418365940917283
- O 0 8.114069350995123e-05
management O 0 5.647162737432154e-08
protocols O 0 3.3141333233288606e-08
in O 0 1.090015855353954e-09
this O 0 3.59907353919553e-10
subset O 0 9.70494529184407e-09
of O 0 2.5765427569268695e-09
FAP B-Disease 0 4.650318260246422e-06
patients O 0 1.616022814232565e-06
. O 0 1.1587352410913354e-08
. O 0 5.218151599706289e-08

Wilms B-Disease 1 0.5931116342544556
' I-Disease 0 0.0011539667611941695
tumor I-Disease 0 0.00011206620547454804
1 O 0 3.6700282635138137e-07
and O 0 1.1540794275788357e-07
Dax O 1 0.7159144878387451
- O 0 7.134881343517918e-06
1 O 0 4.2384854737065325e-08
modulate O 0 4.7202399855450494e-07
the O 0 1.6692725424150012e-08
orphan O 0 7.181159276115068e-07
nuclear O 0 3.895623024163797e-07
receptor O 0 1.1601491678447928e-06
SF O 0 4.5807832066202536e-05
- O 0 1.1758357914004591e-06
1 O 0 2.988934610925753e-08
in O 0 3.630265865695037e-09
sex O 0 1.5907308181795088e-07
- O 0 1.771815050233272e-07
specific O 0 4.796699570874807e-08
gene O 0 8.96674464456737e-07
expression O 0 5.32776823547465e-07
. O 0 1.3620820027426817e-07

Products O 0 6.129946996225044e-06
of O 0 1.5644759798760788e-07
steroidogenic O 0 3.367281533428468e-05
factor O 0 1.057518375091604e-06
1 O 0 1.4801472048020514e-07
( O 0 8.234143678009787e-08
SF O 0 0.01454017125070095
- O 0 2.1763482436654158e-05
1 O 0 9.095523267887984e-08
) O 0 7.152089587236787e-09
and O 0 2.6676273634507197e-08
Wilms B-Disease 0 0.01635846309363842
tumor I-Disease 0 2.8583910534507595e-05
1 O 0 3.785306645909259e-08
( O 0 1.3411114885286679e-08
WT1 O 0 1.2968022247150657e-06
) O 0 4.165296996205825e-09
genes O 0 2.624677186702229e-08
are O 0 6.490285531235429e-10
essential O 0 3.4943101745454896e-09
for O 0 8.872760304257099e-10
mammalian O 0 1.8989337036146026e-07
gonadogenesis O 0 9.26547158996982e-07
prior O 0 5.001410485760971e-08
to O 0 9.694215208355672e-09
sexual O 0 5.559737701332779e-07
differentiation O 0 1.8389183651379426e-06
. O 0 4.2948485656779667e-07

In O 0 1.1564917485884507e-06
males O 0 4.623542736226227e-06
, O 0 4.7800952529541973e-08
SF O 0 0.00023895759659353644
- O 0 4.024901500088163e-06
1 O 0 1.4458010788587217e-08
participates O 0 1.3848075575140228e-08
in O 0 8.872116930014329e-10
sexual O 0 2.0891055996230534e-08
development O 0 8.565331222065709e-10
by O 0 7.474492136338995e-10
regulating O 0 4.6854498947368484e-08
expression O 0 1.1019211321183775e-08
of O 0 5.806746750103287e-10
the O 0 1.6114931611355132e-08
polypeptide O 0 3.9335984183708206e-05
hormone O 0 9.621219760447275e-06
Mullerian O 0 3.9723203371977434e-05
inhibiting O 0 1.0130212103831582e-05
substance O 0 2.3333871013164753e-06
( O 0 9.613201967795248e-08
MIS O 0 0.0004786272475030273
) O 0 6.986653744434079e-08
. O 0 6.932904739187506e-08

Here O 0 1.3589437912742142e-06
, O 0 6.148050601950672e-08
we O 0 3.120039693271792e-08
show O 0 4.943453291161859e-08
that O 0 1.0484805024191246e-08
WT1 O 0 2.9358454412431456e-05
- O 0 8.213403816625942e-06
KTS O 0 2.44008369918447e-05
isoforms O 0 3.1351206075669324e-07
associate O 0 3.8697109516760975e-07
and O 0 2.852219260773836e-08
synergize O 0 6.650976956734667e-06
with O 0 2.056513608295063e-07
SF O 1 0.7176252603530884
- O 0 0.00010206152364844456
1 O 0 5.9042285727173294e-08
to O 0 1.657612713756862e-08
promote O 0 6.008329478390806e-07
MIS O 1 0.7706937789916992
expression O 0 2.2441633973357966e-06
. O 0 2.2314623038255377e-07

In O 0 1.0968194601446157e-06
contrast O 0 1.1440977232268779e-06
, O 0 7.311832916911953e-08
WT1 O 0 4.6661847591167316e-05
missense O 0 6.226163532119244e-05
mutations O 0 6.532830593641847e-05
, O 0 9.738396755665235e-09
associated O 0 3.4247786828700555e-08
with O 0 8.624125769074453e-08
male B-Disease 0 0.17831212282180786
pseudohermaphroditism I-Disease 1 1.0
in O 0 1.142691189670586e-06
Denys B-Disease 1 0.9999949932098389
- I-Disease 1 0.9999996423721313
Drash I-Disease 1 0.9999934434890747
syndrome I-Disease 1 0.9999994039535522
, O 0 2.2684295331032445e-08
fail O 0 1.4981646927481052e-06
to O 0 2.6644951134358053e-08
synergize O 0 7.18453957233578e-05
with O 0 1.6328515357599827e-06
SF O 1 0.987612783908844
- O 0 0.0016564478864893317
1 O 0 9.92742116068257e-07
. O 0 2.759340986813186e-07

Additionally O 0 1.110727771447273e-05
, O 0 9.909356890602794e-08
the O 0 2.0301207825923484e-08
X O 0 0.0010734893148764968
- O 0 0.0007388613885268569
linked O 0 0.00011736615124391392
, O 0 6.3084470980356855e-09
candidate O 0 6.312831146715325e-08
dosage O 0 8.417037520302983e-07
- O 0 2.49446912903295e-07
sensitive O 0 3.1088150080904597e-06
sex O 0 1.3873503803552012e-06
- O 0 4.993870561520453e-07
reversal O 0 1.26352801999019e-07
gene O 0 2.0535209444005886e-07
, O 0 8.63640181592018e-09
Dax O 0 0.40241527557373047
- O 0 5.432772468338953e-06
1 O 0 4.497341166143087e-08
, O 0 6.87488377337786e-09
antagonizes O 0 3.383698015113623e-07
synergy O 0 9.207759887885913e-08
between O 0 3.8939656832326364e-08
SF O 0 0.008586131036281586
- O 0 1.4385480426426511e-05
1 O 0 3.181740737545624e-08
and O 0 1.0068649025640752e-08
WT1 O 0 1.494853563599463e-06
, O 0 2.035470458849886e-09
most O 0 2.2822115308684943e-09
likely O 0 1.0356863811011863e-08
through O 0 1.1232104135672216e-09
a O 0 3.5437501821888873e-09
direct O 0 1.583824449369331e-08
interaction O 0 1.8124160305887926e-07
with O 0 4.809782012671349e-07
SF O 1 0.9932674169540405
- O 0 0.004376433789730072
1 O 0 5.704125101146929e-07
. O 0 1.397717994677805e-07

We O 0 7.289869245141745e-06
propose O 0 1.5918551525828661e-06
that O 0 2.0602152872584156e-08
WT1 O 0 7.529813501605531e-06
and O 0 3.3175490443682065e-07
Dax O 1 0.997782289981842
- O 0 1.903091288113501e-05
1 O 0 3.280749538703276e-08
functionally O 0 3.7349647641349293e-07
oppose O 0 3.930394498752321e-08
each O 0 4.3412642369844434e-09
other O 0 1.6847563344413174e-09
in O 0 1.812371364096066e-09
testis O 0 8.443005867775355e-07
development O 0 6.822462594868739e-09
by O 0 5.718403528476301e-09
modulating O 0 5.482839242176851e-06
SF O 0 0.01554389763623476
- O 0 4.531810918706469e-05
1 O 0 6.127470442152116e-07
- O 0 4.631278898159508e-06
mediated O 0 3.5351690712559503e-06
transactivation O 0 1.590230931469705e-05
. O 0 4.2204955974511904e-08
. O 0 5.977027939252366e-08

A O 0 3.3476255794084864e-06
mouse O 0 7.746771188976709e-06
model O 0 3.2241118788078893e-06
for O 0 7.230906930999481e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 0 0.01137001346796751
- O 0 0.0009518791921436787
centre O 0 1.2915215847897343e-05
mutations O 0 9.234095341525972e-05
. O 0 3.155310253077914e-07

Imprinting O 0 0.00019475538283586502
in O 0 4.008969938240625e-07
the O 0 1.0102566250225209e-07
15q11 O 0 5.078508365841117e-06
- O 0 2.70310670202889e-06
q13 O 0 1.1132696045024204e-06
region O 0 3.173086327024066e-08
involves O 0 9.760171337802603e-09
an O 0 5.680790060580421e-09
imprinting O 0 2.167553702747682e-06
centre O 0 1.1024961850125692e-06
( O 0 1.4638597001237486e-08
IC O 0 5.561890930039226e-07
) O 0 4.569015388256048e-09
, O 0 3.4108638136132186e-10
mapping O 0 2.1604835254152022e-08
in O 0 1.6382188938734998e-09
part O 0 6.446934541770588e-09
to O 0 3.725382669017563e-09
the O 0 7.017944447795799e-09
promoter O 0 2.5686057369966875e-07
and O 0 4.876901105177467e-09
first O 0 9.280150869983572e-09
exon O 0 3.66784490779537e-07
of O 0 3.422297467636781e-08
SNRPN O 0 8.574884122936055e-05
. O 0 3.813355249349115e-07

Deletion O 0 0.00012175798474345356
of O 0 1.8426172232466342e-07
this O 0 3.849767082897415e-08
IC O 0 5.135319952387363e-06
abolishes O 0 3.429018988754251e-06
local O 0 1.299836611678984e-07
paternally O 0 4.979535788152134e-06
derived O 0 1.0729663557640379e-07
gene O 0 1.6783177159140905e-07
expression O 0 6.570606103650789e-08
and O 0 5.0994902522916163e-08
results O 0 3.939141151931835e-06
in O 0 2.42884925683029e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.5935222108964808e-05
PWS B-Disease 1 1.0
) O 0 2.8688060638160096e-07
. O 0 2.1604387256957125e-07

We O 0 5.2893856263835914e-06
have O 0 4.69745877751393e-08
created O 0 2.473022320259588e-08
two O 0 1.5205248615757228e-08
deletion O 0 2.946383028756827e-05
mutations O 0 1.3041161764704157e-05
in O 0 7.1233769993739315e-09
mice O 0 2.1688149445253657e-06
to O 0 2.8287869824339396e-08
understand O 0 1.4283145901572425e-05
PWS B-Disease 1 1.0
and O 0 1.2606200527898181e-07
the O 0 6.746953662428723e-09
mechanism O 0 6.620447834393417e-08
of O 0 1.1837540947468028e-09
this O 0 2.6447568579612835e-09
IC O 0 8.729528417461552e-06
. O 0 1.875778110616011e-07

Mice O 1 0.8089157938957214
harbouring O 0 0.001697359373793006
an O 0 1.6212931086556637e-07
intragenic O 0 1.7857768398243934e-05
deletion O 0 1.3513044905266725e-05
in O 0 4.153002919338178e-08
Snrpn O 0 1.591042564541567e-05
are O 0 3.074522325619e-08
phenotypically O 0 2.278417014167644e-06
normal O 0 3.6730813235408277e-07
, O 0 1.546349603920305e-09
suggesting O 0 2.4747022209226088e-08
that O 0 1.553823736344384e-09
mutations O 0 1.853654225669743e-07
of O 0 1.579633090997845e-09
SNRPN O 0 3.5953116821474396e-06
are O 0 6.587091760934527e-09
not O 0 7.127495482706081e-09
sufficient O 0 4.20033856585178e-08
to O 0 1.3483936811553576e-07
induce O 0 0.0010309579083696008
PWS B-Disease 1 1.0
. O 0 1.3475764717441052e-06

Mice O 0 0.17256046831607819
with O 0 5.0849891408688563e-08
a O 0 9.96253124441182e-09
larger O 0 2.6077511705580037e-08
deletion O 0 1.2980469819012797e-06
involving O 0 5.010452497344886e-08
both O 0 4.9030937532279495e-08
Snrpn O 0 2.2670104954158887e-05
and O 0 2.0969300962292436e-08
the O 0 4.4509349095278594e-08
putative O 0 0.0011106340680271387
PWS O 1 1.0
- O 0 9.492404205957428e-05
IC O 0 1.0316316547687165e-05
lack O 0 1.8546727176271816e-07
expression O 0 3.156227634804054e-08
of O 0 1.447419961664309e-09
the O 0 1.0673872452571231e-08
imprinted O 0 5.567353127844399e-06
genes O 0 5.780413516731642e-07
Zfp127 O 0 1.3705155197385466e-06
( O 0 1.538075800056049e-08
mouse O 0 5.002612510907056e-07
homologue O 0 7.623155511282675e-07
of O 0 1.2519048908643526e-08
ZNF127 O 0 1.3023872270423453e-05
) O 0 1.7148956032997376e-08
, O 0 7.651632216720827e-09
Ndn O 0 4.433584308571881e-06
and O 0 1.9348505020388984e-08
Ipw O 0 2.41399061451375e-06
, O 0 2.0364771202707743e-08
and O 0 8.1662436812735e-09
manifest O 0 1.5053282709232008e-07
several O 0 4.8576653810528114e-09
phenotypes O 0 1.5472745644729002e-06
common O 0 1.422028361730554e-07
to O 0 2.573367282820982e-06
PWS B-Disease 1 1.0
infants O 1 0.9994571805000305
. O 0 7.126232617338246e-07

These O 0 5.977929049549857e-07
data O 0 2.287765710207168e-07
demonstrate O 0 9.593603067514778e-08
that O 0 1.871679256026937e-09
both O 0 4.230341854594144e-09
the O 0 3.1720077675601033e-09
position O 0 1.3019038078709855e-06
of O 0 5.798899693765236e-10
the O 0 2.936157983413068e-09
IC O 0 1.593200863680977e-06
and O 0 5.3060809079852334e-08
its O 0 3.978255058711966e-09
role O 0 2.2853054559845987e-08
in O 0 4.713491819074989e-10
the O 0 8.6031209933779e-10
coordinate O 0 7.130516621600691e-08
expression O 0 1.9944119244996728e-08
of O 0 5.53025736316215e-10
genes O 0 4.988777391190524e-08
is O 0 9.29825327844469e-10
conserved O 0 5.9467661905898694e-09
between O 0 4.164089073555033e-09
mouse O 0 8.474515311718278e-07
and O 0 7.126002543600407e-08
human O 0 1.5412327414310312e-08
, O 0 2.128066611817303e-09
and O 0 4.821058219306451e-09
indicate O 0 2.833677683611313e-07
that O 0 1.5979211287486805e-09
the O 0 3.0384579297049186e-09
mouse O 0 5.35804986157018e-07
is O 0 7.903104282114271e-10
a O 0 1.651105252520324e-09
suitable O 0 6.099670457615503e-08
model O 0 1.0146654005893652e-07
system O 0 2.821523281681948e-08
in O 0 4.6091191974184653e-10
which O 0 4.658347041441857e-10
to O 0 6.468843238849331e-10
investigate O 0 1.2060987764073161e-08
the O 0 1.645816927187127e-09
molecular O 0 3.210612220527764e-08
mechanisms O 0 6.20260820483054e-08
of O 0 9.619466334598314e-10
imprinting O 0 2.8666428875112615e-07
in O 0 3.274671200870216e-09
this O 0 6.303139676866465e-10
region O 0 2.5857094243519896e-09
of O 0 2.9372318466336367e-10
the O 0 2.8715081423769107e-09
genome O 0 2.356589767771311e-08
. O 0 4.504584261155742e-09
. O 0 3.361216016628532e-08

Mutations O 0 5.5709864682285115e-05
of O 0 2.9753289609857347e-08
the O 0 1.3562162948232981e-08
ATM O 0 4.73719182991772e-06
gene O 0 1.327672862316831e-06
detected O 0 1.0195662980549969e-06
in O 0 1.7720271472398963e-08
Japanese O 0 0.00023285127826966345
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999474287033081
: O 0 1.4345743259980281e-08
possible O 0 2.5085959975967853e-08
preponderance O 0 4.5536884840657876e-07
of O 0 3.0399072148412642e-09
the O 0 1.2235928714687816e-08
two O 0 3.758184874413928e-08
founder O 0 6.813888262513501e-07
mutations O 0 5.22127538715722e-06
4612del165 O 0 1.3509169320968795e-06
and O 0 8.163615916600975e-08
7883del5 O 0 9.084407793125138e-06
. O 0 3.340279874919361e-07

The O 0 2.0999054868298117e-06
ATM O 0 6.490970554295927e-05
( O 0 3.3157757570734248e-06
A O 1 0.9999966621398926
- O 1 0.9999971389770508
T O 1 1.0
, O 0 1.8700101023227944e-08
mutated O 0 1.6296733917897654e-07
) O 0 4.355479532591744e-09
gene O 0 6.843174560344778e-08
on O 0 2.2649967235111035e-08
human O 0 9.983991589024299e-08
chromosome O 0 2.931595554400701e-05
11q22 O 0 1.3654269423568621e-05
. O 0 4.802035959983186e-07

3 O 0 2.093027433147654e-05
has O 0 1.466736136990221e-07
recently O 0 1.7701125898383907e-07
been O 0 1.4719061525170218e-08
identified O 0 1.3813491683833945e-08
as O 0 3.2897379265151017e-10
the O 0 4.5205567067441166e-10
gene O 0 4.0875949736118855e-08
responsible O 0 1.4259920355641498e-08
for O 0 6.009544528673416e-10
the O 0 4.844313838958669e-09
human O 0 1.2193174825370079e-06
recessive B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999980926513672
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.10029514878988266
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.35925562922057e-07
. O 0 1.0042797526921277e-07

In O 0 2.8474693181124167e-07
order O 0 2.7331916285788793e-08
to O 0 3.0762807856632435e-09
define O 0 1.0635083214083352e-07
the O 0 2.6383180085076674e-09
types O 0 2.323189960407035e-07
of O 0 3.182129049150717e-08
disease O 0 0.4804098308086395
- O 0 0.0003019664145540446
causing O 0 1.5539482092208345e-06
ATM O 0 3.678707798826508e-05
mutations O 0 1.2780951692548115e-05
in O 0 6.708816169265219e-09
Japanese O 0 7.506711426685797e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.28041782672517e-05
as O 0 7.945731184122451e-09
well O 0 8.217086566730814e-09
as O 0 9.112340881856085e-10
to O 0 1.7916016448182859e-09
look O 0 1.2869948307070445e-07
for O 0 2.4138175902521652e-09
possible O 0 4.044066770347854e-08
mutational O 0 9.362000128021464e-06
hotspots O 0 3.171113121425151e-06
, O 0 2.4371347606688687e-08
reverse O 0 1.945569965755567e-05
- O 0 3.66630956705194e-05
transcribed O 0 5.062536729383282e-06
RNA O 0 3.226958824598114e-07
derived O 0 4.1005026929497035e-08
from O 0 2.9570816906243635e-09
ten O 0 7.730763229574222e-08
patients O 0 9.095679587289851e-08
belonging O 0 2.867694881558691e-08
to O 0 4.627390470801629e-09
eight O 0 7.28846885067469e-08
unrelated O 0 1.2245878622252349e-07
Japanese O 0 2.189757833548356e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 5.530246198759414e-07
was O 0 4.6593470415245974e-08
analyzed O 0 3.243269830477402e-08
for O 0 1.290954343424744e-09
mutations O 0 1.9937280626436404e-07
by O 0 9.070810214062419e-10
the O 0 3.5264620112940293e-09
restriction O 0 7.12668253299853e-08
endonuclease O 0 2.120856606779853e-06
fingerprinting O 0 1.4721553043273161e-06
method O 0 1.9272688405180816e-06
. O 0 7.139408921830181e-07

As O 0 1.4107187098488794e-06
has O 0 6.009114628113821e-08
been O 0 3.754989563731215e-08
reported O 0 3.127898651200667e-08
by O 0 9.238607656669728e-10
others O 0 1.3040863500179967e-08
, O 0 7.806680857314063e-10
mutations O 0 9.109099607940152e-08
that O 0 8.212380775418637e-10
lead O 0 4.045331891688875e-08
to O 0 3.5613065829664947e-09
exon O 0 4.4853311464976287e-07
skipping O 0 2.4192797809519107e-06
or O 0 1.853402636697865e-06
premature O 0 3.462913014118385e-07
protein O 0 5.007738934637018e-08
truncation O 0 4.567920086628874e-07
were O 0 1.014037138702406e-06
also O 0 2.91655695150439e-08
predominant O 0 8.067858630056435e-07
in O 0 8.350308000615314e-09
our O 0 2.6373641048849095e-07
mutants O 0 9.038312782649882e-07
. O 0 9.886042562357034e-08

Six O 0 2.5500951323920162e-06
different O 0 1.4934100533992023e-07
mutations O 0 5.974326086288784e-06
were O 0 2.6081198711835896e-07
identified O 0 1.2589909204052674e-07
on O 0 5.485998766374678e-09
12 O 0 1.2564260742919942e-08
of O 0 4.993884750170707e-10
the O 0 6.367767202419827e-09
16 O 0 1.5163146827035234e-07
alleles O 0 8.109963118840824e-07
examined O 0 1.429408825970313e-06
. O 0 1.1446921632796148e-07

Four O 0 4.273661943443585e-06
were O 0 9.870724682059517e-08
deletions O 0 4.923284109281667e-07
involving O 0 8.873310264334577e-08
a O 0 3.079673263073346e-07
loss O 0 1.672720031820063e-06
of O 0 2.0420654056607646e-09
a O 0 3.383929936262575e-08
single O 0 9.814635859584087e-07
exon O 0 8.092879966170585e-07
exon O 0 7.662507641725824e-07
7 O 0 1.6437573435723607e-07
, O 0 4.978081058482076e-09
exon O 0 1.1603987815078654e-07
16 O 0 3.003696846803905e-08
, O 0 1.415050521202943e-09
exon O 0 1.7106900429553207e-07
33 O 0 1.5201081282611995e-07
or O 0 5.237385991563315e-08
exon O 0 1.6998168348436593e-06
35 O 0 1.6310600585711654e-06
. O 0 4.0378321841672005e-07

The O 0 1.7275666550631286e-06
others O 0 1.149872218775272e-06
were O 0 1.0664556526762681e-07
minute O 0 1.137578138354911e-07
deletions O 0 9.04306318716408e-07
, O 0 2.1234779268297643e-08
4649delA O 0 2.358317061634807e-07
in O 0 3.243936452790308e-09
exon O 0 2.0542515244414972e-07
33 O 0 2.752964007868286e-07
and O 0 1.1078514106088733e-08
7883del5 O 0 2.457644256992353e-07
in O 0 8.889110780785359e-09
exon O 0 1.449727051294758e-06
55 O 0 6.807276236031612e-07
. O 0 2.1078476208913344e-07

The O 0 2.372357357671717e-06
mutations O 0 1.8093753169523552e-05
4612del165 O 0 2.541689582358231e-06
and O 0 5.7380514562055396e-08
7883del5 O 0 1.2481685871534864e-06
were O 0 3.250413840305555e-07
found O 0 6.627773441181262e-09
in O 0 3.2880256850553735e-10
more O 0 1.9394338912626097e-10
than O 0 5.523847490529477e-10
two O 0 4.497476169262882e-09
unrelated O 0 2.7401965141393703e-08
families O 0 8.386060734721923e-09
; O 0 1.013538808436465e-09
44 O 0 8.632382808571037e-09
% O 0 2.221067774144103e-09
( O 0 7.372547572437327e-10
7 O 0 5.048572226939996e-09
of O 0 4.942242171068756e-10
16 O 0 1.8796185941027943e-08
) O 0 4.1662800986941306e-10
of O 0 1.4392018132802775e-10
the O 0 1.7903104554406468e-09
mutant O 0 3.028262938187254e-07
alleles O 0 1.315383286737415e-07
had O 0 2.714256481795019e-07
one O 0 1.8191905759579186e-09
of O 0 3.984738372597718e-10
the O 0 7.264704837695035e-09
two O 0 1.7291080212089582e-07
mutations O 0 1.0481862773303874e-05
. O 0 8.387968364331755e-08

The O 0 8.010939041014353e-07
4612del165 O 0 1.2109519957448356e-05
mutations O 0 3.985346666013356e-06
in O 0 7.58308527082363e-09
three O 0 3.0580633580967742e-09
different O 0 2.7569027061247198e-09
families O 0 2.7413570080625504e-08
were O 0 7.580282357366741e-08
all O 0 1.0795156990539567e-09
ascribed O 0 2.5649917745340645e-08
to O 0 4.041589729553152e-09
the O 0 2.0330501726562034e-08
same O 0 6.6835048073699e-07
T O 0 0.00013766461052000523
- O 0 4.41980500909267e-06
- O 0 2.7819928618555423e-06
> O 0 4.3207300848280283e-08
A O 0 7.292081161125452e-09
substitution O 0 1.54674566488211e-08
at O 0 1.9202328616074738e-08
the O 0 2.0764556740715534e-09
splice O 0 3.818522600340657e-06
donor O 0 1.0211422107886392e-07
site O 0 1.024624651790873e-07
in O 0 1.3328543602142418e-08
intron O 0 4.7794637794140726e-05
33 O 0 5.441655048343819e-06
. O 0 4.784045017913741e-07

Microsatellite O 0 0.0007551767048425972
genotyping O 0 0.00019075660384260118
around O 0 3.2808547985041514e-06
the O 0 1.2241395097589702e-07
ATM O 0 7.30745205146377e-06
locus O 0 7.942604497657157e-06
also O 0 2.454746663715923e-07
indicated O 0 4.229505066177808e-07
that O 0 8.348233215826895e-10
a O 0 5.524187329797314e-09
common O 0 2.554431688395198e-08
haplotype O 0 1.1903397307833075e-06
was O 0 4.7010166781547014e-07
shared O 0 9.391834865368764e-09
by O 0 4.4651307651299987e-10
the O 0 1.2303720264839058e-09
mutant O 0 1.2957387696133082e-07
alleles O 0 4.669524855671625e-08
in O 0 1.5071384140696864e-09
both O 0 9.059544225920035e-08
mutations O 0 7.181164619396441e-06
. O 0 9.202703665778245e-08

This O 0 1.362136572424788e-07
suggests O 0 1.148455908150936e-07
that O 0 1.0041313336373037e-09
these O 0 1.3091497885753256e-09
two O 0 5.7494635719024245e-09
founder O 0 3.400267019060266e-07
mutations O 0 2.6980692382494453e-06
may O 0 1.3845118829181047e-08
be O 0 1.3518716146521115e-09
predominant O 0 6.260442830807733e-08
among O 0 5.295158977958181e-09
Japanese O 0 2.297162353670501e-07
ATM O 0 5.888028681511059e-06
mutant O 0 1.0778244359244127e-05
alleles O 0 8.702415470906999e-06
. O 0 4.771359840560763e-07

W474C O 0 0.000835716724395752
amino O 0 1.5215543498925399e-05
acid O 0 1.1670204003166873e-06
substitution O 0 1.1212379291691832e-07
affects O 0 7.304250004835922e-08
early O 0 2.9070361673433354e-09
processing O 0 6.172358180123183e-09
of O 0 3.814321636319562e-10
the O 0 8.592493938586188e-10
alpha O 0 7.292998649433002e-09
- O 0 1.1652133480311022e-08
subunit O 0 1.4854890650894959e-08
of O 0 1.0220591040166482e-09
beta O 0 7.206688223959645e-08
- O 0 2.499836909919395e-06
hexosaminidase O 0 1.9108997548755724e-06
A O 0 5.22765510879708e-08
and O 0 1.4309916807064837e-08
is O 0 3.301236173314237e-09
associated O 0 3.0743290579948734e-08
with O 0 5.532034919042417e-08
subacute O 0 0.032623786479234695
G B-Disease 0 0.00013973131717648357
( I-Disease 0 1.5773674988395214e-07
M2 I-Disease 0 7.979778456501663e-05
) I-Disease 0 1.9985537846878287e-07
gangliosidosis I-Disease 0 1.148847059084801e-05
. O 0 2.3394468939841317e-07

Mutations O 0 0.00039853097405284643
in O 0 1.4729613440067624e-07
the O 0 2.8921824934968754e-08
HEXA O 0 3.4603352105477825e-05
gene O 0 6.039443860572646e-07
, O 0 2.26395013847025e-09
encoding O 0 9.754718810484064e-09
the O 0 2.6411373088564005e-09
alpha O 0 1.2505398494511155e-08
- O 0 1.83980031209785e-08
subunit O 0 2.6386613782847235e-08
of O 0 3.265540060581884e-09
beta O 0 2.9111862431818736e-07
- O 0 1.610993240319658e-05
hexosaminidase O 0 1.2106171197956428e-05
A O 0 1.664634510234464e-07
( O 0 7.543212277028033e-09
Hex O 0 1.1144238243332438e-07
A O 0 1.20481358223401e-08
) O 0 8.304116283497365e-10
, O 0 3.5172706414066113e-10
that O 0 6.516210349083451e-10
abolish O 0 2.7745454644900747e-07
Hex O 0 8.209630664168799e-07
A O 0 2.5558010818826915e-08
enzyme O 0 8.389638423977885e-07
activity O 0 1.9735593923542183e-06
cause O 0 0.001410957658663392
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.993029773235321
( O 0 3.796825254198666e-08
TSD B-Disease 0 9.334374226455111e-06
) O 0 1.2766208534742418e-08
, O 0 1.542549532551618e-09
the O 0 1.8164454829161514e-08
fatal O 0 0.00010483936785021797
infantile B-Disease 0 0.0004309960640966892
form I-Disease 0 2.2757147633001296e-07
of I-Disease 0 1.1974457869712296e-08
G I-Disease 0 1.0776259841804858e-05
( I-Disease 0 1.7861671253172062e-08
M2 I-Disease 0 2.884377317968756e-05
) I-Disease 0 1.8522646527685538e-08
gangliosidosis I-Disease 0 1.2613755870916066e-06
, I-Disease 0 7.232587861949469e-09
Type I-Disease 0 8.667633437653421e-07
1 I-Disease 0 1.638460958020005e-07
. O 0 1.5856626589538791e-07

Less O 0 5.378149580792524e-05
severe O 1 0.5350844264030457
, O 0 3.368982959273126e-07
subacute O 0 0.24044981598854065
( O 0 1.909291313495487e-06
juvenile O 0 0.0013011092087253928
- O 0 0.3718196451663971
onset O 1 0.9963923096656799
) O 0 1.0000535155541002e-07
and O 0 9.820047353059635e-07
chronic O 1 0.9990851879119873
( O 0 9.780618626109572e-08
adult O 0 0.0005831614253111184
- O 1 0.959838330745697
onset O 1 0.7992848753929138
) O 0 1.3466481263435526e-08
variants O 0 5.292224045660987e-07
are O 0 3.387210156802212e-08
characterized O 0 4.4146048594484455e-08
by O 0 8.02517163833727e-10
a O 0 2.016227851342478e-09
broad O 0 4.0606071394222454e-08
spectrum O 0 6.369580063392277e-08
of O 0 1.6523529211553978e-09
clinical O 0 2.2051001451472985e-06
manifestations O 0 7.713029503975122e-07
and O 0 2.2224504903078923e-08
are O 0 1.0237296343973412e-08
associated O 0 2.5422121296969635e-08
with O 0 6.837822752459033e-09
residual O 0 0.00010259116243105382
levels O 0 5.7375045798835345e-06
of O 0 1.9934449646541452e-09
Hex O 0 6.928879088263784e-07
A O 0 2.945212074223491e-08
enzyme O 0 3.3010181255122006e-07
activity O 0 1.4534799674947863e-07
. O 0 6.679019293187594e-08

We O 0 9.927535757014994e-06
identified O 0 8.925835572881624e-07
a O 0 6.663444196419732e-08
1422 O 0 5.9937688092759345e-06
G O 0 1.997641629714053e-05
- O 0 2.5367315174662508e-05
- O 0 3.8399746699724346e-05
> O 0 4.085193722858094e-06
C O 0 2.5410461603314616e-05
( O 0 5.1999197836494204e-08
amino O 0 3.432607798004028e-07
acid O 0 6.569127464217672e-08
W474C O 0 4.109859830236928e-08
) O 0 4.89036811046617e-10
substitution O 0 1.2581881092543767e-09
in O 0 7.564619486366553e-10
the O 0 1.4064320819073828e-09
first O 0 1.739281607626708e-08
position O 0 1.6627970467197883e-07
of O 0 9.675774625961253e-10
exon O 0 1.9503870873904816e-07
13 O 0 3.962301420301628e-08
of O 0 2.900887974277566e-09
HEXA O 0 2.203247458965052e-05
of O 0 5.81280001910045e-09
a O 0 7.368533516682874e-08
non O 0 6.4209357333311345e-06
- O 0 1.5140117284317967e-05
Jewish O 0 1.96437008526118e-06
proband O 0 1.1047936823160853e-05
who O 0 1.754288661004466e-07
manifested O 0 1.9806724083082372e-07
a O 0 1.6896100518692947e-08
subacute O 0 3.4443182812538e-05
variant O 0 7.5351154009695165e-06
of O 0 2.0973059733364607e-08
G B-Disease 0 2.404338010819629e-05
( I-Disease 0 1.4946583348773856e-07
M2 I-Disease 0 0.00011357912444509566
) I-Disease 0 1.503370015143446e-07
gangliosidosis I-Disease 0 1.6890280676307157e-05
. O 0 3.201385254669731e-07

On O 0 8.801602007224574e-07
the O 0 8.024261433092761e-08
second O 0 6.137464652056224e-07
maternally O 0 7.686237222515047e-05
inherited O 0 1.6787204003776424e-05
allele O 0 6.097054097153887e-07
, O 0 4.569346678806596e-09
we O 0 7.425133397021e-09
identified O 0 1.5314453705173037e-08
the O 0 3.17189896570369e-09
common O 0 3.0320336463773856e-06
infantile O 1 0.9999619722366333
disease O 1 0.9997883439064026
- O 0 0.0006142154452390969
causing O 0 4.10624998039566e-05
4 O 0 2.1707298003548203e-07
- O 0 1.0011563063017093e-05
bp O 0 3.5734788070840295e-06
insertion O 0 1.0113939197253785e-06
, O 0 3.768808909399013e-08
+ O 0 6.377803742907417e-07
TATC O 0 5.343513748812256e-06
1278 O 0 1.8321543393540196e-06
, O 0 1.3048826019712578e-08
in O 0 4.194123714995612e-09
exon O 0 1.2277632777113467e-06
11 O 0 9.401235843142786e-07
. O 0 1.8104138632679678e-07

Pulse O 0 0.004266045987606049
- O 0 0.00027034434606321156
chase O 0 5.526114819076611e-06
analysis O 0 9.417238544529027e-08
using O 0 3.4219587519146444e-07
proband O 0 1.474308555771131e-05
fibroblasts O 0 7.428513981722062e-07
revealed O 0 4.549855248114909e-07
that O 0 1.2162186813213793e-09
the O 0 3.960871630681595e-09
W474C O 0 3.561893322512333e-07
- O 0 5.0563038200834853e-08
containing O 0 1.1054513748831596e-08
alpha O 0 1.114457326423235e-08
- O 0 3.027352946105566e-08
subunit O 0 5.455542506638267e-08
precursor O 0 6.460452794954108e-08
was O 0 7.343503227730253e-08
normally O 0 1.4572406392687753e-08
synthesized O 0 3.557146754928908e-08
, O 0 1.1008386424649075e-09
but O 0 8.403188700434328e-10
not O 0 7.458968998008686e-10
phosphorylated O 0 6.520963324874174e-09
or O 0 1.2665750226403816e-08
secreted O 0 1.8104064025692423e-08
, O 0 8.03629274237494e-10
and O 0 1.1351420914351706e-09
the O 0 2.612205118879274e-09
mature O 0 1.7913498240318404e-08
lysosomal O 0 1.3553298572333006e-07
alpha O 0 1.4692021821360868e-08
- O 0 2.8512348038134405e-08
subunit O 0 6.631822202507465e-08
was O 0 1.002471279321071e-07
not O 0 4.143349841001509e-08
detected O 0 1.0539602044445928e-06
. O 0 5.169619399225667e-08

When O 0 2.7022563244827325e-06
the O 0 1.2129243032177328e-07
W474C O 0 2.0806035081477603e-06
- O 0 4.5156579631111526e-07
containing O 0 1.3824408995333215e-07
alpha O 0 1.2758424361436482e-07
- O 0 1.4432200146075047e-07
subunit O 0 3.105180326201662e-07
was O 0 2.1378606618327467e-07
transiently O 0 1.3382033330344711e-06
co O 0 8.601157333032461e-07
- O 0 1.9526166283867497e-07
expressed O 0 5.614456899394327e-09
with O 0 2.82509771132311e-09
the O 0 8.67324700948302e-09
beta O 0 3.0838723574788673e-08
- O 0 3.6361441857479804e-08
subunit O 0 6.164160026855825e-08
to O 0 1.957471162938873e-08
produce O 0 9.397106026654001e-08
Hex O 0 8.868900067682262e-07
A O 0 9.624943686503684e-08
( O 0 1.0915935710897884e-08
alphabeta O 0 4.752105269290041e-07
) O 0 4.106261108915987e-09
in O 0 3.810986193286681e-09
COS O 0 0.00012792022607754916
- O 0 3.525096417433815e-06
7 O 0 1.461844334471607e-07
cells O 0 3.9785607697240266e-08
, O 0 6.815553121874984e-10
the O 0 9.150989410677823e-10
mature O 0 7.4122001869625365e-09
alpha O 0 3.0208739953963004e-09
- O 0 9.927666688724912e-09
subunit O 0 2.963412981671354e-08
was O 0 4.7258929214422096e-08
present O 0 3.257614622498295e-09
, O 0 9.24206211561085e-10
but O 0 5.861438556742371e-10
its O 0 7.400414170355418e-10
level O 0 6.202158431278804e-08
was O 0 7.084627640097096e-08
much O 0 4.036520451222714e-09
lower O 0 2.6586722157162512e-08
than O 0 1.24920418453911e-09
that O 0 4.049025836838638e-10
from O 0 1.1359521101539372e-09
normal O 0 1.7197761437159897e-08
alpha O 0 1.7077081082561563e-08
- O 0 2.395262832521894e-08
subunit O 0 6.161808840943195e-08
transfections O 0 4.78598906283878e-07
, O 0 1.7090171500200313e-09
although O 0 2.1388908422181885e-09
higher O 0 6.655046735914993e-09
than O 0 1.2574947749754983e-09
in O 0 1.263394389106054e-09
those O 0 1.1546029909936806e-08
cells O 0 2.133566745499138e-08
transfected O 0 8.440334653414538e-08
with O 0 3.9146938468626047e-10
an O 0 1.0729285238042507e-09
alpha O 0 2.3097138424077457e-08
- O 0 1.0479391221451806e-07
subunit O 0 2.734495865297504e-07
associated O 0 3.242373622924788e-07
with O 0 1.9532612327566312e-07
infantile O 0 0.4177709221839905
TSD B-Disease 0 0.0014806052204221487
. O 0 1.9144220004818635e-06

Furthermore O 0 2.998433592438232e-05
, O 0 1.218741658703948e-07
the O 0 9.255897381876821e-09
precursor O 0 3.777358514867046e-08
level O 0 2.2609651040284007e-08
of O 0 8.901084314061336e-10
the O 0 2.0974690873032387e-09
W474C O 0 1.1189328574801038e-07
alpha O 0 9.063930939134934e-09
- O 0 1.689706508045674e-08
subunit O 0 2.452934921848282e-08
was O 0 1.563826401707047e-08
found O 0 3.5171250356569317e-09
to O 0 2.54317589210018e-09
accumulate O 0 1.5267256969764276e-07
in O 0 4.1825704011344556e-10
comparison O 0 5.6619353649978166e-09
to O 0 2.4088411265665854e-09
the O 0 6.976131228242366e-09
normal O 0 4.94916108095822e-08
alpha O 0 3.1826754565145166e-08
- O 0 9.500443809429271e-08
subunit O 0 2.056890195945016e-07
precursor O 0 3.3516971598146483e-07
levels O 0 6.24649999281246e-07
. O 0 5.2746585765817144e-08

We O 0 1.1749810255423654e-05
conclude O 0 7.811274258529011e-07
that O 0 4.661104391345816e-09
the O 0 6.2608709328060286e-09
1422 O 0 3.2095583719637943e-06
G O 0 7.358978564298013e-06
- O 0 2.1619818653562106e-05
- O 0 1.695207174634561e-05
> O 0 2.199509253841825e-06
C O 0 3.298745650681667e-05
mutation O 0 8.334581025337684e-07
is O 0 2.645074603790931e-09
the O 0 1.8853409944341593e-09
cause O 0 3.457846986520963e-08
of O 0 2.307387614308709e-09
Hex B-Disease 0 0.00010032100544776767
A I-Disease 0 0.0003225751279387623
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.188013953878908e-08
the O 0 7.671392410202316e-08
proband O 0 1.7538181054987945e-05
. O 0 1.6570996308473696e-07

The O 0 1.0609023775032256e-06
resulting O 0 8.638000963401282e-07
W474C O 0 2.908845999627374e-06
substitution O 0 3.182776140420174e-07
clearly O 0 3.332484084239695e-07
interferes O 0 1.3708745427720714e-07
with O 0 3.4794989112185704e-09
alpha O 0 2.4919620145169574e-08
- O 0 4.172630241328079e-08
subunit O 0 5.510110412387803e-08
processing O 0 7.826518100273461e-08
, O 0 4.748669013565632e-09
but O 0 1.914873815067608e-09
because O 0 8.391160544185539e-10
the O 0 8.282745600496355e-10
base O 0 1.767369006699937e-08
substitution O 0 1.0870640387850017e-08
falls O 0 1.3930472277934314e-06
at O 0 3.2305148778277726e-08
the O 0 1.2849210584420234e-09
first O 0 1.9160255604333543e-08
position O 0 1.294723404043907e-07
of O 0 3.069784981768464e-10
exon O 0 1.1403751898342307e-07
13 O 0 2.945037813617546e-08
, O 0 2.8986204547720718e-09
aberrant O 0 2.1719786502671923e-07
splicing O 0 1.5337144532168168e-06
may O 0 6.877102691760228e-07
also O 0 1.746245459344209e-08
contribute O 0 1.6528455049069635e-08
to O 0 1.3203899307256961e-08
Hex B-Disease 0 2.5728208129294217e-05
A I-Disease 0 6.601233508263249e-06
deficiency I-Disease 0 9.519253217149526e-05
in O 0 1.0160181584950578e-09
this O 0 1.7873761359865625e-09
proband O 0 1.107435195990547e-06
. O 0 8.374711590874995e-09
. O 0 3.049444430303083e-08

Two O 0 2.4665625915076816e-06
frequent O 0 5.9381683968240395e-05
missense O 0 0.04612469673156738
mutations O 0 0.18165771663188934
in O 0 1.0842171832337044e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.475638550298754e-06

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 9.302656508225482e-06
an O 0 2.5395223929081112e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.0016872396226972342
by O 0 5.301629713017064e-08
early O 0 1.24159005281399e-05
childhood O 1 0.9999923706054688
deafness B-Disease 1 1.0
and O 0 0.1250176727771759
goiter B-Disease 1 1.0
. O 0 5.324610356183257e-06

A O 0 1.1441848982940428e-05
century O 0 9.680006769485772e-07
after O 0 1.9569634801541724e-08
its O 0 1.5158274635496127e-09
recognition O 0 8.026661113547107e-09
as O 0 1.5143717391197242e-08
a O 0 9.222372341355367e-07
syndrome O 1 0.9903765320777893
by O 0 2.102511942325691e-09
Vaughan O 0 5.030850047660351e-07
Pendred O 0 5.772893700850545e-07
, O 0 1.9991488464654594e-09
the O 0 2.0218857699205728e-08
disease O 0 7.769693183945492e-06
gene O 0 2.1360916946377984e-07
( O 0 1.5868240055283422e-08
PDS O 0 6.263779596338281e-06
) O 0 1.2772736646127214e-08
was O 0 2.8282800101919747e-08
mapped O 0 6.363769102790684e-07
to O 0 1.1785543563291867e-07
chromosome O 0 0.00021411037596408278
7q22 O 0 5.462031185743399e-05
- O 0 7.033343717921525e-05
q31 O 0 4.302508386899717e-05
. O 0 8.989246111923421e-07

1 O 0 5.6440403568558395e-06
and O 0 6.827366405559587e-07
, O 0 1.977872443603701e-08
recently O 0 1.1811975753062143e-07
, O 0 1.984492126183568e-09
found O 0 2.7927273826833243e-09
to O 0 2.199105786360178e-09
encode O 0 4.696661051184492e-07
a O 0 1.432367184861505e-07
putative O 0 2.5343377274111845e-05
sulfate O 0 1.4767119864700362e-05
transporter O 0 4.2233721615048125e-05
. O 0 4.4060877257834363e-07

We O 0 3.0773691833019257e-05
performed O 0 2.3246734599524643e-06
mutation O 0 6.120671400822175e-07
analysis O 0 1.819601180841346e-08
of O 0 1.934679749737711e-09
the O 0 1.5450119406068552e-08
PDS B-Disease 0 3.166464375681244e-05
gene O 0 1.0468658047102508e-06
in O 0 1.0727857713277444e-08
patients O 0 2.914077867899323e-07
from O 0 4.707609413401315e-09
14 O 0 2.917024310988836e-08
Pendred B-Disease 0 7.973789593052061e-07
families O 0 2.046308544834119e-08
originating O 0 2.1327812405047553e-08
from O 0 4.622221272398974e-09
seven O 0 9.772670672703043e-09
countries O 0 3.941247328498321e-09
and O 0 1.720136921790072e-08
identified O 0 2.654811623870046e-07
all O 0 7.037433302770069e-09
mutations O 0 1.2215616607136326e-06
. O 0 1.0115986981418246e-07

The O 0 8.334620247296698e-07
mutations O 0 8.756126590014901e-06
include O 0 5.552500326189147e-08
three O 0 1.0470959921349277e-07
single O 0 2.947819439214072e-06
base O 0 3.391335212654667e-07
deletions O 0 1.2708952681350638e-06
, O 0 1.3324068959263968e-08
one O 0 1.4012623061887552e-08
splice O 0 0.00011670358799165115
site O 0 1.3936625009591808e-06
mutation O 0 5.784759650850901e-06
and O 0 5.623998688975007e-08
10 O 0 9.724757177309584e-08
missense O 0 4.6450157242361456e-05
mutations O 0 3.164861482218839e-05
. O 0 6.122925810814195e-07

One O 0 5.909562787564937e-06
missense O 0 8.737092866795138e-05
mutation O 0 1.4062969967199024e-05
( O 0 5.030504368619404e-08
L236P O 0 5.077832270217186e-07
) O 0 1.3897132333795525e-08
was O 0 2.1733316657446267e-07
found O 0 1.6321004991937116e-08
in O 0 5.10566477984753e-10
a O 0 8.015843988573579e-09
homozygous O 0 6.034565558366012e-06
state O 0 2.407343879795576e-09
in O 0 7.704760163207425e-10
two O 0 1.9859470512528787e-08
consanguineous O 0 9.74274444160983e-05
families O 0 5.342701570043573e-07
and O 0 1.3025053036130885e-08
in O 0 1.2431099483123376e-09
a O 0 8.344034796436972e-09
heterozygous O 0 6.002687769068871e-07
state O 0 1.8562601455940353e-09
in O 0 5.638750577574569e-10
five O 0 3.782829161025347e-09
additional O 0 2.363837658947432e-08
non O 0 5.983044047752628e-06
- O 0 5.8571436966303736e-05
consanguineous O 0 0.0021418535616248846
families O 0 9.277408139496401e-07
. O 0 1.241142371100068e-07

Another O 0 1.6503197912243195e-05
missense O 0 0.00044899710337631404
mutation O 0 4.5683631469728425e-05
( O 0 1.1176636860454892e-07
T416P O 0 1.3267411986817024e-06
) O 0 1.2109232727652852e-08
was O 0 2.0646533016588364e-07
found O 0 1.5254865814995355e-08
in O 0 9.221530761216457e-10
a O 0 8.645334226287105e-09
homozygous O 0 3.1762826893100282e-06
state O 0 7.962324688470801e-10
in O 0 5.072497422098365e-10
one O 0 1.1731097870892881e-08
family O 0 2.029659995628208e-08
and O 0 7.724716866164272e-09
in O 0 9.208699913720864e-10
a O 0 3.792994363038815e-09
heterozygous O 0 2.8470617507991847e-07
state O 0 1.7470576096911827e-09
in O 0 1.1086942475202477e-09
four O 0 5.5104678153838904e-08
families O 0 4.3792226733785355e-08
. O 0 3.509273227564336e-08

Pendred B-Disease 0 0.09332111477851868
patients O 1 0.9842363595962524
in O 0 1.1413304434881866e-07
three O 0 1.4412709958833148e-07
non O 0 1.016230908135185e-05
- O 0 2.5304496375611052e-05
consanguineous O 0 0.00033899396657943726
families O 0 4.3867760268767597e-07
were O 0 8.970818043962936e-08
shown O 0 1.0015496876292218e-08
to O 0 3.664360148647461e-09
be O 0 1.1843305891545697e-08
compound O 0 3.8988112294191524e-08
heterozygotes O 0 3.032161259852728e-07
for O 0 3.6799163716239036e-09
L236P O 0 6.937930834283179e-07
and O 0 6.961207787981039e-08
T416P O 0 5.793112450191984e-06
. O 0 1.3917311036948377e-07

In O 0 6.467591333603195e-07
total O 0 4.8476717751100296e-08
, O 0 2.7516964262730426e-09
one O 0 2.0699391090062136e-09
or O 0 1.3885157024162709e-08
both O 0 2.0705472891791032e-09
of O 0 3.058225062080311e-10
these O 0 6.996986545715345e-09
mutations O 0 4.402086688060081e-06
were O 0 7.832631467863393e-07
found O 0 1.8496381315458166e-08
in O 0 1.6636363397992682e-09
nine O 0 3.111826174517773e-08
of O 0 3.184105201725629e-10
the O 0 1.5636473449376354e-08
14 O 0 2.0243291487531678e-07
families O 0 4.246706808430645e-08
analyzed O 0 5.344184614841652e-07
. O 0 8.411598884094929e-08

The O 0 1.6903680943869404e-07
identification O 0 2.1787418802432512e-07
of O 0 5.86869086660613e-09
two O 0 2.9524903411015657e-08
frequent O 0 1.300402800552547e-05
PDS B-Disease 0 0.2624271810054779
mutations O 0 1.9808943761745468e-05
will O 0 2.1300645691724185e-09
facilitate O 0 1.302266827707399e-08
the O 0 2.013630862052196e-08
molecular O 0 8.198066643672064e-05
diagnosis O 1 0.9988677501678467
of O 0 1.2362625056994148e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.144381824109587e-06

Insertional O 0 0.0009970265673473477
mutation O 0 2.9090791940689087e-05
by O 0 3.469897436048086e-08
transposable O 0 2.6974107640853617e-06
element O 0 4.2308931824663887e-07
, O 0 2.0116768695288556e-08
L1 O 0 3.405848110560328e-05
, O 0 2.0675411604997862e-08
in O 0 5.351408649545419e-09
the O 0 5.562422344951301e-08
DMD B-Disease 1 1.0
gene O 0 2.4510216462658718e-05
results O 0 9.248785772797419e-07
in O 0 6.7120190294645e-08
X B-Disease 1 0.9999961853027344
- I-Disease 1 0.9999983310699463
linked I-Disease 1 0.999997615814209
dilated I-Disease 1 0.9999980926513672
cardiomyopathy I-Disease 1 1.0
. O 0 1.9812496248050593e-06

X B-Disease 1 0.999994158744812
- I-Disease 1 0.9999980926513672
linked I-Disease 1 0.9999974966049194
dilated I-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
( O 0 1.0256340829073451e-05
XLDCM B-Disease 0 0.0010862883646041155
) O 0 1.1906317709531322e-08
is O 0 1.822573314491649e-09
a O 0 9.087750996172872e-09
clinical O 0 1.460538351238938e-05
phenotype O 0 2.285106347699184e-06
of O 0 2.8245694672079935e-09
dystrophinopathy B-Disease 0 7.185823051258922e-06
which O 0 7.013126968047345e-09
is O 0 2.036161461660413e-09
characterized O 0 1.4992716401707185e-08
by O 0 3.4573111040714366e-09
preferential O 0 5.3964282415108755e-05
myocardial B-Disease 0 0.42088863253593445
involvement I-Disease 0 3.965035091368918e-07
without O 0 1.8084804764839646e-08
any O 0 4.956725696558806e-09
overt O 0 7.127332537493203e-06
clinical O 0 0.0005664101336151361
signs O 0 2.7268466510577127e-05
of O 0 3.421273220283183e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 1.188554506370565e-05

To O 0 6.00769908487564e-07
date O 0 3.0103441872597614e-07
, O 0 2.0933086375407584e-09
several O 0 1.7728376544567936e-09
mutations O 0 6.483450079031172e-07
in O 0 2.277106725401268e-09
the O 0 7.698832860114635e-08
Duchenne B-Disease 1 0.9994394183158875
muscular I-Disease 1 0.914644718170166
dystrophy I-Disease 1 0.9883266091346741
gene O 0 0.00023805935052223504
, O 0 1.2095837575998303e-07
DMD O 1 1.0
, O 0 9.775563825087374e-08
have O 0 5.962714766383215e-08
been O 0 3.865107345291108e-08
identified O 0 6.024319532116351e-08
in O 0 2.7611390951420844e-09
patients O 0 7.641236265953921e-08
with O 0 4.187330038263326e-09
XLDCM B-Disease 0 0.0002942226710729301
, O 0 1.0142219508679773e-08
but O 0 7.841003957231862e-10
a O 0 9.89469284284894e-10
pathogenic O 0 5.891629584198199e-08
correlation O 0 3.6066502673293144e-08
of O 0 7.993854467258643e-10
these O 0 1.2507068269940191e-08
cardiospecific O 0 3.0555860575987026e-05
mutations O 0 2.3169770429376513e-05
in O 0 2.8202105539776312e-08
DMD O 1 1.0
with O 0 6.668301466561388e-08
the O 0 5.741707553852393e-08
XLDCM B-Disease 0 0.0004019756452180445
phenotype O 0 1.1989689483016264e-05
has O 0 6.885989023430739e-08
remained O 0 5.172400960873347e-07
to O 0 1.490677448146016e-08
be O 0 4.813232834521841e-08
elucidated O 0 3.2853256470843917e-06
. O 0 6.077443259755455e-08

We O 0 3.770031617023051e-05
report O 0 2.1466128430347453e-07
here O 0 6.038295197186017e-09
the O 0 1.4521734925665442e-09
identification O 0 1.611985034344343e-08
of O 0 1.2988479181075263e-09
a O 0 3.66845291921436e-08
unique O 0 2.3683422512021934e-07
de O 0 5.02280963701196e-05
novo O 0 1.8920407001132844e-06
L1 O 0 4.1290577428299e-06
insertion O 0 6.058000394659757e-07
in O 0 1.0091719460092463e-08
the O 0 1.1093314711274616e-08
muscle O 0 5.088948000775417e-07
exon O 0 4.588449371567549e-07
1 O 0 5.5543647903277815e-08
in O 0 3.015682636942074e-08
DMD O 1 1.0
in O 0 1.2755747036408138e-07
three O 0 4.402370734624128e-07
XLDCM B-Disease 0 0.027606574818491936
patients O 0 1.2523476016212953e-06
from O 0 2.5252528956798415e-09
two O 0 6.255833628898699e-09
unrelated O 0 9.779574128288004e-08
Japanese O 0 4.96259360716067e-07
families O 0 1.5880812043178594e-07
. O 0 4.1229952785215573e-08

The O 0 7.711161060797167e-07
insertion O 0 4.226576038490748e-06
was O 0 6.165395802781859e-07
a O 0 5.040204342776633e-08
5 O 0 2.7594452944867953e-08
- O 0 4.499469241636689e-07
truncated O 0 1.8191677497725323e-07
form O 0 7.649796174291623e-08
of O 0 4.3824628370714436e-09
human O 0 3.0804745421164625e-08
L1 O 0 4.630006969819078e-06
inversely O 0 4.1297766983916517e-07
integrated O 0 1.613006475054135e-06
in O 0 1.0870516042871259e-08
the O 0 7.241573563021575e-09
5 O 0 4.422130217562881e-08
- O 0 2.552435717007029e-06
untranslated O 0 1.3969418432679959e-05
region O 0 1.7756312331584923e-07
in O 0 5.889267296055323e-09
the O 0 1.4986085261625703e-08
muscle O 0 3.913477826245071e-07
exon O 0 1.3760353567704442e-07
1 O 0 1.0873170808167743e-08
, O 0 2.0241845977153616e-09
which O 0 1.6827010895781314e-09
affected O 0 1.0912104109195297e-08
the O 0 1.018929163265625e-09
transcription O 0 1.3627382600134297e-07
or O 0 6.480247805029649e-08
the O 0 5.961211524407872e-09
stability O 0 1.4016890759194212e-07
of O 0 3.025364125885943e-10
the O 0 4.774862283341008e-09
muscle O 0 4.900410317532078e-07
form O 0 1.9949750296177626e-08
of O 0 1.3133865106595977e-09
dystrophin O 0 7.711050784564577e-07
transcripts O 0 5.74903822325723e-07
but O 0 2.6758829818618324e-08
not O 0 2.5639437239988183e-09
that O 0 2.1700378993738667e-10
of O 0 2.509478735923665e-10
the O 0 1.4102686130001985e-08
brain O 0 5.4994849051581696e-05
or O 0 4.540202382941061e-07
Purkinje O 0 5.731045803258894e-06
cell O 0 9.53490143729141e-06
form O 0 6.35604806120682e-07
, O 0 2.674847010553094e-08
probably O 0 2.217188210806853e-07
due O 0 7.866923112942459e-09
to O 0 3.61892760203375e-09
its O 0 5.389914292663889e-09
unique O 0 6.42329434086264e-09
site O 0 3.528387892970386e-08
of O 0 1.9275856466549612e-09
integration O 0 4.587303124026221e-07
. O 0 1.7059541335129325e-07

We O 0 2.7758790110965492e-06
speculate O 0 2.2063758819967916e-07
that O 0 1.424797613225337e-09
this O 0 1.9890307456638112e-10
insertion O 0 2.2634244700725503e-08
of O 0 1.2698397888755153e-09
an O 0 5.335427655239755e-09
L1 O 0 0.002820929978042841
sequence O 0 2.543401478760643e-06
in O 0 1.3114025421145925e-07
DMD O 1 1.0
is O 0 1.2736565224713559e-07
responsible O 0 1.0444590969882483e-07
for O 0 1.7850926292695135e-10
some O 0 1.1702236402122423e-10
of O 0 5.3752176321086864e-11
the O 0 2.800273624092853e-10
population O 0 4.866770320077762e-10
of O 0 2.2995572113160279e-10
Japanese O 0 5.357140935302596e-07
patients O 0 8.046238519909821e-08
with O 0 1.186397025065844e-08
XLDCM B-Disease 0 3.49639194610063e-05
. O 0 2.718063285556127e-08
. O 0 7.305601457119337e-08

Severe O 1 0.9947211742401123
early O 0 0.0002700552577152848
- O 1 0.9995501637458801
onset O 1 0.9999995231628418
obesity B-Disease 1 1.0
, O 0 0.007826720364391804
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 6.317351108009461e-06
red O 0 1.832292582548689e-05
hair O 1 0.998511016368866
pigmentation O 1 0.713880717754364
caused O 0 3.666141992653138e-06
by O 0 4.607418446767042e-08
POMC O 0 0.00017281013424508274
mutations O 0 1.4619067769672256e-05
in O 0 3.082096711182203e-08
humans O 0 7.156880883485428e-07
. O 0 1.015342974142186e-07

Sequential O 0 2.3712475012871437e-05
cleavage O 0 2.812571983668022e-05
of O 0 5.084000065380678e-08
the O 0 2.652396702274018e-08
precursor O 0 1.8380750077540142e-07
protein O 0 3.005003463840694e-07
pre O 0 0.0002388569264439866
- O 0 0.0004110443696845323
pro O 0 0.00017206449410878122
- O 0 0.00029355555307120085
opiomelanocortin O 0 5.6124452385120094e-05
( O 0 2.9664214196145622e-08
POMC O 0 3.3058865938073723e-06
) O 0 4.4750056993336784e-09
generates O 0 2.894180184398465e-08
the O 0 1.2465913634684966e-08
melanocortin O 0 1.436601178284036e-05
peptides O 0 1.599506617822044e-06
adrenocorticotrophin O 0 5.124175459059188e-06
( O 0 8.046131938499457e-08
ACTH O 0 2.0112287529627793e-05
) O 0 9.102809173100468e-09
, O 0 5.985775874961519e-09
melanocyte O 0 8.207694918382913e-06
- O 0 2.6829109629034065e-05
stimulating O 0 4.45691475761123e-05
hormones O 0 2.65454436885193e-05
( O 0 1.2497672230438184e-08
MSH O 0 1.544925680718734e-06
) O 0 2.5680158000085385e-09
alpha O 0 5.469062980267836e-09
, O 0 3.796814251888492e-10
beta O 0 1.4958546623589086e-09
and O 0 1.0892448054633519e-09
gamma O 0 6.682100650579059e-09
as O 0 3.5264549058666717e-09
well O 0 3.1666942401642473e-09
as O 0 1.135592508916261e-09
the O 0 1.8778116839257564e-09
opioid O 0 8.875849744072184e-08
- O 0 2.4782357854746806e-07
receptor O 0 5.046288720222947e-07
ligand O 0 6.790036195525317e-07
beta O 0 1.9130368400510633e-06
- O 0 2.196911555074621e-05
endorphin O 0 0.0003537301963660866
. O 0 1.667810920480406e-06

While O 0 1.4184447536536027e-06
a O 0 2.50585099337286e-08
few O 0 4.292454836019033e-09
cases O 0 3.3368900975716542e-09
of O 0 6.774576011281397e-09
isolated O 1 0.8092122077941895
ACTH B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9778042435646057
have O 0 1.5842358891404729e-07
been O 0 2.532316329961759e-07
reported O 0 4.0551205415795266e-07
( O 0 4.081868709704395e-08
OMIM O 0 5.5372471251757815e-05
201400 O 0 9.179892686006497e-07
) O 0 8.890450153842266e-09
, O 0 1.6268100200278468e-09
an O 0 9.416030621878235e-09
inherited O 0 0.1580355316400528
POMC O 0 0.030333103612065315
defect O 0 0.0006615170277655125
has O 0 4.12068388300213e-08
not O 0 2.0880339235418433e-08
been O 0 1.7241180927385358e-08
described O 0 3.692757033491034e-08
so O 0 1.5919288998134107e-08
far O 0 9.35475910068817e-08
. O 0 1.1662388033073512e-07

Recent O 0 2.858446805475978e-06
studies O 0 4.877871333519579e-07
in O 0 1.6789957868468264e-08
animal O 0 3.585066465916498e-08
models O 0 1.1415274059345393e-07
elucidated O 0 3.645964170573279e-07
a O 0 7.1263124290510405e-09
central O 0 6.543015462767698e-09
role O 0 1.0865541355542518e-08
of O 0 6.802760577073741e-10
alpha O 0 4.038578538256843e-08
- O 0 8.141750527101976e-07
MSH O 0 2.2004785478202393e-06
in O 0 7.622713016353089e-10
the O 0 1.1857449466745607e-09
regulation O 0 1.1750199035986952e-08
of O 0 3.7979150380174076e-10
food O 0 5.840093297848625e-09
intake O 0 1.1324437387827402e-08
by O 0 6.651882933361719e-10
activation O 0 1.111222580618687e-08
of O 0 1.2207831412425207e-09
the O 0 2.8833587961685225e-08
brain O 0 5.897317805647617e-06
melanocortin O 0 7.590824225189863e-06
- O 0 1.32609613956447e-06
4 O 0 1.1047773540440176e-07
- O 0 5.100784505884803e-07
receptor O 0 8.231958759097324e-07
( O 0 4.162090405657182e-08
MC4 O 0 1.1755895684473217e-05
- O 0 6.469240815931698e-06
R O 0 1.557689938636031e-05
; O 0 1.8439878957110523e-08
refs O 0 1.6811928844617796e-06
3 O 0 8.119886274471355e-08
- O 0 5.178482069823076e-07
5 O 0 9.551059498846826e-09
) O 0 1.392689852330875e-09
and O 0 9.070221795859368e-10
the O 0 1.0099282521380815e-09
linkage O 0 2.2033290747458523e-07
of O 0 3.874626841593454e-09
human O 0 2.3655995562421595e-07
obesity B-Disease 1 0.9999998807907104
to O 0 1.3391822051289637e-07
chromosome O 0 0.00011055506183765829
2 O 0 5.991100948676831e-08
in O 0 4.227075578455697e-09
close O 0 3.9503078141933656e-07
proximity O 0 2.925673072695645e-07
to O 0 2.5570980000111376e-08
the O 0 3.702065853872227e-08
POMC O 0 1.4697758160764351e-05
locus O 0 9.223084589393693e-07
, O 0 7.264191914657658e-09
led O 0 6.332908419892647e-09
to O 0 1.9865067368840528e-09
the O 0 1.344640288003518e-09
proposal O 0 1.9648691562679232e-09
of O 0 3.117222868720404e-10
an O 0 1.3759421380044046e-09
association O 0 5.8584350703938526e-09
of O 0 1.4296813732883606e-09
POMC O 0 3.760613253689371e-05
with O 0 6.840694766196975e-08
human O 0 2.1869593638257356e-06
obesity B-Disease 1 0.9999998807907104
. O 0 7.76723879880592e-07

The O 0 5.075740432403109e-07
dual O 0 1.7627068018555292e-06
role O 0 1.3909402696299367e-07
of O 0 3.776189583248879e-09
alpha O 0 1.1245170128404425e-07
- O 0 5.9310173128324095e-06
MSH O 0 1.233571492775809e-05
in O 0 3.3950413591554707e-09
regulating O 0 8.559624120607623e-08
food O 0 3.230564260547908e-08
intake O 0 9.081759344553575e-08
and O 0 1.3074036964155766e-08
influencing O 0 1.110010884985968e-06
hair O 0 0.2620294690132141
pigmentation O 0 3.5797438613371924e-05
predicts O 0 2.7334999685990624e-07
that O 0 2.0403057021667337e-09
the O 0 4.846097745314637e-09
phenotype O 0 5.266694643069059e-06
associated O 0 8.4898054808491e-08
with O 0 8.724182265495983e-09
a O 0 3.0459426625384367e-07
defect O 0 0.0001571340544614941
in O 0 1.0783987924867233e-08
POMC O 0 2.1603207642328925e-05
function O 0 1.4236715628612728e-07
would O 0 2.5796520475296347e-08
include O 0 2.1219157986251957e-07
obesity B-Disease 1 1.0
, O 0 4.1445513687676794e-08
alteration O 0 4.972935698788206e-07
in O 0 4.977229295377583e-08
pigmentation O 0 0.43544724583625793
and O 0 0.0010763811878859997
ACTH B-Disease 1 0.9999971389770508
deficiency I-Disease 0 0.20330548286437988
. O 0 3.317817913739418e-07

The O 0 8.251608960563317e-07
observation O 0 2.0498769117693882e-06
of O 0 1.0575688769165481e-08
these O 0 1.1119523435354495e-07
symptoms O 0 0.00033396005164831877
in O 0 3.89371157538676e-09
two O 0 1.143962791161357e-08
probands O 0 1.9556894130801084e-06
prompted O 0 2.3467666920851116e-08
us O 0 7.839303428625044e-09
to O 0 2.196573811730218e-09
search O 0 5.439894223968622e-08
for O 0 6.721650347429886e-09
mutations O 0 3.5813870908896206e-06
within O 0 3.0609594858788114e-08
their O 0 1.9220289004806546e-07
POMC O 0 9.497419523540884e-05
genes O 0 4.024018380732741e-06
. O 0 2.977788255975611e-07

Patient O 1 0.9959064722061157
1 O 0 1.5425964647874935e-06
was O 0 4.3497951196513895e-07
found O 0 9.526098132539573e-09
to O 0 4.0558680858282514e-09
be O 0 1.437225449762991e-08
a O 0 4.750535076425422e-09
compound O 0 1.2797370629868965e-07
heterozygote O 0 2.39259236423095e-07
for O 0 1.0806714412225915e-09
two O 0 6.064819313422731e-09
mutations O 0 2.3258590431396442e-07
in O 0 1.6627164090010638e-09
exon O 0 2.127528517803512e-07
3 O 0 4.5795225389611005e-08
( O 0 9.434889314263728e-09
G7013T O 0 3.1929943133945926e-07
, O 0 4.879254777989672e-09
C7133delta O 0 2.7302797889205976e-07
) O 0 1.2516034875176274e-09
which O 0 1.131035820556292e-09
interfere O 0 1.9721579036513504e-08
with O 0 2.7697577564822495e-09
appropriate O 0 2.7728567886242672e-08
synthesis O 0 3.8770092913864573e-08
of O 0 1.1908678487770885e-08
ACTH O 0 4.2684736399678513e-05
and O 0 1.0942079597953125e-07
alpha O 0 4.3692483586710296e-07
- O 0 1.2355105354799889e-05
MSH O 0 0.0001605384750291705
. O 0 4.7233783107003546e-07

Patient O 1 0.9767668843269348
2 O 0 6.123811544966884e-06
was O 0 1.149059926319751e-06
homozygous O 0 2.6465174869372277e-06
for O 0 2.0666806044289388e-09
a O 0 5.558473681332998e-09
mutation O 0 5.521440584743686e-07
in O 0 3.3907832097668233e-09
exon O 0 4.4340055183056393e-07
2 O 0 6.092415105740656e-08
( O 0 2.1863009180833615e-08
C3804A O 0 9.737747177496203e-07
) O 0 6.803192231785715e-09
which O 0 1.5918317330942955e-08
abolishes O 0 1.3207322808739264e-05
POMC O 0 8.407232962781563e-05
translation O 0 4.514281499723438e-06
. O 0 4.594299412019609e-07

These O 0 4.790537104781833e-07
findings O 0 1.7920986294939212e-07
represent O 0 4.0481108243284325e-08
the O 0 2.003699206554188e-09
first O 0 3.796743808237579e-09
examples O 0 4.058654301530851e-09
of O 0 1.726064957630058e-09
a O 0 3.968885721405968e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 5.2325233923511405e-08
the O 0 1.533549998100625e-08
POMC O 0 1.0482191100891214e-05
gene O 0 2.429792687053123e-07
and O 0 9.896546693255459e-09
define O 0 2.2384448072898522e-07
a O 0 2.834620183023162e-08
new O 0 1.631947270652745e-07
monogenic B-Disease 1 0.9952124357223511
endocrine I-Disease 1 0.9993317723274231
disorder I-Disease 0 0.10518387705087662
resulting O 0 5.777101819148811e-08
in O 0 3.5996454705866654e-09
early O 0 1.037165020534303e-06
- O 1 0.999848484992981
onset O 1 0.9999997615814209
obesity B-Disease 1 1.0
, O 0 0.010323893278837204
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 3.17244393954752e-06
red O 0 1.2080868145858403e-05
hair O 1 0.844459056854248
pigmentation O 0 0.00039164768531918526
. O 0 4.37691767274373e-08
. O 0 1.377356113607675e-07

A O 0 5.809494268760318e-06
European O 0 1.2357288596831495e-06
multicenter O 0 5.281062112771906e-05
study O 0 8.142185379256262e-07
of O 0 4.129416083742399e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.7771823124235198e-08
classification O 0 1.148159114450209e-07
of O 0 1.203379840220009e-09
105 O 0 6.536406260693184e-08
mutations O 0 4.575734237732831e-06
and O 0 4.644544748799717e-09
a O 0 3.530762793246822e-09
general O 0 4.059118818844354e-09
system O 0 2.2633468432786685e-08
for O 0 2.321903558311078e-09
genotype O 0 9.41166581469588e-06
- O 0 3.2972941426123725e-06
based O 0 2.9939215551166853e-08
prediction O 0 3.2857724363566376e-07
of O 0 1.1092362584008697e-08
metabolic O 0 0.008275067433714867
phenotype O 0 0.00010804461635416374
. O 0 9.819308388614445e-07

Phenylketonuria B-Disease 1 0.999265730381012
( O 0 6.268449214985594e-05
PKU B-Disease 0 0.0007568792207166553
) O 0 4.0938689949143736e-07
and O 0 6.366336720020627e-07
mild B-Disease 1 0.9997114539146423
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.010567985475063324
MHP B-Disease 1 1.0
) O 0 6.473502622839078e-08
are O 0 2.8623068359934223e-08
allelic B-Disease 0 0.0006346472073346376
disorders I-Disease 1 0.9999701976776123
caused O 0 6.428009555747849e-07
by O 0 2.5385040736125575e-09
mutations O 0 1.6303788470395375e-06
in O 0 1.1980505476572034e-09
the O 0 1.522434445178078e-08
gene O 0 2.5645913410698995e-06
encoding O 0 1.471729683544254e-05
phenylalanine O 1 0.5114595890045166
hydroxylase O 0 0.2340262532234192
( O 0 3.559625156412949e-06
PAH O 0 0.00015167551464401186
) O 0 1.728168399495189e-07
. O 0 9.99828486669685e-08

Previous O 0 1.1465421266620979e-05
studies O 0 4.751339588437986e-07
have O 0 7.250393707636249e-08
suggested O 0 3.375697588126059e-08
that O 0 4.985167278981351e-10
the O 0 9.04194552564519e-10
highly O 0 5.521304302646968e-08
variable O 0 7.709904821240343e-06
metabolic O 0 0.4671480357646942
phenotypes O 0 0.0015847710892558098
of O 0 5.927127517679764e-07
PAH B-Disease 1 0.9999924898147583
deficiency I-Disease 1 0.8880748748779297
correlate O 0 5.353051528800279e-05
with O 0 2.944068910437636e-06
PAH O 0 0.45156198740005493
genotypes O 0 0.0005816410994157195
. O 0 1.1838991440527025e-06

We O 0 7.358459242823301e-06
identified O 0 1.022074116008298e-06
both O 0 5.031214200812428e-08
causative O 0 2.207474972237833e-05
mutations O 0 6.944073902559467e-06
in O 0 1.6931391400021312e-08
686 O 0 2.5039194042619783e-06
patients O 0 1.2894257451989688e-05
from O 0 1.6509739353409714e-08
seven O 0 4.90331828473245e-08
European O 0 4.856445343648375e-07
centers O 0 6.445179110414756e-07
. O 0 1.5456227231425146e-07

On O 0 4.351114739620243e-07
the O 0 1.2277892480483388e-08
basis O 0 5.873920461141324e-09
of O 0 2.6097038419159446e-10
the O 0 1.6451262574435077e-09
phenotypic O 0 6.85102293118689e-07
characteristics O 0 6.411082154045289e-07
of O 0 4.882839022002372e-09
297 O 0 6.023056471349264e-07
functionally O 0 1.1455135791038629e-05
hemizygous O 0 2.2369014914147556e-05
patients O 0 3.991820449300576e-06
, O 0 1.4053808117253652e-09
105 O 0 2.6196642632925204e-09
of O 0 4.669893916009471e-10
the O 0 9.2232594894881e-09
mutations O 0 3.826910869975109e-06
were O 0 7.74623174493172e-08
assigned O 0 6.31351753099807e-08
to O 0 1.928777138004989e-09
one O 0 5.717182283149214e-09
of O 0 7.419862502189289e-10
four O 0 2.2379937902883285e-08
arbitrary O 0 9.506477454124251e-07
phenotype O 0 2.2259317120187916e-05
categories O 0 8.402045750699472e-06
. O 0 2.3833507611925597e-07

We O 0 6.587517418665811e-06
proposed O 0 2.2879795835706318e-07
and O 0 2.0325273908383679e-07
tested O 0 2.441556034682435e-06
a O 0 9.658078781171753e-09
simple O 0 3.423590300144497e-08
model O 0 1.2260112214335095e-07
for O 0 1.6243204559174274e-09
correlation O 0 3.249332110044634e-07
between O 0 4.351454663265031e-08
genotype O 0 1.4852411368337926e-05
and O 0 8.871042211922031e-08
phenotypic O 0 1.3535021025745664e-05
outcome O 0 2.039615992543986e-06
. O 0 3.081409545302449e-07

The O 0 1.6203468931053067e-06
observed O 0 2.699518290683045e-06
phenotype O 0 7.0472674451593775e-06
matched O 0 1.1332602980473894e-06
the O 0 1.7805717789087794e-08
predicted O 0 4.059907041664701e-07
phenotype O 0 1.3279310451252968e-06
in O 0 3.258820102658433e-09
79 O 0 7.935950918636081e-08
% O 0 5.2337081335451785e-09
of O 0 3.3202990357139583e-10
the O 0 1.4897678646264012e-08
cases O 0 2.758098283095478e-08
, O 0 7.242705990506693e-09
and O 0 2.7297426541394998e-08
in O 0 3.189672970194124e-10
only O 0 1.573777774765972e-09
5 O 0 6.851422207354574e-10
of O 0 1.225958085049328e-10
184 O 0 2.0691190982802254e-08
patients O 0 2.6060016011797416e-07
was O 0 1.6785152823217686e-08
the O 0 1.8816945779320804e-09
observed O 0 4.270945908046997e-08
phenotype O 0 4.8143157016511395e-08
more O 0 6.693450238515197e-10
than O 0 2.2547281819385034e-09
one O 0 8.786102512203797e-09
category O 0 5.915354108765314e-07
away O 0 2.461967767430906e-07
from O 0 4.166599953947525e-09
that O 0 4.232182160279763e-09
expected O 0 7.156418035947354e-08
. O 0 4.8714184686105e-08

Among O 0 1.9524356957845157e-06
the O 0 5.15025107006295e-08
seven O 0 3.1533094357882874e-08
contributing O 0 6.439452704398718e-08
centers O 0 1.1553696666055657e-08
, O 0 6.856704093394228e-10
the O 0 6.653431139369559e-10
proportion O 0 1.646040637126589e-08
of O 0 9.161538749857812e-10
patients O 0 5.196767105530853e-08
for O 0 7.44200145952334e-10
whom O 0 3.099120959859647e-08
the O 0 2.2929143028704857e-09
observed O 0 1.9150908769915986e-07
phenotype O 0 3.8456650486295985e-07
did O 0 2.566328305420029e-07
not O 0 2.6067366931670222e-08
match O 0 1.0216482451141928e-06
the O 0 3.793264014007036e-08
predicted O 0 1.41851774060342e-06
phenotype O 0 2.2789015474700136e-06
was O 0 2.7256643875261943e-07
4 O 0 1.3156586931017955e-08
% O 0 1.998143517312201e-08
- O 0 1.951423200807767e-06
23 O 0 1.478053803793955e-07
% O 0 1.4234021961101462e-08
( O 0 1.5752952720049507e-08
P O 0 7.159951564972289e-06
< O 0 4.992937192582758e-07
. O 0 5.746854547794555e-09
0001 O 0 4.3005951511077e-07
) O 0 1.5809924480691961e-09
, O 0 5.630819144286647e-10
suggesting O 0 8.482679447752162e-09
that O 0 2.2506281560641384e-10
differences O 0 2.4219170668970946e-08
in O 0 3.9786174355072035e-10
methods O 0 4.478261317331089e-08
used O 0 8.314044919188746e-08
for O 0 7.884092489973682e-09
mutation O 0 2.007741841225652e-06
detection O 0 6.728631888108794e-06
or O 0 3.472928256087471e-06
phenotype O 0 8.187074126908556e-05
classification O 0 3.447111521381885e-05
may O 0 1.1323529633955332e-06
account O 0 1.9291610087179833e-08
for O 0 6.767004179231151e-10
a O 0 3.1145086509809516e-09
considerable O 0 1.7401809770944965e-08
proportion O 0 1.7625995951675577e-07
of O 0 1.0493947932843639e-08
genotype O 0 0.0026652163360267878
- O 0 0.007376546505838633
phenotype O 0 0.00020411962759681046
inconsistencies O 0 8.246548532042652e-06
. O 0 5.709708830181626e-07

Our O 0 5.638607035507448e-06
data O 0 6.214230552359368e-07
indicate O 0 5.146520152266021e-07
that O 0 1.1107776032304173e-08
the O 0 8.18268119928689e-08
PAH O 0 0.00017793012375477701
- O 0 3.644925300250179e-06
mutation O 0 3.2428545182483504e-06
genotype O 0 1.0495518836250994e-06
is O 0 1.6467651686724594e-09
the O 0 1.398119287010502e-09
main O 0 3.1814554546372165e-08
determinant O 0 1.7774712546270166e-07
of O 0 3.743295895475285e-09
metabolic O 0 0.002061087405309081
phenotype O 0 5.329797204467468e-06
in O 0 5.4896100998291786e-09
most O 0 3.305749274318259e-08
patients O 0 2.0841858713538386e-05
with O 0 1.181797961180564e-05
PAH B-Disease 1 0.999997615814209
deficiency I-Disease 1 0.5628534555435181
. O 0 1.9682371998896997e-07

In O 0 3.8315820916068333e-07
the O 0 1.7037583788237498e-08
present O 0 1.2924727066376818e-08
study O 0 6.9423768955800824e-09
, O 0 9.071606243971075e-10
the O 0 7.111074507015758e-10
classification O 0 4.932659791734295e-08
of O 0 1.599061438817273e-09
105 O 0 7.457125548171462e-07
PAH O 0 9.184199006995186e-05
mutations O 0 3.495303417366813e-06
may O 0 2.1478532730156985e-08
allow O 0 2.3497259693527894e-09
the O 0 3.421486427512832e-09
prediction O 0 7.794815815032052e-08
of O 0 7.290685832828103e-10
the O 0 5.322478457969737e-09
biochemical O 0 6.578778084076475e-06
phenotype O 0 2.2645315311820013e-06
in O 0 2.666562970432551e-09
> O 0 1.122753090498918e-07
10 O 0 2.03250358765672e-08
, O 0 1.3731029646635307e-09
000 O 0 1.4837731043826352e-08
genotypes O 0 6.596737875952385e-07
, O 0 3.974455431432489e-09
which O 0 5.396713742555903e-09
may O 0 9.478651463723509e-08
be O 0 1.240897384846562e-09
useful O 0 2.7893471976625506e-09
for O 0 7.562541703975967e-10
the O 0 3.8680405545221674e-09
management O 0 3.198882225774469e-08
of O 0 4.354449689714102e-09
hyperphenylalaninemia B-Disease 1 1.0
in O 0 2.8153635867056437e-07
newborns O 0 0.00033374741906300187
. O 0 1.6263012980743952e-07

Somatic O 0 0.0003020055592060089
instability O 0 2.567955198173877e-05
of O 0 7.688721126442033e-08
the O 0 1.1356920737171095e-07
CTG O 0 5.8003693993669e-05
repeat O 0 4.727452051156433e-06
in O 0 1.1243084685474969e-08
mice O 0 8.41559312902973e-07
transgenic O 0 1.5634303451861342e-07
for O 0 3.1984597193002173e-09
the O 0 2.473003917202732e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.8712854600598803e-06
is O 0 2.1154654916699656e-08
age O 0 5.5078405836184174e-08
dependent O 0 2.740614668539365e-08
but O 0 2.053094361187391e-09
not O 0 1.9257042627174314e-09
correlated O 0 2.218198602577104e-08
to O 0 2.724487524474739e-09
the O 0 7.358446296734655e-09
relative O 0 2.5349888232995e-07
intertissue O 0 1.8471934026820236e-06
transcription O 0 5.293874210110516e-07
levels O 0 8.059707283791795e-07
and O 0 1.5434854105933482e-07
proliferative O 0 0.00043660608935169876
capacities O 0 1.3836632206221111e-05
. O 0 3.8188579765119357e-07

A O 0 1.4776065654587e-05
( O 0 1.3072935871605296e-06
CTG O 0 1.3644755199493375e-05
) O 0 4.039272027966945e-08
nexpansion O 0 1.0679166280169738e-06
in O 0 3.3369726981646863e-09
the O 0 6.728088752794292e-09
3 O 0 1.3661357911587402e-07
- O 0 2.5169047148665413e-05
untranslated O 0 0.0007171086617745459
region O 0 7.505034318455728e-07
( O 0 1.0901412217378947e-08
UTR O 0 4.644990099222923e-07
) O 0 1.5974395140005981e-09
of O 0 1.78056414057437e-09
the O 0 5.1990870275631096e-08
DM O 1 1.0
protein O 0 1.7518270851724083e-06
kinase O 0 1.0223957360722125e-05
gene O 0 3.101722541032359e-06
( O 0 3.183926011729454e-08
DMPK O 0 1.7527294176034047e-06
) O 0 2.341096649871588e-09
is O 0 1.4665977321470791e-09
responsible O 0 6.306741795469861e-08
for O 0 2.4368327800061707e-08
causing O 0 0.011616737581789494
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00036470359191298485
DM B-Disease 1 1.0
) O 0 7.622718953825824e-07
. O 0 2.7881682740371616e-07

Major O 0 1.5332976545323618e-05
instability O 0 1.8893157175625674e-05
, O 0 4.259004171558445e-08
with O 0 3.6172715933702193e-09
very O 0 8.33942070954663e-09
large O 0 1.1259173593458627e-09
expansions O 0 3.104374357576489e-08
between O 0 7.506298693726876e-09
generations O 0 4.671047904025727e-08
and O 0 7.053532424805553e-09
high O 0 7.841310178946514e-08
levels O 0 1.2323928899604653e-07
of O 0 5.558704052610608e-10
somatic O 0 1.045568751578685e-06
mosaicism O 0 3.4737397527351277e-06
, O 0 5.925457902122844e-09
is O 0 2.519892960961556e-09
observed O 0 4.9516820865846967e-08
in O 0 9.366825537426848e-09
patients O 0 3.0382631166503415e-07
. O 0 5.1965489689109745e-08

There O 0 1.735919909151562e-06
is O 0 1.1097738727983142e-08
a O 0 8.07036659722371e-09
good O 0 4.444903112243992e-08
correlation O 0 4.249875473760767e-07
between O 0 8.732376954867505e-08
repeat O 0 1.2645308743230999e-05
size O 0 6.410018045244215e-07
( O 0 2.680214272743342e-08
at O 0 1.5337423064920586e-07
least O 0 7.49233830532603e-09
in O 0 1.3834605683271661e-09
leucocytes O 0 1.5517239262408111e-06
) O 0 1.4563174000059576e-09
, O 0 1.0832137409266807e-09
clinical O 0 2.60260662798828e-07
severity O 0 2.510803597033373e-06
and O 0 3.802188075496815e-08
age O 0 1.955805544184841e-07
of O 0 4.898604188952049e-09
onset O 0 0.00031102594221010804
. O 0 2.5782705392884964e-07

The O 0 4.450860615179408e-06
trinucleotide O 0 0.0008329675765708089
repeat O 0 4.767209611600265e-05
instability O 0 3.860631750285393e-06
mechanisms O 0 1.4842635209788568e-06
involved O 0 2.1875402467230742e-07
in O 0 2.9219634711807885e-08
DM B-Disease 1 1.0
and O 0 6.264695429081257e-08
other O 0 1.5279267628898197e-08
human O 0 2.9775997063552495e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.4015822102919628e-07
unknown O 0 9.030696332956722e-07
. O 0 5.962942140058658e-08

We O 0 2.140203605449642e-06
studied O 0 8.931924071475805e-07
somatic O 0 1.0104979992320295e-05
instability O 0 2.3785739813320106e-06
by O 0 1.3371830753783343e-08
measuring O 0 0.00011313249706290662
the O 0 9.234881304109877e-08
CTG O 0 2.6230311050312594e-05
repeat O 0 3.21079505738453e-06
length O 0 5.047390914114658e-07
at O 0 3.827786798638044e-08
several O 0 3.704225370881886e-09
ages O 0 2.0438653791643446e-07
in O 0 3.4869049314600886e-10
various O 0 5.13365394638754e-09
tissues O 0 7.085450874910748e-07
of O 0 2.8044708777485994e-09
transgenic O 0 1.0835966577360523e-06
mice O 0 2.46518698077125e-06
carrying O 0 4.156346733452665e-08
a O 0 2.55837626639277e-08
( O 0 2.4362238448816242e-08
CTG O 0 2.0306163150962675e-06
) O 0 8.686259711510047e-09
55expansion O 0 5.037955475017952e-07
surrounded O 0 5.514715795129632e-08
by O 0 1.8484486163927727e-09
45 O 0 6.017530473911847e-09
kb O 0 1.6241205003098003e-07
of O 0 2.4310424784346196e-09
the O 0 2.026561496393242e-08
human O 0 3.2521006687602494e-07
DM B-Disease 1 1.0
region O 0 2.876660687434196e-07
, O 0 3.7484833015355434e-09
using O 0 2.6182371826166673e-08
small O 0 1.89973619058037e-07
- O 0 0.00011061116674682125
pool O 0 1.8114886188413948e-05
PCR O 0 4.459780393517576e-05
. O 0 4.931455350742908e-07

These O 0 9.355594556836877e-07
mice O 0 2.3133672584663145e-05
have O 0 3.2053012688493254e-08
been O 0 9.298719128025823e-09
shown O 0 1.0143612172441863e-08
to O 0 3.7164686883528475e-09
reproduce O 0 1.1291391274426132e-05
the O 0 7.138501789683005e-09
intergenerational O 0 2.9957126912449894e-07
and O 0 1.1243727726650832e-08
somatic O 0 6.630303914789692e-07
instability O 0 1.85389637863409e-07
of O 0 3.1110709564075023e-09
the O 0 2.6339247227724627e-08
55 O 0 4.86117642140016e-07
CTG O 0 7.535488748544594e-06
repeat O 0 1.0535230785535532e-06
suggesting O 0 1.5811899345408165e-07
that O 0 1.7216196246394588e-09
surrounding O 0 7.1108749999382326e-09
sequences O 0 7.929232737069469e-08
and O 0 7.957059899865726e-09
the O 0 2.6024529198309665e-09
chromatin O 0 4.163249656130574e-08
environment O 0 5.8108739153794886e-08
are O 0 1.5679233467125187e-09
involved O 0 3.0798383843233523e-09
in O 0 5.5228599471490725e-09
instability O 0 1.271844666916877e-06
mechanisms O 0 7.869574801588897e-06
. O 0 5.564501748267503e-07

As O 0 9.773920055522467e-07
observed O 0 1.7567730026257777e-07
in O 0 6.930122031789665e-10
some O 0 1.7063876700529335e-10
of O 0 1.625897194657e-10
the O 0 3.130332437706329e-09
tissues O 0 2.1075293261674233e-06
of O 0 1.7115853623295152e-08
DM B-Disease 1 1.0
patients O 0 0.028328116983175278
, O 0 3.378137103382528e-09
there O 0 2.705730528518302e-09
is O 0 1.0993028709549435e-09
a O 0 2.645059726802401e-09
tendency O 0 2.841303512468585e-07
for O 0 5.7801630148901495e-09
repeat O 0 2.220947635578341e-06
length O 0 2.8910196192555304e-07
and O 0 9.90744464246518e-09
somatic O 0 5.116403940519376e-07
mosaicism O 0 6.241991741262609e-07
to O 0 8.67748362054499e-09
increase O 0 1.6196466390283604e-08
with O 0 7.663023993131901e-09
the O 0 1.9807643525382446e-08
age O 0 1.6561533300318843e-07
of O 0 1.132672178272287e-09
the O 0 2.7028743687651513e-08
mouse O 0 3.929652393708238e-06
. O 0 9.484077168053773e-08

Furthermore O 0 1.371024609397864e-05
, O 0 1.3514139141079795e-07
we O 0 6.608311053923899e-08
observed O 0 5.051734319749812e-08
no O 0 9.841770065577293e-09
correlation O 0 5.622475640620905e-08
between O 0 1.1552616641097302e-08
the O 0 9.701133230066716e-09
somatic O 0 1.5511972151216469e-06
mutation O 0 1.822785065996868e-06
rate O 0 1.3810049495077692e-06
and O 0 4.2461561378104307e-08
tissue O 0 4.339234146755189e-05
proliferation O 0 6.33632089375169e-06
capacity O 0 8.338501800153608e-08
. O 0 4.742697257142936e-08

The O 0 7.571871378786454e-07
somatic O 0 2.6087440346600488e-05
mutation O 0 2.059515827568248e-05
rates O 0 3.699874696394545e-06
in O 0 8.91401796820901e-09
different O 0 1.759002010714994e-08
tissues O 0 5.053102086094441e-06
were O 0 2.8504089755188033e-07
also O 0 1.0932458494039565e-08
not O 0 3.950173521616307e-09
correlated O 0 3.3985934067004564e-08
to O 0 3.0195086431206164e-09
the O 0 7.256312439807289e-09
relative O 0 1.3067401596345007e-06
inter O 0 0.000612314383033663
- O 0 0.025037318468093872
tissue O 0 3.668614590424113e-05
difference O 0 5.2448832832396874e-08
in O 0 9.764691277780457e-10
transcriptional O 0 3.641870591764018e-07
levels O 0 1.103259137380519e-07
of O 0 4.0260844658135397e-10
the O 0 2.742516880260837e-09
three O 0 1.2824634687547132e-08
genes O 0 1.5594990543377207e-07
( O 0 6.385110218332102e-09
DMAHP O 0 1.0378091701568337e-06
, O 0 7.33373006767124e-09
DMPK O 0 2.5214674224116607e-06
and O 0 6.806569530226625e-08
59 O 0 1.323070222269962e-07
) O 0 1.3525679465331564e-09
surrounding O 0 5.0907997817262185e-09
the O 0 8.48484837945307e-09
repeat O 0 1.417408952875121e-06
. O 0 9.997861205590652e-09
. O 0 4.149566379396674e-08

A O 0 4.870675184065476e-06
novel O 0 3.882855253323214e-06
missense O 0 8.527767931809649e-05
mutation O 0 9.896691153699066e-06
in O 0 2.354154915451545e-08
patients O 0 2.462658358126646e-06
from O 0 4.425266819652052e-09
a O 0 4.191918634433023e-08
retinoblastoma B-Disease 0 0.00011067499144701287
pedigree O 0 0.011639359407126904
showing O 0 6.0602087614824995e-05
only O 0 5.3934133603661394e-08
mild O 0 1.1764453120122198e-05
expression O 0 8.316582267298145e-08
of O 0 3.2031362007245434e-09
the O 0 2.4927044250944164e-07
tumor B-Disease 0 2.6811641873791814e-05
phenotype O 0 9.203470654028933e-06
. O 0 1.5853257195885817e-07

We O 0 1.687416443019174e-05
have O 0 7.704444016098932e-08
used O 0 5.013550108401432e-08
single O 0 5.492869377121679e-07
strand O 0 3.661414496036741e-07
conformation O 0 4.302867750993755e-07
polymorphism O 0 5.765081141362316e-07
analysis O 0 3.2168582464464635e-08
to O 0 5.875635089580555e-09
study O 0 8.016150410128375e-09
the O 0 8.975658438714618e-09
27 O 0 3.111196988925258e-08
exons O 0 5.895473620398661e-08
of O 0 2.069568072471384e-09
the O 0 1.9509782234194972e-08
RB1 O 0 3.5840967029798776e-06
gene O 0 1.125450381778137e-07
in O 0 2.9191489225866007e-09
individuals O 0 2.342861238346927e-09
from O 0 7.317922934291232e-10
a O 0 1.1720653780855628e-08
family O 0 9.656130117718931e-08
showing O 0 1.481866911490215e-05
mild O 0 2.731242602749262e-05
expression O 0 1.3191782954891096e-07
of O 0 4.219237847991053e-09
the O 0 1.3262462061902625e-07
retinoblastoma B-Disease 0 5.7736160670174286e-05
phenotype O 0 8.337518374901265e-05
. O 0 3.618498567448114e-07

In O 0 1.9105084447801346e-07
this O 0 1.0876364697764984e-08
family O 0 3.1292117341763515e-08
affected O 0 4.985001211821327e-08
individuals O 0 6.570202604194719e-09
developed O 0 4.188250670722482e-07
unilateral B-Disease 1 0.682438313961029
tumors I-Disease 1 1.0
and O 0 3.8077803310443414e-06
, O 0 8.23753332213073e-09
as O 0 5.164038530125481e-09
a O 0 6.985718670193819e-09
result O 0 1.3235316842497014e-08
of O 0 8.01128552385677e-10
linkage O 0 5.099464488012018e-06
analysis O 0 3.8980607541816426e-07
, O 0 3.728796471591522e-08
unaffected O 0 1.7169793409266276e-06
mutation O 0 7.947521112328104e-07
carriers O 0 3.411297200273111e-07
were O 0 1.0852703979935541e-07
also O 0 7.863083517634095e-09
identified O 0 8.780343563330462e-08
within O 0 5.048784057493094e-09
the O 0 2.0381053289497686e-08
pedigree O 0 4.41396223322954e-05
. O 0 2.7628163934423355e-07

A O 0 7.62973286327906e-06
single O 0 5.243010946287541e-06
band O 0 3.545530660176155e-07
shift O 0 1.2610288990799745e-07
using O 0 1.2273552840724733e-07
SSCP O 0 1.9659235476865433e-05
was O 0 2.405305679076264e-07
identified O 0 4.630147287798536e-08
in O 0 1.5529704189276572e-09
exon O 0 2.520995963095629e-07
21 O 0 9.217072971523521e-08
which O 0 3.266698689330383e-09
resulted O 0 2.1644844139245834e-08
in O 0 1.7840009469693996e-09
a O 0 3.440925411268836e-08
missense O 0 1.0996809578500688e-05
mutation O 0 1.0678656963136746e-06
converting O 0 1.9171410770013608e-07
a O 0 1.2532504456430615e-07
cys O 0 0.0006307749426923692
- O 0 6.371869676513597e-05
- O 0 2.1173475033720024e-05
> O 0 8.189924187718134e-07
arg O 0 1.5158389032876585e-06
at O 0 7.329048656856685e-08
nucleotide O 0 7.102777317413711e-07
position O 0 1.0581428568912088e-06
28 O 0 4.662689789824981e-08
in O 0 1.5517741536186236e-09
the O 0 9.569657954955346e-09
exon O 0 1.6324280522894696e-06
. O 0 1.3337817961200926e-07

The O 0 2.0541235699056415e-06
mutation O 0 1.2273171705601271e-05
destroyed O 0 2.5611454930185573e-06
an O 0 2.5883458931730274e-08
NdeI O 0 4.694091785495402e-06
restriction O 0 2.293756011795267e-07
enzyme O 0 6.976000577196828e-07
site O 0 6.558310587934102e-07
. O 0 3.0569049158657435e-07

Analysis O 0 1.6204551229748176e-06
of O 0 1.5022800781139267e-08
all O 0 1.1192418547523175e-08
family O 0 2.339227656023013e-08
members O 0 2.9880324881048637e-09
demonstrated O 0 5.5775473128960584e-09
that O 0 4.153949129115375e-10
the O 0 4.246607510083322e-09
missense O 0 2.004788984777406e-05
mutation O 0 9.839885933615733e-06
co O 0 3.859707703668391e-06
- O 0 1.908932745209313e-06
segregated O 0 4.693456048698863e-06
with O 0 5.3193556226460714e-08
patients O 0 2.6320224151277216e-06
with O 0 4.7350687282232684e-07
tumors B-Disease 1 1.0
or O 0 0.0002840070810634643
who O 0 9.019747722049942e-07
, O 0 2.2518229503276643e-09
as O 0 3.4043270424888306e-09
a O 0 5.877282660549099e-09
result O 0 2.105868190938054e-08
of O 0 4.48339337877357e-10
linkage O 0 1.325506786997721e-06
analysis O 0 1.1178271961398423e-06
had O 0 3.101948095718399e-05
been O 0 8.529392658829238e-08
predicted O 0 6.438605026914956e-08
to O 0 1.9690598040966734e-09
carry O 0 2.512997809844819e-07
the O 0 4.090816219104454e-08
predisposing O 0 3.5612039937404916e-05
mutation O 0 7.061745691316901e-06
. O 0 2.030419494758462e-07

These O 0 3.494619420507661e-07
observations O 0 4.254619909715984e-07
point O 0 2.564689225437178e-07
to O 0 1.8111592225977802e-08
another O 0 4.065838510314279e-08
region O 0 2.1015946316538248e-08
of O 0 1.722637921197645e-09
the O 0 2.3749187505472946e-08
RB1 O 0 5.287928161124e-06
gene O 0 2.445008817630878e-07
where O 0 1.583957320860918e-08
mutations O 0 2.412351136626967e-07
only O 0 4.736104841640554e-09
modify O 0 1.0279250517442051e-07
the O 0 3.7686205267561945e-09
function O 0 9.423667179930817e-09
of O 0 1.3490016048667286e-10
the O 0 9.97903315536064e-10
gene O 0 3.8427316439992865e-08
and O 0 2.317629421710876e-09
raise O 0 4.292814992368221e-09
important O 0 2.120623454615611e-09
questions O 0 3.934472747602058e-09
for O 0 4.5792380998221915e-10
genetic O 0 9.363056392430735e-07
counseling O 0 1.834607701312052e-07
in O 0 3.4288816230798602e-09
families O 0 1.573748598104885e-08
with O 0 1.335092703058649e-09
these O 0 7.716617567155026e-09
distinctive O 0 1.8183731071985676e-06
phenotypes O 0 3.6698147596325725e-06
. O 0 7.271913293749321e-09
. O 0 6.562089538419968e-08

Maternal B-Disease 1 0.7967109680175781
disomy I-Disease 0 0.19124755263328552
and O 0 0.0005034715868532658
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.00020395680621732026
with O 0 3.4123832648447205e-08
gamete O 0 4.911751602776349e-06
complementation O 0 3.825157546089031e-05
in O 0 4.849666890294202e-09
a O 0 8.52098125392331e-09
case O 0 7.058377438085017e-09
of O 0 2.469533022519954e-09
familial O 0 7.054274465190247e-05
translocation O 0 1.0011687663791236e-05
( O 0 9.174696913305525e-08
3 O 0 3.889274680091148e-08
; O 0 7.036466964649435e-09
15 O 0 1.6733018526338128e-08
) O 0 2.553178335418238e-09
( O 0 3.4590059705408294e-09
p25 O 0 1.0295928376535812e-07
; O 0 3.3205667104851955e-09
q11 O 0 2.0527475896869873e-07
. O 0 3.0978486442734265e-09
2 O 0 3.113363788997958e-08
) O 0 2.511540486693775e-08
. O 0 8.022103514804257e-08

Maternal B-Disease 1 0.9836682677268982
uniparental I-Disease 1 0.9974111914634705
disomy I-Disease 1 0.9429484605789185
( I-Disease 0 0.00016759663412813097
UPD I-Disease 1 1.0
) I-Disease 0 4.928822363581276e-07
for I-Disease 0 1.344789701818172e-08
chromosome I-Disease 0 5.6326909543713555e-05
15 I-Disease 0 6.615562853085066e-08
is O 0 2.858006498129839e-09
responsible O 0 4.4203002147469306e-08
for O 0 7.878301344632632e-10
an O 0 3.0722582256004216e-09
estimated O 0 1.7956120146322974e-08
30 O 0 4.449235202486079e-09
% O 0 1.1222425211343534e-09
of O 0 2.7819974102172296e-10
cases O 0 1.1342985217766e-08
of O 0 7.707830604886112e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.8412099709385075e-05
PWS B-Disease 1 1.0
) O 0 4.85681084683165e-07
. O 0 1.778157781018308e-07

We O 0 4.1623919969424605e-05
report O 0 2.1640929048771795e-07
on O 0 4.51631887443682e-09
an O 0 9.578345894212248e-10
unusual O 0 4.7365293909251704e-09
case O 0 1.707576857690185e-09
of O 0 2.525532227792837e-09
maternal B-Disease 0 0.0005437383078970015
disomy I-Disease 0 7.579517114209011e-05
15 I-Disease 0 1.9306486365167075e-07
in O 0 4.1364568659219e-08
PWS B-Disease 1 1.0
that O 0 2.0030622494005e-08
is O 0 2.7834956561889612e-09
most O 0 2.9826801029031458e-09
consistent O 0 1.7598736690160877e-07
with O 0 1.4766969869128843e-09
adjacent O 0 2.9018838176853023e-07
- O 0 8.676700417709071e-06
1 O 0 2.1481646683696454e-08
segregation O 0 1.9086490965491976e-07
of O 0 8.152452046772396e-10
a O 0 6.364042093309763e-08
paternal O 0 0.02115763910114765
t O 0 3.3846692531369627e-05
( O 0 7.063158058429053e-09
3 O 0 2.6415369447363446e-08
; O 0 5.121722157497288e-09
15 O 0 1.3971177104110666e-08
) O 0 2.739332982670817e-09
( O 0 3.846601703827446e-09
p25 O 0 8.364913384184547e-08
; O 0 2.6978770328867085e-09
q11 O 0 1.299567600199225e-07
. O 0 1.2245541247679625e-09
2 O 0 4.053811064608226e-09
) O 0 1.1092060603346e-09
with O 0 1.3708549850832696e-09
simultaneous O 0 2.6050774977193214e-06
maternal O 0 0.11250528693199158
meiotic O 0 0.00014834440662525594
nondisjunction O 0 5.49301112187095e-05
for O 0 3.769398659869694e-08
chromosome O 0 9.756670624483377e-05
15 O 0 7.073487608977302e-07
. O 0 2.394039313458052e-07

The O 0 7.0805399445816875e-06
patient O 0 0.0002050952462013811
( O 0 2.3784734537457553e-07
J O 0 0.00032546589500270784
. O 0 1.4801944558939795e-08
B O 0 8.51021923153894e-06
. O 0 1.156361228993319e-09
) O 0 1.2104284241587493e-09
, O 0 6.068588409569031e-10
a O 0 5.550422343958417e-09
17 O 0 8.686792796197551e-08
- O 0 6.473762255154725e-07
year O 0 1.0971437980344945e-08
- O 0 1.8901974954133038e-06
old O 0 7.348424333031289e-06
white O 0 5.421942432803917e-07
male O 0 5.913599920859269e-07
with O 0 1.1245448661156843e-07
PWS B-Disease 1 1.0
, O 0 5.0517922289827766e-08
was O 0 6.617316472556922e-08
found O 0 4.04195210634839e-09
to O 0 2.1167236852193128e-09
have O 0 5.9010648811863575e-08
47 O 0 3.141184095056815e-07
chromosomes O 0 5.969833409835701e-07
with O 0 4.4274619526163406e-09
a O 0 3.96758004228559e-08
supernumerary O 0 0.00016487480024807155
, O 0 8.960985553585488e-08
paternal O 0 0.001698712701909244
der O 1 0.9635608196258545
( O 0 2.520153863372343e-08
15 O 0 8.534563278317364e-09
) O 0 3.941892090519872e-10
consisting O 0 1.29526067649266e-09
of O 0 8.071870394310565e-10
the O 0 1.2323478237874497e-08
short O 0 3.404010203666985e-05
arm O 0 0.24670708179473877
and O 0 7.370641696979874e-08
the O 0 8.450173005769557e-09
proximal O 0 9.210206371790264e-06
long O 0 2.298812978551723e-05
arm O 0 0.000913103693164885
of O 0 3.5264349218522284e-09
chromosome O 0 3.119622851954773e-05
15 O 0 5.4033289842436716e-08
, O 0 5.3425970314435745e-09
and O 0 6.419622877729125e-08
distal O 0 0.0007120919763110578
chromosome O 0 0.40091580152511597
arm O 0 0.4382701516151428
3p O 0 0.002518193330615759
. O 0 2.8645433758356376e-06

The O 0 4.733569767267909e-06
t O 0 5.005628918297589e-05
( O 0 5.8926861612462744e-08
3 O 0 3.63093235478118e-08
; O 0 3.6856482310554384e-09
15 O 0 7.636468346561287e-09
) O 0 1.4562256955841235e-09
was O 0 3.9958695907671427e-08
present O 0 2.2542037125816705e-09
in O 0 8.988332300674529e-10
the O 0 4.355496407981718e-09
balanced O 0 9.205108142396057e-08
state O 0 1.6011580949992776e-09
in O 0 1.063397814249356e-09
the O 0 2.6959957821759417e-08
patients O 0 3.9359389347737306e-07
father O 0 8.747046820190008e-08
and O 0 7.73277974985831e-09
a O 0 8.46403267473761e-08
sister O 0 4.149962842348032e-05
. O 0 7.415370362195972e-08

Fluorescent O 0 3.25280889228452e-05
in O 0 1.0876224365574672e-07
situ O 0 7.132896371331299e-07
hybridization O 0 8.653685767967545e-08
analysis O 0 8.06769122618789e-08
demonstrated O 0 6.59672565461733e-08
that O 0 2.701131096571885e-09
the O 0 4.110102835852558e-08
PWS B-Disease 1 1.0
critical O 0 1.0637644436428673e-06
region O 0 1.7235498717127484e-07
resided O 0 1.6804797553504613e-07
on O 0 5.532369673488802e-09
the O 0 1.8839534376979827e-09
derivative O 0 4.0549812752033176e-07
chromosome O 0 7.562013593087613e-07
3 O 0 7.543082602978757e-09
and O 0 5.034014538551901e-09
that O 0 2.415885491657832e-09
there O 0 1.7560116916115476e-08
was O 0 2.781407033580763e-07
no O 0 1.635721780246513e-08
deletion O 0 3.5706202083929384e-07
of O 0 5.021164817264889e-09
the O 0 8.965342885858263e-07
PWS B-Disease 1 1.0
region O 0 1.1525697800607304e-06
on O 0 4.930590336016394e-08
the O 0 1.7449604428065868e-08
normal O 0 1.103326496831869e-07
pair O 0 1.0769274894073533e-07
of O 0 1.072801625312536e-09
15s O 0 1.8301516035990062e-07
present O 0 1.2214406375221643e-08
in O 0 2.5957421101452383e-08
J O 0 0.020780421793460846
. O 0 5.785437906524749e-07

B O 0 0.016739672049880028
. O 0 3.411000216146931e-05

Methylation O 0 7.88207307778066e-06
analysis O 0 6.044018618922564e-07
at O 0 1.1085577966696292e-07
exon O 0 6.802428629271162e-07
alpha O 0 5.988884765883995e-08
of O 0 2.493020900828924e-09
the O 0 6.922410644705224e-09
small O 0 5.6510092605321915e-08
nuclear O 0 5.6948797464428935e-06
ribonucleoprotein O 0 7.451875262631802e-06
- O 0 1.5265659385477193e-05
associated O 0 3.5584230317908805e-07
polypeptide O 0 4.872184945270419e-06
N O 0 2.4208644390455447e-05
( O 0 5.956804471907162e-08
SNRPN O 0 2.426248329356895e-06
) O 0 6.163099808276229e-09
gene O 0 1.4794217406688404e-07
showed O 0 1.349376503867461e-07
a O 0 7.801148171893146e-09
pattern O 0 9.419004527444486e-07
characteristic O 0 1.1394555343713364e-07
of O 0 1.2684818750940963e-09
only O 0 1.050700682014849e-08
the O 0 1.2571476304401585e-08
maternal O 0 0.0003406301257200539
chromosome O 0 4.275448009138927e-05
15 O 0 1.0947319850629356e-07
in O 0 4.2187007665006604e-08
J O 0 0.043975770473480225
. O 0 3.669468355838035e-07

B O 0 0.008273386396467686
. O 0 2.788126039376948e-05

Maternal B-Disease 0 0.49091681838035583
disomy I-Disease 0 0.0016727563925087452
was O 0 2.634187012517941e-06
confirmed O 0 8.06699915756326e-08
by O 0 2.4850879132287673e-09
polymerase O 0 4.2015525991700997e-07
chain O 0 7.002809638834151e-07
reaction O 0 2.9982246019244485e-08
analysis O 0 2.426587109027878e-08
of O 0 6.905794602829474e-09
microsatellite O 0 1.8279959476785734e-05
repeats O 0 8.584247552789748e-06
at O 0 1.1726862680916383e-07
the O 0 1.3460035752643762e-08
gamma O 0 6.958399580980767e-07
- O 0 5.270668043522164e-05
aminobutyric O 0 0.00016664911527186632
acid O 0 2.743719505815534e-06
receptor O 0 5.244358476375055e-07
beta3 O 0 1.0115520581166493e-06
subunit O 0 3.538710586781235e-07
( O 0 9.085813701403822e-08
GABRB3 O 0 4.839791017730022e-06
) O 0 7.297705195696835e-08
locus O 0 7.239626029331703e-06
. O 0 3.302847630948236e-07

A O 0 2.1812395061715506e-05
niece O 0 0.00012243665696587414
( O 0 1.1084642892456031e-06
B O 0 1.0496957656869199e-05
. O 0 5.06630204455405e-09
B O 0 8.484146292175865e-07
. O 0 7.410273505925602e-10
) O 0 6.689340192878035e-10
with O 0 8.390055872276037e-10
45 O 0 1.8554469960463393e-08
chromosomes O 0 1.7285803721733828e-07
and O 0 9.007299794916435e-09
the O 0 2.606506566138478e-09
derivative O 0 2.7125173573949724e-07
3 O 0 6.090463244845523e-08
but O 0 3.1833980784767846e-08
without O 0 5.1813074719575525e-08
the O 0 3.503481593725155e-08
der O 1 0.5778986215591431
( O 0 7.175085414701243e-09
15 O 0 7.788005795816844e-09
) O 0 1.8813322011368427e-09
demonstrated O 0 7.095010357005549e-09
a O 0 6.55373177949059e-09
phenotype O 0 1.6062876966316253e-06
consistent O 0 8.573607601647382e-07
with O 0 3.5037803769455422e-09
that O 0 5.3761457508016974e-09
reported O 0 9.42038198559203e-08
for O 0 1.7962551446260022e-09
haploinsufficiency O 0 1.000346969703969e-06
of O 0 4.24060164760931e-09
distal O 0 9.393874279339798e-06
3 O 0 1.3754752217209898e-06
p O 0 0.0003811966744251549
. O 0 6.099014058236207e-07

Uniparental B-Disease 1 0.9999995231628418
disomy I-Disease 1 0.9999977350234985
associated O 0 5.064626384410076e-05
with O 0 2.289258560495e-07
unbalanced O 0 0.00014345301315188408
segregation O 0 8.601858098700177e-06
of O 0 1.877110733516929e-08
non O 0 1.2395645171636716e-05
- O 0 4.522235394688323e-05
Robertsonian O 0 1.3017229321121704e-05
translocations O 0 9.068826329894364e-06
has O 0 3.5032482514907315e-07
been O 0 3.4798998171936546e-07
reported O 0 3.974586775257194e-07
previously O 0 4.3636518398670887e-07
but O 0 7.64436691724768e-09
has O 0 6.809566688303903e-09
not O 0 9.111042587051088e-09
, O 0 6.790406015255712e-10
to O 0 7.797574252954576e-10
our O 0 2.04799928127386e-08
knowledge O 0 6.090902449074065e-09
, O 0 1.7118488848666402e-09
been O 0 1.212235822833918e-08
observed O 0 1.0102407799195134e-08
in O 0 3.952191074407807e-10
a O 0 2.497937856560384e-09
case O 0 6.23477314221077e-09
of O 0 3.532973735786982e-08
PWS B-Disease 1 1.0
. O 0 4.590349078625877e-07

Furthermore O 0 2.872176446544472e-05
, O 0 9.291241553910368e-08
our O 0 4.402219033750043e-08
findings O 0 1.319934117560706e-08
are O 0 2.619784389423785e-09
best O 0 3.8148932901549415e-08
interpreted O 0 4.927112229324848e-08
as O 0 6.656633466661788e-09
true O 0 6.227929816304822e-08
gamete O 0 1.2581330111061106e-06
complementation O 0 1.3565233530243859e-05
resulting O 0 6.901101983203262e-07
in O 0 9.090978636550062e-08
maternal B-Disease 1 0.9552901387214661
UPD I-Disease 1 1.0
15 I-Disease 0 2.8296450182097033e-05
and O 0 2.0929754100507125e-05
PWS B-Disease 1 0.9999994039535522

Schwartz B-Disease 1 0.982622504234314
- I-Disease 1 0.9995108842849731
Jampel I-Disease 1 0.9979565143585205
syndrome I-Disease 1 0.9999986886978149
type I-Disease 0 0.00012140345643274486
2 I-Disease 0 4.687474586262397e-07
and O 0 5.148679633748543e-07
Stuve B-Disease 1 0.9981251358985901
- I-Disease 1 0.9999997615814209
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 9.053892746635483e-09
a O 0 4.458613478419693e-09
case O 0 4.5531476366988954e-09
for O 0 1.999141296948892e-09
" O 0 5.787513046584536e-08
lumping O 0 2.2142899069876876e-06
" O 0 2.595160992768797e-07
. O 0 6.325860368860958e-08

Recent O 0 2.809738361975178e-06
studies O 0 7.790235940774437e-07
demonstrated O 0 2.052594822998799e-07
the O 0 4.18758538955899e-09
existence O 0 7.60399920807231e-09
of O 0 3.5034847245540846e-10
a O 0 6.881495817623318e-09
genetically O 0 4.3426823026493366e-08
distinct O 0 1.7906391036603964e-08
, O 0 9.062889327893231e-10
usually O 0 9.112467225236287e-09
lethal O 0 1.6580079531536285e-08
form O 0 7.0844627941824e-09
of O 0 1.691698670036601e-09
the O 0 2.4397749598392693e-07
Schwartz B-Disease 1 0.5730040669441223
- I-Disease 1 0.9973424077033997
Jampel I-Disease 1 0.999984860420227
syndrome I-Disease 1 0.9999983310699463
( O 0 5.0700844411721846e-08
SJS B-Disease 0 0.008723524399101734
) O 0 3.4067433318796247e-09
of O 0 2.4102382312207737e-09
myotonia B-Disease 0 0.0002575802500359714
and O 0 2.950405360024888e-07
skeletal B-Disease 0 0.08770021051168442
dysplasia I-Disease 1 0.9495761394500732
, O 0 3.3191181358915856e-08
which O 0 1.3479971805452351e-08
we O 0 3.15916111048864e-08
called O 0 1.0137040362678817e-07
SJS B-Disease 1 0.9424110651016235
type I-Disease 0 3.3802723919507116e-05
2 I-Disease 0 3.746219476852275e-07
. O 0 1.342901185807932e-07

This O 0 3.1546142054139636e-06
disorder O 1 0.8343415260314941
is O 0 1.8403230939156856e-08
reminiscent O 0 2.163193073556613e-07
of O 0 2.3075901189884007e-09
another O 0 3.6372608036572274e-08
rare O 0 1.3499440854047862e-07
condition O 0 1.738030550768599e-05
, O 0 3.903199541355207e-09
the O 0 2.113541874848579e-08
Stuve B-Disease 1 0.9848854541778564
- I-Disease 1 0.9999960660934448
Wiedemann I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999996423721313
( O 0 9.047025173458678e-08
SWS B-Disease 0 0.0003408003249205649
) O 0 1.6345117259675135e-08
, O 0 1.6227256205425533e-09
which O 0 2.1402295491412815e-09
comprises O 0 9.811032875006731e-09
campomelia B-Disease 0 2.5486583581368905e-06
at O 0 1.3883706628803338e-07
birth O 0 4.946660283167148e-06
with O 0 2.0205982664833755e-08
skeletal B-Disease 0 0.004105255473405123
dysplasia I-Disease 0 0.4057169258594513
, O 0 4.253922014640921e-08
contractures B-Disease 0 0.00010323650349164382
, O 0 3.047490793051111e-08
and O 0 1.7886799597022218e-08
early B-Disease 0 2.9750293606412015e-07
death I-Disease 0 4.6524735353159485e-07
. O 0 7.670968216189067e-08

To O 0 1.7865475001599407e-06
test O 0 8.751466111789341e-07
for O 0 7.865093465397877e-09
possible O 0 5.038080175268078e-08
nosologic O 0 5.123017672303831e-06
identity O 0 1.828923075208877e-07
between O 0 1.438742192050313e-08
these O 0 1.6663943824823946e-07
disorders O 1 0.8481627702713013
, O 0 1.0553442564287252e-08
we O 0 1.6372451838719826e-08
reviewed O 0 3.936627024359041e-09
the O 0 9.052696370304147e-10
literature O 0 3.0478379819953716e-09
and O 0 1.1807420818854553e-08
obtained O 0 2.2424803347576017e-08
a O 0 2.401420040598623e-08
follow O 0 3.9617654579160444e-07
- O 0 6.153607682790607e-05
up O 0 5.606176500805304e-07
of O 0 7.260226864147512e-10
the O 0 3.1975324610300504e-09
only O 0 1.012057637694852e-08
two O 0 2.6121018237290627e-08
surviving O 0 0.00011890899622812867
patients O 0 1.6250253054295172e-07
, O 0 3.4956684769049673e-10
one O 0 7.113720168483439e-10
with O 0 5.78258907424356e-09
SJS B-Disease 0 0.08901429921388626
type I-Disease 0 1.3162333743821364e-05
2 I-Disease 0 4.594991409589966e-08
at O 0 1.8575367732864834e-07
age O 0 1.8697127757150156e-07
10 O 0 2.898968620712594e-09
years O 0 1.6664436497393353e-09
and O 0 3.6474019360355214e-09
another O 0 2.448116021014357e-08
with O 0 5.73714302731787e-08
SWS B-Disease 1 0.76006680727005
at O 0 6.0503721215354744e-06
age O 0 5.72674480281421e-07
7 O 0 3.5795522990156314e-08
years O 0 3.873432063983273e-08
. O 0 5.855779150465423e-08

Patients O 1 0.9999434947967529
reported O 0 1.2667180271819234e-05
as O 0 6.430210675034687e-08
having O 0 9.102453759624041e-07
either O 0 8.667610927659553e-06
neonatal O 1 0.9999998807907104
SJS B-Disease 1 0.9999998807907104
or O 0 0.0003155051963403821
SWS B-Disease 1 0.7318562269210815
presented O 0 1.0590024857037861e-07
a O 0 1.1834184299175377e-08
combination O 0 3.402731607593523e-08
of O 0 7.589274209074404e-10
a O 0 5.643318345960324e-08
severe O 0 0.002016559476032853
, O 0 4.4226531770164e-08
prenatal O 1 1.0
- O 1 0.9999998807907104
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 0.9999996423721313
( O 0 2.0673131473358808e-07
with O 0 2.682158424249792e-07
congenital B-Disease 1 0.9999998807907104
joint I-Disease 0 0.005297430325299501
contractures I-Disease 1 0.9999562501907349
, O 0 2.424950480417465e-06
respiratory O 1 0.7585231065750122
and O 0 1.5445971257577185e-07
feeding O 0 1.0647017006704118e-05
difficulties O 0 2.1984481008985313e-06
, O 0 2.7860771467658196e-09
tendency O 0 9.690818103536003e-08
to O 0 3.6452128426844865e-08
hyperthermia B-Disease 0 9.791193588171154e-05
, O 0 1.0472633427127676e-08
and O 0 1.9483675117726307e-08
frequent O 0 2.1491319785127416e-05
death O 0 8.185261322068982e-06
in O 0 3.4057315190239024e-08
infancy O 0 0.009318254888057709
) O 0 1.483930756052132e-09
with O 0 5.689483884019353e-10
a O 0 2.0487766150267817e-08
distinct O 0 1.3883907286071917e-06
campomelic B-Disease 0 0.0009064291371032596
- I-Disease 0 0.030878566205501556
metaphyseal I-Disease 0 0.01155818160623312
skeletal I-Disease 0 0.014760535210371017
dysplasia I-Disease 1 0.6301709413528442
. O 0 2.090073621729971e-06

The O 0 2.590038263861061e-07
similarity O 0 1.1327174576081234e-07
of O 0 2.743259841508916e-09
the O 0 8.151429753411321e-09
clinical O 0 2.882385842895019e-06
and O 0 6.112971817628932e-08
radiographic O 0 0.016240790486335754
findings O 0 1.986149527510861e-06
is O 0 2.573272039896324e-09
so O 0 2.040597468777605e-09
extensive O 0 1.801622495634092e-08
that O 0 5.112430478959595e-09
these O 0 1.5086266103025991e-07
disorders O 0 0.45247137546539307
appear O 0 3.0709597353961726e-07
to O 0 2.6823725463032133e-08
be O 0 5.581935624832113e-08
a O 0 3.409488158467866e-08
single O 0 2.415892231510952e-05
entity O 0 5.812974450236652e-06
. O 0 1.0128149341426251e-07

The O 0 8.699192903804942e-07
follow O 0 1.1319815484966966e-06
- O 0 5.480611889652209e-06
up O 0 9.148624968702279e-08
observation O 0 2.7500303190208797e-07
of O 0 1.0645930803576675e-09
an O 0 3.131538584000282e-09
identical O 0 6.139453034847975e-06
and O 0 8.031530107643903e-09
unique O 0 4.189966151812996e-09
pattern O 0 1.2321878557486343e-06
of O 0 3.0402551587371818e-09
progressive O 0 0.06375983357429504
bone B-Disease 1 0.9986414313316345
dysplasia I-Disease 1 0.9872953295707703
in O 0 2.5766523137349395e-08
the O 0 2.4764680972566566e-08
two O 0 8.326198894792469e-07
patients O 0 3.6561425531544955e-06
( O 0 2.253283781783466e-09
one O 0 5.050199813894096e-09
with O 0 6.833444388121279e-08
SJS B-Disease 1 0.9961410164833069
type I-Disease 0 0.00427747517824173
2 I-Disease 0 1.3253738018192962e-07
, O 0 5.100158517734599e-09
one O 0 9.398966938078956e-09
with O 0 2.192084203045397e-08
SWS B-Disease 1 0.5090445280075073
) O 0 3.29060121373459e-08
surviving O 0 3.9855413547229546e-07
beyond O 0 1.624862591143028e-07
infancy O 0 3.859203388856258e-06
adds O 0 3.199748732640728e-08
to O 0 2.728658410333651e-09
the O 0 3.0380291615728083e-09
evidence O 0 1.0617162260473378e-08
in O 0 1.6985530759683343e-09
favor O 0 4.3049194431432625e-08
of O 0 7.832099413462856e-09
identity O 0 2.8223334993526805e-06
. O 0 2.3494500567267096e-07

The O 0 7.372089498858259e-07
hypothesis O 0 1.6713901231923955e-06
that O 0 1.593308063263521e-08
SWS B-Disease 0 0.0004323968314565718
and O 0 1.9960680219810456e-07
SJS B-Disease 1 0.937482476234436
type I-Disease 0 2.819172732415609e-05
2 I-Disease 0 2.1959801088655695e-08
are O 0 2.337455784484632e-09
the O 0 3.2802849325719308e-09
same O 0 6.990638894421863e-07
disorder O 0 0.009779524989426136
should O 0 2.0583966531262377e-08
be O 0 2.5897322064594164e-09
testable O 0 3.02288114539806e-08
by O 0 9.491325503319104e-10
molecular O 0 7.704340987402247e-08
methods O 0 1.8889991224568803e-06
. O 0 4.877117376622664e-08
. O 0 4.1445751719493273e-08

A O 0 5.955474534857785e-06
mouse O 0 1.2689911272900645e-05
model O 0 2.0218164991092635e-06
of O 0 2.846404925094248e-07
severe O 1 0.9999953508377075
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0010604474227875471
defects O 1 0.9999932050704956
in O 0 2.8499957238636853e-07
hemostasis O 1 0.9935640692710876
and O 0 4.228646866977215e-05
thrombosis B-Disease 1 0.908850371837616
. O 0 1.2188489790787571e-06

von B-Disease 1 0.9997401833534241
Willebrand I-Disease 1 0.9960436820983887
factor I-Disease 0 0.00043910517706535757
( I-Disease 0 9.630206477595493e-06
vWf I-Disease 0 0.003163072979077697
) I-Disease 0 8.458246884401888e-05
deficiency I-Disease 1 0.9999700784683228
causes O 0 0.0044797188602387905
severe O 1 0.9999964237213135
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 5.587089617620222e-07
humans O 0 6.513820153486449e-06
. O 0 2.555241280788323e-07

We O 0 1.5915561561996583e-06
generated O 0 4.857037794181451e-08
a O 0 9.354434560293612e-09
mouse O 0 1.86187108397462e-07
model O 0 7.826920978004637e-08
for O 0 1.7528654083776019e-09
this O 0 6.0089053732781395e-09
disease O 0 5.639371011056937e-06
by O 0 5.13125320011909e-10
using O 0 3.061257203285095e-08
gene O 0 9.190834475703014e-07
targeting O 0 3.80644064534863e-06
. O 0 2.1877488620702934e-07

vWf B-Disease 0 0.023769259452819824
- I-Disease 1 0.9668470621109009
deficient I-Disease 0 0.4939492642879486
mice O 0 0.0003905262565240264
appeared O 0 3.1727042824059026e-06
normal O 0 7.59573083541909e-07
at O 0 4.0262426637127646e-07
birth O 0 1.564772719575558e-05
; O 0 1.3884892346993638e-08
they O 0 6.426924414881796e-08
were O 0 1.4328902864235715e-07
viable O 0 3.243258106522262e-07
and O 0 2.0881254059190724e-08
fertile O 0 1.833276428442332e-06
. O 0 1.2761660173055134e-07

Neither O 0 0.00023490165767725557
vWf O 0 0.0003969869576394558
nor O 0 4.989115768694319e-05
vWf O 0 0.0001156975922640413
propolypeptide O 0 0.00027172680711373687
( O 0 1.6834550251587643e-06
von B-Disease 0 0.4495510160923004
Willebrand I-Disease 0 0.12440238893032074
antigen O 0 0.00018265756079927087
II O 0 3.744420246221125e-05
) O 0 4.181601553909786e-08
were O 0 5.2980713149963776e-08
detectable O 0 8.99952169675089e-07
in O 0 2.0130153099984227e-09
plasma O 0 6.367454119526883e-08
, O 0 5.144259684897179e-09
platelets O 0 2.3348331978922943e-07
, O 0 4.396058184141793e-09
or O 0 4.09307929771785e-08
endothelial O 0 8.364116155235024e-08
cells O 0 9.962721314593637e-09
of O 0 3.538480064513294e-10
the O 0 4.927428687295787e-09
homozygous O 0 1.0116300472873263e-05
mutant O 0 3.882296368828975e-06
mice O 0 6.628352821280714e-06
. O 0 1.2634087909191294e-07

The O 0 1.4043052942724898e-06
mutant O 0 4.80193666589912e-05
mice O 0 0.0035602450370788574
exhibited O 0 0.002185108372941613
defects O 1 0.9998705387115479
in O 0 1.5893501625896533e-08
hemostasis O 0 0.0008518828544765711
with O 0 8.362723846744302e-09
a O 0 5.1182674098981806e-08
highly O 0 6.738584488630295e-06
prolonged O 1 0.9799410700798035
bleeding O 1 0.9966804385185242
time O 0 3.251942359838722e-07
and O 0 1.1551134093679138e-07
spontaneous O 0 3.055414481423213e-06
bleeding O 0 0.011916802264750004
events O 0 3.04120817418152e-08
in O 0 2.5542497006370013e-09
approximately O 0 9.532459266381466e-09
10 O 0 9.366717179659645e-09
% O 0 6.6793481856564085e-09
of O 0 1.2836699703200338e-08
neonates O 0 1.842610254243482e-05
. O 0 3.052377905987669e-07

As O 0 5.26734027062048e-07
in O 0 1.2784874492410836e-08
the O 0 8.580772536959103e-09
human O 0 9.024775948773822e-08
disease O 0 5.447096555144526e-06
, O 0 3.664686887283608e-10
the O 0 6.40932751316825e-10
factor O 0 2.0057230543102378e-08
VIII O 0 1.3840202655046596e-06
level O 0 6.818588076384913e-07
in O 0 7.509707522501685e-09
these O 0 5.965684124475956e-08
mice O 0 8.589914614276495e-06
was O 0 2.3112214364573447e-07
reduced O 0 2.0181909476946203e-08
strongly O 0 1.7919033368229975e-08
as O 0 3.3632026052998754e-09
a O 0 4.1749688151071496e-09
result O 0 6.740651592451741e-09
of O 0 1.478945577115809e-10
the O 0 2.2313180192412574e-09
lack O 0 1.9393173289472543e-08
of O 0 9.704848036307112e-10
protection O 0 2.522582498443171e-08
provided O 0 1.6944831315868214e-08
by O 0 1.7385321626761652e-08
vWf O 0 4.627076123142615e-06
. O 0 2.6344281423007487e-07

Defective O 1 0.9711578488349915
thrombosis B-Disease 1 0.6065462231636047
in O 0 1.366284152481967e-07
mutant O 0 9.875874638964888e-06
mice O 0 0.00011312893911963329
was O 0 4.4406579036149196e-07
also O 0 8.049059196935104e-09
evident O 0 5.6816379156998664e-08
in O 0 1.3817780253333467e-09
an O 0 1.3309153779061944e-09
in O 0 3.213968424731206e-09
vivo O 0 7.222305953291652e-07
model O 0 1.0525543814310367e-07
of O 0 2.6383746742908443e-08
vascular B-Disease 0 0.0075064231641590595
injury I-Disease 1 0.530411958694458
. O 0 4.4627640249927936e-07

In O 0 3.6317882745606767e-07
this O 0 1.0892391877348473e-08
model O 0 8.277146434920724e-08
, O 0 3.357037314799527e-09
the O 0 8.568375342576928e-09
exteriorized O 0 8.993920346256346e-06
mesentery O 0 5.215528290136717e-05
was O 0 2.87111333818757e-07
superfused O 0 9.052615723703639e-07
with O 0 1.6666859892211505e-08
ferric O 0 2.2919944058230612e-06
chloride O 0 4.3161588791917893e-07
and O 0 2.7701343441322024e-08
the O 0 4.299510081295921e-09
accumulation O 0 6.137412356110872e-08
of O 0 5.5012234767559676e-09
fluorescently O 0 0.00013840141764376312
labeled O 0 4.9449045036453754e-05
platelets O 0 6.37823222859879e-06
was O 0 1.2543853245006176e-07
observed O 0 4.136070330673647e-08
by O 0 3.970606510250718e-09
intravital O 0 1.391436740050267e-06
microscopy O 0 2.0923132524330867e-06
. O 0 3.002998028023285e-07

We O 0 5.160687578609213e-06
conclude O 0 2.519421684610279e-07
that O 0 2.7964905946475938e-09
these O 0 8.306876075891978e-09
mice O 0 1.5907868373687961e-06
very O 0 2.2355790108008478e-08
closely O 0 1.4663937690784223e-06
mimic O 0 0.07551232725381851
severe O 1 0.7812926769256592
human O 0 7.421736518153921e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 3.3675419217615854e-06
will O 0 1.1264360466611834e-07
be O 0 1.5144843601433422e-08
very O 0 3.019681393823248e-09
useful O 0 1.568953322816924e-08
for O 0 1.101821744953213e-09
investigating O 0 4.2025021684821695e-08
the O 0 1.8300627679934678e-09
role O 0 1.0322863452927322e-08
of O 0 6.043360811780474e-10
vWf O 0 1.4588167118745332e-07
in O 0 3.753927835248305e-09
normal O 0 2.3536324533779407e-07
physiology O 0 7.362071841043871e-08
and O 0 3.872988685316159e-08
in O 0 3.530360359604856e-08
disease O 0 3.309770909254439e-05
models O 0 2.65376854713395e-07
. O 0 5.525188306876316e-09
. O 0 4.404881792652304e-08

Oral O 0 0.0004612130578607321
contraceptives O 0 0.47916379570961
and O 0 2.7309880579196033e-07
the O 0 7.29286284695263e-08
risk O 0 1.4099819964030758e-05
of O 0 4.886792339675594e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3624980965687428e-06

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999833106994629
Clinical O 0 0.0008267289376817644
Study O 0 1.3263945675134892e-06
Group O 0 1.4533900412061485e-06
. O 0 2.3896004108792113e-07

BACKGROUND O 0 0.0010385712375864387
Women O 0 6.457829294959083e-05
with O 0 7.712147720440043e-08
mutations O 0 5.366853656596504e-06
in O 0 2.844747326591346e-09
either O 0 3.9605559720712336e-08
the O 0 1.6785218548420744e-08
BRCA1 O 0 0.00016827670333441347
or O 0 1.2581027419855673e-07
the O 0 9.011492885235839e-09
BRCA2 O 0 2.259191205666866e-05
gene O 0 1.5304358669254725e-07
have O 0 6.369662575167467e-09
a O 0 4.553998955714178e-09
high O 0 5.4666668347636e-07
lifetime O 0 1.1682480362651404e-05
risk O 0 0.00022001714387442917
of O 0 1.1347061445121653e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.403957175076357e-07

Oral O 0 0.0010206345468759537
contraceptives O 1 0.9973490238189697
protect O 0 0.04392480105161667
against O 1 0.9905347228050232
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.4308987772437831e-08
general O 0 1.560227325114738e-08
, O 0 1.1085552920064856e-08
but O 0 6.678710917640274e-09
it O 0 1.269776839230019e-09
is O 0 3.616538457595908e-10
not O 0 6.722621348487223e-10
known O 0 1.2283226658027502e-09
whether O 0 1.2815629668594397e-09
they O 0 4.1597867372900055e-09
also O 0 5.4564970319859185e-09
protect O 0 3.0170230758130856e-08
against O 0 7.395028145396054e-09
hereditary B-Disease 0 2.7115758712170646e-05
forms I-Disease 0 1.5854253661018447e-06
of I-Disease 0 0.001019190181978047
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.071042383202439e-07

METHODS O 0 2.5402852770639583e-05
We O 0 6.114575512583542e-07
enrolled O 0 3.9921297911860165e-07
207 O 0 6.366373668242886e-07
women O 0 8.679652410137351e-07
with O 0 9.307439540862106e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.0980066633692331e-07
161 O 0 4.795217378728012e-08
of O 0 3.893235955843011e-09
their O 0 1.9031339206776465e-06
sisters O 0 3.447486233199015e-05
as O 0 1.4377656398778527e-08
controls O 0 4.552170139504597e-06
in O 0 5.208880438090091e-09
a O 0 2.5381760693221622e-08
case O 0 4.335010928002703e-08
- O 0 9.480995686317328e-06
control O 0 2.637253601278644e-06
study O 0 1.1706559632784774e-07
. O 0 7.097070664485727e-08

All O 0 5.957440407655668e-07
the O 0 4.412340359749578e-08
patients O 0 6.443089546337433e-07
carried O 0 3.5849158308565165e-08
a O 0 6.059003521130535e-09
pathogenic O 0 3.1437105008080835e-07
mutation O 0 4.025497730708594e-07
in O 0 1.6491288334918863e-09
either O 0 7.561250470189407e-08
BRCA1 O 0 2.8460994144552387e-05
( O 0 1.9501149139955487e-08
179 O 0 7.672431223681997e-08
women O 0 4.0312409055331955e-07
) O 0 1.1729823334860612e-08
or O 0 2.729256607381103e-07
BRCA2 O 0 0.00021757467766292393
( O 0 3.386725921927791e-08
28 O 0 1.8962030878810765e-07
women O 0 4.169866656411614e-07
) O 0 4.058609803792024e-08
. O 0 6.716911116200208e-08

The O 0 1.7732735386744025e-06
control O 0 8.855818123265635e-06
women O 0 1.9878664261341328e-06
were O 0 2.7035810035158647e-08
enrolled O 0 3.864878550530193e-08
regardless O 0 1.3642408092096048e-08
of O 0 4.0677505808162095e-10
whether O 0 8.527225148213802e-09
or O 0 2.0302161374274874e-07
not O 0 6.678484254507566e-08
they O 0 1.0474375500280075e-07
had O 0 4.0575034176981717e-07
either O 0 1.9184231803137664e-07
mutation O 0 2.195617298639263e-06
. O 0 8.730878420237786e-08

Lifetime O 0 4.562955291476101e-05
histories O 0 3.632270363596035e-06
of O 0 1.5919715323775563e-08
oral O 0 4.9677864808472805e-06
- O 0 0.00010089501301990822
contraceptive O 0 0.006346897687762976
use O 0 4.3832983465108555e-06
were O 0 2.416452844045125e-06
obtained O 0 3.511864576921653e-08
by O 0 6.1351621560845615e-09
interview O 0 1.9074257124884753e-06
or O 0 4.672580757869582e-07
by O 0 1.8916732624774113e-09
written O 0 6.829011134357188e-09
questionnaire O 0 7.34603915475418e-08
and O 0 1.4355679311961467e-08
were O 0 1.1730890037142672e-07
compared O 0 1.2516613523416709e-08
between O 0 1.8273569324378514e-08
patients O 0 9.647698107073666e-08
and O 0 1.994141918260084e-08
control O 0 1.8218173863715492e-05
women O 0 1.670272831688635e-05
, O 0 5.160917471158655e-09
after O 0 4.0910870247046205e-09
adjustment O 0 2.7419428505481847e-08
for O 0 1.1715574066428758e-09
year O 0 1.2830843054700836e-09
of O 0 5.871789166000951e-10
birth O 0 5.036590664531104e-06
and O 0 1.7274498986807885e-07
parity O 0 2.731948552536778e-05
. O 0 2.134385255203597e-07

RESULTS O 0 6.636821490246803e-05
The O 0 2.8606976343326096e-07
adjusted O 0 0.00023044341651257128
odds O 0 0.00010629872849676758
ratio O 0 0.0010883351787924767
for O 0 0.01851711980998516
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.0726221262302715e-06
with O 0 1.2023663842342103e-08
any O 0 7.857595463178768e-09
past O 0 5.1823651148197314e-08
use O 0 1.4197553355188575e-08
of O 0 3.705143969412461e-09
oral O 0 3.946541255572811e-06
contraceptives O 1 0.9854058027267456
was O 0 1.8765700588119216e-05
0 O 0 5.434433205664391e-07
. O 0 7.117729694527952e-08

5 O 0 1.0113387361343484e-05
( O 0 3.007692725986999e-07
95 O 0 4.94783478188765e-07
percent O 0 4.661654656956671e-06
confidence O 0 1.6645371943013743e-05
interval O 0 6.331597887765383e-06
, O 0 1.0669273464714024e-08
0 O 0 2.0012597801155607e-08
. O 0 6.933930096764129e-10
3 O 0 6.178930700428964e-09
to O 0 7.20080484128971e-09
0 O 0 1.8400569956611434e-07
. O 0 3.5528597841505416e-09
8 O 0 6.143888953147325e-08
) O 0 1.8300497117706982e-08
. O 0 5.3740365046905936e-08

The O 0 4.096280463272706e-06
risk O 0 2.450853389746044e-05
decreased O 0 1.3027110981056467e-06
with O 0 3.822159921895718e-09
increasing O 0 1.1083523432375841e-08
duration O 0 1.335371422328535e-07
of O 0 6.922222239857945e-10
use O 0 6.000867358579853e-08
( O 0 3.192549158370639e-08
P O 0 1.4967114111641422e-05
for O 0 4.718963886318761e-09
trend O 0 6.057070436327194e-07
, O 0 7.085787068206173e-09
< O 0 1.9711639254182955e-07
0 O 0 3.9976232102389986e-08
. O 0 7.3765138441928e-10
001 O 0 4.759961313993699e-08
) O 0 1.669692051287086e-09
; O 0 4.851320456467079e-10
use O 0 1.0169764586009933e-08
for O 0 9.073237272616552e-09
six O 0 3.870759428536985e-07
or O 0 1.0916439663333222e-07
more O 0 3.293952666183486e-09
years O 0 3.2637295532822463e-08
was O 0 1.8855834582609532e-07
associated O 0 8.195470080352152e-09
with O 0 1.1189744686390668e-09
a O 0 2.3262799686563085e-08
60 O 0 8.679688079382686e-08
percent O 0 1.4457575048254512e-07
reduction O 0 3.236188561572817e-08
in O 0 1.5282065390920252e-08
risk O 0 1.7415993625036208e-06
. O 0 2.8611932378908023e-08

Oral O 0 0.0006001992733217776
- O 0 5.567152038565837e-05
contraceptive O 0 0.0001450726413168013
use O 0 1.5837283626751741e-06
protected O 0 0.003089789068326354
against O 1 0.6590979099273682
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 3.719773156163342e-09
for O 0 7.817423930411849e-10
carriers O 0 2.7458415985393003e-08
of O 0 4.686598331637981e-10
the O 0 1.5886955750943343e-08
BRCA1 O 0 0.0012960029998794198
mutation O 0 5.219543254497694e-06
( O 0 3.011756533055632e-08
odds O 0 7.40120094633312e-06
ratio O 0 4.450817868928425e-06
, O 0 7.237844990015674e-09
0 O 0 1.896099277587382e-08
. O 0 5.200985753184284e-10
5 O 0 1.9384585048243252e-09
; O 0 1.0319689547344524e-09
95 O 0 3.925374869595544e-08
percent O 0 1.589409862390312e-06
confidence O 0 0.00019827112555503845
interval O 0 7.223115972010419e-06
, O 0 5.110694978327501e-09
0 O 0 9.55448431483319e-09
. O 0 6.415601938591919e-10
3 O 0 5.541695102806443e-09
to O 0 6.623855686171964e-09
0 O 0 1.9240314941271208e-07
. O 0 2.0864603378356605e-09
9 O 0 1.3621425765109052e-08
) O 0 2.861146597421538e-10
and O 0 6.824398823823685e-10
for O 0 5.01606978176028e-10
carriers O 0 1.5682111609294225e-08
of O 0 8.607354828882308e-10
the O 0 2.5986201634964345e-08
BRCA2 O 0 0.00010827709047589451
mutation O 0 1.7928900888364296e-06
( O 0 2.1471036504294716e-08
odds O 0 2.2978554170549614e-06
ratio O 0 1.8661514786799671e-06
, O 0 7.313071037629015e-09
0 O 0 2.446025071378699e-08
. O 0 9.432005176890357e-10
4 O 0 5.3768531849129886e-09
; O 0 2.112339636539673e-09
95 O 0 3.9916645988569144e-08
percent O 0 3.6493981951934984e-06
confidence O 0 0.00021863779693376273
interval O 0 1.069533664121991e-05
, O 0 1.295884111129908e-08
0 O 0 2.3874632049114553e-08
. O 0 6.459128232272349e-10
2 O 0 5.007565029302441e-09
to O 0 6.817481246201851e-09
1 O 0 2.5000124637131194e-08
. O 0 2.9651412436493274e-09
1 O 0 1.4249180502190484e-08
) O 0 1.3920690378199652e-08
. O 0 3.736072073934338e-08

CONCLUSIONS O 0 3.9186703361338004e-05
Oral O 0 0.0001227152970386669
- O 0 0.0001069047866621986
contraceptive O 0 0.0002776850014925003
use O 0 5.224694632488536e-07
may O 0 4.596529947775707e-07
reduce O 0 1.0827748297970174e-07
the O 0 1.7347460357086675e-08
risk O 0 7.0683354351785965e-06
of O 0 1.6804651750135235e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 9.635374276228958e-09
women O 0 1.6809302394449332e-07
with O 0 3.768792833369616e-09
pathogenic O 0 8.240363627010083e-07
mutations O 0 2.377276814513607e-06
in O 0 3.080743216088422e-09
the O 0 2.926336151176656e-08
BRCA1 O 0 0.0002081151178572327
or O 0 5.0919711611641105e-06
BRCA2 O 0 0.0021014900412410498
gene O 0 0.00012445218453649431

A O 0 3.8079763271525735e-06
Japanese O 0 1.973386360987206e-06
family O 0 1.8850190031116654e-07
with O 0 1.1226546092757417e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.796904314232961e-07
a O 0 1.4691019600832078e-07
codon O 0 5.6407961892546155e-06
291 O 0 4.2564420255075675e-07
deletion O 0 4.279992026567925e-06
: O 0 1.822678541429923e-08
a O 0 2.265113252519768e-08
clinical O 0 2.06151235033758e-05
, O 0 8.537965889843235e-09
biochemical O 0 1.755655375745846e-06
, O 0 4.5768655532185676e-09
pathological O 0 3.5646593232740997e-07
, O 0 4.094467431769999e-09
and O 0 2.1077728007412588e-08
genetic O 0 2.486533958290238e-05
report O 0 3.2482446954418265e-07
. O 0 7.367788867895797e-08

We O 0 5.372153282223735e-06
report O 0 7.531541967864541e-08
a O 0 1.4670544778994099e-08
Japanese O 0 2.5032576900230197e-07
family O 0 8.486729541345994e-08
with O 0 5.207950266594708e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.004515404812991619
ALD B-Disease 1 1.0
) O 0 3.4920866198717704e-08
with O 0 4.925737595584678e-09
a O 0 2.5017202531785188e-08
three O 0 3.552021254904503e-08
base O 0 6.376982923939067e-07
pair O 0 5.746073838963639e-06
deletion O 0 9.376135494676419e-06
( O 0 2.0587343385614076e-08
delGAG O 0 2.2792900722379272e-07
291 O 0 5.1679435841833765e-08
) O 0 2.1020667428928164e-09
in O 0 2.4424104960729665e-09
the O 0 1.6212668185744405e-07
ALD B-Disease 1 1.0
gene O 0 3.1549650884699076e-05
. O 0 3.7022570609224204e-07

A O 0 1.6348661802112474e-06
variety O 0 1.656949564221577e-07
of O 0 2.160252776661764e-08
phenotypes O 0 7.681482202315237e-06
were O 0 3.04302744780216e-07
observed O 0 5.40168016982534e-08
within O 0 4.695261068832224e-09
this O 0 4.727684022043377e-09
family O 0 2.5738947329045914e-07
. O 0 9.544397272520655e-08

While O 0 5.818653789901873e-06
the O 0 9.660993782745209e-08
proband O 0 1.4322758943308145e-05
( O 0 2.1287341667175497e-07
patient O 0 1.2384893125272356e-05
1 O 0 3.137483162163335e-08
) O 0 6.0513465349743e-09
was O 0 1.925329229379713e-07
classified O 0 3.710354974373331e-07
as O 0 3.781135760050347e-08
having O 0 1.399523910095013e-07
a O 0 3.0721643007325383e-09
rare O 0 7.95716648127609e-09
intermediate O 0 5.4802178794943757e-08
type O 0 1.069021209332277e-06
of O 0 3.5791136721030625e-09
adult O 0 1.2912542842968833e-05
cerebral O 0 0.046507611870765686
and O 0 6.612830816266069e-07
cerebello O 0 0.07151143252849579
- O 0 0.3499780595302582
brain O 0 0.023744666948914528
stem O 0 5.56312670596526e-07
forms O 0 3.9337244572834607e-08
, O 0 2.5891244703757366e-09
his O 0 3.7168387478914156e-08
younger O 0 1.7080539009839413e-06
brother O 0 1.4429780321734142e-06
( O 0 1.604959543044515e-08
patient O 0 1.7606070912279392e-07
2 O 0 7.2590258248794726e-09
) O 0 2.5466708741817e-09
and O 0 5.541814118714683e-08
nephew O 0 0.00012243045784998685
( O 0 1.9669255379994866e-07
patient O 0 6.095814114814857e-06
3 O 0 3.048734953381427e-08
) O 0 3.844093487970213e-09
had O 0 1.7621508163756516e-07
a O 0 3.320448342947202e-07
childhood O 1 0.9872811436653137
ALD B-Disease 1 1.0
type O 0 0.16821233928203583
. O 0 9.030102319229627e-07

Another O 0 2.0533228962449357e-05
nephew O 0 0.00015405897283926606
( O 0 1.3933647551311878e-06
patient O 0 2.5327044568257406e-05
4 O 0 4.0082738905766746e-08
) O 0 2.452348768500201e-09
of O 0 2.8111437622158064e-09
patient O 0 3.207646659575403e-05
1 O 0 4.4752983541229696e-08
was O 0 5.40741098120634e-07
classified O 0 6.359304052239168e-07
as O 0 1.7315196387812648e-08
having O 0 3.4667593240556016e-07
an O 0 8.041264543123816e-09
adolescent O 0 1.7401003788108937e-05
form O 0 1.0693220247048885e-06
. O 0 2.4652101160427264e-07

The O 0 3.7101355587765283e-07
tau O 0 4.5566378048533807e-07
level O 0 4.6353517291208846e-07
in O 0 1.759327439287972e-08
the O 0 2.3700187057329458e-07
cerebrospinal O 1 0.9878813028335571
fluid O 0 0.0007443458889611065
( O 0 1.244583586412773e-06
CSF O 0 0.020961999893188477
) O 0 5.054073604071618e-09
in O 0 4.440824596940729e-09
patient O 0 1.570462927702465e-06
1 O 0 1.0245109649531514e-08
was O 0 1.8272041302225261e-07
as O 0 3.070769860613609e-09
high O 0 2.0638532660655073e-08
as O 0 3.001489945475555e-09
that O 0 3.4075603450034464e-10
of O 0 8.857389821592676e-10
patients O 0 3.003817141689069e-07
with O 0 7.132834980438929e-07
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9742199778556824
( O 0 1.7753324144109683e-08
AD B-Disease 0 3.3450151022407226e-06
) O 0 4.3003076655168115e-08
. O 0 5.709589956381933e-08

His O 0 7.638133865839336e-06
brain O 0 7.068758714012802e-05
magnetic O 0 9.620720220482326e-07
resonance O 0 4.5522783693741076e-06
image O 0 0.00023545752628706396
( O 0 1.7870011959075782e-07
MRI O 0 0.004593430086970329
) O 0 1.6831423010899016e-07
showed O 0 0.0008186962804757059
abnormalities B-Disease 1 0.9968908429145813
in I-Disease 0 3.354374555897266e-09
the I-Disease 0 8.617216273876238e-09
bilateral I-Disease 0 5.31404680259584e-07
cerebellar I-Disease 0 4.831283149542287e-05
hemispheres I-Disease 0 0.0017737882444635034
and O 0 3.6177780202706344e-06
brain O 0 0.027066566050052643
stem O 0 1.8980190361617133e-06
, O 0 6.129828644674262e-09
but O 0 2.2913184682948895e-09
not O 0 2.3807955606969244e-09
in O 0 5.435625838323688e-10
the O 0 1.8795935474713588e-08
cerebral O 0 0.007337638642638922
white O 0 3.221537951958453e-07
matter O 0 4.636295347637542e-09
, O 0 1.0196096189574178e-09
where O 0 1.8880146335220616e-09
marked O 0 4.449780632853617e-08
reductions O 0 6.203104874202836e-08
of O 0 5.401582514608094e-10
the O 0 2.0266465838858494e-08
cerebral O 0 0.013434533961117268
blood O 0 8.175649782060646e-06
flow O 0 7.853613936958936e-08
and O 0 1.3820323374602594e-07
oxygen O 0 2.64136389205305e-07
metabolism O 0 7.185728918557288e-07
were O 0 5.4781594371888787e-08
clearly O 0 2.614165417469394e-08
demonstrated O 0 1.279697503520083e-08
by O 0 2.7628983545469055e-09
positron O 0 7.151000431804277e-07
emission O 0 1.009269340102037e-06
tomography O 0 9.134968422586098e-06
( O 0 8.952973473697057e-08
PET O 0 2.7472358397062635e-06
) O 0 4.4554365530302675e-08
. O 0 6.241795347250445e-08

In O 0 2.1300836579030147e-06
patients O 0 8.227726357290521e-05
2 O 0 6.534374819011646e-08
and O 0 2.2957644674193034e-08
3 O 0 2.5487665311629826e-08
, O 0 1.361162738078292e-09
the O 0 4.120210395086588e-09
autopsy O 0 1.0362977263866924e-05
findings O 0 1.877279487416672e-07
showed O 0 1.0456581549078692e-05
massive O 0 2.251568048450281e-06
demyelination B-Disease 1 1.0
of I-Disease 0 1.910905034208099e-08
the I-Disease 0 9.805049216993211e-08
cerebral I-Disease 0 0.015200250782072544
white I-Disease 0 9.581092399457702e-07
matter I-Disease 0 6.9694419124743945e-09
with O 0 1.879409738947402e-09
sparing O 0 2.8784519656710472e-08
of O 0 3.6046470253126017e-09
the O 0 6.296824750506858e-08
U O 0 0.00011797385377576575
- O 0 0.013957638293504715
fibers O 0 0.00012292647443246096
, O 0 4.412885168392222e-09
compatible O 0 3.593041242311301e-08
with O 0 1.1966072577251907e-09
the O 0 1.9196533251886194e-09
findings O 0 2.302293644618203e-08
of O 0 1.3633122186718083e-08
childhood O 1 0.5125298500061035
ALD B-Disease 1 1.0
. O 0 1.4502498970614397e-06

Oleic O 0 0.019712017849087715
and O 0 5.314078862284077e-06
erucic O 0 0.0017338257748633623
acids O 0 3.244859044571058e-06
( O 0 5.5308746027549205e-08
Lorenzos O 0 1.5961679764586734e-06
Oil O 0 9.227028385794256e-08
) O 0 2.551781008719445e-09
were O 0 8.837937492955916e-09
administered O 0 9.720841021021442e-09
to O 0 1.107908431663418e-08
patients O 0 1.899297785712406e-07
1 O 0 5.130717184442801e-09
and O 0 1.0838343555974461e-08
4 O 0 1.7403534613436022e-08
, O 0 1.153673490073004e-09
but O 0 1.1300956836990395e-09
sufficient O 0 2.5270177061997856e-08
effectiveness O 0 7.531950814154698e-07
was O 0 4.5731769660051214e-07
not O 0 1.5142706644155624e-08
obtained O 0 8.060523981612278e-08
. O 0 8.781381666267407e-08

The O 0 6.640175911343249e-07
findings O 0 1.460659859731095e-07
in O 0 4.388660546084111e-09
this O 0 2.0259034450020863e-09
family O 0 1.2430631635140799e-08
suggest O 0 2.5680758852786312e-08
that O 0 9.254127464330963e-10
delGAG291 O 0 1.212251419246968e-07
is O 0 4.3053424714223354e-10
part O 0 4.2880501927022863e-10
of O 0 2.4266125220329116e-10
the O 0 3.913635637786683e-09
cause O 0 2.8694895348735372e-08
of O 0 2.6543589548566615e-09
Japanese O 0 0.00016037689056247473
ALD B-Disease 1 1.0
with O 0 9.26448464610985e-08
phenotypic O 0 2.5556591936037876e-05
variations O 0 4.636788435163908e-05
. O 0 1.031434180731594e-06

Moreover O 0 1.7594400560483336e-05
, O 0 9.789950183858309e-08
although O 0 4.742477521801902e-09
the O 0 6.386531858915134e-10
scale O 0 4.906480199906582e-08
of O 0 8.872353962630086e-10
the O 0 4.361498273652842e-09
study O 0 6.6121916830752525e-09
is O 0 1.4185176366865448e-09
limited O 0 8.647758953372886e-09
, O 0 2.7391500179163586e-09
there O 0 2.0860464466920803e-09
is O 0 3.535498005469151e-10
a O 0 1.5290950727830932e-09
possibility O 0 4.5198000897528345e-09
that O 0 1.0403543582171437e-09
PET O 0 6.699164600831864e-07
can O 0 7.0767136151062e-08
detect O 0 0.00782539788633585
an O 0 3.034283935221538e-08
insidious B-Disease 0 3.227834531571716e-05
lesion I-Disease 0 0.005028636194765568
which O 0 3.125441949691776e-08
is O 0 1.3499063200583805e-08
undetectable O 0 2.7420742299000267e-06
by O 0 2.3320585462727195e-09
computed O 0 3.734348581474478e-07
tomogram O 0 3.2212781206908403e-06
( O 0 1.3591709979721145e-08
CT O 0 4.248031473252922e-05
) O 0 8.657544903201142e-09
or O 0 4.009650211855842e-08
MRI O 0 4.509350674197776e-06
analysis O 0 2.6162882704738877e-07
, O 0 1.6815723924423764e-08
and O 0 1.1373227692956789e-08
that O 0 1.0213009327131317e-09
the O 0 1.5340991810219862e-09
higher O 0 2.3154919759349468e-08
level O 0 2.840162061090723e-08
of O 0 4.4491563211401797e-10
tau O 0 6.694487186820197e-09
reflects O 0 5.060024843572819e-09
the O 0 7.475148278146548e-10
process O 0 2.5333866116028503e-09
of O 0 2.7600226548685214e-09
neuronal B-Disease 0 1.0749265129561536e-05
degeneration I-Disease 0 0.000608340254984796
in O 0 1.1321844795020297e-06
ALD B-Disease 1 1.0
. O 0 2.4071812276815763e-06

Lorenzos O 0 0.0004443818761501461
Oil O 0 6.354336619551759e-06
should O 0 1.1527001220201782e-07
be O 0 3.895249012231261e-09
given O 0 5.082676501899641e-10
in O 0 3.309038876242454e-10
the O 0 2.0425017233094422e-09
early O 0 1.3401147214153752e-07
stage O 0 5.602463716058992e-06
. O 0 1.8052617178909713e-08
. O 0 6.524274454022816e-08

Nonsense O 0 0.00039988954085856676
mutation O 0 6.694453077216167e-06
in O 0 2.1474436451285328e-08
exon O 0 5.523273216567759e-07
4 O 0 3.1453623705601785e-08
of O 0 1.7583636768847555e-09
human O 0 1.5838486078223468e-08
complement O 0 2.434501311654458e-07
C9 O 0 6.902807399455924e-06
gene O 0 3.757433262308041e-07
is O 0 1.7450061395862804e-09
the O 0 8.488841851672646e-10
major O 0 2.4474061888213328e-08
cause O 0 3.463761188982062e-08
of O 0 2.5823680971370777e-09
Japanese O 0 3.836254563793773e-06
complement B-Disease 0 0.000155582936713472
C9 I-Disease 1 0.973599374294281
deficiency I-Disease 0 0.05391203239560127
. O 0 4.812342240256839e-07

Deficiency B-Disease 1 0.9999462366104126
of I-Disease 0 1.0046878173852747e-07
the I-Disease 0 6.698768828528046e-08
ninth I-Disease 0 1.5675644817747525e-06
component I-Disease 0 1.0435748976078685e-07
of I-Disease 0 1.8276418156659702e-09
human I-Disease 0 1.375669977932148e-08
complement I-Disease 0 2.1407005590390327e-07
( O 0 1.0598750321832995e-08
C9 O 0 1.4708151638842537e-06
) O 0 2.7573812122483332e-09
is O 0 2.752487959778449e-10
the O 0 5.904718380911333e-10
most O 0 4.446944146252463e-09
common O 0 4.700452791439602e-06
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.893976500776944e-09
Japan O 0 1.2472958133002976e-07
but O 0 6.246891004479949e-09
is O 0 5.145993631217038e-10
rare O 0 1.0453908849683557e-09
in O 0 3.7213609971331607e-10
other O 0 1.7184570433315116e-09
countries O 0 1.1388292975311742e-08
. O 0 2.9308161231256236e-08

We O 0 6.397634933819063e-06
studied O 0 3.012090132870071e-07
the O 0 5.4860089804265044e-09
molecular O 0 8.708093446330167e-08
basis O 0 4.727434443907441e-08
of O 0 3.244754864795141e-08
C9 B-Disease 1 0.9998397827148438
deficiency I-Disease 1 0.9510279893875122
in O 0 8.74072103584922e-09
four O 0 4.198592051807282e-08
Japanese O 0 2.038000047832611e-06
C9 B-Disease 0 0.0005992596270516515
- I-Disease 0 0.005185253918170929
deficient I-Disease 0 0.001678406959399581
patients O 0 5.515963493962772e-06
who O 0 2.3406518323554337e-07
had O 0 9.588556167727802e-06
suffered O 1 0.9835636615753174
from O 0 2.0506653527263552e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.3649757875100477e-06

Direct O 0 4.198402621113928e-06
sequencing O 0 1.2536440863186726e-06
of O 0 3.1852138704380195e-08
amplified O 0 2.373842335146037e-06
C9 O 0 8.327442628797144e-06
cDNA O 0 5.373277645048802e-07
and O 0 6.850383016399064e-08
DNA O 0 1.3541299495045678e-06
revealed O 0 6.448984777307487e-07
a O 0 3.024247874350294e-08
nonsense O 0 3.236781651594356e-07
substitution O 0 3.3656039732932186e-08
( O 0 1.5561440136480087e-08
CGA O 0 1.2398567150739837e-06
- O 0 3.0346422136062756e-05
- O 0 7.412566446873825e-06
> O 0 7.725912496425735e-07
TGA O 0 6.581225534318946e-06
) O 0 1.974773944368735e-08
at O 0 1.8643047994260087e-08
codon O 0 1.476875866046612e-07
95 O 0 2.8501798254865207e-08
in O 0 1.3427438050328533e-09
exon O 0 1.3442542012853664e-07
4 O 0 2.6106775408152316e-08
in O 0 2.012804367623744e-09
the O 0 5.246901579880614e-09
four O 0 4.035699419091543e-07
C9 B-Disease 0 0.0017592340009287
- I-Disease 0 0.015038318932056427
deficient I-Disease 0 0.00029170524794608355
individuals O 0 1.2903154811283457e-07
. O 0 6.612371095116032e-08

An O 0 5.363571631278319e-07
allele O 0 4.558421551337233e-06
- O 0 7.660789833607851e-07
specific O 0 6.697337795458225e-08
polymerase O 0 1.7035672499332577e-06
chain O 0 3.387409378774464e-06
reaction O 0 1.1393620269473104e-07
system O 0 6.090428428251471e-08
designed O 0 2.8768445758942107e-07
to O 0 9.64493551691703e-09
detect O 0 0.00024238436890300363
exclusively O 0 1.8361899378760427e-07
only O 0 4.885643445362575e-09
one O 0 1.2509447921971173e-09
of O 0 3.580709617700961e-10
the O 0 2.7390143486627494e-09
normal O 0 1.073076774105175e-07
and O 0 8.371006998686426e-09
mutant O 0 2.9279004820637056e-07
alleles O 0 1.299148806310768e-07
indicated O 0 7.613725472310762e-08
that O 0 5.849789541656492e-10
all O 0 8.7958229588736e-10
the O 0 2.293378154050174e-09
four O 0 2.814582273913402e-07
patients O 0 1.1873698468889415e-07
were O 0 2.8769207460754842e-08
homozygous O 0 2.2009118083587964e-07
for O 0 5.600079844292338e-10
the O 0 1.7951385933301367e-09
mutation O 0 3.6767890065902975e-08
in O 0 4.983817247783406e-10
exon O 0 5.768689703700147e-08
4 O 0 3.31621983207242e-08
and O 0 9.723696514640778e-09
that O 0 1.5162784361422155e-09
the O 0 3.1352920260019346e-09
parents O 0 4.13224547912705e-08
of O 0 6.657633333517765e-10
patient O 0 4.197855787424487e-07
2 O 0 4.002536257985412e-08
were O 0 5.165593393030576e-07
heterozygous O 0 1.5162008821789641e-05
. O 0 2.168700063975848e-07

The O 0 9.188379976876604e-07
common O 0 3.3657013887022913e-07
mutation O 0 1.2183713806734886e-06
at O 0 2.545856325752993e-08
codon O 0 1.664243853838343e-07
95 O 0 2.0124865329762542e-08
in O 0 1.2673089244685798e-09
exon O 0 1.493079793135621e-07
4 O 0 3.801948977866232e-08
might O 0 2.715990454760231e-08
be O 0 3.080819599432516e-09
responsible O 0 1.0698229857553088e-08
for O 0 4.902714900723026e-10
most O 0 4.718972768102958e-09
Japanese O 0 1.5077311218192335e-05
C9 B-Disease 1 0.9263288378715515
deficiency I-Disease 0 0.0005697975866496563
. O 0 1.968850504852071e-08
. O 0 9.466293704463169e-08

BRCA1 O 0 0.002813733648508787
required O 0 2.993944235640811e-06
for O 0 2.9713024929378662e-08
transcription O 0 9.485082955507096e-06
- O 0 0.0002236294822068885
coupled O 0 7.811990508344024e-05
repair O 0 0.0005957884714007378
of O 0 2.5435360484493685e-08
oxidative O 0 7.879007898736745e-05
DNA O 0 4.932470619678497e-05
damage O 0 7.467498653568327e-05
. O 0 2.4408174681411765e-07

The O 0 3.410047065699473e-05
breast B-Disease 1 0.9999984502792358
and I-Disease 1 0.9995368719100952
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.00218123197555542
gene O 0 5.169404539628886e-05
BRCA1 O 0 0.0005257494049146771
encodes O 0 2.909850309151807e-06
a O 0 1.2620530469575897e-06
zinc O 1 0.8060715794563293
finger O 0 0.029765572398900986
protein O 0 4.95982078518864e-07
of O 0 8.327499578797415e-09
unknown O 0 3.4219326039419684e-07
function O 0 3.872187903652957e-07
. O 0 7.623287245905885e-08

Association O 0 4.124720362597145e-06
of O 0 4.213963933352716e-08
the O 0 3.84415379528491e-08
BRCA1 O 0 3.2508429285371676e-05
protein O 0 1.6346933762179106e-07
with O 0 5.919177148427934e-09
the O 0 1.6381633827222686e-08
DNA O 0 1.3540213785745436e-06
repair O 0 1.2430401511664968e-05
protein O 0 5.328870429366361e-07
Rad51 O 0 4.869955319009023e-06
and O 0 1.8483403252389508e-08
changes O 0 7.342575436553034e-09
in O 0 6.25997198522299e-10
the O 0 4.6202619508051157e-10
phosphorylation O 0 1.1021334067606858e-08
and O 0 9.335273887245421e-09
cellular O 0 9.258266686629213e-08
localization O 0 1.688788984210987e-07
of O 0 7.059073880988365e-10
the O 0 2.197906523448978e-09
protein O 0 3.200047871132483e-08
after O 0 1.4784450996785381e-08
exposure O 0 6.567498758158763e-07
to O 0 7.207070495951484e-09
DNA O 0 7.17034527042415e-06
- O 0 1.7438913346268237e-05
damaging O 0 2.0962235794286244e-05
agents O 0 1.2770365742653667e-07
are O 0 5.530048863278125e-09
consistent O 0 1.079648441759673e-07
with O 0 1.6000163416407531e-09
a O 0 7.547832581167313e-09
role O 0 4.1569020226006614e-08
for O 0 5.235874844800037e-09
BRCA1 O 0 6.174572263262235e-06
in O 0 1.785489445182975e-08
DNA O 0 3.6114975046075415e-06
repair O 0 0.00014797048061154783
. O 0 4.768826329382136e-07

Here O 0 1.4717750218551373e-06
, O 0 1.2339214094936324e-08
it O 0 7.152754499806235e-10
is O 0 2.9733177031587843e-10
shown O 0 1.906524493833217e-09
that O 0 7.108226784957594e-10
mouse O 0 1.2602718015841674e-06
embryonic O 0 1.6052156297519105e-06
stem O 0 2.166538934034179e-06
cells O 0 7.774160621920601e-07
deficient B-Disease 0 8.059015499384259e-07
in I-Disease 0 1.735079413478502e-09
BRCA1 I-Disease 0 6.6186184994876385e-06
are O 0 2.4825641986581104e-08
defective O 0 1.7549891708767973e-06
in O 0 1.861394038904507e-09
the O 0 2.2658726006596908e-09
ability O 0 4.3891567713671975e-08
to O 0 3.0575499909701875e-09
carry O 0 8.427529962773406e-08
out O 0 4.306233591933051e-08
transcription O 0 2.9113602977304254e-06
- O 0 3.719748929142952e-05
coupled O 0 3.754932913579978e-05
repair O 0 0.0004355064011178911
of O 0 1.1695910018261202e-08
oxidative O 0 5.066548692411743e-05
DNA O 0 3.994291546405293e-05
damage O 0 3.504339838400483e-05
, O 0 6.620016090863601e-09
and O 0 3.718709118416541e-09
are O 0 5.154886739688891e-09
hypersensitive O 0 2.7236374080530368e-06
to O 0 5.82961305894969e-08
ionizing O 0 0.02204958163201809
radiation O 0 0.11448857188224792
and O 0 2.4714668711567356e-07
hydrogen O 0 1.12840518795565e-06
peroxide O 0 0.00014058465603739023
. O 0 1.8501185650166008e-07

These O 0 9.060017305273504e-07
results O 0 6.903754865561496e-07
suggest O 0 8.284870745001172e-08
that O 0 3.951846405669812e-09
BRCA1 O 0 7.549572274001548e-06
participates O 0 5.058908314481414e-08
, O 0 2.9120861277931454e-09
directly O 0 2.148029487614167e-08
or O 0 6.846007494232254e-08
indirectly O 0 2.2809122413036675e-07
, O 0 1.2402536775368844e-09
in O 0 7.17699732977195e-10
transcription O 0 1.0122759022124228e-06
- O 0 7.909511623438448e-05
coupled O 0 1.0681330422812607e-05
repair O 0 7.377944712061435e-05
of O 0 8.628366465757153e-09
oxidative O 0 5.389567741076462e-05
DNA O 0 6.897381535964087e-05
damage O 0 2.7568194127525203e-05
. O 0 3.2206280309310387e-08
. O 0 1.2741789134906867e-07

Truncation O 0 0.000510370300617069
mutations O 0 0.00042261782800778747
in O 0 7.011082914232247e-08
the O 0 1.5319770341193362e-08
transactivation O 0 2.8724766707455274e-06
region O 0 4.5772868162430314e-08
of O 0 6.445262545895503e-09
PAX6 O 0 3.0039975172257982e-05
result O 0 3.607627547808079e-07
in O 0 1.745060274060961e-08
dominant O 0 5.2346680604387075e-05
- O 0 3.164861482218839e-05
negative O 0 1.6019192116800696e-05
mutants O 0 3.5925456813856727e-06
. O 0 1.4456981034527416e-07

PAX6 O 0 0.0010154127376154065
is O 0 3.8768661170252017e-07
a O 0 3.124303304957721e-08
transcription O 0 3.741238856491691e-07
factor O 0 1.1082659767680525e-07
with O 0 3.546603677406779e-09
two O 0 3.380929669560828e-08
DNA O 0 4.095382337254705e-06
- O 0 6.644180757575668e-06
binding O 0 1.1661770713544684e-06
domains O 0 1.7165339158964343e-06
( O 0 5.610541364831079e-08
paired O 0 2.3154361770139076e-06
box O 0 1.646216901463049e-06
and O 0 6.201366176128431e-08
homeobox O 0 5.643608460559335e-07
) O 0 3.1026146096735374e-09
and O 0 2.7900441956774102e-09
a O 0 1.4019333249848387e-08
proline O 0 4.220047230774071e-06
- O 0 4.159053787589073e-06
serine O 0 4.676763182942523e-06
- O 0 4.082335181010421e-06
threonine O 0 4.840806468564551e-06
( O 0 4.443673873311127e-08
PST O 0 1.4762634918952244e-06
) O 0 2.19698552683667e-08
- O 0 4.029703859487199e-07
rich O 0 1.44839617632897e-07
transactivation O 0 1.115507802751381e-05
domain O 0 9.145098260887607e-07
. O 0 3.2492297918906843e-07

PAX6 O 0 0.007538995239883661
regulates O 0 0.00029514305060729384
eye O 0 0.01617998629808426
development O 0 2.521592250559479e-07
in O 0 1.766196255914565e-08
animals O 0 1.7479683478427432e-08
ranging O 0 1.9144986040942058e-08
from O 0 3.191263031609992e-09
jellyfish O 0 7.692957382232635e-09
to O 0 1.5016003995782512e-09
Drosophila O 0 8.22668724254072e-08
to O 0 9.508525522505806e-09
humans O 0 2.4182224933610996e-07
. O 0 6.03346137495464e-08

Heterozygous O 0 0.0015328861773014069
mutations O 0 4.305751281208359e-05
in O 0 1.3446205038292192e-08
the O 0 7.0128858276063966e-09
human O 0 3.6654455470852554e-08
PAX6 O 0 9.274504009226803e-06
gene O 0 1.0900465667873505e-06
result O 0 5.7421896570986064e-08
in O 0 1.1759027085389562e-09
various O 0 7.292859649510319e-09
phenotypes O 0 1.4377059414982796e-05
, O 0 6.370196814486917e-09
including O 0 2.5907068490482743e-08
aniridia B-Disease 1 1.0
, O 0 1.4076465504331281e-06
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999994039535522
, O 0 1.965459262009972e-07
autosomal B-Disease 1 0.8317213654518127
dominant I-Disease 0 0.040844641625881195
keratitis I-Disease 0 0.005220604129135609
, O 0 7.627825482359185e-08
and O 0 4.536809115052165e-07
familial B-Disease 1 0.9977388381958008
foveal I-Disease 1 0.9829414486885071
dysplasia I-Disease 1 0.9998598098754883
. O 0 5.3776584536535665e-06

It O 0 6.275926125454134e-07
is O 0 1.9427938369176445e-08
believed O 0 2.3496870227290856e-08
that O 0 5.029606731099534e-10
the O 0 8.189512956668921e-10
mutated O 0 2.7752864184549253e-07
allele O 0 2.1845382036644878e-07
of O 0 3.909756074449433e-09
PAX6 O 0 7.41637040846399e-06
produces O 0 8.397172734930791e-08
an O 0 6.204167402046323e-09
inactive O 0 8.955139492172748e-07
protein O 0 1.7112238026584237e-07
and O 0 5.865727530363074e-07
aniridia B-Disease 1 1.0
is O 0 8.139051033140277e-08
caused O 0 2.2311451175482944e-07
due O 0 4.386294705227556e-08
to O 0 3.828385430892922e-08
genetic O 0 0.00016024788783397526
haploinsufficiency O 0 0.00015545613132417202
. O 0 4.975587444278062e-07

However O 0 2.002891960728448e-06
, O 0 1.5425973387550584e-08
several O 0 8.473285184606993e-09
truncation O 0 1.0191006367676891e-06
mutations O 0 1.594759669387713e-05
have O 0 9.283093049816671e-08
been O 0 3.288606009732575e-08
found O 0 9.268068978940391e-09
to O 0 2.9173898852263846e-09
occur O 0 2.0573761361220022e-08
in O 0 3.679242466247956e-09
the O 0 7.048572570056422e-08
C O 0 0.0037782229483127594
- O 0 1.6629805031698197e-05
terminal O 0 6.552397167070012e-07
half O 0 1.7662099338622284e-08
of O 0 8.262595607710921e-10
PAX6 O 0 2.0746892914758064e-06
in O 0 1.669536864312704e-08
patients O 0 6.426532763725845e-07
with O 0 3.663097558614936e-08
Aniridia B-Disease 1 1.0
resulting O 0 7.936129691188398e-07
in O 0 4.24960555633902e-09
mutant O 0 1.218713805428706e-07
proteins O 0 7.568966786664078e-09
that O 0 9.364069519790519e-10
retain O 0 2.1544802564221754e-07
the O 0 5.456726182018201e-09
DNA O 0 2.905827329868771e-07
- O 0 2.1276564154959487e-07
binding O 0 6.25995397740553e-08
domains O 0 1.2023990336729184e-07
but O 0 1.9071729084885192e-08
have O 0 3.08512539959338e-08
lost O 0 7.094579359545605e-07
most O 0 8.025799469457695e-10
of O 0 5.127740454469176e-10
the O 0 1.2623688760982077e-08
transactivation O 0 1.8504008039599285e-05
domain O 0 9.769801181391813e-07
. O 0 2.9132417012078804e-07

It O 0 5.309857442625798e-07
is O 0 1.77778556320618e-08
not O 0 4.216631488418443e-09
clear O 0 1.0412362527745245e-08
whether O 0 1.3004963772544897e-09
such O 0 2.3146164984666484e-09
mutants O 0 8.910790256777545e-07
really O 0 2.8410136110323947e-07
behave O 0 5.441035710873621e-08
as O 0 8.428490794187837e-09
loss O 0 5.358908339303525e-08
- O 0 3.348428947447246e-07
of O 0 5.696239924191104e-09
- O 0 4.872283170698211e-06
function O 0 4.073656043601659e-07
mutants O 0 6.351170327434374e-07
as O 0 2.25417888799484e-08
predicted O 0 3.9724193356960313e-07
by O 0 1.8550789349092156e-08
haploinsufficiency O 0 1.0290799764334224e-05
. O 0 1.479578344287802e-07

Contrary O 0 7.997527973202523e-06
to O 0 3.8957338688305754e-08
this O 0 2.914175345480885e-09
theory O 0 6.7515242285765e-09
, O 0 1.8353061292941675e-09
our O 0 1.0151276264025455e-08
data O 0 1.1568045010790229e-07
showed O 0 7.1505502319269e-07
that O 0 3.706513429513336e-10
these O 0 8.034024001624118e-10
mutants O 0 3.0121128702376154e-08
are O 0 1.1928131815608367e-09
dominant O 0 5.89262924677314e-07
- O 0 1.5713902712377603e-06
negative O 0 5.51316929886525e-07
in O 0 4.056425417786613e-09
transient O 0 3.8636929389213037e-07
transfection O 0 3.523896566548501e-06
assays O 0 7.733263373665977e-06
when O 0 2.380293295800584e-07
they O 0 1.516016112645957e-08
are O 0 2.419394906638672e-09
coexpressed O 0 1.5936126374072046e-07
with O 0 5.178192541421822e-09
wild O 0 2.428675998089602e-07
- O 0 8.6846148406039e-06
type O 0 0.00023138774849940091
PAX6 O 0 0.00041839605546556413
. O 0 8.140842169268581e-07

We O 0 4.171996351942653e-06
found O 0 4.6017273547249715e-08
that O 0 1.95229121757734e-09
the O 0 6.051115608585178e-09
dominant O 0 1.0377594662713818e-05
- O 0 1.3618495358969085e-05
negative O 0 1.2524882549769245e-05
effects O 0 1.6500711353728548e-05
result O 0 9.532935507650109e-08
from O 0 1.4972761919196387e-09
the O 0 1.0732846833505505e-09
enhanced O 0 7.538527313499799e-08
DNA O 0 1.341035300583826e-07
binding O 0 3.830174932772934e-08
ability O 0 3.5943436671459494e-08
of O 0 1.4610750387333837e-09
these O 0 1.1059237969845981e-08
mutants O 0 1.0761702924355632e-06
. O 0 5.872668751294441e-08

Kinetic O 0 5.622202934318921e-06
studies O 0 6.24040296770545e-07
of O 0 1.296512053272636e-08
binding O 0 5.214669158704055e-07
and O 0 1.9182419919161475e-07
dissociation O 0 9.370494808536023e-06
revealed O 0 2.5732396125022206e-07
that O 0 4.134236286645887e-10
various O 0 1.4270714610020718e-09
truncation O 0 4.455883129139693e-07
mutants O 0 7.954679404065246e-07
have O 0 1.612237099379854e-08
3 O 0 1.5157038291135905e-08
- O 0 1.7591448795428732e-06
5 O 0 1.162436831236846e-07
- O 0 1.0878729881369509e-06
fold O 0 1.5547115594927163e-07
higher O 0 2.0024012670205593e-08
affinity O 0 1.610196598278435e-08
to O 0 2.5586091023654944e-09
various O 0 5.495434773905572e-09
DNA O 0 1.8158449677230237e-07
- O 0 9.291985492154708e-08
binding O 0 2.7256326973201794e-08
sites O 0 4.1297955277741494e-08
when O 0 1.8749064523149173e-08
compared O 0 1.3123704789563817e-08
with O 0 1.3398145926046823e-09
the O 0 9.142829604513736e-09
wild O 0 1.3229087869603973e-07
- O 0 5.1746492317761295e-06
type O 0 2.1755826310254633e-05
PAX6 O 0 0.00010888963879551739
. O 0 5.757476628787117e-07

These O 0 1.4777733667870052e-06
results O 0 2.4865528303052997e-07
provide O 0 2.704364732153408e-08
a O 0 8.94464058376343e-09
new O 0 3.967707051799607e-09
insight O 0 2.313249503060888e-08
into O 0 1.682887051934756e-09
the O 0 2.250539088421988e-09
role O 0 8.530770756465245e-09
of O 0 1.2585601449899286e-09
mutant O 0 7.872418450460827e-07
PAX6 O 0 8.357428669114597e-06
in O 0 4.824813970571995e-08
causing O 0 1.6825721104396507e-05
aniridia B-Disease 1 0.9999967813491821
. O 0 1.1384626930066588e-07
. O 0 1.8874330010021367e-07

Reversal O 0 8.584177703596652e-05
of O 0 1.6984945432341192e-06
severe O 1 0.9999645948410034
hypertrophic B-Disease 1 0.9999996423721313
cardiomyopathy I-Disease 1 1.0
and O 0 2.1109381123096682e-05
excellent O 0 3.504734195303172e-05
neuropsychologic O 0 0.00013938744086772203
outcome O 0 6.325776098492497e-07
in O 0 1.4059392761112122e-08
very B-Disease 0 5.636293280986138e-07
- I-Disease 0 0.0016801992896944284
long I-Disease 0 0.0005601355223916471
- I-Disease 0 0.0008634609403088689
chain I-Disease 0 9.831685019889846e-05
acyl I-Disease 0 1.5267347407643683e-05
- I-Disease 0 5.72621638639248e-06
coenzyme I-Disease 0 6.151004072307842e-06
A I-Disease 0 1.607138074177783e-06
dehydrogenase I-Disease 0 0.024542011320590973
deficiency I-Disease 0 0.017559632658958435
. O 0 3.411388433960383e-07

Very B-Disease 0 5.40797809662763e-05
- I-Disease 0 0.0003611082793213427
long I-Disease 0 5.667001096298918e-05
- I-Disease 0 6.90274391672574e-05
chain I-Disease 0 2.297153878316749e-05
acyl I-Disease 0 6.693335762975039e-06
- I-Disease 0 1.6679078953529825e-06
coenzyme I-Disease 0 5.796427444693109e-07
A I-Disease 0 7.801776291671558e-08
dehydrogenase I-Disease 0 1.0639232641551644e-05
( I-Disease 0 1.2803729987354018e-07
VLCAD I-Disease 0 0.0001250240602530539
) I-Disease 0 2.4686445954102965e-07
deficiency I-Disease 0 9.007288463180885e-05
is O 0 2.8753390779456822e-09
a O 0 3.376058188564457e-08
disorder O 0 0.027656007558107376
of O 0 7.454080019897447e-09
fatty O 0 1.9669005268951878e-05
acid O 0 6.476028033830517e-07
beta O 0 2.870206472493919e-08
oxidation O 0 7.170081062213285e-08
that O 0 1.1220076423512637e-08
reportedly O 0 4.5818379135198484e-07
has O 0 3.298013862007565e-09
high O 0 4.751570870098476e-08
rates O 0 2.3868863081588643e-06
of O 0 7.16123471633523e-09
morbidity O 0 0.00011397436901461333
and O 0 6.416844371415209e-07
mortality O 0 0.0002106155880028382
. O 0 1.4887459087731258e-07

We O 0 4.536023425316671e-06
describe O 0 5.923188837186899e-07
the O 0 2.2375115094064313e-08
outcome O 0 5.025555793736203e-08
of O 0 9.786282895163367e-10
a O 0 4.723099067405201e-08
5 O 0 1.1255458787218231e-07
- O 0 1.4494738024950493e-05
year O 0 1.0085104662493904e-07
- O 0 2.7144809791934676e-05
old O 0 0.00023053707263898104
girl O 0 0.00014002673560753465
with O 0 7.896231295489997e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 9.99852886707231e-07
was O 0 1.2830194862090138e-07
first O 0 1.5104427930623388e-08
seen O 0 4.2889629980891186e-07
at O 0 2.2694420565017026e-08
5 O 0 4.9270902913178816e-09
months O 0 3.594643693816124e-09
of O 0 9.585144900015052e-10
age O 0 1.5970176718838047e-06
with O 0 1.1607235137489624e-06
severe O 1 0.9999983310699463
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
, O 0 3.082114926655777e-05
hepatomegaly B-Disease 1 1.0
, O 0 9.992152627091855e-06
encephalopathy B-Disease 1 0.9690160155296326
, O 0 1.4154372784958014e-08
and O 0 9.66645004041311e-08
hypotonia B-Disease 0 0.002967553911730647
. O 0 7.24156222986494e-07

Biochemical O 0 0.0005017220391891897
studies O 0 0.00013739785936195403
indicated O 1 0.9995133876800537
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 3.364610893186182e-05
by O 0 8.440395049547078e-09
a O 0 7.64924195095773e-08
stable O 0 6.896263221278787e-05
yet O 0 1.3535421317101282e-07
inactive O 0 6.681369768557488e-07
enzyme O 0 7.14725047146203e-07
. O 0 4.782202012165726e-08

Molecular O 0 2.7727151973522268e-05
genetic O 0 1.085485564544797e-05
analysis O 0 1.6745381969940354e-07
of O 0 7.803738100164992e-09
her O 0 6.508702881546924e-06
VLCAD O 0 0.03557009994983673
gene O 0 1.0717820259742439e-05
revealed O 0 1.2783712008967996e-06
a O 0 3.1799206823279746e-08
T1372C O 0 2.1957514491077745e-06
( O 0 2.1464405364213235e-08
F458L O 0 7.649328495062946e-07
) O 0 1.2199505405874334e-08
missense O 0 6.158053565741284e-06
mutation O 0 5.545563908526674e-06
and O 0 6.813493058643871e-08
a O 0 3.724333055288298e-07
1668 O 0 0.0004690475470852107
ACAG O 0 0.000622963416390121
1669 O 0 3.53767245542258e-05
splice O 0 0.00021732694585807621
site O 0 8.20951936475467e-06
mutation O 0 5.398909706855193e-05
. O 0 9.34033209887275e-07

After O 0 4.887868726655142e-06
initial O 0 1.365622892990359e-06
treatment O 0 8.708971677151567e-07
with O 0 2.106836305415527e-08
intravenous O 0 1.4429419934458565e-05
glucose O 0 0.00017078856762964278
and O 0 7.671392410202316e-08
carnitine O 0 8.563576557207853e-06
, O 0 1.764422030703372e-08
the O 0 1.3986881874927803e-08
patient O 0 8.535761253369856e-07
has O 0 5.70635316776702e-09
thrived O 0 1.2272066385321523e-07
on O 0 7.030725779344493e-09
a O 0 1.9608643597734954e-08
low O 0 0.0034885755740106106
- O 0 0.00021461170399561524
fat O 0 1.5119451290956931e-06
diet O 0 4.40889955655166e-08
supplemented O 0 6.322796508584361e-08
with O 0 7.678737645733236e-09
medium O 0 8.741475539864041e-06
- O 0 3.245447078370489e-05
chain O 0 1.0569967344054021e-05
triglyceride O 0 2.36086520999379e-06
oil O 0 9.909962273013662e-08
and O 0 8.418497010609372e-09
carnitine O 0 7.66419589126599e-07
and O 0 1.3265492704306325e-08
avoidance O 0 3.399920274205215e-07
of O 0 2.1921302106875373e-08
fasting O 0 1.088132648874307e-05
. O 0 1.660790758251096e-07

Her O 0 0.009637679904699326
ventricular O 1 0.5608972311019897
hypertrophy O 0 0.003648962127044797
resolved O 0 6.305637725745328e-06
significantly O 0 9.794597417567275e-07
over O 0 3.729351405468151e-08
1 O 0 3.557105898721602e-08
year O 0 8.937580453505234e-09
, O 0 3.348761712373971e-09
and O 0 6.624615878081386e-08
cognitively O 0 1.469876769988332e-05
, O 0 2.0439669956573425e-09
she O 0 3.166327289250148e-08
is O 0 2.964088141599319e-10
in O 0 2.1568498376201006e-10
the O 0 8.221188729784501e-10
superior O 0 2.7973030114480935e-08
range O 0 1.3389343678227306e-07
for O 0 1.0324990640242504e-08
age O 0 1.4148712352834991e-06
. O 0 8.521472949496456e-08

Clinical O 0 0.0027700394857674837
recognition O 0 3.1011072678666096e-06
of O 0 3.460787866060855e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.7188825413304585e-08
important O 0 1.1118077125615855e-08
because O 0 2.064002835311385e-08
it O 0 9.628865482724791e-10
is O 0 2.45521658559511e-10
one O 0 3.4891137201675804e-10
of O 0 1.419859507745258e-10
the O 0 2.1990638199298473e-09
few O 0 3.4317622521484736e-08
directly O 0 8.932988748711068e-06
treatable O 0 0.13866282999515533
causes O 0 1.522661676744974e-07
of O 0 2.0049084170636888e-08
cardiomyopathy B-Disease 1 1.0
in O 0 1.6383907563977118e-07
children O 0 2.0791317183466163e-06
. O 0 1.6484346332390487e-08
. O 0 4.1449624177403166e-08

Cloning O 0 1.1318561519146897e-05
of O 0 7.951586411536482e-08
a O 0 5.425843241368966e-08
novel O 0 4.318901147826182e-08
member O 0 7.945458513347603e-09
of O 0 1.4595263886363341e-09
the O 0 2.614464555961149e-08
low O 0 0.008755852468311787
- O 0 0.00028650424792431295
density O 0 1.779168314897106e-06
lipoprotein O 0 0.005767717491835356
receptor O 0 1.4135012861515861e-05
family O 0 6.224960884537722e-07
. O 0 1.281090078464331e-07

A O 0 2.290797056048177e-06
gene O 0 1.9623066691565327e-06
encoding O 0 1.813629779690018e-07
a O 0 4.32477023082356e-08
novel O 0 9.870875317119499e-08
transmembrane O 0 7.536096404692216e-07
protein O 0 6.762545581295853e-07
was O 0 3.716885430549155e-07
identified O 0 6.069033275934999e-08
by O 0 9.077040785676616e-10
DNA O 0 2.6086366844424447e-08
sequence O 0 1.9416750873801902e-08
analysis O 0 2.5373436685072193e-08
within O 0 1.2126382564758842e-08
the O 0 9.316102023149142e-08
insulin B-Disease 1 0.9991447925567627
- I-Disease 1 0.9999390840530396
dependent I-Disease 1 0.9999955892562866
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 3.5061468679487007e-06
IDDM B-Disease 0 0.00017215083062183112
) O 0 1.2911242208701879e-07
locus O 0 2.0466561181819998e-05
IDDM4 O 0 7.798510341672227e-05
on O 0 4.899260943602712e-07
chromosome O 0 0.00016768294153735042
11q13 O 0 3.881714656017721e-05
. O 0 7.961722872096288e-07

Based O 0 1.1378486988178338e-06
on O 0 1.1133806054886008e-07
its O 0 3.194181630306048e-08
chromosomal O 0 0.0001978168002096936
position O 0 1.583110133651644e-05
, O 0 1.893225576310442e-09
this O 0 3.0313943022441947e-10
gene O 0 2.69181317236189e-08
is O 0 4.3036180175093364e-10
a O 0 1.9631984926604673e-09
candidate O 0 2.016121136705351e-08
for O 0 1.7446034616952488e-09
conferring O 0 3.7159639987294213e-07
susceptibility O 0 5.6244949519168586e-05
to O 0 2.2054762212064816e-06
diabetes B-Disease 1 0.9996216297149658
. O 0 5.861701311005163e-07

The O 0 4.954525820721756e-07
gene O 0 2.3358541056950344e-06
, O 0 3.13992565281751e-08
termed O 0 1.2119651273678755e-06
low O 0 0.0006756921648047864
- O 0 3.713043770403601e-05
density O 0 9.850786000242806e-07
lipoprotein O 0 0.000955510709900409
receptor O 0 8.47044702823041e-06
related O 0 1.1873834893094681e-07
protein O 0 1.3643233387483633e-07
5 O 0 3.09751335691999e-08
( O 0 1.0648556703074519e-08
LRP5 O 0 3.950593054469209e-06
) O 0 3.337832010785746e-09
, O 0 3.751363386594875e-10
encodes O 0 1.5296091504524156e-08
a O 0 9.003589873657347e-09
protein O 0 4.5466844511565796e-08
of O 0 4.525355645768059e-09
1615 O 0 3.5596453926700633e-06
amino O 0 3.3294855938947876e-07
acids O 0 1.997968190892152e-08
that O 0 1.6474649422448806e-10
contains O 0 6.085743575745539e-10
conserved O 0 4.260220620722066e-09
modules O 0 7.977971172579146e-09
which O 0 3.0492859348640877e-09
are O 0 1.2404003379984374e-09
characteristic O 0 1.3464991788225689e-08
of O 0 8.145395469227878e-10
the O 0 2.9081135721753526e-08
low O 0 0.2847658395767212
- O 0 0.015718750655651093
density O 0 4.653947598853847e-06
lipoprotein O 0 0.07040861248970032
( O 0 8.24503274543531e-07
LDL O 0 0.0001067466801032424
) O 0 4.0278550272887514e-08
receptor O 0 1.167979007732356e-06
family O 0 1.506483044977358e-07
. O 0 1.6215344089687278e-07

These O 0 6.403199677151861e-07
modules O 0 5.222721597419877e-07
include O 0 2.412621924463565e-08
a O 0 1.6749048370456876e-08
putative O 0 6.84965073105559e-07
signal O 0 4.77916103136522e-07
peptide O 0 8.480257207565955e-08
for O 0 6.246970718493117e-10
protein O 0 1.1923725118379025e-08
export O 0 1.5413091247751254e-08
, O 0 1.6123899992948054e-09
four O 0 7.2763528535801925e-09
epidermal O 0 2.0591866700669925e-07
growth O 0 1.0117530990783052e-07
factor O 0 1.150361015334056e-07
( O 0 2.3337683785484842e-08
EGF O 0 3.3073815757234115e-06
) O 0 6.512610450926104e-09
repeats O 0 1.479811260196584e-07
with O 0 8.628235015351038e-09
associated O 0 7.33611145165014e-08
spacer O 0 1.8586721353130997e-06
domains O 0 3.13623195324908e-06
, O 0 4.2364806773775854e-08
three O 0 1.3727401437790832e-07
LDL O 0 0.0003597704053390771
- O 0 7.431978156091645e-05
receptor O 0 4.7593257477274165e-06
( O 0 4.899877836805899e-08
LDLR O 0 4.508120582613628e-06
) O 0 7.6604225185406e-09
repeats O 0 1.4542952442297974e-07
, O 0 3.4390992276200905e-09
a O 0 9.0438305733187e-09
single O 0 3.0551436793757603e-06
transmembrane O 0 4.6594806235589203e-07
spanning O 0 2.699683250284579e-07
domain O 0 3.108842747678864e-07
, O 0 9.858490912506568e-09
and O 0 4.967931843680162e-09
a O 0 1.8942884594252973e-08
cytoplasmic O 0 3.605313622756512e-06
domain O 0 2.3129157398216194e-06
. O 0 1.6150970338912884e-07

The O 0 3.2919137993303593e-07
encoded O 0 3.3909989838321053e-07
protein O 0 1.938767013598408e-07
has O 0 5.4150670614205865e-09
a O 0 2.8365820803344377e-09
unique O 0 9.097671060942503e-09
organization O 0 6.40333164270146e-09
of O 0 1.4053540553504718e-09
EGF O 0 2.0800956917810254e-05
and O 0 1.80100798274907e-07
LDLR O 0 0.00015460878785233945
repeats O 0 5.879443051526323e-06
; O 0 1.2336860422124118e-08
therefore O 0 2.7168505667418685e-08
, O 0 3.2913336500683954e-09
LRP5 O 0 1.8603640228320728e-06
likely O 0 1.0098847980088976e-07
represents O 0 9.174377701981484e-09
a O 0 4.726981028824184e-09
new O 0 3.1438429637375975e-09
category O 0 3.3025295920197095e-07
of O 0 1.8376600241509777e-09
the O 0 4.2908446573619585e-08
LDLR O 0 0.0001715457037789747
family O 0 4.2285776657990937e-07
. O 0 9.476229934080038e-08

Both O 0 2.947319217128097e-06
human O 0 3.941926536299434e-07
and O 0 7.979785721090593e-08
mouse O 0 1.3234605830803048e-05
LRP5 O 0 7.29744861018844e-05
cDNAs O 0 1.8316076193514164e-06
have O 0 6.666101626251475e-08
been O 0 3.904995793391208e-08
isolated O 0 2.0365553154988447e-07
and O 0 1.803966642732746e-09
the O 0 4.646013018749784e-10
encoded O 0 1.724377796108456e-08
mature O 0 6.8772965100549754e-09
proteins O 0 2.029600931763298e-09
are O 0 8.924799788090354e-10
95 O 0 9.435034087346139e-09
% O 0 1.928116155625048e-08
identical O 0 2.1993896552885417e-06
, O 0 5.475409459165803e-09
indicating O 0 4.6690438182395155e-08
a O 0 3.4731535425436277e-09
high O 0 6.08570260851593e-08
degree O 0 8.512372140501157e-09
of O 0 6.676262320759463e-10
evolutionary O 0 5.1299373637903045e-08
conservation O 0 6.7043903761998536e-09
. O 0 1.5745764692098874e-09
. O 0 2.7801648982972438e-08

The O 0 1.092357820198231e-06
APC B-Disease 0 4.267503754817881e-06
variants O 0 1.0202733164987876e-06
I1307K O 0 1.4453978565143188e-06
and O 0 2.18965201526089e-08
E1317Q O 0 6.34615730632504e-07
are O 0 1.7508881455796654e-08
associated O 0 2.277233079439611e-06
with O 1 0.9760825634002686
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 5.835826414113399e-06
but O 0 7.101336052528495e-08
not O 0 6.600954804980574e-08
always O 0 8.98983145702914e-08
with O 0 1.5818129028843941e-09
a O 0 6.760507886838241e-08
family O 0 2.645043934990099e-07
history O 0 1.3507064977602568e-07
. O 0 1.174666337533381e-07

Classical O 1 0.9389004707336426
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0029564376454800367
FAP B-Disease 0 0.0002120086137438193
) O 0 1.1310972070077696e-07
is O 0 3.5490126393256105e-09
a O 0 7.561304471437325e-09
high O 0 0.00011696829460561275
- O 1 0.9999047517776489
penetrance O 1 0.9999880790710449
autosomal B-Disease 1 0.9999988079071045
dominant I-Disease 1 0.9967049956321716
disease I-Disease 0 0.22148005664348602
that O 0 1.5949157550210202e-09
predisposes O 0 1.9730276790141943e-07
to O 0 3.616526633720696e-09
hundreds O 0 1.2996167697565397e-08
or O 0 2.8761196091409147e-08
thousands O 0 1.1012970979606962e-08
of O 0 5.798186180072662e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9295015931129456
carcinoma I-Disease 1 1.0
and O 0 6.976385975576704e-06
that O 0 9.108922505163264e-09
results O 0 2.1719247911278217e-07
from O 0 4.524337349209873e-09
truncating O 0 2.5469428237556713e-06
mutations O 0 1.3742271676164819e-06
in O 0 1.9963444231052563e-09
the O 0 1.132849902774069e-08
APC B-Disease 0 7.544639970546996e-07
gene O 0 1.3127419151715003e-06
. O 0 1.3949374988442287e-07

A O 0 5.250981757853879e-06
variant O 0 1.1277736120973714e-05
of O 0 1.6944386516115628e-07
FAP B-Disease 0 8.84538603713736e-05
is O 0 1.1348566886226763e-06
attenuated B-Disease 1 0.9972622394561768
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999996423721313
coli I-Disease 1 1.0
, O 0 2.4507983198418515e-07
which O 0 9.494281805189075e-09
results O 0 7.621440545335645e-08
from O 0 1.668941429500137e-08
germ O 0 0.0006986386724747717
- O 0 0.0006019707070663571
line O 0 0.0011298066237941384
mutations O 0 2.744161747614271e-06
in O 0 6.640752947539852e-10
the O 0 6.607296931804285e-10
5 O 0 5.012820381011807e-09
and O 0 3.71663877452022e-09
3 O 0 5.5720823510796436e-09
regions O 0 4.223730698527106e-09
of O 0 9.219807695082238e-10
the O 0 1.051358200498953e-08
APC B-Disease 0 7.706368023718824e-07
gene O 0 9.60881834544125e-07
. O 0 1.5609766990110074e-07

Attenuated B-Disease 1 0.9999910593032837
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.9999998807907104
have O 0 8.663974767841864e-06
" O 0 1.4335630567074986e-06
multiple O 0 0.00064470135839656
" O 1 0.9895742535591125
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.771667766410246e-07
typically O 0 3.419707468310662e-07
fewer O 0 6.729195689558765e-08
than O 0 9.057623095998224e-09
100 O 0 1.637851099189902e-08
) O 0 3.1120146459784337e-09
without O 0 8.998096490131502e-09
the O 0 4.805313924549637e-09
florid O 0 1.7023481632350013e-05
phenotype O 0 1.6213253957175766e-06
of O 0 1.043071051753941e-08
classical O 0 6.867323918413604e-07
FAP B-Disease 0 1.3708782717003487e-05
. O 0 3.6592433616533526e-07

Another O 0 5.244921339908615e-06
group O 0 1.7002498964302504e-07
of O 0 3.367548240262863e-09
patients O 0 7.088675602062722e-07
with O 0 4.48732206947966e-09
multiple O 0 4.48286191385705e-05
adenomas B-Disease 0 0.03714626654982567
has O 0 2.1782017256555264e-07
no O 0 1.403001306243823e-07
mutations O 0 8.25358426936873e-07
in O 0 8.079726332432813e-10
the O 0 3.2614815292930643e-09
APC B-Disease 0 8.399382522839005e-08
gene O 0 3.646117008315741e-08
, O 0 1.188550369235486e-09
and O 0 2.4438830958928293e-09
their O 0 6.678382646896353e-08
phenotype O 0 2.1525549982470693e-06
probably O 0 4.2699687696767796e-07
results O 0 3.2915490777440937e-08
from O 0 2.204405546990529e-09
variation O 0 1.0355762469771435e-07
at O 0 1.9843044185563485e-07
a O 0 1.3759875017171908e-08
locus O 0 2.130741904693423e-06
, O 0 6.586212464299024e-09
or O 0 1.3465710324567226e-08
loci O 0 6.174291655725028e-08
, O 0 2.399047405177157e-09
elsewhere O 0 1.5503076156164752e-08
in O 0 9.785834365061419e-10
the O 0 8.484039248912723e-09
genome O 0 2.8098165216761117e-07
. O 0 7.142126889903011e-08

Recently O 0 6.821283022873104e-05
, O 0 1.2121658699015825e-07
however O 0 1.604506394414784e-08
, O 0 7.29697413603958e-10
a O 0 5.301162175896934e-09
missense O 0 2.0166112335573416e-06
variant O 0 2.1734942947659874e-06
of O 0 1.156873619123644e-08
APC B-Disease 0 1.0762011015685857e-06
( O 0 1.3967500933631527e-08
I1307K O 0 3.659211813555885e-07
) O 0 3.2583975517752606e-09
was O 0 2.0893446972536367e-08
described O 0 9.598871031357703e-09
that O 0 5.114709766829151e-10
confers O 0 6.6083090111135334e-09
an O 0 1.5050757307122353e-09
increased O 0 3.787191928950051e-07
risk O 0 0.0003791352501139045
of O 0 0.00013539937208406627
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.162827498381375e-07
including O 0 1.9415937302369457e-08
multiple O 0 5.001396493753418e-05
adenomas B-Disease 0 0.0008844503900036216
, O 0 8.342129120819664e-08
in O 0 3.29245963825997e-08
Ashkenazim O 0 0.000715493515599519
. O 0 5.995427727611968e-07

We O 0 3.0066345061641186e-05
have O 0 7.226785214697884e-08
studied O 0 6.612446412646023e-08
a O 0 7.361983911380321e-09
set O 0 7.62834595491313e-09
of O 0 2.759610873148688e-10
164 O 0 1.9448799548626994e-07
patients O 0 3.826298211606627e-07
with O 0 6.322700585315033e-08
multiple O 1 0.9999986886978149
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.002261133398860693
/ I-Disease 1 0.9983859062194824
or I-Disease 1 0.9941095113754272
carcinoma I-Disease 1 1.0
and O 0 6.580491117347265e-06
analyzed O 0 1.899238850455731e-05
codons O 0 8.78867012943374e-06
1263 O 0 7.955840374052059e-06
- O 0 5.021654942538589e-06
1377 O 0 3.5655334613693412e-06
( O 0 1.1914499253862232e-07
exon O 0 1.596674906068074e-06
15G O 0 3.987034688179847e-06
) O 0 5.683781445497971e-09
of O 0 5.039564876518909e-10
the O 0 2.9815936386512476e-09
APC B-Disease 0 1.398440616640073e-07
gene O 0 7.560904435877092e-08
for O 0 8.662301986817056e-09
germ O 0 2.3376556782750413e-05
- O 0 1.5279612853191793e-05
line O 0 1.117863484978443e-05
variants O 0 1.7799081888369983e-06
. O 0 1.6384781531542103e-07

Three O 0 2.8276650482439436e-05
patients O 0 0.00042097593541257083
with O 0 1.4047437879582958e-08
the O 0 7.577070526565421e-09
I1307K O 0 4.809043616660347e-07
allele O 0 1.0994218655469012e-06
were O 0 1.8064987727939297e-07
detected O 0 3.6734877539856825e-07
, O 0 1.750473210826442e-09
each O 0 8.395658612769807e-10
of O 0 3.1083069451653955e-09
Ashkenazi O 0 2.414040318399202e-05
descent O 0 2.08094443223672e-05
. O 0 2.7401503643886826e-07

Four O 0 9.413080988451838e-05
patients O 0 0.01838579587638378
had O 0 7.83761493039492e-07
a O 0 2.3981203867151635e-07
germ O 0 0.01484899315983057
- O 0 0.00048485255683772266
line O 0 2.9542297852458432e-05
E1317Q O 0 1.6416421431131312e-06
missense O 0 1.8991995602846146e-06
variant O 0 5.044450404056988e-07
of O 0 2.8475211077960694e-09
APC O 0 1.4574790441201912e-07
that O 0 2.105272622898724e-09
was O 0 1.3400801890384173e-07
not O 0 2.6204041159161306e-09
present O 0 1.4572397732948161e-09
in O 0 1.11170106453784e-09
controls O 0 5.137245352671016e-06
; O 0 4.554381316523859e-09
one O 0 1.002225746837837e-09
of O 0 1.495012447172428e-10
these O 0 3.593882746955046e-09
individuals O 0 6.8972383360232925e-09
had O 0 1.0976276598739787e-07
an O 0 3.25406035450726e-10
unusually O 0 8.486826175158058e-08
large O 0 5.837376360062763e-09
number O 0 8.668814110990297e-09
of O 0 3.550041816069438e-09
metaplastic B-Disease 0 0.0002029323804890737
polyps I-Disease 0 1.2730710295727476e-05
of I-Disease 0 5.645382383789865e-09
the I-Disease 0 1.1906151087259786e-07
colorectum I-Disease 0 5.939674883848056e-05
. O 0 3.0919298410481133e-07

There O 0 1.2549468237921246e-06
is O 0 2.010361122017912e-08
increasing O 0 1.452517661704178e-08
evidence O 0 9.568782211033522e-09
that O 0 9.85205694803426e-10
there O 0 6.121696483063488e-09
exist O 0 1.77477460283626e-07
germ O 0 1.597109621798154e-05
- O 0 1.092224738385994e-05
line O 0 3.7468664686457487e-06
variants O 0 4.2328139215896954e-08
of O 0 4.0331399331350326e-10
the O 0 2.9474471752166664e-09
APC B-Disease 0 5.4467260923729555e-08
gene O 0 2.7077867059688288e-08
that O 0 4.37707231570883e-10
predispose O 0 1.3795562026075459e-08
to O 0 5.848138640018874e-10
the O 0 6.299282206967405e-10
development O 0 1.225921253400486e-09
of O 0 3.1145381829134067e-09
multiple O 1 0.9999685287475586
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9994654059410095
carcinoma I-Disease 1 1.0
, O 0 8.874060881680634e-07
but O 0 2.1791983328967035e-08
without O 0 2.6424791244039625e-08
the O 0 4.8426693766145945e-09
florid O 0 4.135889685130678e-05
phenotype O 0 3.044593995582545e-06
of O 0 2.249487485173063e-09
classical O 0 4.4123570575038684e-08
FAP B-Disease 0 2.7625688403531967e-07
, O 0 3.3961293777196033e-09
and O 0 1.6385188761347536e-09
possibly O 0 7.373760713136335e-09
with O 0 6.5316901887158e-10
importance O 0 1.0012367823719615e-07
for O 0 0.015121832489967346
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0003658005443867296
in O 0 1.2984862074461034e-09
the O 0 1.0416052464989889e-09
general O 0 1.807921035101856e-09
population O 0 5.1648663124126415e-09
. O 0 2.982185165478768e-09
. O 0 2.3588924591422256e-08

Genomic O 0 2.7041256544180214e-05
structure O 0 7.02835450283601e-07
of O 0 6.526388318661702e-09
the O 0 7.382559630286778e-08
human O 0 1.5628949768142775e-05
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999992847442627
diarrhea I-Disease 1 1.0
( O 0 2.7281057555228472e-05
CLD B-Disease 0 0.42930302023887634
) O 0 2.1290752272307145e-07
gene O 0 2.7486300950840814e-06
. O 0 2.713490232508775e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.01317747961729765
CLD B-Disease 1 0.9977522492408752
) O 0 3.9292859810302616e-07
is O 0 1.362711632424407e-08
caused O 0 9.867882511116477e-08
by O 0 3.6387717283759002e-09
mutations O 0 1.5353052731370553e-06
in O 0 1.1196940041813264e-09
a O 0 7.2737167400305225e-09
gene O 0 1.6685633852375759e-07
which O 0 2.9466828976865145e-09
encodes O 0 2.794509157411085e-07
an O 0 5.994118623675604e-08
intestinal O 0 2.635457531141583e-05
anion O 0 5.449735908769071e-06
transporter O 0 5.5388420150848106e-05
. O 0 5.280547838992788e-07

We O 0 2.362636041652877e-05
report O 0 2.1855842646800738e-07
here O 0 7.420672964997266e-09
the O 0 1.4275615134451414e-09
complete O 0 1.5219235649510665e-08
genomic O 0 2.08518116551204e-07
organization O 0 1.8773398835492117e-08
of O 0 8.243030147347952e-10
the O 0 1.1131742638781361e-08
human O 0 6.473256064509769e-08
CLD B-Disease 0 4.3792631913674995e-05
gene O 0 6.64500248603872e-07
which O 0 1.4556404970278436e-08
spans O 0 8.292718121083453e-07
approximately O 0 1.064232648673169e-07
39kb O 0 2.774801714622299e-06
, O 0 1.504195523693852e-08
and O 0 9.82380310432518e-09
comprises O 0 3.443308571604575e-08
21 O 0 1.693921802825571e-07
exons O 0 2.2944416286918567e-06
. O 0 1.8458992201431101e-07

All O 0 1.3993267202749848e-06
exon O 0 2.0494922864600085e-05
/ O 0 2.7754296752391383e-05
intron O 0 7.671532512176782e-05
boundaries O 0 6.458848019974539e-06
conform O 0 1.5933148915792117e-06
to O 0 2.1772457614588347e-08
the O 0 3.1534778344166625e-08
GT O 0 4.591833658196265e-06
/ O 0 0.0002447993028908968
AG O 1 0.7217979431152344
rule O 0 1.0072193390442408e-06
. O 0 1.1387949427899002e-07

An O 0 2.4618597649350704e-07
analysis O 0 9.857817673264435e-08
of O 0 5.172338557457579e-09
the O 0 1.5043360335198486e-08
putative O 0 9.63930801844981e-07
promoter O 0 8.085582408057235e-07
region O 0 7.37255447802454e-08
sequence O 0 1.259747648418852e-07
shows O 0 1.4817260307609104e-07
a O 0 4.5953946425925096e-08
putative O 0 6.783280696254224e-06
TATA O 0 1.3002589184907265e-05
box O 0 2.9456050469889306e-06
and O 0 9.652632115830784e-08
predicts O 0 7.230382834677584e-07
multiple O 0 1.2462584209060878e-06
transcription O 0 1.7420760514141875e-06
factor O 0 2.2490024775834172e-07
binding O 0 3.9473778201681853e-07
sites O 0 8.788156833361427e-07
. O 0 4.7173281814139045e-07

The O 0 7.255443392750749e-07
genomic O 0 3.326018259031116e-06
structure O 0 7.342928256548475e-07
was O 0 1.1585466097585595e-07
determined O 0 4.126535557702482e-08
using O 0 1.773349289635462e-08
DNA O 0 1.8685059899326006e-07
from O 0 2.6600048830260903e-09
several O 0 2.6423516708007355e-09
sources O 0 4.569155276357151e-09
including O 0 2.5991688801241253e-09
multiple O 0 7.703458209107339e-07
large O 0 4.823641006623802e-07
- O 0 0.015734383836388588
insert O 0 0.0007449171389453113
libaries O 0 2.261564259242732e-05
and O 0 1.4832722605717663e-08
genomic O 0 5.711821700060682e-07
DNA O 0 9.99261942524754e-07
from O 0 3.9312190835971705e-08
Finnish O 0 0.00021506668417714536
CLD B-Disease 1 0.9595608115196228
patients O 0 7.399067544611171e-05
and O 0 8.378006555176398e-08
controls O 0 3.6629935493692756e-05
. O 0 5.123474124957283e-07

Exon O 0 9.284052066504955e-05
- O 0 1.005644298857078e-05
specific O 0 1.38698368346013e-07
primers O 0 3.022737018909538e-06
developed O 0 2.1869647071071086e-07
in O 0 1.9597714562280544e-09
this O 0 4.094886929539854e-10
study O 0 2.5670265912935974e-09
will O 0 1.3961101164028378e-09
facilitate O 0 2.7976710725852172e-08
mutation O 0 6.180064815453079e-07
screening O 0 7.756580799878066e-08
studies O 0 1.3651830776950646e-08
of O 0 1.386699421956905e-09
patients O 0 3.3992168368968123e-07
with O 0 6.135560060016587e-09
the O 0 9.913343319567502e-07
disease O 0 0.002681202255189419
. O 0 7.124181422568654e-08

Genomic O 0 2.2947671823203564e-05
sequencing O 0 3.558796834113309e-06
of O 0 6.064288982088328e-08
a O 0 2.5187873120557924e-07
BAC O 0 0.0024610022082924843
clone O 0 0.00021113532420713454
H O 1 1.0
_ O 0 2.2011971623214777e-07
RG364P16 O 0 1.1009033187292516e-06
revealed O 0 1.9531158557128947e-07
the O 0 4.243239537515819e-09
presence O 0 6.319153200706751e-09
of O 0 5.042372630548186e-10
another O 0 1.2236045066060797e-08
, O 0 1.664194893002957e-09
highly O 0 4.84277107304365e-09
homologous O 0 4.2654917820073024e-08
gene O 0 7.939114965438421e-08
3 O 0 3.772647527711115e-09
of O 0 4.1193282118712204e-10
the O 0 2.5596841979336205e-08
CLD B-Disease 0 0.0006649999995715916
gene O 0 1.4634473473051912e-06
, O 0 4.770583927893313e-09
with O 0 1.0079653778305442e-09
a O 0 4.412472609516271e-09
similar O 0 7.917290822945233e-09
genomic O 0 1.7388364881298912e-07
structure O 0 1.0204719274042873e-06
, O 0 2.285740041685358e-09
recently O 0 1.4201643416811294e-08
identified O 0 3.8171712901657884e-08
as O 0 6.477180569675056e-09
the O 0 1.3650771961692953e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.2864581549365539e-05
( O 0 9.224846309052737e-08
PDS B-Disease 0 6.84920814819634e-06
) O 0 3.20139079690307e-08
. O 0 1.5479821868780164e-08
. O 0 1.3494357631316234e-07

The O 0 3.0646217510366114e-06
APCI1307K O 0 7.469022239092737e-05
allele O 0 2.831585516105406e-05
and O 0 3.4032364055747166e-06
cancer B-Disease 0 0.07417099177837372
risk O 0 3.6306355468695983e-06
in O 0 1.4735177522595677e-09
a O 0 6.6785577068628754e-09
community O 0 1.7727169066006354e-08
- O 0 1.7365241546940524e-06
based O 0 9.07676778183486e-09
study O 0 2.594255699150949e-09
of O 0 3.2841036556874315e-09
Ashkenazi O 0 7.007131443970138e-06
Jews O 0 5.513831524694979e-07
. O 0 7.66731105272811e-08

Mutations O 0 0.0006656892946921289
in O 0 1.7359434423269704e-07
APC O 0 5.076164597994648e-06
are O 0 3.548567661937341e-08
classically O 0 9.177614992950112e-05
associated O 0 3.390925940038869e-06
with O 0 4.641584382625297e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 5.166019036551006e-05
FAP B-Disease 0 2.4970540835056454e-05
) O 0 2.3296589546362156e-08
, O 0 2.069911575475203e-09
a O 0 1.4827715055787394e-08
highly O 0 0.00011336684110574424
penetrant O 1 0.9999992847442627
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 9.058609430212528e-05
by O 0 1.8644719546045962e-08
multiple O 0 0.0009238189086318016
intestinal O 0 0.09466564655303955
polyps B-Disease 0 0.002795908832922578
and O 0 2.5518213320196992e-08
, O 0 2.926116904333753e-09
without O 0 8.82841799665357e-09
surgical O 0 1.6281662738037994e-06
intervention O 0 5.762256449770575e-08
, O 0 9.904984610287215e-10
the O 0 1.2646672598037867e-09
development O 0 2.0895001284770842e-08
of O 0 0.00011009869194822386
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 5.31446744389541e-07
CRC B-Disease 0 1.1435543456173036e-05
) O 0 8.395410588946106e-08
. O 0 8.937617934634545e-08

APC B-Disease 0 0.00017567370377946645
is O 0 4.914816145173972e-07
a O 0 4.455262683222827e-07
tumour O 1 0.9999997615814209
- O 0 1.2400622836139519e-05
suppressor O 0 3.747155915334588e-06
gene O 0 5.08827326939354e-07
, O 0 2.7507309763308285e-09
and O 0 4.712901180425888e-09
somatic O 0 4.045454716106178e-06
loss O 0 1.7802173033487634e-06
occurs O 0 1.4183538610268442e-07
in O 0 1.5638390493677434e-07
tumours B-Disease 1 1.0
. O 0 1.276077568945766e-06

The O 0 5.113494353281567e-06
germline O 0 9.352570486953482e-05
T O 0 7.632982305949554e-05
- O 0 1.8670361896511167e-06
to O 0 6.43057873617181e-08
- O 0 5.0538246796349995e-06
A O 0 1.3022450673361163e-07
transversion O 0 2.2449642074207077e-06
responsible O 0 9.648250909322087e-08
for O 0 9.527255651065047e-10
the O 0 8.316119348705797e-09
APC O 0 2.3980791752364894e-07
I1307K O 0 2.925748106008541e-07
allele O 0 1.3931081355167407e-07
converts O 0 4.463704428303572e-08
the O 0 1.1230653740312846e-08
wild O 0 4.138374265494349e-08
- O 0 3.5551735777517024e-07
type O 0 1.2947816685482394e-06
sequence O 0 5.999494590014365e-08
to O 0 1.3068152782125253e-08
a O 0 3.6648415857598593e-07
homopolymer O 0 0.3833356499671936
tract O 0 0.004837823566049337
( O 0 2.7816554393211845e-08
A8 O 0 1.3046796993876342e-05
) O 0 4.6675276976770874e-09
that O 0 6.557679954610762e-10
is O 0 2.9243036880899353e-09
genetically O 0 8.062384182494498e-08
unstable O 0 1.7687132185528753e-06
and O 0 2.1258934168599808e-08
prone O 0 1.4320710761239752e-05
to O 0 3.589534003367589e-08
somatic O 0 5.050479740020819e-05
mutation O 0 3.2011896109906957e-05
. O 0 3.697275019476365e-07

The O 0 1.573837835167069e-06
I1307K O 0 9.492738172411919e-06
allele O 0 3.450545136729488e-06
was O 0 1.8376526611518784e-07
found O 0 3.9384016048416015e-08
in O 0 8.723150202172292e-09
6 O 0 3.8380258615688945e-07
. O 0 1.2930058801430278e-07

1 O 0 7.77631976234261e-06
% O 0 3.647341770829371e-07
of O 0 1.6646653833163327e-08
unselected O 0 2.3716138457530178e-05
Ashkenazi O 0 2.8750211640726775e-05
Jews O 0 3.718413665865228e-07
and O 0 2.2079371220229405e-08
higher O 0 1.4367216749633371e-07
proportions O 0 3.59623328449743e-07
of O 0 2.9877136320521913e-09
Ashkenazim O 0 0.00011057953088311478
with O 0 5.262338831357738e-08
family O 0 1.8401095758235897e-07
or O 0 3.659927187982248e-07
personal O 0 1.9066303138970397e-05
histories O 0 0.00032651142100803554
of O 0 6.230864357803512e-08
CRC B-Disease 0 9.308643348049372e-05
( O 0 1.1565033730676078e-07
ref O 0 0.00011462329712230712
. O 0 8.980145516090943e-09
2 O 0 2.9409010338099506e-08
) O 0 2.007162080985836e-08
. O 0 7.940326440802892e-08

To O 0 5.442342967398872e-07
evaluate O 0 6.266129730647663e-07
the O 0 4.791612440158133e-09
role O 0 1.5960576860152287e-08
of O 0 2.3900770251827907e-09
I1307K O 0 5.64738797947939e-07
in O 0 2.9717334371071047e-08
cancer B-Disease 0 6.2659059949510265e-06
, O 0 2.785104591396248e-09
we O 0 4.619526450255762e-08
genotyped O 0 1.0961523457808653e-06
5 O 0 3.788513680547112e-08
, O 0 1.0358602864357636e-08
081 O 0 5.265057552605867e-06
Ashkenazi O 0 4.584881025948562e-06
volunteers O 0 1.219662522089493e-07
in O 0 2.162675816208548e-09
a O 0 1.1826196022468594e-08
community O 0 3.056583608440633e-08
survey O 0 3.0831308777123922e-06
. O 0 1.5268844322235964e-07

Risk O 0 0.0004469079722184688
of O 0 1.5505759165534982e-07
developing O 0 6.593905709451064e-05
colorectal B-Disease 1 1.0
, I-Disease 0 1.4137126527202781e-06
breast I-Disease 0 0.48704302310943604
and I-Disease 0 2.2159494506013289e-07
other I-Disease 0 2.8726117307087407e-07
cancers I-Disease 1 0.9985225796699524
were O 0 6.889863470860291e-07
compared O 0 3.6989252549801677e-08
between O 0 9.888999841223267e-09
genotyped O 0 4.601254204317229e-06
I1307K O 0 1.0786937991724699e-06
carriers O 0 2.0076238627098064e-07
and O 0 2.6725112789449668e-08
non O 0 6.173502811179787e-07
- O 0 1.9396725292608608e-06
carriers O 0 4.2512172626629763e-07
and O 0 8.73577121751623e-09
their O 0 7.847156702212033e-09
first O 0 4.378746609745576e-08
- O 0 2.5850508791336324e-06
degree O 0 3.7314717360459326e-07
relatives O 0 1.2084035461157328e-06
. O 0 1.7765357540611149e-07

Sperm O 0 0.0002440296084387228
DNA O 0 8.351285941898823e-06
analysis O 0 4.6213688165153144e-07
in O 0 6.3873301314743e-08
a O 0 4.469237921966851e-07
Friedreich B-Disease 0 0.1836487054824829
ataxia I-Disease 1 0.9998016953468323
premutation O 0 0.01431968342512846
carrier O 0 2.6037436327897012e-05
suggests O 0 4.003888420811563e-07
both O 0 1.8000251955641033e-08
meiotic O 0 1.7833506262832088e-06
and O 0 1.4707106643641055e-08
mitotic O 0 9.831142051552888e-07
expansion O 0 1.1441159841751869e-07
in O 0 5.349591880587923e-09
the O 0 2.2764739426861524e-08
FRDA B-Disease 0 1.6185420463443734e-05
gene O 0 1.468688992645184e-06
. O 0 1.5293998956167343e-07

Friedreich B-Disease 1 0.9977338314056396
ataxia I-Disease 1 0.9999934434890747
is O 0 3.191481300746091e-05
usually O 0 2.383733408350963e-05
caused O 0 5.751242611040652e-07
by O 0 1.238639080192172e-09
an O 0 1.0050511534132056e-09
expansion O 0 8.203226542491393e-09
of O 0 5.175802897383619e-09
a O 0 2.754313754849136e-07
GAA O 0 0.00014670073869638145
trinucleotide O 0 4.4932705350220203e-05
repeat O 0 3.915567504009232e-06
in O 0 9.067665729389773e-09
intron O 0 1.228340533998562e-05
1 O 0 3.9863390810523924e-08
of O 0 3.310669516309872e-09
the O 0 6.651863060369578e-08
FRDA B-Disease 0 3.2216783438343555e-05
gene O 0 3.448722509347135e-06
. O 0 2.7575859462558583e-07

Occasionally O 0 0.002175907837226987
, O 0 2.238788567865413e-07
a O 0 2.7284517756243076e-08
fully O 0 9.272918077840586e-08
expanded O 0 3.899674183571733e-08
allele O 0 1.6942675529207918e-07
has O 0 4.559926658487257e-09
been O 0 5.010946768635449e-09
found O 0 2.309100244346496e-09
to O 0 1.3013276012330266e-09
arise O 0 8.905860937602483e-09
from O 0 5.459659391249261e-10
a O 0 3.2446048070511324e-09
premutation O 0 2.2905338425971422e-07
of O 0 5.431677330136608e-10
100 O 0 1.2098705148844147e-08
or O 0 4.779329287885048e-08
less O 0 8.600454748375341e-08
triplet O 0 0.00047604055725969374
repeats O 0 2.6800698833540082e-05
. O 0 5.351789127416851e-07

We O 0 7.732953235972673e-06
have O 0 8.724652644787056e-08
examined O 0 2.951883004698175e-07
the O 0 1.581608621847863e-08
sperm O 0 3.213345394215139e-07
DNA O 0 1.386249834922637e-07
of O 0 3.508093815440816e-09
a O 0 1.2391576831305429e-07
premutation O 0 0.0002236188156530261
carrier O 0 4.554612678475678e-05
. O 0 3.659131380118197e-07

This O 0 1.1144243217131589e-06
mans O 0 3.1998162739910185e-05
leucocyte O 0 5.453723861137405e-05
DNA O 0 9.984645657823421e-06
showed O 0 3.0486298783216625e-06
one O 0 1.6569552840906e-08
normal O 0 7.302271853859565e-08
allele O 0 2.702583969949046e-07
and O 0 5.7018816335130396e-09
one O 0 1.6417722736861151e-09
allele O 0 3.2860853593774664e-08
of O 0 1.1323222359749252e-09
approximately O 0 2.2370635122115345e-08
100 O 0 5.038839390181238e-08
repeats O 0 3.865258804580662e-06
. O 0 4.293677591249434e-07

His O 0 1.1946899576287251e-05
sperm O 0 1.942848030012101e-05
showed O 0 2.0551619854813907e-06
an O 0 4.214203208618983e-09
expanded O 0 1.5139131903652014e-07
allele O 0 5.34221271664137e-07
in O 0 5.355462295852931e-09
a O 0 2.226260420457038e-08
tight O 0 2.187706058975891e-06
range O 0 1.1621796147665009e-07
centering O 0 1.846656374482336e-07
on O 0 1.3740257820415991e-08
a O 0 2.0435382275252323e-09
size O 0 5.21756149396424e-09
of O 0 6.298068178089977e-10
approximately O 0 1.6695878457539948e-08
320 O 0 2.930143523371953e-07
trinucleotide O 0 3.878647476085462e-05
repeats O 0 7.656125490029808e-06
. O 0 3.307200131530408e-07

His O 0 1.066698860086035e-05
affected O 0 1.0138882316823583e-05
son O 0 7.99998360889731e-06
has O 0 3.3444866431864284e-08
repeat O 0 4.0704483694753435e-07
sizes O 0 4.1817412466116366e-07
of O 0 1.2095221713082083e-08
1040 O 0 1.3790373714073212e-06
and O 0 7.556953818266265e-08
540 O 0 1.4471951317318599e-06
. O 0 4.150810184455622e-07

These O 0 3.257306104842428e-07
data O 0 3.2651311698828067e-07
suggest O 0 1.861168215100406e-07
that O 0 1.6153358650683458e-09
expansion O 0 5.351459275715342e-09
occurs O 0 6.682507880384492e-09
in O 0 1.1526133381067893e-09
two O 0 1.8702706938711344e-08
stages O 0 2.8966878744540736e-06
, O 0 2.984125391236603e-09
the O 0 1.2748391231554024e-09
first O 0 1.4124330149911657e-08
during O 0 5.009286496715504e-08
meiosis O 0 2.009782917866687e-07
followed O 0 5.239603595441622e-08
by O 0 3.3262970156044958e-09
a O 0 8.554282615591546e-09
second O 0 1.6410538705713407e-07
mitotic O 0 3.1510001008427935e-06
expansion O 0 8.605769039604638e-07
. O 0 3.724169630459073e-07

We O 0 8.806003279460128e-06
also O 0 4.617817594976259e-08
show O 0 1.1709418856753473e-07
that O 0 9.725101834945349e-10
in O 0 6.500742721904373e-10
all O 0 1.1832055335503355e-09
informative O 0 1.1363550100895736e-07
carrier O 0 1.0265980563417543e-06
father O 0 5.8783392375971744e-08
to O 0 4.015426657844046e-09
affected O 0 1.0324285426577262e-07
child O 0 3.573256890376797e-07
transmissions O 0 4.762139360536821e-05
, O 0 1.3688098654540681e-08
with O 0 9.332402628459135e-10
the O 0 1.1953412704102107e-09
notable O 0 7.059912210394259e-09
exception O 0 1.3148158117815001e-08
of O 0 9.155424751661201e-10
the O 0 1.4965975125846853e-08
premutation O 0 4.595605787471868e-06
carrier O 0 4.28880724712144e-07
, O 0 1.1575836955657337e-09
the O 0 6.539742636313406e-10
expansion O 0 8.713805677018627e-09
size O 0 6.057261003888925e-08
decreases O 0 6.212275138750556e-07
. O 0 9.491239794101602e-09
. O 0 3.443459561935924e-08

The O 0 9.913636631608824e-07
R496H O 0 1.651900493016001e-05
mutation O 0 2.288154973939527e-06
of O 0 1.8642053234430023e-08
arylsulfatase O 0 6.786101494071772e-06
A O 0 2.8369902338454267e-07
does O 0 1.6888276377358125e-07
not O 0 6.125810614321381e-07
cause O 0 0.00011648156214505434
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 1.434201635674981e-06

Deficiency B-Disease 1 0.9999690055847168
of I-Disease 0 2.9496430897779646e-07
arylsulfatase I-Disease 0 4.417705349624157e-05
A I-Disease 0 7.509952979489753e-07
( O 0 1.449728301849973e-07
ARSA O 0 0.000462341500679031
) O 0 4.9545732849765045e-08
enzyme O 0 2.281291244798922e-06
activity O 0 4.017342689621728e-06
causes O 0 0.0001739885046845302
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 7.353725959546864e-05
MLD B-Disease 1 0.9999997615814209
) O 0 8.410899567934393e-07
. O 0 4.543559271041886e-07

A O 0 3.481739440758247e-06
number O 0 1.9264442130406678e-07
of O 0 6.351964287887313e-08
ARSA O 0 0.002244584495201707
gene O 0 1.3606980246549938e-05
mutations O 0 9.928454346663784e-06
responsible O 0 7.956159038258193e-07
for O 0 4.6479765813955964e-08
MLD B-Disease 1 1.0
have O 0 1.2102418622816913e-06
been O 0 2.6284200771442556e-07
identified O 0 7.521191491832724e-07
. O 0 6.293954868397122e-08

Recently O 0 2.899028913816437e-05
, O 0 8.042326271606726e-08
the O 0 1.1278200595654653e-08
R496H O 0 9.157945441984339e-07
mutation O 0 2.5311331341981713e-07
of O 0 3.398624270900541e-09
ARSA O 0 0.00010399671737104654
was O 0 4.48666561680966e-08
proposed O 0 3.709323070921755e-09
to O 0 2.5724082863831654e-09
be O 0 6.906557992181206e-09
a O 0 2.7640702171538578e-08
cause O 0 5.147894057699887e-07
of O 0 3.739786436085524e-08
MLD B-Disease 1 1.0
( O 0 3.158577044359845e-07
Draghia O 0 5.6659686379134655e-05
et O 0 0.0012798765674233437
al O 0 0.03024846874177456
. O 0 1.8401371093546004e-08
, O 0 6.977874722480237e-09
1997 O 0 3.4769929158073865e-08
) O 0 1.1302966562709571e-08
. O 0 2.4435953704937674e-08

We O 0 8.827712917991448e-06
have O 0 5.835687133526335e-08
investigated O 0 1.4291728689386218e-07
the O 0 5.847951900506132e-09
R496H O 0 9.94675360743713e-07
mutation O 0 8.319643143295252e-07
and O 0 1.598284526949101e-08
found O 0 1.4326849040458e-08
this O 0 1.2630955170678249e-09
mutation O 0 2.4238562446043943e-07
at O 0 2.36227357675034e-08
a O 0 5.179368045560295e-09
relatively O 0 1.7672814323077546e-08
high O 0 1.7466053492398714e-08
frequency O 0 4.816217256120581e-07
in O 0 1.4347979471196481e-09
an O 0 1.882462852265121e-09
African O 0 5.390500490420891e-09
American O 0 3.0693765307177046e-09
population O 0 1.854738473916484e-09
( O 0 2.0120825006131327e-09
f O 0 7.765157761241426e-07
= O 0 2.3485522433475126e-06
0 O 0 1.0659370985877104e-07
. O 0 5.7261746455594675e-09
09 O 0 1.3906143294661888e-06
, O 0 1.825740447713997e-08
n O 0 4.947650268150028e-06
= O 0 1.29086274682777e-05
61 O 0 3.389557150512701e-07
subjects O 0 1.77118442934443e-06
) O 0 9.423885671822063e-08
. O 0 1.636725954767826e-07

The O 0 5.319514457369223e-06
ARSA O 0 0.0005093276267871261
enzyme O 0 3.875400580000132e-06
activity O 0 3.050739394439006e-07
in O 0 5.988973317272439e-09
subjects O 0 3.1703646641290106e-07
with O 0 1.7020109766008318e-08
and O 0 1.1656494791623118e-07
without O 0 3.8127549117916715e-08
the O 0 3.041287666150083e-09
R496H O 0 6.356648327709991e-07
mutation O 0 1.9033106468668848e-07
was O 0 2.6445967193922115e-08
determined O 0 4.539968401218175e-08
and O 0 1.209238398303114e-08
found O 0 9.49728828913976e-09
to O 0 1.0645876180603864e-08
be O 0 5.482099751930036e-08
normal O 0 3.5516359275789e-07
. O 0 3.842262685793685e-08

It O 0 9.62690592132276e-07
is O 0 2.9214341168426472e-08
therefore O 0 2.7215806497338235e-08
concluded O 0 9.439966142110734e-09
that O 0 4.3358250323422e-10
the O 0 2.0844874715209016e-09
R496H O 0 3.91388851994634e-07
mutation O 0 1.7890420167532284e-07
of O 0 3.8268503921301544e-09
ARSA O 0 7.759830623399466e-05
does O 0 3.0468168432662424e-08
not O 0 4.5251313807170845e-09
negatively O 0 2.7538140656702126e-08
influence O 0 4.6390820074293515e-09
the O 0 1.843452501759657e-09
activity O 0 3.25416316115934e-08
of O 0 2.0748405216153287e-09
ARSA O 0 0.00028717698296532035
and O 0 1.0052705334828715e-07
is O 0 1.0451122633980958e-08
not O 0 7.817413383293115e-09
a O 0 3.83716560747871e-08
cause O 0 1.0031193369286484e-06
of O 0 2.8263772833270195e-07
MLD B-Disease 1 0.9999996423721313

Down O 0 0.0002774076710920781
- O 0 7.0456412686326075e-06
regulation O 0 5.841505981152295e-07
of O 0 2.9100776899326775e-08
transmembrane O 0 8.04847695690114e-06
carbonic O 0 1.9874034478561953e-05
anhydrases O 0 2.0498304365901276e-05
in O 0 2.1816734374624502e-07
renal B-Disease 1 0.9999374151229858
cell I-Disease 1 0.9999934434890747
carcinoma I-Disease 1 1.0
cell O 0 0.1757449358701706
lines O 0 1.6518484699190594e-05
by O 0 8.959939457042765e-09
wild O 0 1.2082301736882073e-07
- O 0 6.642267544521019e-05
type O 0 0.20772531628608704
von B-Disease 1 0.9999222755432129
Hippel I-Disease 1 0.9998283386230469
- I-Disease 1 0.7315294146537781
Lindau I-Disease 1 0.9775928854942322
transgenes O 0 0.0009791342308744788
. O 0 2.4390076305280672e-06

To O 0 2.5967603960452834e-06
discover O 0 7.934744644444436e-06
genes O 0 2.1508149075089023e-06
involved O 0 3.7969272170812474e-07
in O 0 1.0490069968227544e-07
von B-Disease 1 0.9998735189437866
Hippel I-Disease 1 0.9999957084655762
- I-Disease 1 0.9999548196792603
Lindau I-Disease 1 0.9999951124191284
( O 0 3.050840177820646e-06
VHL B-Disease 0 0.00046094655408523977
) O 0 1.1000924615700569e-07
- O 0 2.9659065603482304e-06
mediated O 0 1.1106759302492719e-05
carcinogenesis O 0 3.423765519983135e-05
, O 0 4.009061171927897e-08
we O 0 6.576900091204152e-08
used O 0 9.447240699955728e-06
renal B-Disease 1 0.9997109770774841
cell I-Disease 1 0.9999810457229614
carcinoma I-Disease 1 1.0
cell O 1 0.5928794741630554
lines O 0 0.0021509442012757063
stably O 0 6.604144437005743e-05
transfected O 0 1.66603804245824e-05
with O 0 4.8643620687016664e-08
wild O 0 5.906470050831558e-07
- O 0 7.850672409404069e-05
type O 0 0.4561294913291931
VHL O 1 0.9141464233398438
- O 0 0.00024445459712296724
expressing O 0 5.4497982091561425e-06
transgenes O 0 6.324089190457016e-05
. O 0 1.116625412578287e-06

Large O 0 4.459978754312033e-06
- O 0 4.837262167711742e-06
scale O 0 1.4828049188508885e-06
RNA O 0 7.808920372553985e-07
differential O 0 5.089083856546495e-07
display O 0 1.9359919178896234e-07
technology O 0 1.0199334354865641e-07
applied O 0 2.833193235574072e-08
to O 0 3.799279557625823e-09
these O 0 1.4209067700221567e-08
cell O 0 5.882017376279691e-06
lines O 0 3.1104405934456736e-05
identified O 0 1.8141919611025514e-07
several O 0 2.1545978334813753e-09
differentially O 0 2.9735656426055357e-07
expressed O 0 3.083200583731127e-09
genes O 0 4.3650626224689404e-08
, O 0 4.68988903268297e-10
including O 0 4.3972300800554365e-10
an O 0 2.5551074589458267e-09
alpha O 0 1.1271173150362301e-07
carbonic O 0 1.428826863048016e-06
anhydrase O 0 1.0493357649465906e-06
gene O 0 3.937651058549818e-07
, O 0 1.4966031969265714e-08
termed O 0 2.0213055904605426e-06
CA12 O 0 3.844129605568014e-05
. O 0 2.219606471953739e-07

The O 0 6.753432444384089e-07
deduced O 0 3.954819021600997e-06
protein O 0 3.285302625499753e-07
sequence O 0 1.4528853853335022e-07
was O 0 1.2190392340016842e-07
classified O 0 1.4433562967042235e-07
as O 0 1.0159431518275142e-08
a O 0 2.5759890220911075e-08
one O 0 1.8681674873732845e-07
- O 0 0.0005918905953876674
pass O 0 2.7151929316460155e-05
transmembrane O 0 5.687384327757172e-05
CA O 0 0.00012258665810804814
possessing O 0 9.306600645686558e-08
an O 0 6.390544093903827e-09
apparently O 0 1.3848665503246593e-06
intact O 0 2.210978209404857e-07
catalytic O 0 4.681671228468076e-08
domain O 0 1.0254673554754845e-07
in O 0 5.431680438761077e-09
the O 0 2.168451196382648e-08
extracellular O 0 3.1511262932326645e-06
CA O 0 0.0002098662662319839
module O 0 2.2465897018264513e-06
. O 0 2.396588740793959e-07

Reintroduced O 0 8.093745418591425e-05
wild O 0 8.682205589138903e-06
- O 0 4.8066558520076796e-05
type O 0 0.00015059670840855688
VHL B-Disease 0 0.0006411263602785766
strongly O 0 5.418798991740914e-07
inhibited O 0 5.070897373116168e-07
the O 0 3.0050872901199455e-09
overexpression O 0 4.614022941495932e-08
of O 0 6.006198316477196e-10
the O 0 3.3163194412821895e-09
CA12 O 0 1.605935381121526e-06
gene O 0 5.814688108785049e-08
in O 0 1.7233050542131423e-09
the O 0 2.3393123882442524e-08
parental O 1 0.6958425045013428
renal B-Disease 1 0.9999910593032837
cell I-Disease 1 0.9999915361404419
carcinoma I-Disease 1 1.0
cell O 0 0.13585703074932098
lines O 0 0.003896784270182252
. O 0 6.464550779128331e-07

Similar O 0 8.27992244012421e-06
results O 0 1.2300753951421939e-05
were O 0 3.2931163218563597e-07
obtained O 0 4.107108964035433e-08
with O 0 1.2105999758205144e-08
CA9 O 0 0.0001978322834474966
, O 0 2.410403654451443e-09
encoding O 0 4.975293066422637e-08
another O 0 7.75924462459443e-08
transmembrane O 0 3.63869548891671e-05
CA O 0 0.013644405640661716
with O 0 1.1856957193856488e-08
an O 0 6.142248309970455e-08
intact O 0 5.541609880310716e-06
catalytic O 0 9.27348025925312e-07
domain O 0 1.8904065655078739e-06
. O 0 3.8989008999124053e-07

Although O 0 1.9762223928410094e-06
both O 0 3.434263362578349e-08
domains O 0 1.0047721588080094e-07
of O 0 3.883639188018151e-09
the O 0 2.5426437844089378e-08
VHL B-Disease 0 2.106136344082188e-05
protein O 0 1.1881253669798753e-07
contribute O 0 1.8508801602479252e-08
to O 0 2.468440341019118e-09
regulation O 0 1.2131846460761153e-07
of O 0 2.560200496048992e-09
CA12 O 0 2.9642056688317098e-05
expression O 0 1.7468927637764864e-07
, O 0 3.693501504642427e-09
the O 0 2.813520083577714e-09
elongin O 0 6.412072366401844e-07
binding O 0 7.297204263068124e-08
domain O 0 1.9734568468265934e-07
alone O 0 3.2023291396399145e-07
could O 0 4.07033127203249e-08
effectively O 0 1.0120442084371462e-06
regulate O 0 2.612498747112113e-06
CA9 O 0 0.0001573817862663418
expression O 0 1.137312779064814e-06
. O 0 2.007003701010035e-07

We O 0 1.6545649486943148e-05
mapped O 0 5.274529758025892e-05
CA12 O 0 0.0002449020685162395
and O 0 7.84804115028237e-07
CA9 O 0 0.000236842010053806
loci O 0 4.1443527152296156e-06
to O 0 5.4179935204956564e-08
chromosome O 0 3.0909664928913116e-05
bands O 0 6.519039743579924e-06
15q22 O 0 6.232247415027814e-06
and O 0 2.5564011707501777e-07
17q21 O 0 1.3316227523318958e-05
. O 0 3.0165347197907977e-07

2 O 0 2.049930117209442e-05
respectively O 0 1.706308580651239e-06
, O 0 2.2445385994274147e-08
regions O 0 1.303475016811717e-07
prone O 0 0.00010242732969345525
to O 0 1.1965417101578169e-08
amplification O 0 5.187467877476593e-07
in O 0 3.2832894181211714e-09
some O 0 9.762871400198492e-09
human O 0 4.4452764313973603e-07
cancers B-Disease 0 0.17882812023162842
. O 0 2.571885318047862e-07

Additional O 0 1.408616071785218e-06
experiments O 0 2.4877983832993777e-06
are O 0 5.8883941278509155e-08
needed O 0 2.7373078026471376e-08
to O 0 4.5333208298359295e-09
define O 0 6.748384748789249e-07
the O 0 5.948207260075833e-09
role O 0 4.178030010848488e-08
of O 0 4.684848509128869e-09
CA O 0 5.260625039227307e-05
IX O 0 3.7453874028869905e-06
and O 0 7.517304538851022e-07
CA O 0 2.6699322916101664e-05
XII O 0 1.1972092579526361e-06
enzymes O 0 2.190003272062313e-07
in O 0 2.2647101971529082e-09
the O 0 2.520032404973449e-09
regulation O 0 6.297137389310592e-08
of O 0 1.893890155812983e-09
pH O 0 2.29656961892033e-06
in O 0 9.932188405059605e-10
the O 0 1.8051093952919928e-09
extracellular O 0 7.143843561152607e-08
microenvironment O 0 5.426349503068195e-07
and O 0 5.053996776638314e-09
its O 0 1.9575263632276574e-09
potential O 0 5.848297401911395e-09
impact O 0 3.030981332585725e-08
on O 0 2.1051397425253526e-07
cancer B-Disease 0 1.738804712658748e-05
cell O 0 1.2215195965836756e-06
growth O 0 2.913941727911151e-07
. O 0 6.844519617743572e-08

A O 0 1.8277878552908078e-06
gene O 0 2.664564135557157e-06
encoding O 0 3.3529761367390165e-07
a O 0 1.0659696414450082e-07
transmembrane O 0 1.4216760746421642e-06
protein O 0 2.1718294362926827e-07
is O 0 3.499886602753577e-09
mutated O 0 1.5687415100273938e-07
in O 0 4.244064655267721e-09
patients O 0 1.892069462883228e-06
with O 0 5.779890216217609e-06
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.03963408246636391
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999997615814209
( O 0 0.06417971849441528
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 3.040205172055721e-07
. O 0 1.6583945239290188e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0004499130882322788
WFS B-Disease 0 0.47436872124671936
; O 0 2.703395466596703e-06
OMIM O 0 0.0028595831245183945
222300 O 0 1.6119614883791655e-05
) O 0 2.3958568462489893e-08
is O 0 2.9913684862492573e-09
an O 0 2.4835111744891947e-08
autosomal B-Disease 1 0.9999995231628418
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 0.9999994039535522
disorder I-Disease 1 0.9999682903289795
defined O 0 1.3193423455959419e-06
by O 0 9.201382766832467e-09
young O 0 2.2557946977030952e-07
- O 0 1.139255709858844e-05
onset O 0 0.11901820451021194
non O 0 0.009987624362111092
- O 1 0.9480534195899963
immune O 1 0.6881245970726013
insulin B-Disease 1 0.8640446066856384
- I-Disease 1 0.5585088133811951
dependent I-Disease 1 0.9730907678604126
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.1509481737448368e-05
progressive O 0 0.03998330235481262
optic B-Disease 1 0.9999996423721313
atrophy I-Disease 1 0.9532304406166077
. O 0 1.6719671975806705e-06

Linkage O 0 0.00015410395280923694
to O 0 1.0729033874667948e-06
markers O 0 4.525142867350951e-05
on O 0 4.6329697056535224e-07
chromosome O 0 0.019370758906006813
4p O 0 0.0014169281348586082
was O 0 4.888628154731123e-06
confirmed O 0 1.2667180726566585e-07
in O 0 3.809670801047105e-09
five O 0 3.707124918150839e-08
families O 0 1.391975388287392e-07
. O 0 1.0604779987488655e-07

On O 0 2.415164033209294e-07
the O 0 1.2611367061765577e-08
basis O 0 2.24874661114427e-08
of O 0 2.6657949181441154e-09
meiotic O 0 2.7934358513448387e-05
recombinants O 0 0.007855160161852837
and O 0 1.6499074263265356e-05
disease O 1 0.969556987285614
- O 0 7.001050835242495e-05
associated O 0 4.093060965715267e-07
haplotypes O 0 1.2011523722321726e-06
, O 0 5.587716511712415e-09
the O 0 4.016437404885664e-09
WFS B-Disease 0 1.2822384633182082e-05
gene O 0 4.874128194387595e-07
was O 0 4.807617415281129e-08
localized O 0 1.9545095142348146e-07
to O 0 2.6783235185234844e-08
a O 0 3.8145989833537897e-07
BAC O 0 0.003281137440353632
/ O 0 1.349537524220068e-05
P1 O 0 1.5975332644302398e-05
contig O 0 1.7190518519782927e-06
of O 0 1.3205756488332554e-09
less O 0 9.700651837363239e-09
than O 0 2.6911546324726032e-09
250 O 0 1.5015841015042497e-08
kb O 0 7.486036338377744e-06
. O 0 1.925485264564486e-07

Mutations O 0 0.00081196881365031
in O 0 9.228084252299595e-08
a O 0 3.654952962506286e-08
novel O 0 1.3348035565741156e-07
gene O 0 8.023883992791525e-07
( O 0 1.0393750748960429e-08
WFS1 O 0 2.4782361833786126e-06
) O 0 1.2986521857882849e-09
encoding O 0 2.906998908258629e-08
a O 0 2.5761019983860933e-08
putative O 0 1.1029367215087404e-06
transmembrane O 0 5.533733542506525e-07
protein O 0 3.038564670987398e-07
were O 0 2.1420689222395595e-07
found O 0 6.180828293622653e-09
in O 0 4.2199924110697395e-10
all O 0 1.8453872874246713e-09
affected O 0 2.3319129738297306e-08
individuals O 0 1.5223408089681811e-09
in O 0 9.965832603597846e-10
six O 0 5.467626706945339e-08
WFS B-Disease 0 2.341763502045069e-05
families O 0 2.6950754516974484e-08
, O 0 7.85612352949272e-10
and O 0 1.0892344803892229e-09
these O 0 2.9358890873965038e-09
mutations O 0 8.821383516988135e-07
were O 0 5.233541244820117e-08
associated O 0 1.3960788969313853e-08
with O 0 8.142386320741934e-09
the O 0 1.4389818261406617e-06
disease O 0 0.003774436190724373
phenotype O 0 1.2175304618722294e-05
. O 0 1.2469710952700552e-07

WFS1 O 0 0.0017618838464841247
appears O 0 5.716586201742757e-06
to O 0 5.869197039487517e-08
function O 0 2.3584969710555015e-07
in O 0 1.047579001323129e-08
survival O 0 8.408276812588156e-07
of O 0 3.488130673190426e-09
islet O 0 7.56780991650885e-06
beta O 0 1.1566438615773222e-06
- O 0 0.00015377237286884338
cells O 0 3.324392991999048e-07
and O 0 1.4679390147875893e-08
neurons O 0 7.219207276421002e-08
. O 0 3.298617823332961e-09
. O 0 2.639174923046994e-08

Stable O 0 0.00015756873472128063
interaction O 0 3.3301333246527065e-07
between O 0 2.046086144957826e-08
the O 0 2.4146371568889435e-09
products O 0 4.155441324371623e-09
of O 0 2.1069025690767518e-10
the O 0 6.854667500277856e-09
BRCA1 O 0 0.0001394644204992801
and O 0 4.0563000425208884e-07
BRCA2 O 0 0.006374917458742857
tumor B-Disease 0 2.2569727207155665e-06
suppressor O 0 8.004844858078286e-07
genes O 0 1.8079154529004882e-07
in O 0 4.008447795911252e-09
mitotic O 0 1.132936176873045e-06
and O 0 2.0897397234875825e-07
meiotic O 0 0.00034431100357323885
cells O 0 1.8398290194454603e-05
. O 0 3.380266377916996e-07

BRCA1 O 1 0.6423817276954651
and O 0 2.7403018520999467e-06
BRCA2 O 0 0.00043924018973484635
account O 0 1.3823421340930508e-07
for O 0 8.034943266288508e-10
most O 0 9.292580593900368e-10
cases O 0 9.193642513949385e-10
of O 0 6.300543420323379e-10
familial O 0 0.0002697835152503103
, O 0 2.18301732246573e-08
early O 0 4.918164222544874e-07
onset O 1 0.8365877270698547
breast B-Disease 1 0.9997087121009827
and I-Disease 0 3.338720853207633e-05
/ I-Disease 1 0.9999995231628418
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.0855840366969005e-09
encode O 0 6.41509387833139e-08
products O 0 3.509588566430466e-07
that O 0 1.2601574228554568e-09
each O 0 3.872647091895942e-09
interact O 0 3.072429777262187e-08
with O 0 1.3266910237064167e-08
hRAD51 O 0 9.452701306145173e-06
. O 0 1.7014177444707457e-07

Results O 0 9.117700756178237e-06
presented O 0 1.1745745354119208e-07
here O 0 8.767871761961032e-09
show O 0 2.9772818876949714e-08
that O 0 1.9837882447859556e-09
BRCA1 O 0 6.775849033147097e-05
and O 0 4.911320843348221e-07
BRCA2 O 0 0.011755404062569141
coexist O 0 1.7534600829094416e-06
in O 0 2.7890332265911866e-09
a O 0 8.588337152559689e-09
biochemical O 0 1.094400545298413e-06
complex O 0 8.827596786886716e-08
and O 0 5.172203643155626e-08
colocalize O 0 1.8417404135107063e-06
in O 0 6.718932521465604e-09
subnuclear O 0 1.548900058878644e-06
foci O 0 7.392873158096336e-07
in O 0 4.785329021927964e-09
somatic O 0 1.077009187611111e-06
cells O 0 2.4259028919004777e-07
and O 0 5.1658908262197656e-09
on O 0 4.809504350333782e-09
the O 0 1.6129683144683327e-09
axial O 0 2.9128655043564322e-08
elements O 0 3.451969021739387e-08
of O 0 5.756508159038276e-09
developing O 0 4.977096637048817e-07
synaptonemal O 0 7.455158993252553e-06
complexes O 0 9.216411172019434e-07
. O 0 1.253874444273606e-07

Like O 0 3.443750028964132e-05
BRCA1 O 0 0.0012805588776245713
and O 0 5.886591338821745e-07
RAD51 O 0 0.00013740100257564336
, O 0 1.0474835221430112e-07
BRCA2 O 0 1.969719960470684e-05
relocates O 0 1.5266776927091996e-06
to O 0 4.789915664105138e-08
PCNA O 0 4.090534275746904e-05
+ O 0 5.186508360566222e-07
replication O 0 3.080445765135664e-07
sites O 0 5.9483120651293575e-08
following O 0 1.7416619257915045e-08
exposure O 0 2.82840960608155e-06
of O 0 8.283207897363809e-09
S O 0 1.0054428457806353e-05
phase O 0 2.1670233252280013e-07
cells O 0 8.677288576564024e-08
to O 0 1.4182965024645e-08
hydroxyurea O 0 8.009174962353427e-06
or O 0 1.374328007841541e-06
UV O 0 0.0006451052031479776
irradiation O 0 8.22115453047445e-06
. O 0 3.5525198427421856e-07

Thus O 0 2.3545182557427324e-05
, O 0 1.5698144295583916e-07
BRCA1 O 0 1.730127405608073e-05
and O 0 6.842913080618018e-08
BRCA2 O 0 2.1246109099593014e-05
participate O 0 6.754270032161003e-08
, O 0 5.443399508919811e-09
together O 0 5.904611910523272e-08
, O 0 1.5487700011362904e-09
in O 0 3.96582849893079e-10
a O 0 6.861469170615919e-09
pathway O 0 1.2703401353064692e-07
( O 0 7.4135004801689774e-09
s O 0 1.567540607538831e-06
) O 0 2.1821919826692238e-09
associated O 0 6.6102248119648266e-09
with O 0 1.020784901051286e-09
the O 0 1.957358275461729e-09
activation O 0 5.443060047127801e-08
of O 0 9.723176930265254e-09
double O 0 4.683039878727868e-05
- O 0 0.001120532164350152
strand O 0 4.299132342566736e-05
break O 0 0.00012839595729019493
repair O 0 0.009094880893826485
and O 0 8.43042982978659e-07
/ O 0 1.739577783155255e-05
or O 0 2.4256090114249673e-07
homologous O 0 3.814842330029933e-06
recombination O 0 7.143562470446341e-06
. O 0 5.743021347370814e-07

Dysfunction O 1 0.8427467346191406
of O 0 9.77204024366074e-08
this O 0 2.2218232587079e-08
pathway O 0 1.4645908095189952e-06
may O 0 4.4680064092972316e-07
be O 0 1.5093304384095063e-09
a O 0 1.0588763199592677e-09
general O 0 1.3623601136103503e-09
phenomenon O 0 1.821330286588818e-08
in O 0 2.950933386536292e-10
the O 0 5.904605693274334e-10
majority O 0 1.7354634396227198e-09
of O 0 1.199964155818023e-10
cases O 0 1.3857422986873758e-09
of O 0 2.226930195803334e-09
hereditary B-Disease 1 0.9998131394386292
breast I-Disease 1 0.9999077320098877
and I-Disease 0 0.004183546639978886
/ I-Disease 1 0.9999997615814209
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.20847870891339e-08
. O 0 1.3907241225297184e-07

A O 0 8.328960575454403e-06
novel O 0 2.062418843706837e-06
Arg362Ser O 0 1.2162945495219901e-05
mutation O 0 3.149816393488436e-06
in O 0 1.3792352149266662e-08
the O 0 5.037052019929433e-08
sterol O 0 1.023123422783101e-05
27 O 0 1.808113552215218e-06
- O 0 5.752714059781283e-06
hydroxylase O 0 2.7212045097257942e-05
gene O 0 2.8390466013661353e-06
( O 0 4.238355799657256e-08
CYP27 O 0 1.6132403288793284e-06
) O 0 3.1820059920306676e-09
: O 0 5.065497465928104e-10
its O 0 1.5027608046835894e-09
effects O 0 2.2772998420350632e-07
on O 0 1.7390263451488863e-08
pre O 0 8.917445484257769e-06
- O 0 4.603316483553499e-07
mRNA O 0 1.4757945621113322e-07
splicing O 0 3.732646405296691e-07
and O 0 2.9767255327328712e-08
enzyme O 0 6.297557888501615e-07
activity O 0 7.796939485160692e-07
. O 0 1.6421027737578697e-07

A O 0 1.0068179108202457e-05
novel O 0 1.159508769887907e-06
C O 0 4.150637778366217e-06
to O 0 1.4612206555852936e-08
A O 0 6.392960472112463e-08
mutation O 0 1.002580006570497e-06
in O 0 2.9820999003504767e-09
the O 0 1.8561831183205868e-08
sterol O 0 1.123669517255621e-05
27 O 0 8.244481932706549e-07
- O 0 3.809309419011697e-06
hydroxylase O 0 1.6766340195317753e-05
gene O 0 1.890897010525805e-06
( O 0 4.0034525028431744e-08
CYP27 O 0 1.3890185073250905e-06
) O 0 3.6950871251661965e-09
was O 0 1.3565138345938976e-08
identified O 0 1.2049077291464982e-08
by O 0 5.929863822196069e-10
sequencing O 0 1.021707163317842e-07
amplified O 0 1.1559955055417959e-06
CYP27 O 0 3.879757059621625e-06
gene O 0 4.232947219406924e-07
products O 0 7.374832478035387e-08
from O 0 1.2696710349757723e-08
a O 0 1.348425797687014e-07
patient O 0 2.5874511266010813e-05
with O 0 1.4235903336157207e-06
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 2.3510262963100104e-06
CTX B-Disease 0 0.0005428548902273178
) O 0 1.8472304930128303e-07
. O 0 1.1247808373582302e-07

The O 0 2.735836460487917e-06
mutation O 0 1.3090690117678605e-05
changed O 0 3.3142538313768455e-07
the O 0 8.706162901717107e-09
adrenodoxin O 0 1.1771911658797762e-06
cofactor O 0 9.088947763302713e-07
binding O 0 9.816480996960308e-07
residue O 0 5.3039334488858e-06
362Arg O 0 3.6332021409180015e-06
to O 0 5.263262536914226e-08
362Ser O 0 7.4648419285949785e-06
( O 0 8.706599174956864e-08
CGT O 0 1.6411961041740142e-05
362Arg O 0 1.8129637737729354e-06
to O 0 3.160619499453787e-08
AGT O 0 2.4416900487267412e-05
362Ser O 0 2.8331853627605597e-06
) O 0 9.10760267203159e-09
, O 0 1.7312943301206474e-09
and O 0 7.9540560804503e-09
was O 0 2.3019364903120731e-07
responsible O 0 1.5492722127419256e-07
for O 0 1.558969131565391e-08
deficiency O 0 2.7597467123996466e-05
in O 0 7.460463358199831e-10
the O 0 6.4566068047611225e-09
sterol O 0 1.1746006975954515e-06
27 O 0 2.5630680511312676e-07
- O 0 4.835804929825827e-07
hydroxylase O 0 1.9058729776588734e-06
activity O 0 2.856501737369399e-07
, O 0 3.3805671595388276e-09
as O 0 2.604459092836464e-09
confirmed O 0 8.837768739056173e-09
by O 0 4.887887317117645e-10
expression O 0 4.198334124794201e-09
of O 0 6.97626123535855e-10
mutant O 0 1.45145492069787e-07
cDNA O 0 1.422990152377679e-07
into O 0 1.1279679057452086e-07
COS O 0 0.00011547605390660465
- O 0 5.594818048848538e-06
1 O 0 2.6852887913264567e-07
cells O 0 7.510446948799654e-07
. O 0 7.968075266262531e-08

Quantitative O 0 1.1130117854918353e-05
analysis O 0 1.2166598253315897e-06
showed O 0 2.3841312213335186e-06
that O 0 1.8889332320526364e-09
the O 0 3.6971314898437413e-09
expression O 0 1.917045366894854e-08
of O 0 2.253180531042176e-09
CYP27 O 0 2.8707925139315194e-06
gene O 0 1.245598468813114e-07
mRNA O 0 6.073341296541912e-08
in O 0 2.3899677792371676e-09
the O 0 1.4100346668044494e-08
patient O 0 4.7579462147950835e-07
represented O 0 1.0050731447108774e-07
52 O 0 6.160669840937771e-07
. O 0 1.2550960093449248e-07

5 O 0 5.036388756707311e-06
% O 0 1.4339566689614003e-07
of O 0 2.86649015635021e-09
the O 0 2.703967716399802e-08
normal O 0 7.837988391656836e-07
level O 0 7.468537660315633e-06
. O 0 4.577989898280066e-07

As O 0 1.3224222357166582e-06
the O 0 1.133525771024324e-07
mutation O 0 2.281045453855768e-06
occurred O 0 2.3484980715693382e-07
at O 0 2.862050152430129e-08
the O 0 8.419172026208344e-09
penultimate O 0 6.52566939152166e-07
nucleotide O 0 1.9460468081433646e-07
of O 0 1.7314727429607046e-09
exon O 0 2.0155256663656473e-07
6 O 0 1.1594817550530934e-07
( O 0 9.127774980299819e-09
- O 0 4.0833020875652437e-07
2 O 0 1.8178942795543662e-08
position O 0 7.297593640487321e-08
of O 0 1.2361396350968334e-09
exon O 0 3.9643202853767434e-07
6 O 0 2.641975811457087e-07
- O 0 2.0097725155210355e-06
intron O 0 2.646948087203782e-05
6 O 0 1.6532182200990064e-07
splice O 0 8.241091563832015e-06
site O 0 2.1113142167905607e-07
) O 0 1.1331561244887212e-09
of O 0 1.3648979169111897e-10
the O 0 2.036782964509598e-09
gene O 0 8.976022058959643e-08
, O 0 2.5064330611002106e-09
we O 0 3.4762352996153822e-09
hypothesized O 0 1.1681752454251182e-08
that O 0 5.499919963902755e-10
the O 0 6.417979481199154e-09
mutation O 0 4.023216661153128e-06
may O 0 2.2384705289368867e-07
partially O 0 1.2547684491437394e-06
affect O 0 1.896717805038861e-08
the O 0 1.3276523214145186e-09
normal O 0 1.206427846511815e-08
splicing O 0 1.596414591631401e-07
efficiency O 0 8.401433859717145e-08
in O 0 1.6069495734072348e-09
exon O 0 1.200666446266041e-07
6 O 0 5.798673186063752e-08
and O 0 1.532827731409725e-08
cause O 0 3.220253219637925e-08
alternative O 0 3.7668254293521386e-08
splicing O 0 1.5917884184091236e-06
elsewhere O 0 8.792197263574053e-07
, O 0 2.315932556840039e-09
which O 0 1.8022573433640332e-09
resulted O 0 1.3469228399287658e-08
in O 0 1.8089867381831937e-09
decreased O 0 9.92757236417674e-07
transcript O 0 1.614460956034236e-07
in O 0 3.895687328281383e-09
the O 0 4.509047712986103e-08
patient O 0 2.08691062653088e-06
. O 0 1.0568211905592761e-07

Transfection O 0 0.0004558474465738982
of O 0 3.2845130704117764e-07
constructed O 0 1.0046080205938779e-05
minigenes O 0 4.154765701969154e-05
, O 0 1.833725526978469e-08
with O 0 9.351277086011578e-09
or O 0 7.833311315152969e-07
without O 0 3.708865037310716e-08
the O 0 4.254406604786709e-09
mutation O 0 2.0542888989893981e-07
, O 0 3.0483029433980846e-09
into O 0 1.4186698038543e-08
COS O 0 0.00013233051868155599
- O 0 4.765280209539924e-06
1 O 0 5.6336826759206815e-08
cells O 0 1.1378592290611778e-07
confirmed O 0 1.0572945186027027e-08
that O 0 1.928176784904423e-10
the O 0 1.0212951595534037e-09
mutant O 0 4.4346228378344676e-07
minigene O 0 1.4702291082357988e-06
was O 0 1.3446965851926507e-07
responsible O 0 2.384241426511835e-08
for O 0 5.349425902245741e-10
a O 0 2.748413052700016e-09
mRNA O 0 4.480448367871759e-08
species O 0 2.985446112546697e-09
alternatively O 0 3.00590308199844e-08
spliced O 0 2.9212558274593903e-06
at O 0 4.162861557688302e-07
an O 0 1.5159264066255673e-08
activated O 0 1.455023721064208e-06
cryptic O 0 4.420300854235393e-07
5 O 0 1.2533743820597465e-08
splice O 0 3.7030235944257583e-06
site O 0 5.610257289845322e-07
88 O 0 4.700465581208846e-07
bp O 0 8.048277777561452e-07
upstream O 0 7.920828437590899e-08
from O 0 4.4401979870656305e-09
the O 0 2.7048017159359006e-09
3 O 0 8.286336949936413e-09
end O 0 2.2633685148321092e-08
of O 0 3.0269935447080343e-09
exon O 0 1.931301767399418e-06
6 O 0 9.634915159040247e-07
. O 0 2.1304197161953198e-07

Our O 0 3.1320385005528806e-06
data O 0 5.1874974360544e-07
suggest O 0 1.3659949615885125e-07
that O 0 4.17769285832037e-09
the O 0 7.398781587397707e-09
C O 0 7.266536385941436e-07
to O 0 4.440960488238943e-09
A O 0 1.5219067961425026e-07
mutation O 0 5.967482366031618e-07
at O 0 4.188170521501888e-08
the O 0 6.0164517812211216e-09
penultimate O 0 6.397157221726957e-07
nucleotide O 0 1.0071437372971559e-07
of O 0 6.569409460865927e-10
exon O 0 8.298486875446542e-08
6 O 0 1.4834052208811954e-08
of O 0 3.6055874952367617e-10
the O 0 3.437918838500309e-09
CYP27 O 0 1.9299595805932768e-06
gene O 0 1.8337854612582305e-07
not O 0 1.2553050154906487e-08
only O 0 8.607457857578993e-09
causes O 0 9.671004619349333e-08
the O 0 1.6919470624543465e-07
deficiency B-Disease 0 2.6385660021333024e-05
in I-Disease 0 1.436224472683989e-09
the I-Disease 0 8.258062678123679e-09
sterol I-Disease 0 2.675970563359442e-06
27 I-Disease 0 3.159824188969651e-07
- I-Disease 0 3.1838052905186487e-07
hydroxylase I-Disease 0 1.1347516419846215e-06
activity I-Disease 0 2.9353904551499e-07
, O 0 5.241620470997077e-09
but O 0 3.4814442440023186e-09
also O 0 1.3493940187458975e-08
partially O 0 8.074478046182776e-07
leads O 0 1.0634065183978691e-08
to O 0 5.855474771720992e-09
alternative O 0 3.2360095048034054e-08
pre O 0 1.6232164853136055e-05
- O 0 4.0449123162034084e-07
mRNA O 0 6.65782877717902e-08
splicing O 0 1.4153920346871018e-07
of O 0 1.9297965447861998e-09
the O 0 1.1874520922106058e-08
gene O 0 3.7006014963480993e-07
. O 0 7.606613650068539e-08

To O 0 8.041250225687691e-07
our O 0 1.665355284785619e-07
knowledge O 0 3.192177899791204e-08
, O 0 2.094079354364453e-09
this O 0 3.2766186985888623e-10
is O 0 5.451750717533344e-10
the O 0 5.134904723647082e-10
first O 0 1.1918381837006109e-08
report O 0 9.91037385489335e-09
regarding O 0 1.1048295611715275e-08
effects O 0 9.262838034373999e-07
on O 0 8.728047617978518e-08
pre O 0 1.4209943401510827e-05
- O 0 2.5587894469936145e-07
mRNA O 0 5.628977817195846e-08
splicing O 0 1.287295532392818e-07
of O 0 3.293915140645254e-09
a O 0 2.781438013244042e-08
mutation O 0 2.334610513798907e-07
at O 0 7.289275316679777e-08
the O 0 1.1082676998341867e-08
- O 0 3.40739325110917e-06
2 O 0 2.555640143953042e-08
position O 0 2.0863724614628154e-07
of O 0 1.1216904072242073e-09
a O 0 2.4622815786301544e-08
5 O 0 6.410421349301032e-08
splice O 0 7.843376806704327e-05
site O 0 3.8125076571304817e-06
. O 0 3.5702933587344887e-07

ATM O 0 0.0027857583481818438
germline O 0 0.0028511860873550177
mutations O 0 0.000290884607238695
in O 0 2.2919017794720276e-07
classical O 0 0.00021002480934839696
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999915361404419
in O 0 1.671257443547347e-08
the O 0 2.5459048202947088e-08
Dutch O 0 8.907693700166419e-05
population O 0 5.34573878496758e-08
. O 0 6.926494222625479e-08

Germline O 0 0.0018189323600381613
mutations O 0 0.00011917541269212961
in O 0 2.1182676945841195e-08
the O 0 4.460468439049237e-09
ATM O 0 2.517637540222495e-06
gene O 0 4.7264424551940465e-07
are O 0 3.876549303782895e-09
responsible O 0 2.717918157202348e-08
for O 0 5.11765962940558e-09
the O 0 0.00027218781178817153
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.06801564991474152
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.7512061845081917e-07
. O 0 7.779323851764275e-08

In O 0 1.0762411193354637e-06
our O 0 4.269215594376874e-07
study O 0 2.8855540179506534e-08
, O 0 4.853756951916921e-09
we O 0 1.5553368371001852e-08
have O 0 3.485696620231238e-09
determined O 0 2.0468041483923116e-08
the O 0 5.187851037646851e-09
ATM O 0 5.644551947625587e-06
mutation O 0 3.5189725622331025e-07
spectrum O 0 5.450186790767475e-08
in O 0 4.283001064919745e-09
19 O 0 5.9050396572501995e-08
classical O 0 1.4265340269048465e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.2063453040318564e-05
, O 0 5.280169634858112e-10
including O 0 1.6194656726753465e-10
some O 0 2.3234351942402753e-10
immigrant O 0 4.6381376961335263e-08
populations O 0 2.1240937897459844e-08
, O 0 4.803643594009088e-10
as O 0 7.917920763489406e-10
well O 0 1.112117331558693e-08
as O 0 6.200192803618165e-09
12 O 0 5.195208263586437e-09
of O 0 1.3382285279917028e-09
Dutch O 0 1.292185697820969e-05
ethnic O 0 8.617943336730605e-08
origin O 0 4.0587110561318696e-07
. O 0 1.272124592333057e-07

Both O 0 1.1340312084939796e-06
the O 0 6.085470261041337e-08
protein O 0 1.9330546763285383e-07
truncation O 0 1.458789029129548e-06
test O 0 1.2842027899750974e-05
( O 0 1.0966336105866503e-07
PTT O 0 2.550080580476788e-06
) O 0 2.5799753444744056e-09
and O 0 1.7435023424994256e-09
the O 0 1.442962638265044e-09
restriction O 0 1.8286156588942504e-08
endonuclease O 0 1.192354034174059e-06
fingerprinting O 0 7.886748676355637e-07
( O 0 2.4930365327691106e-08
REF O 0 4.520347374636913e-06
) O 0 2.848585811676685e-09
method O 0 2.5923378998982116e-08
were O 0 9.667444800243175e-08
used O 0 9.939493139654587e-08
and O 0 1.1567856716965252e-07
compared O 0 2.2193159310290866e-08
for O 0 3.240904489221208e-10
their O 0 6.3563367902474965e-09
detection O 0 2.57384840551822e-07
efficiency O 0 2.2624497830747714e-07
, O 0 2.882048599772702e-09
identifying O 0 1.318083064916209e-07
76 O 0 2.8555506403904474e-08
% O 0 3.9099945503551226e-09
and O 0 7.378853528194895e-09
60 O 0 8.481611857291682e-09
% O 0 3.382179647459793e-09
of O 0 3.59252405601751e-10
the O 0 1.9208263424275174e-08
mutations O 0 2.839035687429714e-06
, O 0 1.0762268409791886e-08
respectively O 0 3.4923604630421323e-07
. O 0 1.076512603503943e-07

Most O 0 1.0000990187108982e-05
patients O 0 0.004114195704460144
were O 0 4.104322215425782e-07
found O 0 2.9251026489873766e-08
to O 0 1.3428724798814073e-08
be O 0 3.635845757798961e-08
compound O 0 4.4579235236597015e-07
heterozygote O 0 1.037786205415614e-05
. O 0 1.5126605035220564e-07

Seventeen O 0 0.00012378901010379195
mutations O 0 0.00010135652701137587
were O 0 3.817164611064072e-07
distinct O 0 4.274303577744831e-08
, O 0 2.991328518220371e-09
of O 0 3.486213262515747e-10
which O 0 1.4342213638940393e-08
10 O 0 1.683889649939374e-08
were O 0 2.8119478656662977e-07
not O 0 2.0005460399374897e-08
reported O 0 1.3729338377288514e-07
previously O 0 3.8918724953873607e-07
. O 0 7.327511752919236e-08

Mutations O 0 0.001470634015277028
are O 0 8.875408497033277e-08
small O 0 5.014448589690801e-08
deletions O 0 3.751593339984538e-06
or O 0 1.9769538539549103e-06
point O 0 2.0869247236987576e-06
mutations O 0 4.930777504341677e-05
frequently O 0 3.154454816467478e-06
affecting O 0 1.1046093959521386e-06
splice O 0 0.00019201976829208434
sites O 0 7.612557510583429e-06
. O 0 1.1186697292941972e-06

Moreover O 0 2.679522913240362e-05
, O 0 2.219519643631429e-07
a O 0 7.119874823047212e-08
16 O 0 3.8126171375552076e-07
. O 0 1.6961848814389668e-07

7 O 0 6.211680738488212e-05
- O 0 2.319139093742706e-05
kb O 0 9.725304153107572e-06
genomic O 0 1.975538452825276e-06
deletion O 0 3.125003104287316e-06
of O 0 4.113889229273582e-09
the O 0 6.146500641790453e-09
3 O 0 2.2197900406695226e-08
end O 0 2.3117587844012633e-08
of O 0 4.059287073143736e-10
the O 0 3.0428541908378293e-09
gene O 0 1.2142982086515985e-07
, O 0 1.1207259564827154e-09
most O 0 1.0175308373661096e-09
likely O 0 2.1086332679942643e-08
a O 0 5.707224026707536e-09
result O 0 9.88579351712815e-09
of O 0 3.3885833028435286e-10
recombination O 0 2.1011096862366685e-08
between O 0 3.3408909416721144e-08
two O 0 2.7829932491840736e-07
LINE O 0 0.008577379398047924
elements O 0 3.838000282030407e-07
, O 0 2.8090765269439544e-08
was O 0 2.2742285921140137e-07
identified O 0 3.7232678096188465e-07
. O 0 3.100776524433968e-08

The O 0 4.6387393126678944e-07
most O 0 5.6567461825807186e-08
frequently O 0 1.3124852102919249e-06
found O 0 8.227596737242493e-08
mutation O 0 6.732404926879099e-07
, O 0 2.7582123252045676e-09
identified O 0 7.063188434131007e-08
in O 0 1.2199801169288094e-09
three O 0 8.12169442809818e-09
unrelated O 0 1.4804662384904077e-07
Turkish O 0 1.4393001038115472e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 2.111630408307974e-07
, O 0 3.3621891937229975e-09
was O 0 1.1512719311213004e-07
previously O 0 1.0371120851004889e-07
described O 0 1.589908116272909e-08
to O 0 3.1203295502990613e-09
be O 0 1.2340437116620251e-08
a O 0 3.555803473886954e-08
Turkish O 0 1.6125641195685603e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
founder O 0 5.724916718463646e-06
mutation O 0 6.782737273169914e-06
. O 0 2.3680532024172862e-07

The O 0 3.076623045217275e-07
presence O 0 1.0492331625755469e-07
of O 0 2.4087216665691358e-09
a O 0 1.1413560763173791e-08
founder O 0 9.075559859184068e-08
mutation O 0 1.5039981349218579e-07
among O 0 1.1761538409871264e-09
relatively O 0 2.584950031803146e-09
small O 0 1.4563422690017092e-09
ethnic O 0 3.4745053500984113e-09
population O 0 5.688249427038272e-09
groups O 0 1.8391326239708405e-09
in O 0 4.77930639508628e-10
Western O 0 9.539607326303212e-09
Europe O 0 3.5880948416888714e-06
could O 0 6.694361900372314e-07
indicate O 0 4.108633788746374e-07
a O 0 1.8306920424038253e-08
high O 0 2.9519677013922774e-07
carrier O 0 3.953680902668566e-07
frequency O 0 1.9086125746525795e-07
in O 0 1.8073141871965959e-09
such O 0 6.76295641710567e-09
communities O 0 1.9859021449519787e-07
. O 0 9.239391118853746e-08

In O 0 5.714318376703886e-06
patients O 0 0.0001870907290140167
of O 0 1.0323691235214483e-08
Dutch O 0 1.5492027159780264e-05
ethnic O 0 4.2202380257094774e-08
origin O 0 7.490869080584162e-08
, O 0 6.963329912679228e-09
however O 0 5.5266746734616845e-09
, O 0 1.0456121524171635e-09
no O 0 3.5601588344036372e-09
significant O 0 3.858336317108524e-09
founder O 0 6.273700137171545e-08
effect O 0 4.0379930510425766e-08
could O 0 8.822008368269962e-08
be O 0 9.749324014762806e-09
identified O 0 2.22223903278973e-07
. O 0 3.0156019903415654e-08

The O 0 3.1809128131499165e-07
observed O 0 6.466974582508556e-07
genetic O 0 6.340500817714201e-07
heterogeneity O 0 1.725562981391704e-07
including O 0 9.423163582766847e-09
the O 0 1.7855677825195926e-08
relative O 0 5.796040909444855e-07
high O 0 1.3604596915683942e-06
percentage O 0 1.049628644977929e-05
of O 0 6.34480468164611e-09
splice O 0 0.07263942062854767
- O 0 0.0009347310406155884
site O 0 1.6641122329019709e-06
mutations O 0 5.56706145289354e-05
had O 0 6.164225396787515e-07
no O 0 2.4607700765955087e-08
reflection O 0 7.303079740950125e-08
on O 0 2.0877671147445653e-08
the O 0 4.056357738591032e-08
phenotype O 0 7.695161912124604e-06
. O 0 9.218585006465219e-08

All O 0 2.6144477942580124e-06
patients O 0 5.079998663859442e-05
manifested O 0 2.5735046165209496e-06
classical O 0 1.3979595223645447e-06
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999988079071045
T I-Disease 1 1.0
and O 0 1.258024866501728e-07
increased O 0 1.4913406687355746e-07
cellular O 0 2.704875896597514e-06
radioresistant O 0 5.688719284080435e-06
DNA O 0 9.389435149387282e-07
synthesis O 0 1.1608542536123423e-06
. O 0 3.0572022069463856e-07

Determination O 0 4.4068160605093e-06
of O 0 1.770493440744758e-08
the O 0 9.610211293420434e-09
genomic O 0 3.235954295632837e-07
structure O 0 1.1131491817195638e-07
of O 0 2.3578026198123325e-09
the O 0 9.767192388210333e-09
COL4A4 O 0 2.4599567041150294e-06
gene O 0 1.1381240483387955e-07
and O 0 2.036782964509598e-09
of O 0 1.937434435106411e-09
novel O 0 7.29567261714692e-07
mutations O 0 0.007730375975370407
causing O 0 0.00025650853058323264
autosomal B-Disease 1 0.999998927116394
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.2428880583902355e-06

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.0086794683702465e-07
a O 0 4.0502661136088136e-07
progressive O 0 0.0024383491836488247
hematuric B-Disease 1 0.9992644190788269
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.001438598963432014
by O 0 1.309876438426727e-07
glomerular B-Disease 0 0.0783228725194931
basement I-Disease 1 0.9634536504745483
membrane I-Disease 0 0.47366875410079956
abnormalities I-Disease 1 0.9999842643737793
and O 0 5.6192380526454144e-08
associated O 0 7.63621059718389e-08
with O 0 5.996780405581603e-09
mutations O 0 6.6085531216231175e-06
in O 0 4.229180117221176e-09
either O 0 8.633605830254965e-08
the O 0 1.7256347462080157e-08
COL4A3 O 0 2.0235263946233317e-05
or O 0 6.924393858298572e-08
the O 0 9.60687529527604e-09
COL4A4 O 0 6.155229129944928e-06
gene O 0 1.5828707944365306e-07
, O 0 1.0565924801753113e-09
which O 0 4.478333537338841e-10
encode O 0 2.1817227136011752e-08
the O 0 5.619931187084148e-09
alpha3 O 0 6.754630703653675e-07
and O 0 1.4749300447647329e-08
alpha4 O 0 2.484047627149266e-06
type O 0 2.5692579583846964e-05
IV O 0 8.964180597104132e-05
collagen O 0 4.391762558952905e-06
chains O 0 4.531326703727245e-05
, O 0 7.673206425806711e-08
respectively O 0 6.754347054993559e-07
. O 0 1.0865773703017112e-07

To O 0 1.1090575071648345e-06
date O 0 6.324364107967995e-07
, O 0 1.1411950495698875e-08
mutation O 0 1.3342969396035187e-07
screening O 0 7.878939811689634e-08
in O 0 3.6802811909097954e-09
the O 0 3.2254892090577414e-09
two O 0 1.1109851705271012e-08
genes O 0 5.538633445212326e-07
has O 0 2.997052561681812e-08
been O 0 5.697731708664833e-08
hampered O 0 1.3752339782513445e-06
by O 0 8.10725098165932e-10
the O 0 1.989456599460482e-09
lack O 0 7.328165185782609e-09
of O 0 3.5382979879372556e-10
genomic O 0 1.6706094640994706e-07
structure O 0 3.528711829403619e-07
information O 0 1.3547456489959586e-07
. O 0 1.5044801671137975e-07

We O 0 1.5158509086177219e-05
report O 0 9.713060222793501e-08
here O 0 1.937656257666731e-09
the O 0 9.216466478889629e-10
complete O 0 2.3250854574996538e-09
characterization O 0 2.7094607446542796e-08
of O 0 9.719760551973877e-10
the O 0 1.0307419806565576e-08
48 O 0 6.497488413970132e-08
exons O 0 1.5793979457612295e-07
of O 0 1.9519375005216943e-09
the O 0 1.7697910692504593e-08
COL4A4 O 0 1.3518174455384724e-05
gene O 0 2.2365522056588816e-07
, O 0 2.5423514404820935e-09
a O 0 3.123836966878457e-09
comprehensive O 0 1.0760157920230995e-07
gene O 0 3.5630552019938477e-07
screen O 0 2.662563929334283e-05
, O 0 2.8913111904671496e-08
and O 0 7.52924123048615e-09
the O 0 1.607323607544231e-09
subsequent O 0 1.2627710432866479e-08
detection O 0 1.109642937535682e-07
of O 0 1.3815566468622364e-09
10 O 0 9.563271952117702e-09
novel O 0 3.2255275783654724e-08
mutations O 0 6.876466045468987e-07
in O 0 5.285068827021178e-09
eight O 0 3.6580256619345164e-06
patients O 0 0.0013190917670726776
diagnosed O 0 0.34966349601745605
with O 0 1.0615450491968659e-06
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.1875414404348703e-06

Furthermore O 0 4.873233046964742e-05
, O 0 2.923564466073003e-07
we O 0 1.348038836113119e-07
identified O 0 8.403421247749066e-08
a O 0 5.179031870028439e-09
glycine O 0 2.0988193227822194e-07
to O 0 1.2236721858016608e-08
alanine O 0 4.6333363457051746e-07
substitution O 0 3.702729856058795e-08
in O 0 1.4683610993770913e-09
the O 0 3.7907810224169225e-09
collagenous O 0 1.548569230180874e-06
domain O 0 2.9298712789227466e-08
that O 0 4.808623721430649e-09
is O 0 1.0352499302257456e-08
apparently O 0 5.794245225843042e-07
silent O 0 6.551215960826084e-07
in O 0 7.579032401672237e-10
the O 0 5.01775643257929e-09
heterozygous O 0 1.0341761935706018e-06
carriers O 0 1.1334630301007564e-07
, O 0 3.999299114099131e-09
in O 0 4.536746089911503e-09
11 O 0 1.402716236498236e-07
. O 0 1.5017708676623442e-07

5 O 0 7.320983968384098e-06
% O 0 1.7869892587896175e-07
of O 0 3.063901798938673e-09
all O 0 2.821268996200388e-09
control O 0 7.163826012401842e-07
individuals O 0 1.5852418044914884e-08
, O 0 1.0352988466522106e-09
and O 0 4.185285895630386e-09
in O 0 1.4944402382255362e-09
one O 0 9.233274589348639e-09
control O 0 5.465540766635968e-07
individual O 0 1.1784944575765621e-08
homozygous O 0 5.185964369047724e-07
for O 0 6.539443431208269e-10
this O 0 7.441532945406948e-10
glycine O 0 3.4176895269411034e-07
substitution O 0 2.4445517965432373e-07
. O 0 1.764380641589014e-07

There O 0 3.4434874578437302e-06
has O 0 1.3401607645846525e-07
been O 0 8.326788503154603e-08
no O 0 2.0971061331920282e-08
previous O 0 6.257363338590949e-08
finding O 0 1.069588329016824e-08
of O 0 2.778402230507737e-10
a O 0 2.2073676220202287e-09
glycine O 0 1.895801631235372e-07
substitution O 0 1.2823803352546292e-08
that O 0 1.7951008457472994e-09
is O 0 1.1845423530942867e-09
not O 0 5.377930101246875e-09
associated O 0 5.475179420955101e-09
with O 0 2.096497198067482e-09
any O 0 2.869620807643969e-08
obvious O 0 5.241133749223081e-07
phenotype O 0 2.2826579879620112e-06
in O 0 2.071907090339664e-08
homozygous O 0 2.5158271455438808e-05
individuals O 0 8.759651848322392e-08
. O 0 9.352546470609013e-08

Founder O 0 0.0001272624940611422
BRCA1 O 0 0.0019038500031456351
and O 0 1.0477367595740361e-06
BRCA2 O 0 0.0008822326199151576
mutations O 0 9.304821105615702e-06
in O 0 1.956926176660545e-08
French O 0 4.789957074535778e-06
Canadian O 0 0.00015977519797161222
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9999713897705078
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.940123977168696e-06
. O 0 2.664175440258987e-07

We O 0 1.0216676855634432e-05
have O 0 1.285571755715864e-07
identified O 0 1.5192239288808196e-07
four O 0 1.1471046335032042e-08
mutations O 0 2.1351792156565352e-07
in O 0 3.728181374729189e-10
each O 0 4.913911499926371e-10
of O 0 5.576608619328738e-10
the O 0 7.377265660579724e-07
breast B-Disease 1 0.9999998807907104
cancer I-Disease 0 0.13419100642204285
- O 0 1.2284388503758237e-05
susceptibility O 0 2.8334929083939642e-05
genes O 0 2.1183439002925297e-06
, O 0 1.002795979587745e-08
BRCA1 O 0 1.3962665434519295e-05
and O 0 1.08113006547228e-07
BRCA2 O 0 8.392910240218043e-05
, O 0 3.847408613921743e-09
in O 0 1.2873545562896993e-09
French O 0 1.4035755384611548e-06
Canadian O 0 4.8487661842955276e-05
breast B-Disease 1 0.9999971389770508
cancer I-Disease 0 0.03993969038128853
and O 0 5.1344632083782926e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.583106136939023e-07
from O 0 6.823493947649695e-08
Quebec O 0 3.478941607681918e-06
. O 0 1.8774157695133908e-07

To O 0 8.505809319103719e-07
identify O 0 6.116685199231142e-06
founder O 0 8.609479209553683e-07
effects O 0 7.69621146901045e-06
, O 0 2.323331216302904e-08
we O 0 4.7133351444017535e-08
examined O 0 5.154029736331722e-07
independently O 0 1.5411275171572925e-06
ascertained O 0 2.5638162242103135e-06
French O 0 2.545488314353861e-06
Canadian O 0 2.4447199393762276e-06
cancer B-Disease 0 1.2941649401909672e-05
families O 0 1.0168561992429659e-08
for O 0 4.740549064408128e-10
the O 0 7.291075521109747e-10
distribution O 0 3.6896852240175804e-09
of O 0 6.879655178870792e-10
these O 0 6.00324634447702e-09
eight O 0 1.8721733852089528e-07
mutations O 0 4.3029353946621995e-06
. O 0 1.0304298569963066e-07

Mutations O 0 0.0018499345751479268
were O 0 2.574793370513362e-06
found O 0 6.142822428500949e-08
in O 0 4.324611335704276e-09
41 O 0 4.316348167776596e-08
of O 0 2.2773718466595483e-09
97 O 0 5.47565150554874e-07
families O 0 1.5282597587429336e-07
. O 0 1.8748569630133716e-07

Six O 0 2.5173012545565143e-06
of O 0 1.4671860171233675e-08
eight O 0 1.4595458708299702e-07
mutations O 0 5.790544037154177e-06
were O 0 1.9333995737724763e-07
observed O 0 1.8688696457047627e-07
at O 0 2.396095055701153e-07
least O 0 1.253145285318169e-07
twice O 0 1.8102116428053705e-06
. O 0 8.77495267559425e-08

The O 0 1.8114516251444002e-06
BRCA1 O 0 0.0008511908818036318
C4446T O 0 1.748324211803265e-05
mutation O 0 1.4901543181622401e-05
was O 0 1.5161541000452416e-07
the O 0 2.017824352051889e-09
most O 0 1.9906485348997194e-09
common O 0 3.335765086376341e-08
mutation O 0 1.4816810107731726e-06
found O 0 3.7310019962433216e-08
, O 0 2.1460913046666974e-09
followed O 0 1.7887821002204873e-08
by O 0 5.816781722955966e-09
the O 0 1.180813526957536e-07
BRCA2 O 0 0.0013884002109989524
8765delAG O 0 1.3598754776467104e-05
mutation O 0 9.806630259845406e-06
. O 0 3.7281569120750646e-07

Together O 0 8.011329555301927e-06
, O 0 2.2214079464788483e-08
these O 0 8.112126970161171e-09
mutations O 0 6.483010679403378e-07
were O 0 2.28688890047124e-07
found O 0 9.893999397547759e-09
in O 0 5.383326007191158e-10
28 O 0 6.5024203799168845e-09
of O 0 4.163515643362814e-10
41 O 0 4.8911097394466196e-08
families O 0 6.768066551643415e-09
identified O 0 3.5116904939513915e-08
to O 0 4.4802153098544295e-09
have O 0 4.137000786386125e-08
a O 0 1.2860084552812623e-07
mutation O 0 1.589185012562666e-05
. O 0 9.101701436975418e-08

The O 0 3.3190110571013065e-07
odds O 0 2.3600907752552303e-06
of O 0 1.5078859272321665e-09
detection O 0 1.5153503341025498e-07
of O 0 1.557776463378957e-09
any O 0 4.6470702841361344e-09
of O 0 7.860709860807447e-10
the O 0 9.55501366917133e-09
four O 0 5.580215542977385e-07
BRCA1 O 0 0.1299690455198288
mutations O 0 6.319062231341377e-05
was O 0 4.3246134850960516e-07
18 O 0 1.3689304978470318e-07
. O 0 9.967190806037252e-08

7x O 0 0.0007097380585037172
greater O 0 1.2427286719685071e-06
if O 0 7.912825594758033e-08
one O 0 6.464160318131462e-09
or O 0 5.942434988526202e-09
more O 0 5.533717928329906e-10
cases O 0 1.933006110732549e-08
of O 0 0.00014787539839744568
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.906073314079549e-05
also O 0 3.8918567923929004e-08
present O 0 6.648892991734101e-09
in O 0 2.000811960556348e-09
the O 0 1.1926704956977119e-08
family O 0 1.1935902932691533e-07
. O 0 4.3202852850754425e-08

The O 0 5.213246936364158e-07
odds O 0 3.916180048690876e-06
of O 0 3.834997652774064e-09
detection O 0 1.0783786308365961e-07
of O 0 6.720672907079006e-10
any O 0 2.0529924427137303e-09
of O 0 5.718815421218437e-10
the O 0 1.2170035645908683e-08
four O 0 6.896358968333516e-07
BRCA2 O 0 0.06994122266769409
mutations O 0 1.5434943634318188e-05
was O 0 1.1862934456985386e-07
5 O 0 5.496800170590177e-08
. O 0 7.45874828567139e-08

3x O 0 0.00034786624019034207
greater O 0 1.281547383769066e-06
if O 0 1.6946133030160127e-07
there O 0 1.937875282465029e-08
were O 0 1.1860513637884651e-07
at O 0 8.687617736313769e-09
least O 0 2.3896942202839e-09
five O 0 8.550771202209262e-10
cases O 0 1.582144859568757e-09
of O 0 3.370949386294342e-08
breast B-Disease 1 0.9999998807907104
cancer I-Disease 0 0.03927945718169212
in O 0 5.227742239100053e-09
the O 0 3.610993459801648e-08
family O 0 2.117139246138322e-07
. O 0 7.07599809857129e-08

Interestingly O 0 1.954294930328615e-05
, O 0 3.7073935033049565e-08
the O 0 2.9719471328348845e-09
presence O 0 5.7912759032774375e-09
of O 0 6.159359688950872e-10
a O 0 1.3834105629939586e-06
breast B-Disease 1 0.9999984502792358
cancer I-Disease 0 0.0002515132073312998
case O 0 5.9702238708325694e-09
< O 0 4.164989775290451e-07
36 O 0 9.837944503487961e-08
years O 0 4.523414087742594e-09
of O 0 7.809049518137101e-10
age O 0 3.3076923955377424e-07
was O 0 4.1821600405000936e-08
strongly O 0 9.848868387507537e-09
predictive O 0 1.243508336301602e-07
of O 0 7.624268993922101e-10
the O 0 1.2055668685562182e-09
presence O 0 2.0903401232175156e-09
of O 0 1.833066198830835e-10
any O 0 1.6446809469883306e-09
of O 0 5.472754471824715e-10
the O 0 9.062063988096725e-09
eight O 0 3.532119023930136e-07
mutations O 0 2.973229811686906e-06
screened O 0 4.417302079673391e-06
. O 0 1.9138163054321922e-07

Carriers O 0 2.3032434910419397e-05
of O 0 1.7339587543574453e-08
the O 0 9.830925407072755e-09
same O 0 1.6983594974817606e-08
mutation O 0 1.727967315900969e-07
, O 0 6.377341432717287e-10
from O 0 3.5922018137846123e-10
different O 0 1.9152719410442387e-09
families O 0 1.2285435779801901e-08
, O 0 9.646439202981583e-10
shared O 0 7.863443229894074e-09
similar O 0 6.705387800565177e-09
haplotypes O 0 5.277079253573902e-07
, O 0 6.5971130780440035e-09
indicating O 0 5.4611231092849266e-08
that O 0 4.22136076094759e-10
the O 0 5.646758061139678e-10
mutant O 0 9.957044966313333e-08
alleles O 0 7.399236068295068e-08
were O 0 8.211073776465128e-08
likely O 0 1.4767429057371828e-08
to O 0 5.224871202358372e-09
be O 0 5.3643486097598725e-08
identical O 0 4.4455475745053263e-07
by O 0 2.3122075365478167e-09
descent O 0 4.7233061195584014e-07
for O 0 3.6429315120045658e-09
a O 0 2.514440211598412e-08
mutation O 0 1.141584448305366e-06
in O 0 3.570113982220846e-09
the O 0 8.484264846231326e-09
founder O 0 1.3200215676079097e-07
population O 0 2.1565723429262107e-08
. O 0 5.092734411960009e-08

The O 0 3.2514773806724406e-07
identification O 0 3.5454294788905827e-07
of O 0 9.607149742407728e-09
common O 0 2.7034010940951703e-07
BRCA1 O 0 0.0008573854574933648
and O 0 3.752251700461784e-07
BRCA2 O 0 0.0028286667075008154
mutations O 0 6.506983936560573e-06
will O 0 6.755401127378491e-09
facilitate O 0 3.792041525230161e-08
carrier O 0 8.29269481528172e-07
detection O 0 9.459720899940294e-07
in O 0 1.401529559075243e-08
French O 0 8.953424185165204e-06
Canadian O 0 0.00012752512702718377
breast B-Disease 1 0.9999973773956299
cancer I-Disease 0 0.29401150345802307
and O 0 0.0001859878102550283
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.068598395359004e-06
. O 0 5.28028579083184e-07

Are O 0 3.160690766890184e-06
Dp71 O 0 5.30304059793707e-05
and O 0 3.916954369742598e-07
Dp140 O 0 2.2463398636318743e-05
brain O 0 5.364688331610523e-05
dystrophin O 0 7.570335583295673e-06
isoforms O 0 4.140380553963041e-07
related O 0 7.313045813361896e-08
to O 0 2.9212667840283757e-08
cognitive B-Disease 0 0.04420388862490654
impairment I-Disease 0 0.0012529576197266579
in O 0 6.915379344718531e-07
Duchenne B-Disease 1 0.9999991655349731
muscular I-Disease 1 0.9999921321868896
dystrophy I-Disease 1 0.9999932050704956
? O 0 0.00011220317537663504

Molecular O 0 1.639612855797168e-05
study O 0 8.120549637169461e-07
and O 0 1.2058082177190954e-07
neuropsychological O 0 9.910536391544156e-06
analysis O 0 2.899253104260424e-07
were O 0 7.280978593371401e-07
performed O 0 1.0438769777465495e-06
concurrently O 0 4.064776248924318e-08
on O 0 6.125471685436423e-08
49 O 0 8.830390470393468e-06
patients O 0 3.9082826219782874e-07
with O 0 1.1904300833975867e-07
Duchenne B-Disease 1 0.999998927116394
muscular I-Disease 1 0.999997615814209
dystrophy I-Disease 1 0.9999977350234985
( O 0 1.5191389138635714e-05
DMD B-Disease 1 1.0
) O 0 8.627448977449603e-08
in O 0 4.126832653383872e-09
order O 0 6.258268125947097e-09
to O 0 3.4717559938002296e-09
find O 0 4.1880191758991714e-08
a O 0 6.801285312718619e-09
molecular O 0 2.4819328814373876e-07
explanation O 0 1.9061655365248953e-08
for O 0 1.390274562140803e-09
the O 0 1.6979837980102275e-08
cognitive B-Disease 0 0.0001776764984242618
impairment I-Disease 0 5.966753178654471e-06
observed O 0 1.2923634074013535e-07
in O 0 3.0543092499613067e-09
most O 0 2.1267656791224e-07
DMD B-Disease 1 1.0
patients O 0 0.001264894031919539
. O 0 3.40232361395465e-07

Complete O 0 1.12870657176245e-06
analysis O 0 1.3140817145540495e-07
of O 0 8.352028402214273e-09
the O 0 2.8534216767184262e-08
dystrophin O 0 9.596605195838492e-06
gene O 0 4.074645403306931e-06
was O 0 6.215007033461006e-07
performed O 0 2.7323062568029854e-07
to O 0 5.084928478282791e-09
define O 0 1.480956370869535e-06
the O 0 4.275263254527317e-09
localization O 0 2.167118395846046e-07
of O 0 1.417062800435076e-09
deletions O 0 3.685657361529593e-07
and O 0 3.385408220424324e-08
duplications O 0 1.921357807077584e-06
in O 0 1.197299681621189e-08
relation O 0 7.992795048039625e-08
to O 0 7.265730239680579e-09
the O 0 3.0445509224819034e-08
different O 0 1.2005809821857838e-06
DMD B-Disease 1 1.0
promoters O 0 3.597155227907933e-05
. O 0 4.017551304968947e-07

Qualitative O 0 1.4509896573144943e-05
analysis O 0 5.152147650733241e-07
of O 0 8.755421276873676e-09
the O 0 2.0062625338823636e-08
Dp71 O 0 2.5485610422038008e-06
transcript O 0 4.437304994553415e-07
and O 0 5.997411989255852e-08
testing O 0 2.0759625840582885e-07
for O 0 1.300568208684183e-09
the O 0 4.188206170763209e-10
specific O 0 1.8323120798413584e-09
first O 0 1.8384032074436618e-09
exon O 0 2.6740613279230274e-08
of O 0 8.493036829371192e-10
Dp140 O 0 4.71666226076195e-07
were O 0 2.078171092989578e-07
also O 0 1.792976789261047e-08
carried O 0 5.928818040956685e-07
out O 0 3.0018125585229427e-07
. O 0 1.2728843046261318e-07

Neuropsychological O 0 0.00035661584115587175
analysis O 0 5.494710876519093e-06
assessed O 0 4.765603080159053e-06
verbal O 0 5.0732105592032894e-05
and O 0 5.989513169879501e-07
visuospatial O 0 0.0005590942455455661
intelligence O 0 3.13005548377987e-05
, O 0 5.158981863928602e-08
verbal O 0 5.047519152867608e-05
memory O 0 0.003290590364485979
, O 0 4.258061991890827e-08
and O 0 3.769046230672757e-08
reading O 0 1.2973159755347297e-05
skills O 0 7.183360867202282e-05
. O 0 2.5969808348236256e-07

Comparison O 0 5.386152679420775e-06
of O 0 4.095024053185625e-08
molecular O 0 4.601543253102136e-07
and O 0 3.606141163459142e-08
psychometric O 0 5.9242032875772566e-05
findings O 0 2.237810861061007e-07
demonstrated O 0 2.6070150482837562e-08
that O 0 3.402215731362901e-10
deletions O 0 1.151734210225186e-07
and O 0 1.041625719011563e-08
duplications O 0 2.6694808639149414e-06
that O 0 2.1918458159575493e-08
were O 0 4.12469518096259e-07
localized O 0 3.5476821835800365e-07
in O 0 3.4672362758669806e-09
the O 0 4.3956727147076435e-09
distal O 0 8.637902055852464e-07
part O 0 7.632595000472975e-09
of O 0 9.032620207349851e-10
the O 0 5.1255333310962214e-09
gene O 0 4.375782793886174e-07
seemed O 0 6.729182899789521e-08
to O 0 7.82975018154275e-10
be O 0 4.395823260949783e-09
preferentially O 0 6.518478556927221e-08
associated O 0 2.4235621509660632e-08
with O 0 1.9066927592348293e-08
cognitive B-Disease 0 0.005680732894688845
impairment I-Disease 0 8.562415314372629e-05
. O 0 2.5831090511019283e-07

Two O 0 2.923446118074935e-06
altered O 0 1.123148831538856e-05
Dp71 O 0 6.800224582548253e-06
transcripts O 0 1.3938259826318244e-06
and O 0 8.004572293884848e-08
two O 0 1.7956702791366297e-08
deleted O 0 3.752301836357219e-06
Dp140 O 0 8.160414495250734e-07
DNA O 0 1.0053818044752916e-07
sequences O 0 1.1056458504299371e-07
were O 0 1.3712119084630103e-07
found O 0 1.2031968310566299e-08
in O 0 1.937286775444136e-09
four O 0 2.912222214490612e-07
patients O 0 1.3171636510378448e-06
with O 0 1.0501962321995961e-07
severe O 1 0.9992944002151489
cerebral B-Disease 1 0.9999924898147583
dysfunction I-Disease 1 0.6290936470031738
. O 0 3.70382537084879e-07

These O 0 9.745106126501923e-07
findings O 0 3.1883629958429083e-07
suggest O 0 1.1857143533688941e-07
that O 0 1.721206066562786e-09
some O 0 7.406091295791839e-10
sequences O 0 3.438668016997326e-08
located O 0 2.0346135443105595e-08
in O 0 2.05367411965085e-09
the O 0 3.860375574760155e-09
distal O 0 8.526624810656358e-07
part O 0 8.174706245256402e-09
of O 0 6.404085595157483e-10
the O 0 2.492863915293242e-09
gene O 0 1.040533987861636e-07
and O 0 1.7594985024516063e-08
, O 0 8.785796534738211e-10
in O 0 2.227235063045896e-10
particular O 0 2.4830411060605684e-09
, O 0 8.217238556262885e-10
some O 0 2.1963391105828123e-09
DMD B-Disease 1 0.9999791383743286
isoforms O 0 9.554269553291306e-08
expressed O 0 8.208971280510013e-09
in O 0 1.9615478130674546e-09
the O 0 2.3394015613575903e-08
brain O 0 0.0006091975374147296
may O 0 8.92463773993768e-08
be O 0 6.13120498815789e-10
related O 0 8.612035529154127e-10
to O 0 2.1443073983107297e-09
the O 0 2.537643695177394e-08
cognitive B-Disease 0 0.01707122102379799
impairment I-Disease 0 3.6548841308103874e-05
associated O 0 4.1895290792126616e-07
with O 0 4.782822315974045e-07
DMD B-Disease 1 1.0
. O 0 2.2572019986455416e-07
. O 0 2.6887275339504413e-07

I1307K O 0 0.00043259706581011415
APC O 0 6.966870569158345e-05
and O 0 3.5222024052927736e-07
hMLH1 O 0 1.0713711162679829e-05
mutations O 0 4.536403594102012e-06
in O 0 8.253432604021782e-09
a O 0 4.6611599913148893e-08
non O 0 7.67681012803223e-06
- O 0 1.4291785191744566e-05
Jewish O 0 4.1565539277144126e-07
family O 0 4.961798083513713e-08
with O 0 1.7941125918241596e-08
hereditary B-Disease 1 0.9991181492805481
non I-Disease 1 0.999881386756897
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.404253559187055e-06

We O 0 5.2397717809071764e-06
describe O 0 1.3028801504333387e-06
a O 0 6.971838217850745e-08
French O 0 3.931890205421951e-06
Canadian O 0 9.740861059981398e-06
hereditary B-Disease 1 0.9999914169311523
non I-Disease 1 0.9999985694885254
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.58436188637279e-05
HNPCC B-Disease 1 0.8854594230651855
) O 0 8.82039330463158e-08
kindred O 0 1.5981617025317973e-06
which O 0 1.4959924854451856e-08
carries O 0 5.030715399811925e-08
a O 0 1.8730728967852883e-08
novel O 0 1.4223660116385872e-07
truncating O 0 5.417773536464665e-06
mutation O 0 6.035710612195544e-06
in O 0 6.227050874940687e-08
hMLH1 O 0 2.218580266344361e-05
. O 0 3.6682229165307945e-07

Interestingly O 0 5.1518996770028025e-05
, O 0 1.5255120899837493e-07
the O 0 2.4074369164850395e-08
I1307K O 0 1.233535272149311e-06
APC O 0 3.2907902891565755e-07
polymorphism O 0 1.807449962143437e-06
, O 0 7.064977491921809e-09
associated O 0 1.515521752537552e-08
with O 0 1.0166889552465364e-09
an O 0 1.4872686415756675e-09
increased O 0 1.2893256098323036e-06
risk O 0 0.0004148648586124182
of O 0 1.2842578144045547e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.840277677611084e-08
is O 0 2.3546926630757525e-09
also O 0 7.18095849450151e-09
present O 0 6.448164668881873e-09
in O 0 1.9791850380812548e-09
this O 0 5.069501707311019e-09
family O 0 3.030178277185769e-07
. O 0 8.89812241666732e-08

The O 0 1.0564709782556747e-06
I1307K O 0 5.465866252052365e-06
polymorphism O 0 8.58949624671368e-06
has O 0 1.3008535404424038e-07
previously O 0 3.3422043088648934e-07
only O 0 1.4197525821657564e-08
been O 0 2.416181921205407e-08
identified O 0 5.7731252667281296e-08
in O 0 7.984833350072051e-10
individuals O 0 3.6287011173641304e-09
of O 0 2.650246022639635e-09
self O 0 0.0010351303499192
- O 0 0.007897302508354187
reported O 0 3.5847974686475936e-06
Ashkenazi O 0 8.520549272361677e-06
Jewish O 0 6.183826712913287e-07
origins O 0 1.1260563042014837e-06
. O 0 1.8588337979963399e-07

In O 0 3.997593296389823e-07
addition O 0 7.167865589963185e-08
, O 0 3.210782306695137e-09
in O 0 4.3988743203549063e-10
this O 0 7.43391459501197e-10
family O 0 1.44923557598986e-08
, O 0 1.1546950062779615e-09
there O 0 2.285269307122917e-09
appears O 0 1.3542414301070949e-08
to O 0 3.7935441454806096e-09
be O 0 4.375465678663204e-08
no O 0 1.80920523007444e-08
relationship O 0 4.964562450027188e-08
between O 0 6.251682727054231e-09
the O 0 3.349617694325957e-09
I1307K O 0 9.406252132748705e-08
polymorphism O 0 3.1795451604921254e-07
and O 0 5.15992359950701e-09
the O 0 9.66161151083611e-10
presence O 0 9.777555654011394e-09
or O 0 4.292358823931863e-08
absence O 0 5.0998892220377456e-08
of O 0 5.669316127665525e-09
cancer B-Disease 0 1.0382069376646541e-05
. O 0 6.840692456933084e-09
. O 0 2.9392802858296818e-08

Identification O 0 4.008062660432188e-06
of O 0 5.038762296294408e-08
a O 0 4.408857279258882e-08
novel O 0 6.411864461597361e-08
mutation O 0 2.162863097510126e-07
of O 0 1.1266090282902042e-09
the O 0 3.597126596588396e-09
CPO O 0 3.9415799619746394e-06
gene O 0 7.323193784714022e-08
in O 0 8.678305851717028e-10
a O 0 9.102427256379997e-09
Japanese O 0 1.955963625732693e-06
hereditary B-Disease 0 0.07013974338769913
coproporphyria I-Disease 0 0.00020205043256282806
family O 0 1.2281285535209463e-06
. O 0 2.066154110025309e-07

Hereditary B-Disease 1 0.9999904632568359
coproporphyria I-Disease 1 0.9645354151725769
( O 0 1.7106660379795358e-05
HCP B-Disease 0 0.00026634885580278933
) O 0 2.7606350982978256e-08
is O 0 1.819322470453244e-09
an O 0 6.352603332260287e-09
autosomal B-Disease 1 0.9999946355819702
dominant I-Disease 1 0.9999986886978149
disease I-Disease 1 0.9995399713516235
characterized O 0 4.135999915888533e-07
by O 0 3.672371517993156e-09
a O 0 6.704789257128141e-07
deficiency B-Disease 0 0.013822423294186592
of I-Disease 0 4.207922010834864e-09
coproporphyrinogen I-Disease 0 3.736847429536283e-05
oxidase I-Disease 0 9.835307537287008e-06
( O 0 1.1270055466638951e-07
CPO O 0 7.077265763655305e-06
) O 0 8.454380306943676e-09
caused O 0 4.8611902059292333e-08
by O 0 1.4747886245558561e-09
a O 0 8.642399684788415e-09
mutation O 0 4.117192702324246e-07
in O 0 2.5397102199065102e-09
the O 0 1.6374137601360417e-08
CPO O 0 8.017834261409007e-06
gene O 0 1.1941360753553454e-06
. O 0 1.3247495189716574e-07

Only O 0 1.6843077901285142e-06
11 O 0 2.4505411033715063e-07
mutations O 0 1.5577600720462215e-07
of O 0 1.0894734003841222e-09
the O 0 3.7077172443389372e-09
gene O 0 3.629956495387887e-07
have O 0 7.822607273055837e-08
been O 0 8.310747290352083e-08
reported O 0 1.767838568866864e-07
in O 0 2.7202677443938228e-08
HCP B-Disease 0 0.003134889295324683
patients O 0 6.899846084706951e-06
. O 0 1.0554774831916802e-07

We O 0 1.9402557882131077e-05
report O 0 2.5764367705960467e-07
another O 0 2.3081943467673227e-08
mutation O 0 4.270693807484349e-07
in O 0 2.6503015337908664e-09
a O 0 1.8763303799573805e-08
Japanese O 0 9.341668487650168e-07
family O 0 2.1650052417498955e-07
. O 0 5.988793105871082e-08

Polymerase O 0 0.0002078188699670136
chain O 0 7.098717469489202e-05
reaction O 0 5.245541160547873e-06
- O 0 1.2804961443180218e-05
single O 0 9.227536565958872e-07
strand O 0 2.374070362520797e-07
conformational O 0 4.217099558445625e-08
polymorphism O 0 6.652630872849841e-07
and O 0 1.8262699796878223e-08
direct O 0 9.409122725401176e-08
sequence O 0 5.883363769498828e-07
analyses O 0 2.795055479509756e-06
demonstrated O 0 1.9229347003602015e-07
a O 0 3.901013201357273e-08
C O 0 1.5392166687888675e-06
to O 0 1.491166656819587e-08
T O 0 8.115734431157762e-07
substitution O 0 9.417486346308124e-09
in O 0 1.2495259271716463e-09
exon O 0 3.716626295613423e-08
1 O 0 7.219287390114459e-09
of O 0 6.431860599676043e-10
the O 0 8.245282678842614e-09
CPO O 0 1.734433794808865e-06
gene O 0 9.649060217498118e-08
at O 0 3.2058515841981716e-08
nucleotide O 0 1.964170053270209e-07
position O 0 2.065215767288464e-06
85 O 0 7.896481690750079e-08
, O 0 3.2665614657645392e-09
which O 0 3.4537122051148117e-09
lies O 0 9.785021859443077e-08
in O 0 1.3934390308278921e-09
the O 0 5.159234817142533e-09
putative O 0 2.6075952064275043e-07
presequence O 0 5.612135964838671e-07
for O 0 2.7953015457882202e-09
targeting O 0 3.422095744554099e-07
to O 0 4.821088595008405e-08
mitochondria O 0 2.426833816571161e-06
. O 0 2.738353259701398e-07

This O 0 5.067832375971193e-07
mutation O 0 2.1531625407078536e-06
changes O 0 5.444731598913677e-08
the O 0 4.133292375030351e-09
codon O 0 1.0622149204664311e-07
for O 0 1.0080807300028027e-09
glutamine O 0 3.074804055813729e-08
to O 0 3.977101759033985e-09
a O 0 1.9547364615846163e-08
termination O 0 1.0063887430078466e-06
codon O 0 1.5260300187946996e-06
at O 0 3.20348050308894e-07
amino O 0 6.583125582437788e-07
acid O 0 5.500239126376982e-07
position O 0 4.3513057335076155e-07
29 O 0 5.611931896964961e-07
. O 0 1.7231029403319553e-07

MaeI O 0 0.0001442305656382814
restriction O 0 1.4830537793386611e-06
analysis O 0 3.693563996876037e-07
showed O 0 6.26712733264867e-07
two O 0 5.673404857020614e-09
other O 0 2.932413645240217e-09
carriers O 0 6.405337416026669e-08
in O 0 1.1546377187698909e-09
the O 0 1.0619005230694256e-08
family O 0 1.192457119714163e-07
. O 0 4.502009787188399e-08

The O 0 5.01985459777643e-06
C O 0 0.013151747174561024
- O 0 0.042608726769685745
T O 0 0.009632752276957035
mutation O 0 1.028677615977358e-06
is O 0 1.5153938104361941e-09
located O 0 6.046477540877504e-09
within O 0 3.904584211511519e-09
a O 0 5.6745736998209395e-09
recently O 0 2.9691610947679692e-08
proposed O 0 1.0362060542945528e-08
putative O 0 2.921451880411041e-07
alternative O 0 4.7048381190961663e-08
translation O 0 1.1482784856298167e-07
initiation O 0 6.527510976184203e-08
codon O 0 6.871044888612232e-07
( O 0 2.194640025265926e-08
TIC O 0 8.517977221345063e-07
- O 0 1.1076400596721214e-06
1 O 0 1.607281596704979e-08
) O 0 1.3885732563778674e-09
, O 0 9.087400276719393e-10
supporting O 0 1.696747098378637e-08
that O 0 1.8903965059990924e-09
TIC O 0 1.1692205816871137e-06
- O 0 1.9657384200399974e-06
1 O 0 6.094830418135189e-09
is O 0 6.211836600655829e-10
the O 0 9.386350585671721e-10
real O 0 1.573920513919802e-07
TIC O 0 6.370393634824723e-07
rather O 0 2.160380496718517e-08
than O 0 6.301075661241384e-09
TIC O 0 2.267226136609679e-06
- O 0 1.8532842886997969e-06
2 O 0 5.1550866686511654e-08
. O 0 1.1067024630051492e-08
. O 0 9.992907479272617e-08

Human B-Disease 0 1.666266871325206e-05
complement I-Disease 0 3.071894752793014e-05
factor I-Disease 0 0.0030896628741174936
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999945163726807
associated O 0 2.205341479566414e-05
with O 0 0.0002397636417299509
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.4567330001445953e-06

This O 0 1.0495553937062141e-07
study O 0 7.187703232602871e-08
reports O 0 8.784196126043753e-08
on O 0 7.28651938786129e-09
six O 0 1.4136053216873279e-08
cases O 0 5.228419919234284e-09
of O 0 3.0904200087888967e-08
deficiency B-Disease 0 0.08088699728250504
in I-Disease 0 6.924639195382554e-10
the I-Disease 0 6.638903871092339e-10
human I-Disease 0 1.6467901486905134e-09
complement I-Disease 0 1.4203187959083152e-08
regulatory I-Disease 0 4.034336242852987e-08
protein I-Disease 0 2.0478671558521455e-07
Factor I-Disease 0 1.017809836412198e-06
H I-Disease 1 1.0
( O 0 1.80862940624138e-07
FH O 0 3.0106424674158916e-05
) O 0 1.7546449848637735e-09
in O 0 2.5066421160957475e-10
the O 0 4.902733219402933e-10
context O 0 5.0867714485036686e-09
of O 0 1.2694185702599725e-09
an O 0 2.805079930112697e-06
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.961110893324076e-07

Five O 0 1.4906865999364527e-06
of O 0 7.545025049182641e-09
the O 0 1.0203260458752084e-08
cases O 0 2.1384025217230374e-08
were O 0 9.11972151129703e-08
observed O 0 4.6723577895591006e-08
in O 0 3.7084810777798793e-09
children O 0 2.6163982624893833e-07
presenting O 0 7.376660846603045e-07
with O 0 2.8954231311217882e-05
idiopathic O 1 0.9999998807907104
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.9053486539633013e-05
HUS B-Disease 1 0.9997439980506897
) O 0 8.521861332155822e-07
. O 0 3.2592387810836954e-07

Two O 0 3.9956799469109683e-07
of O 0 1.591382492449611e-08
the O 0 2.5088830568620324e-08
children O 0 2.376856826913354e-07
exhibited O 0 1.0468847904121503e-06
a O 0 2.884597165575542e-07
homozygous O 1 0.9999489784240723
deficiency O 0 0.006912569981068373
characterized O 0 6.492074788866375e-08
by O 0 9.964730152134393e-10
the O 0 3.1484759244193583e-09
absence O 0 1.7200187940602518e-08
of O 0 5.008231052094914e-10
the O 0 2.6599034086416395e-09
150 O 0 6.607552727189159e-09
- O 0 4.113710261322012e-08
kD O 0 1.2470341914649907e-07
form O 0 1.4089028610442256e-08
of O 0 3.2179001685506137e-09
Factor O 0 3.290903123343014e-07
H O 1 1.0
and O 0 3.538167163696926e-07
the O 0 9.214362606257964e-09
presence O 0 1.8925765843391673e-08
, O 0 5.342044029355009e-10
upon O 0 1.569323559991176e-09
immunoblotting O 0 1.0750476064913528e-07
, O 0 9.851155446938265e-10
of O 0 2.478601768274302e-10
the O 0 5.173207195952045e-09
42 O 0 8.870095058455263e-08
- O 0 2.251455271107261e-07
kD O 0 1.6331457572960062e-06
Factor O 0 5.991101375002472e-07
H O 1 0.9999997615814209
- O 0 7.1191670940606855e-06
like O 0 3.1470243300191214e-08
protein O 0 4.20410586343678e-08
1 O 0 1.4917098667410755e-08
( O 0 7.63622143296061e-09
FHL O 0 3.4265149224665947e-06
- O 0 6.384979087670217e-07
1 O 0 9.597882488776577e-09
) O 0 7.557985348682905e-10
and O 0 9.908989184737038e-10
other O 0 4.205193970818755e-09
FH O 0 0.0001399835164193064
- O 0 1.6364244856958976e-06
related O 0 6.009526742900562e-08
protein O 0 2.225685591383808e-07
( O 0 3.548588267676678e-08
FHR O 0 3.3646563224465353e-06
) O 0 1.3653991715045777e-08
bands O 0 7.268137096616556e-07
. O 0 1.537787568395288e-07

Southern O 0 1.9878318198607303e-05
blot O 0 0.0001813724375097081
and O 0 8.00819179858081e-08
PCR O 0 1.562477905281412e-06
analysis O 0 3.2739233546408286e-08
of O 0 1.1285404832861445e-09
DNA O 0 6.281734243884785e-08
of O 0 8.421447983408825e-10
one O 0 6.158659715538306e-08
patient O 0 8.511549822287634e-06
with O 0 2.789399786706781e-07
homozygous O 1 0.9999375343322754
deficiency O 0 0.019865471869707108
ruled O 0 9.89953363728091e-08
out O 0 1.3935141929266592e-08
the O 0 1.951915074016597e-09
presence O 0 3.886143407072495e-09
of O 0 1.7850040889832997e-10
a O 0 1.3607084348166154e-09
large O 0 1.4398779946134255e-09
deletion O 0 1.9261226213984628e-07
of O 0 1.2828788031882254e-09
the O 0 7.444219907171146e-09
FH O 0 2.0804642190341838e-05
gene O 0 2.049312826102323e-07
as O 0 1.0265139849252591e-08
the O 0 1.2740132504518442e-08
underlying O 0 1.3175091453376808e-06
defect O 0 3.754739509531646e-06
for O 0 1.6556599646833092e-08
the O 0 8.75862156135554e-07
deficiency O 0 0.0016969223506748676
. O 0 9.192353189746427e-08

The O 0 2.622371084726183e-07
other O 0 1.4447865126498982e-08
four O 0 2.1662810212319528e-08
children O 0 3.687717153866288e-08
presented O 0 8.711644738923496e-09
with O 0 4.918417317867352e-08
heterozygous O 1 0.9971991777420044
deficiency O 0 0.03846541419625282
and O 0 1.8741770801966595e-08
exhibited O 0 3.763694849112653e-07
a O 0 2.3628054179880564e-08
normal O 0 6.683810624963371e-07
immunoblotting O 0 3.3085707400459796e-06
pattern O 0 1.4320323771244148e-07
of O 0 4.545387954912883e-10
proteins O 0 5.7710085599183e-09
of O 0 2.077985117310277e-09
the O 0 1.556224731302791e-07
FH O 0 0.004269975237548351
family O 0 7.088627853590879e-07
. O 0 1.5835939848329872e-07

Factor B-Disease 1 0.9565230011940002
H I-Disease 1 1.0
deficiency I-Disease 1 0.9998350143432617
is O 0 1.5000154007793753e-08
the O 0 7.803171442333223e-09
only O 0 8.299917908516363e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 2.3702634734945605e-06
with O 0 2.647539929512277e-07
HUS B-Disease 1 0.9975423812866211
. O 0 9.72386374087364e-07

These O 0 3.419466167997598e-07
observations O 0 6.185666734381812e-07
suggest O 0 3.0489798064081697e-07
a O 0 1.7294436105430577e-08
role O 0 4.0791601207956774e-08
for O 0 7.121611300675568e-09
FH O 0 0.00012276784400455654
and O 0 1.7067335988940613e-07
/ O 0 2.3572931240778416e-05
or O 0 1.1069441825384274e-06
FH O 0 7.47470767237246e-05
receptors O 0 1.7789838580029027e-07
in O 0 2.9229372255912267e-09
the O 0 8.972047105260117e-09
pathogenesis O 0 2.3460110298856307e-07
of O 0 1.2087403078453463e-08
idiopathic O 0 0.00012447246990632266
HUS B-Disease 1 0.9441396594047546
. O 0 1.8428175962981186e-07
. O 0 2.57451603147274e-07

Further O 0 1.3467349617712898e-06
evidence O 0 1.439718602114226e-07
for O 0 3.940240134170381e-09
a O 0 7.703734539177276e-09
major O 0 3.372505830157024e-08
ancient O 0 1.2690239259427472e-07
mutation O 0 0.025703411549329758
underlying O 0 0.003134732833132148
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.934323788394977e-07
linkage O 0 6.918053259141743e-05
disequilibrium O 0 7.817892037564889e-05
studies O 0 4.775183697347529e-07
in O 0 1.381288594615171e-08
the O 0 5.982534467818823e-09
Japanese O 0 3.279160978308937e-07
population O 0 7.115477274055593e-08
. O 0 4.396127550876372e-08

The O 0 7.982114766491577e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.2728859782218933
DM B-Disease 1 1.0
) O 0 8.450207360510831e-07
mutation O 0 4.951331447955454e-06
is O 0 1.2162424845030273e-08
an O 0 1.2478593269804605e-08
unstable O 0 0.00039802162791602314
( O 0 8.551040764359641e-08
CTG O 0 2.6836219149117824e-06
) O 0 1.759404710810486e-08
n O 0 9.190430887429102e-07
repeat O 0 3.641971488832496e-06
, O 0 9.126661204561515e-09
present O 0 1.3437743362487709e-08
at O 0 3.481665089566377e-08
a O 0 5.387766233155844e-09
copy O 0 4.920312335343624e-08
number O 0 4.323547297957475e-09
of O 0 1.2311701658163088e-09
5 O 0 3.781583046702508e-08
- O 0 4.491949766816106e-06
37 O 0 2.654282411640452e-07
repeats O 0 3.5948343679592654e-07
on O 0 6.020356835279017e-08
normal O 0 2.392236240211787e-07
chromosomes O 0 4.132120636768377e-07
but O 0 6.1976388465723176e-09
amplified O 0 1.3325345094017393e-07
to O 0 1.2561528706100944e-08
50 O 0 4.469915637628219e-08
- O 0 3.2016998829931254e-07
3000 O 0 1.973976253566434e-07
copies O 0 1.3632008233344095e-07
on O 0 1.0649794148775982e-06
DM B-Disease 1 1.0
chromosomes O 0 3.80131350539159e-05
. O 0 9.025736744661117e-07

Previous O 0 5.19309141964186e-05
findings O 0 1.0303918998033623e-06
in O 0 3.681055460447169e-08
Caucasian O 0 3.5922203096561134e-06
populations O 0 1.6650996315092925e-07
of O 0 4.666308672796049e-09
a O 0 6.619085525016999e-06
DM B-Disease 1 1.0
founder O 0 5.32864896740648e-06
chromosome O 0 2.6625206373864785e-05
raise O 0 7.927932443863028e-08
a O 0 1.0510193604318374e-08
question O 0 5.7311355661227026e-09
about O 0 4.86820028733348e-10
the O 0 6.859293688599166e-10
molecular O 0 1.9078532531580095e-08
events O 0 1.756534295793699e-08
involved O 0 3.0890351609969e-08
in O 0 1.6634269517368239e-09
the O 0 6.431459365074943e-09
expansion O 0 5.424207927262614e-08
mutation O 0 3.194985083609936e-06
. O 0 9.93520927750069e-08

To O 0 1.0525970992603106e-06
investigate O 0 6.628413871112571e-07
whether O 0 4.892397242883817e-08
a O 0 3.195448883275276e-08
founder O 0 1.9776675230787077e-07
chromosome O 0 3.94913149648346e-06
for O 0 4.201995196240205e-09
the O 0 1.8908831123098935e-07
DM B-Disease 1 1.0
mutation O 0 5.585860344581306e-05
exists O 0 1.7885330549916034e-08
in O 0 6.068958113836231e-10
the O 0 1.2703438301286951e-09
Japanese O 0 6.135515917549128e-08
population O 0 3.658054303912195e-09
, O 0 2.6185356105656865e-09
we O 0 9.222872243697111e-09
genotyped O 0 2.465943396146031e-07
families O 0 7.479173724789234e-09
using O 0 2.563260537158385e-08
polymorphic O 0 2.218608415205381e-06
markers O 0 8.301492198370397e-05
near O 0 6.848032171546947e-06
the O 0 1.5947910014801892e-07
( O 0 7.689000369737187e-08
CTG O 0 2.8348042633297155e-06
) O 0 1.5324213009648702e-08
n O 0 1.5742912182759028e-06
repeat O 0 2.7335154300089926e-06
region O 0 3.8635272403553245e-07
and O 0 1.0841904440894723e-07
constructed O 0 4.958977569913259e-06
haplotypes O 0 6.846628366474761e-06
. O 0 1.9785713334385946e-07

Six O 0 5.249399691820145e-06
different O 0 1.3643051488543279e-07
haplotypes O 0 1.9950891783082625e-06
were O 0 3.2217036505244323e-07
found O 0 1.0577891629282021e-07
and O 0 5.705473995476495e-07
DM B-Disease 1 1.0
alleles O 0 6.630989810219035e-05
were O 0 3.349471171532059e-06
always O 0 2.701833921037178e-07
haplotype O 0 1.377644025524205e-06
A O 0 6.352848345159146e-07
. O 0 2.3725651487893629e-07

To O 0 8.384302532249421e-07
find O 0 1.8138011625978834e-07
an O 0 2.5681334836491487e-09
origin O 0 7.075630747976902e-09
of O 0 8.444319687939128e-10
the O 0 3.7165694521945625e-08
( O 0 5.687373416662922e-08
CTG O 0 4.8648539632267784e-06
) O 0 1.678573013919049e-08
n O 0 1.1225148455196177e-06
repeat O 0 1.5466002878383733e-06
mutation O 0 4.277052028101025e-07
and O 0 7.846902683183998e-09
to O 0 2.3685571282072715e-09
investigate O 0 1.5502898520480812e-08
the O 0 1.913037506184878e-09
mechanism O 0 1.7860037004879814e-08
of O 0 4.5379727753314114e-10
the O 0 1.6731318552842822e-09
expansion O 0 8.734338585725254e-09
mutation O 0 6.45658460030063e-08
in O 0 5.550578330293376e-10
the O 0 1.1021139556532944e-09
Japanese O 0 5.907540412408707e-08
population O 0 2.6478965686749234e-09
we O 0 5.422426063717012e-09
have O 0 1.6601431340745876e-09
studied O 0 2.3977218432946756e-08
90 O 0 2.4774319484777152e-08
Japanese O 0 1.5397070001199609e-06
DM B-Disease 1 1.0
families O 0 7.713413197052432e-08
comprising O 0 1.7290181730800214e-08
190 O 0 5.024980609391605e-08
affected O 0 1.3709896506952646e-07
and O 0 1.0776113334998172e-08
130 O 0 9.682540280664398e-08
unaffected O 0 1.6193722558455192e-06
members O 0 5.588732321371026e-08
. O 0 6.78603626624863e-08

The O 0 1.8099527778758784e-06
results O 0 1.5703340068284888e-06
suggest O 0 1.1701916946549318e-07
that O 0 1.1627262486157974e-09
a O 0 3.436961604208477e-09
few O 0 4.4524273157264815e-09
common O 0 1.3213548477608583e-08
ancestral O 0 5.420727120508673e-07
mutations O 0 1.7926728332895436e-06
in O 0 8.764105552394597e-10
both O 0 7.721755679312992e-09
Caucasian O 0 8.860978368829819e-07
and O 0 2.023016243413167e-08
Japanese O 0 3.8911969113542e-07
populations O 0 2.839273882671023e-08
have O 0 1.2098629875723077e-09
originated O 0 1.4205862042260264e-09
by O 0 9.999986949615902e-11
expansion O 0 6.111695038946152e-10
of O 0 2.1386778459309141e-10
an O 0 2.4948905164023927e-09
ancestral O 0 5.607406023955264e-07
n O 0 3.0293798772618175e-05
= O 0 7.962337804201525e-06
5 O 0 2.643129448642867e-08
repeat O 0 7.726199555690982e-07
to O 0 7.898169229747509e-08
n O 0 0.0017095331568270922
= O 0 0.00018222356447950006
19 O 0 1.6252560044449638e-06
- O 0 5.9604003581625875e-06
37 O 0 5.524136668100255e-07
copies O 0 2.0279425427816022e-07
. O 0 1.3152276778782834e-07

These O 0 3.2102056479743624e-07
data O 0 2.4802454845485045e-07
support O 0 3.6690408933282015e-08
multistep O 0 3.917574247225275e-07
models O 0 2.848599081062275e-07
of O 0 8.326514588929967e-09
triplet O 0 0.0002633399562910199
repeat O 0 1.9659221379697556e-06
expansion O 0 2.8434413934519398e-08
that O 0 2.5126556391086297e-09
have O 0 7.686622005564914e-09
been O 0 2.132186427417082e-09
proposed O 0 1.17344034489264e-09
for O 0 9.307551396275926e-10
both O 0 9.062462709152896e-07
DM B-Disease 1 1.0
and O 0 1.5479903368031955e-06
Friedreichs B-Disease 0 0.00022755090321879834
ataxia I-Disease 0 0.012448035180568695
. O 0 4.647045770411751e-08
. O 0 1.1229844432136815e-07

The O 0 5.508318281499669e-07
molecular O 0 1.2681555290328106e-06
basis O 0 3.0143576168484287e-07
of O 0 8.139716101140948e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.3823243882882252e-08
the O 0 4.725286384399396e-09
western O 0 2.0339539830160902e-08
Cape O 0 3.243477522119065e-07
, O 0 1.035571806085045e-08
South O 0 7.797253687158445e-08
Africa O 0 8.426388831139775e-08
. O 0 5.0056382150387435e-08

Deficiency B-Disease 1 0.9997586607933044
of I-Disease 0 8.304314036422511e-08
the I-Disease 0 3.487414090841412e-08
sixth I-Disease 0 7.010334002188756e-07
component I-Disease 0 1.1807076560899077e-07
of I-Disease 0 1.4795501490638685e-09
human I-Disease 0 1.422555406804804e-08
complement I-Disease 0 2.090575037527742e-07
( O 0 1.5348199156051123e-08
C6 O 0 1.521039052931883e-06
) O 0 8.28971913335863e-09
has O 0 1.0611938883187122e-08
been O 0 1.2658583159463888e-07
reported O 0 9.582704052490953e-08
in O 0 3.5743774606800116e-10
a O 0 1.1343498362847981e-09
number O 0 1.9185697475165853e-09
of O 0 5.376553091629432e-10
families O 0 9.784906218612832e-09
from O 0 5.291178606370295e-10
the O 0 1.7028803922514157e-09
western O 0 8.378290061727967e-09
Cape O 0 1.7625256987230387e-07
, O 0 3.1416012014062744e-09
South O 0 2.5347654641905137e-08
Africa O 0 3.081026633822148e-08
. O 0 1.845212338480451e-08

Meningococcal B-Disease 1 0.9999715089797974
disease I-Disease 1 0.9999864101409912
is O 0 1.8303714455214504e-07
endemic O 0 1.396628022121149e-07
in O 0 3.3189584414117235e-09
the O 0 4.481736759487376e-09
Cape O 0 2.093972994998694e-07
and O 0 2.3507180202386735e-08
almost O 0 9.440794812576314e-09
all O 0 3.818070581917965e-10
pedigrees O 0 2.0316900872785482e-07
of O 0 8.131413764544959e-09
total O 0 0.005074518732726574
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.6214857484774257e-07
C6Q0 O 0 1.3727804798691068e-05
) O 0 5.38404743011256e-09
have O 0 1.1651556164338217e-08
been O 0 2.1712821762776002e-08
ascertained O 0 2.7327232032803295e-07
because O 0 8.176670895920779e-09
of O 0 2.362999396154919e-08
recurrent O 1 0.9982584118843079
disease O 1 0.9122350811958313
. O 0 4.018976653696882e-07

We O 0 9.382727512274869e-06
have O 0 2.9340768037400267e-08
sequenced O 0 9.966488079271585e-08
the O 0 2.327872117291463e-09
expressed O 0 1.7485645154025065e-09
exons O 0 3.6938136105391095e-08
of O 0 6.888820069939072e-10
the O 0 8.642498272593002e-09
C6 O 0 1.0811378388098092e-06
gene O 0 7.541288482570963e-08
from O 0 1.3375854868158399e-09
selected O 0 6.309133215864904e-09
cases O 0 1.7069646807144068e-09
and O 0 1.94241582818222e-08
have O 0 7.60044969183582e-08
found O 0 2.6157314536590093e-08
three O 0 1.3359313655314509e-08
molecular O 0 7.063279917929322e-05
defects O 1 0.9852362871170044
leading O 0 4.864153879680089e-07
to O 0 5.783165590855788e-08
total O 0 8.751902896619868e-06
deficiency O 0 0.060747869312763214
879delG O 0 1.3862354535376653e-06
, O 0 3.745374232977383e-09
which O 0 1.306460717387381e-09
is O 0 6.195838841982493e-10
the O 0 1.585909403800656e-09
common O 0 2.0424059243850934e-07
defect O 0 5.555579264182597e-06
in O 0 4.056394331541924e-09
the O 0 7.76553399362001e-09
Cape O 0 2.009936110880517e-07
and O 0 2.309955959844956e-08
hitherto O 0 6.854499474684417e-07
unreported O 0 1.1993834903023526e-07
, O 0 5.564287253179145e-09
and O 0 1.1670861610468819e-08
1195delC O 0 4.896804171039548e-07
and O 0 5.1914962995169844e-08
1936delG O 0 6.278919499891344e-07
, O 0 2.1631130220356454e-09
which O 0 1.8458131689769175e-09
have O 0 1.981799790939931e-08
been O 0 5.866511543217712e-08
previously O 0 5.182123459235299e-07
reported O 0 6.043769928965048e-08
in O 0 2.467602344680131e-09
African O 0 4.176452250703733e-08
- O 0 5.19287095812615e-06
Americans O 0 7.032028861431172e-07
. O 0 1.160604625738415e-07

We O 0 4.710122539108852e-06
also O 0 4.3042465591724977e-08
show O 0 1.0427074670360525e-07
that O 0 1.5183679868968625e-09
the O 0 4.618519788834874e-09
879delG O 0 1.0133459227290587e-06
and O 0 7.650350397625516e-08
1195delC O 0 0.00020492266048677266
defects O 0 0.31831008195877075
are O 0 4.960811761378636e-09
associated O 0 1.8283749625425116e-08
with O 0 1.8192539030792432e-08
characteristic O 0 0.0005181389860808849
C6 O 0 0.01484082080423832
/ O 0 0.00030193329439498484
C7 O 0 0.00036325989640317857
region O 0 1.4960514818085358e-06
DNA O 0 5.6160033636842854e-06
marker O 0 8.410799637204036e-06
haplotypes O 0 2.132014287781203e-06
, O 0 9.9763353134108e-09
although O 0 5.6654245739196085e-09
small O 0 1.1574518232748687e-08
variations O 0 2.0382469756441424e-06
were O 0 4.434903530636802e-06
observed O 0 1.1806168913608417e-06
. O 0 7.77916042693505e-08

The O 0 2.3273842089110985e-06
1936delG O 0 5.615748159470968e-05
defect O 0 0.0001820132602006197
was O 0 6.569628112629289e-07
observed O 0 1.2385149261717743e-07
only O 0 1.558989914940412e-08
once O 0 5.529324198505492e-08
in O 0 1.487234668751114e-09
the O 0 8.615440805215258e-09
Cape O 0 1.5150108367834036e-07
, O 0 5.4892432821418424e-09
but O 0 1.1784848652496294e-09
its O 0 3.135154580391486e-09
associated O 0 4.866208769271907e-08
haplotype O 0 6.03154035161424e-07
could O 0 2.2115982289960812e-07
be O 0 2.152561506818529e-08
deduced O 0 7.131005759219988e-07
. O 0 5.1097913456032984e-08

The O 0 3.524722842485062e-07
data O 0 2.2801378918302362e-07
from O 0 8.09012412616994e-09
the O 0 3.881550636464226e-09
haplotypes O 0 1.6535857128019416e-07
indicate O 0 1.6065068564330431e-07
that O 0 9.184808469342443e-10
these O 0 1.561283435869143e-09
three O 0 2.751330541173047e-08
molecular O 0 0.0002548161428421736
defects O 1 0.9991010427474976
account O 0 5.511802214641648e-07
for O 0 7.596402618048614e-09
the O 0 4.307391918700887e-07
defects O 1 0.9799915552139282
in O 0 2.2213983985608365e-09
all O 0 1.3210543770014738e-09
the O 0 2.687097655496018e-09
38 O 0 5.253914281411198e-08
unrelated O 0 3.8487026898792465e-08
C6Q0 O 0 1.4125603229331318e-06
individuals O 0 1.2053651410326438e-08
we O 0 1.4558016125931772e-08
have O 0 2.308919722082692e-09
studied O 0 1.892612644383007e-08
from O 0 2.0940273959269007e-09
the O 0 8.565074871569323e-09
Cape O 0 4.6457344637929054e-07
. O 0 8.855624855641508e-08

We O 0 1.3287545698403846e-05
have O 0 1.2013032346658292e-07
also O 0 2.3958293127179786e-08
observed O 0 5.714971962333948e-08
the O 0 1.1327720983445033e-08
879delG O 0 7.587668733322062e-06
defect O 0 1.1241356332902797e-05
in O 0 8.615276492207613e-09
two O 0 2.7439475047685846e-07
Dutch O 1 0.9999940395355225
C6 B-Disease 1 1.0
- I-Disease 1 0.9999971389770508
deficient I-Disease 1 1.0
kindreds O 0 2.9830636776750907e-05
, O 0 2.153867484366856e-08
but O 0 2.595636594548978e-09
the O 0 6.007255137774337e-09
879delG O 0 1.5284622350009158e-06
defect O 0 1.4707885611642268e-06
in O 0 1.8986425764921933e-09
the O 0 4.001992515156871e-09
Cape O 0 1.0528877680826554e-07
probably O 0 1.273218117603392e-07
did O 0 8.806272688843819e-08
not O 0 9.50845358005381e-09
come O 0 4.103755557594013e-09
from O 0 1.3668055576232518e-09
The O 0 4.33615010564381e-09
Netherlands O 0 1.2392467851896072e-06
. O 0 5.901140909259084e-09
. O 0 2.2238708652366768e-08

Complement B-Disease 1 0.9996128678321838
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.773029450509057e-07
seven O 0 5.154457127787282e-08
further O 0 5.81094070639665e-08
molecular O 0 0.0022789074573665857
defects O 1 0.9999885559082031
and O 0 1.7247074879378488e-07
their O 0 6.06590958796005e-07
associated O 0 7.872245646467491e-07
marker O 0 3.302185723441653e-05
haplotypes O 0 1.5294424883904867e-05
. O 0 4.932095407639281e-07

Seven O 0 2.2710153189109406e-06
further O 0 1.5850490342472767e-07
molecular O 0 8.221327902901976e-07
bases O 0 1.0979571925417986e-05
of O 0 2.9195625756983645e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.565907664120459e-07
described O 0 8.408180178776092e-07
. O 0 6.902873650460606e-08

All O 0 1.6444707284790638e-07
these O 0 7.728902851056318e-09
new O 0 9.511155418806538e-09
molecular O 0 1.4817213923379313e-05
defects O 1 0.7937713265419006
involve O 0 4.1175971432494407e-07
single O 0 4.3073527194792405e-05
- O 0 5.034295099903829e-06
nucleotide O 0 1.3963391438664985e-06
events O 0 2.9156836944821407e-08
, O 0 2.3821853378791502e-09
deletions O 0 7.691522796449135e-08
and O 0 2.523891495798125e-08
substitutions O 0 2.1332824928776972e-07
, O 0 2.063143655917088e-09
some O 0 3.5265676490148223e-10
of O 0 4.884625481871296e-10
which O 0 5.835795402475696e-09
alter O 0 1.2821279824493104e-06
splice O 0 2.5117780751315877e-05
sites O 0 8.297385534206114e-07
, O 0 1.4819006466382234e-08
and O 0 2.9493550712800243e-08
others O 0 1.1893066442780764e-07
codons O 0 1.029021063914115e-06
. O 0 1.9499184134019742e-07

They O 0 5.796328423457453e-06
are O 0 1.587950215764522e-08
distributed O 0 5.247541956521218e-09
along O 0 4.463991842840187e-09
the O 0 3.9637964022176675e-09
C7 O 0 9.127948942477815e-06
gene O 0 4.948283276462462e-07
, O 0 6.804152352657411e-09
but O 0 1.9594723621452204e-09
predominantly O 0 9.434169889743771e-09
towards O 0 1.265377314041416e-08
the O 0 7.2724817279379295e-09
3 O 0 5.1099863895842645e-08
end O 0 1.6640312594518036e-07
. O 0 6.385185713497776e-08

All O 0 2.399207687631133e-06
were O 0 4.4552498934535834e-07
found O 0 3.295230044386699e-08
in O 0 7.943003588195552e-09
compound O 0 2.462188319896086e-07
heterozygous O 0 9.389360457134899e-06
individuals O 0 2.0716748849736177e-07
. O 0 1.0336639633123923e-07

The O 0 1.2913380487589166e-05
C6 O 0 0.004676464479416609
/ O 0 0.0013943053781986237
C7 O 0 0.0009711412130855024
marker O 0 7.17517250450328e-05
haplotypes O 0 1.6688398318365216e-05
associated O 0 1.0620300372465863e-06
with O 0 3.705661555386541e-08
most O 0 1.6245355993760313e-07
C7 B-Disease 1 0.9998049139976501
defects I-Disease 1 0.9999921321868896
are O 0 1.581188513455345e-07
tabulated O 0 0.00024918289273045957
. O 0 1.455529474725381e-08
. O 0 4.485159621481216e-08

A O 0 5.394979325501481e-06
genome O 0 2.8124891287006903e-06
- O 0 1.617169914425176e-06
wide O 0 2.7285773285257164e-07
search O 0 1.7894720372169104e-07
for O 0 2.5228278133226922e-08
chromosomal O 0 0.004944146145135164
loci O 0 8.282473572762683e-06
linked O 0 1.4531277884088922e-05
to O 0 8.218249547553569e-08
mental O 0 0.4275965094566345
health O 0 4.173413344688015e-06
wellness O 0 2.693061787795159e-06
in O 0 5.270100800203181e-09
relatives O 0 6.853624512359602e-08
at O 0 1.8103786914025477e-08
high O 0 5.079425591247855e-07
risk O 0 4.225721568218432e-06
for O 0 1.7527391094063205e-08
bipolar B-Disease 1 0.999992847442627
affective I-Disease 1 0.9995877146720886
disorder I-Disease 1 0.9979875087738037
among O 0 1.6606252373208008e-08
the O 0 7.991388883965556e-09
Old O 0 2.131418568751542e-06
Order O 0 7.272929281043616e-08
Amish O 0 8.4802913988824e-06
. O 0 2.4818263000270235e-07

Bipolar B-Disease 1 0.9999998807907104
affective I-Disease 1 0.9999996423721313
disorder I-Disease 1 1.0
( O 0 0.0015840560663491488
BPAD B-Disease 1 1.0
; O 0 0.00019782927120104432
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9999953508377075
) O 0 2.5693694283290824e-08
is O 0 2.2271511301852343e-09
characterized O 0 1.836273355593221e-08
by O 0 6.376345007552686e-10
episodes O 0 5.24043350935699e-08
of O 0 2.4958803912511485e-09
mania B-Disease 0 1.4578277841792442e-05
and O 0 7.15894259428751e-07
/ O 0 0.0008177832351066172
or O 0 3.2871687380975345e-06
hypomania B-Disease 0 0.006459500640630722
interspersed O 0 7.315554285014514e-06
with O 0 2.3473127441775432e-08
periods O 0 1.0035174682343495e-06
of O 0 5.4093924006792804e-08
depression B-Disease 0 0.054889194667339325
. O 0 2.676046904070972e-07

Compelling O 0 8.766512110014446e-06
evidence O 0 3.72254362446256e-07
supports O 0 1.0342970568899545e-07
a O 0 8.822745201086946e-09
significant O 0 1.649491387922808e-08
genetic O 0 6.155243568173319e-07
component O 0 1.2219571488003567e-07
in O 0 2.5075950205177833e-09
the O 0 3.4846194818527465e-09
susceptibility O 0 1.2938954796481994e-06
to O 0 1.0240425041274648e-07
develop O 0 0.0003840505378320813
BPAD B-Disease 1 1.0
. O 0 1.2740712236336549e-06

To O 0 4.3696735474441084e-07
date O 0 4.0478028040524805e-07
, O 0 1.1231296781488709e-08
however O 0 5.168669936495007e-09
, O 0 1.04469721762257e-09
linkage O 0 3.447902940934e-07
studies O 0 2.6859153123837132e-08
have O 0 2.351785255427785e-08
attempted O 0 1.2440585805961746e-07
only O 0 5.538197900278874e-09
to O 0 9.178018345323835e-09
identify O 0 2.8202994144521654e-06
chromosomal O 0 0.00024652929278090596
loci O 0 6.433032808672579e-07
that O 0 8.327213585346271e-09
cause O 0 1.4610165521844465e-07
or O 0 6.085864612259684e-08
increase O 0 1.9805829865049418e-08
the O 0 6.269644359235826e-08
risk O 0 3.6776700653717853e-06
of O 0 7.361015352813638e-09
developing O 0 5.653047082887497e-06
BPAD B-Disease 1 0.9999998807907104
. O 0 3.060411017941078e-07

To O 0 9.147749437943276e-07
determine O 0 5.104326987748209e-07
whether O 0 3.5074933180112566e-08
there O 0 1.2071275534708548e-08
could O 0 3.936456494102458e-08
be O 0 3.2306610719956552e-09
protective O 0 3.5699801514965657e-07
alleles O 0 1.0500359337584086e-07
that O 0 7.705553417558519e-10
prevent O 0 8.718630084558754e-08
or O 0 8.205875445810307e-08
reduce O 0 3.2209203482125304e-07
the O 0 7.330597462384958e-09
risk O 0 1.7129772800217324e-07
of O 0 7.350755559798472e-10
developing O 0 2.0136076273047365e-06
BPAD B-Disease 1 1.0
, O 0 6.825326526183062e-09
similar O 0 3.39720496178586e-09
to O 0 3.1840825531759265e-09
what O 0 1.4548597881969272e-09
is O 0 4.3241885072653474e-10
observed O 0 2.278797150978562e-09
in O 0 1.6069150177155933e-10
other O 0 4.2499806340856594e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.0279227247167455e-08
we O 0 2.404701682223731e-08
used O 0 2.0910645162075525e-06
mental O 1 0.8439860939979553
health O 0 5.365804554458009e-06
wellness O 0 3.915298748324858e-06
( O 0 9.544467438615811e-09
absence O 0 8.289940289785136e-09
of O 0 5.32213051407382e-10
any O 0 6.111596349001047e-07
psychiatric B-Disease 1 0.9975705742835999
disorder I-Disease 1 0.803126871585846
) O 0 2.081467886938526e-09
as O 0 2.6930750962606e-09
the O 0 3.0351856583621384e-09
phenotype O 0 5.172337296244223e-07
in O 0 1.8935504275674475e-09
our O 0 6.795815465920896e-08
genome O 0 4.0806465761988875e-08
- O 0 2.656518631738436e-07
wide O 0 1.81288271505764e-07
linkage O 0 6.642736479989253e-06
scan O 0 0.00011633327085291967
of O 0 4.449235202486079e-09
several O 0 6.067943036924817e-09
large O 0 3.746361798562248e-08
multigeneration O 0 1.878756120277103e-05
Old O 0 5.921720571677724e-07
Order O 0 7.372888966017399e-09
Amish O 0 8.986219768303272e-07
pedigrees O 0 2.0099219000258017e-06
exhibiting O 0 4.907893753625103e-07
an O 0 1.3018595979019665e-08
extremely O 0 4.5439711016115325e-07
high O 0 3.647943685791688e-06
incidence O 0 0.142685666680336
of O 0 4.3973858510071295e-07
BPAD B-Disease 1 1.0
. O 0 2.648072495503584e-06

We O 0 8.522759344486985e-06
have O 0 6.683161046794339e-08
found O 0 1.4733891440243951e-08
strong O 0 3.2456213716614e-08
evidence O 0 1.1089697160571177e-08
for O 0 1.896771184561885e-09
a O 0 2.2620564976705282e-08
locus O 0 7.900963282736484e-06
on O 0 6.762764428458468e-07
chromosome O 0 0.00446355901658535
4p O 0 0.0001007665487122722
at O 0 3.1979647019397817e-07
D4S2949 O 0 1.7210284113389207e-06
( O 0 4.0894430952675975e-08
maximum O 0 3.402758466108935e-07
GENEHUNTER O 0 4.4033131416654214e-05
- O 0 3.397425416551414e-06
PLUS O 0 1.5720753481218708e-06
nonparametric O 0 1.482022344134748e-05
linkage O 0 1.7530506738694385e-05
score O 0 3.4608994610607624e-05
= O 0 5.7237380133301485e-06
4 O 0 3.2618810763551664e-08
. O 0 5.145849524268442e-09
05 O 0 3.5347443372302223e-06
, O 0 2.9262636758176086e-08
P O 0 2.739835690590553e-05
= O 0 1.2616728781722486e-06
5 O 0 7.500488230505198e-09
. O 0 1.2571972352048988e-09
22 O 0 9.5076551076545e-09
x O 0 3.79823092089282e-07
10 O 0 4.0199346074132336e-08
( O 0 1.4743169352016139e-08
- O 0 1.8175392142438795e-06
4 O 0 5.629783572658198e-08
) O 0 2.8302644672351107e-09
; O 0 3.2410421013651103e-09
SIBPAL O 0 1.2281590215934557e-06
Pempirical O 0 6.74615876050666e-07
value O 0 9.842183068542454e-09
< O 0 1.0419977058973018e-07
3 O 0 1.72055703018259e-08
x O 0 1.4397120366993477e-06
10 O 0 6.367915261762391e-08
( O 0 2.731732173799628e-08
- O 0 3.3478713703516405e-06
5 O 0 1.9037710075053837e-08
) O 0 6.76014133560443e-10
) O 0 6.045620670747098e-10
and O 0 5.0491117953299636e-09
suggestive O 0 2.952131580968853e-05
evidence O 0 4.473890058420693e-08
for O 0 2.7537756519535606e-09
a O 0 2.2789588882687895e-08
locus O 0 7.962656127347145e-06
on O 0 1.0603794180497061e-06
chromosome O 0 0.1647113412618637
4q O 0 0.0003134463622700423
at O 0 3.289688663699053e-07
D4S397 O 0 9.186829288410081e-07
( O 0 1.4268489501034765e-08
maximum O 0 1.5096917138635035e-07
GENEHUNTER O 0 4.7266272304113954e-05
- O 0 5.722110927308677e-06
PLUS O 0 1.0098325446961098e-06
nonparametric O 0 7.1311469582724385e-06
linkage O 0 9.611671885068063e-06
score O 0 2.364969259360805e-05
= O 0 3.3061073736462276e-06
3 O 0 3.043622243126265e-08
. O 0 4.882206194878336e-09
29 O 0 7.845738281275771e-08
, O 0 8.715034915951492e-09
P O 0 2.027745358645916e-05
= O 0 1.0460174735271721e-06
2 O 0 1.6961775983759253e-08
. O 0 2.4584605462507625e-09
57 O 0 3.97768040727442e-08
x O 0 8.501989441356272e-07
10 O 0 6.310892786132172e-08
( O 0 1.996650134117317e-08
- O 0 2.1878961433685618e-06
3 O 0 4.4928743392347315e-08
) O 0 4.260757080487565e-09
; O 0 4.674762354994755e-09
SIBPAL O 0 2.421248382233898e-06
Pempirical O 0 9.650483434597845e-07
value O 0 2.3351264033522057e-08
< O 0 1.8434627691021888e-07
1 O 0 3.2278048678335836e-08
x O 0 3.797057161136763e-06
10 O 0 1.314031692345452e-07
( O 0 4.755288074420605e-08
- O 0 6.537805802508956e-06
3 O 0 2.0805877909424453e-08
) O 0 6.808861807705568e-10
) O 0 3.084563438005006e-10
that O 0 1.6314639916803486e-10
are O 0 1.3859113856540262e-09
linked O 0 4.173657544015441e-07
to O 0 6.572523858494606e-08
mental O 0 0.2567926049232483
health O 0 1.6535301256226376e-05
wellness O 0 4.112582973903045e-05
. O 0 4.894885137218807e-07

These O 0 1.877180693554692e-06
findings O 0 5.515015004675661e-07
are O 0 4.004185782946479e-08
consistent O 0 3.0188368782546604e-07
with O 0 1.4988791319225925e-09
the O 0 1.7822323616911717e-09
hypothesis O 0 1.4614186305550447e-08
that O 0 2.9193925055182035e-10
certain O 0 2.4964423861462137e-09
alleles O 0 2.2634921492681315e-07
could O 0 8.553553243473289e-08
prevent O 0 4.7301583094849775e-07
or O 0 4.1359676572483295e-08
modify O 0 3.112716910891322e-07
the O 0 1.1797314236616785e-08
clinical O 0 6.693123282275337e-07
manifestations O 0 1.9067951484430523e-07
of O 0 5.337809749761391e-09
BPAD B-Disease 1 1.0
and O 0 1.393089661405611e-07
perhaps O 0 2.1490293988790654e-08
other O 0 7.4875670108554e-09
related O 0 2.1005523649364477e-06
affective B-Disease 1 0.9987388253211975
disorders I-Disease 1 0.9999423027038574
. O 0 5.776313400929212e-07

Segregation O 0 0.010527168400585651
distortion O 0 0.00567731074988842
in O 0 3.473116521490738e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.8114593331119977e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997442364692688
DM B-Disease 1 1.0
) O 0 8.314883643834037e-07
is O 0 1.2992029674308014e-08
an O 0 1.0719084286847647e-08
autosomal B-Disease 1 0.9999326467514038
dominant I-Disease 1 0.9999909400939941
disease I-Disease 1 0.9991377592086792
which O 0 2.281237776458056e-08
, O 0 1.1536206434570317e-09
in O 0 3.119554614627873e-10
the O 0 1.416708750312523e-09
typical O 0 5.859220095771889e-07
pedigree O 0 6.585686060134321e-05
, O 0 2.2603605653870318e-09
shows O 0 2.074433957943711e-08
a O 0 1.809288008303156e-08
three O 0 3.302736928390004e-08
generation O 0 1.5262264696502825e-07
anticipation O 0 1.2209892474857043e-07
cascade O 0 1.7424016505174222e-06
. O 0 1.4325665631531592e-07

This O 0 1.4768436074064084e-07
results O 0 5.083806513539457e-07
in O 0 5.184490703413758e-08
infertility B-Disease 1 0.9998325109481812
and O 0 0.03318565711379051
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 5.253636572888354e-06
CDM B-Disease 0 1.465594868932385e-05
) O 0 1.6410060865723608e-08
with O 0 2.2112698339071812e-09
the O 0 5.9510782968175135e-09
disappearance O 0 2.9931709377706284e-07
of O 0 2.0528135635800027e-08
DM B-Disease 1 1.0
in O 0 5.272083924978688e-08
that O 0 1.4629329747606334e-08
pedigree O 0 8.368790440727025e-05
. O 0 2.0813943990560801e-07

The O 0 2.3101704016426083e-07
concept O 0 6.728823365165226e-08
of O 0 5.5778670571271505e-09
segregation O 0 2.1942964849586133e-06
distortion O 0 1.0105790352099575e-05
, O 0 1.5096103922473958e-08
where O 0 3.594753383850957e-09
there O 0 7.931342804745611e-10
is O 0 2.9851371374789437e-10
preferential O 0 2.4919383889709934e-08
transmission O 0 1.1677618658723077e-06
of O 0 3.5205191539766645e-10
the O 0 1.3690075739702934e-09
larger O 0 1.7437825405863805e-08
allele O 0 6.838463377789594e-07
at O 0 1.5271116637904925e-07
the O 0 1.1028362223441945e-07
DM B-Disease 1 1.0
locus O 0 2.2955311578698456e-05
, O 0 4.4471672566714915e-08
has O 0 1.6053574469765408e-08
been O 0 2.2195360216414883e-08
put O 0 2.007215549326702e-08
forward O 0 1.0143901718606685e-08
to O 0 3.778841239920894e-09
explain O 0 2.60315999867089e-07
partially O 0 4.4348907977109775e-06
the O 0 2.584807257122179e-09
maintenance O 0 3.389340292869747e-07
of O 0 2.233090157233164e-08
DM B-Disease 1 1.0
in O 0 2.5060133523879813e-08
the O 0 2.0824657553930592e-08
population O 0 6.451758594039347e-08
. O 0 1.0249061688227812e-07

In O 0 4.882991220256372e-07
a O 0 1.4397969039237069e-07
survey O 0 2.404827000646037e-06
of O 0 7.866656659416549e-08
DM B-Disease 1 1.0
in O 0 1.4668620451629977e-07
Northern O 0 3.9032244103509584e-07
Ireland O 0 1.0721612852648832e-05
, O 0 1.8670592183411827e-08
59 O 0 1.9220949809550802e-07
pedigrees O 0 3.934080723411171e-06
were O 0 8.470910870528314e-07
ascertained O 0 4.0991571950144134e-06
. O 0 1.176334478714125e-07

Sibships O 0 0.00020253767434041947
where O 0 2.1106578174112656e-07
the O 0 3.6776990341991223e-09
status O 0 3.790231684064338e-09
of O 0 2.0100601738626267e-10
all O 0 7.761842280018527e-10
the O 0 2.0503081454847916e-09
members O 0 9.81962511303891e-09
had O 0 5.128865723236231e-07
been O 0 1.2092246315376087e-08
identified O 0 2.7507168098850343e-08
were O 0 1.2195084941879486e-08
examined O 0 8.827239383890628e-09
to O 0 1.043466535399773e-09
determine O 0 9.600998396308569e-08
the O 0 7.208362351462938e-09
transmission O 0 5.248268280411139e-06
of O 0 1.6690838711141964e-09
the O 0 4.759534633080875e-08
DM B-Disease 1 1.0
expansion O 0 5.1874380346816906e-08
from O 0 9.733456707294863e-09
affected O 0 1.6249866519046918e-07
parents O 0 3.731308240162434e-08
to O 0 6.204865510284208e-09
their O 0 3.847682705782063e-07
offspring O 0 4.547605385596398e-06
. O 0 1.57014383717069e-07

Where O 0 2.1198093236307614e-06
the O 0 6.54291767432369e-08
transmitting O 0 0.00014031103637535125
parent O 0 3.475731318758335e-06
was O 0 8.077668667283433e-08
male O 0 2.6478630843485007e-07
, O 0 9.119527355494483e-09
58 O 0 2.1681293560504855e-07
. O 0 7.54743254560708e-08

3 O 0 2.326461071788799e-06
% O 0 8.70122036644716e-08
of O 0 9.262851041746956e-10
the O 0 1.3515474073244604e-08
offspring O 0 2.9473922040779144e-06
were O 0 4.0365307540923823e-07
affected O 0 7.680205982296684e-08
, O 0 2.469184412490222e-09
and O 0 4.738860859276883e-09
in O 0 4.861101521314026e-10
the O 0 1.3762571082764907e-09
case O 0 5.716961348767313e-10
of O 0 1.278832317819223e-10
a O 0 1.4915022106265496e-08
female O 0 9.802030035643838e-06
transmitting O 0 0.007482047192752361
parent O 0 1.4808716741754324e-06
, O 0 9.917635601652819e-09
68 O 0 2.0431657787867152e-07
. O 0 7.056159745388868e-08

7 O 0 1.8334079868509434e-05
% O 0 2.0566089915519115e-06
were O 0 4.944471925227845e-07
affected O 0 1.1344249060130096e-06
. O 0 1.8336753271341877e-07

Studies O 0 9.165711162495427e-06
on O 0 3.6866629216092406e-07
meiotic O 0 7.3916007750085555e-06
drive O 0 3.2428699796582805e-06
in O 0 4.416609300506025e-08
DM B-Disease 1 1.0
have O 0 1.3517464481083152e-07
shown O 0 2.6548766740575047e-08
increased O 0 1.3682043942253586e-08
transmission O 0 3.971078683662199e-07
of O 0 3.2871538824252866e-10
the O 0 9.522787003390931e-10
larger O 0 6.697743692996028e-09
allele O 0 3.9212110891639895e-07
at O 0 1.1721596848701665e-07
the O 0 1.4823027072452533e-07
DM B-Disease 1 0.9999996423721313
locus O 0 1.6173695257748477e-05
in O 0 2.6980643497154233e-07
non O 0 0.0005107999895699322
- O 1 0.931596577167511
DM O 1 1.0
heterozygotes O 0 7.550475129391998e-05
for O 0 1.5576263479033514e-07
CTGn O 0 2.7825666620628908e-05
. O 0 6.823258900112705e-07

This O 0 7.315711059163732e-08
study O 0 2.819091982075861e-08
provides O 0 9.261301059382276e-09
further O 0 6.446626787948162e-09
evidence O 0 6.829076859560246e-09
that O 0 1.5969033873020066e-09
the O 0 1.856452236381756e-08
DM B-Disease 1 1.0
expansion O 0 9.865831174238338e-08
tends O 0 2.6074036441059434e-07
to O 0 7.615319930209807e-09
be O 0 3.2658530102480654e-08
transmitted O 0 2.603870143502718e-06
preferentially O 0 1.68212795870204e-06
. O 0 1.518563408353657e-07

Diagnosis O 1 0.9999591112136841
of O 0 1.0733530871220864e-05
hemochromatosis B-Disease 1 1.0
. O 0 9.81932862487156e-06

If O 0 9.003742889035493e-05
untreated O 0 0.39353710412979126
, O 0 9.953245125871035e-07
hemochromatosis B-Disease 1 1.0
can O 0 0.00711025670170784
cause O 0 0.006585733965039253
serious O 0 0.06311038136482239
illness O 1 0.8486825823783875
and O 0 1.395723927544168e-07
early B-Disease 0 6.70537758651335e-07
death I-Disease 0 8.92548598585563e-07
, O 0 3.0840472398097063e-09
but O 0 3.4861484810022603e-09
the O 0 2.2615258998825993e-08
disease O 0 4.5962293370394036e-05
is O 0 2.5384945256945457e-09
still O 0 2.853585101547651e-08
substantially O 0 2.6029664468296687e-07
under O 0 8.827207125250425e-07
- O 1 0.9898847341537476
diagnosed O 1 0.6236664652824402
. O 0 1.6956835224846145e-07

The O 0 7.119562610569119e-07
cornerstone O 0 6.292262924034731e-07
of O 0 4.706092404660467e-09
screening O 0 1.0044426090871639e-07
and O 0 1.3221717054534565e-08
case O 0 3.7028973220998296e-09
detection O 0 1.6577966732711502e-07
is O 0 3.127605063824035e-09
the O 0 1.7534940166541446e-09
measurement O 0 6.73553245178482e-07
of O 0 6.826732512621447e-09
serum O 0 1.4863670685372199e-06
transferrin O 0 7.295247428373841e-07
saturation O 0 1.2940978422193439e-06
and O 0 2.483160699284781e-08
the O 0 1.832389884270924e-08
serum O 0 1.6969207763395389e-06
ferritin O 0 2.9459726647473872e-05
level O 0 1.2532469554571435e-05
. O 0 2.413340496332239e-07

Once O 0 2.178136128350161e-05
the O 0 1.0684876627919948e-07
diagnosis O 0 0.005020585842430592
is O 0 2.539275278934383e-08
suspected O 0 1.3250215715743252e-06
, O 0 5.357291055219093e-09
physicians O 0 4.099533157386759e-08
must O 0 1.7860889656162726e-08
use O 0 1.3980246649225592e-07
serum O 0 6.254918116610497e-05
ferritin O 0 0.014526020735502243
levels O 0 0.003277532523497939
and O 0 1.7653126178629464e-06
hepatic O 0 0.0004047009570058435
iron O 0 0.002940370934084058
stores O 0 2.353186346226721e-06
on O 0 2.692820544325514e-07
liver O 0 4.168898885836825e-05
biopsy O 0 9.849440539255738e-05
specimens O 0 3.25613740415065e-08
to O 0 6.765252802409805e-09
assess O 0 6.56221072858898e-06
patients O 0 2.3696802600170486e-06
for O 0 1.473017596786974e-09
the O 0 7.1727863648618495e-09
presence O 0 4.9810374491698894e-08
of O 0 1.8052961792136557e-08
iron B-Disease 0 0.22300255298614502
overload I-Disease 0 0.0004443047218956053
. O 0 4.635608377157041e-07

Liver O 1 0.9999457597732544
biopsy O 1 0.9998668432235718
is O 0 3.865742144171236e-07
also O 0 1.76986549860203e-08
used O 0 3.8037985206074154e-08
to O 0 5.379459100396389e-09
establish O 0 1.858695668488508e-07
the O 0 5.850160800235926e-09
presence O 0 3.6594240526710564e-08
or O 0 7.700653270603652e-08
absence O 0 6.136803420986325e-08
of O 0 3.6234586442418504e-09
cirrhosis B-Disease 0 0.00014295869914349169
, O 0 4.420551480421864e-09
which O 0 3.159062789137579e-09
can O 0 1.4009300741690822e-07
affect O 0 1.0443915925861802e-05
prognosis O 0 0.00016127123672049493
and O 0 1.073625455205729e-07
management O 0 4.510260964707413e-07
. O 0 7.437638060991958e-08

A O 0 6.942882464500144e-06
DNA O 0 5.192454864300089e-06
- O 0 6.7497244344849605e-06
based O 0 4.2872041916552917e-08
test O 0 1.281925960938679e-07
for O 0 1.7029323506889682e-09
the O 0 5.5322013636782685e-09
HFE O 0 2.386225969530642e-05
gene O 0 1.2703704044270125e-07
is O 0 2.005213328715172e-09
commercially O 0 1.3201481685598537e-08
available O 0 4.384669960444398e-09
, O 0 4.110210838348394e-09
but O 0 1.6849169837129807e-09
its O 0 6.145805531154735e-10
place O 0 1.061704058002988e-08
in O 0 4.94205343315457e-10
the O 0 1.1916222675267818e-08
diagnosis O 0 0.0087783457711339
of O 0 2.6756328708188448e-08
hemochromatosis B-Disease 1 1.0
is O 0 8.144491516759444e-07
still O 0 7.8174372220019e-07
being O 0 4.20514822963014e-07
evaluated O 0 1.0364738045609556e-06
. O 0 1.178969242232597e-07

Currently O 0 1.2875665561296046e-05
, O 0 1.624057688331959e-08
the O 0 6.816827657907254e-10
most O 0 3.0740618384150764e-10
useful O 0 6.043894718033016e-09
role O 0 1.2493954315573319e-08
for O 0 5.856946039273225e-10
this O 0 6.901550997362449e-10
test O 0 1.9369632298094075e-07
is O 0 1.6153420823172837e-09
in O 0 3.0621008506592773e-10
the O 0 7.195995466169336e-10
detection O 0 3.4720335406746017e-07
of O 0 2.014030364705377e-08
hemochromatosis B-Disease 1 1.0
in O 0 2.5635635836351867e-08
the O 0 5.963554539079041e-09
family O 0 8.892824254758125e-09
members O 0 8.074195756435643e-10
of O 0 6.764707127793201e-10
patients O 0 1.4350524679684895e-07
with O 0 1.8537904544757566e-09
a O 0 4.6820193944085986e-08
proven O 0 2.1481889689312084e-06
case O 0 1.6666471536197491e-09
of O 0 7.098147070117022e-10
the O 0 1.7576009270214854e-07
disease O 0 0.00041639924165792763
. O 0 8.301542209210311e-08

It O 0 2.5288048277616326e-07
is O 0 2.3957060335533242e-08
crucial O 0 2.6768483962769096e-07
to O 0 5.856923621649912e-07
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 0 0.20225004851818085
hepatic B-Disease 1 0.9999949932098389
cirrhosis I-Disease 1 0.9999709129333496
develops O 0 4.631335104932077e-05
because O 0 3.5691425637196517e-07
phlebotomy O 0 0.0014036742504686117
therapy O 0 0.007084759417921305
can O 0 5.3689109336119145e-06
avert O 1 0.7706820964813232
serious O 1 0.9957855343818665
chronic O 1 1.0
disease O 1 0.9997361302375793
and O 0 6.940565810964472e-08
can O 0 5.301720875650062e-07
even O 0 7.999495323929295e-07
lead O 0 2.6392035579192452e-06
to O 0 1.0227893199044047e-07
normal O 0 2.072159986710176e-05
life O 0 2.62883901314126e-07
expectancy O 0 1.1333305565131013e-06
. O 0 3.966261541421545e-09
. O 0 3.93813870402937e-08

Prevalence O 0 0.004275335464626551
of O 0 9.656866950535914e-08
the O 0 5.5282271205214784e-08
I1307K O 0 1.703279622233822e-06
APC B-Disease 0 6.888404868732323e-07
gene O 0 2.4292504008371907e-07
variant O 0 6.208881018210377e-07
in O 0 4.237755479863381e-09
Israeli O 0 7.770098591208807e-07
Jews O 0 3.0483978008533086e-08
of O 0 5.781549683447906e-10
differing O 0 2.3800156512265858e-08
ethnic O 0 2.2973939195480853e-08
origin O 0 9.34031660904111e-08
and O 0 4.3360861923247285e-07
risk O 0 0.00012230584979988635
for O 0 7.78512840042822e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0181194056713139e-06

BACKGROUND O 0 0.0008788194973021746
& O 0 5.8300382079323754e-05
AIMS O 0 5.793305717816111e-06
Israeli O 0 3.1560766728944145e-06
Jews O 0 1.1436032565370624e-07
of O 0 1.3351486582990901e-09
European O 0 1.153293169409153e-06
birth O 0 0.00038552703335881233
, O 0 1.854979814197577e-08
i O 0 5.992661158416013e-07
. O 0 7.01751212695001e-10
e O 0 1.3174948776395468e-07
. O 0 6.971432320312942e-10
, O 0 7.61293417195219e-10
Ashkenazim O 0 2.239094783362816e-06
, O 0 2.5103752410160496e-09
have O 0 5.683347126250737e-09
the O 0 6.601886326507156e-08
highest O 1 0.9999899864196777
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.029272809624671936
of O 0 9.817752832930182e-09
any O 0 6.763706750234633e-08
Israeli O 0 0.0004159057280048728
ethnic O 0 1.1395720775908558e-06
group O 0 1.9738190530915745e-06
. O 0 1.217459129065901e-07

The O 0 2.5160700261039892e-06
I1307K O 0 1.8726548660197295e-05
APC B-Disease 0 6.541341917909449e-06
gene O 0 2.404627366558998e-06
variant O 0 8.697279554326087e-06
was O 0 6.162203476378636e-07
found O 0 3.8311831929149776e-08
in O 0 8.290605535421491e-09
6 O 0 1.8722536765380937e-07
. O 0 1.0918146386984517e-07

1 O 0 1.7257274294024683e-06
% O 0 9.120295629827524e-08
of O 0 4.131999187251267e-09
American O 0 2.5794600233552956e-08
Jews O 0 4.803730746516521e-08
, O 0 1.7594709023072141e-09
28 O 0 1.0021611096533434e-08
% O 0 1.8295078785257601e-09
of O 0 1.2212489908236535e-09
their O 0 0.003533346578478813
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 6.374146323651075e-06
, O 0 1.1820919354477155e-08
but O 0 1.0760646595997514e-08
not O 0 9.632636022161023e-09
in O 0 3.117646807382357e-09
non O 0 7.425783223879989e-06
- O 0 2.801484333758708e-05
Jews O 0 1.034028286994726e-06
. O 0 7.421072467650447e-08

We O 0 8.49709704198176e-06
assessed O 0 1.4083838095757528e-06
the O 0 2.7312216488439844e-08
I1307K O 0 1.6466393617520225e-06
prevalence O 0 5.550611604121514e-06
in O 0 2.7330964158522875e-09
Israeli O 0 8.527478598807647e-07
Jews O 0 1.8021928838152235e-08
of O 0 6.296206889189193e-10
differing O 0 1.1444690528605861e-08
ethnic O 0 1.530078996836437e-08
origin O 0 4.925664853772105e-08
and O 0 4.161781816947041e-07
risk O 0 0.00013282620056997985
for O 0 5.684965435648337e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.554517651442438e-07

METHODS O 0 1.7694233974907547e-05
DNA O 0 5.826972483191639e-06
samples O 0 1.968295464394032e-07
from O 0 7.828544923427216e-09
500 O 0 1.4485446619971754e-08
unrelated O 0 2.3339776333841655e-08
Jews O 0 1.2163213547466967e-08
of O 0 3.267693893249657e-10
European O 0 1.035759396472713e-06
or O 0 8.700721991772298e-06
non O 0 4.344141052570194e-05
- O 0 8.821998562780209e-06
European O 0 9.386731107952073e-07
origin O 0 2.8569779431109055e-08
, O 0 9.887862750801446e-10
with O 0 1.3914259744396418e-09
or O 0 2.76633898010914e-07
without O 0 2.1219879187128754e-08
a O 0 2.4520447894360586e-09
personal O 0 3.312201442895457e-06
and O 0 1.206351726068533e-06
/ O 0 0.00019089995475951582
or O 0 2.0085460619156947e-06
family O 0 4.475597137343357e-08
history O 0 8.103575588336298e-09
of O 0 2.4112636332063175e-09
neoplasia B-Disease 0 0.00010903583461185917
, O 0 2.156802736408281e-08
were O 0 7.501593302094989e-08
examined O 0 1.097276012274051e-07
for O 0 7.929921164162579e-10
the O 0 4.024052202566963e-09
I1307K O 0 2.5569889317011985e-07
variant O 0 2.2243064279336977e-07
by O 0 1.1526969379005436e-09
the O 0 2.364909823526773e-09
allele O 0 2.074992693223976e-07
- O 0 1.256340311783788e-07
specific O 0 3.285515148832019e-08
oligonucleotide O 0 2.9750167414022144e-06
( O 0 4.721504964777523e-08
ASO O 0 1.656698077567853e-05
) O 0 1.2793070602867829e-08
method O 0 1.697893878827017e-07
. O 0 6.104791339112126e-08

RESULTS O 0 3.0987397622084245e-05
In O 0 4.29560209624924e-08
persons O 0 7.474185537148514e-08
at O 0 5.2145395557090524e-08
average O 0 5.931741270615021e-06
risk O 0 0.00014209732762537897
for O 0 0.00011412043386371806
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.2793289739838656e-08
I1307K O 0 1.5181869912339607e-06
was O 0 1.5935731312310963e-07
found O 0 7.833383719457743e-09
in O 0 2.834543044727411e-09
5 O 0 4.600910941121583e-08
. O 0 7.88597560585913e-08

0 O 0 2.6296780561096966e-05
% O 0 3.6704551575894584e-07
of O 0 4.9920583222728965e-09
120 O 0 2.4614131177713716e-08
European O 0 2.913872378940141e-07
and O 0 1.1021675305755707e-07
1 O 0 1.885869380657823e-07
. O 0 9.413825807769172e-08

6 O 0 8.572409569751471e-06
% O 0 2.3689113959335373e-07
of O 0 5.924938317747319e-09
188 O 0 1.6197058982925228e-07
non O 0 1.935597992996918e-06
- O 0 3.1104461868380895e-06
European O 0 1.2598993635037914e-06
Jews O 0 9.59711428549781e-07
( O 0 5.0366868009632526e-08
P O 0 0.00010836064757313579
= O 0 7.554008789156796e-06
0 O 0 1.2543767979877884e-07
. O 0 5.373419043053218e-09
08 O 0 5.632070383398968e-07
) O 0 3.753471489176263e-08
. O 0 1.0224226798527525e-07

It O 0 1.5702815971962991e-06
occurred O 0 9.941215921571711e-07
in O 0 2.079960914613821e-08
15 O 0 8.109717697379892e-08
. O 0 5.6790700142528294e-08

4 O 0 8.038957275857683e-06
% O 0 1.6450698581138568e-07
of O 0 7.030215964931585e-09
52 O 0 3.378722794877831e-07
Ashkenazi O 0 9.577799573889934e-06
Israelis O 0 2.1747362097812584e-06
with O 0 7.860627704303624e-08
familial O 1 0.9998787641525269
cancer B-Disease 1 0.8831456899642944
( O 0 1.7346658864880737e-07
P O 0 0.01288609579205513
= O 0 4.0274760976899415e-05
0 O 0 1.2148657901889237e-07
. O 0 6.173594080394196e-09
02 O 0 2.4609612410131376e-06
) O 0 6.660290985394113e-09
and O 0 2.5631823774574514e-08
was O 0 3.4438212992427e-07
not O 0 8.788130223535973e-09
detected O 0 1.3658164732532896e-07
in O 0 2.219060712960186e-09
51 O 0 1.5179206513948884e-07
non O 0 2.6760162086247874e-07
- O 0 5.64640799893823e-07
European O 0 1.0300465902446376e-07
Jews O 0 6.29024654585919e-08
at O 0 9.589798111164782e-08
increased O 0 3.723733243532479e-06
cancer B-Disease 0 8.892221376299858e-05
risk O 0 1.3228271882326226e-06
. O 0 5.3303853775332755e-08

Colorectal B-Disease 1 0.9999773502349854
neoplasia I-Disease 1 0.9563395380973816
occurred O 0 0.00010002813360188156
personally O 0 6.313201447483152e-05
or O 0 1.150441448771744e-06
in O 0 2.8516464745109715e-09
the O 0 5.801303437635852e-09
families O 0 1.7481651681805488e-08
of O 0 3.5955535770959557e-10
13 O 0 6.1118496930134825e-09
of O 0 7.240175126099757e-10
20 O 0 1.6795018709103715e-08
Ashkenazi O 0 1.4175629985402338e-06
I1307K O 0 3.048752716949821e-07
carriers O 0 5.824278304089603e-08
, O 0 7.444982963455971e-10
8 O 0 2.711547875122733e-09
of O 0 4.998496616615e-10
whom O 0 2.0419230395418708e-07
also O 0 9.334991801779324e-08
had O 0 3.733693176855013e-07
a O 0 1.1869130567276898e-08
personal O 0 1.1673437256831676e-05
or O 0 5.810314178233966e-06
family O 0 4.249413265711155e-08
history O 0 2.899855111593297e-08
of O 0 1.905816482405953e-08
noncolonic O 0 0.0006251378217712045
neoplasia B-Disease 0 0.003677000990137458
. O 0 6.865647605991398e-07

CONCLUSIONS O 0 2.7459853299660608e-05
The O 0 3.303572100321617e-07
I1307K O 0 7.660047231183853e-06
APC O 0 3.1756858334119897e-06
variant O 0 1.1043924132536631e-05
may O 0 1.957184423417857e-07
represent O 0 1.2063128274064638e-08
a O 0 1.4395108216547214e-08
susceptibility O 0 1.8728995200945064e-05
gene O 0 7.220471616165014e-06
for O 0 1.6990682638606813e-07
colorectal B-Disease 1 1.0
, I-Disease 0 1.4022640471011982e-07
or I-Disease 0 9.482937457505614e-08
other I-Disease 0 4.544748577473001e-09
, I-Disease 0 2.977395574532693e-08
cancers I-Disease 0 0.005646527744829655
in O 0 1.762917367642558e-09
Ashkenazi O 0 2.1000116703362437e-06
Jews O 0 1.1566202573476403e-07
, O 0 1.872218380327695e-09
and O 0 9.003830570009086e-09
partially O 0 2.3899408461147686e-06
explains O 0 1.4289242677989478e-08
the O 0 8.514511873336517e-10
higher O 0 1.1233528596221731e-07
incidence O 0 0.1334727257490158
of O 0 0.00034456400317139924
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.15780673329391e-08
European O 0 5.012133897253079e-06
Israelis O 0 3.2620162528473884e-05
. O 0 1.807353413596502e-07

Systematic O 0 1.1653815818135627e-05
analysis O 0 8.11167183201178e-07
of O 0 6.777111138944747e-08
coproporphyrinogen O 0 0.0002498878166079521
oxidase O 0 0.0006616056780330837
gene O 0 0.0051940628327429295
defects O 1 0.9432448744773865
in O 0 6.528856033582997e-08
hereditary B-Disease 1 0.8209326267242432
coproporphyria I-Disease 0 0.003224108135327697
and O 0 7.023610351097886e-07
mutation O 0 4.7338086005765945e-05
update O 0 8.696905752003659e-06
. O 0 3.2252020787382207e-07

Hereditary B-Disease 1 0.9999914169311523
coproporphyria I-Disease 1 0.9406086802482605
( O 0 7.2724265010037925e-06
HC B-Disease 0 0.2524985671043396
) O 0 2.0094608998988406e-07
is O 0 1.4904472322996298e-08
an O 0 1.0048564291764706e-07
acute O 1 0.9999399185180664
hepatic B-Disease 1 0.999995231628418
porphyria I-Disease 1 0.9999983310699463
with O 0 2.292645831403206e-06
autosomal O 1 0.9999823570251465
dominant O 1 0.5756064653396606
inheritance O 0 0.00014799133350607008
caused O 0 3.871046828862745e-06
by O 0 1.3356078021331541e-08
deficient B-Disease 0 8.345258720510174e-06
activity I-Disease 0 7.160486603652316e-08
of I-Disease 0 1.239091051985497e-08
coproporphyrinogen I-Disease 0 4.859542605117895e-05
III I-Disease 0 1.1060926226491574e-05
oxidase I-Disease 0 7.829525202396326e-06
( O 0 2.2253226461543818e-07
CPO O 0 4.183909823041176e-06
) O 0 3.7248302220405094e-08
. O 0 3.560500161370328e-08

Clinical O 0 0.026240382343530655
manifestations O 0 2.795887121465057e-05
of O 0 3.0654053517764623e-08
the O 0 1.0926979854275487e-07
disease O 0 0.009196666069328785
are O 0 4.724790336751994e-09
characterized O 0 1.595607841409219e-07
by O 0 9.113805710114775e-09
acute O 0 0.0009059423464350402
attacks O 0 2.0598361516022123e-05
of O 0 3.229474145882705e-07
neurological B-Disease 1 0.9999998807907104
dysfunction I-Disease 0 0.21850931644439697
often O 0 8.654938028485049e-07
precipitated O 0 1.9803022155429062e-07
by O 0 1.8774823917766525e-09
drugs O 0 2.5438758655127458e-08
, O 0 1.898323942484126e-09
fasting O 0 2.3631801582268963e-07
, O 0 3.863071196263945e-09
cyclical O 0 1.1771310710173566e-05
hormonal O 0 3.454950638115406e-05
changes O 0 1.3682408983584082e-08
, O 0 6.080130621199942e-09
or O 0 1.419968725713261e-06
infectious B-Disease 0 0.00035407987888902426
diseases I-Disease 0 0.0003641133080236614
. O 0 5.9639205574058e-08

Skin O 1 0.9999998807907104
photosensitivity O 1 0.9994014501571655
may O 0 0.0024990492966026068
also O 0 1.1746406158863465e-07
be O 0 1.898984081094568e-08
present O 0 2.4667990317084332e-08
. O 0 4.034697909105489e-08

The O 0 5.653315611198195e-07
seven O 0 1.7961983189707098e-07
exons O 0 5.345438580661721e-07
, O 0 8.927221628596271e-09
the O 0 4.291177635451504e-09
exon O 0 9.72935595200397e-07
/ O 0 3.5385621686145896e-06
intron O 0 3.489546725177206e-05
boundaries O 0 2.1640031263814308e-05
and O 0 6.915340122759517e-08
part O 0 5.639140709945423e-09
of O 0 1.1158010071454783e-09
3 O 0 8.990479472004154e-09
noncoding O 0 2.2202181071406812e-07
sequence O 0 4.20562926706225e-08
of O 0 1.1478701322786833e-09
the O 0 1.9423195496415246e-08
CPO O 0 9.537037840345874e-06
gene O 0 5.698279892385472e-07
were O 0 2.5459004859840206e-07
systematically O 0 8.165506528712285e-07
analyzed O 0 3.8119257084190394e-08
by O 0 4.265877651121741e-10
an O 0 1.2520046110964245e-09
exon O 0 1.3993877701068413e-07
- O 0 5.614667770714732e-07
by O 0 1.6929066148918537e-08
- O 0 2.129713948306744e-06
exon O 0 1.0926362847385462e-05
denaturing O 0 0.00034496691660024226
gradient O 0 9.717950888443738e-05
gel O 0 0.002501790877431631
electrophoresis O 0 4.316670310799964e-05
( O 0 1.2487502942803985e-07
DGGE O 0 2.4790092538751196e-06
) O 0 6.2773239939417635e-09
strategy O 0 1.9769974102246124e-08
followed O 0 4.9836672566527795e-09
by O 0 6.652251527405895e-10
direct O 0 3.0344098345125303e-09
sequencing O 0 6.831502474824447e-08
in O 0 7.874639607052814e-09
seven O 0 3.8850931360912e-08
unrelated O 0 2.416403503957554e-07
heterozygous O 0 1.7240678062080406e-05
HC B-Disease 0 0.002233486622571945
patients O 0 4.5979781134519726e-05
from O 0 4.011325671626764e-08
France O 0 0.0006364719592966139
, O 0 2.6851624923551753e-08
Holland O 0 5.833822797285393e-06
, O 0 9.541227363740745e-09
and O 0 2.8556867093243454e-08
Czech O 0 1.320150386163732e-05
Republic O 0 7.488897040275333e-07
. O 0 7.732828066764341e-08

Seven O 0 5.060470357420854e-06
novel O 0 1.2719684718831559e-06
mutations O 0 3.6767617075383896e-06
and O 0 1.8301019366617766e-08
two O 0 6.315104883469758e-09
new O 0 1.459605147857701e-08
polymorphisms O 0 0.00016827398212626576
were O 0 1.4749883803233388e-06
detected O 0 6.020120963512454e-06
. O 0 1.4060725561648724e-07

Among O 0 1.244624058927002e-06
these O 0 8.960797970303247e-08
mutations O 0 1.7027696230798028e-06
two O 0 1.4328843889188647e-08
are O 0 2.450811642518147e-08
missense O 0 5.9113831412105355e-06
( O 0 2.2508750419092394e-08
G197W O 0 4.73502325348818e-07
, O 0 6.21667606282017e-09
W427R O 0 2.732519988057902e-07
) O 0 4.695888122796532e-09
, O 0 1.563008611427108e-09
two O 0 5.087771093315041e-09
are O 0 1.4712044915654587e-08
nonsense O 0 1.3598188388641574e-06
( O 0 4.179063761711177e-09
Q306X O 0 1.8670257873054652e-07
, O 0 3.660169056729501e-09
Q385X O 0 1.3421201572327845e-07
) O 0 1.427752027716167e-09
, O 0 7.769944687652242e-10
two O 0 1.5644610051879226e-09
are O 0 1.3283386612883419e-09
small O 0 6.068452407248515e-09
deletions O 0 4.159744094067719e-06
( O 0 4.335821301992837e-08
662de14bp O 0 3.6036217920809577e-07
; O 0 8.518056482387237e-09
1168del3bp O 0 1.0662721479093307e-06
removing O 0 1.0992534527076714e-07
a O 0 4.780767781653594e-09
glycine O 0 2.231334548241648e-07
at O 0 1.0431251240561323e-07
position O 0 3.0211438684091263e-07
390 O 0 1.2978333074897819e-08
) O 0 1.713508224199245e-09
, O 0 7.621477338126681e-10
and O 0 3.8534384572130875e-09
one O 0 5.324895191449741e-09
is O 0 1.0458436339177979e-09
a O 0 9.006836165781351e-09
splicing O 0 5.876663635717705e-06
mutation O 0 3.2287580324918963e-06
( O 0 3.887227961740791e-08
IVS1 O 0 6.386571385519346e-06
- O 0 2.4521173145330977e-06
15c O 0 1.4603407180402428e-05
- O 0 1.133091609517578e-05
- O 0 4.6198401832953095e-06
> O 0 5.588006501966447e-07
g O 0 3.950469817937119e-07
) O 0 2.7465840712892486e-09
which O 0 1.2568904805831949e-09
creates O 0 5.851991335958928e-09
a O 0 3.272773163587317e-09
new O 0 4.798746733314374e-09
acceptor O 0 2.1415256412637973e-07
splice O 0 2.5189217922161333e-05
site O 0 1.9855208392982604e-06
. O 0 3.390313452200644e-07

The O 0 2.4580711510679976e-07
pathological O 0 6.93596632572735e-07
significance O 0 2.651132113840049e-08
of O 0 1.8826531444915418e-09
the O 0 1.1437838232097874e-08
point O 0 1.1737374734366313e-06
mutations O 0 7.183726665971335e-06
G197W O 0 4.248838081366557e-07
, O 0 4.84434181657889e-09
W427R O 0 2.4745705218265357e-07
, O 0 2.6417623644192645e-09
and O 0 2.7382256462260557e-09
the O 0 3.2622655687930546e-09
in O 0 7.475065899598121e-09
- O 0 1.9866873117280193e-05
frame O 0 0.023748716339468956
deletion O 0 6.220382056199014e-05
390delGly O 0 7.858047865738627e-06
were O 0 1.4179468621478009e-07
assessed O 0 1.2120001002813297e-08
by O 0 7.38146821444019e-10
their O 0 5.773639788486662e-09
respective O 0 1.0160268004710815e-07
expression O 0 1.3522901021190137e-08
in O 0 1.06440833924637e-09
a O 0 4.88619322780437e-09
prokaryotic O 0 2.612420857417419e-08
system O 0 1.7237695715266454e-08
using O 0 4.87463438503255e-08
site O 0 9.118823527387576e-07
- O 0 1.425034270141623e-06
directed O 0 1.2689661161857657e-06
mutagenesis O 0 8.414184776484035e-06
. O 0 4.6105438400445564e-07

These O 0 1.8690564047574298e-06
mutations O 0 2.2587624698644504e-05
resulted O 0 2.6410640430185595e-07
in O 0 1.0575567976900402e-08
the O 0 2.8937936491502114e-08
absence O 0 1.4545437352353474e-06
or O 0 7.690320558140229e-08
a O 0 1.0673241845893244e-08
dramatic O 0 6.183283858263167e-07
decrease O 0 5.804338343295967e-07
of O 0 6.40333164270146e-09
CPO O 0 1.055076063494198e-05
activity O 0 1.214997155329911e-06
. O 0 1.7987352407544677e-07

The O 0 3.829810282240942e-07
two O 0 2.1507644021312444e-07
polymorphisms O 0 5.210935705690645e-05
were O 0 7.196227898020879e-07
localized O 0 9.089199011214077e-07
in O 0 7.854179528976601e-09
noncoding O 0 5.714121016353602e-07
part O 0 1.8676468371836563e-08
of O 0 1.935026583410604e-09
the O 0 8.753200830824426e-09
gene O 0 6.447724132385702e-08
1 O 0 5.580761630596953e-09
) O 0 1.0873393296861877e-09
a O 0 1.4392965930198898e-08
C O 0 8.963094842329156e-06
/ O 0 1.1713823369063903e-06
G O 0 8.674969080857409e-07
polymorphism O 0 1.362325292575406e-06
in O 0 8.723882949368544e-09
the O 0 1.3466377346560421e-08
promotor O 0 2.5659908260422526e-06
region O 0 6.673695907011279e-08
, O 0 2.9332472006871058e-09
142 O 0 2.2278022981936374e-08
bp O 0 2.3090008482995472e-07
upstream O 0 5.548911374830823e-08
from O 0 2.2384238906880682e-09
the O 0 1.8481982611007197e-09
transcriptional O 0 2.4355020400435023e-07
initiation O 0 5.2155346708104844e-08
site O 0 1.5622991611508041e-07
( O 0 2.3926874703761314e-08
- O 0 5.924239872001635e-07
142C O 0 1.3125692248650012e-06
/ O 0 1.3093484767523478e-06
G O 0 6.880054002067482e-07
) O 0 1.7761816462069646e-09
, O 0 6.058618606807897e-10
and O 0 2.89351631543866e-09
2 O 0 5.01192154445107e-09
) O 0 1.1778510389248709e-09
a O 0 4.956063559546919e-09
6 O 0 4.2952663648065936e-08
bp O 0 4.780952735927713e-07
deletion O 0 5.048440243626828e-07
polymorphism O 0 8.786606713329093e-07
in O 0 7.131669921278672e-09
the O 0 4.632812800053898e-09
3 O 0 5.834281946448527e-09
noncoding O 0 7.677393654148545e-08
part O 0 9.477635565247056e-09
of O 0 1.251875603180963e-09
the O 0 1.2923543124543357e-08
CPO O 0 2.8217764338478446e-06
gene O 0 1.4058325348287326e-07
, O 0 2.5342177245590847e-09
574 O 0 4.4254125697307245e-08
bp O 0 1.1639089336767938e-07
downstream O 0 1.945511840517611e-08
of O 0 5.923239676519643e-10
the O 0 3.288591621242176e-09
last O 0 3.6379597112556894e-09
base O 0 6.690262122077684e-09
of O 0 2.7043259298586975e-10
the O 0 5.727911922548401e-09
normal O 0 2.1945695038994018e-07
termination O 0 5.939145921729505e-07
codon O 0 1.3552875088862493e-06
( O 0 3.973654116862235e-08
+ O 0 4.611647455021739e-07
574 O 0 7.447318353115406e-07
delATTCTT O 0 1.987998984986916e-06
) O 0 7.654554678993009e-08
. O 0 1.4099303768944083e-07

Five O 0 2.356560253247153e-05
intragenic O 0 6.930492236278951e-05
dimorphisms O 0 4.046760295750573e-05
are O 0 9.85625661087397e-08
now O 0 2.654795672185628e-08
well O 0 1.3631276551961946e-08
characterized O 0 1.533824161015218e-07
and O 0 3.241179769020164e-08
the O 0 2.919393615741228e-09
high O 0 1.1200836524949409e-07
degree O 0 9.696877967257933e-09
of O 0 1.37206102035492e-09
allelic O 0 4.759584442126652e-07
heterogeneity O 0 4.819838181902014e-07
in O 0 2.2930862542125396e-08
HC B-Disease 0 0.004379254300147295
is O 0 4.7227295851826057e-08
demonstrated O 0 3.141261473160739e-08
with O 0 1.6493930665717471e-09
seven O 0 2.577702939987603e-09
new O 0 4.015547061531066e-10
different O 0 3.4024056905224143e-09
mutations O 0 1.2897076828721765e-07
making O 0 9.93291315865008e-09
a O 0 3.783875435203754e-09
total O 0 3.406301685160429e-09
of O 0 2.6703852462617306e-09
nineteen O 0 1.0625431968946941e-05
CPO O 0 0.0020511564798653126
gene B-Disease 0 0.0003992146230302751
defects I-Disease 1 0.8716737627983093
reported O 0 2.0816892174480017e-06
so O 0 4.7931234092857267e-08
far O 0 5.3626095564140996e-08
. O 0 1.633642199294627e-08
. O 0 1.2389863002226775e-07

Coincidence O 0 7.309925877052592e-06
of O 0 5.8370119404571597e-08
two O 0 4.832365974039021e-08
novel O 0 1.285251869376225e-07
arylsulfatase O 0 2.88316368823871e-06
A O 0 9.616870499939978e-08
alleles O 0 1.0660444331733743e-06
and O 0 9.355579067005237e-08
mutation O 0 6.715131348755676e-06
459 O 0 1.356610368929978e-06
+ O 0 1.3873874422642984e-06
1G O 0 1.8233175069326535e-05
> O 0 1.0706751254474511e-06
A O 0 1.1233549912503804e-07
within O 0 3.707103957140134e-08
a O 0 6.184816925269843e-08
family O 0 4.5715111696154054e-07
with O 0 1.8791758975567063e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 3.7298207189451205e-08
molecular O 0 2.0467268768697977e-07
basis O 0 2.7759472942534558e-08
of O 0 1.3234508600135086e-08
phenotypic O 0 4.790816819877364e-05
heterogeneity O 0 0.00013036081509198993
. O 0 2.0589052383002127e-06

In O 0 6.279098556660756e-07
a O 0 1.0896469149201948e-07
family O 0 8.704539311565895e-08
with O 0 3.81492792911331e-09
three O 0 9.498559450094035e-08
siblings O 0 4.553965845843777e-05
, O 0 1.5345206216821339e-09
one O 0 1.4147294447042214e-09
developed O 0 3.6993906604720905e-08
classical O 0 1.5838129741041485e-07
late O 0 4.845549483434297e-05
infantile O 1 0.9999995231628418
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.661218084336724e-05
MLD B-Disease 1 0.9999997615814209
) O 0 4.908277517756687e-08
, O 0 6.319345935423826e-09
fatal O 0 7.020261364232283e-06
at O 0 2.6198713953817787e-07
age O 0 4.7561542260154965e-07
5 O 0 3.9313823307907114e-09
years O 0 4.287970867267177e-09
, O 0 2.292096512590547e-09
with O 0 1.0290898799780734e-08
deficient O 0 0.0003940211609005928
arylsulfatase O 0 2.9232176075311145e-06
A O 0 8.895542435993775e-08
( O 0 1.5332254577060667e-08
ARSA O 0 5.1705596888496075e-06
) O 0 2.4804425180491307e-09
activity O 0 1.3527028386306483e-08
and O 0 5.704351213609016e-09
increased O 0 6.836442878466187e-08
galactosylsulfatide O 0 0.0001060276263160631
( O 0 3.307578708700021e-07
GS O 1 0.9999995231628418
) O 0 6.930366680535371e-08
excretion O 0 6.677439614577452e-07
. O 0 1.2102356095056166e-07

The O 0 4.130804427404655e-07
two O 0 6.072113478694519e-08
other O 0 1.2646462543841608e-08
siblings O 0 1.0445529369462747e-05
, O 0 1.8856907146869162e-08
apparently O 0 2.5078602448047604e-06
healthy O 0 1.2540802174498822e-07
at O 0 8.371549675700862e-09
12 O 0 7.215322561648918e-09
( O 0 1.639481772564011e-09
1 O 0 6.232014904128391e-09
/ O 0 2.503513201190799e-07
2 O 0 2.0930421840148483e-08
) O 0 1.6217509557492349e-09
and O 0 3.9077672653320406e-08
15 O 0 1.7905435356624366e-08
years O 0 5.779501321967473e-09
, O 0 2.3359494338848208e-09
respectively O 0 1.1752871387216146e-07
, O 0 3.278771254500157e-09
and O 0 1.6632181853992734e-08
their O 0 1.449266591180276e-07
father O 0 1.0976231124004698e-06
, O 0 4.8279225062231035e-09
apparently O 0 4.694502706570347e-07
healthy O 0 2.6840819344897682e-08
as O 0 1.3172801738292605e-09
well O 0 3.375399959537617e-09
, O 0 9.038927939464259e-10
presented O 0 1.1736357663494346e-08
ARSA O 0 0.0001834094146033749
and O 0 1.3794596043226193e-06
GS O 1 0.9999997615814209
values O 0 2.6851606094169256e-07
within O 0 6.850158218441038e-09
the O 0 2.0477131101870327e-09
range O 0 1.1800164401165603e-07
of O 0 5.544510273125525e-08
MLD B-Disease 1 1.0
patients O 0 5.4307180107571185e-05
. O 0 2.1144978745724075e-07

Mutation O 0 6.478215073002502e-05
screening O 0 2.4653938908159034e-06
and O 0 4.674586406849812e-08
sequence O 0 5.874024111562903e-08
analysis O 0 5.223449051072748e-08
disclosed O 0 2.3047481079174759e-07
the O 0 4.1800602978980805e-09
involvement O 0 3.0663528605145984e-08
of O 0 1.9249404292764893e-09
three O 0 5.609468445300081e-09
different O 0 3.333443743258613e-08
ARSA O 0 0.053237415850162506
mutations O 0 2.698334719752893e-05
being O 0 4.3426410911706625e-08
the O 0 1.2270769955691208e-09
molecular O 0 4.767184691445436e-08
basis O 0 2.6193410107566706e-08
of O 0 1.7104952121371753e-08
intrafamilial O 0 2.991735891555436e-05
phenotypic O 0 6.363987631630152e-05
heterogeneity O 0 4.528479985310696e-05
. O 0 1.837515810620971e-06

The O 0 1.1988327059953008e-06
late O 0 3.5666216717800125e-06
infantile O 1 0.9872389435768127
patient O 0 0.33821025490760803
inherited O 0 0.00287875859066844
from O 0 3.331041398269008e-08
his O 0 9.269050451621297e-07
mother O 0 1.2280582268431317e-05
the O 0 6.824428133711535e-09
frequent O 0 1.602231805009069e-06
0 O 0 2.596510285002296e-06
- O 0 1.3535562175093219e-05
type O 0 0.0021355522330850363
mutation O 0 3.070942693739198e-05
459 O 0 1.0179428500123322e-06
+ O 0 8.561123649997171e-07
1G O 0 7.638986062374897e-06
> O 0 6.200171469572524e-07
A O 0 1.6304895211760595e-07
, O 0 6.183634937428906e-09
and O 0 7.987518202412502e-09
from O 0 5.8216760301377235e-09
his O 0 7.390440828203282e-07
father O 0 2.1442242541525047e-06
a O 0 1.1337145444656471e-08
novel O 0 3.6720653184829644e-08
, O 0 4.532343833574259e-09
single O 0 4.586345312418416e-07
basepair O 0 3.1868780752120074e-06
microdeletion O 0 1.0257251688017277e-06
of O 0 4.016559973507583e-09
guanine O 0 2.8528648954306846e-07
at O 0 1.0877987932644828e-07
nucleotide O 0 3.8618435382886673e-07
7 O 0 2.662188691715528e-08
in O 0 1.729254850424411e-09
exon O 0 1.8066675977479463e-07
1 O 0 7.37556433705322e-08
( O 0 1.7914180361344734e-08
7delG O 0 1.9490498743834905e-06
) O 0 4.236820316805279e-08
. O 0 7.152787873110356e-08

The O 0 1.084012069441087e-06
two O 0 5.974019359200611e-07
clinically O 0 0.010606661438941956
unaffected O 0 2.6324056307203136e-05
siblings O 0 1.082238850358408e-05
carried O 0 2.829511061008816e-07
the O 0 2.976782376151732e-08
maternal O 0 6.34424650343135e-05
mutation O 0 4.636772246158216e-06
459 O 0 9.564805623085704e-07
+ O 0 8.504260335939762e-07
1G O 0 1.2847270227211993e-05
> O 0 8.276513199234614e-07
A O 0 5.090841455057671e-07
and O 0 1.5057003110996448e-07
, O 0 4.42897407637588e-09
on O 0 1.4467278930396787e-08
their O 0 1.3108125074268173e-07
paternal O 0 6.543868494190974e-06
allele O 0 6.627332709285838e-07
, O 0 4.2017469503718985e-09
a O 0 6.732402191289566e-09
novel O 0 2.418062905462648e-08
cytosine O 0 1.504527489259999e-07
to O 0 5.21083842741632e-09
thymidine O 0 1.0101600764755858e-06
transition O 0 5.228163786341611e-07
at O 0 2.9313619620552345e-07
nucleotide O 0 3.487405365376617e-06
2435 O 0 5.012659585190704e-06
in O 0 9.187878902139346e-09
exon O 0 3.623274267283705e-07
8 O 0 4.1906876191433184e-08
, O 0 1.3310397228849524e-09
resulting O 0 5.679771319933025e-09
in O 0 5.245298084766148e-10
substitution O 0 2.8063544821321784e-09
of O 0 1.961229845193202e-09
alanine O 0 4.284378064767225e-06
464 O 0 1.9243178428496321e-07
by O 0 3.161559902764566e-08
valine O 0 7.225213630590588e-05
( O 0 6.35679953120416e-08
A464V O 0 7.918303595033649e-07
) O 0 1.172962171835934e-08
. O 0 2.4463467696023145e-08

The O 0 1.8366486074228305e-06
fathers O 0 3.3611660910537466e-05
genotype O 0 1.4399618521565571e-05
thus O 0 2.4195580294872343e-07
was O 0 2.893069108722557e-07
7delG O 0 7.403410108963726e-06
/ O 0 1.7253129044547677e-05
A464V O 0 2.3988437533262186e-05
. O 0 4.474231616313773e-07

Mutation O 0 0.00044085117406211793
A464V O 0 3.8664464227622375e-05
was O 0 1.03736476830818e-06
not O 0 1.716970565723841e-08
found O 0 8.619813307575441e-09
in O 0 4.777978013237316e-09
18 O 0 1.1645328612530648e-07
unrelated O 0 1.9946535303461133e-06
MLD B-Disease 1 1.0
patients O 0 0.00011396534682717174
and O 0 4.2994958704412056e-08
50 O 0 8.498797399170144e-08
controls O 0 6.606316674151458e-06
. O 0 3.6337249298412644e-07

A464V O 0 0.0002372992894379422
, O 0 3.3726124115673883e-07
although O 0 7.584809225136269e-08
clearly O 0 1.634577841969076e-07
modifying O 0 1.327065206169209e-06
ARSA O 0 0.0008650482050143182
and O 0 5.182388122193515e-06
GS O 1 1.0
levels O 0 0.00010722965089371428
, O 0 2.980611313319059e-08
apparently O 0 3.402924164674914e-07
bears O 0 3.9136526908123415e-08
little O 0 4.853562440843007e-09
significance O 0 8.157511111051008e-09
for O 0 3.160256056844446e-09
clinical O 0 1.8174785054725362e-06
manifestation O 0 5.871945631952258e-07
of O 0 6.796087603788692e-08
MLD B-Disease 1 1.0
, O 0 6.99829740824498e-08
mimicking O 0 7.105492386472179e-06
the O 0 1.1222736162608271e-07
frequent O 0 4.1884970414685085e-05
ARSA O 1 0.5176882743835449
pseudodeficiency O 0 0.0002633271797094494
allele O 0 6.629554263781756e-05
. O 0 1.3372311968851136e-06

Our O 0 1.2436092220013961e-05
results O 0 3.473023753031157e-07
demonstrate O 0 4.574825851477726e-08
that O 0 9.69306412912374e-10
in O 0 4.666991237911589e-10
certain O 0 9.188036997898053e-09
genetic O 0 5.0002669013338163e-05
conditions O 0 0.0006079921731725335
MLD B-Disease 1 1.0
- O 0 0.005604865029454231
like O 0 1.7667643987806514e-06
ARSA O 0 0.021417533978819847
and O 0 2.9483760499715572e-06
GS O 1 0.9999998807907104
values O 0 5.986292421766848e-07
need O 0 2.9060840844863378e-08
not O 0 3.4005500637590558e-09
be O 0 1.491902712480453e-09
paralleled O 0 3.567093287415446e-08
by O 0 8.018168351497934e-09
clinical O 0 0.0054239840246737
disease O 0 0.00987114105373621
, O 0 1.4343027876506653e-09
a O 0 4.3835828300586854e-09
finding O 0 4.131922537453647e-08
with O 0 1.4204460718758583e-08
serious O 0 1.6055770402090275e-06
diagnostic O 0 6.859862332930788e-05
and O 0 6.039858249096142e-07
prognostic O 0 0.0008780143689364195
implications O 0 9.282786777475849e-06
. O 0 5.806115268569556e-07

Moreover O 0 2.9761642508674413e-05
, O 0 2.4496745254509733e-07
further O 0 4.792689196619904e-07
ARSA O 0 0.001955676358193159
alleles O 0 8.879082997736987e-06
functionally O 0 2.78932498076756e-06
similar O 0 1.995157639100853e-08
to O 0 1.7113144679115067e-08
A464V O 0 1.8090690900862683e-06
might O 0 1.8829436498890573e-07
exist O 0 4.063520364638862e-08
which O 0 2.45390685549296e-09
, O 0 1.5992474011738977e-09
together O 0 9.368664954934047e-09
with O 0 1.275382022214444e-08
0 O 0 3.218812025806983e-06
- O 0 9.49251334532164e-05
type O 0 0.05523461103439331
mutations O 0 0.00018235738389194012
, O 0 1.3324527259328534e-08
may O 0 1.057165945894667e-07
cause O 0 1.359026384761819e-07
pathological O 0 4.169462954450864e-06
ARSA O 0 0.4924376606941223
and O 0 3.205404937034473e-05
GS O 1 1.0
levels O 0 0.0009257729398086667
, O 0 4.171187839574486e-09
but O 0 2.504373375344926e-09
not O 0 6.671581065376131e-09
clinical O 0 3.3204420901711273e-07
outbreak O 0 1.0577972631153898e-07
of O 0 8.24031010093762e-10
the O 0 3.0756226010453247e-07
disease O 0 0.0004794600827153772
. O 0 7.212006547518968e-09
. O 0 4.514805240773967e-08

Human O 0 0.0007665609009563923
MLH1 O 1 0.9994089603424072
deficiency O 1 0.9980301260948181
predisposes O 0 0.00019605080888140947
to O 0 1.0653247954905964e-06
hematological B-Disease 1 0.9990142583847046
malignancy I-Disease 1 0.9971197843551636
and O 0 1.8907600178863504e-06
neurofibromatosis B-Disease 1 0.9986171722412109
type I-Disease 0 0.0023894873447716236
1 I-Disease 0 1.6272286984531092e-06
. O 0 4.029161573271267e-07

Heterozygous O 0 0.003040256444364786
germ O 0 0.005840705707669258
- O 0 0.0002929773472715169
line O 0 4.653089490602724e-05
mutations O 0 2.868405999834067e-06
in O 0 4.378034379470819e-09
the O 0 4.57339233150833e-09
DNA O 0 8.433428888565686e-07
mismatch O 0 7.437437307089567e-05
repair O 0 0.00025879062013700604
genes O 0 1.0319169632566627e-05
lead O 0 1.778869773261249e-06
to O 0 8.098083981167292e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.465454250952462e-06

The O 0 2.9995371733093634e-06
disease O 0 0.0008423203835263848
susceptibility O 0 1.7415925412933575e-06
of O 0 6.885276793155981e-09
individuals O 0 1.0929606020226856e-07
who O 0 7.065592626531725e-07
constitutionally O 0 5.137485277373344e-05
lack O 0 4.926735996946263e-08
both O 0 1.0316605347782115e-08
wild O 0 5.936003688589153e-08
- O 0 9.19564536161488e-06
type O 0 0.00037620688090100884
alleles O 0 3.8343491723935585e-06
is O 0 3.684630911493514e-08
unknown O 0 3.6700421901514346e-07
. O 0 8.332174417091665e-08

We O 0 9.47703665588051e-06
have O 0 1.2585323361236078e-07
identified O 0 2.1552877171870932e-07
three O 0 1.4582109741922977e-08
offspring O 0 4.0624362895869126e-07
in O 0 1.874727040274138e-09
a O 0 7.764691076772579e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.57130659520044e-06
who O 0 2.0260132771454664e-07
developed O 0 5.115201474836795e-06
hematological B-Disease 1 0.9998316764831543
malignancy I-Disease 1 0.8636832237243652
at O 0 1.166241005989832e-07
a O 0 1.2098336554799971e-08
very O 0 2.482890870680876e-08
early O 0 8.914752669397785e-08
age O 0 1.3403440561887692e-06
, O 0 3.1265015021375575e-09
and O 0 1.0356863811011863e-08
at O 0 1.941273950478717e-07
least O 0 2.8287747699806687e-09
two O 0 7.826435610702731e-10
of O 0 5.627640575767145e-10
them O 0 9.618573493241911e-09
displayed O 0 1.921489683809341e-06
signs O 0 1.192206241285021e-06
of O 0 2.7179789530151766e-09
neurofibromatosis B-Disease 0 0.44445231556892395
type I-Disease 0 7.596232171636075e-05
1 I-Disease 0 2.0963628344361496e-07
( O 0 7.176442551326545e-08
NF1 B-Disease 0 2.0551819034153596e-05
) O 0 4.056690272591368e-08
. O 0 7.59098952585191e-08

DNA O 0 1.591424734215252e-05
sequence O 0 7.262981966960069e-07
analysis O 0 1.4714323981479538e-07
and O 0 3.893238087471218e-08
allele O 0 2.368198465774185e-06
- O 0 5.201566750656639e-07
specific O 0 3.7892942117423445e-08
amplification O 0 5.879101649952645e-07
in O 0 3.3019540435219596e-09
two O 0 5.4375711044940545e-08
siblings O 0 3.3824202546384186e-05
revealed O 0 5.815075496684585e-07
a O 0 9.532480760299222e-08
homozygous O 0 0.000325749977491796
MLH1 O 0 0.000349081470631063
mutation O 0 3.669632860692218e-06
( O 0 4.9857046491297297e-08
C676T O 0 2.1331368316168664e-06
- O 0 7.498939521610737e-05
- O 0 0.00018447067122906446
> O 0 8.714639989193529e-06
Arg226Stop O 0 3.584402656997554e-05
) O 0 1.509255582732294e-07
. O 0 9.713801318866899e-08

Thus O 0 1.2628654076252133e-05
, O 0 7.674055524375945e-08
a O 0 1.26160145441645e-07
homozygous O 0 0.00014370026474352926
germ O 0 0.0005870079039596021
- O 0 0.0001547394786030054
line O 0 0.00023674177646171302
MLH1 O 0 0.006568945944309235
mutation O 0 5.972679900878575e-06
and O 0 4.9086796849451275e-08
consequent O 0 4.568227814161219e-05
mismatch O 1 0.999697208404541
repair O 1 0.9999998807907104
deficiency O 1 0.9999997615814209
results O 0 3.2341049518436193e-06
in O 0 6.550607611899295e-09
a O 0 6.123824647374931e-08
mutator O 0 0.0008690104587003589
phenotype O 0 2.441862307023257e-05
characterized O 0 2.611589309253759e-07
by O 0 1.9671126949560858e-08
leukemia B-Disease 0 0.17584043741226196
and O 0 7.614102059960715e-07
/ O 1 0.9998195767402649
or O 1 0.9999995231628418
lymphoma B-Disease 1 1.0
associated O 0 0.00014552983338944614
with O 0 3.1557496527057083e-07
neurofibromatosis B-Disease 1 0.9999595880508423
type I-Disease 0 0.0073521193116903305
1 I-Disease 0 1.5428068422806973e-07
. O 0 1.279238759366308e-08
. O 0 7.00949200904688e-08

Missense O 0 0.003714307677000761
mutations O 0 0.000415897200582549
in O 0 3.04011216201161e-08
the O 0 3.4777010160524924e-09
most O 0 9.279508828008431e-10
ancient O 0 1.7313207534286335e-09
residues O 0 9.130391021017203e-08
of O 0 5.639374522914409e-10
the O 0 1.187800879876022e-08
PAX6 O 0 3.538259625202045e-05
paired O 0 1.2325850775596336e-06
domain O 0 1.4665319270079635e-07
underlie O 0 2.71509520644031e-07
a O 0 7.523786038632352e-09
spectrum O 0 1.815725596543416e-07
of O 0 1.551991068993175e-08
human O 0 1.5710345905972645e-05
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999920129776001
malformations I-Disease 1 0.8898999691009521
. O 0 6.362428166539758e-07

Mutations O 0 0.0001451014104532078
of O 0 4.119898022736379e-08
the O 0 6.350909842467445e-08
human O 0 2.0249548526862782e-07
PAX6 O 0 0.0005432156613096595
gene O 0 0.00031698914244771004
underlie O 0 0.10188205540180206
aniridia B-Disease 1 1.0
( O 0 0.002077180426567793
congenital B-Disease 1 0.9999997615814209
absence I-Disease 0 2.4589999156887643e-06
of I-Disease 0 3.0927655991774827e-09
the I-Disease 0 4.0051787664197036e-08
iris I-Disease 0 1.7236616258742288e-05
) O 0 3.82905529505706e-09
, O 0 6.432670507372507e-10
a O 0 5.735115493621379e-09
rare O 0 1.4062482023291523e-07
dominant O 1 0.6123979091644287
malformation B-Disease 0 0.23539423942565918
of I-Disease 0 8.597876188787268e-09
the I-Disease 0 2.5366404088345007e-07
eye I-Disease 1 0.7153146862983704
. O 0 1.0800372365338262e-06

The O 0 4.4478250060819846e-07
spectrum O 0 9.748450793267693e-07
of O 0 3.3139436084184126e-08
PAX6 O 0 0.00025905348593369126
mutations O 0 0.00013591018796432763
in O 0 1.996132823478547e-07
aniridia B-Disease 1 1.0
patients O 0 0.001771197305060923
is O 0 3.796091885277519e-09
highly O 0 1.8710768046048543e-08
biased O 0 2.799027470246074e-06
, O 0 5.443399508919811e-09
with O 0 1.7047425693306195e-09
92 O 0 4.944377351989715e-08
% O 0 2.7552677916986568e-09
of O 0 4.248509044568749e-10
all O 0 1.0997689869896021e-08
reported O 0 4.49541147418131e-07
mutations O 0 2.2240506041271146e-06
leading O 0 2.657884294876567e-07
to O 0 5.1386628285854385e-08
premature O 0 1.3247372407931834e-06
truncation O 0 5.118185413266474e-07
of O 0 9.103954923261881e-09
the O 0 1.615839018143106e-08
protein O 0 2.0577554948886245e-07
( O 0 2.6506569383855094e-08
nonsense O 0 7.221768782983418e-07
, O 0 2.5140842740967173e-09
splicing O 0 1.8115935063178767e-07
, O 0 6.3337055600243275e-09
insertions O 0 2.793587441374257e-07
and O 0 1.9283955765558858e-08
deletions O 0 4.6595778258051723e-07
) O 0 8.160389697309256e-09
and O 0 3.485977373429705e-08
just O 0 1.6199747676637344e-07
2 O 0 1.017818629378553e-08
% O 0 5.199351615914338e-09
leading O 0 1.616652944846919e-08
to O 0 1.5322627611169537e-09
substitution O 0 6.609607083873925e-09
of O 0 2.606248106218345e-09
one O 0 5.541666325825645e-08
amino O 0 4.274393461400905e-07
acid O 0 9.466798900348294e-08
by O 0 1.46793543986945e-09
another O 0 1.6519944523452068e-08
( O 0 1.2104407254298621e-08
missense O 0 1.8126646637028898e-06
) O 0 5.099033018041155e-08
. O 0 8.013035568410487e-08

The O 0 2.6011201725850697e-07
extraordinary O 0 9.835581238348823e-08
conservation O 0 9.435844106064906e-09
of O 0 1.1549636802499208e-09
the O 0 8.375478977029616e-09
PAX6 O 0 7.309605280170217e-06
protein O 0 1.4936223635686474e-07
at O 0 7.84903164685602e-08
the O 0 1.193742349414606e-08
amino O 0 3.280055409504712e-07
acid O 0 1.2968203577656823e-07
level O 0 3.862911057694873e-08
amongst O 0 3.0986008425770706e-08
vertebrates O 0 7.734037410500605e-08
predicts O 0 1.7238919269857433e-07
that O 0 3.3039322389072368e-09
pathological O 0 1.0540326229602215e-06
missense O 0 8.296324813272804e-05
mutations O 0 0.00010455764277139679
should O 0 7.423464865041751e-08
in O 0 1.6629636556686478e-09
fact O 0 6.536678753832348e-09
be O 0 4.2721497450770585e-09
common O 0 9.958465163606434e-09
even O 0 4.354966876007893e-08
though O 0 1.5801914443613896e-08
they O 0 2.315527325436051e-08
are O 0 4.718621493537967e-09
hardly O 0 1.5119077545477921e-07
ever O 0 2.69156231524903e-07
seen O 0 6.702756536469678e-07
in O 0 6.728656387622323e-08
aniridia B-Disease 1 1.0
patients O 0 3.0401055482798256e-05
. O 0 1.270867215907856e-07

This O 0 3.705874576098722e-07
indicates O 0 3.8479984709738346e-07
that O 0 1.7228679594083474e-09
there O 0 2.8489011150156784e-09
is O 0 1.0954431806098341e-09
a O 0 5.863018515128715e-09
heavy O 0 5.6178803788498044e-05
ascertainment O 0 0.000448116275947541
bias O 0 3.440956334088696e-06
in O 0 7.713376048990028e-10
the O 0 3.0159616470903927e-10
selection O 0 1.110649905378125e-09
of O 0 5.299117256107877e-10
patients O 0 5.2714806741960274e-08
for O 0 2.170361890208028e-09
PAX6 O 0 1.64960692927707e-05
mutation O 0 3.7808263186889235e-07
analysis O 0 2.407942112370165e-08
and O 0 1.4486772670352366e-08
that O 0 2.648659069848236e-09
the O 0 2.5751390353434545e-08
missing O 0 3.323817509226501e-06
PAX6 O 0 0.0002303570945514366
missense O 0 0.00021300672960933298
mutations O 0 0.0001601099647814408
frequently O 0 1.0157115866604727e-05
may O 0 1.5147320482356008e-06
underlie O 0 1.5291829186026007e-05
phenotypes O 0 1.6068413970060647e-05
distinct O 0 4.469804650852893e-07
from O 0 1.14502846315645e-07
textbook O 0 0.00043759337859228253
aniridia B-Disease 1 1.0
. O 0 1.3152518931747181e-06

Here O 0 2.581719854788389e-06
we O 0 1.8541031465701963e-07
present O 0 2.126793674506189e-08
four O 0 1.836728813486843e-08
novel O 0 2.0342201878520427e-07
PAX6 O 0 5.153162419446744e-05
missense O 0 5.476102160173468e-05
mutations O 0 6.34188691037707e-05
, O 0 9.036036807685832e-09
two O 0 5.2532000971439174e-09
in O 0 2.590992087547761e-09
association O 0 3.641571666435084e-08
with O 0 1.0924016358160316e-08
atypical O 0 1.5449504644493572e-05
phenotypes O 0 0.0002730341220740229
ectopia B-Disease 0 7.650777843082324e-05
pupillae I-Disease 0 2.782091723929625e-05
( O 0 3.7297638755262597e-08
displaced B-Disease 0 1.73500836808671e-07
pupils I-Disease 0 2.6325922135583824e-06
) O 0 6.306873245875977e-08
and O 0 2.6302157039026497e-06
congenital B-Disease 1 0.9999997615814209
nystagmus I-Disease 0 0.3686562776565552
( O 0 6.282237308141703e-08
searching B-Disease 0 4.481833286718029e-07
gaze I-Disease 0 7.561109669040889e-05
) O 0 1.0693679719508964e-08
, O 0 1.4270169490515627e-09
and O 0 5.447803541613894e-09
two O 0 8.421131347802202e-09
in O 0 2.839098955931263e-09
association O 0 1.2280141348242068e-08
with O 0 1.241875269286652e-09
more O 0 1.227388857216738e-08
recognizable O 0 0.0007174073252826929
aniridia B-Disease 1 0.9999997615814209
phenotypes O 0 9.35668358579278e-05
. O 0 2.43577858327626e-07

Strikingly O 0 0.0004161524120718241
, O 0 1.8536577783834218e-07
all O 0 6.878188685277564e-09
four O 0 2.1854337006743663e-08
mutations O 0 7.749067663098685e-07
are O 0 2.8528106543745935e-09
located O 0 1.505966729098418e-08
within O 0 1.1765091123550064e-08
the O 0 6.4562248880406514e-09
PAX6 O 0 9.038606549438555e-06
paired O 0 6.545539008584456e-07
domain O 0 8.805969997638385e-08
and O 0 3.758758637673054e-08
affect O 0 2.532480607442267e-07
amino O 0 1.6546093206670776e-07
acids O 0 1.1215177231349571e-08
which O 0 5.906903854935308e-10
are O 0 8.178897559218967e-10
highly O 0 1.750409817091736e-09
conserved O 0 2.2303647817523142e-09
in O 0 5.799861702016074e-10
all O 0 6.849906752925961e-10
known O 0 1.4581136298374986e-08
paired O 0 1.563026330586581e-07
domain O 0 1.4509926415939844e-07
proteins O 0 2.394116904724797e-07
. O 0 8.997053413395406e-08

Our O 0 1.8860468117054552e-05
results O 0 5.113906240694632e-07
support O 0 5.0999666711959435e-08
the O 0 6.177481637337223e-09
hypothesis O 0 3.460935005250576e-08
that O 0 7.68509256232619e-10
the O 0 1.3489147576706273e-09
under O 0 3.2860583143445865e-09
- O 0 3.508517210093487e-08
representation O 0 1.8781134869527705e-08
of O 0 2.037754409656145e-09
missense O 0 8.632305252831429e-05
mutations O 0 9.0041057774215e-06
is O 0 2.8641948812691e-09
caused O 0 2.425550604812088e-08
by O 0 1.7783172712171336e-09
ascertainment O 0 3.1537538234260865e-06
bias O 0 1.2682643273365102e-06
and O 0 5.095338906357938e-08
suggest O 0 1.1862810112006628e-07
that O 0 1.551362815988e-09
a O 0 5.675093284196464e-09
substantial O 0 3.788600366760875e-08
burden O 0 8.653980785311433e-07
of O 0 4.585288593261794e-09
PAX6 B-Disease 0 0.008316018618643284
- I-Disease 0 0.02912513166666031
related I-Disease 0 3.1743104045744985e-05
disease I-Disease 0 0.2929301857948303
remains O 0 5.2144201845294447e-08
to O 0 5.035973860145759e-09
be O 0 2.2644869090981956e-08
uncovered O 0 1.3450496680889046e-06
. O 0 2.3732072307325325e-08
. O 0 1.0141912554217924e-07

The O 0 8.575079846195877e-07
chromosomal O 0 3.446884875302203e-05
order O 0 1.0844985354196979e-07
of O 0 7.1730323902841064e-09
genes O 0 6.535696570608707e-07
controlling O 0 2.565814611443784e-06
the O 0 7.166851556661413e-09
major O 0 2.648999242182981e-08
histocompatibility O 0 4.944150759911281e-07
complex O 0 2.1024165519634153e-08
, O 0 2.1771073832610455e-09
properdin O 0 3.6861001717625186e-07
factor O 0 5.8835215810404407e-08
B O 0 7.97273332864279e-06
, O 0 4.9563473325520135e-09
and O 0 2.9796689204886206e-07
deficiency B-Disease 0 5.158429303264711e-06
of I-Disease 0 3.730742104135487e-10
the I-Disease 0 3.270389292708842e-09
second I-Disease 0 1.3214902594427258e-07
component I-Disease 0 8.711747767620182e-08
of I-Disease 0 3.0566462694281427e-09
complement I-Disease 0 7.478648171854729e-07
. O 0 1.501881001786387e-07

The O 0 2.8871843937849917e-07
relationship O 0 1.354435568146073e-07
of O 0 1.305942465279486e-09
the O 0 4.351842441963072e-09
genes O 0 8.34214475275985e-08
coding O 0 2.600232278382464e-07
for O 0 3.968796846720579e-09
HLA O 0 2.7846553507515637e-07
to O 0 6.735163537996414e-09
those O 0 1.1412777389807616e-08
coding O 0 2.229781728146918e-07
for O 0 5.141983727696697e-09
properdin O 0 4.155802798777586e-06
Factor O 0 1.4143907378638687e-07
B O 0 2.9663760869880207e-06
allotypes O 0 4.821970946977672e-07
and O 0 2.6809916064962636e-08
for O 0 1.4600979980627926e-08
deficiency B-Disease 0 1.3627835869556293e-05
of I-Disease 0 3.357727151875878e-10
the I-Disease 0 2.9909748011647252e-09
second I-Disease 0 7.969260451545779e-08
component I-Disease 0 6.654071427192321e-08
of I-Disease 0 1.5270985587179098e-09
complement I-Disease 0 1.3625016492824216e-07
( O 0 1.748025191261604e-08
C2 O 0 3.617993206717074e-05
) O 0 4.675136722198658e-09
was O 0 5.824941862186961e-09
studied O 0 7.59321583387873e-09
in O 0 5.945198222612191e-10
families O 0 3.6259337754529497e-09
of O 0 1.524060655455628e-09
patients O 0 2.948875135189155e-07
with O 0 8.700041576048534e-08
connective O 1 0.9999585151672363
tissue O 1 0.9999842643737793
disorders O 1 0.9999749660491943
. O 0 4.385031786569016e-07

Patients O 1 0.9997264742851257
were O 0 5.229051112110028e-07
selected O 0 3.156594985398442e-08
because O 0 5.551481052634699e-09
they O 0 7.30615612454244e-09
were O 0 3.4952851279967945e-08
heterozygous O 0 1.0392055855845683e-06
or O 0 1.5657192875551118e-07
homozygous O 0 9.129101817961782e-05
for O 0 4.050987172377063e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 4.08871869694849e-07

12 O 0 1.710566721158102e-05
families O 0 3.7905883232269844e-07
with O 0 2.0986107074350002e-08
15 O 0 5.564013605408036e-08
matings O 0 3.816479875240475e-06
informative O 0 5.7379278587177396e-05
for O 0 0.006842238362878561
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 4.726050519821001e-06
found O 0 3.1742644068799564e-07
. O 0 8.437051235432591e-08

Of O 0 5.049201377005375e-07
57 O 0 3.031929281860357e-06
informative O 0 2.2448271010944154e-06
meioses O 0 3.36879093083553e-05
, O 0 9.674985257390745e-09
two O 0 3.2828511020710494e-09
crossovers O 0 3.6795256619370775e-07
were O 0 2.467587876253674e-07
noted O 0 9.51153733552701e-09
between O 0 6.946191177803485e-09
the O 0 4.875374088442186e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 9.478976892296487e-08
and O 0 4.5312980034850625e-09
the O 0 5.850350870417742e-09
HLA O 0 1.0351629953220254e-06
- O 0 1.9047727619181387e-05
B O 0 4.295477265259251e-05
gene O 0 1.6010405090582935e-07
, O 0 1.2765811741033417e-09
with O 0 3.349833466170793e-10
a O 0 1.5137241460294604e-09
recombinant O 0 1.4532353098672957e-08
fraction O 0 1.6682699666148437e-08
of O 0 4.283573051822032e-09
0 O 0 6.049156127119204e-07
. O 0 1.9565256081932603e-07

035 O 0 0.0523756705224514
. O 0 0.0001391973637510091

A O 0 1.7258775187656283e-05
lod O 0 0.0002815746411215514
score O 0 6.195057267177617e-06
of O 0 4.184264046358521e-09
13 O 0 4.538193820735614e-08
was O 0 3.832908035406035e-08
calculated O 0 6.55762306678298e-08
for O 0 4.910447160000331e-09
linkage O 0 0.00014977355021983385
between O 0 0.006005519535392523
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.769458831153315e-07
HLA O 0 4.840183464693837e-06
- O 0 4.535018524620682e-05
B O 0 5.887775478186086e-05
at O 0 2.1118493620519985e-08
a O 0 2.14488404814972e-09
maximum O 0 9.030023839784462e-09
likelihood O 0 9.705797054948562e-09
value O 0 7.353588293845803e-10
of O 0 9.753480662011427e-11
the O 0 5.896772514724091e-10
recombinant O 0 7.558103476412725e-09
fraction O 0 1.3586941349785775e-08
of O 0 4.706110168228861e-09
0 O 0 5.231345880929439e-07
. O 0 2.8743542657139187e-07

04 O 0 0.017545629292726517
. O 0 2.726773891481571e-05

18 O 0 5.368838901631534e-05
families O 0 9.72162979451241e-07
with O 0 1.9330135714312746e-08
21 O 0 2.85795334065142e-08
informative O 0 5.76925067719003e-08
matings O 0 1.776120143404114e-06
for O 0 1.0138891504141156e-08
both O 0 8.177470078862825e-08
properdin O 0 1.1044829989259597e-05
Factor O 0 2.9717202210122196e-07
B O 0 2.0377067357912892e-06
allotype O 0 8.465282235192717e-07
and O 0 4.0631096709375925e-08
HLA O 0 4.4496423470263835e-06
- O 0 0.0005914901266805828
B O 0 0.0017892842879518867
were O 0 2.3588390263284964e-07
found O 0 1.0142397144363713e-07
. O 0 6.546462572032397e-08

Of O 0 1.0157482392969541e-06
72 O 0 4.328936029196484e-06
informative O 0 2.4838132048898842e-06
meioses O 0 3.566505984053947e-05
, O 0 3.2260814464279974e-08
three O 0 2.8149814923494887e-08
recombinants O 0 7.448323231074028e-06
were O 0 5.46355522601516e-07
found O 0 1.650734660074704e-08
, O 0 6.451864043022226e-10
giving O 0 7.880074370802959e-10
a O 0 6.978696509563065e-10
recombinant O 0 1.3407789545283322e-08
fraction O 0 1.3193275805178928e-08
of O 0 5.880040898631478e-09
0 O 0 8.266306394943967e-07
. O 0 1.5438519085364533e-07

042 O 0 0.0029781213961541653
. O 0 2.280317130498588e-05

A O 0 2.948142537206877e-05
lod O 0 0.0004566344141494483
score O 0 6.464091711677611e-06
of O 0 4.506027995176964e-09
16 O 0 4.074572501622242e-08
between O 0 2.9524001021741242e-08
HLA O 0 4.6862323870300315e-06
- O 0 1.6788644643384032e-05
B O 0 2.477577254467178e-05
and O 0 2.784962838120464e-08
Factor O 0 1.2261726567430742e-07
B O 0 1.7969640566661838e-06
allotypes O 0 3.8564479609703994e-07
was O 0 8.461821465743924e-08
calculated O 0 4.296749622767493e-08
at O 0 1.063199572826079e-08
a O 0 1.399816373925944e-09
maximum O 0 6.988903678006864e-09
likelihood O 0 9.99073179741572e-09
value O 0 7.932008938560386e-10
of O 0 1.1722027515315148e-10
the O 0 1.0250421622615136e-09
recombinant O 0 7.29244264974227e-09
fraction O 0 2.0237495235164715e-08
of O 0 4.494165928292659e-09
0 O 0 8.797071018307179e-07
. O 0 2.4558050881751115e-07

04 O 0 0.023266088217496872
. O 0 6.075623969081789e-05

A O 0 9.974568229154102e-07
crossover O 0 6.271989150263835e-07
was O 0 3.034446649508027e-07
shown O 0 1.6901966048976647e-08
to O 0 4.5257269043474935e-09
have O 0 1.0796500582443969e-08
occurred O 0 2.121725017900644e-08
between O 0 2.2982429292994766e-09
genes O 0 2.4804814202639136e-08
for O 0 1.3057431802465658e-09
Factor O 0 3.4723605324415985e-08
B O 0 1.1508112720548525e-06
and O 0 1.5695757582534497e-08
HLA O 0 8.461504421575228e-07
- O 0 2.582922206784133e-05
D O 0 4.887810064246878e-05
, O 0 3.457963915209916e-09
in O 0 7.631805187813256e-10
which O 0 8.05019606531232e-09
HLA O 0 9.326055874225858e-07
- O 0 7.343912329815794e-06
D O 0 2.884638888644986e-05
segregared O 0 9.805112313188147e-07
with O 0 1.5613020210025752e-08
HLA O 0 1.65224253123597e-06
- O 0 2.2026767965144245e-06
A O 0 2.1684331841242965e-07
and O 0 2.5095488354054396e-07
B O 0 1.7012171156238765e-05
. O 0 1.4660523106613255e-07

These O 0 3.233955112591502e-07
studies O 0 1.777067808461652e-07
suggest O 0 1.14800911887869e-07
that O 0 1.2411008887269759e-09
the O 0 1.1052779802511736e-09
genes O 0 3.8994357964838855e-08
for O 0 2.9209867857815652e-09
Factor O 0 3.7212515735518537e-07
B O 0 0.12157709151506424
and O 0 0.010240285657346249
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.079751730363569e-09
located O 0 7.031261795020782e-09
outside O 0 8.503333148723868e-09
those O 0 2.045437152986551e-09
for O 0 9.24742227237374e-10
HLA O 0 1.2574142260746157e-07
, O 0 1.4723827712614934e-09
that O 0 2.6921237461507985e-10
the O 0 4.712431000974959e-10
order O 0 1.2157919115907134e-09
of O 0 5.716982998116293e-10
genese O 0 9.866561185845057e-07
is O 0 5.465872199295063e-09
HLA O 0 2.648199028953968e-07
- O 0 9.479914524490596e-07
A O 0 2.051739613762038e-07
, O 0 1.0005377859556575e-08
- O 0 8.690345225659257e-07
B O 0 6.007778665662045e-06
, O 0 4.20052881366928e-09
- O 0 4.512855582561315e-07
D O 0 1.6995785472317948e-06
, O 0 4.757118254872239e-09
Factor O 0 4.2307636505256596e-08
B O 0 4.097085820831126e-06
allotype O 0 1.206104479933856e-05
, O 0 3.269853550591506e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.3245816665730104e-09
that O 0 1.1791677356765007e-10
the O 0 5.376604717000077e-10
genes O 0 3.543772209013696e-08
coding O 0 1.284832023884519e-06
for O 0 1.6420586916865432e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.505237889887212e-07
Factor O 0 1.9864097566824057e-07
B O 0 4.083694420842221e-06
allotypes O 0 3.859104253933765e-07
are O 0 4.282527221732835e-09
approximately O 0 5.858278750991985e-09
3 O 0 2.0622241692080934e-08
- O 0 1.6837858538565342e-06
- O 0 3.0397231967072003e-06
5 O 0 2.537169407901274e-08
centimorgans O 0 2.2064241989028233e-07
from O 0 2.8325812806428985e-09
the O 0 4.212917126267257e-09
HLA O 0 3.080851058712142e-07
- O 0 2.1641257319515717e-07
A O 0 4.031267408777239e-08
and O 0 4.281043075593516e-08
HLA O 0 1.2306564940445242e-06
- O 0 7.756854756735265e-06
B O 0 1.7369234228681307e-06
loci O 0 2.1175566189413075e-08
, O 0 7.250304245864925e-10
and O 0 3.8366052002025697e-10
that O 0 2.009534899594101e-10
the O 0 9.546683443772963e-10
apparent O 0 7.130747547989813e-08
lack O 0 1.5170835254707526e-08
of O 0 9.20494236389402e-10
recombinants O 0 2.739612057212071e-07
between O 0 2.2793404941268136e-09
the O 0 4.032349565363802e-09
Factor O 0 6.670565966260256e-08
B O 0 3.5339655823918292e-06
gene O 0 1.1071247172367293e-06
and O 0 0.00029695339617319405
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.334413241238508e-06
suggests O 0 4.562321009871084e-08
that O 0 1.1188869830647263e-09
these O 0 1.159139007000931e-09
two O 0 9.063481520854566e-09
genes O 0 5.664940658789419e-07
lie O 0 8.050664291658904e-06
in O 0 4.0381147314860755e-09
close O 0 3.5443338219920406e-07
proximity O 0 1.7414168951290776e-07
to O 0 2.2128233467810787e-08
one O 0 3.428334238719799e-08
another O 0 7.558323744660811e-08
. O 0 7.810828606125142e-08

Distribution O 0 2.6952557163895108e-06
of O 0 7.798502821287912e-08
emerin O 0 1.3712861800740939e-05
and O 0 2.3712667029940349e-07
lamins O 0 8.090997289400548e-05
in O 0 1.4511745582979074e-08
the O 0 1.8595567752299758e-08
heart O 0 8.359321554962662e-07
and O 0 4.000947129156884e-09
implications O 0 2.2977138414148612e-08
for O 0 4.567673794753091e-09
Emery B-Disease 0 0.0011289799585938454
- I-Disease 1 0.7834903001785278
Dreifuss I-Disease 1 0.9999700784683228
muscular I-Disease 1 0.9994590878486633
dystrophy I-Disease 1 0.9945212602615356
. O 0 1.6295379055009107e-06

Emerin O 0 0.000853924488183111
is O 0 2.432134351693094e-07
a O 0 4.269024245218134e-08
nuclear O 0 4.915426075058349e-07
membrane O 0 1.274859755540092e-07
protein O 0 6.556797416124027e-08
which O 0 6.240959748993191e-09
is O 0 5.607157849141231e-09
missing O 0 2.896030935062299e-07
or O 0 1.782436385155961e-07
defective O 0 2.903258973674383e-05
in O 0 3.763177502946746e-08
Emery B-Disease 0 0.007195177488029003
- I-Disease 1 0.9950504899024963
Dreifuss I-Disease 1 0.9999946355819702
muscular I-Disease 1 0.9999963045120239
dystrophy I-Disease 1 0.9999943971633911
( O 0 8.926507689466234e-06
EDMD B-Disease 1 0.9999998807907104
) O 0 8.085744411800988e-07
. O 0 2.3917300495668314e-07

It O 0 3.62029709322087e-07
is O 0 8.453219457749128e-09
one O 0 2.375243779439984e-09
member O 0 2.4838560097606432e-09
of O 0 3.907756063181722e-10
a O 0 7.208940111524953e-09
family O 0 1.9207456958270086e-08
of O 0 1.4717959073706766e-09
lamina O 0 5.075482022220967e-06
- O 0 9.691021841717884e-05
associated O 0 2.239982421770037e-07
proteins O 0 1.643665648032311e-08
which O 0 2.018648137536161e-09
includes O 0 6.224815329858302e-09
LAP1 O 0 4.485126737563405e-06
, O 0 8.813763940906938e-09
LAP2 O 0 2.075027623504866e-06
and O 0 5.706225536528109e-08
lamin O 0 0.0002064781729131937
B O 0 0.028497090563178062
receptor O 0 4.495832854445325e-06
( O 0 3.6502717648545513e-07
LBR O 0 0.00019226837321184576
) O 0 1.3709477286738547e-07
. O 0 1.4781103629957215e-07

A O 0 2.2234908101381734e-06
panel O 0 3.699327919548523e-07
of O 0 1.4618618315864751e-08
16 O 0 2.3815741201360652e-07
monoclonal O 0 1.4299118902272312e-06
antibodies O 0 3.0815699574304745e-06
( O 0 1.9285796071244476e-08
mAbs O 0 6.481051286755246e-07
) O 0 3.811749138549203e-09
has O 0 2.1264963123712732e-09
been O 0 4.36262981295954e-09
mapped O 0 6.280644271328129e-08
to O 0 4.57466597936218e-09
six O 0 9.570753078946836e-09
specific O 0 5.585255369311426e-09
sites O 0 4.0636134457372464e-08
throughout O 0 1.307393659999434e-08
the O 0 5.112430478959595e-09
emerin O 0 4.750175435219717e-07
molecule O 0 2.8736302226661792e-08
using O 0 4.944745413126839e-08
phage O 0 4.074083506111492e-07
- O 0 4.89852254759171e-07
displayed O 0 9.288442015531473e-08
peptide O 0 1.2640313684642024e-08
libraries O 0 2.4610313786865845e-09
and O 0 2.8619560055176407e-09
has O 0 1.2631243828664651e-09
been O 0 1.2903217383453125e-09
used O 0 5.53625456589657e-09
to O 0 6.403502617047252e-09
localize O 0 1.7636819393374026e-05
emerin O 0 8.282804628834128e-06
in O 0 1.2631178769595408e-08
human O 0 4.756032012664946e-08
and O 0 1.577519412876427e-07
rabbit O 0 0.00038329485687427223
heart O 0 0.0001142735272878781
. O 0 3.49850751035774e-07

Several O 0 1.7669666476649581e-06
mAbs O 0 6.659759674221277e-05
against O 0 2.4967346234916477e-07
different O 0 1.0897258562181378e-07
emerin O 0 8.844836884236429e-06
epitopes O 0 5.862937541678548e-06
did O 0 3.865727364882332e-07
not O 0 1.4182965024645e-08
recognize O 0 5.003872161069012e-08
intercalated O 0 1.3316008562469506e-07
discs O 0 8.850034646457061e-06
in O 0 1.74942940134315e-08
the O 0 8.407894114270675e-08
heart O 0 2.493998408681364e-06
, O 0 3.4529876735689413e-09
though O 0 4.293928768106525e-09
they O 0 6.143148212345295e-09
recognized O 0 1.047075581794843e-08
cardiomyocyte O 0 4.948377636537771e-07
nuclei O 0 8.36609430621138e-08
strongly O 0 5.8710558192842655e-08
, O 0 2.672780219370452e-09
both O 0 6.842049149469176e-09
at O 0 2.521202588923188e-07
the O 0 7.623661701927631e-09
rim O 0 1.5818565657355066e-07
and O 0 2.4792374375692816e-08
in O 0 2.6916577855473633e-09
intranuclear O 0 2.56178554991493e-06
spots O 0 3.2381940400227904e-06
or O 0 1.9090404634880542e-07
channels O 0 2.456789388816105e-06
. O 0 3.4954126704178634e-07

A O 0 2.778999987640418e-05
polyclonal O 0 0.00029387196991592646
rabbit O 0 6.292160105658695e-05
antiserum O 0 8.762039942666888e-05
against O 0 8.878860739969241e-07
emerin O 0 1.804774183256086e-05
did O 0 3.19193162567899e-07
recognize O 0 4.692372002068623e-08
both O 0 1.2072518984496128e-08
nuclear O 0 1.1929910215258133e-06
membrane O 0 1.2760906997755228e-07
and O 0 1.7173864108599446e-08
intercalated O 0 2.028412495747034e-07
discs O 0 7.8189441410359e-06
but O 0 4.6072955228737555e-08
, O 0 1.2243229763342356e-09
after O 0 9.16816345064575e-10
affinity O 0 1.2921621994621546e-08
purification O 0 2.300928514387124e-08
against O 0 1.7778228666998075e-08
a O 0 6.3239760095257225e-09
pure O 0 1.2122201553665946e-07
- O 0 1.2821725249523297e-05
emerin O 0 9.349554602522403e-06
band O 0 1.6134836755554716e-07
on O 0 4.111810003593064e-09
a O 0 3.888442012822679e-09
western O 0 2.4156795674912246e-08
blot O 0 0.0007011903799138963
, O 0 1.62193423136614e-08
it O 0 5.7519424778718076e-09
stained O 0 9.193592268275097e-05
only O 0 1.22673116109695e-08
the O 0 1.0068322175982303e-08
nuclear O 0 1.335154024673102e-06
membrane O 0 4.992513140678057e-07
. O 0 1.270674516717918e-07

These O 0 1.9425476693868404e-06
results O 0 7.021554324637691e-07
would O 0 5.976833961085504e-08
not O 0 1.217913858653219e-08
be O 0 5.410256243010281e-09
expected O 0 6.492283155523637e-09
if O 0 5.983333384307343e-09
immunostaining O 0 6.899463755871693e-07
at O 0 3.453661534535968e-08
intercalated O 0 1.5284986432106962e-07
discs O 0 1.9436189177213237e-05
were O 0 4.423034624778666e-06
due O 0 3.039978579977287e-08
to O 0 2.533173892871332e-09
a O 0 1.0870889077807533e-08
product O 0 2.60937316198806e-08
of O 0 2.864302406369035e-10
the O 0 2.6623701021577517e-09
emerin O 0 8.274185461232264e-07
gene O 0 7.394157108819854e-08
and O 0 1.8948737690038797e-08
, O 0 3.3607145955016904e-09
therefore O 0 9.936569789203986e-09
, O 0 4.795395192047636e-10
cast O 0 1.4721925012395332e-08
some O 0 1.018130801888617e-09
doubt O 0 1.064494181690634e-08
upon O 0 7.899924603371744e-10
the O 0 9.964236102888435e-10
hypothesis O 0 4.203801040603139e-08
that O 0 3.741384801969616e-08
cardiac B-Disease 0 0.011299324221909046
defects I-Disease 1 0.9949207901954651
in O 0 1.0022073837490098e-07
EDMD B-Disease 1 1.0
are O 0 1.0628639302012743e-06
caused O 0 5.204593662710977e-07
by O 0 1.6492357479691577e-09
absence O 0 3.3811556221508e-08
of O 0 2.5470303643970738e-09
emerin O 0 7.245828783197794e-06
from O 0 4.0991345429119974e-08
intercalated O 0 6.917410701134941e-06
discs O 0 6.481946184067056e-05
. O 0 6.558598215633538e-07

Although O 0 8.582201189710759e-06
emerin O 0 2.0993164071114734e-05
was O 0 2.2011425926393713e-07
abundant O 0 1.8425394543442053e-08
in O 0 1.532245330615467e-09
the O 0 2.1233554914346087e-09
membranes O 0 1.103174554373254e-06
of O 0 1.887823897206431e-09
cardiomyocyte O 0 1.8992612922374974e-06
nuclei O 0 1.6631635446628934e-07
, O 0 5.840428141112852e-09
it O 0 3.841337470333883e-09
was O 0 1.1994761450750957e-07
absent O 0 2.4934360354222918e-08
from O 0 8.316717869938373e-10
many O 0 1.2756125045143563e-09
non O 0 6.744382972101448e-07
- O 0 1.0198919881077018e-05
myocyte O 0 3.7291716580512e-05
cells O 0 2.963187739624118e-07
in O 0 6.451436718180048e-09
the O 0 3.033074946756642e-08
heart O 0 2.624490434754989e-06
. O 0 1.014578288049961e-07

This O 0 2.5945743686861533e-07
distribution O 0 1.1183630732602978e-07
of O 0 6.350737713489707e-09
emerin O 0 5.079006768937688e-06
was O 0 3.3488849027207834e-08
similar O 0 1.0613916412438584e-09
to O 0 1.1270647748418128e-09
that O 0 6.211386960330856e-10
of O 0 6.6829636269361e-10
lamin O 0 6.532177849294385e-06
A O 0 3.9052719102983247e-07
, O 0 3.0004883022627382e-09
a O 0 2.8851783184791202e-09
candidate O 0 2.8805004603782436e-08
gene O 0 6.769244009774411e-08
for O 0 1.450224829113722e-09
an O 0 6.067225832850909e-09
autosomal O 0 0.00023924483684822917
form O 0 9.114328349824063e-07
of O 0 2.5685739046821254e-07
EDMD B-Disease 1 1.0
. O 0 2.073269115498988e-06

In O 0 6.044998599463725e-07
contrast O 0 8.545331411369261e-07
, O 0 8.843775134437237e-08
lamin O 0 0.0003646021941676736
B1 O 1 0.8716740012168884
was O 0 2.5623132842156338e-06
absent O 0 3.328583773054561e-07
from O 0 1.2718523123567138e-08
cardiomyocyte O 0 1.912533434733632e-06
nuclei O 0 2.2835240542917745e-07
, O 0 1.0725771382169569e-08
showing O 0 6.29223848136462e-07
that O 0 1.1068987504359029e-08
lamin O 0 0.00021617313905153424
B1 O 0 0.16292856633663177
is O 0 8.10629607883584e-09
not O 0 3.959504280004467e-09
essential O 0 2.2455437509449894e-09
for O 0 5.602515673608366e-10
localization O 0 9.922501931214356e-08
of O 0 2.6417419363156114e-09
emerin O 0 1.981297145903227e-06
to O 0 2.245082519891639e-08
the O 0 3.690912109277633e-08
nuclear O 0 1.7158861737698317e-05
lamina O 0 8.328714102390222e-06
. O 0 2.2758906936815038e-07

Lamin O 1 0.6750493049621582
B1 O 1 0.9994062185287476
is O 0 5.684954089701932e-07
also O 0 7.184372208257628e-08
almost O 0 8.358948377917841e-08
completely O 0 1.3782682799501345e-06
absent O 0 2.935264262760029e-07
from O 0 3.887642918698475e-08
skeletal O 0 0.00020590604981407523
muscle O 0 4.3510564864845946e-05
nuclei O 0 8.070320291153621e-06
. O 0 2.4899244976950285e-07

In O 0 7.762360837659799e-06
EDMD B-Disease 1 0.9999998807907104
, O 0 2.882918792579403e-08
the O 0 1.194238152812943e-09
additional O 0 6.277827147016524e-09
absence O 0 4.913185236432582e-08
of O 0 5.4095132817622016e-09
lamin O 0 0.000537295825779438
B1 O 1 0.8576372861862183
from O 0 9.733887651464102e-08
heart O 0 1.1759820154111367e-05
and O 0 1.8973118187659566e-07
skeletal O 0 0.002112088492140174
muscle O 0 3.081518298131414e-05
nuclei O 0 7.87062447216158e-07
which O 0 4.0075629925695466e-08
already O 0 6.92899106979894e-07
lack O 0 2.0783397758350475e-07
emerin O 0 1.4033443221705966e-05
may O 0 1.0966483188212806e-07
offer O 0 3.359368561106635e-09
an O 0 1.5809382691855944e-09
alternative O 0 1.9757383284968455e-08
explanation O 0 5.015900139682117e-09
of O 0 6.048285206006199e-10
why O 0 1.645933700444857e-08
these O 0 2.5421527105606856e-09
tissues O 0 3.027884645234735e-07
are O 0 3.0537734563296226e-09
particularly O 0 4.4859469028324384e-08
affected O 0 1.9377169735435018e-07
. O 0 7.672252166912585e-09
. O 0 7.31516678342814e-08

Genetic O 0 6.649656279478222e-05
mapping O 0 8.51788354339078e-06
of O 0 8.228052195136115e-08
the O 0 1.6172178618489852e-07
copper B-Disease 0 3.6200053727952763e-05
toxicosis I-Disease 0 9.649506682762876e-05
locus O 0 2.6860031994146993e-06
in O 0 2.4371255236133038e-08
Bedlington O 0 1.6366371710319072e-05
terriers O 0 1.3823983863403555e-05
to O 0 3.9804888274375116e-08
dog O 0 0.0001304399047512561
chromosome O 0 0.0005694018327631056
10 O 0 9.048543603284998e-08
, O 0 1.8456793871024502e-09
in O 0 1.2507062052691253e-09
a O 0 1.257015735944833e-08
region O 0 8.618206237542836e-08
syntenic O 0 6.624813522648765e-06
to O 0 1.1345689721053986e-08
human O 0 3.8656970957617887e-08
chromosome O 0 1.4729960639670026e-05
region O 0 3.5708859513761126e-07
2p13 O 0 9.730388228490483e-06
- O 0 1.55648394866148e-05
p16 O 0 1.49027227962506e-05
. O 0 3.4585403341225174e-07

Abnormal O 1 0.9999648332595825
hepatic B-Disease 1 0.9999617338180542
copper I-Disease 0 0.0033482378348708153
accumulation I-Disease 0 3.1446959383174544e-06
is O 0 9.47427380992849e-09
recognized O 0 1.0473872436023157e-08
as O 0 6.462594459577531e-09
an O 0 3.7195661661826307e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.9233706183285904e-08
man O 0 2.2270007775659906e-06
, O 0 3.3677343136417903e-09
mouse O 0 3.4276939686606056e-07
, O 0 9.005943546469553e-09
rat O 0 1.740856873766461e-06
and O 0 6.987040279682333e-08
dog O 0 0.0001251750800292939
. O 0 4.501881107898953e-07

The O 0 1.4163711057335604e-06
major O 0 8.131818276524427e-07
cause O 0 1.5312562027247623e-06
of O 0 4.710090806270273e-08
hepatic B-Disease 0 0.06450482457876205
copper I-Disease 0 0.0019048216054216027
accumulation I-Disease 0 4.553016424324596e-06
in O 0 3.1766838048952195e-08
man O 0 1.6025694549171021e-06
is O 0 1.3725058867208872e-09
a O 0 1.2036283969507622e-08
dysfunctional O 0 1.198776863020612e-05
ATP7B O 0 7.973591891641263e-06
gene O 0 1.0150297384825535e-06
, O 0 2.236457596893615e-08
causing O 0 2.646151415319764e-06
Wilson B-Disease 0 0.0001298401621170342
disease I-Disease 0 0.0017279487801715732
( O 0 6.818836340016787e-08
WD B-Disease 0 0.0010518422350287437
) O 0 2.3114948533020652e-07
. O 0 1.4877723231165874e-07

Mutations O 0 0.000416196184232831
in O 0 1.008443177852314e-07
the O 0 2.4868436199199095e-08
ATP7B O 0 3.076962457271293e-06
genes O 0 3.251204532261909e-07
have O 0 2.6142549458540998e-08
also O 0 9.51772527457706e-09
been O 0 4.078055582112938e-08
demonstrated O 0 2.4885327576384952e-08
in O 0 2.4010569088517286e-09
mouse O 0 1.0266959407090326e-06
and O 0 8.128640871518655e-08
rat O 0 4.338568396633491e-05
. O 0 1.197332011315666e-07

The O 0 1.61940465659427e-06
ATP7B O 0 3.5687546187546104e-05
gene O 0 2.377281361987116e-06
has O 0 6.228262350305158e-08
been O 0 4.443868917292093e-08
excluded O 0 1.3236925155979407e-07
in O 0 1.0642581260711381e-09
the O 0 1.745269151420814e-09
much O 0 1.0162241714795073e-08
rarer O 0 9.908031870509149e-07
human O 0 2.518659982797544e-07
copper B-Disease 0 0.004185792058706284
overload I-Disease 1 0.5354295372962952
disease O 0 0.17988239228725433
non B-Disease 0 4.066842848260421e-06
- I-Disease 0 1.1728573554137256e-05
Indian I-Disease 0 2.9925402600383677e-07
childhood I-Disease 0 0.42375168204307556
cirrhosis I-Disease 1 0.5858870148658752
, O 0 3.434329087781407e-08
indicating O 0 1.4739226799065364e-06
genetic O 0 1.2432441508281045e-05
heterogeneity O 0 1.2389700714265928e-05
. O 0 6.720101168866677e-07

By O 0 3.144876927763107e-07
investigating O 0 5.629277666230337e-07
the O 0 6.780252448379542e-08
common O 0 1.4012349538461422e-06
autosomal O 1 0.9933968782424927
recessive O 1 0.9999817609786987
copper B-Disease 0 0.07187101989984512
toxicosis I-Disease 1 0.6244523525238037
( O 0 1.528125608274422e-07
CT B-Disease 0 0.00014796837058383971
) O 0 8.236071380451904e-09
in O 0 1.7925965156706525e-09
Bedlington O 0 1.0455853953317273e-05
terriers O 0 7.587247819174081e-05
, O 0 7.016899949974231e-09
we O 0 1.968974494559461e-08
have O 0 4.0474295026626805e-09
identified O 0 1.5848911516513908e-08
a O 0 5.974469252656434e-10
new O 0 1.4514479618199516e-09
locus O 0 9.222064250025142e-07
involved O 0 1.0649819870423016e-07
in O 0 8.139656415551144e-08
progressive O 1 0.9999490976333618
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.4233039564715e-06

We O 0 3.4699255593295675e-06
examined O 0 8.065312044891471e-07
whether O 0 2.327185200101667e-08
the O 0 2.1331393540435784e-08
WD B-Disease 0 0.001816777978092432
gene O 0 9.632594810682349e-06
ATP7B O 0 3.551863119355403e-05
was O 0 1.910927664994233e-07
also O 0 7.207262786579349e-09
causative O 0 6.81789913414832e-07
for O 0 5.378545608891727e-09
CT B-Disease 0 7.03581899870187e-05
by O 0 1.667099347457679e-08
investigating O 0 1.7021595510868792e-07
the O 0 1.6042035255736664e-08
chromosomal O 0 0.0006577499443665147
co O 0 4.429998807609081e-05
- O 0 7.356294986493594e-07
localization O 0 1.0281775075782207e-06
of O 0 8.428136410998377e-09
ATP7B O 0 1.2667675036936998e-05
and O 0 3.123749436895196e-08
C04107 O 0 1.3516007868474844e-07
, O 0 7.91487098084076e-10
using O 0 3.934712999864587e-09
fluorescence O 0 3.7946318087733744e-08
in O 0 3.7131808738877226e-09
situ O 0 4.276762410881929e-07
hybridization O 0 6.8349827131442e-08
( O 0 3.4384058267278306e-08
FISH O 0 1.3578578261785879e-07
) O 0 2.4331310299885445e-08
. O 0 6.439563549065497e-08

C04107 O 0 0.00028225654386915267
is O 0 2.635898113112489e-07
an O 0 2.7266100488532174e-08
anonymous O 0 5.641897473651625e-07
microsatellite O 0 1.7089621906052344e-05
marker O 0 1.571440589032136e-05
closely O 0 2.1097132503200555e-06
linked O 0 5.552152288146317e-06
to O 0 1.6504772304415383e-07
CT B-Disease 0 0.21075624227523804
. O 0 9.810752317207516e-07

However O 0 7.2556204031570815e-06
, O 0 4.429770399383415e-07
BAC O 0 0.00011587259359657764
clones O 0 4.530454589257715e-06
containing O 0 4.0105956600200443e-07
ATP7B O 0 1.9773839085246436e-05
and O 0 1.7424028442292183e-08
C04107 O 0 2.0806480449664377e-07
mapped O 0 5.325618985807523e-07
to O 0 1.0817814199981513e-08
the O 0 8.994819111762808e-09
canine O 0 0.0002527827746234834
chromosome O 0 0.0022392920218408108
regions O 0 1.4687603879792732e-06
CFA22q11 O 0 3.0963532481109723e-05
and O 0 1.732491767825195e-07
CFA10q26 O 0 5.099303962197155e-06
, O 0 5.059368479720661e-09
respectively O 0 7.129170143116426e-08
, O 0 5.950848147584509e-10
demonstrating O 0 8.138411722313776e-09
that O 0 2.1216146617319964e-09
WD B-Disease 0 0.00020223759929649532
cannot O 0 5.047227205068339e-07
be O 0 5.810206538114926e-09
homologous O 0 1.7464846280290658e-07
to O 0 8.172013110652188e-08
CT B-Disease 0 0.18637165427207947
. O 0 1.3021659697187715e-06

The O 0 1.4642473615822382e-06
copper O 0 3.1975791898730677e-06
transport O 0 3.6033364381182764e-07
genes O 0 1.3267158465168905e-06
CTR1 O 0 6.703243798256153e-06
and O 0 6.296056653809501e-08
CTR2 O 0 5.02871407661587e-05
were O 0 6.588891210412839e-07
also O 0 1.3910976370823391e-08
excluded O 0 8.631135273162727e-08
as O 0 1.4179279972381664e-09
candidate O 0 2.2749807371269526e-08
genes O 0 2.509687035967545e-08
for O 0 2.082706895834008e-09
CT B-Disease 0 0.0007285344763658941
since O 0 2.3741495169815607e-07
they O 0 1.702371221767862e-08
both O 0 7.0852466116377855e-09
mapped O 0 1.1188852795385174e-06
to O 0 2.9722945882326712e-08
canine O 0 0.015784382820129395
chromosome O 0 0.035600446164608
region O 0 5.778352715424262e-06
CFA11q22 O 0 0.00011899952369276434
. O 0 7.238758712446725e-07

2 O 0 7.30031679267995e-05
- O 0 0.000133293608087115
22 O 0 4.682118742493913e-06
. O 0 7.376125950031565e-07

5 O 0 0.00013463720097206533
. O 0 7.39426559448475e-06

A O 0 4.222205006954027e-06
transcribed O 0 5.509813036042033e-06
sequence O 0 6.099031111261866e-07
identified O 0 3.870419789109292e-07
from O 0 7.874880303404552e-09
the O 0 1.2184111497504091e-08
C04107 O 0 6.093442607379984e-06
- O 0 1.463410535507137e-05
containing O 0 1.2527549415608519e-06
BAC O 0 8.413352043135092e-05
was O 0 2.0504114672803553e-07
found O 0 2.8259383721973563e-09
to O 0 1.3788346020504605e-09
be O 0 1.8023570413916445e-09
homologous O 0 3.260736747279225e-08
to O 0 2.186758552014112e-09
a O 0 5.347296383462208e-09
gene O 0 1.5036768274967471e-07
expressed O 0 2.7633728638676303e-09
from O 0 2.796767928359145e-09
human O 0 1.4531827297048494e-08
chromosome O 0 4.296899078326533e-06
2p13 O 0 1.6244439393631183e-06
- O 0 2.813274932123022e-06
p16 O 0 8.583842827647459e-07
, O 0 8.148786534434294e-09
a O 0 8.93563711912293e-09
region O 0 2.7639856625683024e-08
devoid O 0 1.3286134503687208e-07
of O 0 1.4294960770655507e-09
any O 0 2.0389373744933437e-08
positional O 0 1.1668851584545337e-05
candidate O 0 1.5989797248039395e-05
genes O 0 8.559705747757107e-06
. O 0 5.861555791852879e-07

Molecular O 0 2.8896188268845435e-06
analysis O 0 2.8349185754450446e-07
of O 0 8.452349042897822e-09
the O 0 1.37822278034605e-08
APC B-Disease 0 2.7464659524412127e-07
gene O 0 7.814971780817359e-08
in O 0 1.390348947083453e-09
205 O 0 3.0326233968480665e-08
families O 0 1.4779488743954516e-08
: O 0 5.322315921318932e-09
extended O 0 1.7989479772495542e-07
genotype O 0 0.00017754406144376844
- O 0 2.081670936604496e-05
phenotype O 0 3.0595638236263767e-06
correlations O 0 5.759893610957079e-07
in O 0 1.3905935958291593e-08
FAP B-Disease 0 6.71247960326582e-07
and O 0 1.7015565845213132e-08
evidence O 0 7.19890946854207e-09
for O 0 7.048257533170954e-10
the O 0 2.3043440489090017e-09
role O 0 1.4292159455919773e-08
of O 0 1.7348974479247659e-09
APC B-Disease 0 5.364032062971091e-07
amino O 0 1.2221542533552565e-07
acid O 0 9.378519649771988e-08
changes O 0 5.78116932103967e-08
in O 0 1.0148556611966342e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.1056385189294815
. O 0 5.775900717708282e-07

BACKGROUND O 0 0.00023381235951092094
/ O 0 9.308377048000693e-05
AIMS O 0 2.743565119089908e-06
The O 0 1.5869572322912973e-08
development O 0 3.743505061493124e-08
of O 0 6.722038506268291e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.4492361799511855e-07
a O 0 7.309040928049626e-09
variable O 0 1.262568076754178e-07
range O 0 1.1600403126976744e-07
of O 0 5.834293048678774e-09
extracolonic O 0 0.0001807290391298011
manifestations O 0 2.804761788866017e-05
in O 0 2.273136715302826e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 8.475754839309957e-06
FAP B-Disease 0 5.965404852759093e-06
) O 0 1.4337182108192792e-08
is O 0 7.279625235945275e-10
the O 0 7.890889053285832e-10
result O 0 3.9140761742828545e-09
of O 0 3.3936672916290433e-10
the O 0 1.3131066012306292e-08
dominant O 0 0.0001227314496645704
inheritance O 0 5.1017086661886424e-05
of O 0 4.733953574032057e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999998807907104
( O 0 1.1248606597291655e-06
APC B-Disease 0 4.2346127884229645e-06
) O 0 7.024106452035994e-08
gene O 0 3.896937414538115e-06
mutations O 0 1.4840703443042003e-05
. O 0 2.64663611915239e-07

In O 0 2.7712820838132757e-07
this O 0 4.228986494325682e-09
study O 0 6.519446316133326e-09
, O 0 1.2684454597788886e-09
direct O 0 1.2199365073684021e-08
mutation O 0 2.9054726269350795e-07
analysis O 0 6.0463158924051186e-09
of O 0 5.745119935340881e-10
the O 0 3.764683231821664e-09
APC B-Disease 0 1.7988297429383238e-07
gene O 0 1.801038962412349e-07
was O 0 1.0336088251960973e-07
performed O 0 1.2550684402867773e-07
to O 0 4.436743861191417e-09
determine O 0 1.064733623934444e-06
genotype O 0 0.00013753498205915093
- O 0 2.2075717424741015e-05
phenotype O 0 3.1611189115210436e-06
correlations O 0 3.590685366816615e-07
for O 0 1.0930269134235004e-08
nine O 0 2.2758408135814534e-07
extracolonic O 0 2.8533320346468827e-06
manifestations O 0 3.84296299671405e-07
and O 0 6.19532203316453e-09
to O 0 3.1725460036824416e-09
investigate O 0 6.189088708197232e-08
the O 0 8.87174866903706e-09
incidence O 0 1.3498541193257552e-05
of O 0 4.0771666043326604e-09
APC B-Disease 0 7.365322289842879e-07
mutations O 0 7.603624112562102e-07
in O 0 1.0530400551544972e-08
non O 0 0.001986253773793578
- O 1 0.9999959468841553
FAP O 1 0.9999970197677612
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.439410309307277e-06

METHODS O 0 1.708892159513198e-05
The O 0 1.769528665818143e-07
APC B-Disease 0 1.6733741858843132e-06
gene O 0 6.776367058591859e-07
was O 0 4.0609560159055036e-08
analysed O 0 8.659514350028985e-08
in O 0 1.0243932369036202e-09
190 O 0 1.8911187282810715e-08
unrelated O 0 5.3740571104299306e-08
FAP B-Disease 0 2.5430810524085246e-07
and O 0 1.4099513556686816e-08
15 O 0 1.3420945776942972e-07
non O 0 0.00019263796275481582
- O 1 0.9998375177383423
FAP O 1 0.9999922513961792
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00010570932499831542
using O 0 3.1292717039832496e-07
denaturing O 0 0.0024977433495223522
gradient O 0 0.0002535036765038967
gel O 0 0.1592007428407669
electrophoresis O 0 3.359359106980264e-05
, O 0 1.1021292323221132e-08
the O 0 2.599149118154287e-09
protein O 0 2.1616788359324346e-08
truncation O 0 1.9629359826467407e-07
test O 0 2.91835976895527e-06
, O 0 3.0380755688952377e-09
and O 0 1.2739203025802226e-09
direct O 0 3.591013353343442e-08
sequencing O 0 1.2262443078725482e-06
. O 0 3.3912900221366726e-07

RESULTS O 0 0.00018798587552737445
Chain O 0 2.159459654649254e-05
terminating O 0 5.220209914114093e-06
signals O 0 3.1524189125775592e-06
were O 0 1.847343327199269e-07
only O 0 9.263491307365257e-09
identified O 0 1.2082313105565845e-07
in O 0 6.687659759307962e-09
patients O 0 1.2583500108576118e-07
belonging O 0 4.1393530381128585e-08
to O 0 3.090230071833844e-09
the O 0 2.1833006513816144e-08
FAP B-Disease 0 5.552616357817897e-07
group O 0 3.9957097186515966e-08
( O 0 6.03058314396776e-09
105 O 0 5.583127915542718e-08
patients O 0 2.2504937646772305e-07
) O 0 1.2205184418689896e-08
. O 0 2.5427018712775862e-08

Amino O 0 0.00012242019874975085
acid O 0 4.776286004926078e-06
changes O 0 4.992041979789974e-08
were O 0 1.1410094202801702e-07
identified O 0 5.099480304693316e-08
in O 0 1.0759861890363709e-09
four O 0 7.923548395183388e-08
patients O 0 2.443989899347798e-07
, O 0 7.875777252586147e-10
three O 0 1.5070923398141645e-09
of O 0 5.886827136869499e-10
whom O 0 1.470965145244918e-07
belonged O 0 1.5503614747558458e-07
to O 0 2.9894577924238774e-09
the O 0 8.592023093001444e-09
non O 0 2.5507226837362396e-06
- O 0 8.877862455847207e-06
FAP O 0 2.395167939539533e-06
group O 0 1.7009408281865035e-07
of O 0 1.6220785710174823e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0007732928497716784
. O 0 2.384473702932155e-07

Genotype O 0 0.14147330820560455
- O 0 0.007554534822702408
phenotype O 0 9.767879237188026e-05
correlations O 0 9.628370207792614e-06
identified O 0 3.990670847997535e-06
significant O 0 5.047111528710957e-08
differences O 0 1.9728593088075286e-06
in O 0 5.112352319258662e-09
the O 0 2.2304413871410134e-09
nature O 0 4.633864403302823e-09
of O 0 2.6651580942171904e-10
certain O 0 9.084597074604517e-09
extracolonic O 0 8.075270670815371e-06
manifestations O 0 2.447752365242195e-07
in O 0 6.432587795757172e-09
FAP B-Disease 0 1.3713992075281567e-06
patients O 0 3.348227721744479e-07
belonging O 0 3.131301440362222e-08
to O 0 4.965033273407471e-09
three O 0 4.540003573083595e-08
mutation O 0 5.715413863072172e-06
subgroups O 0 1.7684063777778647e-06
. O 0 1.6032743133109761e-07

CONCLUSIONS O 0 4.359429294709116e-05
Extended O 0 8.137169970723335e-06
genotype O 0 0.0008755297749303281
- O 0 6.906952330609784e-05
phenotype O 0 5.399802830652334e-06
correlations O 0 1.0480584933247883e-06
made O 0 5.97270854996168e-08
in O 0 1.8179419081221226e-09
this O 0 5.310408779379827e-10
study O 0 4.084257376746336e-09
may O 0 9.177602322552048e-08
have O 0 3.5767524497742897e-09
the O 0 5.086497334438889e-10
potential O 0 1.3898875383944187e-09
to O 0 8.478615587392824e-10
determine O 0 1.7697201926125672e-08
the O 0 3.9067873935927366e-10
most O 0 2.8953145436716454e-10
appropriate O 0 1.1912238973010858e-09
surveillance O 0 7.39342382871655e-08
and O 0 1.1961788892733694e-08
prophylactic O 0 4.589194759319071e-06
treatment O 0 1.9331800160671264e-07
regimens O 0 1.8695862991080503e-07
for O 0 2.025563494711946e-09
those O 0 3.273973092632332e-08
patients O 0 2.5501847744635597e-07
with O 0 4.247190599215855e-09
mutations O 0 2.3588447220390663e-05
associated O 0 7.744754526584074e-08
with O 0 2.743721516651476e-08
life O 0 9.98301857180195e-07
threatening O 0 0.00045496210805140436
conditions O 0 3.3548767532920465e-05
. O 0 1.1932921495372284e-07

This O 0 4.980173073931837e-08
study O 0 2.672939558578946e-08
also O 0 6.8236989392289615e-09
provided O 0 1.0585739396162808e-08
evidence O 0 5.678211678628031e-09
for O 0 1.2145124905771354e-09
the O 0 3.927762115552014e-09
pathological O 0 7.082518891365908e-07
nature O 0 2.8872660706724673e-08
of O 0 3.4538900628433566e-09
amino O 0 6.993799956944713e-07
acid O 0 4.730329550284296e-08
changes O 0 3.808043214093004e-09
in O 0 1.599567700516502e-09
APC O 0 6.899319515696334e-08
associated O 0 1.1026212831666271e-08
with O 0 1.3668134402067267e-09
both O 0 1.7207341329594783e-08
FAP B-Disease 0 3.0979688858678855e-07
and O 0 6.92938826318823e-08
non O 0 0.004675172735005617
- O 1 0.9999643564224243
FAP O 1 0.9999867677688599
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0010178068187087774
. O 0 2.7357890175494504e-08
. O 0 1.1299565016997803e-07

Inherited B-Disease 1 0.9999979734420776
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999990463256836
and O 0 0.017081817612051964
cancer B-Disease 1 0.999530553817749
risk O 0 3.390216443222016e-05
of O 0 8.43807690387166e-09
the O 0 4.405579190347453e-08
APC O 0 4.1319963202113286e-06
I1307K O 0 7.0250898716039956e-06
polymorphism O 0 1.2039946341246832e-05
. O 0 4.189145386135351e-07

Germ O 0 0.015712112188339233
- O 0 0.0017962328856810927
line O 0 1.047068235493498e-05
and O 0 2.862437753492486e-08
somatic O 0 2.800490619847551e-06
truncating O 0 3.0820312986179488e-06
mutations O 0 3.0055878141865833e-06
of O 0 3.101390033677376e-09
the O 0 7.39421057716072e-09
APC B-Disease 0 1.8157290071485477e-07
gene O 0 5.1204356310563526e-08
are O 0 2.1938775240926134e-09
thought O 0 9.511047061039335e-09
to O 0 5.89688786689635e-09
initiate O 0 0.0014184726169332862
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9442657828330994
formation O 0 1.3266413589008152e-05
in O 0 4.017274022771744e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.950931800820399e-05
sporadic O 1 0.9997673630714417
colorectal O 1 1.0
carcinogenesis O 1 0.9953423738479614
, O 0 9.72689804257243e-07
respectively O 0 2.644809455887298e-06
. O 0 2.2360957530054293e-07

Recently O 0 2.0650779333664104e-05
, O 0 1.327607748180526e-07
an O 0 4.0406590073871484e-08
isoleucine O 0 0.01196548342704773
- O 0 0.0001183005515486002
- O 0 3.682842361740768e-05
> O 0 1.177743797597941e-06
lysine O 0 1.2133031077610212e-06
polymorphism O 0 3.032449967577122e-06
at O 0 1.7391333528848918e-07
codon O 0 1.0040095048680087e-06
1307 O 0 1.7880679479276296e-06
( O 0 1.723572218281788e-08
I1307K O 0 7.869958551509626e-08
) O 0 1.0096624647459862e-09
of O 0 1.9860019184747557e-10
the O 0 1.8244863397853806e-09
APC B-Disease 0 7.513606448128485e-08
gene O 0 5.972070482584968e-08
has O 0 3.757373523427532e-09
been O 0 5.346276754636392e-09
identified O 0 1.4916274437837274e-08
in O 0 5.988307627546874e-10
6 O 0 1.458770171325341e-08
% O 0 1.1302944358249079e-08
- O 0 8.006265375115618e-07
7 O 0 6.668021512723499e-08
% O 0 2.9465592188415712e-09
of O 0 4.139507348011051e-10
the O 0 1.1576328340368036e-08
Ashkenazi O 0 2.512624178052647e-06
Jewish O 0 2.0253334298558912e-07
population O 0 2.4984919022585927e-08
. O 0 2.985812130873455e-08

To O 0 5.951636694589979e-07
assess O 0 4.534401341516059e-06
the O 0 3.215331290107315e-08
risk O 0 2.564209751199087e-07
of O 0 1.876421518165472e-10
this O 0 7.079460906389556e-10
common O 0 2.7717304007524035e-08
APC B-Disease 0 2.7152452730661025e-07
allelic O 0 7.525467822233622e-07
variant O 0 3.090135214733891e-05
in O 0 6.578443390026223e-07
colorectal O 1 1.0
carcinogenesis O 0 0.06568622589111328
, O 0 3.3991776149377984e-07
we O 0 2.4226542905125825e-07
have O 0 7.643405020019145e-09
analyzed O 0 5.5357613604201106e-08
a O 0 2.254702424764332e-09
large O 0 3.573042972604412e-09
cohort O 0 1.8816349722783343e-07
of O 0 2.3931425729983857e-09
unselected O 0 9.177790161629673e-06
Ashkenazi O 0 1.0471201676409692e-05
Jewish O 0 1.9825944264084683e-07
subjects O 0 3.4615263189152756e-07
with O 0 5.5157041600750745e-08
adenomatous B-Disease 0 0.0007729937206022441
polyps I-Disease 0 0.00021159101743251085
and O 0 1.7126409090906236e-07
. O 0 6.834670074340465e-08
or O 1 0.9985074400901794
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 8.38278246817481e-09
for O 0 1.1153562518018134e-09
the O 0 1.9564447839570676e-08
APC O 0 2.195617298639263e-06
I1307K O 0 2.3689324279985158e-06
polymorphism O 0 1.4717493286298122e-05
. O 0 6.692625902360305e-07

The O 0 3.163169594699866e-06
APC O 0 1.4397392988030333e-05
I1307K O 0 1.0144511179532856e-05
allele O 0 5.371467068471247e-06
was O 0 5.496128778759157e-07
identified O 0 2.1890595292006765e-07
in O 0 3.680800553240715e-09
48 O 0 5.8256890866914546e-08
( O 0 2.482728689301439e-09
10 O 0 4.464229874656667e-09
. O 0 3.617932342603325e-10
1 O 0 4.740443149131579e-09
% O 0 1.972405350159079e-09
) O 0 5.29861154952016e-10
of O 0 8.861935629767004e-10
476 O 0 6.474867291217379e-07
patients O 0 9.786148211787804e-07
. O 0 1.1655183129732904e-07

Compared O 0 3.306704820715822e-05
with O 0 3.496752043474771e-08
the O 0 6.823933418331762e-09
frequency O 0 5.730432803829899e-07
in O 0 2.641278529225133e-09
two O 0 3.3147764533225654e-09
separate O 0 1.4159071248798227e-08
population O 0 6.526824414265775e-09
control O 0 6.615903203055495e-08
groups O 0 2.3592960918250583e-09
, O 0 5.02829278214989e-10
the O 0 1.935248183926319e-09
APC O 0 1.2066031729318638e-07
I1307K O 0 1.3081411509574536e-07
allele O 0 7.988283101667548e-08
is O 0 3.1108333686802325e-09
associated O 0 3.931532432943641e-09
with O 0 7.712449567875979e-10
an O 0 1.76781322913655e-09
estimated O 0 3.238868728772104e-08
relative O 0 2.0643080915760947e-06
risk O 0 1.9134035937895533e-06
of O 0 5.227034360899552e-09
1 O 0 1.6317478923610906e-07
. O 0 9.62143857918818e-08

5 O 0 4.191229891148396e-05
- O 0 4.592189725372009e-05
1 O 0 1.0740633342720685e-06
. O 0 2.169254429418288e-07

7 O 0 4.914554301649332e-05
for O 0 2.9865323085687123e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9907689690589905
( O 0 8.28689167065022e-07
both O 0 1.4067487654756405e-06
P O 1 0.8262118101119995
= O 0 0.0004956213524565101
. O 0 6.05601329084493e-08
01 O 0 3.363464929861948e-05
) O 0 6.554496678745636e-08
. O 0 8.506273729835812e-08

Furthermore O 0 2.601135020086076e-05
, O 0 1.7413987052350421e-07
compared O 0 1.6257754964499327e-07
with O 0 9.802521461210745e-09
noncarriers O 0 8.76878675626358e-06
, O 0 1.956911255263094e-08
APC O 0 5.089083856546495e-07
I1307K O 0 6.444312248277129e-07
carriers O 0 1.6405155633947288e-07
had O 0 2.732534731819669e-08
increased O 0 1.0927392324333596e-08
numbers O 0 2.3415802630211147e-08
of O 0 2.5603956732567212e-09
adenomas B-Disease 0 8.107418398139998e-05
and O 0 0.000994415837340057
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999994039535522
per O 0 1.3592272807727568e-05
patient O 0 0.002164682373404503
( O 0 1.0090934665640816e-07
P O 0 0.06946045160293579
= O 0 9.418692934559658e-05
. O 0 1.2649573832845817e-08
03 O 0 1.0377772923675366e-05
) O 0 6.2605485240396774e-09
, O 0 7.464975304571908e-10
as O 0 1.4051986241270242e-09
well O 0 3.5250362628858056e-09
as O 0 1.6925830736980174e-09
a O 0 9.749027363170626e-09
younger O 0 7.282047818080173e-07
age O 0 1.2270943727799022e-07
at O 0 1.567101151067618e-07
diagnosis O 0 0.0003542214981280267
. O 0 2.8564909371198155e-07

We O 0 6.946286248421529e-06
conclude O 0 3.435738449297787e-07
that O 0 2.421915556993781e-09
the O 0 4.050456858806228e-09
APC O 0 3.3504380780868814e-07
I1307K O 0 4.041114607389318e-07
variant O 0 1.2832142601837404e-06
leads O 0 9.204845241583826e-08
to O 0 3.099404821682583e-08
increased O 0 1.627440178708639e-05
adenoma B-Disease 1 1.0
formation O 0 1.5552602690149797e-06
and O 0 1.54878261326985e-08
directly O 0 3.0999725453284555e-08
contributes O 0 1.7788677197927427e-08
to O 0 2.017350952954189e-09
3 O 0 3.479938825989848e-08
% O 0 1.641209657066156e-08
- O 0 3.2151294249160856e-07
4 O 0 1.3229209727683156e-08
% O 0 1.8464646478477675e-09
of O 0 4.829283639651294e-10
all O 0 2.4780792529099926e-08
Ashkenazi O 0 0.011232845485210419
Jewish O 1 0.9871765971183777
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.3664103991904994e-06

The O 0 6.940895787010959e-07
estimated O 0 6.056775987417495e-07
relative O 0 4.5024134465165844e-07
risk O 0 1.2141816796429339e-06
for O 0 2.019853617696299e-09
carriers O 0 3.331416564833489e-07
may O 0 4.372378725747694e-08
justify O 0 6.618957826276528e-08
specific O 0 1.6072752018203573e-08
clinical O 0 1.375377962631319e-07
screening O 0 4.443004186782673e-08
for O 0 1.1761673857080268e-09
the O 0 1.4256431590808916e-09
360 O 0 7.4006014649796725e-09
, O 0 1.9058337130672953e-09
000 O 0 4.369241857204997e-09
Americans O 0 7.63023777494709e-09
expected O 0 1.9809751616861604e-09
to O 0 2.0441386361369496e-09
harbor O 0 4.9314557770685497e-08
this O 0 7.552249381426179e-10
allele O 0 4.911732887080689e-08
, O 0 1.205107125201721e-09
and O 0 5.757781806892126e-09
genetic O 0 4.5173592866376566e-07
testing O 0 3.6921377954968193e-07
in O 0 2.5371584833067118e-09
the O 0 1.7788667205920206e-09
setting O 0 7.18365953389366e-08
of O 0 1.4275178816802736e-09
long O 0 2.1189239305385854e-06
- O 0 5.4008301958674565e-05
term O 0 1.3180847417970654e-05
- O 0 5.830179816257441e-06
outcome O 0 2.0357392216396875e-08
studies O 0 1.533798688058141e-08
may O 0 3.2352506451616136e-08
impact O 0 1.3767309781087533e-07
significantly O 0 4.857074600295164e-06
on O 1 0.6972893476486206
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 9.09383743419312e-06
in O 0 4.031419198469166e-09
this O 0 2.7993349860366834e-09
population O 0 3.1856757232162636e-08
. O 0 6.463028512371238e-08

Localization O 0 1.9619772501755506e-05
of O 0 7.459559725475629e-08
human O 0 1.444685153728642e-07
BRCA1 O 0 3.519954771036282e-05
and O 0 5.7428469091291845e-08
its O 0 1.310894504058524e-08
loss O 0 1.4307151730008627e-07
in O 0 1.952883410538675e-09
high O 0 3.834005383396288e-06
- O 0 0.0035377396270632744
grade O 0 0.004478751681745052
, O 0 4.015719667904705e-08
non B-Disease 0 3.460322113824077e-05
- I-Disease 1 0.9063209891319275
inherited I-Disease 1 0.9999586343765259
breast I-Disease 1 0.9999966621398926
carcinomas I-Disease 1 1.0
. O 0 2.0237725948391017e-06

Although O 0 1.955186007762677e-06
the O 0 4.405276499142019e-08
link O 0 2.8302667942625703e-07
between O 0 4.3902620205926723e-08
the O 0 1.7616854108837288e-07
BRCA1 O 1 0.9985648989677429
tumour B-Disease 1 0.9999998807907104
- O 0 4.678164259530604e-06
suppressor O 0 4.7881717364361975e-06
gene O 0 1.2794688473150018e-06
and O 0 2.2009790257015993e-07
hereditary B-Disease 1 0.9999984502792358
breast I-Disease 1 1.0
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.0285723323354432e-08
established O 0 1.3905459006480214e-08
, O 0 8.282998176234457e-10
the O 0 8.5258544668676e-10
role O 0 7.84451188451385e-08
, O 0 2.110265739929673e-09
if O 0 5.841093719816115e-10
any O 0 6.78763545369776e-10
, O 0 4.290136024209801e-10
of O 0 4.124737218447194e-10
BRCA1 O 0 1.1464699127827771e-05
in O 0 1.4137860659957369e-08
non B-Disease 0 0.0005971256177872419
- I-Disease 1 0.9283958673477173
familial I-Disease 1 0.9999963045120239
cancers I-Disease 1 0.9999969005584717
is O 0 3.5178242541178406e-08
unclear O 0 1.6121178703087935e-07
. O 0 5.6919422064538594e-08

BRCA1 O 1 0.8177134990692139
mutations O 0 0.00017873235628940165
are O 0 5.2304976350114885e-08
rare O 0 2.9478874452593118e-08
in O 0 8.456542133217226e-09
sporadic B-Disease 0 0.33598998188972473
cancers I-Disease 1 0.9999996423721313
, O 0 8.134566087392159e-08
but O 0 5.892820809094701e-08
loss O 0 9.970785441737462e-08
of O 0 2.4518858054989323e-09
BRCA1 O 0 0.0019473694264888763
resulting O 0 1.4157579926177277e-06
from O 0 2.4953676458494556e-08
reduced O 0 5.094017296869424e-07
expression O 0 6.80760763316357e-07
or O 0 9.547890158501104e-07
incorrect O 0 3.195799945387989e-05
subcellular O 0 5.908000093768351e-05
localization O 0 6.2858844103175215e-06
is O 0 6.218431547466707e-09
postulated O 0 4.597007574602685e-08
to O 0 2.3131645487950436e-09
be O 0 1.653979952997986e-09
important O 0 1.5394456820416735e-09
in O 0 2.4206501247903134e-09
non B-Disease 0 1.1946603990509175e-05
- I-Disease 1 0.5991562604904175
familial I-Disease 1 0.9999995231628418
breast I-Disease 1 1.0
and I-Disease 1 0.9999986886978149
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 2.272319534313283e-06

Epigenetic O 0 0.0001257301337318495
loss O 0 0.00010886411473620683
, O 0 4.879974468963155e-08
however O 0 1.3075333704648529e-08
, O 0 2.9999447370698817e-09
has O 0 1.91292803819465e-09
not O 0 1.324927723089786e-09
received O 0 1.2400384052924096e-09
general O 0 2.6562430033294504e-09
acceptance O 0 4.394584962597037e-08
due O 0 3.7615773607058145e-08
to O 0 2.5046646978665876e-09
controversy O 0 5.558770777014388e-09
regarding O 0 1.4231959610810918e-08
the O 0 3.4360831957513938e-09
subcellular O 0 1.5383875506813638e-06
localization O 0 5.121099775351468e-07
of O 0 7.708115035143237e-09
BRCA1 O 0 1.1326368621666916e-05
proteins O 0 5.7547328680129795e-08
, O 0 2.8915245753324825e-09
reports O 0 1.0787237769704916e-08
of O 0 4.2977776892882957e-10
which O 0 4.37681535458978e-09
have O 0 1.5097169736577598e-08
ranged O 0 8.503652111357951e-07
from O 0 8.057416067686063e-09
exclusively O 0 6.65105162056534e-08
nuclear O 0 3.851629344353569e-07
, O 0 1.1800863619626512e-09
to O 0 3.0374152082401906e-09
conditionally O 0 5.329073715643062e-08
nuclear O 0 4.651923291021376e-08
, O 0 4.719158952504188e-10
to O 0 8.508894144831913e-10
the O 0 1.7646542005422816e-08
ER O 0 2.5974341042456217e-05
/ O 0 9.207002449329593e-07
golgi O 0 1.9386463918635854e-06
, O 0 1.0169163289219796e-08
to O 0 7.033864157790504e-09
cytoplasmic O 0 3.341495130371186e-06
invaginations O 0 9.463760761718731e-06
into O 0 4.093064021049031e-08
the O 0 2.2061565019271256e-08
nucleus O 0 8.192720883926086e-07
. O 0 7.467403406735684e-08

In O 0 4.552107952804363e-07
an O 0 1.6531354063431536e-08
attempt O 0 1.3280914856750314e-07
to O 0 2.9792362354896795e-08
resolve O 0 7.407849125229404e-07
this O 0 8.39111280459548e-10
issue O 0 7.177685557024915e-09
, O 0 4.5943759907629556e-09
we O 0 6.495379789583922e-09
have O 0 6.289020859640004e-09
comprehensively O 0 4.287930096324999e-06
characterized O 0 1.3277370669584343e-07
19 O 0 3.6655013246900126e-08
anti O 0 1.3721305549552198e-06
- O 0 0.00026951206382364035
BRCA1 O 0 0.0012219889322295785
antibodies O 0 1.3929203305451665e-05
. O 0 2.9103287602083583e-07

These O 0 7.138816613405652e-07
reagents O 0 3.871390163112665e-06
detect O 0 1.1100480151071679e-05
a O 0 5.086308263457795e-08
220 O 0 1.2952557426615385e-07
- O 0 6.151112756924704e-07
kD O 0 1.8771341956380638e-06
protein O 0 1.6419774340192816e-07
localized O 0 3.1870712291492964e-07
in O 0 3.1083662310749105e-09
discrete O 0 1.9810767071248847e-07
nuclear O 0 3.7452159631357063e-06
foci O 0 1.6358877701350139e-06
in O 0 9.295137104459172e-09
all O 0 2.5799225866762754e-08
epithelial O 0 1.6012252217478817e-06
cell O 0 1.3884297914046329e-05
lines O 0 4.2985302570741624e-05
, O 0 1.737168964233149e-09
including O 0 1.0583431908628427e-09
those O 0 3.351969812825928e-09
derived O 0 3.166200812643183e-08
from O 0 4.412559206912192e-08
breast B-Disease 0 0.33524614572525024
malignancies I-Disease 0 0.0007298450800590217
. O 0 7.94023321759596e-07

Immunohistochemical O 0 0.001770228031091392
staining O 0 0.00023267907090485096
of O 0 1.613494475805055e-07
human O 0 9.127758744398307e-07
breast O 1 0.5512310862541199
specimens O 0 3.5501997786013817e-07
also O 0 9.48581373449997e-08
revealed O 0 3.5326954730408033e-06
BRCA1 O 0 0.0012747645378112793
nuclear O 0 3.970210855186451e-06
foci O 0 1.5254496247507632e-05
in O 0 1.4194932873579091e-07
benign O 1 0.9641627073287964
breast O 1 0.984434187412262
, O 0 5.1566207304176714e-08
invasive B-Disease 0 0.0009213098092004657
lobular I-Disease 1 0.9998630285263062
cancers I-Disease 1 0.9999985694885254
and O 0 1.272732902179996e-06
low B-Disease 1 0.9968401193618774
- I-Disease 1 0.9993534684181213
grade I-Disease 1 0.9996067881584167
ductal I-Disease 1 0.9998782873153687
carcinomas I-Disease 1 1.0
. O 0 5.0016192290058825e-06

Conversely O 0 0.00010750219371402636
, O 0 7.669664796594589e-07
BRCA1 O 0 8.637023711344227e-05
expression O 0 1.11705787730898e-06
was O 0 6.602149937862123e-07
reduced O 0 1.921497414514306e-07
or O 0 6.404023906725342e-07
undetectable O 0 9.279706318920944e-06
in O 0 7.839000004672414e-10
the O 0 1.5692517285614827e-09
majority O 0 3.698951367425707e-09
of O 0 6.888924986014899e-10
high O 0 4.534198069450213e-06
- O 0 0.024900171905755997
grade O 0 0.004850940313190222
, O 0 7.905191523605026e-08
ductal B-Disease 0 0.0026437793858349323
carcinomas I-Disease 1 1.0
, O 0 4.2992741811076485e-08
suggesting O 0 8.851554866851075e-08
that O 0 1.1036432878697156e-09
absence O 0 1.194343646204743e-08
of O 0 1.3031705714539044e-09
BRCA1 O 0 0.00010355496488045901
may O 0 2.3301929275021394e-07
contribute O 0 1.1515042253051888e-08
to O 0 3.454087904586345e-09
the O 0 4.301462297462422e-09
pathogenesis O 0 1.808994731788971e-08
of O 0 1.338712890541771e-10
a O 0 2.106533836254698e-09
significant O 0 5.532707625377498e-09
percentage O 0 6.14195016623853e-07
of O 0 9.38162969532641e-09
sporadic B-Disease 1 0.9979251623153687
breast I-Disease 1 1.0
cancers I-Disease 1 0.9999973773956299
. O 0 1.048642914724951e-07
. O 0 1.9193326750155393e-07

